<SEC-DOCUMENT>0000950170-24-018787.txt : 20240222
<SEC-HEADER>0000950170-24-018787.hdr.sgml : 20240222
<ACCEPTANCE-DATETIME>20240222161550
ACCESSION NUMBER:		0000950170-24-018787
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240222
DATE AS OF CHANGE:		20240222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		24664994

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>atha-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:atha="http://athira.com/20231231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_56099921-7fc5-49df-ae85-a3e4a88a58dd" name="dei:DocumentFiscalPeriodFocus" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39">FY</ix:nonNumeric><ix:nonNumeric id="F_09e53c69-5e8c-48df-b3c1-14bbd57a338d" name="dei:AmendmentFlag" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39">false</ix:nonNumeric><ix:nonNumeric id="F_c89404e0-2311-4662-97b2-93f429554497" name="dei:EntityCentralIndexKey" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39">0001620463</ix:nonNumeric><ix:nonNumeric id="F_b400847d-1662-41db-b50c-4bdbe2ef14f7" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_008d8a94-a39b-433f-b0b0-77ae3c042f6f" format="ixt-sec:duryear">3</ix:nonNumeric><ix:nonNumeric id="F_4a281260-fb9a-463b-8549-038a2ea1ba92" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atha-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8d0e6b76-9bb3-4df6-8c45-7670935b83c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf2c465b-8587-438c-a9ea-4095cfc62594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a260444-47e3-4eab-963c-2dcc49dd3cc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa6a601d-80ed-42d8-a96f-8238a263db27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_922fddad-facf-4336-aa77-97c53317edac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82ce7c28-19ff-4ba2-94b4-dcbd68834f11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91a3cdff-44c7-4be8-8690-9251ebfd8a0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfc5356d-4026-41a2-a82b-2bbf62ac66e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d98123fe-9e7e-4c2e-8b91-5f07a93c8aaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70e3a64b-76f2-4b45-b67d-b2027a3e900e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ab0bd04-d950-4018-bfb6-93d46d159ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16f4eb07-f770-4874-8b9e-47c09374ee0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">atha:PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_226d7a94-53b9-413a-83c4-4c853fb51f40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ffcc58d-1976-40bc-bf55-155e02e95431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b2efe00-aef3-4b37-ae0e-6491160765f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e33a3149-ce72-41bd-94ff-d0cab93ff8db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:JawandhaVAthiraPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7714a687-7731-4c13-9881-449c6a18a2ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e32575d-a6b9-41a8-91fa-2a9ebdb1b43a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c4d91a5-91db-41e6-9a2a-b4d994e6373c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfa9f2b7-2752-4887-a960-266fea4dee22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e72d8ea-ec67-44e7-a900-766be31764bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_426e1064-11b7-4ec3-aed5-1a083b3b037d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8d204cf-7cc0-42a8-aeea-d8322af589cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7402318-2099-403e-80e2-e4d9762b5a2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_151605f2-8e8c-4ccb-9f19-d395e2a884b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df96098e-d6ae-4e99-9e22-f4b1da15f310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6694722e-57a7-407b-9dfb-5cabe2faff30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f87c6bfa-07b2-48b3-b0a9-3098dcc3e0c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_008d8a94-a39b-433f-b0b0-77ae3c042f6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaee46db-7780-4ebe-846f-913aa5aea294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ff49d7f-fac0-41a7-929e-e4558c77c522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4594933-cd27-4b2d-b47f-3c26d3044474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:FurnitureFixturesAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a58c8276-7213-4745-af91-33501a2c6737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a65c107a-c260-47d4-aa36-25401168c1ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f1121d9-b05d-4e5f-9477-a1f96b0362c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0eab557-b7e2-4d8e-b61f-6fd05508c61b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bceb79c-22f4-4e48-96e9-071508ac7697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7faad1c-e70a-40a8-bf1f-ea0da7846fb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1e4e5a0-6260-4827-a357-156d12d260b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_187e872f-6f06-4138-a5a3-73aa8c516e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6b0b8ce-ab31-4162-be7e-4e0e4f188f69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6a26653-10d9-4f44-88dc-82ea78ded141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7c67d33-aae0-4112-9efb-f133ec67b36b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69c9026a-c50a-44e3-a00c-4b6fe771b199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd062a54-8e0f-43d9-b4fd-677356eb4cb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:LicensedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e4222da-d4ac-4e84-9095-1eaa081f11b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94d38940-3716-4ae8-8dcc-05162812b209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:AthiraPharmaIncVDrKawasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f18bc7ab-5af1-44c8-924a-3f2688d049f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atha:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c6c7189-5e14-4367-b988-8d2df4618d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d40879de-c9cf-4ff8-8428-c0e65b0b4d5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c75da740-1967-4b45-a209-94145e24aaeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bbc5dbc-159a-4e8b-8825-ecd0d466bf04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42990ac9-086f-46cd-8523-da23f22d1e85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5ff6d80-d652-482d-85d9-7a260cc2826b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:NonVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53baa5a0-6766-48f8-b2f6-ddb46f1ed143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ed353a2-ea15-493f-8aa1-8373fc805f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_690c503b-308d-4f02-ae74-3a40f7694b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">atha:PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1e4cdcc-57d2-49b5-a143-ac39a470f80c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a516322c-a580-416f-a571-a5d4cce10d51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f3b7167-3bdb-4617-add9-35c0246bd8d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:SlyneVAthiraPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a2f43c4-1117-4672-90c6-75792b11123e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a3946d-c3f8-41ed-a196-a68791521aff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9177032-05f2-4b4d-b7e2-81d23fa814d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c68e4dfb-d60e-49f2-96b2-46587068c474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2df3ffa4-7e0f-4475-8dc6-103f27566e6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1bdc52f-55b0-42e4-9b73-d791b4867499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_056747a7-1c94-4990-92ab-823ab0bc1868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12a10015-c94d-4aee-aab4-44e3ae370c9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d250931b-a0c2-4920-858c-160fb803eaac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e73c2da-bf36-4271-ae86-4b1f0e2f86d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aeb7363-11f2-4452-9d7a-75e6115d7d8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49dc3275-db5d-457d-9e82-3b59ada8e823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dea600eb-6bff-47e0-a4fc-ba972dd836c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1316502c-52a2-42d4-b1b3-95c55a6319ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ac800dc-b01c-45e8-b2ee-046ba0e16083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:WangVAthiraPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3680b5de-5819-4049-8d87-083dce72c5cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_897ba1ad-56e2-437d-9cf7-9403bc286825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_710fe844-0726-4f65-be5c-3fa87ea575cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9095dfc0-3298-479d-99a1-25f51998f25b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_053a40d1-bb28-4f1e-bcd3-ded475336474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28696d50-3838-41f2-a0ee-404e5265a50e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1c93451-1f41-49f8-b231-c5cf477afc39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ab74e21-5321-4b29-9cf8-94356358cf01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:NonVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39cb2c60-d4de-4766-bbf7-e3322d14b6f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_719ee044-1cd6-4354-9d45-5838c649c6cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5545a951-56b7-41cd-9b84-87819c3182e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atha:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_580e918a-d59f-4636-90ec-2ca1df182f19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a2a914d-8abd-447a-9b84-978f4cf3df2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7cba87e-57f4-4dd8-a43e-4d3b53a7003d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_656fadf4-0d29-4caa-a75d-c735f8deb466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d6df006-0245-4a7f-aaeb-b183142fe722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:FurnitureFixturesAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efe731a6-8644-49ad-81df-a7f77a40963f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe8e26c7-136f-405d-890c-308874394d43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5908b88-dd8b-4d05-a20d-6351018e760a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3cbf114-5760-4876-a9ac-f26ffd0959d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5c26a41-a1f5-40f5-9d35-4bb1846d30b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df1e6e77-ce5e-4ac7-b222-0ce56ac33d5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4726f01b-7636-4549-a578-0b2798df0841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41b276ca-ace1-420e-a094-64afac7af863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10175cd6-83a3-4603-bad5-7b3b43f819ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e32a1c8-6ec3-4e35-b166-fee2b12394c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_303a3846-845e-456f-8c82-d8f63126fa9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf9a9c4d-ab5c-403b-b958-e051da05ad42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab70a86c-b366-4a92-835f-b2e57888bb70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e223ef3-d9c1-4fbc-a123-56fabdfa0705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aef30744-a5ec-4f04-bf7c-7c0d2dcb4975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89aa2ae1-d511-40d1-b6b5-55800463bae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1961c4e3-fcb5-421a-969d-a6cea22d51f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>atha:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.6in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Arial;"><ix:nonNumeric id="F_7b26413e-2717-4bd5-8554-bf9c963d0a64" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5f3bc295-d377-41c0-940d-687ac488a9e7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_924aeb93-d06a-4996-b345-d15edc195f54" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_35007346-0aac-4942-9670-3f5941cadb5a" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_0bc91f8e-cce8-49a2-881e-90a73ead47dd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e35e32d6-d878-421f-b969-fc56b59b2ac7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">Commission File Number </span><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_5cca3d8a-4a2f-420c-b708-19d5daad653e" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">001-39503</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Arial;"><ix:nonNumeric id="F_47adc4cd-e08a-4145-b0bb-6bbb66a6b413" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_cb99d7f0-2774-4182-a49c-f1a757c1ad9d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_68c23bed-257e-4b0f-bcbb-334a6a4232dd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">45-3368487</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_e5bc9124-ddd4-4bf6-825e-dec0f1239ec3" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">18706 North Creek Parkway,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_805ce964-73b9-4e5c-82be-6d14c6237504" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">Suite 104</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_3c7c2163-7af8-4eb7-a9f7-5409deb447a5" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">Bothell,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_7a499113-b0fd-4153-9bf9-c917535ec736" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">Washington</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_24d59df7-af68-4b52-afb3-ea823058a155" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">98011</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">(Address of principal executive officer)</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_1e39efea-38c1-498f-be22-d7775106cae4" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">425</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_23a4b2c1-a267-497f-8074-25c08e8c538a" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">620-8501</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:39%;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Trading</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_799010fb-8e6c-4fbc-87a5-90598d1b88fd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_68fc2e2e-c1e9-45fd-90e4-9ce5f21fe090" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATHA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_1f466f58-8c94-40b0-8e78-a35eccd321b7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_e828e187-7d46-4b31-9d88-9a88c6fefdf8" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_0df31b0d-19cd-41a4-9a98-b24e772dd253" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">N</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">o</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_f0e46f8d-8180-421f-af64-8e87aad6041c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Y</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">es</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> NO </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_386643e5-a11d-47a4-94cd-75f03fbeff77" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Y</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">es</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> NO </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.457%;"/>
    <td style="width:1%;"/>
    <td style="width:53.389%;"/>
    <td style="width:1.04%;"/>
    <td style="width:24.435%;"/>
    <td style="width:1%;"/>
    <td style="width:1.68%;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_226f6418-b14d-40ce-a62e-8bf2c9bb2bdc" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_d31edab6-62ea-4587-b70e-8b9a929b1029" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_87844833-162c-4513-8e91-9c5a79c104ef" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7385b879-2f87-4792-8c6f-c768968fbe18" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8404fdb3-91bb-4923-82ec-b6a3a024d5ec" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7.5pt;font-family:Arial;"><ix:nonNumeric id="F_22890cea-8b59-4b80-bb9d-3bda884aca8c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> NO </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f18e5629-9c4e-4111-9df1-2a340b1e244c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant, based on the closing price of the shares of common stock on June 30, 2023 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) as reported by The Nasdaq Stock Market LLC on such date was approximately $</span><span style="font-size:7.5pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57d7fc42-dcbb-4878-977d-8dd9bff8a77f" contextRef="C_d4a3946d-c3f8-41ed-a196-a68791521aff" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> million. Shares of the registrant&#8217;s common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant have been excluded from this computation. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 19, 2024 was </span><span style="font-size:7.5pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9fe8a11-bedd-4e3c-8899-d4546b2fc2a3" contextRef="C_0bbc5dbc-159a-4e8b-8825-ecd0d466bf04" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,326,652</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="font-size:8pt;font-family:Arial;"><ix:nonNumeric id="F_b451bc93-f562-4f77-8ec4-a5888bdb06d7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Portions of the definitive proxy statement to be delivered to stockholders in connection with the 2024 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:82.82%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART I</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">45</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">114</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART II</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">158</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">158</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">159</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">159</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART III</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:6.85pt;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 16</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">164</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="summary_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Summary Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">k Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned &#8220;Risk Factors.&#8221; The following is a summary of the principal risks we face:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a late clinical-stage biopharmaceutical company with a limited operating history. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our development of fosgonimeton may never lead to a marketable drug product.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our approach to targeting neurotrophic factors through the use of small molecules is based on a novel therapeutic approach, which exposes us to unforeseen risks. We have limited data from our Phase 1a/1b and Phase 2 clinical trials to date, and we cannot be certain that future trials will yield data in support of the safety, efficacy and tolerability of our drug candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have concentrated our research and development efforts on the treatment of central and peripheral nervous system, or PNS, degenerative disorders, a field that has seen very limited success in product development.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at Washington State University, or WSU. The special committee&#8217;s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSU&#8217;s dihexa patent, exclusively licensed to us, incorporated certain of these altered images. WSU has undertaken a review of claims of potential research misconduct involving our former chief executive officer&#8217;s doctoral research at WSU. We cannot predict when WSU&#8217;s investigation will be completed or what conclusions WSU will reach.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations and other legal, regulatory and administrative proceedings and face potential liability and expenses related thereto, which could have a material adverse effect on our business, operating results and financial condition.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any &#8220;topline&#8221;, interim, initial, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale preclinical studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale potentially pivotal clinical trials across multiple clinical trial sites. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical drug candidates would be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the drug candidates we develop, our commercial opportunities will be negatively impacted.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The loss of any of our key personnel could significantly harm our business, results of operations and competitive position.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will require substantial additional funding to finance our operations, complete the development and commercialization of fosgonimeton, and develop and commercialize other and future drug candidates. If we are unable to raise this funding when needed, we may be forced to delay, reduce, or eliminate our drug product development programs or other operations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our drug candidates, we will not be able to commercialize, or will be delayed in commercializing, our drug candidates, and our ability to generate revenue will be materially impaired. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We rely on third parties to conduct our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our drug candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if approved, our drug candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have never commercialized a drug candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any drug products on our own or together with suitable collaborators.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we experience delays or difficulties in the enrollment or retention of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a manufacturing preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers, which could adversely affect our ability to successfully develop and commercialize our drug products.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert management&#8217;s attention.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Actions by activist stockholders have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">T I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. This section should be read in conjunction with our audited consolidated financial statements and related notes included in Part II, Item 8 of this report. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; "possible," &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target&#8221;, &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the sufficiency of our existing cash, cash equivalents and investments to fund our future operating expenses and capital expenditure requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our drug candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the ability of our nonclinical studies and clinical trials to demonstrate safety and efficacy of our drug candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the success, cost and timing of our development activities, nonclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the rate and degree of market acceptance of our drug candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential learnings from our ACT-AD and SHAPE trials and LIFT-AD independent unblinded interim efficacy and futility analysis and their ability to inform and improve future clinical development plans;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential of LIFT-AD to show clinical benefits of fosgonimeton;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing and focus of our future clinical trials, and the reporting of data from those trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our plans relating to commercializing our drug candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any drug candidates for which we obtain approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to attract and retain key managerial, scientific and clinical personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the pricing and reimbursement of our drug candidates, if approved; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our reliance on third parties to conduct clinical trials of our drug candidates, and for the manufacture of our drug candidates for nonclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the beneficial characteristics, safety and efficacy of our drug candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory developments in the United States and other jurisdictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our drug candidates in the United States and other jurisdictions, and any related restrictions, limitations or warnings in the label of any approved drug candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">future agreements with third parties in connection with the commercialization of our drug candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our plans, capacity and capability relating to the further development and manufacturing of our drug candidates, including additional indications for which we may pursue regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the outcome of legal proceedings which have been or may in the future be instituted against us and certain of our directors and officers, including the legal proceedings discussed in Part I, Item 3 &#8212; "Legal Proceedings,&#8221; and elsewhere in this report;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the actions by activist stockholders, which have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of our business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the size and growth potential of the markets for our drug candidates, if approved for commercial use, and our ability to serve those markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential benefits of any strategic collaboration agreements we may enter into; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part I, Item 1A &#8212; &#8220;Risk Factors,&#8221; and elsewhere in this report. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This report includes our trademarks and registered trademarks, including Athira, Athira Pharma, the Athira logo, and other trademarks, trade names, or service marks of Athira. Each other trademark, trade name or service mark appearing in this report belongs to its holder. Solely for convenience, trademarks, trade names, and service marks referred to in this report are listed without &#174; or TM symbols, but we will</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">assert, to the fullest extent under applicable law, our or the rights of the applicable licensors to these trademarks, trade names, and service marks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Athira,&#8221; and &#8220;the Company&#8221; refer to Athira Pharma, Inc. and its wholly-owned subsidiary.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1. Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At Athira, our scientific philosophy is rooted in the need for a healthy neuronal network to help build, restore, and maintain connections. Loss of neuronal network connections can be an underlying cause for numerous neurological diseases, which in turn may result in the loss of personal connections for people afflicted by these diseases. Our mission is to restore these neuronal networks and, in turn, personal connections by advancing bold therapies for neuronal health, thoughtfully and urgently.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Our approach is designed to modulate the neurotrophic hepatocyte growth factor, or HGF, system, that is critical to normal brain function and may play a key role in maintaining the health and functioning of neuronal networks. We believe that by acting on the neurotrophic HGF system and its multiple downstream signaling pathways, we may be able to enhance the body&#8217;s natural ability to protect and repair neuronal networks by reducing inflammation, promoting regeneration, and reducing disease-specific protein pathologies, thereby positively impacting the course of disease. We aim to achieve these goals by advancing our pipeline of novel small molecule compounds which are designed to and have exhibited properties in enhancing the neurotrophic HGF system in either the central nervous system, or CNS, by crossing the blood brain barrier, or BBB, or the PNS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Over time, the body&#8217;s innate ability to heal itself deteriorates due to a variety of factors associated with the normal aging process and other internal and external factors leading to various injuries and insults at the cellular and molecular level. In the case of neurodegenerative diseases, where neuronal networks may be damaged due to inflammation, oxidative stress, protein pathologies, excitotoxicity, or synaptic dysfunction, the neurotrophic HGF system function is often reduced, thereby limiting the body&#8217;s ability to protect and repair neurodegeneration. Hallmarks of neurodegeneration include neuronal damage, loss of network connectivity, loss of function and, ultimately, disease progression.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Scientific evidence supporting the neurotrophic HGF system as a naturally occurring repair mechanism is backed by over 30 years of research, which includes establishing its multimodal mechanism of action and critical role to healthy nervous system functioning. HGF&#8217;s receptor, known as MET, is one of the most stably expressed genes in the adult human brain and is a signature of a healthy, viable nervous system. In Alzheimer&#8217;s disease, or AD, neuronal MET expression is reduced in the brains of patients by approximately 25% and 75% in the frontal cortex and hippocampus, respectively. And although evidence supports the HGF/MET signaling system as an attractive target with its multimodal mechanism of action for combating neurodegenerative diseases, it has proven a difficult drug target. There are approved and in-development gene therapy approaches to increase HGF expression beyond normal physiological levels, but these are limited primarily due to challenges with delivery. Athira has chosen a different approach. Athira&#8217;s novel approach is to positively modulate the neurotrophic HGF system through our proprietary small molecules.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have developed and tested preclinically a series of novel small molecule drug candidates, of which three candidates are in, or nearing, clinical phase, that we believe show promising evidence in modulating the neurotrophic HGF system and producing potential multimodal downstream effects. Our pipeline consists of both BBB permeable and peripherally restricted drug candidates for CNS, PNS and other indications. Today, our most advanced drug candidate is fosgonimeton (formerly known as ATH-1017), which is currently being evaluated in a Phase 2/3 clinical trial for mild-to-moderate AD, and has recently completed an exploratory Phase 2 clinical trial for Parkinson&#8217;s disease dementia, or PDD, and dementia with Lewy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">bodies, or DLB. We are also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, or ALS, Parkinson&#8217;s disease, or PD, and other neurodegenerative diseases. For example, ATH-1020 completed a Phase 1 single ascending dose, or SAD, evaluation in healthy volunteers and is under consideration for further testing in neuropathic pain and/or neurodegenerative diseases and we expect to submit an Investigational New Drug, or IND, application for ATH-1105 in ALS and initiate a Phase 1 clinical trial in the first half of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Pipeline</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Figure 1 below illustrates the current development stage of our proprietary drug candidates and early discovery and development programs. Our pipeline consists of both BBB permeable and peripherally restricted drug candidates for CNS, PNS and other indications. In addition, we are exploring the use of our proprietary ATH compounds in additional indications in the CNS and PNS as we aim to improve neuronal health in multiple neurodegenerative diseases. Our drug discovery efforts are focused on designing and testing new early compounds to enhance the neurotrophic HGF system for a variety of clinical applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 1. Summary of Our Preclinical and Clinical ATH Programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_0.jpg" alt="img105269759_0.jpg" style="width:616px;height:266px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fosgonimeton (ATH-1017)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our lead drug candidate, fosgonimeton, is a potentially first-in-class small molecule designed to positively modulate the neurotrophic HGF system for potential treatment of CNS disorders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Alzheimer&#8217;s Disease</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The effects of fosgonimeton in its primary target indication, AD, are currently being evaluated in multiple clinical trials:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In vitro studies in primary neuron cultures with fosgonimeton active metabolite, or fosgo-AM, showed enhanced synaptogenesis and neurite outgrowth, supporting the neurotrophic effects of positively modulating the neurotrophic HGF system. Treatment of primary neuron cultures with fosgo-AM prevented neuron death when exposed to several neurotoxic insults, supporting the neuroprotective effects of positively modulating the neurotrophic HGF system. In an animal model of cognitive deficit and dementia, treatment with fosgo-AM rescued this cognitive impairment. In a separate inflammation-induced animal model of cognitive impairment, fosgonimeton also reversed cognitive deficits. These study results were published in Neurotherapeutics in December 2022 and support the therapeutic potential of fosgonimeton to promote neuroprotective and anti-inflammatory effects and procognitive benefits in animal models of dementia.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fosgonimeton was assessed in a Phase 1a/b clinical trial and was well tolerated in healthy young and elderly volunteers and AD subjects, without serious adverse events. This clinical trial recruited a total of 88 participants, including 11 with mild to moderate AD, who were randomly assigned to active and placebo groups. Findings from the Phase 1 trial provided safety data, as well as translational and supportive evidence of fosgonimeton crossing the BBB and improving brain network activity by significantly improved event-related potential, or ERP, P300 latency. P300 latency is a functional measure that is highly correlated with cognition; however, we have not yet established a connection between these ERP P300 latency results and improved cognition. Trial results were published in the Journal of Alzheimer&#8217;s Disease in April 2022, and helped inform the study design of our exploratory Phase 2 ACT-AD and Phase 2/3 LIFT-AD trials.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ACT-AD* was a randomized, double-blind, placebo-controlled, parallel-group 26-week exploratory Phase 2 clinical trial in mild-to-moderate AD, with ERP P300 latency as the primary endpoint. Initiated in November 2020, the trial was designed to better characterize the overall effects of fosgonimeton on working memory processing speed and cognitive measures and inform the Phase 2/3 LIFT-AD trial. Topline results for this exploratory Phase 2 ACT-AD trial were announced in June 2022, and the primary and all secondary endpoints were not met by protocoled analysis. However, a post hoc analysis of results from ACT-AD in a pre-specified subgroup suggested positive effects on measures of cognition, function and neurodegeneration in participants taking fosgonimeton alone without background acetylcholinesterase inhibitors, or AChEIs. Additionally, data from post hoc analysis of plasma biomarkers from participants on fosgonimeton without background AChEIs showed descriptive improvements (non-statistically significant) in markers of neuroinflammation and AD-specific protein pathologies when compared to placebo. Fosgonimeton was generally well tolerated in the ACT-AD study, with a favorable safety profile, and there were no treatment related serious adverse events or deaths observed.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">LIFT-AD is a randomized, double-blind, placebo-controlled, parallel-group 26-week Phase 2/3 clinical trial with fosgonimeton for the treatment of mild-to-moderate AD. In September 2020, we began site initiation and patient screening for LIFT-AD. The primary endpoint for the Phase 2/3 LIFT-AD trial will be measured by the Global Statistical Test, or GST, which is a composite score that combines the scores from cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog11), and function (Alzheimer&#8217;s Disease Cooperative Study-Activities of Daily Living, or ADCS-ADL23). Guided by the results from the completed exploratory ACT-AD Phase 2 trial, in September 2022, we proactively amended LIFT-AD to focus on participants not on background AChEIs. In October 2022, we announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee, or DMC, recommended continuation of the LIFT-AD trial. The committee also determined that, with the additional enrollment of fewer than 150 participants for a total enrollment of less than 300 participants without background AChEIs, the amended trial will be well powered for the primary endpoint given the preliminary effect size observed. In May 2023, we further amended LIFT-AD to focus on 40 mg dosing, which we have selected for further development and as the potential dose for regulatory approval of fosgonimeton in this indication. This selection was based on a review of the totality of the preclinical and clinical data, biomarker results, observations from the open label extension study and in consultation with independent regulatory and biostatistical consultants based on patients treated with 40 mg fosgonimeton without concomitant AChEIs. In January 2024 we announced the completion of enrollment with a total of approximately 315 patients randomized. We expect to report topline LIFT-AD results in the second half of 2024. In July 2023, we completed an end of Phase 2 meeting with the FDA to gain alignment on our plans for the continued clinical development of fosgonimeton as a treatment for mild-to-moderate AD. During this meeting we provided an update and discussed with the FDA the ongoing LIFT-AD trial, including use of the 40 mg dose, concomitant AChEIs use, biomarker analyses including neurofilament light chain, or NfL, and the statistical analysis plan, or SAP. The FDA noted the importance of showing effects on both cognition (ADAS-Cog11) and function (ADCS-ADL23) in the trial population. The FDA is open to ongoing dialogue with us regarding the LIFT-AD trial once completed as well as other aspects of our program to develop fosgonimeton as a potential treatment for mild-to-moderate AD.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2021, we announced that we are enrolling participants into a 26-week open-label extension trial*, or OLEX*, for our LIFT-AD and ACT-AD clinical trials, allowing us to collect up to a total of one year of safety data with fosgonimeton. In May 2022, we announced that we extended the 26-week OLEX for our LIFT-AD and ACT-AD clinical trials for an additional 12 months, enabling eligible participants who have completed either trial and elect to participate in the ongoing OLEX to receive up to 18 months of open-label treatment with fosgonimeton. In May 2023, we amended the OLEX to further extend the trial by an additional 12 months. Eligible participants who have completed the LIFT-AD or ACT-AD trials and elect to participate in the ongoing OLEX may now receive up to 30 months of open-label treatment, which allows us to collect up to 36 months total of long-term exposure data.</span></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">*The ACT-AD trial and the related OLEX for ACT-AD participants have been supported by a grant from the National Institute on Aging of the National Institutes of Health under Award Number R01AG06268. The information presented is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Parkinson&#8217;s Disease</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In PD-relevant cellular and animal models, treatment with fosgonimeton or fosgo-AM resulted in significant neuroprotective and neurotrophic effects as well as improvements in motor function. Fosgo-AM significantly protected against neurotoxic insults and reduced PD-related toxic protein (&#945;-synuclein) aggregation in neuron-based models of disease. Neurotrophic effects, with or without neurotoxic insults, were significantly enhanced following fosgo-AM treatment. Cellular effects translated to improvements in motor function in an animal model, including improved coordination, balance and strength. These data were presented at the Society for Neuroscience Annual Conference in November 2022, the American Society for Experimental Neurotherapeutics Annual Meeting in March 2023, and at the AD/PD Conference in March 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2023, we announced the completion of the 28-patient exploratory Phase 2 SHAPE trial, which tested 40 and 70 mg fosgonimeton doses versus placebo in PDD and DLB. The primary endpoint of the trial, a composite score of the change in ERP P300 latency and cognitive assessment (ADAS-Cog13), was not met by protocoled analysis compared with placebo. Directionally positive results were observed for the 40 mg fosgonimeton dose group with improvements in cognitive, functional and biomarker measurements. In particular, the five patients in the modified intent to treat (mITT) population treated with fosgonimeton 40 mg once daily saw improvement in ADAS-Cog13 individually, and collectively improved compared with placebo (n=7 mITT, one-sided p=0.0321).  Results for patients in the 70 mg dose group were inconsistent.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">ATH-1105</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ATH-1105 is a novel, orally available, next generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Amyotrophic Lateral Sclerosis</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In preclinical models of ALS, treatment with ATH-1105 resulted in improvements in motor neuron survival and function. In vitro, ATH-1105 treatment protected spinal motor neurons from glutamate toxicity and prevented accumulation of toxic protein aggregates. In a preclinical mouse model of ALS, treatment with ATH-1105 significantly prevented loss of body weight, and improved motor function including balance, coordination and muscle strength. We additionally reported that treatment with ATH-1105 significantly improved electrophysiological measures of functional nerve signaling and protected against motor neuron axon degeneration and demyelination. ATH-1105 treatment also significantly reduced biomarkers of inflammation and neurodegeneration and prolonged survival. Study results were presented at the Motor Neurone Disease Association International Symposium in December 2022 and 2023. Weight loss, motor deficits, inflammation, loss of functional nerve signaling, and motor neurondegeneration and demyelination are all hallmarks of ALS disease; treatment with ATH-1105 significantly improved all of these aspects in the preclinical models tested.  We expect to submit our IND application for ATH-1105 and initiate a Phase 1 clinical trial in the first half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">ATH-1020</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ATH-1020 is a novel, orally available, next generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system. We filed an IND application with the FDA for ATH-1020 at the end of 2021 and received notice of acceptance in January 2022. This compound was originally assessed for neuropsychiatric indications in preclinical models as presented at the American Society for Experimental Therapeutics Annual Conference in February 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Neuropathic Pain</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In preclinical models of diabetic neuropathic pain, we demonstrated significant improvements in two aspects of disease that are prominent symptoms in people suffering from neuropathic pain: increased sensitivity to mechanical and thermal stimulation. The significant improvements in neuropathic pain were partially sustained after seven days of not receiving ATH-1020, suggesting persistent and potentially disease-modifying effects. Data from these studies were presented at the Society for Neuroscience Annual Conference in November 2022 and the American Society for Experimental Neurotherapeutics in March 2023. We have completed the SAD escalation portion of our Phase 1 trial, in which ATH-1020 demonstrated a favorable safety profile and which was well-tolerated in healthy volunteers. We plan to evaluate options with this compound and will consider its advancement in relation to other opportunities and resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Early Compounds</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the compounds described above, we have several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications where we believe positive modulation of the neurotrophic HGF system may have therapeutic potential.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Upcoming Pipeline Milestones</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For AD, we anticipate reporting topline data for our Phase 2/3 LIFT-AD trial in the second half of 2024. At the end of 2023, our ongoing OLEX trial for completers of ACT-AD and LIFT-AD had a greater than 85% participation rate. As with any voluntary clinical trial, participant dropout in the OLEX has also been observed.  In 2024, we anticipate continuation of the OLEX trial and continued collection of long-term fosgonimeton safety data.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We plan to file an IND application and initiate first-in-human studies of ATH-1105 as a treatment for ALS in the first half of 2024.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our strategic imperative and responsibility to people with neurological diseases is to advance our pipeline of small molecule drug candidates designed to target and enhance this naturally occurring repair mechanism to help build, restore, and maintain healthy neuronal connections. The multimodal mechanism of action of the neurotrophic HGF system has the potential to address complex multifactorial neurological diseases. We are encouraged by the scientific evidence we have generated thus far and will continue adding to the scientific foundation behind this neuroprotective and reparative approach with the potential to transform the treatment paradigm and provide meaningful therapeutic options for AD, PD, ALS, neuropathic pain, and other neurodegenerative diseases and neurological disorders, where limited effective options exist today. Key aspects of our business strategy to achieve these goals are to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Advance fosgonimeton through clinical development for mild-to-moderate AD. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe fosgonimeton has the potential to rapidly improve cognition and function to help improve the lives of the millions of people suffering from AD who currently have limited therapeutic options. We initiated both the exploratory Phase 2 ACT-AD trial and the ongoing Phase 2/3 LIFT-AD trial in 2020 and have applied learnings from the completed ACT-AD trial to help inform the LIFT-AD trial. The topline results for our ACT-AD trial were announced in June 2022 and are discussed in further detail in the section of this Annual Report on Form 10-K titled &#8220;Business&#8212;Our Pipeline.&#8221; While the primary and secondary endpoints were not achieved, encouraging results from our post hoc analyses of a subgroup in the ACT-AD trial informed our decision to proactively amend LIFT-AD to focus on participants not on background AChEIs and the independent unblinded interim analysis further supported our decision. We announced completed enrollment for the LIFT-AD trial in January 2024 and anticipate reporting topline data in the second half of 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expand the development of fosgonimeton to maximize opportunities in AD. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are developing fosgonimeton as a treatment for mild-to-moderate AD, but over time we aim to expand development of fosgonimeton to cover more stages of AD, either delivered alone or in combination with other approved therapies.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Advance innovative research to expand and develop our ATH pipeline of small molecule drug candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our strategy is to advance drug candidates that show both strong pharmacokinetics and pharmacodynamics, or PK/PD, translation and early predictive clinical data. We plan to continue growing our discovery organization across neurological disorders in general, but with a near-term focus on neurodegenerative diseases, by building upon the strong foundational knowledge of our ATH positive modulators and enhancing the multimodal mechanism of action through the neurotrophic HGF system. It is our goal to advance our pipeline of next generation ATH positive modulators, designed to enhance the body&#8217;s naturally occurring repair mechanism. With several drug candidates in development, we will prioritize development to potentially address a wide range of clinical applications ranging from CNS and PNS diseases to other indications. Our ATH-1105 program targeting ALS is our next priority beyond fosgonimeton, with an IND application and first-in-human studies expected to be initiated in the first half of 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Optimize the value of fosgonimeton and next-generation positive modulators of the neurotrophic HGF system in major markets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own worldwide rights to fosgonimeton as well as our pipeline of next generation, proprietary small molecule drug candidates. We plan to develop and pursue approval of fosgonimeton and other future drug candidates across major markets. Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our programs.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Mechanism of Disease</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Causes of neurodegenerative diseases are not fully understood as these diseases are complex with several contributing factors including inflammation, oxidative stress, neurotoxicity, excitotoxicity, synaptic dysfunction, and protein pathologies that ultimately lead to neuronal damage, neuronal network degeneration and a decline in function. Intrinsic to these diseases is the disruption of a healthy neuronal network that can be overcome and repaired or maintained when the body&#8217;s natural repair mechanisms are intact. However, a loss of or reduction in ability of the body to repair itself can lead to dysregulation that then manifests as symptoms and overall functional decline. One such naturally occurring repair mechanism is the neurotrophic HGF system.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Scientific evidence supporting the neurotrophic HGF system as a naturally occurring repair mechanism is backed by over 30 years of research. MET is one of the most stably expressed genes in the adult human brain and is a signature of a healthy, viable nervous system, In AD, neuronal MET expression is reduced in the brains of participants by approximately 25% and 75% in the frontal cortex and hippocampus, respectively. And although evidence supports the neurotrophic HGF system as an attractive target for combating neurodegenerative diseases with its multimodal mechanism of action, it has proven a difficult drug target. There are approved and in-development gene therapy approaches to increase HGF expression beyond normal physiological levels, but these are limited as potentially viable treatment options for neurological disorders due to more invasive delivery requirements, such as intrathecal or intravenous, or locally restricted to the periphery, such as via intramuscular routes of administration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To date, drug developers have been deploying approaches that typically address only a single factor of the cascade of pathologies that lead to neurodegeneration, yet translating early successful results to meaningful clinical benefit has been mixed if not elusive. We believe that to address such complex and multifactorial diseases requires a novel multimodal approach, such as targeting the neurotrophic HGF system through non-invasive or minimally invasive small molecules that enhance innate levels of HGF system activation to protect and repair neuronal networks.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Mechanism of Action</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have developed a pipeline of proprietary small molecule compounds, or ATH positive modulators, designed to enhance the neurotrophic HGF system and promote its neuroprotective, neurotrophic and anti-inflammatory effects, including protection of neurons from a variety of insults. Our novel small molecules are designed to cross the blood-brain barrier for CNS disorders or remain in the periphery for PNS and other indications, and mechanistically produce a series of multimodal effects that support their therapeutic promise to: reduce inflammation, promote regeneration, provide neuroprotection, and, ultimately, slow disease progression.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Figure 2 below illustrates the hypothesized mechanism of action of ATH positive modulators and the cellular disease state where diseased neurons generate a biomarker of neurodegeneration, NfL, as well as other signature markers of neuronal damage. Contributing to a diseased neuron are also proinflammatory cytokines produced by activated microglia. In the treated neuron state where ATH positive modulators are designed to enhance HGF/MET signaling to promote neuroprotective and neurotrophic pathways, reduced neuron degeneration and NfL production occur while the treated glia show reduced activation and production of proinflammatory cytokines, illustrating the potential reduction in neurodegeneration and inhibition of neuroinflammation through the enhancement of the neurotrophic HGF system.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 2. Hypothesized Mechanism of Action of ATH Positive Modulators.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_1.jpg" alt="img105269759_1.jpg" style="width:624px;height:362px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As ATH positive modulators interact with the HGF system, neurotrophic and neuroprotective pathways are activated downstream, including the activation of the extracellular-signal regulated kinase, or ERK and protein kinase B, or AKT pathways, which play critical roles in protecting neurons from damage and death, including from oxidative stress, excitotoxicity, and apoptosis. Figure 3 below shows cell culture data demonstrating that one of the key mechanisms of action of ATH positive modulators is through activation of ERK and AKT via MET activation.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 3. Enhancement of HGF/MET by Fosgo-AM Activates ERK and AKT Signaling Pathways.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_2.jpg" alt="img105269759_2.jpg" style="width:624px;height:208px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as mean + SEM. Statistics applied: One-way ANOVA with Tukey&#8217;s multiple comparisons.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">** p&lt;0.01; *** p&lt;0.001 vs. HGF only.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">AKT, protein kinase B; ERK, extracellular-signal regulated kinase; Fosgo-AM, fosgonimeton active metabolite; GSK3b, glycogen synthase kinase-3 beta; HGF, hepatocyte growth factor.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Positively modulating the neurotrophic HGF system promotes its multimodal effects, which we believe can potentially address the complex pathology in neurodegenerative diseases. These positive multimodal effects taken together may lead to improvement in function. Figure 4 below illustrates the therapeutic potential of enhancing the neurotrophic HGF system to protect and repair neurons.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 4. ATH Compounds are Designed to Protect and Repair Neuronal Networks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_3.jpg" alt="img105269759_3.jpg" style="width:575px;height:376px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Fosgonimeton</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fosgonimeton is being assessed in multiple preclinical and clinical studies of neurodegenerative diseases, including AD and PD.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fosgonimeton for AD - Clinical Trials and FDA Interaction</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 1 Clinical Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The IND application for fosgonimeton in AD was submitted in September 2017. Since then, we have completed our Phase 1 clinical trial, which enrolled a total of 88 participants, including 48 healthy young male participants (mean age = 33.4 &#177; 6.3), 29 healthy elderly participants (mean age = 63.8 &#177; 4.0; 14 male, 15 female), and 11 AD participants (mean age = 69.2 &#177; 7.1; 5 male, 6 female, median [range] Mini-Mental State Exam, or MMSE, = 20 [5&#8211;29]) was completed in 2019. In both the SAD and multiple ascending dose, or MAD, parts of the trial, fosgonimeton was well tolerated, without serious adverse events. All participants were randomly assigned to active and control groups. Findings from the Phase 1 trial provided safety data, as well as translational and supportive evidence in the form of quantitative electroencephalography, or qEEG, measures to evaluate effects of fosgonimeton on brain activity in study participants. Results from qEEG measures demonstrated fosgonimeton crossing the BBB and improving brain network activity by significantly improved ERP P300 latency, a measure of working memory processing speed, over 8-days. Trial results were published in the Journal of Alzheimer&#8217;s Disease in April 2022, and helped inform the study design of our exploratory Phase 2 ACT-AD and Phase 2/3 LIFT-AD trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 2 ACT-AD Trial*</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ACT-AD was a randomized, double-blind, placebo-controlled, parallel-group 26-week trial evaluating fosgonimeton in participants with mild-to-moderate AD. The trial enrolled 77 participants in the United States and Australia (age 55 to 85 years, MMSE score of 14-24 and Clinical Dementia Rating, or CDR, scale global score of 1 or 2). Participants were allowed to continue receiving background AChEIs; 60% remained on stable doses of AChEIs and 40% were not receiving AChEIs during the study. Participants were randomized 1:1:1 to receive placebo or fosgonimeton at either 40 mg/day or 70 mg/day. The primary endpoint for ACT-AD was ERP P300 latency, a measure of working memory processing speed, measured by change from baseline, or CFB, averaged over Weeks 12, 16, 20, and 26. Secondary endpoints included correlation of CFB in ERP P300 latency with a composite score of cognition and executive memory defined by ADAS-Cog11, and the Controlled Oral Word Association Test, or COWAT; various composite scores of clinical assessments as measured by the GST, Alzheimer&#8217;s Disease Cooperative Study-Clinical Global Impression of Change, or ADCS-CGIC, a measure of global clinical change; and ADCS-ADL23, a measure of functional change as well as measures of caregiver burden, quality of life, resource utilization, and psychiatric symptoms. Plasma samples were also bio banked for future analysis. Safety data was evaluated throughout.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ACT-AD was completed in 2022; topline data was reported in June 2022, later presented at the Alzheimer&#8217;s Association International Conference in August 2022, and in early 2023 was finalized. The finalized data show some numerical differences from the previously reported preliminary topline data, which we had reported were not statistically significant (n.s.). As reported previously, we did not meet the primary endpoint of a statistically significant change in ERP P300 latency by protocoled analysis nor did we meet the secondary endpoints. However, the data showed a numerical improvement in the functional measure of ADCS-ADL23, which evaluates participants&#8217; activities of daily living as assessed by their caregivers, compared to placebo at 26 weeks (41% or +1.7 points improvement, n.s.). Although not statistically significant, a post hoc analysis of results from ACT-AD in a pre-specified subgroup suggested positive effects on measures of working memory processing speed and cognition, plus improvements in plasma biomarkers of neurodegeneration, inflammation and AD-specific protein pathologies in participants taking fosgonimeton alone without background AChEIs. All data and analyses presented are from pooled 40mg and 70mg of fosgonimeton. During the ACT-AD trial, fosgonimeton, at either dose, was generally well tolerated with a favorable safety profile, and there were no treatment related serious adverse events or deaths observed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In participants treated with fosgonimeton alone, a potentially beneficial change in ERP P300 latency (-28 milliseconds, n.s.), as well as cognitive improvement, as measured by ADAS-Cog11 (74% or -3.0 points, n.s.), compared with placebo at 26 weeks was observed post hoc (Figure 5).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 5. Treatment with Fosgonimeton Results in Consistent Directional Improvements in Working Memory Processing Speed and Cognition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_4.jpg" alt="img105269759_4.jpg" style="width:624px;height:234px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Data from ACT-AD were additionally analyzed post hoc for effects across plasma biomarkers in participants treated with fosgonimeton without background AChEIs. In concert with the multimodal mechanism of action, targeting the neurotrophic HGF system with fosgonimeton resulted in directional improvements across plasma biomarkers of inflammation and AD-specific protein pathologies, and a statistically significant improvement in neurodegeneration, all of which are pending further analysis and clinical investigation in our ongoing Phase 2/3 LIFT-AD clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Figure 6 below shows that treatment with fosgonimeton appears to improve neuroinflammation in mild-to-moderate AD as measured by glial fibrillary acidic protein, or GFAP, and chitinase-3-like protein 1, or YKL-40. The observed nominal GFAP improvement and statistical trend in YKL-40 improvement, plus the magnitude of decrease below baseline for those on active treatment is encouraging in this continuously progressive condition and indicates the translation of the anti-inflammatory effects of fosgonimeton.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 6. Treatment with Fosgonimeton Appears to Improve Neuroinflammation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_5.jpg" alt="img105269759_5.jpg" style="width:586px;height:248px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Treatment with fosgonimeton additionally resulted in a statistical trend and directional improvements in plasma biomarkers of AD-specific protein pathologies, A&#946; and pTau, respectively. The changes observed, as shown in Figure 7, continue to support the relevance of targeting the neurotrophic HGF system and its relevance to AD, with a potentially disease-modifying effect by impacting these protein pathologies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 7. Treatment with Fosgonimeton Induces Directional Improvements in Protein Hallmarks of AD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_6.jpg" alt="img105269759_6.jpg" style="width:605px;height:261px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Supportive of the potentially neuroprotective mechanism of action of the neurotrophic HGF system, treatment with fosgonimeton showed a statistically significant improvement in NfL (an objective marker of neurodegeneration) levels, even to the extent of improvement below baseline (Figure 8). This decrease of NfL below baseline levels (-6.49 pg/mL, p=0.0241), is suggestive of repair in this continuously progressive condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 8. Treatment with Fosgonimeton Shows Neuroprotective Effects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_7.jpg" alt="img105269759_7.jpg" style="width:359px;height:300px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">With the potential of fosgonimeton to be both neuroprotective and anti-inflammatory for AD, we assessed the relevance or predictive value of these biomarkers potentially translating to clinical effects. A correlation analysis of NfL and GFAP with the GST, a composite endpoint of cognition (ADAS-Cog11), and function (ADCS-ADL23), and the primary endpoint of our ongoing Phase 2/3 LIFT-AD trial was performed. In Figure 9, scatterplots from the full ACT-AD trial population are shown with the CFB in the GST on the Y axis and on the X axis, CFB in NfL on the left and GFAP on the right, respectively. From this analysis, we showed the statistically significant correlation between clinical and plasma biomarker improvements, and despite the limited trial size, these data support the interpretation of the clinical results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 9. Decreases in Disease-State Biomarkers Significantly Correlate with Improvements in Cognitive and Functional Measures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_8.jpg" alt="img105269759_8.jpg" style="width:624px;height:277px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consistent clinical effects and plasma biomarker data from this exploratory Phase 2 ACT-AD trial clinical effects and plasma biomarkers continue to support the multimodal mechanism of action by enhancing the neurotrophic HGF system through fosgonimeton and suggests that fosgonimeton may have potential benefit for Alzheimer&#8217;s patients.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 2/3 LIFT-AD Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">LIFT-AD is a randomized, double-blind, placebo-controlled, parallel-group 26-week Phase 2/3 clinical trial with fosgonimeton for the treatment of mild-to-moderate AD. In September 2020, we began site initiation and patient screening. The primary endpoint for LIFT-AD will be measured by the GST, which is a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23). Guided by the results from the completed exploratory Phase 2 ACT-AD trial, in September 2022, we proactively amended LIFT-AD to focus on participants not on background AChEIs. An unblinded adjudication of drug safety was performed by the drug safety monitoring board, which resulted in no serious adverse findings to date for both participants on or off background AChEIs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">An independent DMC consisting of one neurologist and two biostatisticians, performed an unblinded efficacy and futility interim analysis using a 2011 published method by Mehta and Pocock. This adaptive method enables a sample-size re-estimation using actual observed interim data based on our co-key secondary endpoints, ADAS-Cog11 and ADCS-ADL23, which these two endpoints inform our primary endpoint, GST.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pre-specified constraints were protocolled in the interim SAP which consisted of a sample size range with a maximum enrollment limit, and a minimum target power. The formal efficacy analysis was then based on approximately 100 completers at week 26 (end of the double-blind treatment period) without background AChEIs. The primary analysis used was a mixed model for repeated measures, or MMRM, to compare the CFB in the GST between fosgonimeton treatment and placebo. Two potential outcomes were also pre-specified: 1) to stop the study for futility or 2) to continue the enrollment within the pre-specified range to achieve an adequate target power for the primary endpoint.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Following this interim analysis, the DMC recommended to &#8220;continue LIFT-AD study&#8221; and also determined that, with the additional enrollment of fewer than 150 participants for a total enrollment of less than 300 participants without background AChEIs, the study will be well-powered for the primary endpoint given the preliminary effect size observed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Figure 10 below shows the pre-specified decision framework and potential outcomes for the primary GST composite endpoint of cognition (ADAS-Cog11) and function (ADCS-ADL23). The shaded area in grey was pre-determined as the futility zone where the recommended sample size would exceed Athira's pre-specified maximum and shaded in green are the GST combinations resulting in a recommendation from the DMC to continue the study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 10. Independent DMC Recommends to Continue LIFT-AD after Unblinded Interim Analysis Using a Published Methodology and Pre-Specified Decision Framework.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_9.jpg" alt="img105269759_9.jpg" style="width:624px;height:249px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Conducted by DMC: Chair neurologist (MD) and two biostatisticians (PhD); </span><span style="color:#a6a6a6;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Arial;min-width:fit-content;">1</span><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Primary endpoint is the global statistical test, an unweighted composite of ADAS-Cog11 and ADCS-ADL23. AD, Alzheimer&#8217;s disease; ADAS-Cog11, Alzheimer&#8217;s Disease Assessment Scale&#8211;Cognitive Subscale; ADCS-ADL23, Alzheimer&#8217;s Disease Cooperative Study&#8211;Activities of Daily Living; DMC, data monitoring committee.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The results from the DMC unblinded analysis give us confidence in a potentially positive outcome for LIFT-AD. Stringent evaluation criteria were applied based on validated and clinically meaningful cognitive and functional outcomes, which support the potential clinical benefits and underscores the rationale for continued development of fosgonimeton.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In May 2023, we amended the LIFT-AD trial to focus ongoing enrollment and the primary analysis on the 40 mg dose versus placebo. Enrollment of the 70 mg arm of the trial was discontinued. The dose selection was based on a review of the totality of the data across preclinical and clinical studies, observations from the OLEX and in consultation with independent regulatory and biostatistical experts based on patients treated with 40 mg fosgonimeton without concomitant AChEIs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2023, we completed an end of Phase 2 meeting with the FDA to gain alignment on our plans for the continued clinical development of fosgonimeton as a potential treatment for mild-to-moderate AD. We provided an update and discussed with the FDA the ongoing LIFT-AD trial including use of the 40 mg dose, concomitant AChEI use, biomarker analyses including NfL, and the SAP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The LIFT-AD trial is ongoing with the completion of enrollment announced in January 2024 and topline data expected in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Open Label Extension Trial*</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2021, we announced that we are enrolling patients into an optional 26-week OLEX for our LIFT-AD and ACT-AD clinical trials. In May 2022 and again in May 2023, we announced extensions of the 26-week OLEX for our LIFT-AD and ACT-AD clinical trials for a total of 24 additional months. These extensions enable eligible participants who have completed either trial, and elect to participate in the ongoing OLEX, to now receive up to 30 months of open-label treatment with fosgonimeton, which will allow us to collect up to a total of three years of safety data with fosgonimeton. As of year-end 2023, greater than 85% of patients who have completed either study have elected to participate in the OLEX and currently more than 60 patients have continued on OLEX beyond 18 months of investigational treatment.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">*The ACT-AD trial and the related OLEX for ACT-AD participants have been supported by a grant from the National Institute on Aging of the National Institutes of Health under Award Number R01AG06268. The information presented is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fosgonimeton for PD</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In PD-relevant cellular and animal models, treatment with fosgonimeton or fosgo-AM demonstrated significant neuroprotective, neurotrophic and motor function improvements. Data supporting these findings were presented at the Society for Neuroscience Annual Conference in November 2022, the American Society for Experimental Neurotherapeutics Annual Meeting in March 2023, and at the AD/PD Conference in March 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fosgo-AM significantly protected against neurotoxic insults and minimized PD-related toxic protein buildup in neuron-based models of disease. Figure 11 below shows results from cell models of PD exposed to the neurotoxin rotenone. Tyrosine hydroxylase, or TH+, staining in green identifies dopaminergic neurons, the neurons primarily affected in PD, and &#945;-synuclein staining in red identifies the toxic aggregates found in PD pathology. The leftmost image shows cultures not exposed to rotenone toxin where TH+ dopaminergic neurons are abundant with robust neurites and minimal accumulation of &#945;-synuclein within the cell. In the rightmost image, treatment with fosgo-AM significantly preserved the number of healthy dopaminergic neurons and reduced toxic &#945;-synuclein aggregation in rotenone-toxic conditions, compared to the middle image showing cultures exposed to rotenone but treated with vehicle only. Quantification of fosgo-AM effects on reducing rotenone-induced dopaminergic neuron death and &#945;-synuclein aggregation are shown in the bar charts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 11. Fosgo-AM Reduces &#945;-synuclein Aggregation and Protects Dopaminergic Neurons from Degeneration Induced by the Neurotoxin Rotenone in Primary Mesencephalic Neurons.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_10.jpg" alt="img105269759_10.jpg" style="width:624px;height:239px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as mean + SEM. Statistics applied: 1-way ANOVA with Fisher least significant difference test. ***p&lt;0.001 versus Rotenone Control. Scale bar = 100 &#956;m. n=5-6 per group</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#945;-syn; alpha synuclein; fosgo-AM, fosgonimeton active metabolite; TH, tyrosine hydroxylase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Cellular improvements translated to improvements in motor function in several behavioral assessments, including improved coordination, balance and strength. Figure 12 below are two examples of improved motor function in a 6-hydroxydopamine, or 6-OHDA, rat model of PD, where treatment with fosgonimeton rescues muscular strength in the grip test, balance and coordination deficits in the rotarod test.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 12. Fosgonimeton Rescues Grip Strength and Balance and Coordination Deficits in a Rat Model of PD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_11.jpg" alt="img105269759_11.jpg" style="width:624px;height:286px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#a6a6a6;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as means &#177; SEM. Statistics applied: 2-way ANOVA with Dunnett test. Statistical significance indicated with * represent sham control versus disease control; # represent fosgonimeton versus disease control. For all symbols: *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001 versus disease control.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">6-OHDA, 6-hydroxydopamine.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Exploratory Phase 2 SHAPE Trial</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The exploratory Phase 2 clinical trial, SHAPE, tested 40 and 70 mg fosgonimeton doses versus placebo in PDD and DLB.  The trial enrolled 28 participants and we reported topline results in December 2023.  The primary endpoint of the trial, a composite score of the change in ERP P300 latency and cognitive assessment (ADAS-Cog13), was not met by protocoled analysis compared with placebo.  Directionally positive results were observed for the 40 mg fosgonimeton dose group with improvements in cognitive, functional and biomarker measurements.  In particular (see Figure 13 below), the five patients in the mITT population treated with fosgonimeton 40 mg once daily saw improvement in ADAS-Cog13 individually, and collectively improved compared with placebo (n=7 mITT, one-sided p=0.0321).  Results for patients in the 70 mg dose group were inconsistent.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 13. ADAS-Cog13 Score Change from Baseline in mITT Population.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_12.jpg" alt="img105269759_12.jpg" style="width:562px;height:349px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#a6a6a6;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;">ADAS-Cog13: Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale 13-item version; CI: Confident Interval; Baseline is defined as the mean of the pre-dose measurements. Multiple efficacy assessments are averaged if they fall at the same visit.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe the totality of the preclinical and clinical evidence supports continued testing of neurotrophic HGF system modulators in PD. In the future we will consider how best to progress fosgonimeton or another of our neurotrophic HGF system modulators in clinical testing for this complex disease.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ATH-1105</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">ATH-1105 Preclinical Evidence for ALS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ATH-1105 is a novel oral small molecule drug candidate being assessed as a potential treatment for ALS. In a spinal motor neuron model, ATH-1105 significantly protected against neuron death by glutamate-induced excitotoxicity, while reducing pathological aggregation of TAR DNA-binding protein 43, or TDP-43. Figure 14 summarizes the data with images of microtubule-associated protein-2, or MAP-2-labeled spinal motor neurons in green, and extranuclear TDP-43 in red. In the control image on the left with no excitotoxic insult (glutamate), there is minimal overlap of MAP-2 neurons with extranuclear TDP-43. When glutamate is applied to the motor neuron cultures, there&#8217;s an overall reduction in the number of neurons and increased extranuclear TDP-43 as shown by overlapping red-green staining in the middle image. When cell cultures were treated with ATH-1105, the effect of glutamate-induced excitotoxicity on the overall number of motor neurons and extranuclear TDP-43 protein aggregation was significantly reduced, as seen in the rightmost image and as quantified in the bar graphs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 14. ATH-1105 is Neuroprotective Against Excitotoxic Insult and Reduces Extranuclear TDP-43 Levels in Spinal Motor Neurons.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_13.jpg" alt="img105269759_13.jpg" style="width:624px;height:251px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as mean + SEM. Statistics applied: 1-way ANOVA with Fisher least significant difference test. *p&lt;0.05; **p&lt;0.01;  ***p&lt;0.001 versus Glutamate Control. Scale bar: 100 &#181;m. n=5-6 per group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">MAP-2, microtubule-associated protein-2; TDP-43, TAR DNA-binding protein 43.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Plasma biomarkers of inflammation and neurodegeneration were significantly reduced following treatment with ATH-1105 in a transgenic TDP-43-driven mouse model of ALS (Figure 15). These results support the anti-inflammatory and neuroprotective effects of ATH-1105 through enhancement of neurotrophic HGF system signaling. In the TDP-43-driven ALS model, significant increases in the proinflammatory cytokines tumor necrosis factor alpha, or TNF-alpha, and interleukin 6, or IL-6, were observed compared to healthy wild-type, or WT, control animals. When ALS-model mice, or ALS mice, were treated with ATH-1105 significant reductions in both TNF-alpha and IL-6 were observed, demonstrating anti-inflammatory activity. Consistent with the neuroprotective effects demonstrated in cell-based models, a significant reduction in plasma levels of the neurodegeneration biomarker, NfL, was observed in ALS mice treated with ATH-1105, which is indicative of neuroprotection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 15. ATH-1105 Improves Biomarkers of Inflammation and Neurodegeneration in a Mouse Model of ALS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_14.jpg" alt="img105269759_14.jpg" style="width:526px;height:175px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Graphical representation of plasma IL-6, TNF-&#945; in fold-difference over the WT + vehicle group, and NfL levels in ng/ml at two months of treatment. N=10 per group. Data presented as mean &#177; SEM. Statistical significance was determined by 1-way ANOVA with the Dunnett&#8217;s test versus ALS + vehicle. ****p&lt;0.0001.</span><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">ALS, amyotrophic lateral sclerosis; IL-6, interleukin 6; NfL, neurofilament light chain; TNF-&#945;, tumor necrosis factor alpha; WT, wild-type.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Treatment with ATH-1105 in a mouse model of ALS protected against axon degeneration and demyelination as observed from histological examination of cross-sections of the sciatic nerve. Figure 16 below includes an image of the sciatic nerve from a WT healthy control animal, on the left, featuring a large number of large diameter axons surrounded by a consistent and highly regular coating of myelin sheath. In the middle, a sciatic nerve image from an ALS disease control animal is shown, where a marked reduction in the number of axons, a decrease in average axon diameter, and irregular myelination is observed. On the right, when ALS animals are treated with ATH-1105, sciatic nerve integrity is preserved with a greater population of large diameter axons and preservation of regular myelination. Graphs below the images are quantified data showing these effects of ATH-1105 in a mouse model of ALS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 16. Treatment with ATH-1105 Protected Against Axon Degeneration and Demyelination in a Mouse Model of ALS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_15.jpg" alt="img105269759_15.jpg" style="width:521px;height:332px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Histology images of sciatic nerve cross-sections stained with toluidine blue to label myelin. Scale is 10 &#956;m (all panels). Graphical representation of the number of axons (per 100 &#181;m2), axonal diameter (in micrometers), and mean of myelin g-ratio, defined as the ratio of the inner axonal diameter to the total axonal diameter, following two months of treatment. Data presented as mean + SEM. Statistical significance was determined by 1-way ANOVA with the Dunnett&#8217;s test versus ALS + vehicle. ****p&lt;0.0001.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">ALS, amyotrophic lateral sclerosis; WT, wild-type.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further analyses of electrophysiological and behavioral assessments indicated the protection of the motor neurons with ATH-1105 translated to improved nerve and motor function (Figure 17). Compound muscle action potential, or CMAP, and nerve conduction velocity, or NCV, are two electrophysiological measures of functional nerve signaling. Treatment with ATH-1105 in a mouse model of ALS demonstrated consistent and significant improvements of nerve function compared to ALS disease control animals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Two examples of motor function improvements are shown by the rotarod, an assessment of balance and coordination, and the grip test, an assessment of strength. ALS disease control animals showed significant motor impairments compared to WT healthy control animals. ATH-1105 treatment in this mouse model of ALS led to significant improvements in both the rotarod and grip tests compared to the vehicle treated ALS disease control animals, demonstrating preservation of motor function. Other motor behavior tests assessing balance, coordination and muscle strength were the balance beam and Kondziela screen tests. Across all motor function measures, significant improvements were seen in ALS animals treated with ATH-1105 compared to ALS animals treated with vehicle.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 17. Treatment with ATH-1105 Improves Nerve and Motor Function in a Mouse Model of ALS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_16.jpg" alt="img105269759_16.jpg" style="width:468px;height:470px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Graphical representation of CMAP amplitude, NCV, rotarod latency, and grip strength at baseline and after one and two months of treatment. Data presented as mean &#177; SEM. Statistical significance was determined by 2-way ANOVA with the Dunnett&#8217;s test versus ALS + vehicle. **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. N=10 per group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">ALS, amyotrophic lateral sclerosis; CMAP, compound muscle action potential; NCV, nerve conduction velocity; WT, wild-type.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The above study results, depicted in Figure 17, were presented at the American Academy of Neurology, or AAN, in April 2023, and the ALS Drug Development Summit in May 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Treatment with ATH-1105 in a mouse model of ALS extends survival and improves other disease-related measures. Figure 18 below compares ALS mice treated with oral ATH-1105 20 mg/kg once daily in blue with oral vehicle once daily treated ALS mice in red. Mice were treated from one month of age to a humane endpoint maximum of five months of age, for a total of up to four months of treatment. ATH-1105 increased time to first mortality and significantly prolonged survival compared to ALS disease control animals (p=0.0035). ATH-1105 also significantly protected against body weight reduction (p&lt;0.01). These findings were reported at the AAN 2023 Annual Meeting in April 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 18. ATH-1105 Significantly Improved Survival in a Mouse Model of ALS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_17.jpg" alt="img105269759_17.jpg" style="width:431px;height:293px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as Kaplan-Meier curve</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Statistics applied: Log-rank (Mantel-Cox) test for survival curve comparison, **p&lt;0.01. n=20 mice per group at start</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Treatment with ATH-1105 in a mouse model of ALS outperforms treatment with riluzole under the conditions tested in assessments of motor function, nerve function, and in reducing disease-related plasma biomarkers. Figure 19 below compares performance in the grip test of WT mice (grey) and transgenic ALS mice treated daily with vehicle (red), intraperitoneal riluzole 5 mg/kg (green), oral ATH-1105 20 mg/kg (blue), or both ATH-1105 and riluzole (purple). Mice treated with ATH-1105 alone and co-administration of riluzole and ATH-1105 consistently outperformed the vehicle-treated ALS disease control group. In both the ATH-1105 and the co-administration of ATH-1105 and riluzole groups, performance on the test approached that of the WT healthy control group. ATH-1105 treatment outperformed riluzole treatment in tests of motor function including the grip, rotarod, Kondziela screen, and balance beam tests. ATH-1105 also outperformed riluzole in tests of nerve function preservation including CMAP amplitude and NCV. ATH-1105 treatment further reduced plasma levels of IL-6 and TNF-alpha compared to riluzole, which are biomarkers of inflammation. ATH-1105 treatment also more greatly reduced plasma levels of NfL compared to riluzole, which is a biomarker of neurodegeneration. These findings were reported at the Northeast ALS Consortium meeting in October 2023, and the Motor Neurone Disease Association conference in December 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 19. ATH-1105 Preserves Motor and Nerve Function and Reduces Plasma NfL Compared with Riluzole in a Mouse Model of ALS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_18.jpg" alt="img105269759_18.jpg" style="width:624px;height:297px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Graphical representation of change from baseline following two months of treatment in grip test, CMAP amplitude, and Plasma Nfl. Data presented as mean &#177; SEM, or box-and-whisker plots</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Statistics applied: One-way ANOVA with Dunnett&#8217;s test. *p&lt;0.05; **p&lt;0.01; *** p&lt;0.001; **** p&lt;0.0001. n=10 mice per group;  Abbreviations: CFB, change from baseline, CMAP, compound muscle action potential, NfL, neurofilament light chain</span><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Clinical Development Plan for ATH-1105 in ALS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Weight loss, motor deficits, inflammatory effects, loss of muscle integrity, nerve degeneration and demyelination are all classical hallmarks of disease in people with ALS; treatment with ATH-1105 significantly improved all of these deficits preclinically. We expect to submit an IND application to the FDA and commence ATH-1105 clinical testing in healthy volunteers in the first half of 2024. In this single ascending dose and multiple ascending dose, or SAD/MAD, Phase 1 trial, we expect to evaluate and establish safety and determine one or more doses for further potential testing in ALS patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ATH-1020</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">ATH-1020 Preclinical Evidence for Neuropathic Pain</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ATH-1020 is a novel, orally available, next generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system. Enhancing HGF/MET signaling promotes neuroprotective, neurotrophic, and anti-inflammatory effects, and as neuropathic pain disorders, including diabetic neuropathy, or DNP, have components of oxidative stress, nerve damage, and inflammation, positive modulation of the HGF/MET pathway may provide therapeutic benefit in these disease areas. Data below were presented at the Society for Neuroscience Annual Conference in November 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This compound was originally assessed for neuropsychiatric indications in preclinical models as presented at the American Society for Experimental Therapeutics Annual Conference in February 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In animal models of DNP hypersensitivity to mechanical and thermal pain are commonly experienced, which are also representative of symptoms in people with neuropathic pain. Shown in Figure 20 below, treatment with ATH-1020 significantly reduced pain behaviors over the testing period compared to DNP controls alone.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 20. Reduced Mechanical and Thermal Pain-Related Behaviors Following ATH-1020 Treatment in a Rat Model of Diabetic Neuropathic Pain.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_19.jpg" alt="img105269759_19.jpg" style="width:599px;height:204px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as means + SEM. ****p&lt;0.0001 using one-way ANOVA with Dunnett test vs DNP control.</span><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">ANOVA, analysis of variance; AUC, area under the curve; DNP, diabetic neuropathic pain; PWL, paw withdrawal latency; PWT, paw withdrawal threshold.</span><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Persistence of reduced pain behaviors following ATH-1020 treatment were assessed after a short-term (23-hour) or a long-term (7-day) washout period. Study results demonstrated that even after short- and long-term washout periods, where no drug is present, the effects of ATH-1020 reduction of pain behaviors remained persistent, suggesting a potential disease modifying effect (Figure 21).</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 21. Persistent Pain Reduction after 7-day Washout Following ATH-1020 Treatment.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_20.jpg" alt="img105269759_20.jpg" style="width:591px;height:193px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Data presented as means + SEM. *p&lt;0.05; **p&lt;0.01; ****p&lt;0.0001 using one-way ANOVA with Dunnett test vs DNP control.</span><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#a6a6a6;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">ANOVA, analysis of variance; AUC, area under the curve; DNP, diabetic neuropathic pain; PWL, paw withdrawal latency; PWT, paw withdrawal threshold.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">ATH-1020 Clinical - Phase 1 Trial in Healthy Volunteers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We filed an IND application with the FDA for ATH-1020 at the end of 2021 and received notice of acceptance in January 2022. In September 2022, we completed the single-ascending dose escalation portion of the Phase 1 trial. ATH-1020 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers. We plan to evaluate options with this drug candidate for future testing in either neuropathic pain or other neurodegenerative diseases.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Market Opportunity</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">AD and Dementia</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe fosgonimeton has the potential as a viable treatment option across all stages of AD but is initially being developed for mild-to-moderate stage of disease. Stages of this progressive disorder start with mild cognitive impairment, or MCI, mild AD, moderate AD, and finally severe AD. The AD dementia market, as last reported in 2023, consists of approximately 6.7 million Americans age 65 and older and is projected to reach nearly 13 million by 2050 in the U.S. alone. Worldwide, as many as 55 million people are estimated to have AD and other dementias, and this number is projected to grow to nearly 140 million by 2050. AD may account for an approximate 60-70% of all diagnosed dementia cases, however, with the continued innovation of diagnostic approaches coupled with better understanding of the disease pathology, diagnosis of AD and overall cases could continue to grow.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As shown in Figure 22 below, our initial focus is on mild-to-moderate AD as this stage has been identified where disease may progress rapidly and currently available therapies are few with only modest effects. Currently 81% of all diagnosed cases of AD are mild-to-moderate, and with many new therapies under development targeting earlier stages in AD, this is a highly underserved population with a high unmet need. Fosgonimeton is initially being developed for mild-to-moderate AD, but as we continue to advance fosgonimeton, and with our multimodal mechanism of action, we believe we will have the opportunity to address all stages of AD as well as expand into other dementias.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Figure 22. Significant Opportunity for Fosgonimeton in AD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_21.jpg" alt="img105269759_21.jpg" style="width:623px;height:237px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Target Indications</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our next potential target indications for our small molecule positive modulators include PD, ALS and neuropathic pain. PD is the second most common neurodegenerative disease after AD with a prevalence of nearly one million people and more than 10 million people in the United States and worldwide living with PD, respectively. Growth projections of United States cases of PD are expected to reach 1.2 million in the United States by 2030.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">An estimated 16,000 Americans are affected with ALS while global estimates exceed 150,000 (1.9 per 100,000 to 6 per 100,000). Currently, there are only four approved drugs that are specifically indicated for the treatment of ALS, of which none target neurotrophic factor systems with a multimodal mechanism of action with the potential to offer neuroprotective, anti-inflammatory and potentially disease modifying effects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Potential Commercialization Plan</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fosgonimeton is our proprietary, potentially first-in-class small molecule drug candidate designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the CNS, and is initially being developed in mild-to-moderate AD. For this patient population, our commercialization strategy will consider the following key elements:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential first-line therapy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">an add-on therapy for patients on existing therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a therapeutic option for patients who are not suitable for AChEIs; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a therapeutic option for patients who have stopped AChEIs due to loss of effect or side effects.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will initially target launching fosgonimeton in the US with plans to expand into the European Union, or EU, and Asian markets as part of our global strategy. Beyond our regional launch plans, and because of our multimodal mechanism of action, we also expect to advance fosgonimeton beyond the mild-to-moderate AD stage into both earlier and later stages of disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We aim to establish the potential value of fosgonimeton by demonstrating improvement in cognition, independence, and markers of neurodegeneration, inflammation and AD protein pathology, which could result in improved outcomes and reduced total healthcare costs for this progressive and potentially fatal disease.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are focused on the development of small molecule therapeutics which enables us to use well-established and widely available manufacturing processes and infrastructure, formulation compositions, and drug administration technologies or devices. We do not currently operate our own facilities for manufacturing, storing, or distributing our drug candidates. We utilize third-party contract development and manufacturing organizations, or CDMOs, to manufacture and supply our preclinical and clinical materials during the development of our drug candidates. We and various regulatory bodies have audited the CDMOs we contract with, and they have a proven track record of FDA-compliant manufacturing with an infrastructure to support both clinical supplies and subsequent large and commercial scale manufacturing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have a robust fosgonimeton clinical supply chain to ensure sufficient supply for our LIFT-AD Phase 2/3 clinical trial in AD and the open-label extension of our LIFT-AD and ACT-AD clinical trials. We believe the synthesis of fosgonimeton is reliable and reproducible and the synthetic routes can be further optimized to enable large-scale production that continues to avoid use of toxic materials or specialized equipment or handling during the manufacturing process. We continue to optimize the manufacturing process to support future large-scale and commercial supply. Fosgonimeton is purified as a stable solid and then released to additional CDMOs for formulation and packaging into final drug product for use in clinical testing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The final drug product profile is a ready-to-use pre-filled syringe with a clear, non-viscous aqueous solution of fosgonimeton. The syringes utilize materials and components that are readily available commercially. The fosgonimeton drug product has shown extended stability (at least two years) in the proposed prefilled syringe supporting use of the drug product under refrigerated conditions as well as short-term dispensation and at-home storage in ambient conditions. Room temperature short-term storage allows patients to avoid cumbersome storage requirements and reduces overall burden.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We plan to maintain our focus to identify and develop small molecule drug candidates that are expected to have cost-effective manufacturing using third party CDMOs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to use similar contract resources for commercialization of our drug candidates, at least until our resources and operations are at a scale that potentially justifies investment in internal manufacturing capabilities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The biotechnology and biopharmaceuticals industries are characterized by rapid technological advancement, significant competition, and an emphasis on intellectual property. As a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and slow neurodegeneration, with our most advanced drug candidate focused on the treatment of AD, we face, and in the future may face, increased competitive pressures from both large and small pharmaceutical companies and from established and emerging biotechnology companies, as well as academic, government, and public and private research institutions. Any drug candidates that we successfully develop and commercialize will compete with current treatments and new treatments that may become available in the future. With the advancement of fosgonimeton as a novel small molecule therapeutic that positively modulates the neurotrophic HGF system, we must consider companies as competitors who are developing other novel approaches, including those that target other neurotrophic systems to address AD and other neurological diseases. Additionally, because fosgonimeton is being advanced as a once daily liquid formulation for subcutaneous delivery, we must also consider as competitors companies developing AD therapies as subcutaneous or other routes of administration, including oral formulations, and dosing frequency.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Because of the range of potential competitors, many of our competitors, alone or with strategic partners, have greater access to financial resources, market presence, and resources and expertise in development, preclinical and clinical testing, manufacturing, commercialization, the regulatory approval process, or marketing and sales than we do. In addition, these same competitors, who may be in a clinical development stage, could also be competing with us for patient recruitment, clinical research organization, and operational resources. These entities also compete with us in the recruitment and retaining of qualified scientific and management personnel, as well as the acquisition of enabling or complementary technologies for advancing fosgonimeton across all competitors. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, more convenient or less expensive than our comparable drug products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our drug candidates. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of other treatments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The AD market is experiencing a significant transformation where innovation and drug approvals have been limited for nearly 20 years. With the approval of two new monoclonal antibody therapies since 2021 (Biogen&#8217;s Aduhelm and Biogen/Eisai&#8217;s Leqembi), the potential approval of Eli Lilly's Donanemab this year, and the increased attention on novel approaches to AD, we are focused on strategically positioning ourselves in the evolving landscape to maximize our competitive advantage. Key competitive forces that could potentially affect the success of our drug candidates, if approved, are safety, efficacy, price, adoption, convenience, time-to-market, level of promotional activity, intellectual property protection, and reimbursement likelihood from government and private payors. Despite these forces, we view our competitive advantage in not only our lead drug candidate, fosgonimeton, but also our novel pipeline of therapeutics targeting the neurotrophic HGF system with a focus on overall neuronal health. In particular, the following summarizes certain categories of our potential competition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our direct competitors can potentially be viewed through two different lenses &#8211; stage of disease and mechanism of action, or MOA. While the AD space has just recently seen two new approvals specifically addressing earlier stages of disease, MCI and mild AD, limited options exist for the mild-to-moderate disease stage. Companies developing therapies for mild-to-moderate AD, such as AB Science, Annovis Bio, Biomed Industries, BioVie Pharma, or Cassava Sciences, may emerge as direct competitors if they are quicker to market, demonstrate superior clinical effects, are safe and offer treatment options to our same initial target patient population.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Monoclonal antibody therapies have been the focus of drug developers over the past several decades, and though the recent approval of Leqembi provides an option for those in early AD, more novel approaches and treatment options are needed. Through the MOA lens, companies developing non-amyloid, non-tau, or NANT, therapies may be direct competitors as well. Companies developing NANT therapies include those targeting other neurotrophic systems such as Alzecure, anti-inflammation such as AB Science, translational inhibitors such as Annovis Bio, and several other companies developing assets with novel targets like Cassava Sciences and BioVie Pharma.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Specific to targeting HGF/MET however, we are not aware of any direct competitors currently developing small molecules targeting the neurotrophic HGF system for neurological conditions. We are aware of several companies developing HGF/MET-directed therapies for other disease indications, including ANG-3777, an HGF mimetic, developed by Angion for the treatment of kidney injury; KP-100, a recombinant HGF protein, developed by Kringle Pharma for acute spinal cord injury and ALS; and Collategene developed by Mitsubishi Tanabe and AnGes as a gene therapy for the treatment of critical limb ischemia. Although ANG-3777 was reported to not have reached primary endpoints for their Phase 2 and 3 trials in 2021, the scientific basis remains unchanged, and the company is evaluating next steps for the program. KP-100 is currently in Phase 3 studies for acute spinal cord injury and Phase 2 studies for ALS. Collategene was launched in Japan in the third quarter of 2019. In addition, we are aware of VM-202, a regenerative plasmid DNA therapy candidate in Phase 3 development by Helixmith for the treatment of diabetic peripheral neuropathy and diabetic foot ulcers. VM-202 is in Phase 2 trials for Claudication and ALS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fosgonimeton has the potential to offer neuroprotective and anti-inflammatory effects by targeting the HGF/MET system. Our preclinical and clinical data have demonstrated this multimodal approach may have positive benefits across several biological and clinical measures. While several potential direct competitors may exist, we have not yet identified any competitive asset that has demonstrated consistent and congruent positive effects offering neuroprotection, anti-inflammation, reducing disease-specific protein pathologies, neurotrophic, and functional benefits. AD is a complex multifactorial disease, and we view our opportunity with fosgonimeton as potentially complementary to several approaches, including the recently approved monoclonal antibody therapies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own or have in-licensed numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of our drug candidates, including related manufacturing processes and technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, our patent portfolio includes our exclusively owned intellectual property, including one issued U.S. patent, four pending U.S. patent applications, six issued patents in jurisdictions outside of the United States (not including certain European country validations or other registrations), forty-four pending patent applications in jurisdictions outside of the United States, and six pending international patent applications filed under the Patent Cooperation Treaty. The patents and patent applications issued and pending outside the United States are counterparts to the foregoing U.S. patents and patent applications and are generally held in Europe, Canada, Japan, Argentina, Australia, Brazil, China, Hong Kong, India, New Zealand, Singapore, South Africa, South Korea and Taiwan. Our owned patents and patent applications have claims directed to fosgonimeton and our other small molecule drug candidates, including ATH-1020 and ATH-1105, as compositions of matter and methods of use thereof. Our patent portfolio also includes seven issued U.S. patents and nine patents issued in jurisdictions outside of the United States (not including European country validations) that are exclusively licensed to us by WSU. Our in-licensed patents include, among others, claims directed to dihexa, the active metabolite of fosgonimeton, and its use.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Individual patents are in force for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are in force for 20 years from the earliest nonprovisional filing date. In addition, in certain instances, a patent term can be adjusted or extended to recapture a portion of the term effectively lost as a result of the United States Patent and Trademark Office, or USPTO, delay or the FDA regulatory review period (a patent term adjustment or patent term extension, respectively). The restoration period for FDA delay cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest nonprovisional filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. Our in-licensed issued patents will expire on dates ranging from 2027 to 2035, exclusive of any patent term adjustment or patent term extension. Our owned issued patents will expire in 2037, exclusive of any patent term adjustment or patent term extension. If patents are issued on our owned pending non-provisional patent applications, the resulting patents are projected to expire on dates ranging from 2037 to 2043, exclusive of any patent term adjustment or patent term extension.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">When appropriate, we seek to protect aspects of our technology and business not amenable to, or that we do not consider appropriate for, patent protection as trade secrets. We seek to protect this intellectual property, in part, as trade secrets, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators, and advisors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We seek trademark protection in the United States and in certain other jurisdictions where available and when we deem appropriate. Our trademark portfolio includes issued trademark registrations for Athira Pharma and other pending trademark applications in the United States and internationally.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our Collaboration and Grant Agreements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Amended and Restated WSU License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are party to an amended and restated exclusive license agreement with sublicensing terms with WSU that we entered into in 2015. Under this agreement, we have an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The initiation of our first Phase 2 clinical trial in September 2020 triggered a $50,000 liability to WSU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may also be obligated to pay to WSU the following if the related milestones are reached:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$300,000 &#8211; At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$600,000 &#8211; Marketing approval in the United States, European Union or Japan for the first licensed product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are obligated to pay WSU a royalty in the mid-single digits of net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, under the agreement we have the right to sublicense the licensed rights, subject to additional payments to WSU for sublicense consideration received. Such amounts are dependent on the terms of the underlying sublicense, and range from the mid-single digits to mid tens of any non-sales based payments received, and low twenties of net sales-based sublicense royalties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The term of the agreement will continue until the earlier of (1) the date that no valid claim in a licensed patent remains enforceable and (2) payment of earned royalties, once such payments begin, ceases for more than four consecutive calendar quarters. We have not yet commenced payment of royalties to WSU pursuant to the terms of the agreement, since, as of the date of this report, we do not have any approved products with respect to which we may generate revenue. If any of our drug candidates to which the patents relate are approved for commercial sale, our obligations to pay royalties would commence upon net sales of such approved drug candidates and cease no later than the date that no valid claim in a licensed patent remains enforceable. We may terminate this agreement with 90 days&#8217; prior written notice to WSU. WSU may terminate this agreement with 90 days&#8217; prior written notice if we fail to achieve certain performance milestones by the agreed upon dates. WSU may also terminate this agreement with 90 days&#8217; prior written notice (or thirty days&#8217; prior written notice in the case of our failure to make a timely payment owed to WSU) following our failure to conduct certain development activities for two consecutive calendar quarters or upon</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our material breach of the agreement and our failure to cure any such breach within 90 days of our receipt of notice of such breach from WSU (or within 30 days in the case of our failure to make a timely payment owed to WSU).</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">National Institutes of Health Grant</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2020, we accepted a grant from the National Institute on Aging, or NIA, of the National Institutes of Health, or NIH, to support our ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), our lead drug candidate being developed for the treatment of individuals with mild-to-moderate AD. Under the terms of the agreement and approval received from the NIH, we were awarded an aggregate of $15.2 million, all of which had been received as of December 31, 2023. Post award, we received approval from NIA to use these grant funds to support our open label extension of the ACT-AD trial. As this grant involves federally funded research, per the Bayh-Dole Act of 1980, or the Bayh-Dole Act, we are obligated to (1) report each new invention to the government, (2) decide whether to retain ownership, (3) file for patent protection to retain title, and (4) provide a license to the government to practice the invention. The &#8220;march-in&#8221; rights provided by the Bayh-Dole Act would apply to new subject matter arising from the use of the NIH funds, but would exclude pre-existing subject matter such as our drug candidates existing prior to the receipt of such grant. We also are expected to commercialize any inventions we file patent protection on for the benefit of public health. For more information see the section of this report titled &#8220;Risk Factors&#8212;Risks Relating to Our Intellectual Property. Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Government authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, nonclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrate the drug&#8217;s quality, safety, and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">U.S. Drug Development Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s good laboratory practice, or GLP, requirements and other applicable regulations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">approval by an independent institutional review board, or IRB, ethics committee, either centralized or with respect to each clinical site, before each clinical trial may be initiated; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice, or cGMP, requirements to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity, and of selected clinical investigation sites to assess compliance with GCPs; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">studies assessing the toxicology, pharmacology, and PK/PD characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which may review data and endpoints at designated check points, make recommendations or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a clinical trial may move forward at designated check points based on access to certain data from the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">NDA Review and Approval Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development nonclinical and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process, or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a risk evaluation and mitigation strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use. It could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">tools. The FDA also may offer conditional approval subject to, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. Even if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our drug product candidates as appropriate. On December 29, 2022, the Consolidated Appropriations Act, 2023, including the Food and Drug Omnibus Reform Act, or FDORA, was signed into law. FDORA made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">fines, warning letters, or untitled letters; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical holds on post-approval or Phase IV clinical studies, if applicable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">drug product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases, and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA permits patent term restoration of up to five years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an NDA for a new chemical entity in the United States. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2) (505(b)(2) NDA), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pharmaceutical manufacturers are subject to additional healthcare laws, regulation, and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">their business. Such laws include, without limitation, U.S. federal anti-kickback, anti-self-referral, false claims, transparency, including the federal Physician Payments Sunshine Act, consumer fraud, pricing reporting, data privacy, data protection, and security laws and regulations as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information; state and local laws which require the tracking of gifts and other remuneration and any transfer of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act of 1996, or HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The risk of our being found in violation of these or other laws and regulations is increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts and their provisions are open to various interpretations. These laws and regulations are subject to change, which can increase the resources needed for compliance and delay drug approval or commercialization. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Also, we may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments. Actual or alleged violation of any such laws or regulations may lead to investigations and other claims and proceedings by regulatory authorities and in certain cases, private actors, and violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, additional reporting obligations, and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of operations, exclusion from participation in government healthcare programs and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and related services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; it required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; it implemented a new methodology under which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; it expanded the eligibility criteria for Medicaid programs; it created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and it established a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, in June 2021 the U.S. Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case on procedural grounds without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and healthcare measures promulgated by the Biden administration will impact the ACA, our business, financial condition and results of operations. On January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2032 with the exception of a temporary suspension implemented under various novel coronavirus disease, or COVID-19, relief legislation. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, to review the relationship between pricing and manufacturer patient programs, and to reform government program reimbursement methodologies for pharmaceutical products. For example, under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. In August 2022, Congress passed the Inflation Reduction Act of 2022, or IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Various industry stakeholders, including certain pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges, legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the government on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug candidates if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our drug products. It is possible that additional governmental action may be taken to address the COVID-19 pandemic. Furthermore, there has been increased interest by third party payors and governmental authorities in reference to pricing systems and publication of discounts and list prices. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had 67 employees, 65 of whom were full-time and 45 of whom were engaged in research and development activities. Twenty-five of our employees hold Ph.D. or M.D. degrees.  None of our employees is represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We were incorporated in Washington as a corporation in March 2011 under the name M3 Biotechnology, Inc. In October 2015, we converted to a Delaware corporation and subsequently changed our name to &#8220;Athira Pharma, Inc.&#8221; Our principal executive office is located at 18706 North Creek Parkway, Suite 104, Bothell Washington 98011. Our telephone number is (425) 620-8501. Our website is www.athira.com. Information contained in, or that can be accessed through, our website is not a part of,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and is not incorporated into, this report, and the inclusion of our website address in this report is an inactive textual reference only.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Exchange Act. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">k Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">You should carefully consider the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">following risk factors, in addition to </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the other information </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">contained in this Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, including the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> and our consolidated financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Our Business and the Development of Our Drug Candidates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are a late clinical-stage biopharmaceutical company with a limited operating history.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Our limited operating history may make it difficult to evaluate the success of our business. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have not completed a pivotal clinical trial, obtained marketing approval for any drug candidate, manufactured a commercial scale drug candidate, or conducted sales and marketing activities necessary for successful drug candidate commercialization. Our history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. If we do not address these risks and difficulties successfully, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may fail to or be unable to design and execute clinical trials to support marketing approval of fosgonimeton or any of our other drug candidates. We cannot be certain that our current or planned clinical trials or any other future clinical trials will be completed on time or be successful. We cannot guarantee that the FDA or foreign regulatory authorities will agree with our study design, protocol or protocol amendments, or statistical plan, or that they will interpret clinical trial results as we do, and more clinical trials could be required before we are able to submit applications seeking approval of our drug candidates. To the extent that the results of the clinical trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional clinical trials in support of potential approval of our drug candidates (including potential confirmatory or Phase 3 registrational trials). Even if regulatory approval is secured for any of our drug candidates, the terms of such approval may limit the scope and use of our drug candidate, which may also limit its commercial potential.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business depends entirely on the successful discovery, development and commercialization of our drug candidates. We have no drug products approved for commercial sale and do not anticipate generating any revenue from drug product sales for the next several years, if ever. Our ability to generate drug product revenue will depend heavily on the successful clinical development and eventual commercialization of fosgonimeton and one or more of our other future drug candidates. Our ability to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">successful and timely completion of nonclinical and clinical development of our drug candidates and any future drug candidates, as well as the associated costs, including any unforeseen costs&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development, both in the United States and internationally, of our drug candidates and any future drug candidates&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">timely submission of application for and receipt of marketing approvals from applicable regulatory authorities for any drug candidates for which we successfully complete clinical development&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">making any required post-marketing approval commitments to applicable regulatory authorities&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developing an efficient and scalable manufacturing process for our drug candidates, including obtaining finished products that are appropriately packaged for sale&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for drug candidates that we develop, if approved&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether inhouse or with one or more collaborators&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a continued acceptable safety profile following any marketing approval of our drug candidates&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">commercial acceptance of our drug candidates by patients, the medical community and third-party payors&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">identifying, assessing and developing new drug candidates&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">protecting our rights in our intellectual property portfolio&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">defending against third-party interference or infringement claims, if any&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our drug candidates&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining coverage and adequate reimbursement by hospitals, government and third-party payors for drug candidates that we develop&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">addressing any competing therapies and technological and market developments&#894; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attracting, hiring and retaining qualified personnel.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may never be successful in achieving our objectives and, even if we are, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our drug candidates on a timely or profitable basis, if at all. Changes in the manufacturing process or facilities will require further comparability analysis and approval by the FDA before implementation, which could delay our clinical trials and drug candidate development, and could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">require additional clinical trials, including bridging studies and potential confirmatory or Phase 3 registrational trials, to demonstrate consistent and continued safety and efficacy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have not previously submitted an NDA to the FDA or similar approval filings to a comparable foreign regulatory authority, for any drug candidate. An NDA or other relevant regulatory filing must include extensive nonclinical and clinical data and supporting information to establish that the drug candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the drug product. We cannot be certain that our current or future drug candidates will be successful in clinical trials. Further, even if they are successful in clinical trials, our drug candidates or any future drug candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future drug candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a drug candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our development of fosgonimeton may never lead to a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are developing fosgonimeton as a small molecule aimed at restoring neuronal health. We have not received regulatory approval for fosgonimeton and cannot be certain that our approach will lead to the development of an approvable or marketable product, alone or in combination with other therapies. The primary and all secondary endpoints of the ACT-AD and SHAPE trials were not met by protocoled analysis. While we are continuing with the LIFT-AD study, we may not succeed in demonstrating safety and efficacy of fosgonimeton in our LIFT-AD trial or in other clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Advancing fosgonimeton as a small molecule aimed at restoring neuronal health creates significant challenges for us, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining marketing approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">if fosgonimeton is approved, educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating fosgonimeton into existing treatment regimens, including in combination with other treatments for AD or as a monotherapy&#894; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establishing the sales and marketing capabilities upon obtaining any marketing approvals to gain market acceptance.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our prospects are highly dependent on the successful development of fosgonimeton. If we do not demonstrate the safety and efficacy of fosgonimeton in our LIFT-AD trial, we may explore strategic alternatives to maximize stockholder value, which could involve, without limitation, exploring the potential for a possible merger, business combination, investment, a purchase, license or other acquisition of assets or return of capital to stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our approach to targeting neurotrophic factors through the use of small molecules is based on a novel therapeutic approach, which exposes us to unforeseen risks. We have limited data from our Phase 1a/1b and Phase 2 clinical trials to date, and we cannot be certain that future trials will yield data in support of the safety, efficacy and tolerability of our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have discovered and are developing a platform of small molecule drug candidates from which we have selected our lead drug candidate, fosgonimeton, which is under development to treat AD, PDD, and DLB. Our drug candidates target an endogenous neurotrophic factor which is expected to protect and repair neuronal networks, which we believe could ultimately result in improvements in clinical outcomes and disease-relevant biomarkers. The therapeutic promise of neurotrophic factors in neurodegenerative diseases had been hampered in earlier therapies by the lack of efficient and non-invasive delivery to the CNS. Our small molecule drug candidates are designed to penetrate the BBB and enhance the activity of a neurotrophic factor, but we cannot be certain of the safety and efficacy of our drug candidates in applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">patients or that our clinical trials will provide sufficient evidence that our design approach results in the intended therapeutic effect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based on the results of our nonclinical and clinical studies to date, we believe fosgonimeton has the potential to rapidly improve cognition, function and restore the lives of patients suffering from AD. However, these ideas and this approach are novel, and we currently have limited data based on our Phase 1a/b and Phase 2 clinical trials to date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The primary and all secondary endpoints of our Phase 2 ACT-AD clinical trial in AD were not met by protocoled analysis. A subsequent post hoc analysis of the data in a pre-specified subgroup from patients on fosgonimeton without background therapy, or AChEIs, showed a meaningful, but not statistically significant, improvement in both ERP P300 latency and cognitive performance compared to placebo at 26 weeks. Although post hoc analyses cannot be used to establish efficacy, these analyses can be helpful in informing the design of current and future clinical studies. Following an unblinded interim efficacy and futility analysis, an independent DMC recommended continuation of the LIFT-AD study of fosgonimeton in patients with mild-to-moderate AD. The committee also determined that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 patients without background therapy (AChEIs), the study will be well powered for the primary endpoint given the preliminary effect size observed. There is no assurance that the amendments to our ongoing LIFT-AD trial based on our findings from the ACT-AD trial and our interim analyses will ultimately result in a successful trial. For example, our biomarker data may not translate into a statistically significant clinical benefit, the FDA may not agree with our statistical plan or analyses, or the trial may not be sufficiently powered for our endpoint measures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, the primary endpoint of our Phase 2 SHAPE clinical trial in PDD and DLB was not met by protocoled analysis. Directionally positive results were observed for the 40 mg fosgonimeton dose group with improvements in cognitive, functional and biomarker measurements. In particular, the five patients in the mITT population treated with fosgonimeton 40 mg once daily saw improvement in ADAS-Cog13 individually, and collectively improved compared with placebo (n=7 mITT, one-sided p=0.0321).  Results for patients in the 70 mg dose group were inconsistent.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Data from our Phase 1a/1b and Phase 2 clinical trials to date were obtained from a relatively small number of subjects and we cannot be certain that future trials involving a larger number of subjects and clinical sites will yield data in support of the safety, efficacy and tolerability of our drug candidates. We may ultimately discover that fosgonimeton, or any of our other small molecules, do not possess certain properties required for therapeutic effectiveness. We have limited evidence regarding the efficacy, safety and tolerability of fosgonimeton and other small molecules in our drug product platform. We may spend substantial funds attempting to develop these drug candidates and never succeed in doing so.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have concentrated our research and development efforts on the treatment of central and peripheral nervous system degenerative disorders, a field that has seen very limited success in product development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have focused our research and development efforts on addressing CNS and PNS degenerative disorders. Collectively, efforts by pharmaceutical companies in the field of CNS and peripheral degenerative disorders have seen very limited successes in product development. The development of CNS therapies presents unique challenges, including an imperfect understanding of the biology, the presence of the BBB that can restrict the flow of drugs to the brain, a frequent lack of translatability of preclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance. There are few effective therapeutic options available for patients with AD and other CNS or peripheral disorders. Our future success is highly dependent on the successful development of our technology and our drug candidates for treating CNS and peripheral disorders. Developing and, if approved, commercializing our drug candidates for treatment of CNS and peripheral disorders subjects us to a number of challenges, including ensuring that we have selected the optimal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">doses, executing an appropriate clinical trial to test for efficacy and obtaining regulatory approval from the FDA and other regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at WSU. The special committee&#8217;s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSU&#8217;s dihexa patent, exclusively licensed to us, incorporated certain of these altered images. WSU has undertaken a review of claims of potential research misconduct involving our former chief executive officer&#8217;s doctoral research at WSU. We cannot predict when WSU&#8217;s investigation will be completed or what conclusions WSU will reach.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer, Dr. Leen Kawas, in connection with her doctoral research at WSU, including, among other things, an investigation of allegations that Dr. Kawas altered images used in research published by Dr. Kawas in connection with her doctoral studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The independent special committee&#8217;s primary finding was that our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014. While the conduct that was the subject of the allegations is not related to any of our current drug candidates or ongoing clinical research, this finding could have a material adverse effect on our reputation, our in-licensed patents and pending patent applications, licenses and grants, and could lead to further investigation from government agencies, including the FDA, any of which could have a material adverse impact on our business and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As disclosed elsewhere in this report, including in this &#8220;Risk Factors&#8221; section under the heading &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">&#8212;We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert management&#8217;s attention</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,&#8221; and in &#8220;Part I, Item 3&#8212;Legal Proceedings,&#8221; lawsuits have been filed against us and certain of our directors and officers, alleging violations of federal securities laws related to alleged false and misleading statements in connection with the alleged misconduct of Dr. Kawas and others associated with us. As a result of these allegations and the ongoing litigation against us and certain of our directors and officers and related matters, we have been the subject of negative publicity. This negative publicity may harm our credibility, reputation and relationships with current and future investors, government regulators, patent offices, courts, current and prospective employees, key opinion leaders, prospective collaborators, advocacy groups, current and future patients enrolled in our clinical trials, physicians and prospective patients and vendors. For example, this negative publicity may adversely affect our ability to recruit and hire talented employees, maintain existing business relationships with CROs, clinical trial sites and other parties, enter into new business relationships, enroll patients in our clinical trials, and maintain a viable business in the future. Also, it is possible that the negative publicity and its effect on our work environment could cause our employees to terminate their employment or, if they remain employed by us, result in reduced morale that could have a material adverse effect on our business. In addition, negative publicity has and may continue to adversely affect our stock price and, therefore, employees and prospective employees may be less inclined to seek or continue employment with us. As a result, our business, financial condition, results of operations and cash flows could be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">WSU has undertaken a review of claims of potential research misconduct involving our former chief executive officer&#8217;s doctoral research at WSU.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the investigation of the independent special committee of our board of directors noted above, WSU has also announced that it has undertaken a review of claims of potential research misconduct involving research conducted by Dr. Kawas during her doctoral studies at WSU. We understand this review is ongoing, and at this time we cannot predict what, if any, effect the investigation will ultimately have on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our business and reputation. We are also unable to predict with any certainty when WSU&#8217;s investigation will be completed. It is possible that the ongoing investigation by WSU will come to different conclusions, or uncover additional or different information, than the investigation of the independent special committee of our board of directors, the conclusions of which are discussed under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at WSU. The special committee&#8217;s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSU&#8217;s dihexa patent, exclusively licensed to us, incorporated certain of these altered images. WSU has undertaken a review of claims of potential research misconduct involving our former chief executive officer&#8217;s doctoral research at WSU. We cannot predict when WSU&#8217;s investigation will be completed or what conclusions WSU will reach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8221;. The conclusions from WSU&#8217;s investigation could have a material adverse impact on our business, reputation, scientific credibility, and prospects, as well as our in-licensed patents and pending patent applications, current grants and pending grant applications, and our relationship with WSU, from whom we in-license patents and patent applications underlying certain of our drug candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations and other legal, regulatory and administrative proceedings and face potential liability and expenses related thereto, which could have a material adverse effect on our business, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations and other legal, regulatory and administrative proceedings. In November 2022, we received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand seeks documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH, and our receipt of a NIH grant in 2020. We are cooperating with the Department of Justice with respect to the Demand. In February 2023, the Securities and Exchange Commission, or SEC, sent us a subpoena seeking documents and information relating to, among other things, our former chief executive officer&#8217;s alteration of images in certain research papers. We are cooperating with the SEC with respect to the subpoena.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The outcome of these or any other investigations, claims, or proceedings cannot be predicted with any degree of certainty. In the ordinary course of business we have been and may in the future be the subject of various legal claims. Any such claims, investigations or proceedings against us, whether meritorious or not, could be time-consuming, result in costly litigation, be harmful to our reputation, require significant management attention and divert significant resources, and the resolution of any such claims, investigations or proceedings could result in substantial damages, settlement costs, fines or penalties that could adversely affect our business, financial condition or operating results or result in harm to our reputation and brand, sanctions, consent decrees, injunctions or other remedies requiring a change in our business practices.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, under certain circumstances we may have contractual or other legal obligations to indemnify and to incur legal expenses on behalf of investors, directors, officers employees, customers, vendors or other third-parties. For example, our amended and restated bylaws provide that we will indemnify our directors and officers, and may indemnify our employees, agents and other persons, to the fullest extent permitted by the Delaware General Corporation Law. We have also entered into indemnification agreements with directors and officers that require us, among other things, to indemnify them against claims that may arise due to their service in those capacities. These indemnification agreements also require us to advance expenses reasonably and actually incurred by them in investigating or defending any such claims, and it may be difficult or impossible to recover any advanced expenses if it turns out the person was not entitled to indemnification. If we are required or agree to defend or indemnify, or advance expenses to, any of our investors, directors, officers, employees, customers, vendors or other third-parties, we could incur material costs and expenses that could adversely affect our business, results of operations or financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale preclinical studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale potentially pivotal clinical trials across multiple clinical trial sites. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our lead drug candidate, fosgonimeton, is in clinical development for the potential treatment of AD, PDD and DLB. Our additional early drug candidates, including ATH-1105 for ALS, are in preclinical development. It is impossible to predict when or if any of our drug candidates will prove to be effective and safe in humans or will receive regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our drug candidates, we must demonstrate through lengthy, complex and expensive nonclinical studies and clinical trials that our drug candidates are both safe and effective for each target indication. Nonclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the nonclinical study and clinical trial processes, and, because our drug candidates are in an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. The results of nonclinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in nonclinical studies and early clinical trials, they may not prove to be safe or effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and therefore, the results of animal studies may not accurately predict safety and effectiveness in humans. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through nonclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. For example, our Phase 1a/b clinical trial, which enrolled 88 patients, including only 11 patients with mild-to-moderate AD, of whom seven patients were treated with fosgonimeton and the other four patients were randomized to the control, suggested improvements in brain network activity including potentially positive effects on brain function. However, our Phase 2 ACT-AD clinical trial in AD, which included a larger patient population, approximately 60% of which were receiving standard-of-care AChEIs, did not meet its primary endpoint of a change in ERP P300 latency for the full study population nor did it meet the secondary endpoints. Although a post hoc analysis of results from ACT-AD in a pre-specified subgroup suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton alone without background AChEIs, we cannot be sure that data from future trials will support our earlier findings or demonstrate the safety and effectiveness of fosgonimeton for treatment of AD to the satisfaction of the FDA and other regulatory authorities in order to support regulatory approval. Likewise, early, smaller-scale studies, biomarker analyses, and clinical trials with a single or relatively few clinical trial sites may not be predictive of eventual safety and effectiveness in large-scale pivotal clinical trials across multiple clinical trial sites. Even if data from a pivotal clinical trial are positive, regulators may not agree that such data are sufficient for approval and may require that we conduct additional clinical trials (including potential confirmatory or Phase 3 registrational trials), which could materially delay our anticipated development timelines, require additional funding for such additional clinical trials, and adversely impact our business. Our ability to achieve regulatory approval for fosgonimeton is further complicated by the nature of AD, which historically has been a challenging indication for drug development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence nonclinical studies and clinical trials are never approved as products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different nonclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. For example, we believe the topline results of our Phase 2 ACT-AD clinical trial may have differed from the treatment data from our Phase 1a/b clinical trial at least in part due to differences in the patient population and treatment duration, and potential effects from background AChEI treatment. If future trials show that the effect of fosgonimeton when given in combination with add-on standard-of-care AChEIs is diminished, we may be required to seek a narrower indication or restrict our target population to those where fosgonimeton shows a greater effect, which could have a material adverse effect on our business and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On July 6, 2021, we announced the initiation of an open-label extension for the LIFT-AD and ACT-AD trials and in May 2022 we announced the extension of the open label extension for an additional 12 months. In May 2023, we amended the open-label extension trial to further extend the trial by an additional 12 months. Upon completion of the 26-week treatment period during the LIFT-AD or ACT-AD trials, patients may continue on the open-label extension and receive treatment with fosgonimeton for up to an additional 30 months. Investigators and patients remain blinded to treatment group assignment in the original trials. Such open-label extension studies are, and some of the clinical trials we conduct in the future may be, open-label in study design conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by a data safety monitoring board for such clinical trial or by the FDA or comparable foreign regulatory authorities. Clinical trials can be delayed or terminated or fail to meet endpoints for a variety of reasons, including delays or failures related to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing with our ATH clinical development strategy or statistical plan;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in governmental regulations or administrative actions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in our ability to commence a clinical trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining IRB approval at each clinical trial site;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a clinical trial on a timely basis;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">having subjects complete a clinical trial or return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical trial sites deviating from clinical trial protocol or dropping out of a clinical trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">protocol deviations or non-compliance with GCP requirements, or other data integrity reasons, that cause us or the FDA or other regulatory authorities to exclude data from non-compliant sites or investigators, which may cause the trial to be underpowered to meet the endpoints;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays by us or our CROs in qualifying or analyzing patient data at the completion of clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">failure to demonstrate a benefit from using a drug candidate;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">addressing subject safety concerns that arise during the course of a clinical trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adding a sufficient number of clinical trial sites; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining sufficient supply of drug candidate for use in nonclinical studies or clinical trials from third-party suppliers.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we intend to do for our drug candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our drug candidates. If we experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of our drug candidates will be harmed, and our ability to generate product revenues from any of these drug candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the results of our current and future clinical trials are inconclusive with respect to the efficacy of our drug candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our drug candidates, we may:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">incur unplanned costs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">be delayed in or prevented from obtaining marketing approval for our drug candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings including boxed warnings;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">be subject to changes in the way the drug candidate is administered;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">have regulatory authorities withdraw their approval of the drug product or impose restrictions on its distribution in the form of a modified REMS;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">be subject to the addition of labeling statements, such as warnings or contraindications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">be sued; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">experience damage to our reputation.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Any &#8220;topline&#8221;, interim, initial, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our nonclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or clinical trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, we may also disclose interim data from our nonclinical studies and clinical trials. For example, in October 2022 we announced that an independent DMC had conducted an unblinded interim efficacy and futility analysis with respect to our Phase 2/3 LIFT-AD clinical trial. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, we rely on data received from clinical trials, whether preliminary or final, to inform decisions on future clinical trials, including trial design, trial size, and whether or not to initiate additional clinical trials (including any potential confirmatory or Phase 3 registrational trials). For example, in November 2020, we initiated ACT-AD, an exploratory Phase 2 clinical trial, to better understand the overall effects of fosgonimeton on working memory processing speed and cognitive measures. Topline results of ACT-AD were announced in June 2022. We used these data to help inform strategic decisions around LIFT-AD and expect to use these data to help inform strategic decisions in the future around current clinical trials and any additional trials that we may initiate. Topline results are based on a preliminary analysis of then-available data, and a more comprehensive and full review of the data may result in different conclusions, which could have a negative impact on our decisions regarding any additional trials for fosgonimeton. There is no assurance that the amendments to our ongoing LIFT-AD trial based on our findings from the ACT-AD trial and our interim analysis of the LIFT-AD trial will ultimately result in a successful trial. For example, our biomarker data may not translate into a statistically significant clinical benefit, the FDA may not agree with our statistical plan or analyses, or the trial may not be sufficiently powered for our endpoint measures.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment or retention of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to recruit and enroll a sufficient number of eligible patients to participate in these clinical trials through completion of such trials as required by the FDA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. Patient enrollment may also be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; programs. Additionally, publicly reported results of our completed clinical trials may impact enrollment of our trials in progress. If we are unable to locate a sufficient number of such patients, our clinical trial and development plans could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are delayed or unsuccessful in enrolling the desired number of subjects in our trials, whether as a result of the outcomes of prior trials conducted by us, competing clinical trials, overly stringent eligibility requirements, or other factors, our clinical trial results could be delayed, the costs of our clinical trials could materially increase, and the overall development timeline for fosgonimeton could be negatively impacted. For example, enrollment in our ongoing clinical trials had slowed due to the effects of the COVID-19 pandemic, including governmental restrictions imposed in Australia, where certain of our clinical trial sites are located. In our ACT-AD clinical trial, this slowed recruitment resulted in a change in the timing of topline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">results from our Phase 2 ACT-AD clinical trial, which were announced in June 2022. We cannot ensure that similar enrollment issues will not occur again in the future. Even if we are successful in enrolling the targeted number of subjects in our trials, the FDA and other regulators may request additional clinical trials with larger numbers of subjects (including potential confirmatory or Phase 3 registrational trials) as a condition to any regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Further, to the extent any of our clinical trial sites fail to comply with the approved study protocol, good clinical practices, or FDA regulations, we may be required to exclude such sites, participants such sites may have enrolled, as well as the data collected by such sites. If any of these events were to occur, or if we are required to exclude any data for any reason, we may be required to recruit more sites or more participants than we initially thought. Enrollment delays or other delays in our clinical trials may result in increased development costs for our drug candidates and jeopardize our ability to obtain marketing approval for the sale of our drug candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the drug candidates we develop, our commercial opportunities will be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While we believe that our scientific knowledge, platform technology and development expertise provide us with competitive advantages, we face competitive pressures from both large and small pharmaceutical companies, emerging biotechnology companies, as well as academic, government and private research institutions. Many of our competitors have access to greater financial resources, market presence, expertise in development, preclinical and clinical testing, manufacturing, commercialization, regulatory approval process, or marketing and sales than we do. Our competitors may compete with us in patient recruitment, clinical research organization, and operational resources. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Drug candidates that we may successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. For example, the FDA recently granted traditional approval for lecanemab, a drug developed by Biogen Inc. and Eisai Co., Ltd., and Eli Lilly and Company is also developing drug candidates for AD. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our drug products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our drug candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our drug products. For example, CMS announced a two-part National Coverage Determination, or NCD, under which Medicare will cover monoclonal antibodies that target amyloid (or plaque) for the treatment of AD that receive traditional approval from the FDA under coverage with evidence development. Additionally, for drugs that FDA has not determined to have shown a clinical benefit or that received an accelerated approval, Medicare will provide coverage in FDA or NIH approved clinical trials. In June 2023, CMS announced that Medicare will cover new Alzheimer&#8217;s drugs with traditional FDA approval when a physician and clinical team participate in CMS&#8217; registry to collect evidence about how these drugs work in the real world. Current and future CMS coverage restrictions on classes of drugs that encompass our drug candidates could have a material adverse impact on our ability to commercialize our drug candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For additional information regarding our competition, see the section of this report titled &#8220;Part I, Item 1 &#8211; Business&#8212;Competition&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and drug candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or drug candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and drug candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may develop drug candidates in combination with other therapies, which exposes us to additional risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may develop drug candidates in combination with one or more other approved or unapproved therapies. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our drug product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our drug candidates are replaced as the standard of care for the indications we choose for any of our drug candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own drug products, if approved, being removed from the market or being less successful commercially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We also may choose to evaluate drug candidates in combination with one or more therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell any drug candidate we develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our drug product. In addition, unapproved therapies face the same risks described with respect to our drug candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our drug candidate we develop, we may be unable to obtain approval of or market such combination therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our long-term prospects depend in part upon discovering, developing and commercializing additional drug candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize drug candidates beyond those we currently have in clinical and nonclinical development. A drug candidate can unexpectedly fail at any stage of nonclinical and clinical development. The historical failure rate for drug candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from nonclinical testing or early clinical trials of a drug candidate may not be predictive of the results that will be obtained in later stage clinical trials of the drug candidate.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The success of other future drug candidates we may develop will depend on many factors, including the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">generating sufficient data to support the initiation or continuation of clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining regulatory permission to initiate clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">contracting with the necessary parties to conduct clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timely manufacture of sufficient quantities of the drug candidate for use in clinical trials; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adverse events in the clinical trials.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if we successfully advance any other future drug candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other future drug candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have conducted certain research and development operations through our Australian wholly owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2020, we formed a wholly owned Australian subsidiary to conduct various preclinical and clinical activities for our drug product and development candidates in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor, develop and commercialize our drug product and development candidates in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our drug candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, current Australian tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. If we lose our ability to operate our subsidiary in Australia, or if we are ineligible or unable to receive the research and development tax credit, or the Australian government significantly reduces or eliminates the tax credit, our business and results of operations may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The loss of any of our key personnel could significantly harm our business, results of operations and competitive position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In order to compete, we must attract, retain, and motivate executives and other key employees. Hiring and retaining qualified executives, scientists, technical and legal and accounting staff are critical to our business, and competition for experienced employees in our industry can be high. The loss of one or more of these key employees, or our inability to hire additional key personnel when needed, could have a material adverse effect on our business and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Health Epidemics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The potential effects of health epidemics could adversely impact our business, including our nonclinical studies and clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business could in the future be adversely impacted by the effects of possible health epidemics and other outbreaks which could cause disruptions that could severely impact our business, nonclinical studies and clinical trials. Such disruptions may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays or difficulties in enrolling and retaining patients in our clinical trials, particularly elderly subjects, who may be at a higher risk of severe illness or death, which can be further complicated by the presence of comorbidities that are often present in AD subjects;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">difficulties interpreting data from our clinical trials due to the possible effects of such diseases on cognition of the subjects enrolled in our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption of, or delays in receiving, supplies of our drug candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruptions in nonclinical studies due to restricted or limited operations at our laboratory facility;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">limitations on employee resources that would otherwise be focused on the conduct of our nonclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruptions, difficulties or delays arising in our existing operations and company culture as a result of some or all of our employees working remotely;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption or delays to our sourced discovery and clinical activities; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For example, in the event of a disease outbreak or resurgence of COVID-19, we could be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from such diseases. On May 11, 2023, the federal government ended the COVID-19 public health emergency, which ended a number of temporary changes made to federally funded programs while some continue to be in effect. Since March 2020, the FDA has issued various COVID-19 related guidance documents for sponsors and manufacturers, many of which have expired or were withdrawn with the expiration of the COVID-19 public health emergency declaration, although some COVID-19 related guidance documents continue in effect. The full impact of this termination of the national emergency and the wind-down of the public health emergency on FDA and other regulatory policies and operations is unclear.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trading prices for shares of biopharmaceutical companies have in the past been and could in the future be highly volatile as a result of health epidemics, including the COVID-19 pandemic, and the trading prices for shares of our common stock could also experience high volatility. In the event of an emergence of new disease outbreaks or a resurgence of COVID-19, we could face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from a health epidemic, including a resurgence of COVID-19, could materially and adversely affect our business and the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The ultimate impact of a possible health epidemic or other outbreak, including a resurgence of COVID-19, on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. In addition, our business could be significantly adversely affected by other business disruptions to us or our third-party providers that could seriously harm our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our CROs, commercial manufacturing organizations, or CMOs, and other contractors, consultants, and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our drug candidates. Our ability to obtain clinical supplies of our drug candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Our Financial Position and Capital Needs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have not generated any revenue from drug product sales and our drug candidates will require substantial additional investment before they may provide us with any revenue. We had net losses of $117.7 million and $95.6 million for the years ended December 31, 2023 and 2022</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively, and an accumulated deficit of $309.2 million as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have devoted most of our financial resources to research and development, including our clinical and nonclinical development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> activities. To date, we have financed our operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue our research and nonclinical and clinical development of our drug candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expand the scope of our clinical studies for our current and prospective drug candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">initiate additional nonclinical, clinical or other studies for our drug candidates, including any potentially pivotal trials with respect to fosgonimeton for the treatment of mild-to-moderate AD in addition to LIFT-AD, and continue the open label extension of the ACT-AD and LIFT-AD trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">change or add additional manufacturers or suppliers and manufacture drug supply and drug product for clinical trials and commercialization;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek regulatory and marketing approvals for any of our drug candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attract, hire and retain additional personnel;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">operate as a public company;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue to expand our facilities and lab space;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek to identify and validate additional drug candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">acquire or in-license other drug candidates and technologies or engage in other strategic transactions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">make milestone or other payments under our in-license or other agreements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">maintain, protect and expand our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">create additional infrastructure to support our operations and our drug product development and planned future commercialization efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">incur expenses in connection with legal proceedings, and addressing potential stockholder activism; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">experience any delays or encounter issues with any of the above.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our expenses could increase beyond expectations for a variety of reasons, including if we are required by the FDA, the European Medicines Agency, or EMA, or other regulatory agencies, domestic or foreign, to perform clinical and other </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in addition to those that we currently anticipate. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We will require substantial additional funding to finance our operations, complete the development and commercialization of fosgonimeton, and develop and commercialize other and future drug candidates. If we are unable to raise this funding when needed, we may be forced to delay, reduce, or eliminate our drug product development programs or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations, and we expect our expenses to increase substantially in the foreseeable future in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of, and seek marketing approval for, fosgonimeton. Developing fosgonimeton and conducting clinical trials for the treatment of AD, PDD, DLB, and any other indications that we may pursue in the future will require substantial amounts of capital. In addition, if we </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtain marketing approval for fosgonimeton or any future drug candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing, and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. As of December 31, 2023, we had cash, cash equivalents and investments of $147.4 million. Based upon our current operating plan, we estimate that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report. However, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> amount and timing of our future funding requirements depends on many factors, some of which are outside of our control, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the progress, costs, clinical trial design, results of and timing of our LIFT-AD trial and other clinical trials of fosgonimeton, including for potential additional indications that we are pursuing beyond AD, such as PDD, DLB, and the continuation of the open label extension of the ACT-AD and LIFT-AD trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the willingness of the FDA and EMA to accept our LIFT-AD trial, as well as data from our completed and planned clinical and nonclinical studies and other work, as the basis for review and approval of fosgonimeton for AD and the potential need for additional clinical trials (including potential confirmatory or Phase 3 registrational trials); </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the outcome, costs and timing of seeking and obtaining FDA, EMA and any other regulatory approvals; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number and characteristics of drug candidates that we pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to manufacture sufficient quantities of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our need to expand our research and development activities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs associated with securing and establishing commercialization and manufacturing capabilities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs of acquiring, licensing or investing in businesses, drug candidates and technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost, timing and outcomes of any litigation involving our company, including securities class actions and government investigations which we may be or may in the future become involved in;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our need and ability to retain management and hire scientific, clinical and other personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the effect of competing drugs and drug candidates and other market developments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the economic and other terms, timing of and success of any collaboration, licensing or other arrangements into which we may enter in the future.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In January 2023, we entered into a sales agreement with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, and BTIG, LLC, or BTIG, to sell shares of our common stock having aggregate sales proceeds of up to $75.0 million, from time to time, through an at-the-market, or ATM, equity offering program under which Cantor Fitzgerald and BTIG are acting as sales agents. We have not sold any securities pursuant to this ATM offering. However, additional funding may not be available to us on acceptable terms or at all. Any such funding may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. If we are </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">unable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to obtain funding on a timely basis, we may be required to significantly curtail or abandon one or more of our research or development programs. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of our technologies or drug candidates or otherwise agree to terms unfavorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. In addition, we may seek additional capital to take advantage of favorable market conditions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">or strategic opportunities even if we believe we have sufficient funds for our current or future operating plans. Based on our research and development plans, we expect that our existing cash, cash equivalents and investments will enable us to fund our operations for at least 12 months following the date of this report. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. For example, the current inflationary economic environment, health epidemics, and rising interest rates have resulted in a disruption of global financial markets. If the disruption persists or deepens, we could be unable to access additional capital, which could negatively affect our ability to consummate certain corporate development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to us when we need them, on terms that are acceptable to us, or at all, we may be required to take steps that could adversely impact our business, including delaying, limiting, reducing or terminating nonclinical studies, clinical trials or other research and development activities or eliminating one or more of our development programs altogether, or delaying, limiting or reducing or terminating efforts to prepare for commercialization of any future approved drug products. We currently have a shelf registration statement effective and an existing ATM equity offering program, however, our ability to raise capital under this registration statement and through our ATM equity offering program may be limited by, among other things, SEC rules and regulations impacting the eligibility of smaller companies to use Form S-3 for primary offerings of securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Adverse events or perceptions affecting the financial services industry could adversely affect our operating results, liquidity, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Limited liquidity, defaults, non-performance or other adverse developments affecting financial institutions or parties with which we do business, or perceptions regarding these or similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank, or SVB, was closed and placed in receivership and subsequently, additional financial institutions have been placed into receivership. We did not hold cash deposits or other accounts with SVB and did not, and as of the date of this report do not, otherwise have a direct business relationship with SVB or similarly situated financial institutions. However, companies that did have a business relationship with SVB faced:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">loss of access to revolving existing credit facilities or other working capital sources or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential or actual breach of obligations, including U.S. federal and state wage laws and contracts that required them to maintain letters or credit or other credit support arrangements; and<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">termination of cash management arrangements or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"><br/>As a result of U.S. government intervention, account holders subsequently regained access to their accounts, including the uninsured portion of deposit accounts; however, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB and similarly situated financial institutions were unable to access to such sources of liquidity. There is no guarantee that the U.S. government will intervene to provide access to uninsured funds in the future in the event of the failure of other financial institutions, or that they would do so in a timely fashion. In such an event, parties with which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we have commercial agreements may be unable to satisfy their obligations to, or enter into new commercial arrangements with, us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Concerns regarding the U.S. or international financial systems could impact the availability and cost of financing, thereby making it more difficult for us to acquire financing on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any of these risks could materially impact our operating results, liquidity, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The value of our investments is subject to significant capital markets risk related to changes in interest rates and credit spreads as well as other investment risks, which may adversely affect our operating results, liquidity, financial condition and prospects.</span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our results of operations are affected by the performance of our investment portfolio. Our excess cash is invested by an external investment management service provider, under the direction of our management in accordance with our investment policy. The investment policy defines constraints and guidelines that restrict the asset classes that we may invest in by type, duration, quality and value. Our investments are subject to market-wide risks, and fluctuations, as well as to risks inherent in particular securities. The failure of any of the investment risk strategies that we employ could have a material adverse effect on our operating results, liquidity, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The value of our investments is exposed to capital market risks, and our results of operations, liquidity, financial condition or cash flows could be adversely affected by realized losses, impairments and changes in unrealized positions as a result of: significant market volatility, changes in interest rates, changes in credit spreads and defaults, a lack of pricing transparency, a reduction in market liquidity, declines in equity prices, changes in national, state/provincial or local laws and the strengthening or weakening of foreign currencies against the U.S. dollar. Levels of write-down or impairment are impacted by our assessment of the intent to sell securities that have declined in value as well as actual losses as a result of defaults or deterioration in estimates of cash flows. If we reposition or realign portions of the investment portfolio and sell securities in an unrealized loss position, we will incur realized losses. Any such charge may have a material adverse effect on our results of operations and business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our ability to use net operating </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">losses</span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> to offset future taxable income may be subject to certain limitations.</span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had federal net operating loss carryforwards, or NOLs, to offset future taxable income of approximately $9.5 million and federal tax credit carryforwards of approximately $12.4 million, which expire over a period of 8 to 14 years. Federal NOLs of $138.7 million were generated after 2017, and therefore do not expire. At December 31, 2023, we also had state NOLs of $3.3 million, which expire over a period of 18 to 20 years. A lack of future taxable income would adversely affect our ability to utilize these NOLs. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its NOLs to offset future taxable income. We may have already experienced one or more ownership changes. Depending on the timing of any future utilization of our NOLs and tax credit carryforwards, we may be limited as to the amount that can be utilized each year as a result of such previous ownership changes. However, we do not believe such limitations will cause our NOL and tax credit carryforwards to expire unutilized. In addition, future changes in our stock ownership as well as other changes that may be outside of our control, could result in additional ownership changes under Section 382 of the Code. Our NOLs may also be impaired under similar provisions of state law or limited pursuant to provisions of the Tax Cuts and Jobs Act amendments to the Code, as modified by the Coronavirus Aid, Relief, and Economic Security Act. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Changes in tax laws could have a material adverse effect on our business, cash flows, results of operations or financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">are subject to the tax laws, regulations, and policies of several taxing jurisdictions. Changes in tax laws, as well as other factors, could cause us to experience fluctuations in our tax obligations and effective tax rates and otherwise adversely affect our tax positions or our tax liabilities. For example, many countries and local jurisdictions and organizations such as the Organization for Economic Cooperation and Development have proposed or implemented new tax laws or changes to existing tax laws, including additional taxes on payroll or employees. Any new or changes to tax laws could adversely affect our effective tax rate, operating results, tax credits or incentives or tax payments, which could have a material adverse effect on our business, cash flows, results of operations or financial condition</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Regulatory Approval and Other Legal Compliance Matters</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our drug candidates, we will not be able to commercialize, or will be delayed in commercializing, our drug candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. Before we can commercialize any of our drug candidates, we must obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Obtaining approval by the FDA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Further, securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our drug candidates, the FDA and other comparable foreign regulatory authorities may approve our drug candidates for a more limited indication or a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the drug product&#8217;s commercial potential. We have not submitted for, or obtained, regulatory approval for any drug candidate, and it is possible that none of our drug candidates will ever obtain regulatory approval. Further, development of our drug candidates or regulatory approval may be delayed for reasons beyond our control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Applications for our drug candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or other comparable foreign regulatory authorities may determine that our drug candidates are not safe and effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that our drug candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval or resulting in delays in our regulatory approval, including, for example, legislation or agency policies that aim to reform the accelerated approval process and FDA&#8217;s increased scrutiny of post-approval confirmatory studies, which can result in withdrawal of accelerated approval if such studies fail to confirm a clinical benefit.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our drug candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we obtain approval of our drug candidates, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS. Regulatory authorities may not approve the price we intend to charge for drug products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could seriously harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or comparable foreign regulatory approval processes and are commercialized. The lengthy approval processes as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug candidates, which would significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our current or future drug candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our drug candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If our drug candidates are associated with undesirable side effects or have unexpected characteristics in nonclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the clinical trial, or result in potential product liability claims. Any of these occurrences may prevent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">us from achieving or maintaining market acceptance of the affected drug candidate and may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Patients in our clinical trials may in the future suffer significant adverse events or other side effects not observed in our nonclinical studies or previous clinical trials. Some of our drug candidates may be used as chronic therapies or be used in populations for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our drug candidates are used in combination with other therapies, our drug candidates may exacerbate adverse events associated with the therapy. Patients treated with our drug candidates may also be undergoing separate treatments which can cause side effects or adverse events that are unrelated to our drug candidate, but may still impact the success of our clinical trials, including, for example, by interfering with the effects of our drug candidates. A pre-specified group analysis of patients in our ACT-AD clinical trial identified a potential diminished effect of the combination of standard-of-care (AChEIs) and fosgonimeton. While more clinical studies are needed to determine the safety and efficacy of fosgonimeton, to the extent standard-of-care AChEIs impact the effects of fosgonimeton and if a significant portion of the patient population has already been treated with AChEIs, the potential target patient population or the indication we seek for fosgonimeton may be significantly smaller than we had anticipated, which could materially harm our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The inclusion of elderly patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our clinical trials, or we may be required to abandon the clinical trials or our development efforts of that drug candidate altogether. We, the FDA other comparable regulatory authorities or an IRB may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that subjects in such clinical trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage clinical trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, if any of our drug candidates obtains marketing approval, toxicities associated with such drug candidates and not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the drug product or the withdrawal of the drug product from the market. We cannot predict whether our drug candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on nonclinical studies or early-stage clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our drug candidates in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a drug candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the drug candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our drug products is also subject to approval.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of drug candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our drug products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential drug candidates will be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any regulatory approvals that we receive for our drug candidates will require surveillance to monitor the safety and efficacy of the drug candidate. The FDA may also require a REMS in order to approve our drug candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our drug candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations, GLP regulations and GCP regulations for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our drug candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">restrictions on the marketing or manufacturing of our drug candidates, withdrawal of the drug product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">imposition of a REMS, which may include distribution or use restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the drug product;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">fines, warning letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our drug candidates; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. It is difficult to predict how current and future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">legislation, executive actions, and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business, our clinical development, and the FDA&#8217;s and other agencies&#8217; ability to exercise their regulatory authority, including FDA&#8217;s pre-approval inspections and timely review of any regulatory filings or applications we submit to the FDA. To the extent any executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if the Supreme Court reverses or curtails the Chevron doctrine, which gives deference to regulatory agencies in litigation against FDA and other agencies, more companies may bring lawsuits against FDA to challenge longstanding decisions and policies of FDA, which could undermine FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt FDA&#8217;s normal operations, which could delay FDA&#8217;s review of our marketing applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our drug candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To the extent the FDA&#8217;s normal operations are disrupted or delayed, for example due to travel restrictions, public health or geopolitical issues, staffing shortages, or lack of funding, the FDA may not be able to complete the necessary inspections or provide feedback in a timely manner during our clinical development or review period. If any such delays or disruptions were to occur, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional nonclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous postmarketing requirements, the FDA may seek to withdraw accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may seek an accelerated approval for one or more of our drug candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Prior to seeking accelerated approval for any of our drug candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our drug candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our drug candidate would result in a longer time period to commercialization of such drug candidate, could increase the cost of development of such drug candidate and could harm our competitive position in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, to the extent the FDA materially changes its policies or regulatory requirements with respect to the accelerated approval program or its internal review process for such program, our clinical development plans and regulatory approval under such program could be materially impacted or delayed. On December 29, 2022, the Consolidated Appropriations Act, 2023, including the FDORA, was signed into law. FDORA made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements. It is unclear how these proposals, future policy changes, and changes in FDA regulation will impact new drug applications in the treatment of AD and our clinical development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our drug candidates or any future drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a drug product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes to our manufacturing arrangements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">additions or modifications to drug product labeling; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the recall or discontinuation of our drug products; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div></div>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA contained provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the U.S. Department of Health and Human Services Secretary, or HHS Secretary, as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extending the rebate program to individuals enrolled in Medicaid managed care organizations. The ACA also established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. In December 2020, the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As discussed above, since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Further, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how additional challenges and healthcare reform measures of the Biden administration will impact the ACA. Complying with any new legislation and regulatory requirements could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Bipartisan Budget Act of 2018 also amended the ACA, effective January 1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has published a final rule to give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. The American Taxpayer Relief Act of 2012, or ATRA, among other things, reduced Medicare payments to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Other legislative changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2032 with the exception of a temporary suspension implemented under various COVID-19 relief legislation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition for prescription drugs. In August 2022, Congress passed the IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Further, the Biden administration released an additional executive order on October 14, 2022, directing the U.S. Department of Health and Human Services, or HHS, to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. Various industry stakeholders, including pharmaceutical companies, the U.S. Chamber of Commerce, the National Infusion Center Association, the Global Colon Cancer Association, and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of IRA are unconstitutional.  The impact of these judicial challenges as well as other legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the government on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug candidates if approved.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In April 2022, CMS released a finalized national policy for coverage of aducanumab, or Aduhelm, and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating AD. According to the two-part NCD, Medicare will cover monoclonal antibodies that target amyloid (or plaque) for the treatment of AD that receive traditional approval from the FDA when furnished in accordance with the coverage criteria specified under coverage with evidence development. CMS will also provide enhanced access and coverage for Medicare patients participating in CMS-approved studies, such as data collection through routine clinical practice or registries. Additionally, for drugs that FDA has not determined to have shown a clinical benefit or that received an accelerated approval, Medicare will provide coverage in FDA or NIH approved clinical trials. In June 2023, CMS announced that Medicare will cover new Alzheimer&#8217;s drugs with traditional FDA approval when a physician and clinical team participate in CMS&#8217; registry to collect evidence about how these drugs work in the real world. Current and future CMS coverage restrictions on classes of drugs that encompass our drug candidates could have a material adverse impact on our ability to commercialize our drug candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our drug products, once approved, or put pressure on our drug product pricing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our drug products. Further, FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare or impose price controls may adversely affect:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the demand for our drug candidates, if we obtain regulatory approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to set a price that we believe is fair for our drug products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a drug product;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the availability of capital.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect that other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drug candidates. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure to what extent the trajectory of these legislative and regulatory proposals will be implemented by the federal and state governments, whether additional legislative changes will be enacted, whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities, and our participation in the federal health care programs and acceptance of federal grant funding, such as funding from the NIH, may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our drug products for which we obtain marketing approval. Similarly, our participation in the federal health care programs and acceptance of federal grant funding from the NIH may subject us to federal false claims laws, civil penalties and assessments, criminal prosecution, and other administrative, civil, and criminal remedies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The laws that may affect our ability to operate include, but are not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, or FCA. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">federal civil and criminal false claims laws, including the FCA, which can be enforced through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, impose criminal and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. Under the FCA, a &#8220;claim&#8221; also includes any request (including grant request) or demand for money or property made to the United States or to a contractor, recipient, if the Federal government provides or will reimburse any portion of the funds claimed. &#8220;Funds&#8221; include money that the NIH awards as part of research grants. Even if a federal grant is not awarded, the grant applicant may be subject to FCA liability if the information contained in or submitted as part of a grant application, including its certifications and assurances, is found to be false, fictitious, or fraudulent.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities, including our advisory board arrangements with physicians, some of whom receive stock or stock options as compensation for services provided, and any sales and marketing activities after a drug candidate has been approved for marketing in the United States, could be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the risks relating to the outcome of the independent special committee&#8217;s investigation noted above, we are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Our Reliance on Third Parties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs, and strategic partners to conduct and support our nonclinical studies and clinical trials under agreements with us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to have to negotiate budgets and contracts with CROs, clinical trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our nonclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">control over the conduct, timing and completion of these nonclinical studies and clinical trials and the management of data developed through nonclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for drug candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In particular, protocol deviations or non-compliance with GCP requirements, or other data integrity reasons, can cause us or the FDA or other regulatory authorities to exclude data from non-compliant sites or investigators, which may cause the trial to be underpowered to meet the endpoints. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical drug product produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing, clinical and non-clinical drug candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our drug candidates. As a result, our financial results and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Switching or adding third parties to conduct our nonclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of our drug candidates for nonclinical studies and our clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture supplies of our drug candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our drug candidates for nonclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our drug candidates are sourced, in some cases, from a single-source supplier and sometimes involve long lead times from order to receipt of the materials. If we were to experience an unexpected loss of supply of any of our drug candidates or any of our future drug candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. We expect to continue to rely on third-party manufacturers for the commercial supply of any of our drug candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the failure of the third party to manufacture our drug candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our drug candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the breach by the third-party contractors of our agreements with them;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the failure of third-party contractors to comply with applicable regulatory requirements&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the failure of the third party to manufacture our drug candidates according to our specifications&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales&#894; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our drug candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our drug candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our drug candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of our drug candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drug candidates that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In order to commercially produce our drug products either at our own facility or at a third party&#8217;s facility, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our drug candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our drug candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our drug candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If our third-party manufacturers use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may use strategic collaborations, licensing arrangements or partnerships to accelerate the development and maximize the commercial potential of our programs,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">and we may not realize the benefits of such collaborations, arrangements or partnerships.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own worldwide rights to fosgonimeton as well as our pipeline of small molecule candidates. Where appropriate, we may use strategic collaborations, licensing arrangements or partnerships to accelerate the development and maximize the commercial potential of our programs. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy and obtain marketing approval. In addition, the effects to our business and reputation discussed in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at WSU. The special committee&#8217;s findings included that (1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSU&#8217;s dihexa patent, exclusively licensed to us, incorporated certain of these altered images. WSU has undertaken a review of claims of potential research misconduct involving our former chief executive officer&#8217;s doctoral research at WSU. We cannot predict when WSU&#8217;s investigation will be completed or what conclusions WSU will reach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,&#8221; may discourage potential counterparties from entering into relationships with us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our drug candidates or bring them to market and generate product revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if we are successful in entering into collaborations involving our drug candidates, these relationships are subject to numerous risks, which may include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may not pursue development and commercialization of our drug candidates or may elect not to continue or renew development or commercialization of our drug candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our drug candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more drug products may not commit sufficient resources to their marketing and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable drug candidates; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may own or co-own intellectual property covering our drug products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a result, if we enter into additional strategic collaborations, licensing arrangements or partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic collaboration, licensing arrangement or partnership, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic collaborations, licensing arrangements or partnerships related to our drug candidates could delay the development and commercialization of our drug candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, we evaluate various acquisition opportunities and strategic transactions and partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the issuance of our equity securities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Our Ability to Commercialize our Drug Product</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Even if approved, our drug candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if our drug candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance or reimbursement of any of our approved drug candidates will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing of market introduction of the drug candidate as well as competitive products&#894;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the clinical indications for which the drug candidate is approved&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the extent of physician acceptance of FDA-approved therapies for AD or other target indications; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">restrictions on the use of our drug candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential and perceived advantages of our drug candidates over alternative treatments&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost of treatment in relation to alternative treatments&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">pricing and the availability of coverage and adequate reimbursement by third-party payors, including government authorities&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the availability of the approved drug candidate for use as a combination therapy&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">relative convenience and ease of administration&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the effectiveness of sales and marketing efforts&#894;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">unfavorable publicity relating to our drug products or drug candidates or similar approved products or product candidates in development by third parties&#894; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the approval of other new therapies for the same indications.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If any of our drug candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from such drug candidates and our financial </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> could be negatively impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have never commercialized a drug candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any drug products on our own or together with suitable collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have never commercialized a drug candidate. We may license certain rights with respect to our drug candidates to collaborators, and, if so, we will rely on the assistance and guidance of those collaborators. For drug candidates for </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">which we retain commercialization rights and marketing approval, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Factors that may affect our ability to commercialize our drug candidates, if approved, on our own include recruiting and retaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of our approved drug candidates, ensuring regulatory compliance of our company, employees and third parties under applicable healthcare laws, and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our drug candidates upon approval. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our drug candidates, we may not generate revenues from them or be able to reach or sustain profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If the market opportunity for any drug candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We intend to initially focus our drug candidate development on treatments for various CNS and PNS disorder indications. The addressable patient populations that may benefit from treatment with our drug candidates, if approved, are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">surveys</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">CNS and PNS disorders. Any regulatory approval of our drug candidates would be limited to the therapeutic indications examined in our clinical trials and as determined by the FDA, which would not permit us to market our drug products for any other therapeutic indications not expressly approved by the FDA. Additionally, the potentially addressable patient population for our drug candidates may not ultimately be amenable to treatment with our drug candidates. For example, pre-specified subgroup analysis based on topline data from our ACT-AD clinical trial identified a potential diminished effect of the combination of standard-of-care (AChEIs) and fosgonimeton. If such hypothesis is supported by additional research, patients receiving AChEIs could be excluded from the addressable patient population for fosgonimeton. Even if we receive regulatory approval for any of our drug candidates, such approval could be conditioned upon label restrictions that materially limit the addressable patient population. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any drug candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We face an inherent risk of product liability as a result of the planned clinical testing of our drug candidates and will face an even greater risk if we commercialize any drug products. For example, we may be sued if our drug candidates cause or </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our drug candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">decreased demand for our drug candidates or drug products that we may develop;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">diversion of management&#8217;s time and our resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">substantial monetary awards to clinical trial participants or patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">drug product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">exhaustion of any available insurance and our capital resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the inability to commercialize any drug candidate; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a decline in our share price.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of drug products we develop, alone or with corporate </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Our drug candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would harm our business. Failure to obtain or maintain adequate coverage and reimbursement for new or current drug products could limit our ability to market those drug products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a drug product in a particular country, but then be subject to price regulations that delay our commercial launch of the drug product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if any drug candidates we may develop obtain marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our drug candidates will depend in part on the extent to which coverage and adequate reimbursement for these drug </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or other future drug candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our drug candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our drug candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">prices</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of medicines</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our drug candidates. Accordingly, in markets outside the United States, the reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drug products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drug candidates, and our overall financial condition</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates third-party payors for any approved drug products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drug products and our overall financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> drug candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment outcomes with our drug products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our drug candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">A variety of risks associated with marketing our drug candidates internationally may materially adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We plan to eventually seek regulatory approval of our drug candidates outside of the United States and, accordingly, we </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">differing regulatory requirements in foreign countries, such as the lack of pathways for accelerated drug approval, may result in foreign regulatory approvals taking longer and being more costly than obtaining approval in the United States;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials or our interpretation of data from nonclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">impact of health epidemics, including COVID-19, on our ability to produce our drug candidates and conduct clinical trials in foreign countries;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">compliance with legal requirements applicable to privacy, data protection, information security and other matters;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;   </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">profitable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Our Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our drug candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our drug candidates, proprietary technologies and their uses that are important to our business. We may also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending applications from third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or the patent applications of any current or future licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, found unenforceable or invalidated by third parties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties or the patent owner before various patent offices or in courts. Thus, the degree of future protection for our and any current or future licensors&#8217; proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties or limitations in our ability to properly protect the intellectual property rights relating to our drug candidates could have a material adverse effect on our financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We cannot be certain that the claims in our pending patent applications or those of any current or future licensors will be considered patentable by the USPTO courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our owned or in-licensed patents will not be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our drug candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">patents and patent applications may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes to patent laws in the United States or in other countries may limit the ability to obtain, defend or enforce patents, or may apply retroactively to affect the terms or scope of patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential drug candidates;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope or term of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The patent prosecution process is also expensive and time-consuming, and we and any current or future licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or any current or future licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed. Certain of these parties may also be subject to public information disclosure statutes and could determine to disclose patentable aspects of our research and development output pursuant to a request thereunder, notwithstanding the existence of a non-disclosure and confidentiality agreement. Any of these actions could jeopardize our ability to seek patent protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates or their use might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications and those of any current or future licensors may not result in patents being issued which protect our drug candidates or their use or which effectively prevent others from commercializing competitive product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or in-license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or may be narrowed, invalidated or rendered unenforceable as a result of challenges by third parties. Consequently, we do not know whether our drug candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents or the patents of any current or future licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents or the patents of any current or future licensors may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">PGR, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> review, or IPR, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our drug candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, our patents or the patents of any current or future licensors may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our claim of priority of invention, scope, validity or patentability with respect to our patents and patent applications and those of any current or future licensors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For example, in view of the lawsuits disclosed elsewhere in this report including in this &#8220;Risk Factors&#8221; section under the heading &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">&#8212;We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert management&#8217;s attention</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,&#8221; and in &#8220;Part I, Item 3&#8212;Legal Proceedings,&#8221; third parties may challenge the validity or enforceability of our in-licensed patents and patent applications. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar technology and drug products such as other modifications to dihexa not covered by our issued patents. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our in-licensed patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future drug candidates. Further, these proceedings could have a material adverse effect on our business, results of operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even though we own patents and patent applications covering fosgonimeton and its use, our patents and any future patents we obtain may not effectively prevent others from developing or commercializing products similar to our drug candidates. While the fosgonimeton patent family is distinct from, and not part of the same patent family as, the dihexa patent licensed from WSU, and therefore is not implicated in the allegations that Dr. Kawas altered images in connection with her doctoral studies, third parties may use these allegations to cast doubt on the validity and enforceability of our owned patents or patent applications. Such events may result in substantial cost and require significant time from our scientists and management, and could dissuade companies from collaborating with us to license, develop, or commercialize current or future drug candidates, even if the eventual outcome is favorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We or WSU may in the future file one or more requests for supplemental examination of certain patents for the USPTO to reconsider the enforceability and validity of the patents (including any patents relating to dihexa) in view of the allegations that Dr. Kawas altered images in connection with her doctoral studies. The outcome of any supplemental examination procedure is unpredictable. If a substantial new question of patentability is found, the USPTO Director will order ex parte reexamination of the patent. An adverse determination in such a proceeding could reduce the scope of, or invalidate or render unenforceable, the affected patent rights. While supplemental examination proceedings that result in our favor would bolster the presumption of validity and enforceability of the examined patents, third parties may still challenge the patents and patent applications in litigation or other legal proceedings.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">others may be able to develop products that are similar to our drug candidates but that are not covered by the claims of the patents that we own or license;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we or any current or future licensors or collaborators might not have been the first to make the inventions covered by the issued patents or patent application that we own or license;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we or any current or future licensors or collaborators might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">it is possible that the pending patent applications we own or license will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the patents of others may have an adverse effect on our business; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our drug candidates and drug products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation and other legal actions, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, reexaminations, IPR proceedings and PGR proceedings and oppositions before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing drug candidates. There may be third-party patents or patent applications with claims to compositions, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our drug candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents or patent applications that may be infringed by commercialization of any of our drug candidates, and we cannot be certain that we were the first to file a patent application related to a drug candidate, its use, or our technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our drug candidates or their use may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our drug candidates that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any defense to claims of patent infringement asserted by third parties would be time consuming and could:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">result in costly litigation that may cause negative publicity;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cause development delays;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">prevent us from commercializing any of our drug candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">subject us to significant liability to third parties; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent our drug candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our drug candidates, treatment indications, or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our drug candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion for management and other personnel. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or a future strategic partner were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our drug candidates, our treatment indications, or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our drug candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our drug candidates and technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our drug candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property, or if we are unable to maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or any current or future licensors&#8217; patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or any current or future licensors&#8217; patents could be found invalid or unenforceable if challenged in court.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable, or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our drug candidates or their method of use, the defendant could counterclaim that our patent or the patent of any current or future licensors is invalid or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including allegations of a lack of novelty, obviousness, lack of sufficient written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent application misrepresented or fraudulently withheld relevant information from the USPTO or made a misleading statement during prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, PGR, IPR, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents or any current or future licensors&#8217; patents in such a way that they no longer cover our technology or platform, or any drug candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to a validity claim, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any drug candidates that we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The outcome following legal assertions of invalidity or unenforceability is unpredictable, and prior art could render our patents or any current or future licensors&#8217; patents invalid. There is no assurance that all potentially relevant prior art relating to our patents and patents applications or the patents and patent applications of any current or future licensors has been found. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or the patents and patent applications of any current or future licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Additionally, a finding that issued claims lack sufficient written description or are not enabled could render our patent or any current or future licensors&#8217; patent invalid.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If a third party were to prevail on a legal assertion of invalidity or unenforceability, we may lose at least part, and perhaps all, of the patent protection on such drug candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of any current or future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented drug product and practicing our own patented technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Intellectual property litigation or legal proceedings may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the course of any intellectual property litigation or legal proceeding, there could be public announcements of the initiation of the litigation or legal proceeding as well as results of hearings, rulings on motions, and other interim proceedings. If securities analysts or investors regard these announcements as negative, the perceived value of our existing drug candidates, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future drug products, which could have a material adverse effect on our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of any current or future licensors or of third parties. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other personnel. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our drug candidates to market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of any current or future licensors and the enforcement or defense of our issued patents or those of any current or future licensors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that filed a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours or our current or future licensors even if we or our current or future licensors had made the invention before it was made by such third party. This requires us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we may not be certain that we or any current or future licensors are the first to either (1) file any patent application related to our drug candidates, their use, or our technology or (2) invent any of the inventions claimed in the patents or patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Leahy-Smith Act also included a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of printed publications to the USPTO during patent prosecution and additional procedures to attack the validity or enforceability of a patent by USPTO-administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims or those of our current or future licensors that would not have been invalidated if first challenged by the third party in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of any current or future licensors and the enforcement or defense of our issued patents or those of any current or future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future. As an example, European patent applications now provide the option, upon grant of a patent, of becoming a Unitary Patent, which is subject to the jurisdiction of the Unitary Patent Court, or UPC. The option of a Unitary Patent is a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation in the UPC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our drug candidates or their use are obtained, once the patent life has expired, we may be open to competition from competitive products, including generic versions of our drug products. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug products similar or identical to ours.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for our drug candidates, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, one or more of our U.S. patents or those of any current or future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our drug candidates, although the requirements and terms of such extensions vary country-by-country. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products or launch generic versions of our drug products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and nonclinical data and launch their drug product earlier than might otherwise be the case.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We will not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own and in-license patents and pending patent applications in the United States and in jurisdictions outside of the United States. However, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we will not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing drug products made using our inventions in and into the United States or other jurisdictions. Competitors may use our inventions in jurisdictions where we have not obtained patent protection to develop their own drug products and, further, may export otherwise infringing drug products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These drug products may compete with our drug candidates, and our patents, the patents of any current or future licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or any current or future licensors&#8217; patents or marketing of competing drug products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of any current or future licensors at risk of being invalidated or interpreted narrowly and our patent applications or the patent applications of any current or future licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Geopolitical actions could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have a predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents or applications and those of any current or future licensors. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:14.25pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our drug products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest, and it may be difficult and costly to register, maintain or protect our rights to these trademarks and trade names in jurisdictions in and outside of the United States. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with our employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party improperly disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have entered into and may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners, lessees of shared multi-company property and other third parties. We may become subject to litigation where a third party asserts that we or our employees inadvertently or otherwise breached the agreements and used or disclosed their trade secrets or other information proprietary to the third parties. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our drug candidates. Failure to defend against any such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, operating results, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our drug candidates. Many of these consultants, and many</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize our drug candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have entered into license agreements with third parties and we may enter into additional license agreements in the future with others to advance our research and development or allow commercialization of drug candidates. These and other licenses may not provide exclusive rights to use such intellectual property and other rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our drug candidates in the future. Further, these and other licenses may also include certain restrictions or obligations that limit our ability to engage with third parties, including potential restrictions on sublicensing or outsourcing certain activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering our drug candidates that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If any of our current or future licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our licensors and any future licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-license. If it is later determined that third parties own the rights to our in-licensed patents, or if other third parties have ownership rights to our in-licensed patents, such third parties may be able to license such patents to our competitors, and our competitors could market drug products similar or identical to our drug candidates. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same rights licensed to us. In that event, we may be required to expend significant time and resources to redesign our drug candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current manufacturing methods, drug candidates, methods of use, or future methods or drug candidates resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights or other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Disputes may arise between us and our current or future licensors regarding intellectual property and other rights subject to a license agreement, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">whether and the extent to which our drug candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our right to sublicense to third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our right to transfer or assign the license;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, the agreements under which we license intellectual property or other rights from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or other rights, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property or other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize drug candidates covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, drug products identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The patent protection and patent prosecution for some of our drug candidates may be dependent on third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patent applications and patents relating to our drug candidates and their use, there may be times when the filing and prosecution activities for patent applications and patents relating to our drug candidates are controlled by licensors or collaboration partners. If a licensor or collaboration partner fails to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patent applications and patents covering our drug candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those drug candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling drug products similar or identical to our drug candidates. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a manufacturing preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers, which could adversely affect our ability to successfully develop and commercialize our drug products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We entered an exclusive license agreement with WSU for certain licensed patents that include intellectual property that was generated through the use of U.S. government funding, and we received a grant from the NIA of the NIH to support our ACT-AD clinical trial.  Pursuant to the Bayh-Dole Act, the U.S. government may have certain rights in any invention developed or reduced to practice with government funding. In addition, in the future we may discover, develop, acquire, or license new intellectual property that has been generated through the use of U.S. government funding or grants in which the U.S. government may have certain rights pursuant to the Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). Such &#8220;march-in&#8221; rights would apply to new subject matter arising from the use of such government funding or grants and would not extend to pre-existing subject matter or subject matter arising from funds unrelated to the government funding or grants. If the U.S. government exercises its march-in rights in our intellectual property rights that are generated through the use of U.S. government funding or grants, we could be required to license or sublicense intellectual property discovered or developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. Reporting of a subject invention and compliance with the Bayh-Dole Act requirements were delayed for the patent family directed to methods of treating AD with fosgonimeton. As such, this patent family may be subject to U.S. government action which may include loss of rights in the subject invention, suspending or terminating the grant or future awards, or withholding further awards. Should any of these events occur, it could significantly harm our business, results of operations and prospects. In addition, the Bayh-Dole Act requires that, in certain circumstances, any products embodying intellectual property generated with the use of U.S. government funds or produced through the use of any such intellectual property be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property, which could adversely affect our ability to successfully develop and commercialize our drug products and have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Cybersecurity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are dependent on networks, infrastructure and data, which exposes us to data security risks, including security failures or breaches of our systems or those used by our CROs or other contractors or consultants. We are dependent upon our own or third-party information technology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">systems, infrastructure and data, including mobile technologies, to operate our business. The multitude and complexity of our computer systems may fail or suffer security breaches.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As discussed in this report in "Part I, Item I.C&#8212;Cybersecurity,&#8221; we have implemented various processes and policies for identifying, assessing, and managing material risks from cybersecurity threats. However, despite the implementation of such safeguards and security measures, our internal computer systems and those of our CROs and other contractors and consultants may nevertheless be vulnerable to damage from computer viruses and unauthorized access. Likewise, data privacy or security incidents or breaches by employees or others may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public or may otherwise be misused. Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our personal, sensitive, confidential or proprietary information and information technology systems, and those of the third parties upon which we rely. For example, in April 2023, CRO Evotec SE faced a cybersecurity attack that temporarily disrupted its systems and operations. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. Increases in remote work impacting how our employees work and access our systems could lead to additional opportunities for bad actors to launch cyberattacks or for employees to cause inadvertent security risks or incidents and may amplify the impacts of any security breach or incident. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may rely on third-party service providers and technologies to operate critical business systems to process sensitive information and other company data in a variety of contexts. We may also rely on third-party service providers to provide certain products or services, or otherwise to operate our business. Our ability to monitor these third parties' information security practices is limited, and these third parties may not have adequate information security measures in place. Security incidents or other interruptions suffered by our third-party service providers could cause us to experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy- or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business partners face similar risks, and any security breach of, or security incident impacting, their systems or that they otherwise suffer could adversely affect our security posture. A security breach or incident or privacy violation that leads to loss of or unauthorized use, disclosure or modification of, or access to trade secrets, company resources, personal, sensitive, confidential or proprietary information, including protected health information or other patient information, or that prevents access to patient information, as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">well as the perception that any of the foregoing has occurred, could harm our reputation, compel us to comply with federal or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, cause us to provide other notification or take other steps in response to such breach or violation, require us to verify the correctness of database contents and otherwise subject us to litigation, claims, investigations, penalties or other liability under laws and regulations, any of which could disrupt our business or result in increased costs or loss of revenue or company resources. Moreover, the prevalent use of mobile devices that access confidential information, increase the risk of security breaches and incidents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite efforts to create security barriers to the above-described threats, it is impossible for us to entirely mitigate these risks. To date, we have not experienced any material impact to our business, financial position or results of operations resulting from cyberattacks or other information security incidents such as phishing, social engineering, ransomware or malware attacks; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of such attacks, our business, financial position or results of operations could be adversely impacted in the future. We may be unable to anticipate or prevent techniques used to obtain unauthorized access or to compromise our systems because they change frequently and are generally not detected until after an incident has occurred. If a compromise or other security breach or incident were to occur and cause the loss or corruption of data or interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss, unavailability, or corruption of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any disruption or security breach or incident resulting in loss or unavailability of, or damage to, our data or systems, or inappropriate use, disclosure or modification of personal, sensitive, confidential or proprietary information, could result in us incurring liability and in delays to further development and commercialization of our drug candidates could be delayed. While we have invested, and continue to invest, in the protection of our data and information technology infrastructure, there can be no assurance that our efforts will prevent service interruptions, or prevent or identify vulnerabilities or security breaches or incidents, that could adversely affect our business and operations or result in the loss, unavailability, or corruption of, or inappropriate access to or use of, critical or sensitive information or company resources. Any such interruptions, breaches or incidents, or the perception any have occurred, could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other privacy and security breaches or incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As we conduct our clinical trials and continue to enroll patients in our current and future clinical trials, we may be subject to additional restrictions relating to privacy, data protection and data security. The collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals in the European Economic Area, or EEA, is subject to the EU General Data Protection Regulation, or GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Certain aspects of cross-border data transfers under the GDPR are subject to uncertainty, including as the result of legal proceedings in the EU. For example, in 2020, the Court of Justice for the EU invalidated the EU-U.S. Privacy Shield and imposed additional obligations in connection with the use of standard contractual clauses approved by the EU Commission. These and other developments with respect to cross-border data transfers may increase the complexity of transferring personal data across borders and may require us to review and amend our mechanisms relating to cross-border data transfer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, the exit of the United Kingdom, or UK, from the EU has created uncertainty regarding data protection regulation in the UK. The UK has implemented legislation similar to the GDPR, referred to as the UK GDPR, which provides for fines of up to the greater of up to the greater of &#163;17.5 million or 4% of global turnover. The GDPR and UK GDPR increased our responsibility and liability in relation to personal data that we process where subject to these regimes, and we may be required to put in place or modify policies and measures to ensure compliance with the GDPR, including as implemented by individual countries, and the UK GDPR, each of which may require us to modify our policies and procedures and engage in additional contractual negotiations, and which may cause us to incur liabilities, expenses, costs, and operational losses. Compliance with the GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite our efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our activities in the EEA and the UK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, in the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). California has enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The California Privacy Rights Act of 2020 (CPRA), which became operative January 1, 2023, expands the CCPA&#8217;s requirements, including applying to personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA and CPRA may increase compliance costs and potential liability with respect to other personal data we maintain about California residents. Additionally, numerous other states have proposed or enacted laws addressing privacy and security, including Washington's My Health, My Data Act, and several laws imposing obligations similar to those of the CCPA. The CCPA, CPRA, and other evolving legislation relating to privacy, data protection, and information security may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA/CPRA, require us to impose specific contractual restrictions on our service providers, and we may also be subject to use and disclosure limitations in our contracts with providers who share information with us for clinical trials. Additionally, we may publish privacy policies, marketing materials and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources. These obligations may necessitate changes to our business model, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Any actual or alleged failure to comply with U.S. or international laws and regulations relating to privacy, data protection, and information security could result in governmental investigations, proceedings and enforcement actions (which could result in civil or criminal penalties), private litigation or adverse publicity, harm to our reputation, and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information or impose other obligations or restrictions in connection with our use, retention and other processing of information, and we may otherwise face contractual restrictions applicable to our use, retention, and other processing of information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with laws relating to privacy, data protection, or information security, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Relating to Ownership of Our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert management&#8217;s attention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As described elsewhere in this report in &#8220;Part I, Item 3&#8212;Legal Proceedings,&#8221; we and certain of our executive officers and directors have been named as defendants in a class action lawsuit that generally alleges that we and certain of our officers and directors violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and Sections 11, 12, and 15 of the Securities Act by making allegedly false or misleading statements and omitting material adverse facts regarding our business. Certain of our executive officers and directors have also been named as defendants in derivative actions, which are based on similar allegations, and generally allege that defendants breached their fiduciary duties to us, among other things. We are named as a nominal defendant in these derivative proceedings. These complaints seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys&#8217; fees, and other relief. As of the date of this report, we are unable to predict the outcome of these matters. Although we have insurance, it provides for a substantial retention of liability and is subject to limitations and may not cover a significant portion, or any, of the expenses or liabilities we may incur or be subject to in connection with class action lawsuit or other litigation to which we are party. Moreover, any conclusion of these matters in a manner adverse to us and for which we incur substantial costs or damages not covered by our directors&#8217; and officers&#8217; liability insurance would have a material adverse effect on our financial condition and business. In addition, the litigation has caused and will continue to cause our management and board of directors to divert time and attention to the litigation and could adversely impact our reputation and further divert management and our board of directors&#8217; attention and resources from other priorities, including the execution of our business plan and strategies that are important to our ability to grow our business and advance our drug candidates, any of which could have a material adverse effect on our business. In addition, additional lawsuits may be filed, the conclusion of which in a manner adverse to us and for which we incur substantial costs or damages not covered by our directors&#8217; and officers&#8217; liability insurance would have a material adverse effect on our financial condition and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Actions by activist stockholders have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business could be negatively affected as a result of stockholder activism, which could be disruptive and cause uncertainty about the strategic direction of our business. For example, in February 2022, an activist stockholder announced his intention to nominate himself and one other candidate for election to our board of directors at our 2022 annual meeting of stockholders. While this proxy contest was unsuccessful, stockholder activism could recur and have an adverse effect on our business, results of operations, and financial condition. For example, at times our market capitalization has been less than the aggregate value of our cash, cash equivalents and investments. Other biotechnology companies in this situation have received proposals from shareholder activists to liquidate and return capital to investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We strive to maintain constructive communications with our stockholders and welcome their views and opinions with the goal of enhancing value for all stockholders. However, a proxy contest or other activist behaviors could have an adverse effect on us because:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">responding to actions by activist stockholders can disrupt our operations, is costly and time-consuming, and diverts the attention of our board of directors and senior management team from the pursuit of business strategies, each of which could adversely affect our results of operations and financial condition;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">perceived uncertainties as to our future direction as a result of changes to the composition of our board of directors may lead to the perception of a change in the direction of our business, as well as instability or lack of continuity, all of which may be exploited by our competitors, may result in the loss of potential business opportunities, may cause concern for those enrolling in our clinical trials, and make it more difficult to attract and retain qualified personnel and business partners;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">actions by activist stockholders may interfere with any efforts that we undertake in the future to raise capital;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">actions by activist stockholders could cause significant fluctuations in our stock price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">if individuals are elected to our board of directors with a specific agenda as a result of a proxy contest, it may adversely affect our ability to effectively implement our business strategy and to create additional value for our stockholders.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if a proxy contest or other activist efforts are not successful, the increased costs that we would bear and the distraction of our board of directors and senior management could negatively impact our business, although we cannot predict with certainty the extent of such negative impacts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We do not know whether an active market for our common stock will be sustained, and, as a result, it may be difficult for you to sell your shares of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If an active market for our common stock is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our drug product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The market price of our common stock may be volatile. As a result, you may not be able to sell your common stock at or above the price that you paid for such shares. Some of the factors that may cause the market price of our common stock to fluctuate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">results of nonclinical studies and clinical trials;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential impact of health epidemics, including COVID-19, on our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the success of existing or new competitive products or technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing and results of clinical trials for our current drug candidates and any future drug candidates that we may develop; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">commencement or termination of collaborations for our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">failure or discontinuation of any of our drug candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">results of nonclinical studies, clinical trials or regulatory approvals of drug candidates of our competitors, or announcements about new research programs or drug candidates of our competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">investor reactions to other companies&#8217; drug development results, including product failures or negative responses from regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">negative press coverage;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the status of ongoing litigation and government investigations and potential commencement of additional litigation or investigations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the results of the investigation by the independent special committee of the board of directors and the separate ongoing investigation by WSU;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the level of expenses related to any of our research programs, drug candidates that we may develop; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the results of our efforts to develop additional drug candidates or drug products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">announcement or expectation of additional financing efforts, including, but not limited to, under our ATM offering; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">sales of our common stock by us, our insiders, or other stockholders; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">volatility with the banking system; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">direct or indirect impacts on our business, our suppliers and other third parties and our clinical sites as a result of geopolitical events, including the Russia-Ukraine war;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">general economic, industry, and market conditions; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the other factors described in this &#8220;Part I, Item 1A&#8212;Risk Factors&#8221; section. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. In addition, shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available-for-sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, as of December 31, 2023, the holders of approximately 5.7 million shares of our common stock are eligible to exercise certain rights, subject to various conditions and limitations, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also register shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our directors, executive officers and significant stockholders own a substantial percentage of our common stock, which could limit your ability to affect the outcome of key transactions, including a change of control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our directors, executive officers, significant holders of our outstanding common stock and their respective affiliates beneficially own a substantial amount of our outstanding common stock as of December 31, 2023. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, Section 404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. We cannot predict whether investors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Failure to build and maintain our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the regulations of The Nasdaq Global Select Market, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. We must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. We may experience difficulty in meeting these reporting requirements in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The process of building and maintaining our accounting and financial functions and infrastructure has required and will continue to require significant additional professional fees, internal costs and management efforts. Any disruptions or difficulties in implementing or using such a system could adversely affect our controls and harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. In addition, we may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware or Washington law could make an acquisition of us difficult, limit attempts by our stockholders to replace or remove our current management and limit our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, the amended and restated certificate of incorporation and amended and restated bylaws:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">permit the board of directors to issue up to 100,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provide that the authorized number of directors may be changed only by resolution of the board of directors;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">divide the board of directors into three classes;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provide that a director may only be removed from the board of directors by the stockholders for cause;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be taken by written consent;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s notice;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">prevent cumulative voting rights (therefore allowing the holders of a plurality of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provide that special meetings of our stockholders may be called only by the chairman of the board, our chief executive officer or by the board of directors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provide that stockholders are permitted to amend the bylaws only upon receiving at least two-thirds of the total votes entitled to be cast by holders of all outstanding shares then entitled to vote generally in the election of directors, voting together as a single class.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Likewise, because our principal executive offices are located in Washington, the anti-takeover provisions of the Washington Business Corporation Act may apply to us under certain circumstances now or in the future. These provisions prohibit a &#8220;target corporation&#8221; from engaging in any of a broad range of business combinations with any stockholder constituting an &#8220;acquiring person&#8221; for a period of five years following the date on which the stockholder became an &#8220;acquiring person.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court in Delaware or the federal district court for the District of Delaware) will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising under the Delaware General Corporation Law, our certificate of incorporation or our amended and restated bylaws; any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or our amended and restated bylaws; and any action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar exclusive federal forum provisions in other companies&#8217; organizational documents has been challenged in legal proceedings, and while the Delaware Supreme Court has ruled that this type of exclusive federal forum provision is facially valid under Delaware law, there</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">is uncertainty as to whether other courts would enforce such provisions and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find either exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our advisors and consultants are classified as independent contractors, and we can face consequences if it is determined that they are misclassified as such.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There is often uncertainty in the application of worker classification laws, and consequently there is risk to us that our independent contractors could be deemed to be misclassified under applicable law. The tests governing whether a service provider is an independent contractor or an employee are typically highly fact sensitive and can vary by governing law. Laws and regulations that govern the status and misclassification of independent contractors are also subject to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">divergent</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> interpretations by various authorities, which can create uncertainty and unpredictability. A misclassification determination or allegation creates potential exposure for us, including but not limited to monetary exposure arising from or relating to failure to withhold and remit taxes, unpaid wages, and wage and hour laws and requirements (such as those pertaining to minimum wage and overtime); claims for employee benefits, social security, workers&#8217; compensation and unemployment; claims of discrimination, harassment, and retaliation under civil rights laws; claims under laws pertaining to unionizing, collective bargaining, and other concerted activity; and other claims, charges, or other proceedings under laws and regulations applicable to employers and employees, including risks relating to allegations of joint employer liability. Such claims could result in monetary damages (including but not limited to wage-based damages or restitution, compensatory damages, liquidated damages, and punitive damages), interest, fines, penalties, costs, fees (including but not limited to attorneys&#8217; fees), criminal and other liability, assessment, or settlement. Such an allegation, claim, adverse determination, including but not limited to with respect to advisors and consultants that provide services to us could also harm our brand and reputation, which could adversely impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If </span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If no or few analysts commence coverage of us, the trading price of our stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and we expect that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we will continue to need to hire, additional accounting, finance, and other personnel in connection with our efforts to comply with the requirements of being a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We continue to evaluate and monitor these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of Sarbanes-Oxley Act Section 404, which require annual management assessments of the effectiveness of our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The rules governing the standards that must be met for management to determine that our internal control over financial reporting is effective are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Attention to ESG (environmental, social and governance) matters may cause us to incur additional costs or expose us to additional risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A variety of stakeholder groups, including investors, governmental and nongovernmental organizations are focused on corporate environmental, social and governance, or ESG, practices. Our ESG practices may not meet the standards of our investors or other stakeholders, and they as well as advocacy groups may campaign for us to change our business, operations or practices to better address ESG-related concerns. A failure, or perceived failure, of us to respond to any such campaigns could harm our business and reputation and have a negative impact on the market price of our common stock. Moreover, if ESG best practices, reporting standards and disclosure requirements continue to develop, we may incur increasing costs related to ESG monitoring and reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1B. Unresolved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Cybersecurity Risk Management Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have implemented various processes and policies for identifying, assessing, and managing material risks from cybersecurity threats. Our cybersecurity risk management strategy is designed following the Cybersecurity Framework set by the National Institute of Standard and Technology, or NIST.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We assess our information technology, or IT, environment against the NIST Cybersecurity Framework, as well as various cyber-attack vectors, working to identify and remediate risks. We implement reasonable administrative, technical and procedural safeguards to manage cybersecurity risks, for example, by enforcing single sign-on or multi-factor authentication where supported, and the use of mobile device management to secure company resources on employee personal devices. Additionally, we engage third-party cybersecurity experts to assess the security of our network and perform continuous system monitoring, and we engage a third party to perform internal audits of our IT General Controls, or ITGCs. We have implemented certain processes to oversee and identify risks from cybersecurity threats associated with our use of third-party service providers, for example, by evaluating such service providers&#8217; own cybersecurity processes and reviewing available certification and audit reports, including International Organization for Standardization, or ISO, certifications for information security management systems, and System and Organization Controls, or SOC, reports.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At this time, we have not experienced cybersecurity incidents, or are aware of any risks from cybersecurity threats, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Cybersecurity Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Board of Directors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our board of directors is responsible for general oversight and regular review of information regarding our risks, including cybersecurity risks. Members of management communicate an overview of our current cybersecurity environment to our board of directors at least annually and provide updates to our board of directors regarding cybersecurity matters periodically throughout the year. Additionally, our third-party auditors inform the audit committee of our board of directors of our ITGC framework and control testing results, which include controls related to cybersecurity risks. Further, management has established cybersecurity incident response processes for escalating the communication of cybersecurity incidents up to the board of directors, as appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Management</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Material risks from cybersecurity threats are assessed and managed by a dedicated team comprised of internal and external IT professionals experienced in cybersecurity threat risk management, who ultimately report to our chief operating officer. Our chief operating officer has extensive strategic and operational experience at several life sciences companies, leading a wide range of business functions, including IT. Our technology team leader has over 20 years of experience with IT and cybersecurity risk management, having served in senior executive-level IT positions at multiple Fortune 500 companies and companies within the life sciences industry.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The technology team leader oversees our internal team of IT professionals, which continuously monitors our IT environment for cybersecurity threats and incidents. Our IT professionals routinely report on cybersecurity incident prevention, detection, mitigation, and remediation efforts to our technology team leader and chief operating officer. Additionally, we have established policies addressing processes for responding to potential cybersecurity incidents, including assessment, communication, and remediation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">protocols. Our incident response processes further provide for the escalation of cybersecurity incidents to our executive management team and board of directors, as appropriate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">operties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our corporate headquarters is located in Bothell, Washington, where we currently lease approximately 19,326 square feet of laboratory and office space, which leases expire in August 2027. We believe these facilities will be adequate for the foreseeable future and that suitable additional or substitute space will be available as and when needed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, we are subject to various legal proceedings or claims that arise in the ordinary course of business. The following is a brief description of the more significant legal proceedings in which we are involved.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Securities Class Actions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On June 25, 2021, plaintiffs Fan Wang and Hang Gao filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against us and our former chief executive officer, Dr. Leen Kawas, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang v. Athira Pharma, Inc., et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Exchange Act, and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding our business. Specifically, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiffs allege that we failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU including the manipulation of data, and that as a result, the defendants&#8217; positive statements about our business, operations, and prospects were materially misleading. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys&#8217; fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">That same day, on June 25, 2021, plaintiff Harshdeep Jawandha filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against us, Dr. Kawas, our then chief financial officer, certain members of our board of directors at the time of our IPO, as well as the IPO underwriters, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha v. Athira Pharma, Inc., et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00862. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that that our IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas&#8217;s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to Athira&#8217;s efforts to develop treatments for Alzheimer&#8217;s, that, as a result, and that the defendants&#8217; positive statements about our business, operations, and prospects were materially misleading. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys&#8217; fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Also on June 25, 2021, plaintiffs Timothy Slyne and Tai Slyne filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against us, Dr. Kawas, our then chief financial officer, and the same members of our board of directors and underwriters as in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> complaint, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne v. Athira Pharma, Inc. et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00864. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas&#8217;s doctoral research at WSU should have been disclosed in our IPO registration statement. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> plaintiffs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek unspecified compensatory damages, reasonable costs and expenses, including attorneys&#8217; fees, and injunctive and other equitable relief.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against us, Dr. Kawas, our then chief financial officer, certain members of our board of directors at the time of our IPO and secondary public offering, or SPO, and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas&#8217;s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs&#8217; consolidated amended complaint for failure to state a claim under the federal securities laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On August 12, 2022, defendant Dr. Kawas filed a motion for partial reconsideration of the court&#8217;s July 29, 2022 order. On October 4, 2022, the court denied the motion. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, we and Dr. Kawas filed our individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On March 10, 2023, following a mediation and the parties&#8217; agreement in principle to settle the securities class action for $10.0 million, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffs&#8217; motion for preliminary approval without prejudice, citing the motion&#8217;s failure to satisfy the court&#8217;s questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffs&#8217; renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024 proposing a date on which the court may schedule the final approval hearing, among other things. In its order, the court preliminarily approved the proposed settlement and certified a class and two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a result of the foregoing, we recorded a legal settlement expense of $10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $10.0 million on the accompanying consolidated balance sheets. Additionally, we recorded an insurance recovery of $1.6 million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $1.6 million on the accompanying consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by our insurers.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Shareholder Derivative Actions</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of our board of directors, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bushansky v. Kawas et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:22-cv-497. Plaintiff purports to bring the action derivatively on our behalf, and we are a nominal defendant to the action. The derivative complaint alleges that our board of directors breached its fiduciary duties by failing to prevent alleged misstatements in our public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint seeks unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys&#8217; fees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain of our current and former directors and officers, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Houlihan v. Kawas et al</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">., No. 2:22-cv-620. Plaintiff purports to bring the action derivatively on our behalf, and we are a nominal defendant to the action. The derivative complaint alleges that certain of our current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in our public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint seeks unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys&#8217; fees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. We believe we have adequate reserves related to this matter as of the balance sheet date.</span></p>
  <p style="font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Government Investigations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2022, we received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand seeks documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH and our receipt of a NIH grant in 2020. We are cooperating with the Department of Justice with respect to the Demand.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2023, the SEC sent us a subpoena seeking documents and information relating to, among other things, our former chief executive officer's alterations of images in certain research papers. We are cooperating with the SEC with respect to the subpoena.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We cannot predict the outcome of these lawsuits or government investigations. Failure by us to obtain a favorable resolution of these actions could have a material adverse effect on our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our common stock began trading on The Nasdaq Global Select Market under the symbol &#8220;ATHA&#8221; on September 18, 2020. Prior to that date, there was no public trading market for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of February 16, 2024, there were approximately 42 holders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We currently intend to retain all available funds and future earnings to fund the development and growth of our business and we do not anticipate paying any cash dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a smaller reporting company, we are not required to provide the information requested by this item pursuant to Item 201(e) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Issuer Repurchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 6. [</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">eserved].</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">You should read the following management&#8217;s discussion and analysis of financial condition and results of operations in conjunction with our consolidated financial statements and notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section of this Annual Report on Form 10-K titled &#8220;Risk Factors&#8221; and elsewhere in this report. You should carefully read the &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section of this report titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Our approach is designed to modulate the neurotrophic HGF system, that is critical to normal brain function and may play a key role in maintaining the health and functioning of neuronal networks. We believe that by acting on the neurotrophic HGF system and its multiple downstream signaling pathways, we may be able to enhance the body&#8217;s natural ability to protect and repair neuronal networks by reducing inflammation, promoting regeneration, and reducing disease-specific protein pathologies, thereby positively impacting the course of disease. We aim to achieve these goals by advancing our pipeline of novel small molecule compounds which are designed to and have exhibited properties in enhancing the neurotrophic HGF system in either the CNS, by crossing the BBB, or the PNS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our lead drug candidate, fosgonimeton, is a potentially first-in-class, small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of CNS disorders. The effects of fosgonimeton in its primary target indication, AD, are currently being evaluated in multiple clinical trials:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ACT-AD* was a randomized, double-blind, placebo-controlled, parallel-group 26-week exploratory Phase 2 clinical trial in mild-to-moderate AD, with ERP P300 latency as the primary endpoint. Initiated in November 2020, the trial was designed to better characterize the overall effects of fosgonimeton on working memory processing speed and cognitive measures and inform the Phase 2/3 LIFT-AD trial. Topline results for this exploratory Phase 2 ACT-AD trial were announced in June 2022, and the primary and all secondary endpoints were not met by protocoled analysis. However, a post hoc analysis of results from ACT-AD in a pre-specified subgroup suggested positive effects on measures of cognition, function and neurodegeneration in participants taking fosgonimeton alone without background AChEIs. Additionally, data from post hoc analysis of plasma biomarkers from participants on fosgonimeton without background AChEIs showed descriptive improvements (non-statistically significant) in markers of neuroinflammation and AD-specific protein pathologies when compared to placebo. Fosgonimeton was generally well tolerated in the ACT-AD study, with a favorable safety profile, and there were no treatment related serious adverse events or deaths observed.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">LIFT-AD is a randomized, double-blind, placebo-controlled, parallel-group 26-week Phase 2/3 clinical trial with fosgonimeton for the treatment of mild-to-moderate AD. In September 2020, we began site initiation and patient screening for LIFT-AD. The primary endpoint for the Phase 2/3 LIFT-AD trial will be measured by the GST, which is a composite score that combines the scores from cognition (ADAS-Cog11), and function (ADCS-ADL23). Guided by the results from the completed exploratory ACT-AD Phase 2 trial, in September 2022, we proactively amended LIFT-AD to focus on participants not on background AChEIs. In October 2022, we announced that following an unblinded interim efficacy and futility analysis, an independent DMC recommended </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continuation of the LIFT-AD trial. The committee also determined that, with the additional enrollment of fewer than 150 participants for a total enrollment of less than 300 participants without background AChEIs, the amended trial will be well powered for the primary endpoint given the preliminary effect size observed. In May 2023, we further amended LIFT-AD to focus on 40 mg dosing, which we have selected for further development and as the potential dose for regulatory approval of fosgonimeton in this indication. This selection was based on a review of the totality of the preclinical and clinical data, biomarker results, observations from the open label extension study and in consultation with independent regulatory and biostatistical consultants based on patients treated with 40 mg fosgonimeton without concomitant AChEIs. In January 2024 we announced the completion of enrollment with a total of 318 patients randomized. We expect to report topline LIFT-AD results in the second half of 2024. In July 2023, we completed an end of Phase 2 meeting with the FDA to gain alignment on our plans for the continued clinical development of fosgonimeton as a treatment for mild-to-moderate AD. During this meeting we provided an update and discussed with the FDA the ongoing LIFT-AD trial, including use of the 40 mg dose, concomitant AChEIs use, biomarker analyses including NfL, and the SAP. The FDA noted the importance of showing effects on both cognition (ADAS-Cog11) and function (ADCS-ADL23) in the trial population. The FDA is open to ongoing dialogue with us regarding the LIFT-AD trial once completed as well as other aspects of our program to develop fosgonimeton as a potential treatment for mild-to-moderate AD.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2021, we announced that we are enrolling participants into a 26-week OLEX trial* for our LIFT-AD and ACT-AD clinical trials, allowing us to collect up to a total of one year of safety data with fosgonimeton. In May 2022, we announced that we extended the 26-week OLEX for our LIFT-AD and ACT-AD clinical trials for an additional 12 months, enabling eligible participants who have completed either trial and elect to participate in the ongoing OLEX to receive up to 18 months of open-label treatment with fosgonimeton. In May 2023, we amended the OLEX to further extend the trial by an additional 12 months. Eligible participants who have completed the LIFT-AD or ACT-AD trials and elect to participate in the ongoing OLEX may now receive up to 30 months of open-label treatment, which allows us to collect up to 36 months total of long-term exposure data.</span></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">*The ACT-AD trial and the related OLEX for ACT-AD participants have been supported by a grant from the National Institute on Aging of the National Institutes of Health under Award Number R01AG06268. The information presented is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following figure illustrates the current development stage of our proprietary drug candidates and early discovery and development programs. Our pipeline consists of both BBB permeable and peripherally restricted drug candidates for CNS, PNS and other indications. In addition, we are exploring the use of our ATH compounds in additional indications in the CNS and PNS as we aim to improve neuronal health in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">multiple neurodegenerative diseases. Our drug discovery efforts are focused on designing and testing new early compounds to enhance the HGF/MET system for a variety of clinical applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105269759_22.jpg" alt="img105269759_22.jpg" style="width:624px;height:269px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We constantly strive to grow and optimize our portfolio through in-house discovery and plan on additional external business development activities enabled by our innovative internal research and development capabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We were incorporated in March 2011 and since our inception, we have devoted substantially all of our resources to our research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. We do not have any drug products approved for commercial sale, and we have not generated any revenues related to our drug products since inception. Our ability to generate drug product revenue sufficient to achieve profitability, if ever, will depend on the successful development of one or more of our drug candidates which we expect will take a number of years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are focused on the development of small molecule therapeutics which enables us to use well-established and widely available manufacturing processes and infrastructure, formulation compositions and drug administration technologies or devices. We do not currently operate our own facilities for manufacturing, storing, or distributing our drug candidates. We utilize third-party CMOs to manufacture and supply our preclinical and clinical materials during the development of our drug candidates. We believe the synthesis of fosgonimeton is reliable and reproducible and the synthetic methods can be further optimized to enable large-scale production that continues to avoid use of toxic materials or specialized equipment or handling during the manufacturing process. We plan to continue to optimize the manufacturing process to support future large-scale and commercial supply. Our goal is to identify and develop small molecule drug candidates that are cost-effective to manufacture and easily transferable to third party CMOs. We expect to use similar contract resources for commercialization of our drug products, at least until our resources and operations are at a scale that justifies investment in internal manufacturing capabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of our drug candidates. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To date, we have funded our operations primarily through proceeds from the sale of equity securities, including proceeds from the sale and issuance of common stock in our IPO and in a subsequent follow-on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">public offering, the sale and issuance of convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From inception to December 31, 2023, we have raised aggregate net cash proceeds of approximately $407.4 million primarily from the issuance of our common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. We have incurred significant operating losses to date. Our net losses were $117.7 million and $95.6 million for the years ended December 30, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $309.2 million and cash, cash equivalents and investments of $147.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to continue to incur increasing operating losses for the foreseeable future as we:</span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue to advance fosgonimeton and our other drug candidates through preclinical studies and clinical trials, and continue the open label extension of the ACT-AD and LIFT-AD trials;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expand our pipeline of drug candidates;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue to grow our discovery organization and invest in the ATH platform;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ramp up manufacturing activities;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attract, hire and retain additional personnel;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtain, maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">operate as a public company;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expand our laboratory and office facilities;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">implement and maintain operational, financial and management information systems;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek regulatory approval for any drug candidates that successfully complete clinical trials;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval; and</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">incur legal expenses associated with ongoing litigation, as further described in &#8220;Part I, Item 3&#8212;Legal Proceedings,&#8221; and elsewhere in this report.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will require substantial additional funding to support our continuing operations and further the development of our drug candidates. Until such time as we can generate significant revenue from drug product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaboration, licensing or similar arrangements, for the foreseeable future.  Adequate funding may not be available when needed or on terms acceptable to us, or at all. If we are unable to raise additional capital as needed, we may have to significantly delay, scale back or discontinue development of our drug candidates. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our drug product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to drug candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. Based upon our current operating plan, we estimate that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Collaboration and Grant Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Amended and Restated WSU License Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are party to an amended and restated exclusive license agreement with sublicensing terms with WSU that we entered into in 2015. Under this agreement, we have an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration. The term of the license continues until the earlier of the date in which no valid claim remains enforceable and the payment of royalties ceases for more than four consecutive quarters after such royalty payments begin.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The initiation of our first Phase 2 clinical trial in September 2020 triggered a $50,000 liability to WSU, which was paid in full as of December 31, 2020.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are obligated to pay to WSU the following if the related milestones are reached:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$300,000 &#8211; At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$600,000 &#8211; Marketing approval in the United States, European Union or Japan for the first licensed product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are obligated to pay WSU a royalty in the mid-single digits of net sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, under the agreement we have the right to sublicense the licensed rights, subject to additional payments to WSU for sublicense consideration received. Such amounts are dependent on the terms of the underlying sublicense, and range from the mid-single digits to mid tens of any non-sales based payments received, and low twenties of net sales-based sublicense royalties.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">National Institutes of Health Grant</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2020, we accepted a grant from the NIH to support our ACT-AD Phase 2 clinical trial for fosgonimeton. Under the terms of the agreement and approval received from the NIH, we were awarded an aggregate of $15.2 million, all of which had been received as of December 31, 2023. For additional information regarding this grant, see the section of this report titled &#8220;Business&#8212;Our Collaboration and Grant Agreements.&#8221; We recognized $0.2 million and $5.2 million of income related to our NIH grant during the years ended December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022, we received cash of $1.4 million and $6.3 million, respectively, in connection with the NIH grant. As of December 31, 2022, we had incurred qualifying expenses in excess of cash received of approximately $1.2 million, which is included in unbilled grant receivable on the consolidated balance sheets. As of December 31, 2023, we had recognized aggregate grant income of $15.2 million in connection with the NIH grant, equal to the total grant amount approved. We will not recognize any additional grant income in connection with the NIH grant in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of the ATH platform, our drug discovery efforts and the development of our drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of the date of this report, we cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our drug candidates. Drug candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase for the foreseeable future as we continue to invest in research and development activities related to developing our drug candidates, as our drug candidates advance into later stages of development, as we conduct larger clinical trials, as we seek regulatory approvals for any drug candidates that successfully complete clinical trials, as we expand our drug product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts. In particular, we have seen, and expect to continue to see, our research and development expenses increase as we conduct our clinical trials for fosgonimeton, including open-label extensions for those trials. Additionally, we may experience an overall increase in research and development expenses as a result of inflation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our drug candidates is highly uncertain. Our research and development expenses may vary significantly based on factors such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number and scope of preclinical and IND-enabling studies;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the phases of development of our drug candidates;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the progress and results of our research and development activities;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">per subject trial costs;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number of trials required for regulatory approval, in particular with respect to fosgonimeton for the treatment of mild-to-moderate AD (including any potential confirmatory or Phase 3 registrational trials);</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the continuation of the open label extension of the ACT-AD and LIFT-AD trials;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number of sites included in the trials;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the length of time required to enroll eligible subjects and initiate clinical trials;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number of subjects that participate in the trials;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the drop-out and discontinuation rate of subjects;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the duration of subject participation in the trials and follow-up;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost and timing of manufacturing of our drug candidates;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the receipt of regulatory approvals from applicable regulatory authorities;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the hiring and retention of research and development personnel;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the degree to which we obtain, maintain, defend and enforce our intellectual property rights; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the impact of health epidemics, including COVID-19, on timelines and clinical operations, which may lead to increased costs; and</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the extent to which we establish collaboration, licensing or similar arrangements and the performance of any related third parties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of any of our drug candidates could significantly change the costs and timing associated with the development of that drug candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, business development fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect that our general and administrative expenses will increase for the foreseeable future as we increase our headcount to support our continued research activities and development of our programs. We also anticipate that we will continue to incur expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services. We expect continued legal expenses related to our ongoing legal proceedings and proposed settlement to resolve such claims. We also expect to continue to increase the size of our administrative function to support the growth of our business. Additionally, we may experience an overall increase in general and administrative expenses as a result of inflation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Legal Settlement and Insurance Recovery Related to Legal Settlement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Legal settlement expense and insurance recovery related to legal settlement consist of the proposed settlement of the securities class action litigation and the amount to be covered by our insurers. For more information see Part I, Item 3 &#8220;Legal Proceedings&#8212;Securities Class Actions".</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Grant Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Grant income consists of income related to the NIH grant and is recognized as qualifying expenses under the grant agreement are incurred. As of December 31, 2023, we had recognized aggregate grant income of $15.2 million in connection with the NIH grant, equal to the total grant amount approved. We will not recognize additional grant income in connection with the NIH grant in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other income, net consists primarily of interest earned on our cash, cash equivalents and investments and the amortization of premiums and accretion of discounts on our available-for-sale securities. Absent further fundraising, we expect interest earned on our cash, cash equivalents and investments to decrease as we continue to expend our cash balances to fund our ongoing operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes our results of operations for the periods presented:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.001999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.602%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Dollar</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">93,790</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">61,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32,326</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">53</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">33,304</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32,552</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">752</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Legal settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(10,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Insurance recovery related to legal settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,628</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,628</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">125,466</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">104,016</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21,450</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(125,466</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(104,016</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(21,450</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Grant income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">157</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,161</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(5,004</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(97</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7,637</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3,216</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4,421</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">137</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(117,672</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(95,639</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(22,033</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">23</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table shows the primary components of our research and development expenses for the periods presented:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.32%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:9.1%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:11.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:11.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:9.52%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Dollar</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Direct costs:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Fosgonimeton (ATH-1017)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">66,524</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">39,416</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">27,108</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">69</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">ATH-1020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">704</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,874</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,170</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(62</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Preclinical programs and other direct costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6,619</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,978</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">641</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">11</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total direct costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">73,847</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">47,268</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">26,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Indirect costs:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Personnel-related costs, including stock-<br/>&#160;&#160;&#160;based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">17,955</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">12,620</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,335</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">42</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Facilities and other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,988</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,576</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">412</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">93,790</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">61,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32,326</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">53</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development expenses increased by $32.3 million, from $61.5 million for the year ended December 31, 2022 to $93.8 million for the year ended December 31, 2023. The increase was driven primarily by an increase in expenses for fosgonimeton of $27.1 million related to continued patient enrollment and clinical site visit activity for our Phase 2/3 clinical trial and the corresponding open-label extension for our Phase 2 and Phase 2/3 clinical trials, as well as higher costs relating to manufacturing process development and increases in manufacturing batch size capabilities, an increase in personnel-related costs of $5.3 million due to changes in headcount and an increase in stock-based compensation expense in connection with current period equity grants to new hires and existing employees, an increase in preclinical research and development expenses of $0.6 million, and an increase of $0.4 million related to facilities and other indirect costs, partially offset by a decrease in ATH-1020 program expenses of $1.2 million.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General and administrative expenses increased by $0.7 million, from $32.6 million for the year ended December 31, 2022 to $33.3 million for the year ended December 31, 2023. The increase was primarily due to an increase in personnel-related expenses of $1.0 million driven by changes in headcount, an increase in consulting and professional services expenses of $0.7 million, an increase in business development expenses of $0.4 million, and an increase in facilities expenses of $0.3 million, partially offset by a decrease in general corporate expenses of $0.9 million and a decrease in legal costs of $0.8 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Legal Settlement Expense and Insurance Recovery Related to Legal Settlement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In connection with the proposed settlement of the securities class action litigation, we recorded a legal settlement expense of $10.0 million for the year ended December 31, 2022. Additionally, we recorded an insurance recovery of $1.6 million for the year ended December 31, 2023, representing the amount of the settlement to be covered by our insurers. For more information see the section of this report titled &#8220;Legal Proceedings&#8212;Securities Class Actions".</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Grant Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Grant income decreased by $5.0 million, from $5.2 million for the year ended December 31, 2022 to $0.2 million for the year ended December 31, 2023. Grant income recognized during the year ended December 31, 2023 of $0.2 million represented the remaining balance of the total $15.2 million approved grant amount available at the beginning of the year, all of which was recognized during the three months ended March 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other income, net, increased by $4.4 million, from $3.2 million for the year ended December 31, 2022 to $7.6 million for the year ended December 31, 2023 due to higher income from accretion of discounts on debt securities purchased below par value and held to maturity, in addition to higher interest income earned on our available-for-sale securities resulting from rising interest rates on debt securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since our inception, we have funded our operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From our inception through December 31, 2023, we have raised aggregate net cash proceeds of $407.4 million primarily from the issuance of our common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had $147.4 million in cash, cash equivalents and investments and have not generated positive cash flows from operations. Since our inception, we have devoted substantially all of our resources to our research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Material Cash and Future Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our material cash requirements include our operating leases for laboratory and office facilities. As of December 31, 2023, we had lease payment obligations of $1.8 million, with $0.5 million payable within 12 months. For additional information regarding our lease commitments, see Note 7 to our consolidated financial statements included elsewhere in this report. We are contingently committed to $0.9 million of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential future milestone payments, in addition to sales-based payments and royalties, under our license agreement with WSU. Payments generally are due and payable only upon achievement of certain developmental, regulatory, and sales milestones for which the specific timing cannot be predicted. Refer to Note 6 to our consolidated financial statements for additional information regarding the WSU license agreement. Additionally, we have purchase obligations and open purchase orders that support normal operations and are primarily due in the next 12 months. These purchase obligations and open purchase orders are generally cancellable in full or in part through the contractual provisions. We also anticipate that our research and development expenses and our general and administrative expenses will increase over at least the near-term as we advance our clinical development and our drug candidates through clinical trials, increase our headcount to support our operations, and incur legal and other professional expenses related to our ongoing legal proceedings. We cannot predict with certainty the amount and timing of these increased expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based upon our current operating plan, we estimate that our $147.4 million of cash, cash equivalents and investments at December 31, 2023 will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report. We will need to raise substantial additional capital to fund the development of our drug candidates. Until such time as we can generate significant revenue from drug product sales, we expect to finance our operations through the sale of equity securities, debt financings, or other capital, which could include income from collaboration, licensing or similar arrangements with third parties, or receiving research contributions, or grants. For example, in January 2023, we entered into a sales agreement with Cantor Fitzgerald and BTIG to sell shares of our common stock having aggregate sales proceeds of up to $75.0 million, from time to time, through an ATM equity offering program under which Cantor Fitzgerald and BTIG are acting as sales agents. As of the date of this report, we have not sold any securities pursuant to this ATM offering. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our drug product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to drug candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope, timing, progress and results of our ongoing preclinical studies and clinical trials of our drug candidates;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number of trials required for regulatory approval, in particular with respect to fosgonimeton for the treatment of mild-to-moderate AD;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other drug candidates that we may pursue;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to establish and maintain collaboration, licensing or other similar arrangements, and the financial terms of any such arrangements, including the timing and amount of any future milestone, royalty or other payments due thereunder;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs, timing and outcome of regulatory review of our drug candidates;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs and timing of future commercialization activities, including drug product manufacturing, marketing, sales and distribution, for any of our drug candidates for which we receive marketing approval;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the revenue, if any, received from commercial sales of our drug candidates for which we receive marketing approval;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs related to ongoing legal proceedings;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">any expenses needed to attract, hire and retain skilled personnel;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs of operating as a public company;</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs associated with expanding our laboratory and office facilities; and</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the extent to which we acquire or in-license other companies&#8217; product candidates and technologies or engage in other strategic transactions.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A change in the outcome of any of these or other factors with respect to the development of any of our drug candidates could significantly change the costs and timing associated with the development of that drug candidate. Furthermore, our operating plan may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plan.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.897%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(100,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(72,469</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">95,089</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">57,664</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">493</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">654</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(5,171</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(14,151</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, net cash used in operating activities was $100.8 million. This consisted primarily of a net loss of $117.7 million, partially offset by non-cash charges of $10.4 million and a decrease in our net operating assets of $6.5 million. The non-cash charges primarily consisted of stock-based compensation expense, depreciation expense, and amortization of premiums and accretion of discounts on our available-for-sale securities. The decrease in our net operating assets was primarily due to a decrease in unbilled grant receivable and an increase in accounts payable and accrued expenses, partially offset by the recognition of an insurance recovery receivable related to the securities class action litigation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2022, net cash used in operating activities was $72.5 million. This consisted primarily of a net loss of $95.6 million, partially offset by non-cash charges of $11.2 million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and a decrease in our net operating assets of $11.9 million. The non-cash charges primarily consisted of stock-based compensation expense, depreciation expense, and amortization of premiums and accretion of discounts on our available-for-sale securities. The decrease in our net operating assets was primarily due to a decrease in unbilled grant receivable, an increase in accounts payable and accrued expenses, and an accrual for legal settlement expenses related to the securities class action litigation, partially offset by an increase in prepaid expenses and other current assets.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, net cash provided by investing was $95.1 million. This consisted of maturities of available-for-sale securities of $123.1 million, partially offset by purchases of available-for-sale securities of $27.7 million and property and equipment of $0.3 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2022, net cash provided by investing was $57.7 million. This consisted of maturities of available-for-sale securities of $154.1 million, partially offset by purchases of available-for-sale securities of $95.3 million and property and equipment of $1.1 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, net cash provided by financing activities was $0.5 million, consisting of proceeds received from exercises of stock options.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2022, net cash provided by financing activities was $0.7 million, consisting of proceeds received from exercises of stock options.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Grant Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2020, we accepted a grant from the NIH to support our ACT-AD Phase 2 clinical trial for fosgonimeton. As of December 31, 2023, we have recognized aggregate grant income of $15.2 million in connection with the NIH grant, equal to the total grant amount approved and we will not recognize any additional grant income in connection with the NIH grant. We recognized income related to the NIH grant within the consolidated statement of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred. We recorded qualifying expenses incurred in excess of cash received in unbilled grant receivable on the consolidated balance sheets.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs, including costs associated with our clinical trials, are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. We estimate the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, we will adjust the amounts recorded accordingly. We have not experienced any material differences between accrued or prepaid costs and actual costs since inception.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We maintain a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We recognize stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based compensation costs for stock options are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Because we were privately held prior to September 2020 and do not yet have sufficient trading history for our common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">See Note 9 to our consolidated financial statements included elsewhere in this report for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We recorded stock-based compensation expense of $10.6 million and $10.6 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there was $16.0 million of total unrecognized stock-based compensation expense related to non-vested stock options which we expect to recognize over a remaining weighted-average period of 1.99 years. We expect to continue to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We recognize deferred income taxes for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. In evaluating our valuation allowance, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had $9.5 million of federal NOL carryforwards and $12.4 million of tax credit carryforwards which expire over a period of 8 to 14 years. As of December 31, 2023, we had $138.7 million of such NOLs that do not expire. As of December 31, 2023, we also had state net operating loss carryforwards of $3.3 million, which expire over a period of 18 to 20 years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, substantial changes in our ownership may limit the amount of NOL and research and development credit carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state NOL carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if cumulative changes in ownership exceeds 50% within any three-year period. We have not completed a Section 382/383 analysis under the Code regarding the limitation of NOL and credit carryforwards. If a change in ownership were to have occurred, the annual limitation may result in the expiration of NOL carryforwards and credits before utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We record unrecognized tax benefits as liabilities or reduce the underlying tax attribute, as applicable, and adjust them when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">See Note 2 to our consolidated financial statements included elsewhere in this report for additional information.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Emerging Growth Company Status</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company and (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year in which the fifth anniversary of our initial public offering occurred.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a smaller reporting company, we are not required to provide the information requested by this item pursuant to Item 305 of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Index to Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-family:Arial;"><ix:nonNumeric id="F_aa1eace3-1e30-43da-b214-52f0a8add3a6" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Consolidated Statements of Stockholders' Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_unaudited_condensed_consolidate"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">140</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">eport of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To the Stockholders and the Board of Directors of Athira Pharma, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Athira Pharma, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_f4c159d8-8ecc-4383-a6f5-3403b9623165" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2018.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_261056d5-ea41-4e39-8f1c-24c42ad5d6c4" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Seattle, Washington</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">135</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">alance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:61.64%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:14.18%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:17.18%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6454332f-8b73-4198-8283-8af0605f63c2" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,584</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2d8cdd0-f472-440f-9c0a-9d0754cb4ae9" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca82a795-7f51-4752-8686-b26f07bf1973" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2fb53b4-ffdd-4309-a231-55def65dcbed" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,378</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unbilled grant receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d894d79-448b-4892-9262-b2ae67ce3ecc" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="atha:UnbilledGrantReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb91448e-5a2e-4ee5-a001-972e5ef4fa92" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8041bc6-cf1b-4641-829f-c9e00cc0eb39" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,962</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Insurance recovery receivable related to legal<br/>&#160;&#160;&#160;settlement (Note 7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc24044d-9651-49cf-a3f9-99780736da87" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:InsuranceSettlementsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0859c435-8536-493c-9559-3d884d46e142" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,729</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4498946-9e3c-4874-8c38-4e2f4af2a7c5" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,533</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72c9b6d9-31f4-4e93-a7c5-6ed2563ef6fb" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03c16c83-069c-499d-ac70-690860b82af5" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b598461d-0d7e-426f-9dee-231ab4277bfb" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,388</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88ad8841-200b-47c3-9949-a9f4e89c2b19" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,053</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a09e98a-5a77-428a-9d6d-7812fa226b85" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,049</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0577975a-9084-4a17-a457-c3d9abdad433" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Long-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_459b6c8d-f7d4-48e4-a2a6-2bb74dc18ceb" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_837e2882-8c4e-4dd8-a930-577613cfc3ca" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf3969d8-c6db-445e-a61b-86b09986b44a" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1acf749-050f-4d0c-88d1-dda553776d7e" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be21ea31-835b-4cee-9c3e-7151cf3cd8c1" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bd0abd7-9c8e-4478-91e5-2da8fd42abcd" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1803487c-7f54-477f-a298-5b7dc4dee33f" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,501</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40b277d6-0260-422f-a822-5324e45009f9" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,343</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62544e47-2610-4601-b826-6ce7349a365d" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued legal settlement (Note 7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4869d438-6230-4c7f-9564-5393e9e86158" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e068bd2a-2068-47f1-be1b-a6c46da0e7ef" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c97614d-b99c-4142-a626-59e4f0432bf8" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a1eba38-dc1d-4776-981e-f665df2ddce6" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e0209a8-80f4-4846-97e6-fda6df6dab05" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0a90e98-e25f-4f29-8fd7-f76760066224" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liability, less current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fb99bcb-09fd-49f1-9b37-b8e46beab7b1" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9110324d-fe2b-42f0-9b68-423ee0ac4365" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,585</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12b92181-d40e-4365-83d6-f3b58f6183cc" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_999e639a-e373-48ff-81ac-b38326c93af5" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Common stock, $</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e712a6a-2dc7-4ff8-86c5-93513e85e542" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_3a4d8585-b645-4a20-a0a0-0375dcdacc81" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;par value; </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f11bf4df-dc18-43eb-9c82-0f78196e2679" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b363f0a4-a2ff-4a0b-9e53-29097dc41aa8" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">900,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;shares <br/>&#160;&#160;&#160;authorized at December 31, 2023 and December 31, 2022, <br/>&#160;&#160;&#160;respectively; </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dda03be-689f-44e1-b5dc-760b97ffabdb" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b5704737-e656-44ea-9de7-da8b2c57fd95" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,172,603</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;and </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_674222cd-5151-4c29-9ca6-74e55ebf6aa6" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_099c998e-4532-4806-87a9-1909dfba147b" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,877,387</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;shares issued<br/>&#160;&#160;&#160;and outstanding at December 31, 2023 and December 31,<br/>&#160;&#160;&#160;2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_911f69c3-23cf-4583-82dc-ffc1363d6bf4" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55c03263-0344-4bb7-8eae-cc8fdfcdb9db" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dda5c6f-adcd-4266-b763-a6e7235f610d" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8425b109-86e1-46a7-a21e-12207ea898b4" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df3ab6ff-1cc1-4a8b-8736-1d2b9fc4f58a" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6082c9e7-1a01-4618-a5bb-7793a8034dc6" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97a1f562-7e2f-4cb6-9b28-b236ff6697d4" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">309,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b86999bc-fd33-4f20-b875-3aee5b982acc" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">191,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_867d036f-f25e-4acb-b421-4b383829f1b1" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e831535-6dc3-4b65-a310-17acdc6a3e2d" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,137</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1191983e-b5c5-4eb3-baf5-ebf8b5747d37" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2d88191-2a5d-4e6b-b870-0b8682d9ea49" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">136</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consolidated Statements of Ope</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">rations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d724a475-3fb5-41ad-a95c-baee1c1b454b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e3be7ff-126c-4e7f-8495-8c2ab6c50038" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41cd6e85-a86f-4661-80a2-29348e821368" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8427f55-a10a-49a3-9bc7-4d3dc07a243b" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Legal settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbbf3436-fae3-45a5-aa11-36870976e586" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:LitigationSettlementExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Insurance recovery related to legal settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eb9fd5a-d15d-4334-a0f6-8a341d4a5bfb" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:InsuranceRecoveries" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41950d62-3ed8-4ad7-9294-44a1ca1b57cc" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,466</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1292b5ff-010c-4963-82c7-ba65e06492c6" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e569aa7-2b65-4a26-a728-51eee26d3b3c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,466</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8986ccfd-224a-44fd-b4e4-d287ba21b586" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">104,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Grant income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6426937-75e9-49cb-89db-57a0ed85baee" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca33427-b378-42e2-9f39-8cf9754de354" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="atha:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8cfa22f-7a6c-4f95-b4b6-543137275fd1" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,637</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d24a8cff-014b-4741-b665-30ee0e5cc517" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b2f073b-ef9a-459e-a3da-acb294b0e20b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6df01ed5-1879-47f0-8a15-e345cc5065f2" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized gain (loss) on available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a130db3e-7392-4b71-a625-f7bf4a731c83" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5f0518b-caa1-44ee-b120-1863cf3e7353" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d1bfd8a-9805-442c-8497-76cc9bd214b0" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b20283-e92b-4f3c-aa73-305fa8f62cc5" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share attributable to common<br/>&#160;&#160;&#160;stockholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c240b0ea-8342-4415-b7a9-ee741d63774c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9d59cbef-694c-4c2f-9515-7edb87e11eb6" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.09</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfec29e8-59a4-412c-a681-9fe67c2170c6" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ac4cfb7e-f2e7-4741-b5ba-6e5f1236d0d8" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.53</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average shares used in computing<br/>&#160;&#160;&#160;net loss per share attributable to common<br/>&#160;&#160;&#160;stockholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ddcae88-8a1d-4c0b-8564-c2481e361527" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fb1fabc8-a142-40ea-b97f-d8973e853052" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">38,020,182</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_764f51a8-cf71-44c4-9d4e-55459e22ba5d" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_65707767-b59d-41f7-acae-b3d2e010d1f4" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,733,240</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30.839%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:8.626999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:8.147%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:8.147%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:9.447999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:8.147%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:8.147%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of January 1, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75da91fd-923e-4848-9245-97029cf6a1a1" contextRef="C_49dc3275-db5d-457d-9e82-3b59ada8e823" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,379,077</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78a1ba22-dc1d-453d-adb0-76a769341ccd" contextRef="C_49dc3275-db5d-457d-9e82-3b59ada8e823" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4cdae48-49da-46a4-a999-ca1dbb298695" contextRef="C_f87c6bfa-07b2-48b3-b0a9-3098dcc3e0c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">417,363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d494ac8d-d651-44f8-970d-0abf34a32f18" contextRef="C_efe731a6-8644-49ad-81df-a7f77a40963f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">388</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5967c3b-299a-4497-8c74-8ef92538ed71" contextRef="C_4e32575d-a6b9-41a8-91fa-2a9ebdb1b43a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82c2306c-b4b8-4e7d-bb4a-84ec84df58bd" contextRef="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">321,084</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock upon exercise of<br/>&#160;&#160;&#160;common stock options and vesting of<br/>&#160;&#160;&#160;restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02645baf-683e-4727-ac19-a07dae97a2f3" contextRef="C_91a3cdff-44c7-4be8-8690-9251ebfd8a0b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">419,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_430a577c-963a-4fa4-8214-92306ec915bc" contextRef="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69f6357a-7b99-42ab-9857-094f5aabcb00" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock under<br/>&#160;&#160;&#160;employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17a12739-ffae-4e8f-930a-ec932e634a57" contextRef="C_91a3cdff-44c7-4be8-8690-9251ebfd8a0b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">78,361</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_166cdbc0-714c-4e3b-918d-8a2a9be7970d" contextRef="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c75f0144-f0e4-432b-b67f-f4ab1c4a807b" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c27bedc7-0220-431f-9b96-c5abe0a690cb" contextRef="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7926d48b-0add-413c-a9a9-3fb24a61d9c2" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc9820e1-ef99-4fa8-8989-c9b092d045ee" contextRef="C_28696d50-3838-41f2-a0ee-404e5265a50e" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13071ec6-f027-4712-ba1e-fdf4b4df3b63" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00aa9105-210c-4dda-8f51-472e8feb4886" contextRef="C_1a260444-47e3-4eab-963c-2dcc49dd3cc1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbb0e9a9-5dc1-4763-a04a-0a808a6040b0" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd0a0cd6-88ff-45ff-81cf-b3693337ef92" contextRef="C_42990ac9-086f-46cd-8523-da23f22d1e85" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,877,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_887df976-a164-42eb-975e-9290598b0d59" contextRef="C_42990ac9-086f-46cd-8523-da23f22d1e85" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c9761b9-2ca4-46e0-93d2-a7bc98711aea" contextRef="C_1a2f43c4-1117-4672-90c6-75792b11123e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10f15bdf-b3cc-45ff-841f-b7638ef5910b" contextRef="C_39cb2c60-d4de-4766-bbf7-e3322d14b6f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c70654c-8fb8-4942-95e9-afe5e721d3f1" contextRef="C_a516322c-a580-416f-a571-a5d4cce10d51" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">191,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05a57b58-4f41-48fb-a7d1-e7a400f8a1ed" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,137</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock upon exercise of<br/>&#160;&#160;&#160;common stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b66f75-7b2e-4332-8b6e-25087105957d" contextRef="C_bf2c465b-8587-438c-a9ea-4095cfc62594" name="atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">128,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac87c4ee-56e0-4205-bbc4-7d728e43f6b6" contextRef="C_a58c8276-7213-4745-af91-33501a2c6737" name="atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e8ec307-f9f1-4363-a829-6f412aba3e4d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock under<br/>&#160;&#160;&#160;employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd51b2bc-1215-48f4-90b3-b2635e213334" contextRef="C_bf2c465b-8587-438c-a9ea-4095cfc62594" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">166,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9561c21d-f292-43fc-a947-ff079a84212b" contextRef="C_a58c8276-7213-4745-af91-33501a2c6737" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cdfd5c4-9b68-4420-8583-fb266c16353b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c805998-ff5b-40f1-bd9d-46a6e7c12005" contextRef="C_a58c8276-7213-4745-af91-33501a2c6737" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fdfc992-5ea9-4718-acd0-3b8742f081fe" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68b2b96c-92f0-4e1d-a305-2179e302e5b1" contextRef="C_3b2efe00-aef3-4b37-ae0e-6491160765f3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_194e302e-f54b-46a1-8e34-f11f9623cb25" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_300d9a3b-9bdd-4b43-aced-dfbd5dd3a5b0" contextRef="C_4726f01b-7636-4549-a578-0b2798df0841" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f4c7d06-e47a-42a7-999f-3e978ad75194" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c3652b4-c5b9-49ed-9aa5-b674da80dbf1" contextRef="C_eaee46db-7780-4ebe-846f-913aa5aea294" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,172,603</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a00aa878-e52b-4d1f-9ebb-4a19311f018e" contextRef="C_eaee46db-7780-4ebe-846f-913aa5aea294" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82e7dfbc-9870-4c4f-be1b-97efed43d6cf" contextRef="C_89aa2ae1-d511-40d1-b6b5-55800463bae5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c915fad-c57e-4955-b61b-d828979b60a3" contextRef="C_f8d204cf-7cc0-42a8-aeea-d8322af589cd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4d5c7a8-ad03-4de2-9b9b-50f7b937dbc1" contextRef="C_897ba1ad-56e2-437d-9cf7-9403bc286825" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">309,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c60d8076-6d87-4010-9daf-01d6c47ac2d8" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_214017f5-9abd-4b28-aded-73b67f686e75" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1aa3060-b2c1-4523-8591-d4be2f26f7e1" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:28pt;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_668ef31e-b44d-4977-882c-3d4867a009de" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93566066-85fc-4e50-adab-4b06ddfa577c" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67d0493c-2b1b-4c23-a0d7-3e9a2fc5811e" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56291506-2645-4586-a903-1bb40e12b5c0" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b660f4-f302-4c8f-b2ca-aa7438fec6a7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ed66582-07d6-4315-a4d9-e857293ab208" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Amortization of premiums and accretion of discounts on<br/>&#160;&#160;&#160;available-for-sale securities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c90cf984-8495-44b3-be31-d58d1e2b3065" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,414</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6a0fa98-2c6c-4a47-a97a-fd0289e7755b" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:28pt;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:42pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unbilled grant receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e15c3ed4-a4e2-47ac-b58c-be41fc373cf8" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:IncreaseDecreaseInUnbilledGrantReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,227</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11c24dd4-2df1-407e-a1aa-3fe6a928c1ba" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="atha:IncreaseDecreaseInUnbilledGrantReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,109</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:42pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other current and long-term assets, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c80c2a7f-bfae-4004-8484-9cbd253427d7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7834f8d9-e807-42f5-a0e1-7a347647a710" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:42pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Insurance recovery receivable related to legal settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22963cb4-bef7-49d6-8e67-632f5cd1f94d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:42pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accounts payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df89004a-3138-44a8-8f8d-64c5dd2060e9" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9f957e4-0b1c-45b6-a943-39a4a4341a2e" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,101</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:42pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued legal settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8f98531-5fba-49b8-823a-bb05be3aed3a" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="atha:IncreaseDecreaseInAccruedLegalSettlement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:42pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a328dd13-76e0-45e1-81c0-5bfc81238434" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0afdc923-3d92-4892-bd5a-0fe686463d6a" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:56pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:56pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6c28f0f-6069-4edb-8e28-8648040e68cc" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100,753</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a22b751c-7075-4165-a074-cca88832abf6" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Purchases of available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34c78476-9e91-468f-a9d6-1a2cf19cf0c8" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,671</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332a4730-6a67-43cb-89a9-c13de20a0141" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Maturities of available-for-sale securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff180d9c-a7c1-4253-bea6-d97dac12e8b7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57264dbe-70bd-4079-bcb4-4698f6bd76a4" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,093</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f250ff2-ab43-44a3-8659-3429afaa0610" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a844069-ffa8-41c3-945c-24060cd89786" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:56pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:56pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75efb0f6-3c8d-4cdc-8ec1-54fd7b73d6fd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,089</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_990c27de-ce5c-4948-9901-cc97bfb6091a" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,664</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Proceeds from exercise of common stock options and issuance<br/>&#160;&#160;&#160;of common stock under employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26de9625-e22d-4beb-9d42-2d515d250309" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f1a1258-a01c-436f-99ea-5e4a190bd583" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="atha:ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">654</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:56pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:56pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_442f17b4-17d0-4de8-8528-e40a518744fd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f26389c6-6d00-4a76-a29b-f236532e3324" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">654</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fb620d5-3943-4ed3-8ddf-641024c5815b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,171</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd55be34-096d-4ce8-a4ff-3a395f0476c1" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,151</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5afb549-f3d3-4462-91ef-9251613a04bb" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62f2856b-df36-4289-9799-8431c6749486" contextRef="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,537</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb02045-3ca8-41d2-8ebf-94da39562145" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fc00c4e-56a4-4be7-bb61-3053984b7fe0" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ATHIRA PHARMA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_unaudited_condensed_consolidate"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Notes to Co</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">nsolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_7bc632c3-5703-4236-b537-dde1a071cc93" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1. Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc. (the &#8220;Company&#8221;) was incorporated as M3 Biotechnology, Inc. in the state of Washington on </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_cf9893d6-18de-45f3-826b-0f4334608a5a" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">March 31, 2011</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and reincorporated in the state of Delaware on </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_28edcb9c-3a0b-4c17-ae20-ac1b78a4da25" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:EntityReincorporationDateOfReincorporation" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">October 27, 2015</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since the Company&#8217;s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company&#8217;s inception through December 31, 2023, it has raised aggregate net cash proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68540617-0aae-47fd-9c52-968adbe784f8" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">407.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million primarily from the issuance of its common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abe2f733-4205-4ba4-82b0-3d2c88ce0425" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:InvestmentsAndCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">147.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in cash, cash equivalents, and investments and had not generated positive cash flows from operations. Since the Company&#8217;s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company&#8217;s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based upon the Company&#8217;s current operating plan, it estimates that its $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58f3a63a-56b7-4aab-bc97-a1c719c0ff73" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:InvestmentsAndCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">147.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million of cash, cash equivalents, and investments at December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the date of the Company&#8217;s Annual Report on Form 10-K.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">At The Market Common Stock Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In January 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the Company entered into a sales agreement with Cantor Fitzgerald and BTIG to sell shares of our common stock having aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2637dfe-9144-4e0e-a34d-d230eb1090fd" contextRef="C_5545a951-56b7-41cd-9b84-87819c3182e2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, from time to time, through an &#8220;at the market&#8221; (&#8220;ATM&#8221;) equity offering program under which Cantor and BTIG are acting as sales agents. The Company has </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_911c1b1a-d39a-400f-8e06-4566dfde2f50" contextRef="C_f18bc7ab-5af1-44c8-924a-3f2688d049f8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">not</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> sold any securities pursuant to this ATM offering.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_644ebdfe-7ae7-4551-a349-17880239931f" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_8a820bdd-9880-4ece-bcee-fe2f95b7d5f4" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_33fbb955-7b0a-4975-9a55-85b4ab4f8aab" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">140</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">factors </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d0e761dc-fc5c-44d8-9f43-b3af560d874a" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1ea70a7b-748a-497a-a4c0-104faf053ad2" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Restricted cash consists primarily of collateral pledged in connection with the Company's corporate credit cards. </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_838acaab-6291-4d1e-90f8-36a81f2d70b2" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true" continuedAt="F_838acaab-6291-4d1e-90f8-36a81f2d70b2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_838acaab-6291-4d1e-90f8-36a81f2d70b2_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;"/>
          <td style="width:1.62%;"/>
          <td style="width:1%;"/>
          <td style="width:12.883%;"/>
          <td style="width:1%;"/>
          <td style="width:1.62%;"/>
          <td style="width:1%;"/>
          <td style="width:12.883%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bce973df-ff0b-4771-9d15-ca4f99bf98e5" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,584</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3511c026-74a4-417d-bae0-9c5b5d15abf7" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,966</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13fa9c1f-bca7-4c20-86d7-842ea1d03e9f" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48a8831d-212f-4517-9a7e-155908a33549" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">420</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77e8dbf9-32ab-4f2c-9eb2-e61f38ee8bd0" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,215</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09d50a39-dc19-44a3-b83e-b7c0c6a1f5e7" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,386</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d1e6f610-88d0-4264-ac1b-349421c25d5e" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Short-term and Long-term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_15f86720-951a-49b7-b0aa-c0d9ba4152cc" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_184fb083-e0fc-4e20-851c-0bb95b5e4b10" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_184fb083-e0fc-4e20-851c-0bb95b5e4b10_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment consist of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment, excluding leasehold improvements, are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life, generally </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_b400847d-1662-41db-b50c-4bdbe2ef14f7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_47de4f7c-6401-480e-9111-649bd46ad8df" contextRef="C_a7402318-2099-403e-80e2-e4d9762b5a2a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of their useful life or the remaining lease term. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess of the asset's carrying amount over its fair value. Gains and losses from asset disposals and impairment losses are classified within the consolidated statements of operations and comprehensive loss in accordance with the use of the asset. There were </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_480556c8-f90f-446a-b9fb-671222232384" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c0b87bb9-3e38-4b84-a137-d5e9ade2c23c" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> impairment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">141</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_184fb083-e0fc-4e20-851c-0bb95b5e4b10_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">losses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">in the years ended December 31, 2023 and 2022 as there have been no events warranting an impairment analysis.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_90319e19-23fa-41cc-8e75-f671d03fec0e" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_8f6df98b-36a7-4fb3-8598-aec6f9a6d8be" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:GrantIncomePolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Grant Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2020, the Company accepted a grant from the National Institute on Aging (&#8220;NIA&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company&#8217;s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer&#8217;s disease. The Company recognizes income related to the NIH grant in the accompanying consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred. As of December 31, 2023, the Company has recognized aggregate grant income of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c20d2e19-a705-4ed8-8f1f-cf7ca483a509" contextRef="C_056747a7-1c94-4990-92ab-823ab0bc1868" name="atha:AggregateGrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in connection with the NIH grant, equal to the total grant amount approved. The Company will </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69d24b4d-6422-48dc-a106-02f7efa45147" contextRef="C_303a3846-845e-456f-8c82-d8f63126fa9f" name="atha:AdditionalGrantIncome" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t recognize any additional grant income in connection with the NIH grant in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recognized grant income of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbb00dd1-3c9e-41e2-a96d-be53eadc7ee7" contextRef="C_303a3846-845e-456f-8c82-d8f63126fa9f" name="atha:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85953d2b-79b1-42ee-8b7c-4f676ea6b4e0" contextRef="C_cf9a9c4d-ab5c-403b-b958-e051da05ad42" name="atha:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_483a48ee-64b4-4a2d-9464-c19c846ed0ca" contextRef="C_12a10015-c94d-4aee-aab4-44e3ae370c9d" name="atha:UnbilledGrantReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, which is included in unbilled grant receivable on the consolidated balance sheets. The Company received cash of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d538caa-0c8a-466e-b205-16a4c9c542df" contextRef="C_303a3846-845e-456f-8c82-d8f63126fa9f" name="atha:GrantsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million related to the NIH grant during the year ended December 31, 2023, compared to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72a4c9cb-6180-4db1-98c5-627a8dea1fe9" contextRef="C_cf9a9c4d-ab5c-403b-b958-e051da05ad42" name="atha:GrantsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the year ended December 31, 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0337defd-09c7-4cad-82b2-69ae76b6e274" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company&#8217;s proprietary drug discovery platform (&#8220;ATH platform&#8221;), the Company&#8217;s drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company&#8217;s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_f98ebe84-9751-4fac-9078-8c168ca5a453" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true" continuedAt="F_f98ebe84-9751-4fac-9078-8c168ca5a453_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">142</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_f98ebe84-9751-4fac-9078-8c168ca5a453_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. </span></ix:continuation></span><span style="font-size:10pt;font-family:Arial;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_2b018278-ad8a-4902-a61f-cad1e981c391" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_e15293fa-0f1c-4e5c-a40e-1c41375e50ae" contextRef="C_0aeb7363-11f2-4452-9d7a-75e6115d7d8c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Accounting Standards Codification (&#8220;ASC&#8221;) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Topic 842 - Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> effective </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_090322bd-7e5d-4407-a1bd-bbe9c771e3b8" contextRef="C_0aeb7363-11f2-4452-9d7a-75e6115d7d8c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company&#8217;s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company&#8217;s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company&#8217;s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company&#8217;s lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company&#8217;s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company&#8217;s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1a9b0fb4-6637-4d92-9324-c10a1d3645f5" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company&#8217;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">143</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d6a9c295-e107-4d3e-bba3-bbdc3fa04232" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In assessing the Company&#8217;s ability to realize deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future income, tax planning strategies in making this assessment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company accrues interest and penalties related to unrecognized tax benefits in its provision for incomes taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_80293b74-4ba1-425c-b757-d8094979b6b9" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comprehensive Loss Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders consists of net loss and other gains and losses affecting stockholders&#8217; equity that, under U.S. GAAP, are excluded from net loss. The Company&#8217;s comprehensive loss attributable to common stockholders is comprised of net loss and unrealized gains and losses on available-for-sale securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_854713c6-db5d-4d05-baeb-bac2fd01f6e6" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_54d54d6b-39fb-4599-8059-e30ae9932be6" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Foreign Currency Transaction Remeasurement Adjustments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at the balance sheet date. Income and expenses denominated in foreign currencies were translated into U.S. dollars at the average exchange rate for the period and the transaction remeasurement adjustments are reported within other income, net in the consolidated statement of operations and comprehensive loss. The functional currency of the Company&#8217;s Australian subsidiary is the U.S. dollar.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0051fb47-9689-4403-b379-6908e920f7b7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has determined that it operates and manages </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7764a9d-3b91-44ae-b8e7-37ee337cdd12" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">144</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_e61cdcb3-d40d-469f-a58c-4e822c08086b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_73afb95b-6efe-4e93-9b67-1aa1f4fab10b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bed5ec41-d1b4-43f2-8c93-b528205d314b" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4a281260-fb9a-463b-8549-038a2ea1ba92;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ASU 2016-13</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> effective </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bb4ed510-ce86-441d-ad95-45d4d249ece7" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and it did </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_b1ec0d48-8db1-4a50-9c3a-cd6c580609bc" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t have a material impact on its financial condition, results of operations or cash flows.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_9533eb05-f11a-4912-b141-03b4348ac22d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Fair Value</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Inputs are generally unobservable and reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The determination of a financial instrument&#8217;s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">145</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d8e7d0a4-c433-4507-873f-fa0140b4fa66" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following tables reflect the Company&#8217;s financial asset balances measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f348bf76-450a-400d-8639-9dff7afca7b4" contextRef="C_a7c67d33-aae0-4112-9efb-f133ec67b36b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2972dea-4ede-4858-add9-841e612de624" contextRef="C_a7c67d33-aae0-4112-9efb-f133ec67b36b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dc0bbd6-dbbc-49ac-809c-35088c1e6c94" contextRef="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,227</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_628bcf1a-eb10-44de-b75c-fee92c74bf22" contextRef="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4" name="atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79c46fb8-05b3-47fe-a072-5be525308bbf" contextRef="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e618c96-f6b4-4983-b381-33f48d0be890" contextRef="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_434b3e52-0123-4cc6-aafe-03bfedee552c" contextRef="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b" name="atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02c6af9d-548d-4f0e-82da-c242784902d1" contextRef="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_874cedda-c70f-41eb-898d-389b586e2845" contextRef="C_9095dfc0-3298-479d-99a1-25f51998f25b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,431</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7297e05-3851-4694-b4a7-6961e169c2cf" contextRef="C_9095dfc0-3298-479d-99a1-25f51998f25b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c078e4-4664-419d-84a0-d0b6dc432c0f" contextRef="C_9095dfc0-3298-479d-99a1-25f51998f25b" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,427</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_670cb96e-7cd3-4e67-8390-f8035f7ea2f6" contextRef="C_1ff49d7f-fac0-41a7-929e-e4558c77c522" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e32350a1-de93-4141-b9ef-548321373846" contextRef="C_1ff49d7f-fac0-41a7-929e-e4558c77c522" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28d4a7b2-f050-42c7-b7f3-e158b89d416e" contextRef="C_1ff49d7f-fac0-41a7-929e-e4558c77c522" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,408</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4febaccc-6828-46ad-9a93-9f78080934a3" contextRef="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f01a3ac8-44c0-40ff-987c-c50df0c5ff3a" contextRef="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5b419ea-7fb0-4467-98a3-3122bf10aa39" contextRef="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,835</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:7.96%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95882b82-5a89-4bea-9089-a30fdaa470da" contextRef="C_187e872f-6f06-4138-a5a3-73aa8c516e11" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_191f84bb-e913-4a61-8930-01d05ee0b9e9" contextRef="C_187e872f-6f06-4138-a5a3-73aa8c516e11" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf490e48-9e2a-4fef-8a8a-6c6c039ca72f" contextRef="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,028</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9878412-95aa-461e-ae64-9a6b4a18cae7" contextRef="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f" name="atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3dd8876-7538-4d46-aaad-5ae29c9d6402" contextRef="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,002</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53d68293-b40d-42a9-a0fd-179272675e21" contextRef="C_d1e4e5a0-6260-4827-a357-156d12d260b6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,035</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52695db6-b752-43a5-90ea-39743025181a" contextRef="C_d1e4e5a0-6260-4827-a357-156d12d260b6" name="atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1282f798-b46b-4993-a14b-26e2540ac869" contextRef="C_d1e4e5a0-6260-4827-a357-156d12d260b6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,009</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b3c6d71-5d4e-4401-b2c5-02afd7e65cf0" contextRef="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,933</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_262b0948-17bf-41f0-8506-740c79c32dd3" contextRef="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1adc2fde-0c70-4921-9603-a77d96771d30" contextRef="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,765</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce484033-5162-4e9a-aec7-2cd8d2796336" contextRef="C_7714a687-7731-4c13-9881-449c6a18a2ae" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75998d4c-4039-48be-b746-6bb80baaa652" contextRef="C_7714a687-7731-4c13-9881-449c6a18a2ae" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">784</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0618e9b3-c312-4b7c-b21a-bef54c6f82a9" contextRef="C_7714a687-7731-4c13-9881-449c6a18a2ae" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,373</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2837f0f8-826d-4672-86f9-6c8a52765a56" contextRef="C_e1bdc52f-55b0-42e4-9b73-d791b4867499" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f52e96f3-5a54-4c9f-9f3f-f2c026bbdee7" contextRef="C_e1bdc52f-55b0-42e4-9b73-d791b4867499" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f991b8ab-5174-4059-890b-d2e43c26a6c0" contextRef="C_e1bdc52f-55b0-42e4-9b73-d791b4867499" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,240</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00ce9e0a-aa50-410d-8ca2-3122aaccec49" contextRef="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,392</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64154ab8-07c0-4255-84f8-449e3d854b6e" contextRef="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_384d7425-2055-4570-9ffe-b162fdb0dd14" contextRef="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,378</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Long-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6d4e249-cd34-4cc9-b09b-bfa75165de53" contextRef="C_719ee044-1cd6-4354-9d45-5838c649c6cb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,745</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b685e3f-0c39-4481-87b9-f52d6aadc5ed" contextRef="C_719ee044-1cd6-4354-9d45-5838c649c6cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fab2c16f-f96c-4d2b-8fa2-796a01258197" contextRef="C_719ee044-1cd6-4354-9d45-5838c649c6cb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_586987aa-9a3b-4d3a-b483-7f57d0b5a5ed" contextRef="C_922fddad-facf-4336-aa77-97c53317edac" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,745</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1770eead-527f-4dff-8f1a-8c5df120019e" contextRef="C_922fddad-facf-4336-aa77-97c53317edac" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d4d7d7-a8ae-462c-8e6a-a05f9a372795" contextRef="C_922fddad-facf-4336-aa77-97c53317edac" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All the commercial paper, U.S. government debt, and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_a8c0e22b-c455-478a-be17-16a951cd6819" contextRef="C_3f1121d9-b05d-4e5f-9477-a1f96b0362c3" name="atha:ShortTermInvestmentsMaturityTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from the respective balance sheet date. Those that are designated as long-term investments have an effective maturity date that is more than </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_2abc4b27-dd8b-4e56-bd68-11012479af7e" contextRef="C_d98123fe-9e7e-4c2e-8b91-5f07a93c8aaa" name="atha:LongTermInvestmentsMaturityTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, but less than </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bb9b4e5e-aec8-40ab-bbc3-95e302fcfdf6" contextRef="C_3f1121d9-b05d-4e5f-9477-a1f96b0362c3" name="atha:LongTermInvestmentsMaturityTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, from the respective balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of December 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized gains (losses) for available-for-sale securities were recorded in other comprehensive loss.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">146</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_dfa91633-4c1d-49a0-9fff-942c3dad4b45" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">4. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_de1e251d-632a-4f19-8070-3bbc03665a45" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_712f1947-1d97-4ee3-8b78-995f48eefcf1" contextRef="C_d6a26653-10d9-4f44-88dc-82ea78ded141" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ded9df3-9486-4053-ae2f-0b2edb0b1c50" contextRef="C_41b276ca-ace1-420e-a094-64afac7af863" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture, fixtures, and<br/>&#160;&#160;&#160;computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_461bf61a-28d8-40bd-a6ea-1982e60a451e" contextRef="C_a4594933-cd27-4b2d-b47f-3c26d3044474" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1647742-6836-47a9-b474-e4c771048824" contextRef="C_4d6df006-0245-4a7f-aaeb-b183142fe722" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_286adaf3-4b50-4ada-bf29-d0c686e14a0f" contextRef="C_0e4222da-d4ac-4e84-9095-1eaa081f11b0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,322</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5a92b62-c3bc-4a32-9093-5286c7aa9fdc" contextRef="C_e6b0b8ce-ab31-4162-be7e-4e0e4f188f69" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cddacca8-be7b-4e54-ad76-057b1de89199" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaa0873f-6377-4db4-971a-1bafe1c0f9b5" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,421</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b42e2dd5-892d-4bd0-8bf9-4e33da03fe63" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_641394b2-16aa-4fac-b5f3-f39331984278" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,368</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d59d7d52-2e9b-47bf-993e-1fa1c62687da" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3f7241c-028c-46c1-8207-e93d8b87ba71" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,053</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a21f7b4-0473-471d-96f3-5c00685df613" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">969,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8580eb02-d429-4299-8a5d-604611cbb2a2" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">845,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1ce90d43-d7eb-4fb1-9a84-15110ab09e12" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_ce75641b-cd55-490d-b4db-e6bf20a86f9c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77bde78e-44b0-429f-a51d-c479a100fd38" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="atha:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9002f3fc-d7a5-4dcc-8710-70336e5b6ce8" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="atha:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82a6bc45-71f4-468e-bab6-129a3c92c1e6" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,545</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f80a4a79-db29-4133-b38f-5193502db8e0" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,415</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Professional services and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63f88142-9d94-46f0-a150-c94a4e02a14c" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="atha:AccruedProfessionalServicesAndOtherCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f29822dc-6256-4c12-b047-08ea0ebcda3f" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="atha:AccruedProfessionalServicesAndOtherCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcf3f0bd-0539-43fd-bb78-d12579d0dfc4" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,343</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2dbd334-2134-487b-909b-77dbaff1e833" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,604</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_22f1c9a4-53e0-4648-bbb3-2317681e3e0c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_22f1c9a4-53e0-4648-bbb3-2317681e3e0c_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">6</span></ix:nonNumeric></span><span><ix:continuation id="F_22f1c9a4-53e0-4648-bbb3-2317681e3e0c_1" continuedAt="F_22f1c9a4-53e0-4648-bbb3-2317681e3e0c_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Significant Agreements</span></ix:continuation></span></p>
  <div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_22f1c9a4-53e0-4648-bbb3-2317681e3e0c_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">WSU License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is party to an amended and restated exclusive license agreement with sublicensing terms with WSU that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2020, the Phase 2 clinical trial milestone had been reached and a payment of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22792b92-078c-48f9-a857-5b8fda37053c" contextRef="C_690c503b-308d-4f02-ae74-3a40f7694b5a" name="atha:PaymentOnAchievementOfDevelopmentMilestone" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to WSU was recorded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company may also be obligated to pay the following if the related milestones are reached:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ddd3461-eb4f-40ac-949c-4129e3eb0196" contextRef="C_16f4eb07-f770-4874-8b9e-47c09374ee0c" name="atha:MilestonePaymentsAmountPayableUponTrialInitiation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8211; At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc7e5e9c-4987-450e-a42a-2d92a79e0479" contextRef="C_69c9026a-c50a-44e3-a00c-4b6fe771b199" name="atha:MilestonePaymentsAmountPayableUponMarketingApproval" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8211; Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d99806f-24eb-40a3-baeb-b53623286c06" contextRef="C_a0eab557-b7e2-4d8e-b61f-6fd05508c61b" name="atha:NetSalesExemptFromRoyaltyPayment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of net sales being exempt from royalty payment, and annual minimum royalty payments of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2706a031-216b-4d4f-998b-329413854826" contextRef="C_a0eab557-b7e2-4d8e-b61f-6fd05508c61b" name="atha:AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> beginning after the first commercial sale of a licensed product. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21873b4e-b86f-4a61-8aab-47d1e784040d" contextRef="C_fd062a54-8e0f-43d9-b4fd-677356eb4cb7" name="us-gaap:Revenues" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> sales of any licensed products had occurred and the Company had </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e2f0729-73a5-4a03-9c77-2609f7051ff1" contextRef="C_aa6a601d-80ed-42d8-a96f-8238a263db27" name="atha:RoyaltyObligation" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t incurred a royalty obligation under this agreement.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">147</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based payments received, and low twenties of net sales based sublicense royalties. As of December 31, 2023, the Company has not entered into or incurred any liability from a sublicense agreement.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_93e96cd0-2e12-475e-817f-f575e117725f" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Securities Class Actions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0f7b6a10-5ef5-41d4-97a9-b035e99f19a0" contextRef="C_8ac800dc-b01c-45e8-b2ee-046ba0e16083" name="us-gaap:LossContingencyLawsuitFilingDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 25, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, plaintiffs </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_474fac8f-d9da-4573-95b4-7b80cc5b00fd" contextRef="C_8ac800dc-b01c-45e8-b2ee-046ba0e16083" name="us-gaap:LossContingencyNameOfPlaintiff"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fan Wang and Hang Gao</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Company&#8217;s former chief executive officer Dr. Leen Kawas, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang v. Athira Pharma, Inc., et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Company&#8217;s business. Specifically, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects were materially misleading. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys&#8217; fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">That same day, on </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0d4baf36-3694-4cd5-8ab5-8f0e5f3ead8e" contextRef="C_e33a3149-ce72-41bd-94ff-d0cab93ff8db" name="us-gaap:LossContingencyLawsuitFilingDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 25, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, plaintiff </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_08ef418d-139b-45f5-8692-55e9e0c5a2cf" contextRef="C_e33a3149-ce72-41bd-94ff-d0cab93ff8db" name="us-gaap:LossContingencyNameOfPlaintiff"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Harshdeep Jawandha</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company&#8217;s then chief financial officer, certain members of the Company&#8217;s board of directors at the time of the Company&#8217;s initial public offering ("IPO"), as well as the IPO underwriters, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha v. Athira Pharma, Inc., et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00862. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933 ("Securities Act"), alleging that that the Company&#8217;s IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas&#8217;s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Company&#8217;s efforts to develop treatments for Alzheimer&#8217;s disease, and that the defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects were materially misleading. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys&#8217; fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Also on </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_82e7fdf1-fdc2-464b-9334-335575bd04e2" contextRef="C_9f3b7167-3bdb-4617-add9-35c0246bd8d1" name="us-gaap:LossContingencyLawsuitFilingDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 25, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, plaintiffs </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_a8b5c89c-b25c-4bf0-9f2d-774b23821d80" contextRef="C_9f3b7167-3bdb-4617-add9-35c0246bd8d1" name="us-gaap:LossContingencyNameOfPlaintiff"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Timothy Slyne and Tai Slyne</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company&#8217;s then chief financial officer, and the same members of the Company&#8217;s board of directors and underwriters as in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne v. Athira Pharma, Inc. et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00864. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas&#8217;s doctoral research at WSU should have been disclosed in the Company&#8217;s IPO registration statement. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> plaintiffs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek unspecified compensatory damages, reasonable costs and expenses, including attorneys&#8217; fees, and injunctive and other equitable relief.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">148</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Company&#8217;s then chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering ("SPO"), and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas&#8217;s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs&#8217; consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_864d3854-c45b-4e7f-a7c2-905494eb695d" contextRef="C_94d38940-3716-4ae8-8dcc-05162812b209" name="us-gaap:LossContingencyLawsuitFilingDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">August 12, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, defendant </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c531fb02-0df3-4da3-b4ca-1e4e873d0f1e" contextRef="C_94d38940-3716-4ae8-8dcc-05162812b209" name="us-gaap:LossContingencyNameOfDefendant"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Dr. Kawas</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a motion for partial reconsideration of the court&#8217;s July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On March 10, 2023, following a mediation and the parties&#8217; agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffs&#8217; motion for preliminary approval without prejudice, citing the motion&#8217;s failure to satisfy the court&#8217;s questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffs&#8217; renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024 proposing a date on which the court may schedule the final approval hearing, among other things. In its order, the court preliminarily approved the proposed settlement and certified a class and two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a result of the foregoing, the Company recorded a legal settlement expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8c5ec86-eaed-4182-a78b-7a8a7fae821f" contextRef="C_1316502c-52a2-42d4-b1b3-95c55a6319ad" name="us-gaap:LitigationSettlementExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in operating expenses in the fourth quarter of 2022 and an accrued liability of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b30699b-8573-401c-b395-7dfa6ac6ed35" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million on the accompanying consolidated balance sheets. Additionally, the Company recorded an insurance recovery of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75649e64-c0ab-4f87-9e9b-cd0a127a2c58" contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc" name="us-gaap:InsuranceRecoveries" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_605b4895-f6b2-45ee-a716-6912341d3091" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:InsuranceSettlementsReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million on the accompanying consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by the Company's insurers.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">149</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Shareholder Derivative Actions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Company&#8217;s board of directors, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bushansky v. Kawas et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:22-cv-497. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that the Company&#8217;s board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Company&#8217;s public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint seeks unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys&#8217; fees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Houlihan v. Kawas et al</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">., No. 2:22-cv-620. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that certain of the Company&#8217;s current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Company&#8217;s public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint seeks unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys&#8217; fees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. The Company believes it has adequate reserves related to this matter as of the latest balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Government Investigations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice (the "Demand"). The Demand seeks documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH, and our receipt of a NIH grant in 2020. The Company is cooperating with the Department of Justice with respect to the Demand.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2023, the Securities and Exchange Commission ("SEC"), sent the Company a subpoena seeking documents and information relating to, among other things, the Company's former chief executive officer's alterations of images in certain research papers. The Company is cooperating with the SEC with respect to the subpoena.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company cannot predict the outcome of these lawsuits or government investigations. Failure by the Company to obtain a favorable resolution of these actions could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date the Company has not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">150</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company enters into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_326b2794-05ae-4125-ba58-45e1f7c34a79" contextRef="C_e1e4cdcc-57d2-49b5-a143-ac39a470f80c" name="atha:OperatingLeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">August 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The initial terms of the leases range from </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_5496fc95-8093-45b6-9d04-ce4183a87a12" contextRef="C_151605f2-8e8c-4ccb-9f19-d395e2a884b6" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_7f961bde-50fd-4d7c-9cee-710ba57dd301" contextRef="C_8e223ef3-d9c1-4fbc-a123-56fabdfa0705" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and the Company has </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_129fc8a9-29a9-492b-a83e-32dbc387e254" contextRef="C_e1e4cdcc-57d2-49b5-a143-ac39a470f80c" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">options to extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> the leases for an additional </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_425179f8-0154-41e6-b81d-c17cb686a7f2" contextRef="C_2df3ffa4-7e0f-4475-8dc6-103f27566e6e" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> that it is not reasonably certain to exercise. As of December 31, 2023, the Company was not party to any finance leases.</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_ac30f4e4-a423-48aa-8c39-b89f313e83c7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table reconciles the Company&#8217;s undiscounted operating lease cash flows to its operating lease liability (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c2d454-1201-4a46-a541-13ad0537ad2b" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84dc826a-5ff9-4d47-a30c-292c4b97bf2c" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb889257-c8da-4042-a492-1b13a0e45134" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">509</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd25c41d-c22a-41c1-8864-e786bd88103a" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="atha:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1206a565-a9f0-4319-9eee-764254b90e55" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Present value adjustment for minimum lease<br/>&#160;&#160;&#160;commitments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e54d12f-1720-43e2-b579-0e2aee775e6c" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3feb3f8d-0f64-4c35-8cb6-1a04a75f585e" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,585</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_4763e717-e80e-4e46-a73c-892a6118f2b3" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.143%;"/>
        <td style="width:1.429%;"/>
        <td style="width:1%;"/>
        <td style="width:19.429%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_f87fb9ad-e3b8-4b7b-af70-e4b55658f398" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6d19827-e52b-42be-9c06-54a57ada51a7" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating lease expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93f5e399-bf15-4b44-ae18-a9395ba98161" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">353,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_746fd1ac-53e2-4668-afab-2ffa31bb7e7d" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">368,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively. Separately, variable lease expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3345171-4ecc-4f25-8808-6c172a7a9b28" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:VariableLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">186,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e715733-4824-491f-9f7c-803f514fbc00" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:VariableLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">167,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for operating leases during the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_474f19bc-131b-40f9-8923-1afcc6789f66" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_474f19bc-131b-40f9-8923-1afcc6789f66_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span></ix:nonNumeric></span><span><ix:continuation id="F_474f19bc-131b-40f9-8923-1afcc6789f66_1" continuedAt="F_474f19bc-131b-40f9-8923-1afcc6789f66_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Common Stock</span></ix:continuation></span></p>
  <div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_474f19bc-131b-40f9-8923-1afcc6789f66_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Company&#8217;s board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">151</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_7abd9397-eb48-4be6-bca5-1421ed342702" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.568%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:16.557%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:17.716%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares issuable upon the exercise of outstanding<br/>&#160;&#160;&#160;common stock options and the vesting of<br/>&#160;&#160;&#160;outstanding common restricted stock<br/>&#160;&#160;&#160;units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1678767-17b5-4ad9-99ab-a586b696627c" contextRef="C_1961c4e3-fcb5-421a-969d-a6cea22d51f1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,130,956</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ceef88b-da00-4df7-a0bd-f62401964a5a" contextRef="C_aef30744-a5ec-4f04-bf7c-7c0d2dcb4975" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,269,861</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the 2020<br/>&#160;&#160;&#160;Equity Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8eaba3cc-56e8-473d-b57f-ef11e8660671" contextRef="C_1a2a914d-8abd-447a-9b84-978f4cf3df2c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,158,094</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ba378fc-f105-428c-bb2b-e40ab5398921" contextRef="C_3680b5de-5819-4049-8d87-083dce72c5cb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,253,854</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the<br/>&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10fda105-aa3e-4c7a-bca8-da4289b40b5e" contextRef="C_2bceb79c-22f4-4e48-96e9-071508ac7697" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,128,732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b4ab7a4-545d-4860-aee7-2095017d9b2d" contextRef="C_cfa9f2b7-2752-4887-a960-266fea4dee22" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">916,640</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9449ea3-8765-4b79-9640-3cdbefc3db62" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,417,782</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89cccbf8-391f-472a-a6ec-14fb5d06117f" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,440,355</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c578381a-39fc-44a9-83ee-f6eb35b983cd" contextRef="C_a3cbf114-5760-4876-a9ac-f26ffd0959d6" name="atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,230,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, (2) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efc82eb1-e0e3-4713-9bcc-4a6f776a295b" contextRef="C_a3cbf114-5760-4876-a9ac-f26ffd0959d6" name="atha:ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company&#8217;s board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7db238ae-4a61-4873-9595-55053ba6daa0" contextRef="C_226d7a94-53b9-413a-83c4-4c853fb51f40" name="atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">646,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, (2) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38b69fa3-9be7-414e-9267-a9b2bd94c84a" contextRef="C_226d7a94-53b9-413a-83c4-4c853fb51f40" name="atha:ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company&#8217;s board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Effective January 1, 2023, the Company&#8217;s 2020 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_567bd508-ce68-406a-8c53-cb7e44bc6e1b" contextRef="C_f7cba87e-57f4-4dd8-a43e-4d3b53a7003d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,893,869</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a16a9dd0-442f-4a4a-978e-78c911ec78b1" contextRef="C_8d0e6b76-9bb3-4df6-8c45-7670935b83c7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">378,774</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Effective January 1, 2024, the Company&#8217;s 2020 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48d9948e-9e59-4de9-9fbe-dbfa186d59cd" contextRef="C_a5c26a41-a1f5-40f5-9d35-4bb1846d30b8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,908,630</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71c35157-430b-4992-baf9-dc29d4864347" contextRef="C_a9177032-05f2-4b4d-b7e2-81d23fa814d3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">381,726</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, respectively.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bd9f7262-8a7a-4187-b7c4-9d55f84e75fb" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_bd9f7262-8a7a-4187-b7c4-9d55f84e75fb_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">9</span></ix:nonNumeric></span><span><ix:continuation id="F_bd9f7262-8a7a-4187-b7c4-9d55f84e75fb_1" continuedAt="F_bd9f7262-8a7a-4187-b7c4-9d55f84e75fb_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Stock-based Compensation</span></ix:continuation></span></p>
  <div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_bd9f7262-8a7a-4187-b7c4-9d55f84e75fb_2"><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_f0a5a3c3-bbd0-4a08-9a4a-a6b983f4ac3f" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock&#8209;based compensation expense recognized was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6174ec34-5e37-4f5d-a030-f8f698b42082" contextRef="C_4e72d8ea-ec67-44e7-a900-766be31764bf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,003</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5f01457-6a7b-4220-97af-329c265b84e5" contextRef="C_a5908b88-dd8b-4d05-a20d-6351018e760a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff9b6dc-21e8-4f10-bb62-dba1a7b4f1d0" contextRef="C_df1e6e77-ce5e-4ac7-b222-0ce56ac33d5b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,620</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c211590-1e13-49bb-82fc-a19b3fd85dbb" contextRef="C_c68e4dfb-d60e-49f2-96b2-46587068c474" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f44b21a1-b538-4041-91a4-d0a1acaa323b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,623</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f10f8e00-0c0c-4e9b-9432-d8a8195db73e" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,606</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">152</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_048724a3-205f-4cf2-937b-240616258909" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></div></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0f396b60-dcd4-4375-80c0-7272013d66b7" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of each stock option was estimated using the Black&#8209;Scholes option&#8209;pricing model with the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.218%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.218%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b37d6bb0-a594-4259-b564-63d3de8f49b5" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.54</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27cbb03d-ea8c-44a0-9cfc-11b5befefbf1" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48a45637-748c-444b-b881-0e82629c7e41" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">99.18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc03cba1-0616-4387-bc8e-80ce9f965a79" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">92.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_9dd67770-0ceb-4ade-af4d-4695500661bd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.84</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_b5ebf1eb-6a87-4546-b362-c9b3d80889df" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.02</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The grant date fair value of restricted stock units is based upon the fair market value of the Company&#8217;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of options granted during the years ended December 31, 2023 and 2022 were $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed89fdbd-6d8c-4dff-99f0-091c090bbf42" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2a2b36a-2c2c-477c-98ff-21b8856d29f8" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively. The fair value of restricted stock units granted during the year ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447f49fc-0331-4364-8e22-2f9d2c38140a" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65181d41-2698-4890-ad38-677143da1455" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_6b2b64d5-9f95-486c-8740-092402307558" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Changes in shares available for grant under the 2020 Plan during the year ended December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:16.24%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Available <br/>for Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for grant at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aabbc2b-078d-4373-890f-b3d1939df00d" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,253,854</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2020 Plan reserve increase on January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e824ff4-9d57-405d-9a7e-f85c8ce95e70" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,893,869</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options and restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7513aed9-ad3f-4687-830d-109bcec31df0" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,834,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options and restricted stock units forfeited, <br/>&#160;&#160;&#160;cancelled, or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1891b4e4-1590-4135-9f0c-e9b545da9124" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">845,154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_310fdd69-9c72-407c-b31f-e7163f626079" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,158,094</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">153</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_b23b4dc8-ef11-4335-852a-01b4baef312d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A summary of option activity for the year ended December 31, 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:12.643%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:12.643%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>price<br/>per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in<br/>thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_527f0bc2-4605-4a6c-b00e-7b6b0bcb60a3" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,033,522</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_868f4213-7800-4b36-bc80-a03d03c6006d" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_7ac321ef-ec51-4bea-8673-63095a2f0373" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_052e1cd5-2cf7-488e-afef-8e271d40c151" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">827</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d712fbf-e625-424d-bef8-487a0ed55c04" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,696,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c9367c8-161e-436b-b841-3743288a779d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaacf40f-3b36-40d2-8cc8-43eb6573207b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">128,534</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_042f6b89-a606-463b-8b30-c461a5d9234c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.29</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Forfeited/expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a489df0f-ee96-482a-8058-0de7fa81b4d6" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">780,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_171e363f-e6a5-4956-bb80-f451b37ef80c" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.72</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9c94b84-cc37-42bc-bbe6-c332627c3a31" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,820,869</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38232f17-d05a-410d-9929-e899860a7c61" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_e19eb2a3-7d9f-4fad-a17b-224d6726ec42" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.24</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ade322fe-deb1-4457-bb55-f16024c258a7" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected to vest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e56ecfc-0174-4302-aa63-716d1187dbf9" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000,554</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c72e63e8-28fd-46e8-a68f-c01e4bfb0cb2" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_08f6a16b-c871-4ccf-af03-526596c4b61a" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.72</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options exercisable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32bada16-cf03-485b-9ff9-3e954c554b61" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,820,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eeb1cfd-8058-40ab-94c5-2b30f32d0066" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_d179af65-79bd-41ad-884a-7addccb09ec5" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8283ef4c-ed61-4bd5-ac6d-2966fd97ee6e" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The total fair value of options granted that vested during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d60529c4-e17a-42c1-a30f-0fceefd72551" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa32e554-dcb5-4da2-a7f4-c41ead5518ad" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock underlying all options that were in-the-money at December 31, 2023. The aggregate intrinsic value of options exercised was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f72cb4d6-60e5-4442-91b5-f53fdd21bb24" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87782b0b-85da-475d-bf2d-e0f4c56884a7" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the year ended December 31, 2023 and 2022, respectively, determined as of the date of option exercise. As of December 31, 2023, there was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b03dac58-bb31-404c-925c-1e7d5aba05ea" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1b4681b0-d2bc-4b40-ab78-1ac9e7f47d6d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1.99</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years. The Company utilizes newly issued shares to satisfy option exercises.</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_3db57156-58d9-446d-afce-bd4897bb4bcd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options outstanding and exercisable consisted of the following at December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:19.2%;"/>
        <td style="width:1%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:19.2%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-family:Arial;min-width:fit-content;">Exercise Price ($)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Exercisable</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5403aa37-8fff-48b4-aed4-0afee8b9c162" contextRef="C_d40879de-c9cf-4ff8-8428-c0e65b0b4d5a" name="atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d035eb2a-9abc-4d7c-a581-380100193e46" contextRef="C_580e918a-d59f-4636-90ec-2ca1df182f19" name="atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.22</ix:nonFraction></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed1833db-95c9-43a5-8ee5-70589a724daa" contextRef="C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,709,593</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_920fbf5b-42b6-4d32-868f-9d78a7929049" contextRef="C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,005,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88650d0c-ebac-4462-bc71-ec3e7a4e743d" contextRef="C_1ab0bd04-d950-4018-bfb6-93d46d159ba7" name="atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e9c806c-eaf1-4498-a831-8e953c61bbdc" contextRef="C_82ce7c28-19ff-4ba2-94b4-dcbd68834f11" name="atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">19.94</ix:nonFraction></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98260cb2-1097-4324-9582-e95f7ae42d12" contextRef="C_dea600eb-6bff-47e0-a4fc-ba972dd836c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,759,028</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d455443-069f-4066-b16a-60b4e669c535" contextRef="C_dea600eb-6bff-47e0-a4fc-ba972dd836c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,615,758</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e617fdb-8b35-4f3e-92f8-bef89d8c539c" contextRef="C_ab70a86c-b366-4a92-835f-b2e57888bb70" name="atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">20.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba3e0f11-c2d1-4f2f-917c-898790273705" contextRef="C_426e1064-11b7-4ec3-aed5-1a083b3b037d" name="atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">29.41</ix:nonFraction></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f3cac46-077b-4a56-8663-c23833d1bd08" contextRef="C_c75da740-1967-4b45-a209-94145e24aaeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">352,248</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4ac6004-d4e8-48af-af9d-82e6a024ef78" contextRef="C_c75da740-1967-4b45-a209-94145e24aaeb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">198,772</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0c9960d-0577-4440-bc34-9f60a3b651e6" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,820,869</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4eb2d3c-b53e-4896-96f0-ca432a049fff" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,820,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Stock Unit Activity</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_4007b0cf-a5bd-4330-93ab-0ecd186708d5" contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A summary of RSU activity for the year ended December 31, 2023 is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:13.3%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.879999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Share<br/>Equivalent</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d7255a-a2f4-43e6-a2ba-1e57e28c8441" contextRef="C_a65c107a-c260-47d4-aa36-25401168c1ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">236,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f4f277f-6757-49d7-96cc-8d86217e5f58" contextRef="C_a65c107a-c260-47d4-aa36-25401168c1ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3eaf2946-2468-421b-8dcf-7042b355bc44" contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">138,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8c3a13c-e4f0-492f-ad64-2abb8b775abf" contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9ce3c9a-c83e-4fc9-90b3-db18123139ee" contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">64,252</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d547eb2-6c66-4d72-abc5-49c700260a36" contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dddb10c-3af8-445b-9ab8-61d159b62e14" contextRef="C_70e3a64b-76f2-4b45-b67d-b2027a3e900e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">310,087</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d2503cc-30e6-451c-9cf7-c3a31e8d7cf1" contextRef="C_70e3a64b-76f2-4b45-b67d-b2027a3e900e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">154</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bdc52a36-9091-456b-b87c-fc498134ce55" contextRef="C_9ed353a2-ea15-493f-8aa1-8373fc805f50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the ESPP, eligible employees can authorize payroll deductions for amounts up to the lesser of </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c26f5fc-413f-42ce-a1ce-0ab8fe0cc87d" contextRef="C_4ffcc58d-1976-40bc-bf55-155e02e95431" name="atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of their qualifying wages or the statutory limit under the U.S. Internal Revenue Code. The ESPP provides for offering periods of </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1b1f51fb-e3ec-4bf5-b1bd-5c86628f1f51" contextRef="C_6e73c2da-bf36-4271-ae86-4b1f0e2f86d6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in duration with one purchase period per offering period beginning May 18 and November 18 of each year. </span></ix:nonNumeric></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Participants in an offering period will be granted the right to purchase shares of our common stock at a price per share that is </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f9ed5e6-d7e5-401d-a7b0-f5ccbc09d0ad" contextRef="C_6e73c2da-bf36-4271-ae86-4b1f0e2f86d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the lesser of the fair market value of the shares at (1) the first day of the offering period or (2) the end of each purchase period within the offering period. A maximum of </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e23ad1c8-7947-4758-aaf7-d3cc24b72f07" contextRef="C_a7faad1c-e70a-40a8-bf1f-ea0da7846fb1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock may be purchased by each participant at the purchase date during the offering period. The fair market value of the ESPP options granted is determined using the Black-Scholes model and is amortized on a straight-line basis. Stock-based compensation expense recognized during the years ended December 31, 2023 and 2022 associated with the ESPP was $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d18b55c-71c5-4c6f-867d-c978baa4fb81" contextRef="C_9ed353a2-ea15-493f-8aa1-8373fc805f50" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd0bed4e-79b5-4c93-9a83-e5e6e37848fb" contextRef="C_6694722e-57a7-407b-9dfb-5cabe2faff30" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f3d47a2-6c8e-48c1-828d-091acab61b64" contextRef="C_bf2c465b-8587-438c-a9ea-4095cfc62594" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">166,682</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock to employees under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_650a74f4-9c1c-45d8-830c-f3f4077dc2c2" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">10. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Components of Income and Income Tax</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_6530ab1d-d078-4730-aa54-f81736ed5ff2" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company did not record a provision (benefit) for income taxes for the years ended December 31, 2023 and 2022. Net loss is attributable to the following tax jurisdictions (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">United States</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f09adfc-9c9a-45da-80ea-08c98eb5bf04" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,440</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e549e31-e396-4a57-8f99-6e5eb5738245" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,778</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff4ace4d-47e0-46fd-ae1f-6d07374b20f3" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_915dfe8e-1d0f-4233-9158-0d5694df0b01" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Net Loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2ad8133-dd1a-4b7d-91f6-c80b5cbbf0a2" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3adab774-e542-42f7-be1c-ea09162e3e2c" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1efe2ee9-cd35-4bbd-9179-eb297a8346aa" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The provision for income taxes differs from the amount expected by applying the federal statutory rates to the net loss before taxes as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:13.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:13.282%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_473e4ace-8c52-42ae-9cec-47419010ffc3" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cebc939f-19b3-462c-aed5-bd04306ffaeb" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">State taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_908202a8-9001-4db4-a4e3-4813ef0a1d24" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b88022e0-80a4-44ed-845f-7abb83b653fe" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fb371ab-8aaf-42bb-af43-b13d1cb0dd5a" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-deductible expenses and others</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d391b5a-79e6-4277-9705-90063ce40935" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db5e486d-1380-4855-8c36-b6baedaa5e4e" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4819e022-6ca0-423d-82b8-69fad88a6441" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49ff5c53-4a8f-4713-a9f9-37ed0c1ea656" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20eb00ce-eca9-4633-b8c9-0bd1d4b167a2" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8dac838-7228-44a7-b072-c209cea561cd" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">21.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e732ae4-7af7-46dd-9afa-cde2fa825899" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01c108c5-d588-4c6d-8c8e-7705bb712022" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">155</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Deferred Tax Assets and Liabilities</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c4ce0495-1edd-4749-bd0f-b89f22974c35" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0cded50-84cb-4a22-8807-01e3bd34ecc3" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,342</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5156a88d-74d3-452e-a6e9-920fdef4d0e3" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,092</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development tax credit<br/>&#160;&#160;&#160;carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97a150f9-24f9-4899-8351-770f45dff448" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,327</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97711b1d-d72e-4aad-b78f-9eda73f0d2fb" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,218</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec580dbb-78e2-4def-b8c6-dd8ba1623718" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,828</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a436a76-42e4-44ad-805d-aa0fcd4a99e6" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,781</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67ec60de-5268-4939-ac94-1b99cbe0717c" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,564</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e094bfa-9100-46de-ae7c-5ea6e4e4f19b" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34fb36b1-8ad2-4b4d-9745-1ab88be16aff" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="atha:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f80c1e11-c251-40e9-8799-d47885099bb9" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="atha:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83b64d2e-30fb-4444-b0df-7f653b1e0db8" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f468e2e3-0357-44c0-adfb-6f582a638147" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_619d19fa-a45b-4e01-ba1e-3863c1e59aab" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="atha:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,182</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2a911ea-6eb9-45e2-90f3-862cc59e5b4a" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="atha:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,729</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a3dadef-80fe-4a08-842d-172a7c98df0e" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,756</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abb45758-0862-4863-80e1-d42079c11f6c" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,021</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eb5669d-aaea-4c0a-8079-63fa0fab9f77" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="atha:DeferredTaxAssetsRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c510799c-e80c-4e8d-8e60-899fa743ebda" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="atha:DeferredTaxAssetsRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9664d4f6-041c-4c9a-8578-3824b9ff6053" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed85c4d2-b7ff-436b-b77e-67fc4d093cac" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1289c964-81d2-4834-9ca8-3d98b773eeab" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acba3768-5967-4f6b-817c-de49791eb7e4" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d7e1d0f-31a5-4f95-bfa7-a39eaf6547f1" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">510</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f4a75f-2df4-407e-affa-b440673e772b" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,036</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b80fbe-cbfc-4e27-8615-3ee420f6841d" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_349ca7f2-a925-4815-b2ea-1a5857a4d50a" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,985</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f790d076-35da-4ee5-a74c-6097d35b5988" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eaac286-cc59-4720-ba1e-6105723e3a93" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Deferred income taxes reflect temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes, and operating losses and tax credit carryforwards. The Company considers a number of factors concerning the realizability of its net deferred tax assets, including its history of operating losses, the nature of the deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible, all of which require significant judgment. As of December 31, 2023, the Company has recorded a full valuation allowance on its net deferred tax assets as the Company has concluded that it is not more likely than not that such losses or credits will be utilized. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad59a4e9-dd5c-4662-b366-64db9728a089" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.3</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862d122a-12d5-4516-a470-f9535068500c" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.4</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At December 31, 2023, the Company has federal net operating loss and tax credit carryforwards of  $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b0bce5-2048-4655-a40b-b5e822baa773" contextRef="C_053a40d1-bb28-4f1e-bcd3-ded475336474" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_331f0ef0-091e-4c17-a895-51f4e40c092d" contextRef="C_053a40d1-bb28-4f1e-bcd3-ded475336474" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively, which expire over a period of </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_6e7d97c8-29cb-444c-865d-2006d0ca03ff" contextRef="C_df96098e-d6ae-4e99-9e22-f4b1da15f310" name="atha:NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" format="ixt-sec:duryear"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span></ix:nonNumeric></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d8343e6c-73d0-40ea-a886-181377ea8425" contextRef="C_710fe844-0726-4f65-be5c-3fa87ea575cb" name="atha:NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" format="ixt-sec:duryear"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">14</span></ix:nonNumeric></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years. Net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e479ef6b-d0c1-4c33-ada6-9679f218bb04" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">138.7</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million were generated after 2017, and therefore do not expire. As of December 31, 2023, the Company also had state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eab4833f-0c76-4546-bba0-a4ad88edac25" contextRef="C_7c4d91a5-91db-41e6-9a2a-b4d994e6373c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, which expire over a period of </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_a48361b6-f8c0-431f-955c-8a50be22a06e" contextRef="C_3e32a1c8-6ec3-4e35-b166-fee2b12394c3" name="atha:OperatingLossCarryForwardsExpirationPeriod" format="ixt-sec:duryear"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_11545012-286a-4005-b99f-17f9650bc31e" contextRef="C_656fadf4-0d29-4caa-a75d-c735f8deb466" name="atha:OperatingLossCarryForwardsExpirationPeriod" format="ixt-sec:duryear"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in years beginning on or after January 1, 2022.  Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software, or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. We have included the impact of this provision, which results in a deferred tax asset of approximately $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3820a36d-7ce6-43c0-86fe-ff26e348d3d0" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.2</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million as of December 31, 2023.</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company files federal income tax returns. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years prior to 2016. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">156</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">were generated and carried forward and may make adjustments to the amount of the net operating loss or credit carryforward amount. The Company is not currently under examination in any jurisdiction.</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_30a1345c-64e0-4d05-ad5d-131820aa85eb" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A reconciliation of the beginning and ending amount of unrecognized tax benefits for uncertain tax positions were as follows (in thousands):</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03135702-241a-4f7f-a6da-338f995000d9" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f21e340a-976e-41ba-8f98-3e2d7b84bbe1" contextRef="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions for tax positions taken in prior<br/>&#160;&#160;&#160;years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf769b81-c14e-4054-9b4e-ca2f4e5b5b47" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions for tax positions taken in the current<br/>&#160;&#160;&#160;year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7e8091d-d82e-4db5-bc6b-eeec878a7c40" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c06ea06c-a8d9-4252-82e0-fb341493d318" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d12a8ee-8202-488c-849d-9afb153abe76" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,109</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_783ee32c-c2b4-4e78-b589-07f2a0322d66" contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023 are recognized, there will be no impact to the effective tax rate due to the valuation allowance. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated financial statements. At December 31, 2023, there were </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a93adc54-4f58-4e89-b7d7-52a8ee86c768" contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> material interest and penalties on uncertain tax benefits. The Company does not anticipate any significant changes to its unrecognized tax benefits in the next 12 months.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c17aa8b9-7bca-4de3-9b44-4e9a60135e8b" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">11. Employee Benefit Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has a 401(k) Plan for all of its employees. The 401(k) Plan allows eligible employees to defer, at the employee&#8217;s discretion, up to </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bc96673-f717-4b3a-90af-33feafc7cdcc" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of their pretax compensation up to the Internal Revenue Service annual limit. The Company made matching contributions of $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d49661d3-5b51-4bc9-a825-ea4879140b81" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a4896a5-4710-44e5-9f9e-ea6440c64637" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0baff936-12f7-4af2-95fa-08865646102e" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_0baff936-12f7-4af2-95fa-08865646102e_1"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">12. </span></ix:nonNumeric></span><span><ix:continuation id="F_0baff936-12f7-4af2-95fa-08865646102e_1" continuedAt="F_0baff936-12f7-4af2-95fa-08865646102e_2"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></ix:continuation></span></p>
  <div><ix:continuation id="F_0baff936-12f7-4af2-95fa-08865646102e_2"><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_20172ed7-d8bc-47d0-a04d-5c576bfad06d" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.248%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:16.777%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:16.777%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32c05fcb-0816-43a8-9e1a-762cd5a5540c" contextRef="C_fe8e26c7-136f-405d-890c-308874394d43" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,820,869</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db286fa8-650b-41c7-bbac-2f0fe433fde6" contextRef="C_bfc5356d-4026-41a2-a82b-2bbf62ac66e0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,033,522</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested Restricted Stock Units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61de9796-0eb4-4c56-9b21-df78b805ba96" contextRef="C_e5ff6d80-d652-482d-85d9-7a260cc2826b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">310,087</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a8300a-87e4-4f5d-a052-f8aa8c190012" contextRef="C_3ab74e21-5321-4b29-9cf8-94356358cf01" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">236,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_129dcca4-b406-464d-85ea-fed5d29367b7" contextRef="C_10175cd6-83a3-4603-bad5-7b3b43f819ec" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ddbe2b3-5b09-438b-8274-5b83c202ccf7" contextRef="C_53baa5a0-6766-48f8-b2f6-ddb46f1ed143" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,148</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_095211c3-678e-4ee4-94d4-95271bee4dfd" contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,134,451</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b493cddd-28c1-46ca-9aca-ecfdef65d7e3" contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,275,009</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">         </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">157</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9A. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Evaluation of disclosure controls and procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our disclosure controls and procedures are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our management, with the participation and supervision of our chief executive officer and our chief financial officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on such evaluation, our chief executive officer and chief financial officer have concluded that as of such date, our disclosure controls and procedures were, in design and operation, effective at a reasonable assurance level.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Management&#8217;s annual report on internal control over financial reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f) and Rule 15d-15(f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of that assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for emerging growth companies.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Changes in Internal Control</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Annual Report on Form 10-K that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Inherent Limitations on the Effectiveness of Controls</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, in designing and evaluating the disclosure controls and procedures, management recognizes that any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurance of achieving the desired control objectives. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">158</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During our last fiscal quarter, no director or officer, as defined in Rule 16a-1 (f) of the Exchange Act, </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_91dfc117-c56b-414b-a2c5-e5b3fcf0f7c6" contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_36caf105-b7ac-45c8-a0be-85f981943da2" contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_730fff7c-9d23-4688-80cb-5b9ee683ffc9" contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_321c7619-6a5b-4b94-9e9a-f71ef53ca790" contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; each as defined in Item 408 of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">159</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We maintain a Code of Business Conduct and Ethics that incorporates our code of business conduct and ethics applicable to all employees, including all directors and executive officers. Our Code of Business Conduct and Ethics is published on our Investors website at https://investors.athira.com/ under &#8220;Governance.&#8221; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendments to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on the website address and location specified above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The remaining information required by this Item 10 of Form 10-K will be included in our definitive proxy statement to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023 in connection with the solicitation of proxies for our 2024 Annual Meeting of Stockholders (2024 Proxy Statement) and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 11 of Form 10-K will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 12 of Form 10-K, including with respect to our equity compensation plans, will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 13 of Form 10-K will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ting Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 14 of Form 10-K will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">160</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">List the following documents filed as a part of the report: </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All financial statements;</span></div></div>
  <p style="margin-left:8.8%;text-indent:4.971%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">See Index to Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:8.8%;text-indent:4.971%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All financial statement schedules have been omitted because the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the financial statements or the accompanying notes.</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibits</span></div></div>
  <p style="margin-left:8.8%;text-indent:4.971%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Index to Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.838%;"/>
    <td style="width:1%;"/>
    <td style="width:48.29%;"/>
    <td style="width:8.858%;"/>
    <td style="width:11.418%;"/>
    <td style="width:6.319%;"/>
    <td style="width:15.277%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;padding-right:0.014in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.014in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.014in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Description</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.015in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.015in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;3.1</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020053574/atha-ex31_153.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Company</span><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">November 12, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;3.2</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017022025442/atha-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amended and Restated Bylaws of the Company</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">November 18, 2022</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020043324/atha-ex41_478.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Specimen Common Stock Certificate of the Registrant</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 14, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;4.2</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex42_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Investors&#8217; Rights Agreement, dated May 29, 2020, as amended, by and among the Registrant and the Investors and Key Holders party thereto</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;4.3</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.1**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020041369/atha-ex101_530.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of Director and Executive Officer Indemnification Agreement</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 26, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.2**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex102_90.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">2014 Equity Incentive Plan, as amended</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.3**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex105_89.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">2020 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.4**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex106_88.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of Stock Option Agreement under the 2020 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.5**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex107_87.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of Restricted Stock Award Agreement under the 2020 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.6**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex108_86.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of RSU Agreement under the 2020 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">161</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.838%;"/>
    <td style="width:1%;"/>
    <td style="width:48.29%;"/>
    <td style="width:8.858%;"/>
    <td style="width:11.418%;"/>
    <td style="width:6.319%;"/>
    <td style="width:15.277%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020041369/atha-ex109_529.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amended and Restated Standard Exclusive Licensing Agreement with Sublicensing Terms, dated October 28, 2015, by and between the Registrant and Washington State University, and amendments thereto</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 26, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.8**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-ex10_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">2020 Employee Stock Purchase Plan, as amended and Form of Subscription Agreement Thereunder</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">March 23, 2023</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.9</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex1011_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Lease agreement, dated July 20, 2020, by and between the Registrant and North Creek Parkway Center Investors, LP</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.10**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Outside Director Compensation Policy, as amended</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">March 23, 2023</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.11**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex1013_83.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Executive Incentive Compensation Plan</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.12**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex1015_534.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Confirmatory Employment Letter between the Registrant and Mark Litton, Ph.D.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.13**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex1016_533.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Confirmatory Employment Letter between the Registrant and Kevin Church, Ph.D.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.14**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/d457287dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Offer Letter between the Registrant and Andrew Gengos</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">May 22, 2023</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.15**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000119312522023358/d290928dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amended and Restated Change in Control and Severance Agreement between the Registrant and Mark Litton, Ph.D.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">January 31, 2022</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.16**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000119312523149921/d457287dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Change in Control and Severance Agreement between the Registrant and Andrew Gengos</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">May 22, 2023</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.17**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020043324/atha-ex1021_821.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Offer Letter between the Registrant and Hans Moebius, Ph.D.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 14, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.18**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">First Amendment to Employment Agreement between the Registrant and Hans Moebius, Ph.D.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.27</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">March 28, 2022</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;10.19**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020043324/atha-ex1022_820.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Change in Control and Severance Agreement between the Registrant and Hans Moebius, Ph.D.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-248428</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 14, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.20**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459021044641/atha-ex101_72.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Offer Letter between the Registrant and Rachel Lenington</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 16, 2021</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.21**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459021044641/atha-ex102_71.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Change in Control and Severance Agreement between the Registrant and Rachel Lenington</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 16, 2021</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.22**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459021044641/atha-ex103_70.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Offer Letter between the Registrant and Mark Worthington</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 16, 2021</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.23**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459021044641/atha-ex104_69.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Change in Control and Severance Agreement between the Registrant and Mark Worthington</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 16, 2021</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459021044641/atha-ex105_68.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">First Amendment to Lease by and between the Registrant and Nitrogen Propco 2020, L.P., as</span><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 16, 2021</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">162</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.838%;"/>
    <td style="width:1%;"/>
    <td style="width:48.29%;"/>
    <td style="width:8.858%;"/>
    <td style="width:11.418%;"/>
    <td style="width:6.319%;"/>
    <td style="width:15.277%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459021044641/atha-ex105_68.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">successor-in-interest to North Creek Parkway Center Investors, L.P., dated June 28, 2021</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.25**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Change in Control and Severance Agreement between the Registrant and Kevin Church</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">March 28, 2022</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/atha-ex1_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Controlled Equity Offering Sales Agreement</span><span style="color:#0000ff;top:-4.6899999999999995pt;white-space:pre-wrap;text-decoration:underline;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">SM</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">, dated January 6, 2023, among the Registrant, Cantor Fitzgerald &amp; Co. and BTIG, LLC</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1.01</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">January 6, 2023</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.27**</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/atha-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Executive Transition Agreement between the Registrant and Hans Moebius dated January 5, 2024</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39503</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">January 8, 2024</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;21.1</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1620463/000156459020042848/atha-ex211_15.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">List of Subsidiaries of the Registrant</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-24828</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 9, 2020</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;23.1</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;24.1</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Power of Attorney (included in signature pages hereto)</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;31.1</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;31.2</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Principal Accounting and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;32.1*</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;32.2*</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Principal Accounting and Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">97</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="atha-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amended and Restated Compensation Recovery Policy</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.CAL</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.DEF</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">163</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.838%;"/>
    <td style="width:1%;"/>
    <td style="width:48.29%;"/>
    <td style="width:8.858%;"/>
    <td style="width:11.418%;"/>
    <td style="width:6.319%;"/>
    <td style="width:15.277%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.LAB</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.PRE</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:77.778%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Arial;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">	The certifications filed as Exhibits 32.1 and 32.2 are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof irrespective of any general incorporation by reference language contained in any such filing, except to the extent that the registrant specifically incorporates it by reference.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Arial;min-width:fit-content;">**</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">	Indicates a management contract or compensatory plan.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Arial;min-width:fit-content;">&#134;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">	Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted by means of marking such portions with asterisks because the Registrant has determined that the information is not material and would likely cause competitive harm to the Registrant if publicly disclosed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">164</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.38%;"/>
    <td style="width:4%;"/>
    <td style="width:4.22%;"/>
    <td style="width:46.4%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Date: February 22, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">President and Chief Executive Officer (</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;min-width:fit-content;">Principal Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark Litton and Andrew Gengos, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with Exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or substitute or substitutes may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.12%;"/>
    <td style="width:2.36%;"/>
    <td style="width:42.42%;"/>
    <td style="width:2.38%;"/>
    <td style="width:20.72%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Mark Litton</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Mark Litton</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;min-width:fit-content;">Principal Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Andrew Gengos</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chief Financial Officer and Chief Business Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Andrew Gengos</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;min-width:fit-content;">Principal Financial and Accounting Officer</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Kelly A. Romano</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chairwoman of the Board of Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Kelly A. Romano</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Joseph Edelman</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Joseph Edelman</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ John M. Fluke, Jr.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">John M. Fluke, Jr.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ James A. Johnson</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">James A. Johnson</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Barbara Kosacz</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Barbara Kosacz</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Michael Panzara</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Michael Panzara</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Grant Pickering</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Grant Pickering</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">165</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>atha-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 4.3</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;min-width:fit-content;">REGISTERED PURSUANT TO SECTION 12 OF THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;min-width:fit-content;">SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended. These securities are listed on the Nasdaq Global Select Market under the symbol &#x201c;ATHA.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our authorized capital stock consists of 900,000,000 shares of common stock, par value $0.0001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following is a summary of the rights of our common stock and preferred stock. This summary is not complete. For more detailed information, please see our certificate of incorporation and bylaws, which are filed as exhibits to our annual report on Form 10&#x2011;K for the period ended December 31, 2023, and to the applicable provisions of Delaware and Washington law.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Common Stock</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Dividends</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Voting Rights</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Each share of common stock held as of the applicable record date is entitled to one vote per share on all matters (including the election of directors) submitted to a vote of stockholders, unless otherwise required by law or our certificate of incorporation. Our certificate of incorporation and bylaws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the voting power of the shares of common stock present in person or represented by proxy at the meeting of stockholders and entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares, cast affirmatively or negatively, shall be the act of the stockholders, except as otherwise provided by law, our certificate of incorporation, our bylaws or the rules of any applicable stock exchange on which our securities are listed. The holders of a majority of the voting power of the capital stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders, unless otherwise required by law, our certificate of incorporation, our bylaws or the rules of any applicable stock exchange on which our securities are listed.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidation</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Upon a liquidation event, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Rights and Preferences</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #808080;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Holders of common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fully Paid and Nonassessable</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All of our outstanding shares of common stock are fully paid and nonassessable.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. No shares of preferred stock are outstanding.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Anti-Takeover Effects of Delaware and Washington Law and Our Certificate of Incorporation and Bylaws</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Delaware Law</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with any &#x201c;interested stockholder&#x201d; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">at or subsequent to such time the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.993%;"></td>
    <td style="width:1.569%;"></td>
    <td style="width:97.437%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Section 203 defines a business combination to include:</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.015%;"></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">any merger or consolidation involving the corporation, or any direct or indirect majority-owned subsidiary of the corporation, and the interested stockholder</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">or any other entity if the merger or consolidation is caused by the interested stockholder;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #808080;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.015%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">any sale, lease, exchange, mortgage, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation or any direct or indirect majority-owned subsidiary of the corporation;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.015%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation, or any direct or indirect majority-owned subsidiary of the corporation, to the interested stockholder;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.015%;"></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">subject to exceptions, any transaction involving the corporation, or any direct or indirect majority-owned subsidiary of the corporation, that has the effect of increasing the proportionate share of the stock or any class or series of the corporation</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">or such subsidiary beneficially owned by the interested stockholder; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.015%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These provisions may have the effect of delaying, deferring or preventing changes in control in our Company.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Washington Business Corporation Act</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The laws of Washington, where our principal executive offices are located, impose restrictions on certain transactions between certain foreign corporations and significant stockholders. In particular, the Washington Business Corporation Act, or WBCA, prohibits a &#x201c;target corporation,&#x201d; with certain exceptions, from engaging in certain &#x201c;significant business transactions&#x201d; with a person or group of persons which beneficially owns 10% or more of the voting securities of the target corporation, an &#x201c;acquiring person,&#x201d; for a period of five years after such acquisition, unless the transaction or acquisition of shares is approved by a majority of the members of the target corporation&#x2019;s board of directors prior to the time of acquisition. Such prohibited transactions may include, among other things:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">any merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the acquiring person;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">any termination of 5% or more of the employees of the target corporation as a result of the acquiring person&#x2019;s acquisition of 10% or more of the shares;</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.993%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:98.014%;"></td>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">allowing the acquiring person to receive any disproportionate benefit as a stockholder; </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">and</font></p><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">liquidating or dissolving the target corporation.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">After the five-year period, a significant business transaction may take place as long as it complies with certain fair price provisions of the statute or is approved at an annual or special meeting of stockholders.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will be considered a &#x201c;target corporation&#x201d; so long as our principal executive office is located in Washington, and: (1) a majority of our employees are residents of the state of Washington or we employ more than one thousand residents of the state of Washington; (2) a majority of our tangible assets,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">measured by market value, are located in the state of Washington or we have more than $50 million worth of tangible assets located in the state of Washington; and (3) any one of the following: (a) more</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #808080;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">than 10% of our stockholders of record are resident in the state of Washington; (b) more than 10% of our shares are owned of record by state residents; or (c) 1,000 or more of our stockholders of record are resident in the state.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we meet the definition of a target corporation, the WBCA may have the effect of delaying, deferring or preventing a change of control.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Certificate of Incorporation and Bylaws</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that the authorized number of directors may be changed only by resolution of the board of directors;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">divide our board of directors into three classes, each of which stands for election once every three years;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that a director may only be removed from the board of directors by the stockholders for cause;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:7.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and also meet specific requirements as to the form and content of a stockholder&#x2019;s notice;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">not provide for cumulative voting rights (therefore allowing the holders of a plurality of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that special meetings of our stockholders may be called only by the board of directors, the chairman of the board of directors, our chief executive officer or president;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that stockholders will be permitted to amend certain provisions of our bylaws only upon receiving at least two-thirds of the votes entitled to be cast by holders of all outstanding</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #808080;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.987%;"></td>
    <td style="width:0.987%;"></td>
    <td style="width:98.027%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">shares then entitled to vote generally in the election of directors, voting together as a single class; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">provide that, unless we otherwise consent in writing, a state or federal court located within the State of Delaware shall be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation and bylaws (as either may be amended from time to time), or (4) any action asserting a claim against us governed by the internal affairs doctrine; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:98.016%;"></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, against any</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">person in connection with any offering of our securities, including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The amendment of any of these provisions would require approval by the holders of at least two-thirds of our then outstanding common stock, voting as a single class.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#x2019;s address is 250 Royall Street, Canton, Massachusetts 02021.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #808080;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>atha-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form S-3 No. 333-261073 of Athira Pharma, Inc.; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form S-8 Nos. 333-263907, 333-254735 and 333-270792 pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan; and 333-248910  pertaining to the 2020 Equity Incentive Plan, the 2020 Employee Stock Purchase Plan, and the 2014 Equity Incentive Plan, as amended, of Athira Pharma, Inc.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of our report dated February 22, 2024, with respect to the consolidated financial statements of Athira Pharma, Inc., included in this Annual Report (Form 10-K) of Athira Pharma, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Seattle, Washington</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">February 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>atha-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)<br><br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Mark Litton, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Athira Pharma, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d&#x2013;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"></td>
    <td style="width:60%;"></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mark Litton</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Litton</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>atha-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)<br><br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Andrew Gengos, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Athira Pharma, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d&#x2013;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"></td>
    <td style="width:53%;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Andrew Gengos</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Andrew Gengos</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer and Chief Business Officer</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>atha-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Athira Pharma, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Mark Litton, President and Chief Executive Officer (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principal Executive Officer) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.8968727694042435%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.8968727694042435%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.14%;"></td>
    <td style="width:64.86%;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mark Litton</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Litton</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Athira Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>atha-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Athira Pharma, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Andrew Gengos, Chief Financial Officer and Chief Business Officer (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principal Financial and Accounting Officer)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.8968727694042435%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.8968727694042435%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"></td>
    <td style="width:60%;"></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Andrew Gengos</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Andrew Gengos</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer and Chief Business Officer</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Athira Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>8
<FILENAME>atha-ex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html>
 <head>
  <title>EX-97</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.65in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	ATHIRA PHARMA, INC.	</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDED AND RESTATED COMPENSATION RECOVERY (&#x201c;CLAWBACK&#x201d;) POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As amended and restated on November 13, 2023</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is committed to strong corporate governance. As part of this commitment, the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this Amended and Restated Compensation Recovery (&#x201c;Clawback&#x201d;) Policy (the &#x201c;Policy&#x201d;). The Policy is intended to further the Company&#x2019;s pay-for-performance philosophy and to comply with applicable laws by providing rules relating to the reasonably prompt recovery of certain compensation received by Covered Executives in the event of an Accounting Restatement. The application of the Policy to Covered Executives is not discretionary, except to the limited extent provided below, and applies without regard to whether a Covered Executive was at fault. Capitalized terms used in the Policy are defined below, and the definitions have substantive impact on its application so reviewing them carefully is important to your understanding.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is intended to comply with, and will be interpreted in a manner consistent with, Section 10D of the Securities Exchange Act of 1934 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), with Exchange Act Rule 10D-1 and with the listing standards of the national securities exchange (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on which the securities of the Company are listed, including any official interpretive guidance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Persons Covered by the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is binding and enforceable against all Covered Executives. A &#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Executive</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is each individual who is or was ever designated as an &#x201c;officer&#x201d; by the Board in accordance with Exchange Act Rule 16a-1(f) (a &#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 16</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Officer</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Compensation Committee may (but is not obligated to) request or require a Covered Executive to sign and return to the Company an acknowledgement that such Covered Executive will be bound by and comply with the terms of the Policy. The Policy is binding on each Covered Executive whether or not the Covered Executive signs and/or returns any acknowledgment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration of the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board has full delegated authority to administer the Policy. The Compensation Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another committee of the Board made up of independent members of the Board, in which case all references to the Compensation Committee will be deemed to refer to the independent members of the Board or the other Board committee, as applicable. All determinations of the Compensation Committee will be final and binding and will be given the maximum deference permitted by law.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatements Requiring Application of the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Compensation Committee must determine the Excess Compensation, if any, that must be recovered. The Company&#x2019;s obligation to recover Excess Compensation is not dependent on if or when restated financial statements are filed.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation Covered by the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy applies to certain </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (certain terms used in this Section are defined below) that is </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) during the Covered Period while the Company has a class of securities listed on a national securities exchange. Such Incentive-Based Compensation is considered &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Clawback Eligible Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; if the Incentive-Based Compensation is Received by a person after such person became a Section 16 Officer and the person served as a Section 16 Officer at any time during the performance period for the Incentive-Based Compensation. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excess Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based Compensation that otherwise would have been Received had such Clawback Eligible Incentive-Based Compensation been determined based on the restated amounts. Excess Compensation must be computed without regard to any taxes paid and is referred to in the listings standard of the Exchange as &#x201c;erroneously awarded compensation&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Determining Excess Compensation for Certain Incentive-Based Compensation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must maintain documentation of the determination of that reasonable estimate and provide that documentation to the Exchange.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Repayment of Excess Compensation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must recover Excess Compensation reasonably promptly and Covered Executives are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Covered Executive to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Compensation Committee determines to be appropriate (these determinations do not need to be identical as to each Covered Executive). These means include (but are not limited to):</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:10%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation or vest based on the achievement of performance goals;</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:10%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Covered Executive, including, but not limited to, payments of severance that might otherwise be due in connection with a Covered Executive&#x2019;s termination of employment and without regard to whether such amounts are Incentive-Based Compensation; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">cancelling outstanding vested or unvested equity awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation; and/or </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">taking any other remedial and recovery action permitted by law, as determined by the Compensation Committee. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The repayment of Excess Compensation must be made by a Covered Executive notwithstanding any Covered Executive&#x2019;s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore not subject to clawback.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to enforce a Covered Executive&#x2019;s obligations to the Company or to discipline a Covered Executive. Failure of a Covered Executive to comply with their obligations under the Policy may result in (without limitation) termination of that Covered Executive&#x2019;s employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities or change in role.  The decision to take any actions described in the preceding sentence will not be subject to the approval of the Compensation Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For avoidance of doubt, any decisions of the Company or the Covered Executive&#x2019;s employer to discipline a Covered Executive or terminate the employment of a Covered Executive are independent of determinations under the Policy. For example, if a Covered Executive was involved in activities that led to an Accounting Restatement, the Company&#x2019;s decision as to whether or not to terminate such Covered Executive&#x2019;s employment would be made under its employment arrangements with such Covered Executive and the requirement to apply this no-fault and non-discretionary Policy will not be determinative of whether any such termination is for cause, although failure to comply with the Policy might be something that could result in a termination for cause depending on the terms of such arrangements.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limited Exceptions to the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must recover the Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below is met, and the Compensation Committee determines that recovery of the Excess Compensation would be impracticable:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A.	The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover such Excess Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B.	Recovery would violate a law in the country in which the Company is incorporated where that law was adopted prior to November 28, 2022. Before reaching this conclusion, the Company must obtain an opinion of local counsel, acceptable to the Exchange, that recovery would result in such a violation, and must provide such opinion to the Exchange; or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">C.	Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Defined Terms in the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The capitalized terms in the Policy have the following meaning, unless clearly required otherwise by the context.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Determination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earliest to occur of:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Determination Date. In addition, Covered Period can include certain transition periods resulting from a change in the Company&#x2019;s fiscal year.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; are measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company&#x2019;s right to recover under the Policy has lapsed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following items of compensation are not Incentive-Based Compensation under the Policy: salaries, bonuses paid solely at the discretion of the Compensation Committee or the Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure, bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period, non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures, and equity awards for which the grant is not contingent upon achieving any Financial Reporting Measure and vesting is contingent solely upon completion of a specified employment period (e.g., time-based vesting equity awards) and/or attaining one or more non-Financial Reporting Measures.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means this Compensation Recovery (&#x201c;Clawback&#x201d;) Policy, as it may be amended from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; under the Policy in the Company&#x2019;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment, vesting, settlement or grant of the Incentive-Based Compensation occurs after the end of that period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the avoidance of doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to the Effective Date.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Important Information in the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, as well as any other applicable laws, regulatory requirements, rules, or pursuant to the terms of any existing Company policy or agreement providing for the recovery of compensation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the terms of any of the Company&#x2019;s organizational documents (including, but not limited to, the Company&#x2019;s Bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide expense advancement for any Covered Executive against any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that the Company is required to recover Excess Compensation pursuant to the Policy from a Covered Executive who is no longer an employee, the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement that individual may have signed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee or Board may review and modify the Policy from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of the Policy or the application of any such provision to any Covered Executive is adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Covered Executive, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy will terminate and no longer be enforceable when the Company ceases to be listed issuer within the meaning of Section 10D of the Exchange Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGEMENT</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that I have received and read the Compensation Recovery (&#x201c;Clawback&#x201d;) Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Athira Pharma, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand and acknowledge that the Policy applies to me, and all of my beneficiaries, heirs, executors, administrators or other legal representatives and that the Company&#x2019;s right to recovery in order to comply with applicable law will apply, regardless of the terms of any release of claims or separation agreement I have signed or will sign in the future.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I agree to be bound by and to comply with the Policy and understand that determinations of the Compensation Committee (as such term is used in the Policy) will be final and binding and will be given the maximum deference permitted by law.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand and agree that my current indemnification rights, whether in an individual agreement or the Company&#x2019;s organizational documents, exclude the right to be indemnified for amounts required to be recovered under the Policy.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand that my failure to comply in all respects with the Policy is a basis for termination of my employment with the Company and any affiliate of the Company as well as any other appropriate discipline.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand that neither the Policy, nor the application of the Policy to me, gives rise to a resignation for good reason (or similar concept) by me under any applicable employment agreement or arrangement.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that if I have questions concerning the meaning or application of the Policy, it is my responsibility to seek guidance from the General Counsel and Compliance Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), Human Resources or my own personal advisers.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that neither this Acknowledgement nor the Policy is meant to constitute an employment contract.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Please review, sign and return this form to the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Executive</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:50%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:50%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">print name</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;margin-right:50%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:50%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">signature</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;margin-right:50%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:50%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img105269759_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +C!J\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**X^X\1W\=S*BF/"N0/E]Z .PHKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**
MXO\ X2;4?6+_ +XH_P"$FU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^
M^* .THKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**XO\ X2;4?6+_ +XH_P"$
MFU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^^* .THKB_P#A)M1]8O\
MOBC_ (2;4?6+_OB@#M**XO\ X2;4?6+_ +XH_P"$FU'UB_[XH [2BN+_ .$F
MU'UB_P"^*/\ A)M1]8O^^* .THKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**
MXO\ X2;4?6+_ +XH_P"$FU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^
M^* .THKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**XO\ X2;4?6+_ +XH_P"$
MFU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^^* .THKB_P#A)M1]8O\
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M_P +O\8?W[+_ ,!__KT?\+O\8?W[+_P'_P#KT<C ^EZ*^:/^%W^,/[]E_P"
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MA_?LO_ ?_P"O1_PN_P 8?W[+_P !_P#Z]'(P/I>BOFC_ (7?XP_OV7_@/_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><7?_'[/
M_P!=&_G7H]><7?\ Q^S_ /71OYT 0T444""BBB@ HHHH **** "BBB@ HHHH
M ***Z:Q:*V\."Y^RQS2!B,,O7F@#F:*Z>YB@O]!ENVLUMI8^1@8S4>A*BZ1=
MSFW2:1&RJLN<\=* .<HKK;,1ZG'-'=:8ENJKD.%Q65X=BCDU8HZJZA&X89%
M&/174R75RDKJNAQE02 =G45BV=M_:6KB)E\M7<EE'8>E %"BNEN-5L[&\-I'
M81-"AVNQ')K(U,V;7NZRSY1ZC& #[4 4:*W/$4,4/V3RXU3='D[1C-8J??7Z
MT -HK;\211Q7T(C14!C!(48[UJ:OI,5QIX>WC59HU#848W"@#D**W+Z&-?#5
ME((U#D\L!R>M.>&,>$TE\M?,W_>QSUH P:*WM)M;>WTV;4KF,2[3A$/2E&J:
M??6TL=Y:I"P'R-&.: ,"BI(8FGG2*/EG8**ZR^T^UDTV:U@1//MT5B0.3Q0!
MQ]%6+%0U_;JP!!D (/UJ[XABCAU9TC147:O"C Z4 95%%% !1110 4444 %%
M%% !1110 4444 %%%% ',^/_ /D4+OZK_.O%*]K\?_\ (H7?U7^=>*5K#8 H
MHHJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MKTGX7>&]+NK35O$NN0^?8Z6F5A/1VQDY]>,?G2;L!YM17K]E\1_">O&ZT_Q#
MX:L[&Q9#Y,UNF77T!P.ON*YGX9V5A>_$^TM6C6ZL2TVU9DR&4(VTD'\*+@<-
M16]XV@BMO&VLP01K'$ETZJB# 49Z 5O_  ?L[:^\?0P7=O%/$89"4D4,,X]#
M1?2X'!45Z3X1L;2?XX2V<MM"]L+NY'DL@*8 ? QTK9^(W@BUTWQ=I.M:;!'_
M &;>7<<<T: ;$DW@$8Z8/IZYI<VM@/':*]"^*EE:V?Q,^SVMO%##LA_=QH%7
MGKP*M_&K3K2Q\56$-C:PVZO:*2L2!03N/I3N!YE17MFIOHOPH\/:7 NBVNIZ
MS>1B2:6Y&0OKCVR<"N6\;:[X1\2>'K.^L+)=/UW/[Z"&/"8Y!R>GN*2=P//*
M*[KX4>'H]>\8QO=1J]E9(9Y@XRIQT!_'^5;WQ:T;3+G2])\4Z#!$EA< PR>4
M@4 \[20/H1^%.^M@/)Z*]/\ @MIMCJ6L:LE]:0W"I:;E$J!@#GJ,UYK<@+=3
M # #L /QHOK8"*BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %K3/^0K9_\ 7=/_ $(5]J5\5Z9_R%;/_KNG_H0K[4K.
MH,****S **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5.3V.:ZFY.+68D@81N2,@<>G>J6@,'T*S998Y08^'BB\M3]%[4 9'_")2?\
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M )^U_P"^/_KT?\(E)_S]K_WQ_P#7KIXY8Y5W1NKKZJ<BG4 <M_PB4G_/VO\
MWQ_]>C_A$I/^?M?^^/\ Z]= =1L02#>6X(Z@RK_C4D-S!<9\F:.3'78P./RH
M YO_ (1*3_G[7_OC_P"O1_PB4G_/VO\ WQ_]>NIHH Y;_A$I/^?M?^^/_KT?
M\(E)_P _:_\ ?'_UZZFHXIX9]WE2I)M.#L8'% '-?\(E)_S]K_WQ_P#7H_X1
M*3_G[7_OC_Z]=-++'"F^61(U_O,<"FM<P)LW31KYGW,L!N^GK0!S?_")2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCJ!W^E1:.YDT:S=I))"T2DO)'Y;-QU*]C[4 7J*** /'_B82/BCX0 )^^/\
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M;=,W0 $T1<L<'A?[I]ZU:RM8E:.XTT+--'NN0"(X0X88/#'^$>]:M !1110
M4444 %%8/B'QGH7A:2"/6+S[.TX)C'ELV0.O054TCXC>%-;ODLK'5HVN9#A$
M=&3<?09 R: .IHK(@\3Z3<^(IM!BN=VI0IO>+8>!QWQCN*UZ "BBB@ HHHH
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M %%%% !1110 5R/Q/_Y)SK/_ %Q'_H0KKJYWQUI=WK7@O4]/L8Q)<SQ[8T+
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MH\'@[P_/9SQ3!I;@1>6 ,C!./3&<UZ+\0/"NKZ[XO\,W]A;"6VLIU>X8N!M
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MN(UX#;L<>O?ZU1\1!#X?O1)]EV^7S]JSY7_ L=JNVF/L4&-F/+7&S[O3M[4
M34444 %%%% !1110 4444 5=2CAETN[BN)A#"\+H\A;&P$$$Y[5X/;:;XH\*
M:#=6D.DZ;X@\.R%V:6(!BR]R&4Y'ZXKWN\M(;^RGL[A-\,\;1NOJI&#7EL?P
MN\4:;:SZ5H_B[R-'F+9B>(EE!Z@?_K% '$^*GL]3\#>'+S0GDL=/^V^0;%CO
M\J8Y._<>O_UZ[7Q;=ZOHEIHNFW7C1+11$3/-'"6N9SDX(0=N@ZUH:C\)HI/
M]EH&G:AY5Q:7(NA<2)D.^"#D#IU_2FWGPZ\0S:GI>N0^(8/[:M(3#+-);Y1Q
MD\@=B V/PH$<79:]KOB'P3XPTZYU>:6.PC$J331;9)(^<H1VS@?2FVM[KOAK
MX1Z9?VNLRA;N]18HU7'DI\^Y<]\G!KNM'^&-U8+XCCO-:%T-:@,<DGD[65CG
MYNN#U/%4X_A5JDW@F7P[?Z[%(L4R2V+I"0(B-V<^N=WX4 6O&NOZIIWC7PC9
MVEY)%;WD@$\:])!N'6N+\2>+]?A\5ZK;:IKE_HBQ2$6*16VZ)E'0L>N#QR,U
MUZ?#37KS7-&U;6?$D=W-ITBG8(,+M4@X!SU]ZFUCX>>(+F\OQ9>)5>POB=\&
MH0^>8L_W">G7VH ZWPA?RZEX7LKF>_M[^5DPUQ "%<CV/0^M;E87A#PU#X2\
M.P:3#,TPC)9I&&-S$Y)QVK=H&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <WXD\">'_%<T<^J6C-/&-JS1N4;'ID=:D\->"M"\)B4Z5:%
M))?ORR.7=AZ9/:N@HH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G75
M1H;3S%M"!=1D?:6*@'/\/^UZ"M:LG7Y5BALRTT$>Z[C4&:+?GGH/0^A[5K4
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M#QZ=JIZZ7&AW9C>X1_+X:V3?(/\ ='<U<M<_9(<ER=BY+C#'CN/6@"6BBB@
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MWK;_ )&C%]ZV_P"1H LT56Q?>MO^1HQ?>MO^1H LT56Q?>MO^1HQ?>MO^1H
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MY&C%]ZV_Y&@"S15;%]ZV_P"1HQ?>MO\ D: +-%-C\S8/,V[^^WI3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O
M7(?.BM!Y EVW4;8,WE[<'K[X].]:E9&O^7Y-GY@M"/M<>/M1(&<_PX_B]*UZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDY!P?N?[5:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E^
M(A&?#]Z)1:%/+Y%VV(NO\1]*W;/'V&WV[,>6N/+.5Z=O:L'Q)((O#M\[310A
M8\^9-%YB+SU*]ZWK([K"W(96S$IW*N >!R!VH GHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,K7
M658K3=-%%FZC ,D/F;CGH/0^_:M6LO6Y7BBM"DEPF;F-3Y$8<D9Z'/1?4UJ4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<
MY(MY2"P.P\H,GIV]ZQM(9GTJW9WN'8KRURH60_[P'0ULW )MI0 Q.P\*<$\=
MCVKR^R^*GA73K1+.YN+V.>#,;I+&TC @\@MW^M4HN6R&DWL>B45P?_"X?!__
M #^7'_@,W^%'_"X?!_\ S^7'_@,W^%/V<^P^678[RBN#_P"%P^#_ /G\N/\
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MY<?^ S?X4?\ "X?!_P#S^7'_ (#-_A1[.?8.678[RBN#_P"%P^#_ /G\N/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4V218HV=CA5&33JHZPQ739<=\"L<14]E2E471-E0CS24>Y3'B
M&/S,&%MGKFM6"XBN8P\3!A_*N)!!Z$5:LKR2SF#H?E_B7U%?+X3/:T:EJ^L7
M^!Z=7!1<?<W.QHJ."9+B%94.585)7UL9*24H[,\MIIV845!>)-):NL#;9#T-
M,L(YXK4+</N?/7/:LO:OVOL^5VM>_3T*Y5R\URU17*0>-H]4UNXTO1;)KV2V
M_P!=,9 D:\XZ\YK>L[V::5H+FU:WF5=V-VY6'L:Z'!K<EIHNT45F_P!M6_\
M;7]F;7\S;GS,?+NQG;GUQS22N(TJ*RKC6)(]0EL[?3YKEXE5G9&4 9SCJ?:I
M[#5(K]Y(O+DAGBQOAE&&&>A]Q[T68KEJX -M*" 04/!. >/7M7QCJ8"ZK> *
MJ@3N JMN ^8\ ]Q[U]FW6/LDV=N-C??^[T[^U?&.HX_M.[P8R/.?!C^[U/3V
MKIPN[-J6[*U%%%=AN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:WRV,UA!ON+@KN$4THRY( /(! JQX^:2X\':%-_:0UI4DE634\\[CSY>#\W
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MU236M9N]2EC6.2YD,C*O0$T04KW8)/J4*Z_P!_Q_W?\ US'\ZY"NO\ ?\?\
M=_\ 7,?SK>G\2-([GHMN\D<J/$Q612"I7J#78>(DCDTNSN;P"/4F4 JO\0]Z
MR_#BZ?:*^I7TT9:+_509^9F]<53OK^;4KQ[F8_,QX'91Z4YISJ*W3^K#EK+T
M&;%D0HZAE/!!&0:CL]'TZRG,UM90Q2'^)4 -9WB.9[?0+B2.1XV!0;D."!N&
M<5#8W4-I8W-Y8O?WK1*"\=PS#CN5W"HG)<UF3)JYIP^'+.34+NZO(8;DS2*Z
M!TR4P,5KW.E6&HHBWEI#,$^[O7.WZ5S-WXDGN-(U"ZTJ',4"#;<,0/F/)P".
M<5HMK]Q9:;9-<VJ?;+I@L<?F@*>,EBW85BW#H1=&_!IME#Y'E6L2?9\^3M4#
M9GKBKMM:P6\DKPQ(CS-OD*C&YL8R:Y4^+O)TRZG>SS<6TZ0O%'(&!W$8*MWZ
MU;B\436[7L>HZ<\$MM;?:E1'#[T_#O63E$AM&]>:)I>JNCW]A;W+(,*94#$"
MGGPUHDZ0++I=JRP#;$#&,*/0>U<]=ZS/=^$[N]NK<PP[4:-K6Z!9@3TR.A%:
M=QXAO%OY[+2],-XUI&KW#-*$ R,A1GJ<5C*Q#-B7PWHMW#'#<:9:R1Q)Y<:M
M&#M7K@>E7#I&G-IHTXV4!L@-H@*#9CZ5S?\ PF<EP-+72],>ZEU")W16D">6
M5.&#$^AS6YX?UDZWI\D[VYMYH9G@FB+;MKKUY[CD5DR&.M_#NCVEG+:6^FVT
M=O*09(U08<CIGUK3  &!T%%%( HHHH **** ,SQ"ZQZ!>NTT<*B/)DDA\U5Y
MZE/XOI6[9D&RMR&# QK\P7:#QUQV^E8?B"1XM!O'C>Y1UCR&MH_,D'/\*]S6
MY9DM90$ER3&I)<88\=QV- $CNL:,[L%51DL3@ 55L]7T[47=+*^M[AD^\L4@
M8C\JY#XL32)X6MH1(T=M<7\,-TRG&(B><GTX%4/%^F>'?#MI'>Z3BPU=;*=+
M)+-<>=\ASN '.!SDT =X-:TMKW[&-1M3<YQY0E&[/TIUUJVGV)<75];P% "P
MDD"X!Z=:\IO="\/0_!B/4X8X%OEMUG2\4CS3/Q_%USGC%6](TNW\0_$B.77+
M5+F1-"@E:*9<KYAP"2I[\G\Z /1WU[2(HX9'U.T5)O\ 5L9EP_TYYJ2YU73[
M+_CZO;>'Y-_[R0+\OK]*\B\/^%]'G\*>-99K&*5[:YNHK<N,F%4!*A/[O/I3
MM(L[#6/&'A!=6"3C^P5=4FY#N&.,@]: /1_$/B2/3O"%]K>FR078@CW)A]RL
M<^HK0&L6EOI=M>7]S!:K-&K9D<*,D X&:\DUN*'3W^(&G::JIIBVD,ICC^Y'
M,3R .@R.U37L-]J?Q L[9;&POUMM(A>WM[^4K'R!N8#!!- CT3Q)XML=!\+S
MZW&\5U&H B5)1B1B<8!K1CUK3SI,.HS7EO';R*#YAD&W)'3->*:II3V?AGQE
M#.-,6-'AE2RM93(+20L <9'RY'I6MKEK--XX\/:59Z?I\]G%I@FM[2Y;RX'D
M/WC@#!/3B@#UR#4+.ZM3=6]U#+;@9,J."H_&I89XKF%9H)$DB<95T.01[&O-
M_!^E36WBS7K2\32[>TN+53/IMG.66-LXW8P-H()KT+3K.TT_3X+2PC2.TB7;
M$B'( ]J!F)I7C"TU7Q7JNAQ^4IL0@5_,!,I(RV![5KQ:UI<]X;2+4;5[@<&)
M906_*O(-9ACT_5OB-<V%O%%=0P0^4\: -&&7YROID$YQ6AXBT/0-,^%MCJ>F
M1017\2PRVUU%@2O*2,_-U.<GB@#T^ZUG3+%F6[U"V@9" PDE"D9Z=:Q_$WB=
MM(@T>:R$-Q'?WT5L7W9&UC@D$5R^EZ5I>K_%37'U>""XN([*W*13 $#*#<<'
MOV_&N3CQ"WV&U8MIEMXLB2TYRJC/*K[ T >OV.KW!O=6&HM9P6EK*J0R+,"2
MI'\?/RG-7H-8TRYNVM(+^VDN%ZQ)*"P_"O'?$'.D_$@9Q_IL%;OB7P]I?A^7
MP;<:79QVUP-0BA:6,89U*'.X]\X[T >BWFL:;I\JQ7E_;6\C_=660*3^=7%9
M70.C!E(R"#D&O$M(L]2US7/%-Q-I.DZC,+V2%SJ,Q5X8P2%"C!P,=Q7??#..
MX@\&Q03W=O="*:1(G@D,BA,\+N/7'(H ["BBB@ HHHH **** "BBB@ HHHH
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M\UT8><8MW9I3:6YYE17IG_"D/$G_ #]Z=_W\?_XFC_A2'B3_ )^]._[^/_\
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MFC_A2'B3_G[T[_OX_P#\31[6'<.>/<\SHKTS_A2'B3_G[T[_ +^/_P#$T?\
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M^/\ _$T?\*0\2?\ /WIW_?Q__B:/:P[ASQ[GF=%>F?\ "D/$G_/WIW_?Q_\
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M7<3@5T#ND4;/(RHBC+,QP *Y?4/&5NFN:)8Z;-:7D5_<-#,Z2;C'A<\8/\Z
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M,5E90)!;1#:D:#@"N8M/&IU#Q%X?L[6!/L>JV3W6]\[T(&0/2KWBSQ#/X?\
M[)\B&.3[;?Q6K[\_*K'!(QWH Z*BN+O_ !-XBO-?O=,\-Z1:S)8!1/<7DK(K
M,1G:H _6M/PGXH7Q'HLMY/;_ &.>VE>&YB9LA'7K@^E '0T5QGA7QU_PE/BC
M5;"WMPMC:(K0S'.Z7)P6^G'%=G0 4444 %%%% !1110 4444 %%%% !1110
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M10 44U75D#JP*GOGBD2:.1B$<,1UP:3DD[-A;J/HHHI@%%%% !1110 4444
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M\7O_ $ X/^_Y_P */85.P>SD>W45XC_POB]_Z <'_?\ /^%'_"^+W_H!P?\
M?\_X4>PJ=@]G(]NHKQ'_ (7Q>_\ 0#@_[_G_  H_X7Q>_P#0#@_[_G_"CV%3
ML'LY'MU%>(_\+XO?^@'!_P!_S_A1_P +XO?^@'!_W_/^%'L*G8/9R/;J*\1_
MX7Q>_P#0#@_[_G_"C_A?%[_T X/^_P"?\*/85.P>SD>RZ@VW3KEMX3$;'<5W
M <=<=_I4>CMOT>S;S%DS$IWK'L#<==O;Z5XU-\=+Z6"2-=&AC9E(#K.<K[CB
MFVOQRO[>UBA?2(IF10ID><Y8^IXH]A4[![.1[I17B/\ POB]_P"@'!_W_/\
MA1_POB]_Z <'_?\ /^%'L*G8/9R/;J*\1_X7Q>_] .#_ +_G_"C_ (7Q>_\
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M_P#"^+W_ * <'_?\_P"%'_"^+W_H!P?]_P _X4>PJ=@]G(]NHKQ'_A?%[_T
MX/\ O^?\*/\ A?%[_P! .#_O^?\ "CV%3L'LY'MU%>(_\+XO?^@'!_W_ #_A
M1_POB]_Z <'_ '_/^%'L*G8/9R/;J*\1_P"%\7O_ $ X/^_Y_P */^%\7O\
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MY)&K16<-5S_RR_\ 'JD74,_\L_UI>SD@Y67:*K"[S_!^M2+-G^&IY6*Q+12
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M7$F+J,D02B,@9ZGU'J.]:M96N(CQ6F^&&3%U&1YLWE@'/4>I]N]:M !1110
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MO?>/7WKIPN[-J6[*E%%%=AN%%%% !1110 4444 %%%% !1110 4444 %%%%
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MOA;2-9\(>)[W4+19YXC(L3,3^[PI.1Z'-9]Q+))^S_:AV+!-4*KD]!UQ^IH
M]_36K&VAM(]0U"SANIH1)L:91NXY*\\CKS3(?%&@W%M-<0ZS8O#!_K76=<)]
M>:\A\86$&J>._ UE=+O@FLHED7.-PSTI(?".BR?'6?1_L2#35M_.-L,A"0@Z
MCTR<T >U6&JZ?JML;FPO8+J$'!>&0,!]<56M_$NAW=\;*WU>REN@<>4DZEL_
M3->!V<MQHND_$.VTMGBCBD6-0A/R)YI4X_#BJK:+<R>"])N[72M.T^3S T6J
MM?A7D;T(/0^W;% 7/8-9^(]GI?CJQ\.YMQ')S<W,DH"Q<'Y?8].OK75ZAKFE
M:3&DFH:C:VJO]TS2A=WTSUKQ;6=&L+OXQ:##J%M"PO;6.6[&?EDD*G)S]15K
M3=.T[Q+\9M=M/$BK+':H4L[:5L+M& ,#O\O/XYH ]DMM1L;RS^V6UW!-; %C
M+'(&4 =>15&3Q9X>ACCDDUS3U24X1C<+AOIS7D'A,)IWB[QMI.DR%]&2TF*J
M&W*I XQ^9'X5G^&?"VD7GP7U?6+FT62_0R&.9B<IMQ@#T[T ?0L<B2QK)&ZN
MC#*LIR"/4&G5Q7PFE>7X;:478L0KJ"3V#G KM:!F7KAD6*T\MKL'[5'G[,NX
MXS_%Z+ZFM2LW68VDBM0L,\N+E"1%+LV\]3ZCU'>M*@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &E 9 _\0&*=11222 ****8!1110 4444 %%%% $=P-UM*,%
MLH1@'&>/7M7QCJ:[-5O%*E<3N-I;<1\QXSW^M?9MSC[+-D*1L;(8X'3O[5X=
M#\%8M3C^W?VVD?GL9-D$0=%R3PK;N1710G&#?,:4Y);GC-%>U?\ "AH?^@^_
M_@,/_BJ/^%#0_P#0??\ \!A_\571[>GW-?:1/%:*]J_X4-#_ -!]_P#P&'_Q
M5'_"AH?^@^__ (##_P"*H]O3[A[2)XK17M7_  H:'_H/O_X##_XJC_A0T/\
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MC-N"5/ID-1[>GW#VD3QNBO:O^%#0_P#0??\ \!A_\51_PH:'_H/O_P" P_\
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M6BO:O^%#0_\ 0??_ ,!A_P#%4?\ "AH?^@^__@,/_BJ/;T^X>TB>*T5[#=?
M_P A[=8]6EF$D@1R( -@_O<MS5G_ (4-#_T'W_\  8?_ !5'MZ?</:1/%:*]
MJ_X4-#_T'W_\!A_\51_PH:'_ *#[_P#@,/\ XJCV]/N'M(GBM%>U?\*&A_Z#
M[_\ @,/_ (JC_A0T/_0??_P&'_Q5'MZ?</:1/%:*]J_X4-#_ -!]_P#P&'_Q
M5'_"AH?^@^__ (##_P"*H]O3[A[2)XK17M7_  H:'_H/O_X##_XJC_A0T/\
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M1N>[=A[UN68 L;<!54"-<!6W <=CW% %#Q)XAM/#.CR:C=AW4,$CBC&6D<G
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MP.NSAH$V(?H.PK<N#MMI6R5PA.0,D<>G>L71Y#-I-M(TKREDR7DC\MF^J]J
M+U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 5M0 ;3KD%48&)OE=MJGCN>PJ+1E":-9JL<<8$2@)$^]1QT![CWJ:_Q_
M9]SN,87RVR91E1QW'I46D;?['L]C0,OE+@P+B,\?PCL* +M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E:PBO/II:&"3;=
M@RR["O!Y7U/M6K67J^SS].WO:J?M(V^>N23@_<]&K4H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,KQ*4'AR^WM:JOE\F[4M$.?X@.U;UEC
M[!;X*$>4N#&,+T'3VK$\02^1H-Y+YY@VQY\T0^;M]]G\7TK<M&W64#;MV8U.
M[;MSQUQV^E $U%%% !1110 4444 %%%% &5=:#;W7B2QUMY)!/9Q/$B#&TAN
MN?RK5HHH **** "BBB@ HHHH **** "D55484 #T I:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^%'VN+TD_P"^#_A0!/14'VN+TD_[X/\ A1]KB])/^^#_ (4 3T5!]KB])/\
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MP!9@6\E.",?Q9'W?I5[[7%Z2?]\'_"@">BH/M<7I)_WP?\*/M<7I)_WP?\*
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M[]M_A0!9HJM]NA])?^_;?X4?;H?27_OVW^% %FBFQR"1 ZYP?48IU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5
MKB,\5H%AEEQ=1DB.;R\<]3ZCV[UJUE:[$DL5H'CMWVW4;#SY2@!SU&.K>@[U
MJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$5R ;28$*04;AS@=._M6'H2+'HEHB+;JH3A;9BT8_P!TGJ*W+D@6LI)4 (>6
M&0..XK%T619=&M71X9%*9#0Q^6A^B]A0!?HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ^BF>;'_ ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= #Z*9YL?\
MST7\Z/-C_P">B_G0 ^BF>;'_ ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_
M )Z+^= #Z*9YL?\ ST7\Z/-C_P">B_G0 ^BF>;'_ ,]%_.CS8_\ GHOYT /H
MIGFQ_P#/1?SH\V/_ )Z+^= #Z*9YL?\ ST7\Z/-C_P">B_G0 ^BF>;'_ ,]%
M_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= #Z*9YL?\ ST7\Z/-C_P">
MB_G0 ^BF>;'_ ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= #Z*9Y
ML?\ ST7\Z/-C_P">B_G0 ^BFB1"<!U)^M.H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R_$4
MAB\/7L@F:$K'GS%A\TKSUV?Q?2MVS.ZQMSN+9C4[BNW/'7';Z5C:[N_L2[V&
M[#;./LF/-_X#GC-;5KG['!G?GRUSYGWNG?WH FHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S6C
M((K7R_MG_'S'G[+C.,_Q?[/K6G67K<+316@6!Y=MS&V$F\O;@]3Z@>G>M2@#
MS7XLV4.HW/A6SN$+P3:F$D4$C*D 'D5M67PO\(6-W'<QZ2KRQG<OG2,X!^A.
M*ZV2&*4J9(T<H<J67.#ZBGT >7^*=<NE^(/]DS:O'X?L4M!(M[Y2[YR>JAR.
M /3VKF](F@EO_'?D:A=7\;Z6"ES<YW3  @D>V>E>VW-C:7FW[3;0S;>GF(&Q
M^=*+2V&<6\0RNPX0?=]/I0!YEKD07]GN%$7;_H-OP!W++5;PM;R?#KQ':VUU
M(T^EZ]%&R7<@^:.?'W6/H<\5ZP8(6A\EHD,6,;"HVX^E$EO#*JK)$CJIRH90
M0/I0!XGJ2D^!_'((/.M]/^!+76?$Y /#GA\*OW=4ML8'3@UWYM;<HZ&",JYW
M,-@PQ]33I(8I559(T<*<@,N<'UH \AU?^QE\8ZQ-'K=]X5U5&!=V?]U=C'#A
M>A^E57U74KO1/"OB36(C+:Z?J<HFFCAVAHC@++M].#7L5SI]G>,K7-I!,5Z&
M2,-C\ZF,,1B\HQH8\8V;1C'TH \Q\2:S8>+_ !=X6L]!F6]DM;O[3//""5BC
M [GW]*N_#1 +/Q2=N"=6N,\=:[VVL;2S!^S6T,.[KY:!<_E4D<,4081QH@8Y
M;:N,GU- '%_"<8\"Q#&/]*G_ /1AKCK^32(-:URZLO$-[X7U..=C+:S-NCN#
MV<+T(->RQQ1PILB147KA1@5#/IUE=2B2XLX)9%Z,\88C\30!A^ M3U'5_!MC
M>ZI"(KJ0'(";-P!X;';(KD[S7M,\/_&?4+G5;M;6%]-B17<$@G/3@5Z@ %
M  '0"H9;&TG??-:PR/TW/&": /,O$NNVGQ!U/2-"T#S+NWCNTN;RZ$;+'&B\
MXR0,FH=2^S#Q'X_-[837MJ;:V\R&$X<CGD?3K^%>K0V\-NNV&&.,>B*!_*E$
M,0=W$:!G&&;:,M]?6@#Q6UU9]&OM%C\,>*9M:@N+A(SIEPOF/$AZG/5<?A3-
M.BBT?Q3XCM-7\37^@2R7;3QE"%2=#T()')KV>#3K&VE,L%G!%(>KI& 3^(I;
MFPM+PJ;FUAF*]/,C#8_.@#QJ'4'T7P1=ZAI/VHPW^K*'OM1B5]JXP9@N.G'>
MJVN7-N_B;PP8_%-UKKK?HTKG'DQ9Z8VC )_D*]R:WA:#R&B0Q8QL*C;CZ5#'
MIMC#&(XK.W1 =P58P!GUH \AO7T>+Q!KES::]>^%=3CG8RP2MNCN3_?"]"#5
M75KG5-3TCP;X@U>:XL88I)HY[JUCVF($@))MQP"!Z5[3/IUE=2+)<6D$KKT:
M2,,1^=3/#%)$8GC1HR,;"H(Q]* /)=-CTS4?B#H_V77M4U^:U#R^?N4Q0#'1
MCCOZ"O7:@MK*ULU*VMM#"#U$:!<_E4] !1110 4444 %9'B;4Y-*\/WMU \2
MW$<1:/S#CFM>O"?%%]+?Z_?;Y6>,2LJJ6R !Q6^'H^UE:YSXC%K"\LW&^NQP
M\EZ^HW$ER\QFEE8LSDY))KVOX:ZE<6N@"QO@=D<A\I\YPIYQ^=>,MI=E8W<!
MC>422R!5CW9!Y_E7IEIXEDM@EN=/ C08#(_&/QKQ.(\3B<$X1PUG?77LCZ7$
M\1X7,,)&FXM._;MV/7 0P!!R#2UGZ+J,.IZ9%<0@A?ND'J"*2'5!>M+]AB\]
M(G,;2;@%+#J!ZXKT:,O:TU-=4>%==#1HK/N=4%I87=Q- ZM;1&5D_O #/!JO
MX8\01>)M%CU*&%X4=F78YR>#6O)+EYN@KJ]C8HHHJ1A1110 4444 17(W6LP
MV[LHPQG&>/7M7QKJ4LR:I=IN=-LSC;YA;;R>,]_K7V5<X^RRYVXV'._[O3O[
M5\9:EC^U+O:(P/.? C.5^\>GM75A=V:TMV0^?-_SU?\ [Z-'GS?\]7_[Z-1T
M5V&Q)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!
M)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W
M_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_
M^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1
MY\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_
M #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?
M_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU
M'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!
M)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W
M_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_
M^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1
MY\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_
M #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?
M_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU
M'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!
M)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W
M_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_
M^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1
MY\W_ #U?_OHU'10!TG@::5O'.B@R.0;M."Q]:^J*^4_ O_(]:+_U]I_.OJRN
M+$_$C&KN%%%%<QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!F>(HVE\/WJ+#),S1X$<<WE,W/0/_#]
M:W+,%;&W!4J1&HVEMQ''3/?ZUA^(E1_#]ZLB6SH8^5NI/+C//\3=A6Y9@"QM
MP @ C7 0Y4<=CW% $Q( ))P!U)JG#J^FW%QY$-_;23=-B2J3^6:R/'MCJ>H^
M"]0M=)W&[=1A4;:SJ&!90?4C(KS)G\"7UA!ICV5QX7UE"GEW4\#(R.".K]\^
M] 'MK3PK.L#2H)6&50L-Q'J!1+/#!L\Z5(][;5W,!D^@]Z\P\5ZQ%X?^)?AN
M\O#/=(FFR*S6\9=G).,@"J/B_P :Z?XCN_#EK:6VH0NFK12$W%LT:D8(ZGOS
M0!ZY/<06L?F7$R1)G&YV &?QI[2(D9D9U" ;BQ/ 'K7G'CV >+/$]AX3$VR"
M*"2\N6#8P=I$8_[Z.:DT?67U;X1ZI'<-F]L;2>TN!GG<B$9_$8- ';KK.ELP
M"ZC:$GH!,O\ C4]Q?6EJBM<7,,2O]TNX4'Z9KQ/0I_ABO@BT&J):MJ7V;$NR
M-_-+^Q ZUGW!:W\+>"&\1PSS68OIB8I4+.T'&T$=3Q0![LFL:9(ZHFH6K.QP
M%$JDD_G5VO+M%NOAO=ZU9P:?H$D=XTH\EVL74*PY!R>G2N^\127<7AW4'L50
MW"P.5WL5'3DY% &D&##(((]12UY)X5\6ZKI/@?0+-;**\U'469+%/-/S*"2S
MR$],&NGL?%FK6VO-HGB#3[>"ZDMGN+66VD+1RA1DKSR"* .TJ)KJW21XVGC#
MHN]E+#*KZGVKSBU\?>*+GPT?$PT&T_LJ+)D7SCYK*IPS*,8P/?TJJ^IVUYXU
MU_4DC%Q:R^'4F$;$@.IYP<=* /5(Y$FC62-U=&&593D$4ZO-D\97>F:-X1L]
M&T:%VU6WQ% 92%BPH(&3V'?/I5^V\<WVFWFK6?B>R@MIK"T^V![5RZR1],#/
M?/% '=45YL?B#K=G86VMZEIE@FD3,NY8KG=/$C'AF'0_2N_O;^"PTR>_F;]Q
M#$96(] ,T 3RS101&6:18XUZLYP!^-.!# $'(/0BO'O&'B/Q-K'P\N+^?1K>
M#2+WRS&RS$S1J74JS#I@X'YUU]WKNO13V>FZ/I<+*MHDLEY>L4A''W5(ZF@#
MLB0H))  [FEKR#Q-XNU;7/ &K*+>W@NK&]2WNS%.2I&004(ZY/%=;=:[XH@^
MP6%MH]LUY)"9)[F21A;1 '  ;')/'% '945R?A#Q5=ZY>ZIINHVUO#>Z>ZJ[
M6TF^-PPR"#764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!DZ^$,-GOCM7_P!+CQ]HDV@'/5?5O05K
M5DZ\R+#9[Y+9,W48'GQ[P3GHOHWH:UJ .+^('B/6-!_L:#11:_:-0N_L^;E"
MRC(XZ$5EZCKOQ!\,6K:GJUGI-_IT/-PMGO61%[L,GM4GQ-_Y"W@[_L++_2NE
M\;:A::=X,U::[=51K61 "?O,RD #\30!>@US3IM$AUAKJ.*REC$@EE8* #ZD
MT_3M9TS5XGETZ_M[I$^\T,@;;]<=*\1NK?5!I_@#1FLHKJ-[=Y_LES)Y<<KY
MR Q]@>GO6[I^FZQ8_$.QN9-,TG11-;R)/:VET"9TVG!V8'0XH ](D\5>'XFB
M5]:L%,IQ&#.OS<XXY]>*F_X2#1_[2&G?VI:?;3P(/.7>?PS7D'A[PUI%S\'M
M=U*XLH9;QOM3K,RY9"A.W:>W2I=;T'3-,^%>@ZG:VD<>H":VE^U!?WA9B"26
MZT >NZEK6EZ.J-J6H6UH'^[YT@7=],T\:IIYT_\ M 7MN;/&?/\ ,&S'3[W2
MO(IHM4U;XH>(&CT33]8DM5CCBBOYMHB0CJJD'.?7_&J4]C?:=X*\;VMQ'9VL
M!:)ULK6X\T6[EQN'M0(]BA\1Z)<:A]@AU:SDN^GDK,I;\LUC0>.+2?Q]/X;\
MRV5(H PE,HW/*3]P#U [=:XWQEX<TG1/ ^A7NG6,-O>0W5L5N(UPY)ZY/4UI
MZ=IUB?CAJ;&T@)73HYE/ECAR1EA[^] SK=#U6XDTZ\NM7O-/VPW$BB2WD&Q$
M!X#'/#>M6].\1:+JTS0Z?JEI=2J,E(I0QQ]*\@@N--3P=<VM_:W-[)<>()1;
MV<#[//<-P&/]VIIX;^T^(GA*:Y\/:=H9DN"BI:2AG=<8.[  QS0(]LK(D\5>
M'XKW[%)K-@MSG;Y1G7.?3KUJUK%S;V>BWUS=2O%;Q0.TCQ_>50#DCWKPZ_M&
MF^'ES-I_@ZSMM*\LR)J-[< W##/## SD_6@9[E=ZMIU@^R[OK>!MADQ+(%.T
M=3SVI--UC3=8B:33;ZWNT4X8PR!L'WQ7E3:?;:_XM\!PZD@N(FTCS'1^0Y"9
M&?7FK&HVR>'/'7B-=$@6VW: TXBA7:OF#(! '?B@#L?$WC/3]+TC4S8ZE8R:
MI:PLZ6[2!CN'8J#FM?P_?2ZGX=TZ_G"B:XMHY7"C R5!.*\NF\->'I/@@=0-
MM ;HVGGFZ('F&7_>Z]>,5Z1X._Y$O1/^O*+_ -!% '*7&O\ C34O&FM:1H3:
M4EOIYCYNHV+'<H/4'US5O2?%FO6'B:VT#Q996L<MX";2[M"?+D(ZJ0<X-1^%
MO^2I^,_^W?\ ] %1>.IH[WQQX.TZV8/=Q7WVF15.2D:]2?3.* .SU'7]'TB1
M(]1U.TM9'Y59I0I/X&IY=2L8+6.ZEO($MY2 DK2 *Q/3!Z'->,Z/;:OK'B+Q
M+=KX<TS6)?MKP.U]/M:)!T4*0<#'>J5YI]U#\.)--O)+<P#78TCBM[CS1"I)
MRF?:@1[3;^)=#NGG2#5[*1H 6E"SJ=@'4GGI4^G:QINKH[Z;?V]VJ'#&&0-M
M/OBO-/%'A#0H_&W@^RATZ"&WF:1)DC7:)55=P#8Z\CO5;5HE\-^.?$PT2!;3
M_B0&81P+M <'&X =Z!GIK>)-#74?[/;5K(7F=ODF9=V?3&>M6+O5M.L'*7E]
M;V[!#)B60*=HZGGM7ANGZ'J=Y\.T9/#6BF"6'S3JDMYME#==Y.."#VS6ZFEI
MKGC7P;;ZX(KPKI+22X;>DK*.#GN.] 'IB>)-'GTRXU"VU*TFMH 3)(DRE5]B
M>U<S8>-[C7O"%OJFG7&F6UXURB317$V5C0L1@\CYB!Q63#H^GV/Q.U[3K>SA
MCL;C2%EDM@@\LMD\[>G:N<AM+:#X,://#!&DLVHP^:ZJ 7Q*<9/>@1[+J6N:
M5HX4ZEJ-M:;_ +OG2A2?IFI[*_L]2MA<V-U#<PMTDB<,/S%>::RT%]X_U!-*
M\,C7=1@A2.X>]F58+<'D!00>33OA(LL&J>*K62&"W\N\7,%LVZ*-L'(7VH&>
MHUYWXH^'[SW#7FD8W.V7A8]SW!KT2BM*=65-WB8UZ$*T>69\[7/@Z^TWQ)YV
MISKOA8-'&@R,=N:UJ])\6^'+C5Y(;BS"&51M8,<9':N/D\*ZS&X4V;')QE2"
M*^1SA8ROB7*HFTMK+2WR,'2Y/=2T-KP%>/YUS8'=L==X(_A/2L.TB^('A"2X
ML-/L(K^R,K/&Y&>ISZBO1M T2+1; 1@ SOS(_J?3Z5:\^[A)62V,P!^5XV R
M/<'I7T>4QJ8;#*G42?D^ANH/E5V>?V?C/4-7TS7-'UO3OL6HPV4D@ ! 9=OH
M:@\$633?"R:?[5/')&)FB,3E=A'.>.O-=5?>'9]1GU34I$1+N>R:TMXMV=H(
M/+'U)_*J_A7PYJ&D> 9='NEC%VRR@!6R/FSCFO5=2')[NFJ!1=]2AX1\5BZ\
M!1W^NZAY)28Q&;HSXZ#ZU0\8:]+H=[HU[I%S=1K/+ME@GW;9$..<-5(?#?6C
MX*M+(M"+ZTO&G$7F?*ZG'&?7BMKQEX>UKQ3%I!M[*. VL@>5991GMG&.W%6O
M9*K=/1M^@O>Y;%>TU/4;[XMWVEO?3+8+"&\E6P!\BGCTY-/EUF\\/?%&#1UN
M99=.O(@WE2MNV,<]">>U9UAY\7QMU$PH)'2W&4SC<-B]#ZUO)X8O]7^("^(M
M0B2VMK:,1P0EPSL1GDXX'4TI<D7[VW+^(*[V[E'PKX@?Q3?ZU<W]Q,D,4GE6
MT,9("#GGCJ>E:GP^U+6[J"^M=9CG_P!'EQ!-,A4NG/YTWPYX;OO".LZE]GB%
MUIEZ_F)L8!XFYX(/4<UV%N\\FYI8Q&,_*N<G\:QK3AJHK1VMY%03TN+<G%K,
M20,(W+#(''<=Z^,M2(;5+M@RL#,YW(NT'D\@=A7V=.<6\I!880\J,D<=A7QE
MJA+:O>DL[$SN=SKM8_,>2.QHPN[.JENRI11178;A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 7-(M$O]:L;.4L(Y[A(
MF*]0&8 X_.NH\4:3X=TZ\NM+T[3]6CO(KCR$N+F=/)8@XS]T=?K7-Z%/';>(
M=-GF<)%%=1N['H &!)KM?&T]WK-Y=O\ \)A8W>FR76^&U^T,2@)P#C;@8!]:
MSDWS(E[G*W/A+6;,WXN;3RA8LBS,S #+?= /?.>U7+OP!XBLK2>XGLU @3S'
MC$JEPG]_;G.WWKK?%&O:3KGA^+2+74RTNC20A)9#_P ?X "EA[@]/:K^KMIN
M@^,]:UZXUJWE+630BQ&[S?,:(*%(QC;WSFIYY$\S.)U/PPUQ)X>M='M&>YO=
M/6>0!NK;FRQST&!5&\\&ZU97%G"\$<@O)/*@DAE5T=_[NX'&:ZRRU[2?M&F6
MTM^D*S: UB\_)$$C,Q&['^>:33[[3/#EAHND2:K:W<O]KI>S2P,6C@11CJ0.
M3G-'-)#NSF9O NNV]]'930P1SLC2,K7"#RU&,E^?EZCK5S2?A[J5YXGM='O7
MBMEN(S,LZR*ZLG/*G.&Y':I-%DT6_P#%^M3ZI-;OYGG/9M=,PA>0M\N\CG&*
MZ>7Q!H]KXG\&.;ZQ,5E'+'<M: B*(L3C&><<T.4M@;9P47A#5KC5KC3H$AE>
MW3?+*LRF-%]2^<#\Z>?!.O?VS#I2V8>ZGB,L.QP5D0#)*L.#TK>TM=/MM-\1
M^&IM9LHY;TQ2P7BL3"VPDE"V,CKZ5J:?K>E:1>Z+IO\ :L,_]GV%VLEVA.SS
M)%8A%)Y..!3<Y= NSA]4\)ZMH]K+<W441ABD6.1HI5?:S#(!P?8U0U'2[O2I
M8HKR/RWEB695SD[6Y&?2NP^&HM]6U&_\/:@S?8]0B\QG'.QHSN#?D"/QKF_%
M.JC6O$M]>KQ$TA6(>B+PH_("J3?-9C3=['9?\(;X9GO;;0XFU.+5)]/6[6X9
MT:'<8]Y!7 ('7O5.^^']W>Z+H5UH]K&7N+,O-NF ,L@8_=!/)P.@I?%?C>[!
MM[/2+R$6S:=##+)%&N\G8 RE\9_"@:W9#4_ CB\398Q1BX.[B(^82<_A6:Y]
MR=3F]*\*:IK"R-;)"@27R3Y\RQY?^Z-QY-/M/!^LW<]Y$+=(39R"*=KB58U5
MST7).,\5U.DOX>E6_NS<:8+_ /M-W9[_ '%1;]0T8'4YS6D=6LKWQ3KC'5-(
MET6[O%:>VO"PWJ /WB$#KU%4YR'S,X33_!^L:DDKPPQ*D<I@W2S*@>0?PJ2?
MF/TK(GM9;.]>UNT>*2)]DJD<J0>:],M]5T>XT--/TJXTF/[#?3/$NJJ?FB9L
MJRGUP.:X+7;J35?$]U/<75O(\TV'GA!$9Z#<!UQ51DV]1IMG0OHGAC5/#&JW
MVC?VE#<:8L;,]TRE)@QQP /E/MFL7PIH">(-6>&><P6=O"UQ<RJ,E8UZX]SD
M"NK\1V^GVOA<:1H6O:2;"(":X_>MY]W*!W&W&!V&:Y_P-JUCINJW=OJ4ABLM
M1M)+228#/E[L$-CTR!4IOE;0E>Q9CM_!^HZKIUMID.IQR/>Q1/'=.K++&6P3
ME0"IJ/4_#T AOQ9V,WFKJYLX9?-&P ]$P><^]2V^C:9X?UC3;U_$=A=E+Z(A
M+;<V(PV2S$@8QZ<UIMK>F_9[A?MD>6\2K= 9ZQ<?/]*+OH'H<[J?@77](LI[
MN[M$6.W($RK*K-'DX!90<@'UJ:\\*7-WK%O8Z3IT\9:RCN9!/,I !4$N6Z*I
MSWK6FUNQ?6?'$IO$:.]@=;=B>)3YBD8_"M9M=T>^EO\ 3#J4-O\ ;]#M;:.Z
M;.Q)4 )1B.F>E+FD%V<5_P (9K U%[)DMU98A,96N$$>PG ;?G'6M#2/"CV^
MLZA8:U;#?%ILUS%M?*DA<JP(ZBK6BZ7H-A>7MM=:IIE]>+;*ULTS.+82;OF4
MGO@<^F36WJ.NZ0-=5H[ZS:-/#TEJ6@!$?FX;Y5!Y[BAR>P-LX7PTFA37HM]:
MM[Z7SG1(C:RJFTDX.[(.>U;7B'P]I!\2MX;\.6FH/J4=PT):XG1DDP"> %&.
ME<KIDB0ZM9RR,%1)D9B>P!%=G%K-@GQGEU;[7&+$WDCB?/RX*L :J5T[H;W,
MMO"5QIEOJBZG9L]Q!:"=#!<(1"=^W+C],=:JMX,UE=,>_P#)A:-(A,\:3J9%
M0_Q% <@5:T74K:*P\5"XN%$EW:E8MQYD;S >/PKK[6Z\-Z9I]X]C=Z5';S:4
MT2?>-T\I3D-G@<_TI.4D)MHX?Q)IEI8:9X?FMH]CW=B)ICDG<VXC/Z5SU=)X
MGOK:[TKPY';S+(]OIXCE"_P-N)P:YNKCMJ4MCH/ O_(]:+_U]I_.OJROE/P+
M_P CUHO_ %]I_.OJRN3%?$C&KN%%%%<QD%%%% !1110 4444 %%%% !1110
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MN_+K3[BZM[1-]S/%"G3=(X4?K0!X[#X7NI=.M=+C\!V\.I*52>^N"&@VCJP
M.23Z5ZMJ^EC4_#]WI>X()[=H00.!D8%7T=)4#QNKHPR&4Y!IU 'D6IQ^,+OP
M"OA(>&Y#<0I'"]T)5\MXT(P5YSD@#]:L:SH.I-XJ6XU71+O6M*^QQ1VT$$P"
MPR #=N7(SSGFO5:* /&[?PAKH\)^*K,:*MI+=745Q:VT;@J5&#M!]1BKVLV6
MKZQK=AJ6K>&]0N]+-IL_LZ.< PR@_>8 @$$?SKU:B@#SOX?:#J.D>(]<N;G1
METRTNUC:WBC8,J #&TX[^M>B444 %%%% !1110 4444 %%%% !1110 4444
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MI6G0!R.K_#S2M4U674HKF^T^ZG&V=K*<QB4?[0%3GP%H0\/V^BQPR16D$ZW
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M4 %%%% !1110 4444 %%%% !1110 4444 =!X%_Y'K1?^OM/YU]65\I^!?\
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M;^VN;B&%H;>"U0B- PP3D\G@FJ5IX6\9^';6YTC0;_37TN5W:"2Y#"6W#')
M &#U- C*A\7:WXETKPWI$-X;*^U">:*\NHA\P6+@E?0FG'1KW1/B_P"'XKC5
M;G4+=K:<P-<D&1/E.X$CJ.E;,OPZN+'0M&71KY$U?29'ECGF4[)6?[X;'0&B
MR\+^*KWQOIWB/7+K3@MK%)%]FMBWRA@1D$CG)/- '+'QSJ]A\/I)?MKF]NM8
MEM$N7&XPQ@\D#O@=*?9^)SI&OZ0=+\0:KJ\-S.L%[!>0-@!CC>IP,8/:MV'X
M:7;>$)--EO88M0BU)[^TGCRRHQ.0#D#\:TK32?&VH:G8OK.HV5I9VCAW33V;
M=<D=FR!A?:@#C]7URZ7Q!J\.O^(-6T2=9B-.\I,6Q3'RDG!S[UZGX:GN+GP[
M8RW5[;WL[1#?<V_W)#ZBN5U#0/&22ZC:6MUIFI:;>.S(-2W,\ /\(&""!VKH
MO!_AT>%?#%II'G^>T():3& 6)R<#TH&;M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!%<X^R39V8V-]_[O3O[5P&F^ O"U]I
M\-U/I%A)+*-S-;EC&3G^')Z5W]P<6LI) &P\D9 X].]8NBLK:/;,LL<JE.'C
MB\M3]%[4TVM@NT8G_"M_"/\ T!+?]?\ &C_A6_A'_H"6_P"O^-=513YY=Q\S
M.5_X5OX1_P"@);_K_C1_PK?PC_T!+?\ 7_&NJHHYY=PYF<K_ ,*W\(_] 2W_
M %_QH_X5OX1_Z EO^O\ C7544<\NX<S.5_X5OX1_Z EO^O\ C1_PK?PC_P!
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M7_A6_A'_ * EO^O^-'_"M_"/_0$M_P!?\:ZJBCGEW#F9RO\ PK?PC_T!+?\
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M/^%6:* *WVZ#U?\ [X/^%'VZ#U?_ +X/^%6:* *WVZ#U?_O@_P"%'VZ#U?\
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M2Z=>JQ2AB/PK2H **@N;RUL_+^TW$4/FN(X_,8+N8] ,]34] !1110 4444
M%%02WEM#<PV\MQ$D\V?+C9@&?'7 [U/0 4444 %%%% !1110 4444 17)VVL
MS;@N$8Y(SCCT[UB:)*)M&M9!*LH9,[TB\L-]%[5N7&1;2D%@=AY49/3M[UP5
MKXUL+.V2WF%]++&-K/+&%<GW&>#6=2K"FKS=C6E0J57:FKG8T5RG_"?Z7_SQ
MN?\ OD?XT?\ "?Z7_P \;G_OD?XUE]<H?S(V^H8G^1G5T5RG_"?Z7_SQN?\
MOD?XT?\ "?Z7_P \;G_OD?XT?7*'\R#ZAB?Y&=717*?\)_I?_/&Y_P"^1_C1
M_P )_I?_ #QN?^^1_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G_ +Y'^-'_  G^
ME_\ /&Y_[Y'^-'URA_,@^H8G^1G5T5RG_"?Z7_SQN?\ OD?XT?\ "?Z7_P \
M;G_OD?XT?7*'\R#ZAB?Y&=717*?\)_I?_/&Y_P"^1_C1_P )_I?_ #QN?^^1
M_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G_ +Y'^-'_  G^E_\ /&Y_[Y'^-'UR
MA_,@^H8G^1G5T5RG_"?Z7_SQN?\ OD?XT?\ "?Z7_P \;G_OD?XT?7*'\R#Z
MAB?Y&=717*?\)_I?_/&Y_P"^1_C1_P )_I?_ #QN?^^1_C1]<H?S(/J&)_D9
MU=%<I_PG^E_\\;G_ +Y'^-'_  G^E_\ /&Y_[Y'^-'URA_,@^H8G^1G5T5RG
M_"?Z7_SQN?\ OD?XT?\ "?Z7_P \;G_OD?XT?7*'\R#ZAB?Y&=717*?\)_I?
M_/&Y_P"^1_C1_P )_I?_ #QN?^^1_C1]<H?S(/J&)_D9T=_@Z?<[A&5\MLB4
MX3IW]JBT@*-'M @@"^4N!;G,?3^$^E<Y=>.M.FM)HXXI@[H54N@*YQW&>14=
MAXXL+;3X()HI3)&@5C'&%4GV&>!1]<H?S(/J&)_D9VE%<I_PG^E_\\;G_OD?
MXT?\)_I?_/&Y_P"^1_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G_OD?XT?\)_I?
M_/&Y_P"^1_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G_OD?XT?\)_I?_/&Y_P"^
M1_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G_OD?XT?\)_I?_/&Y_P"^1_C1]<H?
MS(/J&)_D9U=%<I_PG^E_\\;G_OD?XT?\)_I?_/&Y_P"^1_C1]<H?S(/J&)_D
M9U=%<I_PG^E_\\;G_OD?XT?\)_I?_/&Y_P"^1_C1]<H?S(/J&)_D9U=%<I_P
MG^E_\\;G_OD?XT?\)_I?_/&Y_P"^1_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G
M_OD?XT?\)_I?_/&Y_P"^1_C1]<H?S(/J&)_D9U=%<I_PG^E_\\;G_OD?XUHQ
M>)K.:))%CEPPR,@?XTXXJC+:0G@<0MX,VJ*R/^$AM?[DOY"E_P"$@M?[DGY"
MK]O3[D_5*_\ *S6HK*_MZU_N2?D*7^W;;^Y)^0H]M3[A]5K?RAJX0SZ=O6U)
M%R-OGL00<'[GJU:E<_?ZDMS+:-"% BF#OYD08E?]GT/O5[^V[?\ N2?E1[:G
MW%]5K?RFE16=_;-O_<D_*E_MB#^Z_P"5/VT.X?5JO\IH45G_ -KP?W7_ "I?
M[5@_NO\ E1[6'<7U>K_*7Z*H_P!J0_W7_*E_M.'^Z_Y4_:0[A["IV+M%4_[1
MB_NM2_;XC_"U'M(]Q>QJ=BW157[='Z-3OMD?HU/GCW%[*?8L45!]K3T:E^TI
MZ&CF0O9R[$U%1?:%]#2B93V-/F0N278DHIGFCT-+O%%T*S'44@;-+3$%%%%
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M% !1110!'<9-M+@,3L/"G!Z=CZUX+<AA=2AEE5@YRLK;G'/<]S7O-R-UK,N
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MM[::ZD\N",N^TM@>@&32202Q)&\D;*L@RA(P&'M3L[7%=7L1T444AA766/\
MQXP?[@_E7)UUEC_QXP?[@_E73AOB9C6V+0ZT\4U" X)4, >A[UTNFVVC:@FW
MRC'-CE#(?TKT:=/G=DSSZ]94ES--KR.>%/%:>I:'-8DR1YD@]1U7ZUF"G*#B
M[,4*D:D>:+'"G"F=*K?VMIZPPS&\A$<[;(F+##GT%"382:6Y?%.%0&Y@2X2!
MI5$KJ65">2!U-58=?TB:80QZC;-(3@+Y@R3Z523(E)+=FF*>*C9E12[$!0,D
MGL*HV_B#2+I]D&H02-@MA6SP!DU239$FEN:@IXZ5G1ZQ8RRV\<<X8W$;2Q$
MX95ZG-6[6Z@O;9+BWD$D3C*L.AJK,BZ>Q9%/%,%/%6B&.%/%5KJ[M["U>YNI
M1%"@RSGH*L(P=593D$9!JT8LD'6GBF9 Y/2J-IK^DWMX;2VU"WEN!G]VK@DX
MZX]:M&<F:@Z4X5EW&OZ1:7@L[C4;>.X) \MG (STSZ4^\U_2-.N%M[S4;>"9
ML81W //\JM&3:-44X5!)<0P6SW$LJ)"B[FD8X 'KFEL[NWOK6.YM9DF@D&4D
M0Y##VJD9,LCM3Z8.U/JT9L****9(4444 %%%% !1110 4444 %%%% !1110
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M'Y0[C(Y.:R[+6+JPB\N#R@025<Q@LI/H:<YTU5OTMV7_  PJ=.JZ-M;W[O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:_;S:[J<-EI<L/DQ138W'8OWOR_6NT\6^&/^$GL;6*.^DLKBTN%N8)T0-M8
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MKZY;=//;(\C>K8Y-;-9^A:4NAZ%9:6LIE6UB$0D*X+8[XK0H&%%%% !1110
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M_D>W_:6%_G_,XFBNV_X5Y-_S_I_WP:/^%>3?\_Z?]\&CZAB/Y?R#^TL+_/\
MF<317;?\*\F_Y_T_[X-'_"O)O^?]/^^#1]0Q'\OY!_:6%_G_ #.)HKMO^%>3
M?\_Z?]\&C_A7DW_/^G_?!H^H8C^7\@_M+"_S_F<317;?\*\F_P"?]/\ O@T?
M\*\F_P"?]/\ O@T?4,1_+^0?VEA?Y_S.)HKMO^%>3?\ /^G_ 'P:/^%>3?\
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M/LLV=N-C9W_=Z=_:L/0MIT2TV&V*[.#; B/_ ("#VH T:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O06L9PHD8F-
M@!&<,>.Q]:CTM632[56696$:@K.VYQQ_$>YIVH#=IUR-@?,;?*6V@\=,]OK4
M>CKLT:S7RUCQ$HV+)O"\= W?ZT 7:*** "BBB@ HHHH **** "BBB@ HHHH
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M^V_NR?\ ?UO\:/[/MO[LG_?UO\:M44 5?[/MO[LG_?UO\:/[/MO[LG_?UO\
M&K5% %7^S[;^[)_W];_&C^S[;^[)_P!_6_QJU10!5_L^V_NR?]_6_P :/[/M
MO[LG_?UO\:M44 5?[/MO[LG_ '];_&C^S[;^[)_W];_&K5% %7^S[;^[)_W]
M;_&C^S[;^[)_W];_ !JU10!5_L^V_NR?]_6_QH_L^V_NR?\ ?UO\:M44 5?[
M/MO[LG_?UO\ &C^S[;^[)_W];_&K5% %7^S[;^[)_P!_6_QH_L^V_NR?]_6_
MQJU10!5_L^V_NR?]_6_QH_L^V_NR?]_6_P :M44 5?[/MO[LG_?UO\:/[/MO
M[LG_ '];_&K5% %7^S[;^[)_W];_ !H_L^V_NR?]_6_QJU10!5_L^V_NR?\
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M;_&C[%!Z/_W\;_&K%% %?[%!Z/\ ]_&_QH^Q0>C_ /?QO\:L44 5_L4'H_\
MW\;_ !H^Q0>C_P#?QO\ &K%% %"]LX%L9V(48C8_O9&V=._/2H]+M+=]*M6
MC(,2G-N[>7T_AYZ5:U!MFG7+%PF(V.XKN XZX[_2H]'<2:/9N)%E#1*=ZQ[
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M?[%!Z/\ ]_&_QH^Q0>C_ /?QO\:L44 5_L4'H_\ W\;_ !H^Q0>C_P#?QO\
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M^[)_W];_ !H_L^V_NR?]_6_QJR2!U(%8_B?Q!%X9T5]2EA:9%D1-B'!^8XH
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M%8O_  E6D?\ /R?^^&_PH_X2K2/^?D_]\-_A1R2[!=&U16+_ ,)5I'_/R?\
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M\-_A1_PE6D?\_)_[X;_"CDEV"Z-JBL7_ (2K2/\ GY/_ 'PW^%'_  E6D?\
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ML'UN/4T>2-H[ V"1)C:(S_6HX_!ME'X(/A43S&T,1B\SC?@G/THN!R=G:_\
M";>,[ZUUBXN/LMA9VYAMXI3&&9T#%SCKR:Y>[CDM?!_BVR>\FNDMM9ACC>5R
MQV@CC-=-XGMK;3O$\;31:SIXCLTABU+307,Z@8V.H'!'8TWP=X&&H^%-6M[]
M+RTMM0U 7$(E/[[8N,%L]R<TP*6K7%QKOCW5;2\TW5-2LM/CC2&VLIA&JEAD
MLW(R?2M3PMKFL>'](OHKS2-6O8(KS9:1 K+/'&1G#G/;I72:MX)AOM9_MBPU
M*\TN_:,12RVQ&)5'3<",&M#PWX:L_#5G+#;/+-+/(99YYFW/*YZDFE=6 XGQ
M+KEMK@TI;ZWUNV\R23_B3Q1;9KD #YB0W"BLKP])?V_B3Q'I.FI=Z3&^E^=!
M!?3[_*DS@-G)VYS7H?B#PI'K>H6>I0W]S8:A:*R1SP8SM;J"#P16=:?#G3H=
M0O+VZO;R]EOK8VUT;A@?,!/7IQC QBBZ X/1_)T:^T<ZO;:UH^H"95>^$QGM
M[PGL3G #=:V?#NBQ^.;?6]8U>_NUN1>2P6YCG9%M53[I !Q^=;]O\.84-E!=
MZWJ-YIUE(LD%G,PV*5^[D@9.*?=_#V"2\OI=/U>_TZWOV+75M;L DA/4C(XS
M[470'%ZI>7=_XHL-!G>^UZPM-/65OL$@C^TN21O8[N0,8Z]:K7LVLZ?X7\3V
M8AO[&P3R9+-;F8-+"2X#+D$G'>O0[SX?Z<XT^33+FYTNZL(O(AN+8C=L_NMG
M@CK^=1CX=:>VDZC:7%Y=7%SJ+(US>2$&1MIR!TP![4[H#FM7T-/"6J^%+_3[
MR]-S=WR0732SLXF#+SD'BG:%HZ>-I?$.JZK>W:W,%[);6PBG9!;*@&" .,\]
MZ[K6?#=MK3:69Y9$_LZY6XCV8^9E&,'VK)OOA_;SZC>W5CJM_IL=^<WD%LX"
MRGN>1P3[4K@</H$LT'AGP'&DS@-JLBN5;&\?-U]:OZ3X;@\1W'BVYU&[O7-M
M?SI;HEPRK%CG( /6NNL_ 6GV6GZ+9QW$YCTFX-Q"21EB<\'VYK2TOPY;:4NJ
M+%+(W]HW#SR;L?*6'('M1<#S'0[N\\6IX2T34[ZX%I):SS3E)"K7!C<JJEAS
MT )K=\.::-#^+%]IEM>7$MD-.62.&64OY66Z<_G^-0>(O#MGX=L-"L1;ZFUK
M:/(4U2R.9[9F)/*@<J<XH^'VD2OXUU37(UU%K)[=85N=0!$MP^<EL'H.@I@>
MHT445 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &5KL*S16@:&*7;=1L!)-Y>W!ZCU/MWK5K(
MU]D6&SWFS&;N,#[4"1G/\./XO2M>@ HIK2(F-[JN3@9.,TK,%4LQ  ZD]J %
MHI%8,H92"#T(I: "BBB@ HHHH **1F5%+,P51U). * 00"#D'H10 M%%% !1
M110 4444 %%%% !1110 44U75\[6#8.#@YP:=0 4444 %%1O/#$<22HA]&8"
MG)(D@RCJP]5.: '44W>A<IN&X#)7/-.H **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<D$@@\#WQ0N8-"Q>:);QZ9)>0)=Q&)U!%PH&\'N,=*A\2.T?B*5U.&780?\
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MPLSG**Z/_A#-2_OP?]]4?\(9J7]^#_OJCGCW"S.<HKH_^$,U+^_!_P!]4?\
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MK76[O6-0O]0MT9 \[+@J1C& .,<T70' Z'X;CU7X>:KKMW?W[7]N]PULXN7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP_6M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC!).!D]*+ >V4445(!1110 4444 %%%% !1110 457-V ?\ 43_]\4GVP?\
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M_OB@">BH/M0_YXR_]\4?:A_SQE_[XH GHJ#[4/\ GC+_ -\4?:A_SQE_[XH
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M]3Z"M>LK77C2&T\QK10;J,#[2A8$Y_A]&]#6K0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 17./LLV2H&PY+#(''<>E8NB%
M&T:U,;P.FSAH$V(?HO85MW!VVTI!(PA.0,D<>G>L319#+H]M(99)2R9WR1>6
MQ^J]J +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 5M04-IURI5&!B8%7;:IX[GL*BT9!'HUFBI'&!$H"1/O4<= >X
MJ:_(&GW)8QA1&V3*,KT[CTJ+2&5M'M&0PE3$N# NV,\?PCL* +M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E:S&LEQII:*
M!]MT"#+)M*G!Y7U/M6K67J[HL^G!VM03<@+YZ;B3@_<]&]ZU* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\2>7_PCM]YK6JIY?S&[7=$.
M?XAW%;MEC[#;[2A'E+@QC"].WM6'XAF\CP_>RB8P;8\^8(?-*\]=G\7TK=LV
MWV-NV[=F-3NV[<\=<=OI0!-1110 4444 %%%% !1110 4444 %%%% !1110
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M@A"B5@!"<H.?X3W%?5-R0+68DJ $;EAD#CN*^5M28/JETZO&X,K$-&FU3SU
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M*UM2:^C@\737>J0RV=W$6M(Q<!MXW@@JN> !Q7EE&32=)7N 5W_PD_Y&B?\
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M3RW329F:4='W>M=A10!PT_PRM;Y8#J6N:O>RV[J\#R2K^[*G/ QCMU-6]1\
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MU:^MUU>":]M8#<^0L9^:+@YW=C@YQ1:> KFZM[4&[V7EU#YT,/D,5Q@D!GZ
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M\+6U#PKHEC#J/D:II"@0W2J<'G/3J.<57MOAEK<WBC2O$&L>(A>W=I("X,6
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MPIT?]!<_]^O_ *]'_"G1_P!!<_\ ?K_Z]>IT4?6:O<+'EG_"G1_T%S_WZ_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** ,W53()]/V?:\?:!N^S],8/W_\
M9K2K-U6+S)K ^0\NVX!RLVS9P>2/XA[5I4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6OO7^\/SJN=.LFZVD)QSR@I?L%G_ ,^L/_? H GWK_>'YT;U_O#\Z@^P6?\
MSZP_]\"C[!9_\^L/_? H GWK_>'YT;U_O#\Z@^P6?_/K#_WP*/L%G_SZP_\
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M]\"C[!9_\^L/_? H GWK_>'YT;U_O#\Z@^P6?_/K#_WP*/L%G_SZP_\ ? H
MGWK_ 'A^=&]?[P_.H/L%G_SZP_\ ? H^P6?_ #ZP_P#? H GWK_>'YT;U_O#
M\Z@^P6?_ #ZP_P#? H^P6?\ SZP_]\"@"?>O]X?G1O7^\/SJ#[!9_P#/K#_W
MP*/L%G_SZP_]\"@"?>O]X?G1O7^\/SJ#[!9_\^L/_? H^P6?_/K#_P!\"@"?
M>O\ >'YT;U_O#\Z@^P6?_/K#_P!\"C[!9_\ /K#_ -\"@"?>O]X?G1O7^\/S
MJ#[!9_\ /K#_ -\"C[!9_P#/K#_WP* )]Z_WA^=&]?[P_.H/L%G_ ,^L/_?
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MY!Q_">XK6.G61&#:0_\ ? H&G60&!:0@?[@H K[E_O#\Z-R_WA^=6/[/L_\
MGUA_[X%']GV?_/K#_P!\"@"ON7^\/SHW+_>'YU8_L^S_ .?6'_O@4?V?9_\
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MP_.K']GV?_/K#_WP*/[/L_\ GUA_[X% %?<O]X?G1N7^\/SJQ_9]G_SZP_\
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MO]X?G4'V"S_Y]8?^^!1]@L_^?6'_ +X% $^]?[P_.C>O]X?G4'V"S_Y]8?\
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img105269759_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -K!>,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_&91_.KT.L:;<?ZG4+63_<F4_P!:+,=R[134D1QE&5A['-.I %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %![44'M0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4456U":2#3
MKB6&-I)4C8HBC)+8XI2=E=B;LKGG&L:K:WGCE9;I\65K($Z9SMY/'NU,\8ZM
MINJW5K=Z?*QF1=KY0KP#D'^=:OA#PR)_M=SK%D69B BS+CW)K9UKPGILNCW*
MV5C%'<A-T;(.<CG'X]*^>6&Q-:A.>GO.^M[Z;'E*C6J4I2TUU\S6T34!J>C6
MMV,;G0;QZ,.#^M<'X-_Y'2Y_W9?_ $(5N^ TOK:RN;.\M98E1P\9=2,YZC]/
MUK-\*:9?6WBVYGGM98XBLF'9< Y88K><IUOJ\VM;ZFLI2J>RDUZG8:[_ ,@&
M_P#^O=_Y&O,O#OA^^UJ*X>TO%MQ$0&!9AG.?2O4-8C>;1;V.-2SM X51U)Q7
M-^ +&ZLK:^%U;R0EW3;O7&>#6N,PZK8NG&2TLRL1252O!/:S.5\0^';_ $:V
MAEN[U9UD?: &8X./>O1?"_\ R+.G_P#7(5D>/K*ZO=.M5M8))F64E@BYP,5M
M>'89+?P]8Q3(R2+$ RL,$4L)AU1QDXQ6EE^@4*2IXB2BM+$^K?\ (&OO^O>3
M_P!!->8>&+W6K3[2-(M!.7V[R5SMZX[UZCJ:-+I5Y&BEG:!U4#N2IKE/ %A=
MV0OOM5M+#NV;=ZXSUIXRE*IBJ2BVM'JAXB$IUX6TWU*^C^&-3OM<&JZX-FU@
M^S(RS#H,#H!5+5(UU?XC+:7.3")%3:3_  A<D?B<_G7I5<)XJT/48=<CUO2X
MVD;*LP49*L..G<$"L\7@U1HKD3E[R<NK9%?#JG37*KZW?F:7C#1[#_A&YI4M
MHHI+< QLBA2.0,<=N:S-$MKG6/AW<V43?O!(5CR>N"K8_F*J:EJ7B/Q':C3U
MTJ2%&8>80A&['J3T%=+%87WA[PH(-.1)[V,AV7&0Q)&['3M27)6KRJ0B^3E:
M>EK^@ERU*KG%/EM9Z;G*:)KX\/1MI>K:6?+W$LQ3YN?4'[PKH_%$MK-X$DDL
MMOV9A'Y808 &\<8[5AZQJ6L>(;,6)T"1)=P/F;3Q]"1Q6M?:-=6GP\_LU4:6
MY7:2J<\E]Q ^F:SI.?LZE*/O0479VL_3S)@Y<DX+6*3L[6^0OABV@N? H6>&
M.55\U@)%# ')YYK(^'UC:7IU'[5:P3[/+V^;&&VYW9QGZ"ND\)64T/A5+:XB
M:*1C("KC!&2:Y'2UU_PO?744&FO,),*<H2IQG!!'U-.453^KU)QT2UTOT!KD
M]E.2T2UT\BW\1P!>6    B; 'U%7_B)8"2QM;]5^:)O+8^QZ?J/UJOXYT_4-
M0ET^2&TED81'>(USM8XXKL-8L%U/1[FT89,D9V^S#D'\\5H\.ZT\1&V_+;[B
MW2=2556WM8XW6]>6Y\!60#?OKG$;C_<^\?S _.K#PMHOPU?9E9IU#,1ZN1_[
M+Q7-:?X>U6[O[6SN;2X2V$GS%E("@_>Y_"O3M8TQ=3T:>P!";T 0]@1R/U%9
MX:-;$*=62L^7E7K;4BBJE52FUK:R.!\,ZO\ V9IK(F@37C2,2TZKD,/3[IZ5
M/X0M[V+Q7+,MA<6UI*KY5T(51G(&2.>U&E7WB#PQ%)8R:3)<1!R5PI."?0C.
M173:#JNLZE>R&]TT6EH(\J2#N+9''/MGM486"DZ<92=X].6UOF*A%-P3;NNE
MOU.@HHHKZ$]4**** "BBB@ HHHH **** "BBB@ HI"0!D\ 5S&M_$'PYH0=;
MB_66=?\ EC!\[9]..!^--)O8+V.HI&8*"6( '<UXEK'QLOY@R:3816R]I)SO
M;\AQ_.N3-QXS\8R'#:C?*QZ)E8Q^6%K14GU(<UT/>-4\<^&]'8I=ZM;^8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG,%AJMC=2A=QC@N$=@/7 /3D5?I#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *#VHH/:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9>G>&]%TBY-QI^F6MK,5*%XHPI*G!Q^@K4HHI#"BBB@ HHHH **** "BBB@
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M(9"/;YUKM-?T.WUZS6WFD,<BG=&XY(/?CN*HZ#X4&BZK/??:_-\U&3;LQC+
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M' OK[>YKVCP7\/\ 3_"EN)G"W.I,/GN&'W?9?0?K6J2IZO<SNY;'*^"?A+'
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M>#0S;_P-;7NN7.KPZOJ]A<W"JLGV.=4! &!_"3^M:>BZ&VC"8-JVIZAYF/\
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M^!D?^-)IL-#7HJO9W]GJ,)FL;N"ZB!VEX) ZY],@U8I#"BBB@ HHHH ****
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M10J>AD<+G\Z=;W,%W$);>:.6,_Q1L&'Z5IS1ORWU+NKV):*JRZE8PW*V\MY
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M=+M!BVTVTAQ_SSA5?Y"KU%?.-MG?9"!0HPH  ["EHHI#"BBB@ HHHH ****
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MY,]^PWN3U7/(4^XH<;*]P3U-RBBBI&%![44'M0 4444 %%%% !1110 4444
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M5&7II:@"7=2;JBW4F^@"4.#TI=]0;J-U $^ZEWU7WTH>@"QOIP>JVZG;Z +
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M,:B8T]C4+&F UFJ)FI6-1,U, 9JC+4A:HV:@!Q:F%J:6J%YT1U1F 9ON@]Z
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MH5%'85;!KM;N=2) :44T4ZI&+1112&+1110 4444 %%%% !0>U%![4 %%%%
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M;9%)[US]YK"R-F"W(/8R'./P%9!#NQ9W9F)R237)4QM-/W=1J)JZW=137"M
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M''O@_4FG%=&)OJAGBG2+Y/A-;W^IZIJ$UXVR22)YR8SYC@@,I_N@@#GBNYU
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M5UH^HAXY#M/*L.C"J7,[K8C0W+75+;2F6)XP(FX9O\:BUN>;2[E+VP8M$XW
MJ<@^WUK#N+F'5X3*/W<C#EARI/N.U9MIKTVF2-8:AS 3@;N15<FMPUM8[FTU
MRVUVSVDJ)#PP]_<=C7)ZYIFI:9.;O2YV@D'.5Y5OJ*JZE;0A1?Z9<M;7 Y#*
M>#]1W%01^/?]#\G4E5;@<-M&X-[CTJ;*&G0>LM1T>M6_B9OLNJ(;+5T'$JG
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M<Q*:1N37Q;5I-%L8O6K<(JJ%YJU#65;8Y*Q;0<5#J4>_39Q_L$U82DN0#9S
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M@]I'_@.?_B:/[-^(_P#T'M(_\!S_ /$T<OF%_([BBN'_ +-^(_\ T'M(_P#
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MNN+Q6:1ADHHY%4[) E<OWD=]H]R\D+>;'GE1T-12:O!J%NWGJL;*.?,4C_\
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MV3ZMJ3W%PYE@B;[Q& [>WM755LY>S7+'<BU]6<'K7]I0RK;7TID0 E&'1O\
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MHHF 0..<]J')L+6)+A2\9KG[U-N>.*TCJ ;Z>N:R-0NQ\PSG/2A(#BM9<EF
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MCUQ4@-8/_",VC>)1KOGSF<# CW?)TQ6X#0K]0DDK69)2TS-+FF2.S2TVES0
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M#3X1#;Q#"J/YU>HHKG;OJR1:***0"BBDI: "BBB@ H/:B@]J "BBB@ HHHH
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ML_#EL+&'HUR>;B;W9_X?HN*SE+HAI7.?M/ _BB[56CT:Z53T,P$7_H1%7?\
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M_P"$7\5)#8Y^S3A980W.TY^[^=;/B*#7[/0";O3(H+=Y%$DPG#DYZ8'85?\
M&%C>ZIKNE2Q1-+%"1O?/W1N!YJYXP:2Y\/R1Q!Y7+J,#GOUKKEA:=>IAJM57
ME!W7WHY:E.$G)M!\,_#\=O!_;UY*#-,"L"?W%]?J:ZOQ5;Q:OH<UDKH2_(SV
M(Y!K T"ZCLM)L[:4L&6,!E/:MZTU+31,&G=BHZ KQ6>)C.=5U)79T4^5121B
M^#M1D?PZ%=2\BL8V]B.*OWUYJ4&G+#%N* 8+CKBJ/@]K2>SUF,RJBOJ$K1<X
M^6GW4<]BS-'<@H>@W5%&TGJM?,=2Z13LI@UQNEZ@9P?6K%_K/E6S;:QIY2S,
M<X;-5+EI3&$/\70&NN>'YY79E"KRJR+FF2OJDS0EL1(IFD/L*].TXJ=.MRGW
M3&,?E7D-B'MI)5!*EEVG'I7JVAW*W.CV[KV0*1Z$5S8VGR15MC2G/F;N:5%>
M/>,OB+K5IXCN]-TN5+>&V8(6V!F8XYZUV'@#Q7<^(]+<:AY0O(FQE< R#UVU
MA+!U8TO;-:%*HG+E6YV.:6FTM<A8M+3<TM $=S;Q7EK-;3+NBE0HX]01@UY%
MIOP;ELO$VZZNHYM#0EPI.'([*:]A) !). .IK'ANO[=N76$G^SX6PSC_ ):L
M.P]A5PG*-W%V+C.4=F7-)T[3+&WQIMG#;QG_ )YQA<UI"F*   !@"GBLQ'-^
M,$,%O9ZHHR;.=6;']TG!JIJVLS:[/'I6E,-DH!>0>A_H*3QWK,<.GG3(R&FF
MQO [+6GX/T8:9I,<DB?Z1*NYB1R!V%=22C24Y;]"=7*R-K3+&/3;"&UB'RHN
M"?4]S4QO(TNUMY/D=AE">C?3WJ053U>S:^TV5(CB=1NB;T8=*X]WJ:&7K,,E
MOXNT34$X5]]M(?J,C^5=2*Y$W4^M^$[6]3B[MI5DD7'1D.&'\ZZR-M\:L.XS
M3GLD^F@T2BG"F"G"LBAXI:04M(8X44"B@!:***0PI:2EH **** "@]J*#VH
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M ES3@:B!IP-("3-+FF TH- #Z6F@TM #J*2EH 6BDI: "BBB@ HHHH ****
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M3U/N:Z*G)6T 6BBBH&%+24M !1110 4'M10>U !1110 4444 %%%% !1110
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M1)8K$J(PQVQQ@<*,U?DN4<;V0CW%9\]S947NGH6FA6/[ZX;MCO5/4S$;<.F
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M?.K!S$\G!]OI790>*I;9A'JFC75D@X\U5WH/RZ"MYPC"-J;N^K_R$FV]3J0
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M -3PU B<&G U"#3P: )@:>#40-/!I 2 T\5&#3@: 'TM-I: %I:2B@!:***
M"BBB@ HHI* "BBB@#BOBEHPU;P5<R*N9K,BX3\.&_0FOFZ9>C5]@W$"7-O+!
M* T<BE&![@C%?*6OZ2^BZU>Z9)G-O*4!/<=C^6*Z</*SL95$8W>G8HQ0#S7H
M'.)C% SFEQS3@M,0 4H3O3E6G@4 ,*UN>"E_XKC0S_T^Q?\ H0K'*Y%;G@H?
M\5MHG_7[%_Z$*4_A8UN7I?\ 6O\ [QIHY%22K^]?_>-(HK,H9U-*!BG8P:=B
MF P'!J]=Z9<VEA:7DJJ(;L,8B&R3@X.?3K5,KSQ7>7-CIM[X0T#[?JGV+:DN
MS]R7W_,,].E1*7+8:5SCQI=U_9']J87[-YODYW<[L9Z59TOP]J&K1O- B);Q
M\//,X1 ?3)KI-2M+*U^'WEV-\+R(WP)D\LI@[3Q@U!XH7R8-"TM9!#9_94D+
M?P[F/S,<=:E3;T0<MC%U+PY>Z9;+=NUO-;,VWS;>42+GTXJS!X4OY;."Y::R
MA2=-\8FN50E?7!I][X?%IHS7]OJEO=VXF$3"(,/FP2.H_P YK8U72[6]TC0G
MGU6VLRMBH"RAB6Y// H<WIJ%CD+FV>UNGMV9'9&VYB8,I/L1UK:G\+S'6H=(
MLV\R[\@23!R $?&2,^PQ1X=TZ*3Q(-\BS6EGNGEE4?*53G(SZG'YUI>&+N34
M/&-U>R??FBF<CTR.E.4FMNB!),YB^L)]-O9;2Y39-&<,,YJY:^'[^[TF?4XH
MU^RPYW,S8)QUP._6M;6X9-9TW3-5B0O,^+2<#J9%X4_B*W3(D.GZQI,)_=6&
MG",D=&D)RY_,X_"DYNRMN"BKG(6/AN]O[ 7J26T4!<H&GF5,D?6C_A';C[;]
ME^U6&_R_,W?:DVXSC&<]?:MZVMK*X\!VJWU\;1!>.5;RB^3CI@5S%];VL%T4
ML[K[5#@8D\LID_0TXMMM":2--_!NH1(CR7&GHL@RC-=( P]O6L!X]CLI()4X
MR#D5TWB(?\2'P[_U[-_,5SJIO=5'5C@54&VKL4K)Z$6*7'M76Z@^E>'KT:8=
M)BO&C13<32NP9B0"0N.G6K%MH.G0^);^WFC:6R%BUQ$,_, 0I'XC)%+VBM>P
M<IQ>/:C KJ4&FZQH^H^3ID=I+9QB6*1')+#."&SUKFHR$F1V0.%8$HW1O8U2
M=Q-6%FM)[=8FFB>-94WQEAC<OJ*GU+3&TX6A:17^TVZ7 P,;0W:NH\47]L=+
MTV,:;;AIK-2CY;,0R>%Y_G3=6O\ 3[&'1C/IJ7DS:?""9F(55QV []>3[5"F
MW;0OE1Q5&.*[$^&K23QE):1I(;-8/M7E!OF(V@[ ?J<58FT9;W3;TW6C0Z:T
M$1D@EB?KC^%LDYSZT_:1#D9PM &:<5YKLM2.BZ+?VL(T:*?SH(WE,CG !'.T
M ]>^:J3L["2N<45YI0*[.+PO;-XKU*V$;RVUFAE6$-@OP"%S^-.O='%QHM[/
M<Z/#IL]LH>)XGXD&<%2"3S[U/M(CY6<73=M=#X@LK>UM-':")4::R220C^)C
MWK4BTBP;Q=I-HUNOV>:T1Y$YY8QDD_F,T<ZM<.7H<5MI<8KK+6#3M>UFWTRU
ML5M+:)F+3!B9)$ []L\?AFG:?)H^MZB-*&D16T<N5AN(W;S%.."<GGI0Y^0<
MIQYIH4YKK+&UTZS\,SWU[8BYN(;XPJNXJ#\HX;';J:BUJWL[C1+#5K6T2T>9
MWBEBC)*Y7H1GI3Y];"MH<WBDVU(!Q2&K$1-UQ1MIV,FEQ0!>\/#_ (J72_\
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M:I*T31.1\T;=5/<5/0*;;>X"T445(Q:*** "BBB@ H/:B@]J "BBB@ HHHH
M**** .4\=>*+WPQ8V+Z?9QW5Q=7(@6-\\Y!X&.Y.!6KH>NP:[X=@U:W  DC+
M,F<[&'53]#7._$+_ )"'A'_L-P?SJE: >#?&E[I+?+I>M*T]H>T<V/F3\?\
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MI#4[FJSF@9 YJ!C4KFH6I@07$T=O"\LK!449)->3:O>M>7\]PQR';Y?85O\
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M+TZTM/EW4RY7:_%.S2,W)2D('.:T+9N!68G)%:=N, 4XF=78Z0*TED @4D@
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MV.#\H%.\4L6\0D.Q**J  ]A@4H2E9*X-+4S[;PYJ%Q$DJI&@D&8UED",_P!
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M4"U*M("=:D%0K4JF@"44\5&IIXI 2"EIHIU "T"BB@!:2EI* "BBB@ HHHH
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M; B-'*A2/ND<57V1=2S+D@@'!]:RF2+[?.Z2RL\B@$;LHF/3T/-7[L389H7
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ME3C=+5_@0U=B*BQQJB*%51@ =JC>54=5;C<< ]LU(34-Q"EQ"T3CY6';J*R
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M!0!3@*D8 4X"@"G 4A@!3@*04X4AABG"DIU(84M%% "BBBBD,*6BB@ HHHH
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M8'IMC;'^%2ZB*1V$MQ#",RS1H/5F K-G\1:;#D"8R'T1<U6L_ACXLOV!>Q$
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MAX%. I *<!68P IU&*44ABXI:*44AA3J04M !2T44AA2BDI: "BBB@ HHHH
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MMNMU9S0.,JZ%2*YGP(KQ:==6KAAY,Y49JT[PL+J=1BDJ0BDQ4#&8I"*?BC%
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M,M+!;C0-/UN'6(BK).T$F93GYMY[Y&:Z3Q%-<:QK'A[0I));>"^C,]VJ$JS
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M_ )?_BJ[>G"CG8<J.'_X0_Q5_P!#[=?^ 2__ !5+_P (?XJ_Z'VZ_P# )?\
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M'_AYI&BE)I5-W<CG?(. ?85UX  P!@"L*F,45RTD2V<KH/@#1]$&]H_M4_\
MSTE&0/H*ZE46-=J*% [ 8IU%<,YRF[R8@HHI:D!**6EH&)12T4@$H/3BEI*
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M=M.Q2XH ;BEQ2XI<4 )BEQ2XI<4 )BEQ2T8I %+BEQ1B@ Q2T4N* #%+110
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MAI33:8"&D-+330(0TE*:0TQ"&FFE---,0E--.---,#SG6M-67XB07!.#OC(
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MV,YOL7U>[U"5Y992+=B%5FY)-1:M=1::JPK<9;'S8 )JCXAN;FUOA8$F-;<
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M** "BBB@ HHHH **** "BBB@ HHHH **** "@]J*#VH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ H/:B@]J "BBB@ HHHH **** "BBB@ HHHH
M*2EI#0 E)3J;B@!I%(13Z:10 S%&*=BDQ0 W%&*=BC% #<48IV*,4 )BC%.Q
M1B@!,48IV*7% #<4N*7 I<4 )BBC%+0 F*,4ZB@!*,4N*7% #<48I<48H 2B
MEHH 2BEHH 2EQ110 8HQ11B@ HHI: $HI:* $HQ2T4 %%%% !1110 44M% !
M1110 4444 %%%% !1110 444E !1110 444M !1110 4444 %)2TE !1110
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MBB@ HHHH **** "BBB@ HHHH **** $I*=24 --%+10 W%)BG44 -Q1BG44
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M<UG:?;M@EAQ6];1+Y+<\GM6->=SIP%*UF5!3@*-N#3@*YSV@ IX% %. I#%
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MC31)(L;2(KM]U2P!/T%9NL>(=/T-5^UNQ=QE8XURQ%<A>ZM::SXTT:YLW+(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 )1110 4444
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M$:84<TJV_EAMA^\<\]J>%P,55S!0DY7D1A,?7UHQ4A%)BD:VL1XI,5)BDQ3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[G#_ /";^(/^A$U/_OX/_B:/^$W\0?\ 0B:G_P!_!_\ $UW%%%UV"S[G#_\
M";^(/^A$U/\ [^#_ .)H_P"$W\0?]")J?_?P?_$UW%%%UV"S[G#_ /";^(/^
MA$U/_OX/_B:/^$W\0?\ 0B:G_P!_!_\ $UW%%%UV"S[G#_\ ";^(/^A$U/\
M[^#_ .)H_P"$W\0?]")J?_?P?_$UW%%%UV"S[G#_ /";^(/^A$U/_OX/_B:/
M^$W\0?\ 0B:G_P!_!_\ $UW%%%UV"S[G#_\ ";^(/^A$U/\ [^#_ .)H_P"$
MW\0?]")J?_?P?_$UW%%%UV"S[G#_ /";^(/^A$U/_OX/_B:/^$W\0?\ 0B:G
M_P!_!_\ $UW%%%UV"S[E/2KR>_TV&ZN;*2RFD&6MY#EDYZ&KA[44'M4C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG8HQ4#&XHQ3L48H ;BEQ2XHQ0 F*,4[%&* $Q1BG8HQ2&)BEHQ2T &**6B@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHFF2W]XS"&/&0HRQ).  .YR:G%[;%XXS-&DLB[EB9@'(^G6N7\3!=9\4:-H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.2..U=G12Y@L<?8&YU_QK'K(L;FUT^SM6AB:YC,;3.Q!)"GG 'K2>!K.ZM/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;45Y[9IXDE\2:AX:/B"3[+ B3_:S&IN-K#[@.,#G//7^FIX<O]2FM]<TN[U
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MPW-IY2B$*YQ\G&1CU/7O1RA<[VB@<BBI&%%%% !1110 4444 9VM_P#(./\
MOK6L.@K)UO\ Y!Q_WUK6'054O@7S)7Q,6BBBLRPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *5]IZW9617,4Z?=D7^1JMG6(OE-O#-C^-7QG\ZUJ*M3
M:5GJ2X*]T9/G:O\ \^,?_?P?XT>=J_\ SXQ_]_!_C6M13Y_)"Y/-F3YVK_\
M/C'_ -_!_C1YVK_\^,?_ '\'^-:U%'/Y(.3S9D^=J_\ SXQ_]_!_C1YVK_\
M/C'_ -_!_C6M11S^2#D\V9/G:O\ \^,?_?P?XT>=J_\ SXQ_]_!_C6M11S^2
M#D\V9/G:O_SXQ_\ ?P?XT>=J_P#SXQ_]_!_C6M11S^2#D\V9/G:O_P ^,?\
MW\'^-'G:O_SXQ_\ ?P?XUK44<_D@Y/-F3YVK_P#/C'_W\'^-'G:O_P ^,?\
MW\'^-:U%'/Y(.3S9D^=J_P#SXQ_]_!_C1YVK_P#/C'_W\'^-:U%'/Y(.3S9D
M^=J__/C'_P!_!_C1YVK_ //C'_W\'^-:U%'/Y(.3S9D^=J__ #XQ_P#?P?XT
M>=J__/C'_P!_!_C6M11S^2#D\V9/G:O_ ,^,?_?P?XT>=J__ #XQ_P#?P?XU
MK44<_D@Y/-F3YVK_ //C'_W\'^-'G:O_ ,^,?_?P?XUK44<_D@Y/-F3YVK_\
M^,?_ '\'^-'G:O\ \^,?_?P?XUK44<_D@Y/-F3YVK_\ /C'_ -_!_C1YVK_\
M^,?_ '\'^-:U%'/Y(.3S9D^=J_\ SXQ_]_!_C1YVK_\ /C'_ -_!_C6M11S^
M2#D\V9/G:O\ \^,?_?P?XT>=J_\ SXQ_]_!_C6M11S^2#D\V9/G:O_SXQ_\
M?P?XT>=J_P#SXQ_]_!_C6M11S^2#D\V9/G:O_P ^,?\ W\'^-'G:O_SXQ_\
M?P?XUK44<_D@Y/-F3YVK_P#/C'_W\'^-'G:O_P ^,?\ W\'^-:U%'/Y(.3S9
MD^=J_P#SXQ_]_!_C1YVK_P#/C'_W\'^-:U%'/Y(.3S9D^=J__/C'_P!_!_C1
MYVK_ //C'_W\'^-:U%'/Y(.3S9D^=J__ #XQ_P#?P?XT>=J__/C'_P!_!_C6
MM11S^2#D\V9/G:O_ ,^,?_?P?XT>=J__ #XQ_P#?P?XUK44<_D@Y/-F3YVK_
M //C'_W\'^-'G:O_ ,^,?_?P?XUK44<_D@Y/-F3YVK_\^,?_ '\'^-'G:O\
M\^,?_?P?XUK44<_D@Y/-F3YVK_\ /C'_ -_!_C1YVK_\^,?_ '\'^-:U%'/Y
M(.3S9D^=J_\ SXQ_]_!_C1G6)?E%O##G^-GSC\JUJ*7/Y(.3S92L=.6T+2.Y
7EG?[TC?TJ[114MMN[*225D%%%%(9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img105269759_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %;!!,# 2(  A$! Q$!_\0
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MR#19@34444@"BBB@ HHHH **** "JQN&&I+;8&PPF3/?((']:LU1;_D/1_\
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MT^RFM(KF\ABDO'V6ZLW,K>B^M4I_%OAVVU3^S)]:L8[W=M\EIE# ^A]#[4K
M;-%<HOCW2V\=MX7\R-9$BR9FD&&F) $2C^]C)-6/#OB&2]T*ZU+5[C2XE@N)
M(VEM;C=$J*1C<QZ-ZBG9@='16;I?B'1];BDETS4[6[2+_6&&0-M^OI59?&'A
MMY+:-=<L"]U_J%\]<OSCCGUXI6 VZ*** "BBB@ HHHH **** "BBB@ HHHH
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M6WN8GLG/GO@%HT)^Z,GANE:^K_$3PUH>IR:?>7KF>+'G^3"\BPYZ;RH(6BS
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M>%#J7FBP%Y)]I:+=N"87.-O/Y4_P7/X!AU_R_#MQJ#ZA/!(BK.9BI4#<?O\
M ^[7J!56Z@'ZBD"*#D* ?855]+ ?/N@^![K6OAM<ZKIUW?KJ$5S-FR\]EAN$
M5N5VC&"1W[UI>)KS3]?^%OAJ/1[4Z?&-2BMW@C4YMI,,#UY/)SD]<U[B  ,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJ"[E>"V9X]N_( W=.2!_6F$7_.#;=\9#>__ -C^M %JBJV+[/6WQGT;IG_"
MD O^,FV[9P&]O_LOTH M455QJ&.MMG'HW7'^-!%]S@VWMPWO_P#8_K0!:HJM
MB^SUM\9]&Z9_PS2 7^!DVWOPWM_]E^E %JBJI%_C@VV<>C>A_KC]:"+[)P;?
M';AO?_[']: (;C5H[;5K;3VAE9YU+!U7Y1]36A57%]N!)MOR;ID?_7_2@"_P
M,FVSCGAO;_Z_Z4 6J*JD7^#@VV<<<-[_ /UOUI2+[/!M\9]&]3_3'ZT 6:*J
M@7V1DVV._#>W_P!E^E &H8Y-MG'HW7 _KF@"U154B_P<&V[XX;W_ /L?UI<7
MV>MOC/HW3/\ AB@"S154"_XR;;MG ;V_^R_2FL=06,G-KD+GHV,X_P : +E%
M1P2>=;QRXQO0-@'.,BI* "BBB@ JBW_(>C_Z]F_]"6KU46_Y#T?_ %[-_P"A
M+30%ZBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEJ6QC=M((:MRFU8 HHHI %%%% !1110 4444 %%%% !4?VB$*S&:/:IP3N&
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MS ASG/X[O_BF_.DU''V-LXQO3KC^\/6K5 %;^S[0-GR$SG/XY!_F!2#3K,
M6Z<8 _#'_P 2OY5:HH JG3;,@@VZ8(Q^A'\B?SI3I]H228$R22?U/_LS?G5F
MB@"L-/M 01 F0<_J#_0?E2#3;,  6Z8 P/R _P#91^56J* *ITVS((-NF",'
M\B/_ &8_G2G3[0DDP)DG/ZD_S)_.K-% %8:?: @B!,C!'X8/_LJ_E2#3;,*
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MI&5K\XLR<X^=.<X_B'N/Y_GTJS5:_P _9#C.=R=,_P!X>E6: "BBB@ HHHH
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MH"]5>^BFGT^XAMY/*F>-ECDSC:Q'!JQ5"YOI8=9L+-54QW"2LY/4;0N,?G2
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M#*%&\H,*3WP#T%/H **** "BBB@ K$F_Y'FS_P"P;/\ ^C(JVZQ)O^1YL_\
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MC\S54ZE<"<0'39O,92X'F)T! /?W%>9CQ-K>/^0G/^G^%-_X2+6#*)#J,V\
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MD#LN<X]L5K53TN_74]-AO%B:$2 _NV()7!(P<=^*N4#"BBB@ K"\+_ZG5/\
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MSMK/QVR6MO# K:8"5B0*"?-Z\5TE-B1YM\0/^0[#_P!>Z_\ H35RE=7\0/\
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MP?%(NKN0IKZP;E"#]PT2X5E/<YP:[.BLB#CYOAUI=Q<WWG22&SN]+BTS[,H
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ML?\ KXC_ /0A7M%<]?=&E,\?^*G_ ",\'_7HO_H3UPU=S\5/^1G@_P"O1?\
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M>FD!L455@L5@D#B>Y<^DDS,/R-6J0&!XL_Y!\'_77^AKD:Z[Q9_R#X/^NO\
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M_P S\?\ L%C_ -&UO5RNFZ@-1\<22"TN[;;IH7;<Q>63^\Z@=Q754V)'FWQ
M_P"0[#_U[K_Z$U<I75_$#_D.P_\ 7NO_ *$U<I0 5M>$O^1GLO\ >/\ Z":Q
M:VO"7_(SV7^\?_030!ZU5/2O^07;_P"[5RJ>E?\ (+M_]VCH,N4444@*;_\
M(:A_Z]Y/_0DIFN?\@'4/^O>3_P!!-/?_ )#4/_7O)_Z$E,US_D ZA_U[R?\
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M;Q-&OS5/7MTVY13DCFDDGH%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KEM=M$&M&ZO=+CU.V>W$<*-)&/)8$[OE<@?-D?,.1BNIKE+RR
M;4M:?4;73M+U:V>!(A]IFYC968D ;& Z\]^* -GP_!+:Z#:0SR*\B)@E7WA1
MDX7=WP,#/M6E5#3)H1"MFL=K;SQ+F2VMW#+%DG'0#K]!5^@ HHHH *PO"_\
MJ=4_["ES_P"AUNUA>%_]3JG_ &%+G_T.FMA&[117D6J:IJ":M>(E]<JJSN !
M*P &X^](9Z?J_P#R#F_ZZ1_^AK5ZO%FU2_==KWMRP]#*Q_K2_P!K:C_S_P!U
M_P!_F_QIB/:*IZI_QXG_ *Z1_P#H:URO@&[N;J2_^T7$LNT)CS'+8^]ZUU6J
M?\>)_P"ND?\ Z&M"W&7****0!5.P_P!;>_\ 7P?_ $%:N53L/];>_P#7P?\
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M>L7_ *"*OUYCW.M;!1112&%)@>@I:* #&**** "BBB@ HHHH *Q)O^1YL_\
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M?_;=_P"E6?&G_(GZE_US'_H0KE_Y>?,U^R>"4445WG,%>]>"?^1.TW_KF?\
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M]GV_P[=V[/UJY5-BL<3J_@[6=:NUN;G6;%75 @$=BP& 2>\GO5#_ (5OJ/\
MT&[;_P  F_\ CE>BT4KA8\Z_X5OJ/_0;MO\ P";_ ..59T_P+JVFWT5W#K-F
M9(SD![)L=,?\]*[RBBX6,3[-XG_Z"FE_^ #_ /QVH[>P\26T"0IJFEE4& 38
M/G_T;6_11<+&)]F\3?\ 03TK_P  )/\ X[1]F\3?]!/2O_ "3_X[6W11<+&
M=/\ $AN5G_M73-RH4 ^P/C!(/_/7VIMUIWB2[M9K:35=,"2H4;;8/G!&./WM
M=#11S,+'G?\ PK>__P"@S;_^ A_^+H_X5Q?_ /09M_\ P$/_ ,77HE%7[6?<
M7(CSO_A7%_\ ]!FW_P# 0_\ Q=;NF:)X@TFQ2SM]6TXQ(207L7)Y.>THKIZ*
M3J2>X**1R>M>'==U[3S8WFK6"PE@Q,5BX.1]9#7-?\*DG_Z#47_@*?\ XNO4
M:*(U)15D#@GN>7?\*DG_ .@U%_X"G_XNE'PDG!_Y#47_ ("G_P"+KU"BJ]M/
MN+V<>QS]KIWB2TM(;:/5=,*0HL:[K!\X P,_O:NV4.MI<AKZ^L9H,'*0VK1M
MGMR9#_*M.BL[E6"BBBD,**** "BBB@ HHHH HZT;@:)?&UW^?Y#^7L^]G!Z>
M]9GAW[)]MO?[,+'3_+BVG+%?,PV[&>^-N:Z&B@#/U"+5Y)5.G7EG!'M^99[9
MI"3Z@AUKG9;?Q#_PF%JIU+3?.^P3$-]B?:%\R+(QYG7..<]C7954:PC;5XM1
M+-YL<#P!>V&96)^OR"FF)HS_ +-XG_Z"FE_^ #__ !VL?6/"6M:W-'+<ZQ8J
MR+M'EV+ 8SGO)[UV=%%PL>=?\*WU'_H-VW_@$W_QRC_A6^H_]!NV_P# )O\
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MTO'G2UD$A+DQ'#;ACC."1@GI0!TE%%% !16;KU[>:?I$]Q86PGG520&8*J
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M* L><OX5UU['3K5XD9],6Z6"<2* W"F$@9R.1CVQ6WX0T*]T>[OI;N-5-S%
MS,&!W2X8R=/]IJZNB@+!1110,*Q]=T^ZNIM.O;)8Y)[&<RB*1]@D!4J1NP<'
MG/3M6Q10!E^'-+DT?0K:RF=7E3<TA7IN9BQ SVR:U*** "BBB@#G?$.D7]U?
M17NGK#)(+6:U=)7* "3&&! /0CIWK7TNR_LW2;.Q#;_L\*1;O7: ,_I5NB@
MI" 001D'J*6B@#'TC2I-/U;5Y]D26]R\1@6/C"K&%/&..16%'X;U9+Z%"EL;
M:&_N;H2B4[F656P-N.,%N>:[6B@+'FZ> M26TBBWPGRH8"B;^!*'3S#T_NH*
M](HHH *QK+27L_$M]>I'%':S6\4:*G'S*7)X_P"!5LT4 <;<>'M5;59/+CMF
MM'U>+4/-,I#!5 !7;CKQZUCGP#J;6+P,\&'MYB4W\&<N^P]/[CUZ510*PR%2
MD$:-U50#^5/HHH&%%%% !7->+M:N](.G+;3I +F5DDD:!IMH"Y&%7DUTM5+G
M3H+N]LKN3?YMF[/%M.!EE*G/KP: ,2+Q*UM:01RI-J5VT#74AMX/*VPAB-Q5
MR#GMCJ<&I8O&%C<ZM#86T,TOFI&XDRJ@JXR" Q#,,=2 <5<U/0+359UGDDN(
M9?+,+/!(4+QGDHWJ/UJ&?PMI]Q-;LS7 AMRACMED_=*4^[@=1T'0C/>@1#'X
MNM9;R&(6ER+>::6&.Z.WRV,8)<]<@?*>W-.L_%EC<,AN(I;*&: W$$UR55)8
MP0"V03CJ#@XX(JA;>$[I-?BN99(5L8;B:=(4D=@?,4@C8>%^\2>3[8K5L/#&
MG6$@=1+.$B,,27#^8L49.=J@]N!UST% :F/X@\8FPOK3[!+;36BQ"YNG+ [H
MBX4;#GD_>/X5'J/B^[L/$NI6C"%K*&U!@..3,R;E&<\@X-;,OA'1+B>ZFN+&
M*=[@!?WB@^4 , )Q\H[\=ZC7P;I64+^?(RO X+R9),((3/'H>?6@-27PEJ=W
MJ_AZ*[O@@N3)(CA!@?*Y7^E;=5--TZ#2K3[-;;O+WO)\QR<LQ8_J35N@8444
M4 8_B#4;BQCL8;0HL][=I;+(Z[A&""2V,C/"GBG^'=2FU321-<J@GCEDAD*#
M"L48KD#MG&:L:GIEOJMND,YD4QR++')&VUXW'1@?7_&GZ=I]OI=C':6RL(TR
M<L<EB3DDGN2230!:HHHH *QM=U"ZMI]-LK-HXY[Z<QB:1-XC 0L3C(R>,?C6
MS5'4]*@U2.)96ECDA?S(I86VO&V",@_0D4 0^'-3DUC0;:^F14E<,KA>FY6*
MG'MD5J56L+&WTRPALK5-D$*[5!.3]2>YJS0!RWB/7K^POKB&R\E5L[ WTOFH
M6\T;L;!R,< \\]JT=;U2\M/#SWVG6@GF,1D&]@%C&TMN;UQCH.M.U7P[8ZO.
MLUQYRMY9A?RI"OFQDYV-ZC(JR^EQ207T#RSM%>*59#)D1@KMP@_A&/UH J'6
MUM=$TR]N49VNS!&?+ &&DP,\GIDUA:WXRN+:[M5L8@(DOI;:Z$J]5C"LS+@\
M<$UT=UHEI=Z1#IKF58H/+\IT?#H4QM(/KQ5%?!VF ?.US(?,FE)DER6:5-CD
M\>E BMX:\0W>LZ[JT$HC^QP[6M2J\LA9QDGOG;FKVN:A>07VFZ=8O'%->M)^
M^D3>$")N^[D9).!^=3Z7H-EI$ADM1("8([?YFS\J9Q^/)S4NIZ1;ZJ(3*\T4
ML#%HIH'VNF1@X/N#B@"KIFLW.H^%;;58;/S;F6(,(%8*"V<'D]!GGZ56TOQ#
M*?!C:WJ*!I(EE>581C[CL,#)]!6I9:5;Z<8A;-*D,4"P)!O)C !SG'][WJ*+
M0;&+0I-'VNUI(KJP9OF(<DGGZDT#,/Q)XKN+2UN8M+B_TV%K;!E7*L)B< <]
M>*;I7BNZU7Q9#9Q"+^SY+4OD#YO,"J6&?;>!^%:,?A#3D9G>:[F=G@=FEEW$
MF(DIVZ<U8L/#.G:;<PSVRR*\/F[<MQ^\(+9_(8H$;%%%% PHHHH *K3Z=971
MS<6<$I]7C!_G5FB@F45)6DKE&+1M,A;=%IUJC#NL*@_RJZ %&  !Z"EHHN$8
M1C\*L%%%%!04R2*.5=LB*X]&&:?10!5_LRP!S]BM\_\ 7,582-(UVHBJ/0#%
M.HH **** "BBB@ JEJ.D6&K1>7>VZ2@=&Z,OT(YJ[133:U0FDU9G(O\ #O1F
M8E9+I1Z!Q_A2?\*YTC_GM=?]]+_A77T5?M9]S/V-/L<A_P *YTC_ )[77_?2
M_P"%'_"N=(_Y[77_ 'TO^%=?11[6?</8T^QRD'P^T6*0,_VB4#^%W 'Z 5TM
MK:6]E L%M"D42]%08%345,IRENRXPC'9!1114E!1110 445#=7=O90^;<RK'
M'G&YO6DVDKL:3;LB:BLO_A(M(_Y_XOUH_P"$BTC_ )_XOUK/V]+^9?>C7ZO6
M_D?W,U**R_\ A(M(_P"?^+]:/^$BTC_G_B_6CV]+^9?>@^KUOY']S-2BLO\
MX2+2/^?^+]:/^$BTC_G_ (OUH]O2_F7WH/J];^1_<S4HK+_X2+2/^?\ B_6C
M_A(M(_Y_XOUH]O2_F7WH/J];^1_<S4HK+_X2+2/^?^+]:/\ A(M(_P"?^+]:
M/;TOYE]Z#ZO6_D?W,U**R_\ A(M(_P"?^+]:/^$BTC_G_B_6CV]+^9?>@^KU
MOY']S-2BLO\ X2+2/^?^+]:/^$BTC_G_ (OUH]O2_F7WH/J];^1_<S4HK+_X
M2+2/^?\ B_6C_A(M(_Y_XOUH]O2_F7WH/J];^1_<S4HK+_X2+2/^?^+]:/\
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MX4>SGV8&]16#_P )KX;_ .@O;_F?\*/^$U\-_P#07M_S/^%'LY]F!O45@_\
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M;_F?\*/^$U\-_P#07M_S/^%'LY]F!O45@_\ ":^&_P#H+V_YG_"C_A-?#?\
MT%[?\S_A1[.?9@;U%8/_  FOAO\ Z"]O^9_PH_X37PW_ -!>W_,_X4>SGV8&
M]16#_P )KX;_ .@O;_F?\*/^$U\-_P#07M_S/^%'LY]F!O45!9WEO?VJ75K*
MLL$F=KKT.#C^8J>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<2YSO#$-GUS322S%F)))R2>IK*O756VEK?D:X>@Z-];WM]XE%%%<YTA1110
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MT2L0N,D#(XSC%=,UE96GB7Q5/;03)>QI;M&+.%))D5E!=D1N,D]:\B\^8P+
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MCKG/ 7_(D:9_N-_Z&U='7C5/C?J6%%%%0 4444 %%%% !1110 4444 %%%%
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M,T:J8?,89";>N/?-;PM=*<>"([.&YM9K@EDE4H2!_$6^7YFSC!]*YF;QB]U
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M!1110 4444 %%%% !1110 4444 %%%% 'T'X"_Y$C3/]QO\ T-JZ.N<\!?\
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M_P#T6M>AA/C?H<[.1HI:*]$D2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH ^@O 7_ ")&F?[C?^AM71USG@+_ )$C
M3/\ <;_T-JZ.O'J?&_4L****@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img105269759_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )+ X(# 2(  A$! Q$!_\0
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M*?7=1G/_ !\&,>D?%53?WC')NY_^_AJO17FNI-[L]2-*$=DB?[;=_P#/W/\
M]_6_QH^VW?\ S]S_ /?UO\:@HI<TNX^2/8G^VW?_ #]S_P#?UO\ &C[;=_\
M/W/_ -_6_P :@HHYI=PY(]B?[;=_\_<__?UO\:/MMW_S]S_]_6_QJ"BCFEW#
MDCV)_MMW_P _<_\ W];_ !H^VW?_ #]S_P#?UO\ &H**.:7<.2/8G^VW?_/W
M/_W];_&C[;=_\_<__?UO\:@HHYI=PY(]B?[;=_\ /W/_ -_6_P :/MMW_P _
M<_\ W];_ !J"BCFEW#DCV)_MMW_S]S_]_6_QH^VW?_/W/_W];_&H**.:7<.2
M/8G^VW?_ #]S_P#?UO\ &C[;=_\ /W/_ -_6_P :@HHYI=PY(]B?[;=_\_<_
M_?UO\:/MMW_S]S_]_6_QJ"BCFEW#DCV)_MMW_P _<_\ W];_ !H^VW?_ #]S
M_P#?UO\ &H**.:7<.2/8G^VW?_/W/_W];_&C[;=_\_<__?UO\:@HHYI=PY(]
MB?[;=_\ /W/_ -_6_P :/MMW_P _<_\ W];_ !J"BCFEW#DCV)_MMW_S]S_]
M_6_QH^VW?_/W/_W];_&H**.:7<.2/8G^VW?_ #]S_P#?UO\ &C[;=_\ /W/_
M -_6_P :@HHYI=PY(]B?[;=_\_<__?UO\:/MMW_S]S_]_6_QJ"BCFEW#DCV)
M_MMW_P _<_\ W];_ !H^VW?_ #]S_P#?UO\ &H**.:7<.2/8G^VW?_/W/_W]
M;_&C[;=_\_<__?UO\:@HHYI=PY(]B?[;=_\ /W/_ -_6_P :/MMW_P _<_\
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M?\)#K7_07O\ _P "7_QK-HHL@N:7_"0ZU_T%[_\ \"7_ ,:/^$AUK_H+W_\
MX$O_ (UFT4607-+_ (2'6O\ H+W_ /X$O_C1_P )#K7_ $%[_P#\"7_QK-HH
ML@N:7_"0ZU_T%[__ ,"7_P :/^$AUK_H+W__ ($O_C6;119!<TO^$AUK_H+W
M_P#X$O\ XT?\)#K7_07O_P#P)?\ QK-HHL@N:7_"0ZU_T%[_ /\  E_\:/\
MA(=:_P"@O?\ _@2_^-9M%%D%S2_X2'6O^@O?_P#@2_\ C1_PD.M?]!>__P#
ME_\ &LVBBR"YI?\ "0ZU_P!!>_\ _ E_\:/^$AUK_H+W_P#X$O\ XUFT4607
M-+_A(=:_Z"]__P"!+_XT?\)#K7_07O\ _P "7_QK-HHL@N:7_"0ZU_T%[_\
M\"7_ ,:/^$AUK_H+W_\ X$O_ (UFT4607-+_ (2'6O\ H+W_ /X$O_C1_P )
M#K7_ $%[_P#\"7_QK-S119!<TO\ A(=:_P"@O?\ _@2_^-'_  D.M?\ 07O_
M /P)?_&LVBBR"YI?\)#K7_07O_\ P)?_ !H_X2'6O^@O?_\ @2_^-9M%%D%S
M2_X2'6O^@O?_ /@2_P#C1_PD.M?]!>__ / E_P#&LVBBR"YI?\)#K7_07O\
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M^E26G_(ER_\ 7.3^9I0I*%6<7V94ZSG2A)/JKD/ARRM+FRG>XMTD*OP6&<#
MI3?>'"<&SQSU\K_Z]3^%<'3[D'IYG/Y"FV_A_2;HDPW3R@'Y@KC_  K2$9.G
M#D2^9E.<55GSMV\BMK>D6L5DM]9?*G&5!X(/0BN>KH-=U2(VXTVWC=%C(#%A
MCIT KGZY,3R>T]S^F=F%Y_9^_P#T@HHHKG.D**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIH=6!((
M..N*I1;U2$Y):-CJ*8)%9&89(%()08RX!P*OV-3MY$>VI]_,DKL/#W_( ?\
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MJ%KAG5<\=67T^HKDZ4,P& Q ],TE*M4527-:S'0I.E'EO== HHHK$V"BBB@
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M6(****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KHO
MG_(\:3_UV/\ Z":YVE5BK!E)!'0@X-)JZL-:,[OXNA3XO@. ?]$7_P!":N#
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MM3_>'\Z]>^+9!\,Z5@C_ %X_] ->/TYI9' #R.P'0,Q-5*-VGV$G9-%O1_\
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M(XA=$U!%VBSDQ]1_C2_V-J7_ #Z2?F/\:[:BLW@X-W;9HL=-*R2.)_L;4?\
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MV:/!O^$&\3_] :X_-?\ &C_A!O$__0&N/S7_ !KWFBCVT@]FCP;_ (0;Q/\
M] :X_-?\:/\ A!O$_P#T!KC\U_QKWFBCVT@]FCP;_A!O$_\ T!KC\U_QH_X0
M;Q/_ - :X_-?\:]YHH]M(/9H\&_X0;Q/_P! :X_-?\:/^$&\3_\ 0&N/S7_&
MO>:*/;2#V:/!O^$&\3_] :X_-?\ &C_A!O$__0&N/S7_ !KWFBCVT@]FCP;_
M (0;Q/\ ] :X_-?\:/\ A!O$_P#T!KC\U_QKWFBCVT@]FCP;_A!O$_\ T!KC
M\U_QH_X0;Q/_ - :X_-?\:]YHH]M(/9H\&_X0;Q/_P! :X_-?\:/^$&\3_\
M0&N/S7_&O>:*/;2#V:/!O^$&\3_] :X_-?\ &C_A!O$__0&N/S7_ !KWFBCV
MT@]FCP;_ (0;Q/\ ] :X_-?\:/\ A!O$_P#T!KC\U_QKWFBCVT@]FCP;_A!O
M$_\ T!KC\U_QH_X0;Q/_ - :X_-?\:]YHH]M(/9H\&_X0;Q/_P! :X_-?\:/
M^$&\3_\ 0&N/S7_&O>:*/;2#V:/!_P#A!_$__0&N/S7_ !HKW>BCVT@]FBZ_
MWS]:;3G^^?K3:XF=""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S%U59M7ET
MTP2KA3^\Z<_T'O32;!LLWUVUK8S7$4?G-&/NJ?Y_2J$EF/$&FVLMPLENZG)
M'7UQ]:L:5I0TM)AY[R^8VXAN@_\ KUHT[J.PK7W&HH1%4$G:,9/)IU%%2,**
M** "BBB@ HHHH **** "BBB@ HHHH *D7_5_\"'\ZCJ1?]7_ ,"'\Z<=Q2V*
M-%%%;&84444 %%%% !1110 4444 %%%% !1110 54FL]EG/%8A+>27G<!QFK
M=% &4MX='TR#^TIC)*QV_+R?_KXK31UDC61#E6&0?:FSV\-RFR:)9%SG##-4
MKF+4FU6W>WE1;0##K_/([^U/1B-&BJ\-_;3W,MO'*#+&?F7_  ]:L4AA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% "4444 77^^?K3:<_WS]:;6#-4%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $#VJMRORG]*K/$\?WAQZBM"CK3N!F45<DME;E.#Z=JJ,C(<,,&G<0E%%%,
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M'@#O0DK/0+LZ#P7K7V_3]4N+CQ!_:<=O<,&FDM?LX@4#)7W ZYI(?B;X0GU
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MZT)7!NPQ8R>3P*E  &!2T5:5B&[A1113$%%%% !1110 4444 %%%% !1110
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MP%4CH>F'7!K7V1?[2$?E?:-QSMZ8QG'Z5H44K@8NJ^$?#^N7B7>IZ5;W-P@
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M97!RK\W9'-FTU&AR]V:]%%%?1GS(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4KB+8VX?=/Z5#6BZAU*GO6>RE&*GJ*I,0E%%%,
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M5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 2BBB@"Z_P!\_6FTY_OGZTVL&:H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K-E@U(ZU'-',%LL ,F[KQZ?6M*LRTL
M;R#5+BYENM\$F=L88X!)]*J/43-.BBBI&%%%% !1110 H&6 JQ4,8R_TJ:JB
M3(****HD**** "BBB@ HHHH **** "BL[79+B'1Y[BU)\Z "51_>VG)'XC-/
MTC5K;6=/CN[9LJP^9>Z'N#3Y7:Y/,K\I>HHHI%'E/QX\(?V]X/&K6T1:^TQM
MPVC)>)B R_AP?P-=9\.O"L?@_P %6&F[0+DIYURP_BE;D_EP/PK>FU*QCOHM
M/DG3[3-]V+J2.O/I2V.IV6HB3[)<)(8V*NHZJ?<4[/<7,KV+=%%%(9SFO^!M
M \1,9+RS"7)_Y>(3L?\ $CK^-<'?_!24,3IVL*5[+<Q<_FO^%>B>)-=31[,1
MQ$-?7!V01]\GC<?85KV\;0VT4;,695 +'N<=:Z(5ZM-*ST*C6DGRIGAK?!WQ
M(K$+<6##U\QA_2K%M\&-:D8?:=1LH5[[0SG^E>W45?UVJ:>WF>=Z1\']#LG6
M34)I]0<<[6^1/R')_.N^M;6WLK=+>U@CAA085(U"@?@*FHK"=6<_B=S.4G+=
MA5?4+07^FW5F7*"XA>(L!G;N!&?UJQ169)P,GPML+CX:6_@RYOI)(X'#I=B,
M!@V\MD#/H2.O>M2^\$6UWXL\/ZY'=- NBPO#%;+&"KJ5P.<\8%=510!P>H?#
M:3^V+[4/#_B74="_M!M]Y!;JKI(_=@#]UCZBI9OA;H,G@I/#2-<QI'-]I2\#
MYG$__/7=Z_TKMZ* //$^&-W/JNC:GJOB[4M2N=+NEGC$\:A"H_AVCH3W;DU9
MU#X<23>++S7M*\2:CI#:@JK>PVRJ1+M& 03]TX[X-=U10!YPOPEMD\#:EX87
M6+@Q7M]]L^T/&&=/F4[3S\WW>I]:U]7\#2W7B2+Q!I&N7.DZB+<6L[QQ+*D\
M8Y *MP"/6NPHH XW1/A]!I4?B..YU.YOUUT_OVF4!URI4\C@]?08JG8_"^!/
M!TWAG5=9O-2L@R&T9E6-[3;G;L([CWKOJ* ."L/AK(=7L;_Q!XEU'75T]_,L
M[>Y54CC<=&8#[S#U-;>D^%(]*\8:YXA6[>1]56)6A* "/RQC@YYS7144 <'J
M?P]U._EOH8?&NK0:9?,QGLW1)<!OO*CMRH]NU=AI6F6NBZ3::99(4MK6)8HU
M)R0H&!DU<HH **** "BBB@ H(R"#WHHH S2-K$>AI*EN%VS-[\U%5""BBBF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!****
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M)F7*6R&3\>@_G7K=<V)EJD=6%C:+D<-\7-$U+Q#\/;O3M)M6N;MY8F6)2 2
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M=1116Y 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!#<G$)^M4JMW9^11ZFJE4A!1113 **** ,YM/F;6EO1=?N@.8<
MGTK1K-BTY5UJ2^%UN)!!B';C%:5-@@HHHI %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 E%%% %U_OGZTVG/]\_6FU@S5!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,EC
M\V%X\XWJ5SZ9JCH]@NG020K<B<EMQQ_#Q]:T:RM,L;33[NX2&[$DTG+1Y&5
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MZCX9%JZR65M'<&<L-KA^P%)R;W'&*CHCH****0PHHHH **** "BBB@ HHHH
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MQX:OKBUUC3U,BK$WRW$8Y9&4\$]Q^7>OG2T^*?B^7Q/<ZE9&#^U]2ACLRZ0
MDX.%VJ> QH ^P:*Y[P;H=YHFA1+JM]/?:K.!)>7$SELN?X5[!1T 'U[UT- !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5
M+MLL%].:MDX&36<[;W+>M- -HHHJA!1110 5EF]M+O638O:[Y8N5D(! QS^%
M:;-M1FP3@$X%9^E7S:BDDLEJ(7C;9D]3_6FNX&C1112 **** "BBB@ HHHH
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M3'M_AGSM)_F?QHL!Z5X?\26'B6WN+C3A.88)C"7ECVAF'7;SR*UZY_P1HO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH R9K"VLM2DU>:Y=% Y7/&>GX_2M"UN8KRW2>!MT;=#_2G30QW$+PRJ&C
M<8(-9CW@TW4+73;>Q;R7'WE_F/ZYJOB7F+8UZ***D84444 %%%% !2@E3D4E
M% $ZN&'O3JK D'(J9'W<'K5)DM#Z***HD**** "BBB@ HHHH **** "BBB@
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MABO0U2D2XEBBHQ+ZBG!U/0T[H5F.HHHIB"BBB@ HHHH **** "BBB@ HHHH
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M6FU@S5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%4J*+ 6C=^B?F:C:ZD/3 J&BBP#F=V^\Q--HHI@%%%% !1110 4444 %%%%
M!12,RHI9F"J.22< 5G7]U=2Z>LVDE)2S8W#DX]J$K@6)=1M8+R.UDE EDZ#T
M^OI4%E:7T-_=2W%SYD+GY%(_SCTJ<6<4[P7%U!&;F->HY /]:M4[@( %
M'0"EHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% %U_OGZTVG/\ ?/UI
MM8,U04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!0&DVR:HVH@.9B#\I/&?
M45'IM_>3FZ-];"W2)N&/''I^ [UIU%<V\=W;/!+G8XP<'!JN:^XK=AT4L<T:
MR1.KHW(93D&GUCS03Z+HXCTR)IG#Y8D9..YQW]*N&_BMX;<WSI!+*/NYX![T
M./8+]RY1114C"BBB@ HHHH **** "BBB@ HHHH *D7_5_P# A_.HZD7_ %?_
M  (?SIQW%+8HT445L9A1110 4444 %%%% !1110 4444 %%%07=[;V,0DN)
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M:&1YI)1E0_'/7^=-L[V]@TRXN=4CVM$3@ 8+#^76CE[!?N:U%4[34K>[L1>
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'DN\,&/S< 9'7C^=<UIOAGQ5X6BN-*T_0-%U:U:8O;WMT5#1@]F!Y->J447
MJZ;#+!IT$<\%K!,%_>1VJXB5N^WI5JBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 444JC+ 4 )@T5>$*X&>M%*X#W7</>H""#@
MU9I" >HJ&KE)V*]%*PP>*2H+"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J1?]7_ ,"'\ZCJ1?\ 5_\
M A_.G'<4MBC1116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !112CK0  $]*M00[?F:I(D4*#BI*EL
'84444@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img105269759_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J G # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVGQ123I)87+7,$P?YP68EE)[J<D8K3T71[?0M.%E:LYB$CR9<Y.68L?U--M
M<3XO\8:KI'B2[LK.\MHE@LDGA@DM6E:X<LPV J>.@JY>>*-<TS6K$WT5LEG=
MV[R_9]C!H]L>XYD/!?<"-N.G-=5%H]O%KUQK"L_VB>!(&!/R[5)(P/7FLZ?P
M?8W6LF_N+B[FC\PS"T>4F$2%=I8#MP3QTHN@.4A\<:Z(HK6;[&;W4$M9;218
MR$A$[$889^;;CVS74:#KMWJ/A>\O+@1B\M'GA=D&%9HR1N [ X'%5H?A[I4-
MG/!]HO'=_+$,[2Y>W$9S&$.. #6SIV@VFF:*VEP&0Q.'\R1VR[L^=S$^I)H;
M0'-VGC]+?3M&;4K69I;Z&)GGC"A [\  $Y//ITJ*S^)*KIHGU#39DN)+F>.*
M&,KS'$?F;)/;]3TJX?AOI.^ K<7BB)(4VAQAO*.4)XS]0.M.E^'FFR(0MW>(
MRSRS1,&4F,2??49!X/7VHT 63X@Z>MSLCL[R6W7[/YERJ#8@F V$Y.>^*DD\
M<0JE[/%I.HS65J),W21@QN8SAP.<C'/7K@U8E\&:;+'=1[YPMR;<OANGDXVX
M_+FH6\)QZ?)>7=A)<SEUE:+3Y;C;;[Y/O<8[Y/7.*- -32]=MM7N[R&U5V2U
M\L--QM8LH; ^@(S6I7/^"_#S>&?#4%A*RO<%FDF93D;F.< GJ!P/PKH*3 **
M**0!1110 4444 %%%% !1110 4444 %%%("& *D$'H10 M9VNZO'H6C7.HRH
M9/*7Y8U/,C$X51[DD"M&L#Q/X<;Q*MC;2W;0V4,XGG2/(>0J/E ;M@\_A0@,
MUO'$DVC:-=V.EF>ZU*8P?9GF"&*102RL2.Q4BGR>.8X?#^HWLVG2QZA83"VD
ML-X+-*<;55AP=V1@UG?\*_O[&Z5])U9%BAOOML"W:&4JY0J^3D9R3FI3\/9K
MN>.74=5>0R7;7MVUN#$7E"[8PI!^55'XU6@%F^\?06^BZ1?V]J'?4V*JLTPB
M2)E'S*[G@'/ '<UOZ=JWVO0EU.ZMI+,"-GDCD(8H%SDY'!'&0?2N6C\!W^GV
M<MEIVJPM9?:GFCM;V#SHV5Q\ROGDD-D@CU-6]+^']C:Z5:6M[/-/);^:1Y4C
M1QC><E0@.-H[ YHT FTKQ=>7_DW5QH5Q;:3<1M+#>>8K[449S(HY3(Z=:KVO
MCJ:0V%W>:+-:Z1J$@CMKQIE8Y.=I=!RH.*?I7A75[58+"]UL3Z/;0O!';QP[
M'F0C:!(V><#TQ5:V\$:D8].TW4-8CN-%TZ59(85@VRR;?N*[9Q@>PYQ1H!9L
MO&=W?S6]Q;Z%,VD7$QBBNA,N\C.-_E]=F1UJT/&5L=<U'3S9W0CL;?SFE\LY
MD.[:0BXRW/>L)_AS=N;&R;4[<Z78W FMLV_^D1KNW>6'SC&>,XSBNK71G7Q;
M+K7G#8]DMKY6.00Y;.?QH=@%\-:X/$6B1:D+9[82,Z^4YRR[6*\^_%9.L>-#
MI\EREK8"Y\F]AL0S3",-*XR1DC@#C)]ZU?#>C/H.C+8O,)F$LDF\+C[SEL?K
M7-S^#Y=2NM2L;E0+-M7BU-6==RS)M&Z/ZY!'Y4M+@7M.\?Z;*EPFJ[=.NH+C
M[,T;2"0.^W=\C+][@UKP>)M%N=3?38M1@:[3.8PWH,D9Z9 ZCM527PG9QZCH
MTUA%!:6^G2R2F%(\;RZ[<_7WK'C\ 3&=+6?44;28;B:YAC2+$V^0,"&?/0;C
M^E/0#>A\8>'Y[>YN(]5MS#; &5\X"@G /N">!BE/BW01IT=^=3A^SR2>4K9.
M2XZKCKD5@#P3JLVC)876KVS?8Q"+%DM0,&)LJ9.<MG&".G>J.H>&M4TB>VUF
M)I;O57OI+B9[6W#1H&C"$",D$\ <YSFBR ZF7QIX<A@BFDU:W$<J&1&R2&4-
MM)^@(JI?^.M.TN[>&ZP4-S#!$\3ARWF+NW$=@!^=86@^!;X^'U%Y*MO<3:3/
M8M&R9*&24N&.#CH>15Y_ MVH9[?4(5G%Q9SQEXB5S!'L((SWZT60&Y8>*+"Z
M,Z33P0RQ&9MOF;LQQMAFS_,=JE7Q1HC75M;#48?.N55XER?F#<K],]L]:YR]
M^'C7NFK;G4/*F^WS7#RHGWH92=\7XCO[5+?> OM'B1M0AN(5M)9(998)$8E3
M$,*$P0.PZ@X[4: :WBKQ(WANVLI$M4N'NK@6ZB281*I()R6/ '%8]U\01I]O
MIOVNSMUN+ZY:)5BNQ*B(HR7+J#^76M7Q;X=G\0V]@MO-;1R6ET+C%S#YB/@$
M8*_C56V\*WOGZ1-<SV$9T^ZDGV6=MY2.&0KC&>O.<T*P#-&^(6DZCIIO[R2*
MQB>=XH5=]S,J]6( X'/T'K6Q<>*-$M;\6,VHPK<E=WE@YZC(Z<9(Y [UR<OP
MVG-A8Q1:A"9K>&:WD\R-MCQR.6Z @Y'OP:U+3PA?:;JDC6.HP1Z;/)'+-$]N
M&DRB!,*2< $ >X[4: 6-&\;6.MR::UO$ZP:@)1$[\$21GE"/<<BNGKA]-\,:
MA87OAZQE=9[?3)+B?[0B;1A@0B'GEOF;/TKN*3\@"BBBD 4444 %%%% !111
M0 4444 %%%% ',>/_P#D4Y_^NB?SKSG2;IK2V8I#<F5V.R2-QA1T. 1UY'->
MC>/_ /D4Y_\ KHG\Z\[T9[AX#% ]J7#'$4D99R#@G&#TX%9RW/(QG^\*W8Z'
MX; C6-1#9W",9SUSNKTJO-?ANS-K6I,_WC'D\8YW5Z551V.O _P5\PHHHJCL
M(9[2VNE(G@CD!4K\R@\&L:#P;I%JR?98Y($$AD:..0A7Z':1Z94<>U;]% &%
MJ$$,?B?1G2*-78SY95 )^4=ZW:QM3_Y&/1/K/_Z"*V: "BBB@ HHHH ****
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MW=YK3+2;Q(5D9=X;[P.#R#@<4[H9DKXRD"_:Y=/"Z=Y[0>8)<R;A&7SMQC&
M1UZTD_C&[L@JWFF1I)/'$]N(YRX8R-M ;Y<C'? /MFML:#IT=JMO%;JBI*9D
MSDA9"I7=@]>">*R-,\&6\#3M?&.821I$J1;U"A3D,"6)!STQ@#M3T U]&U27
M5;"29[8P31R-&4;.UB.X) .#]*YG2O$VIVUG$U["MR9(IKV>0S?ZN-7"[5&W
MD\\#]:["QL+;3K?R+5"J%BQRQ8LQZDD\DU#%HNGP;1':H L+0 ')&QCDK^)I
M: 83^*]0BN[:PDTN$7MV$>%1<DH$;/+';D$;>@!JUHOB.YU.ZMHKBP2W2YAD
MDC*S;SF-@K C XRW!_E5RU\-:39R))#:_O(V#(SR,Q7 ( !)Z $\=*M6^E65
MJ\#PP!&@5TC()^4.06'XD"C0#BM8U;5[?5-8F@FU 16<L6UHUC,$:X!;>#\Q
M&,DXK5NO&3V^I"WCLX[F-G:)/)ERY8(7&1C:,XQC=GVK4N?"^D7E[+=3VS-)
M,09!YSA7(Z94'!_*B3PMHTT[2R688LYDVEVVAB,$A<X!()IW0&0OC9S9H3:1
M&\DG$*Q+(^%.W<=XV;EP >-M58_%=S+?"9XIHH]\:_9R0,-LE+<D9(.P>G:N
MA'AC21 T7V=CN=7\PRN9 5&%(;.1@$]Z>GAO2(PH6S7Y<8RQ)X##).>3AF_.
ME= 8K^,[BW@0W6FHDUQ'#);(DQ<$2' #?+D$=\ UNZ+JCZK8M/+;M!)'(T;*
M<X)'=<@'!]P*)M TRXC6.2U!"Q)$I#$%54Y7!!R"#WZU9L;"VTZV\BV0JFXL
M<L6+$]22>2:- .;?QC<106UW)IJ_8[O<T#)-E]BGYBRXX.W)P"?2H[CQPRW4
MT5KIYG2(-('#D^9&IVY7"GDD'&<#CK6[!X=TJWGDFCM0&D5DP78JH;[P4$X7
M/M4;^%]'>"W@%F$CMX_)C6-V7]WUVG!Y'L:- %T+5[G6!=3-:+!;1S/#$QDR
M[E6*DD8XZ>IK#AUN^E\0N\LES%9IJ)L5 5#$<+P"/OY)_BZ"NLM+.WL8FBMH
MQ&C.TA4?WF))/YDU5.A:<=2&H&W_ -(#>9G<=N_&-VW.-V.,XS1H!FZYXDNM
M*O+B*#3TN(K:V2YF8S;#M9V7"C!R?ESVJ-/$NH2WK:9'IL!U))'#*;@B/8J@
MYW;<Y.X#&*V[G2K*\>=YX [3Q+#(23\R*20/S)JO=>'M+O'=YK<^8[F0NCLK
M9("GD'/(&,4: 8EKXTGOD%S!IRBR\Z*!G>;#AY ,87&, D \U1L_$^N1J+JX
M@@G1+(3S()=H'[PC*_+R<=N!QUKK(]"TR&(Q1VB)&9(Y=HSC<F I_#:*9%X=
MTJ&*:-+4!)D*."['*DYQUX&31= 4M/\ $KWFO/ITMJL"_-Y1>0AW Q\P!&"#
MGL3CO70UFV^@Z;;7WVR*WQ,"2N78JI/!(4G )]JTJ& 4444@"BBB@ HHHH *
M*** "BBB@ HHHH YCQ__ ,BG/_UT3^=>=Z4E]]B_T;RO+D8EMT(8C! Z_C7H
MGC__ )%.?_KHG\Z\ST]HUMCY]PUO'NXD28AL^R?Q5G+<\?&_Q_D=5\.$*:WJ
M2$@E4P2/]ZO2:\T^&F/[6U#!+#RA@GO\U>EU4=CLP/\ !7S"BL_79&AT#494
MG-NZ6TC+,!G80IYQ[5RWPT74QI]\^I-?EWD5@+M6')!)*[NW0?\  <]ZH[#J
MKZ'4I)XVM+F%+<#][&T1+O\ [K;AM_(UQEKI&J)-#ML;Y(1<LUJ))1FW)*$L
MX#<C <=\YZ<UZ%10!S%S%J2>,-+>ZN[>2V)G\J..$JR_*.K;CG\A73UC:G_R
M,>B?6?\ ]!%;!!((!P?6@!:*HZ3--<6"RSN'=F89"XZ,1_2KU#T **** "BB
MB@ HHHH **SM<3?I,YW.I4 @HY4@Y]15]$$:*BYPHP,G-/H ZBBBD 4444 %
M%%% &?J.M6>EL%N3+N*E@$B9N/P%96C>-M.U> /Y=Q"YD*!3$S#KQR!BNEJ.
M"WAMH_+@B2-,D[4&!D]:I.-MA:F%X@\07&E:C8V=NEL6N0QW3LP'! P-H/KW
MIMUXVTBRCF>X-RHB.T-Y#8E^;:2A_B )QFMQK2%KQ+LK^^1"BG/8]:R)_!VD
M7 N@\<^+C.X"=L*"=Q"C. ">2*D8R3QGI,4YC;[3M"%A((&V,0 =@/=OF''O
M36\:Z8&6,)=)*5RPDMV B;) 5_[IRI%4X_ =HNK-,TN-/$12.T3< I( SG=U
M^4'(&:U8_"NE1P-%Y4C!]N]GE9F<ABP))ZG)- %5/&^DM(J,+D'C=)]G;RP,
MX+;L?=!P,^]0I\0-'F=#;^?+$7=9)!&<(%7=G'<'H*TU\-:6L/D^03'L*%2Q
MY4L&(_,"JL/@G0X('ACMG6-I"Y D;N",?3!H 6V\8:9<W\=D$O(YW8(RR6[+
MY;'HKGL3VKH*Q[3PQIED=T<<K2&1)6DDE9F9US@DGKUK8H **** /*/&6/\
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MHH **** .8\?_P#(IS_]=$_G7FNFW$44"KYJQ,)<R[H]WFI_=''Z<5Z5X_\
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M\0I;LV(+O]VP/0-V/]*]CKSZL.25BDPHHHK,84444 %%%% ',>/_ /D4Y_\
MKHG\Z\ZTGSI;4PQO:,<LHBE0LY#8SCU'%>E>-H_-\,S+C^-/YUP&GEK6!XUF
M2+<V3F'<3^/]*SEN>3C%^_3\C6^&HQJ^H C&(P,8Q_%7I=>?_#^#RM3O6]8Q
MV]Z] JH['7@E:BOF9/B61!H-W SRH;B)X4>.-G*DH><+SVK ^',4<6GWBI#;
MQX= ?(M)H-W'4B4Y/X5O>);&*^T.X$D-Q,85,R103/$SLH.!E2#S7._#.X-S
MIMZYMIHP)0/,>69@Y&1@"7D8&.GJ*HZSN:A:ZMT9%:XB5I&*("X!9AU ]34-
MU8R7-U#,M_=0)']Z&(KLD_WL@G\B*YR7PO<I+;K;Q6ODK+(<LQS"K2APR<<G
M QVZT :VI_\ (QZ)]9__ $$4OB)F>T@LT!9KJ=8RHZE1\S?H#5&YL9;?Q?I4
M[ZA=3K(9\0RE=B?*.F%!_,FK[?Z5XI0=4LK<L?\ ?<X'Z _G3CO<3)M%6:/3
MECGMW@=7?Y6(/!8D=/K3+_2G>X^W:?(+>^ P21\DH_NN._UZBM2BB^MPL<Z-
M9AGUC3H+H?9;Q6D5X)#SDKP5/<'L:Z*L#6]%T_5-:TM[NW$C*7 .2. N0./>
MK'_"-:8/NQS)_NW$@_K5/ET$KFO161_PCMJ/N75^G^[=O_C2?V"1]S5M37_M
MOG^8J;+N/4E-U!9ZAJ$]Q*L421Q;F8]/O55Q>Z_][S;+3#V^[+./_95_4U2T
MSPQ;V_B:^N[BYGO' C=!<'(!.><="1CCTKJJIM+82UW,S4;:&TT&:"WB6.)$
M 55& .14>IV4\-R-5TY<W2#$L/03IZ?[P['\*MZI#+<:?+#"H9W&!DX JVI)
M4%A@]QZ4KCL065[#J%HES;MN1_7@@]P1V(I+>\6XGFB6*13"=K%@,$^W-9M[
M#)H]V^J6B,]O(<WD"C_R(H]1W'<59TN6.>XO9HG5XW=65E.01M%%NH7-*BJ%
MYK6GV)VS7*>9VC3YG/X#FJO]I:G><6&F&-#_ ,M;QM@_[Y&6_E2Y6%S6E=8X
MG=V"JJDDDX %4=!N(;K1+62"5)$V8W*<C(ZU5ET.XOXG75=1EGC88:" >5&1
MZ'')_.I?#=A;:=H5M#:Q"-"N\@=R>IIV5@UN:JLK?=8'Z&EJH(TCU%=B*NZ,
MYP,9YJW4C"BBB@ HHHH **** "BBB@ HHHH \J\7JK^.B&E,0V(=ZL 1\O8G
MBJ%J OB_3@)FF E7]XS*<_0+P*T?%J;O'))C#@H@ .,9V\=>/SK/M+81>+[!
MDB\L-,A*C& >AQCCWK)[GA5%^]?^(]CJ&Z@^U6LD'FRQ;QC?$VUU]P>QJ:BM
M3W3D-9T/4EMX;&RBDU&UEWB[EN[L";8<?NU8J<*<<_2M#5K:1=4TJ;[1((_M
M*KY'&P?*>?6M^LG6?^/K2O\ K['\C0!J2.L<;.[!5 R2>@K.TV_M%T*"Y:XC
M$(3!<M@9]/K5;Q?D^&+N-)"DL@"1X&2S$C 'UK%\&^%)K'2X[B\N,W3'?$OW
MUB'I@\9^E+75_P##_P"122Z_\ Z$W5[J(VV47V> ];B=>2/]E/ZG\JP-%\%6
MFGZQ?7,%[=K,K!4</R,C)S_>Y/>NH^T7%O\ \?,.]!_RTAY_,=1^M4=*U6RO
M=5U"*WG5WWJ0!W&T XH59+W;V!TI;VN3[=8MONR6]XH[./+<_B,C]*/[86'B
M]M+FV_VBF]/S7/ZXK3HJK]R+&)J>L::L=E(;ZWV-=( 1(#SS6V#D9%<GXN\+
M66L2V,K1A)?/6-F4[=RGL>/UK8CT7[/&J6E_>6ZJ  OF>8!_WT#3?+;0-34H
MK-\G6(ON75K<#TEB*'\P3_*C[;J,7^NTLN.[03*P_(X-*P7-*J6D_P#(,B_X
M%_Z$:KR^(;&VB>6\%Q:JHR3-"RC\\8JKX3URRUK2_P#1'.Z%B'1A@C))!_&G
MRNUPNKF_1114C"BBB@ KD?B-=FW\+M$IP9Y50^XZG^5==7"_% '^Q[(CH+CG
M_ODUI25YH3V/+:**5T:(@2*4) (#<<'O7H$'5P?\2OX=S7"<3ZE/Y1;N(U[?
MI^M2>'KK0X/#EQ:W&HR65[=/MED2,LWECHHXX!KDFN97A2!IG,2G*QEOE'T%
M1Y'J*CDNM1W.[\>-!9:G87=E>R+?)$H50,;4 X;-5H+Z\_L@:CJ%TS7FHM]C
MM6;CRXL_.P';TKD9KB6X8//,\C 8!=LX'I2S7<TZQ)-.SK$NR,,WW!Z#TI*G
MHD%SKO$FAZ?9Z7>26UDUJ]E=+;HY8GSU*YSSW^E<;5FYU.]O(DBNKR::./[J
MR.2%JO@[0V#M)P#VJHII:@.BE:":.9/O1L''U!S7T):S"XM(9@<[T#?F*^>#
MT->^Z("-#L0W7R$S^588E:(<2_1117(4%%%% !1110!E>(HO/T>1/5E_G7&_
MV;_LUZ!=Q>=;E,=2*S_[-_V:EHY:U+GE<SO"UK]GNISC&4 _6NHJE8VOV=V.
M,9&*NTT;4H\L;%#6VVZ#J#?:OLN+>0^?S^[^4_-QZ5R/PP938Z@1J,UXQD5G
M,B2+ACG)&_G';_@([UTGBG4H=,\/7<LUNUQOC:-(1$T@=BIP"%!.#7/?#=46
M'4PD?!DC8S?9I(-Y()*[7).%]1QR:9H=U116%K>L7.GZA:PP^0$9=\BR9W2#
M<J[4YZ_-GOTH DU/_D8]$^L__H(IV@_OUO;\\_:KABI_V%^5?Y9_&N;\7>()
M[*_M9(=,O3)")U1VCPK$J!N![CO6]H>I6HTVVL_+FMW2!?EF78<XZ?6AR45J
M]P47)Z(W:*SK"[+:<LVR:4ER"/O'J:N><?/$?E28(SOQ\OTI1?,DQR7*VBM=
MV,]Q>VUQ'=^4(,_)Y8;=G@\_2KU5_M1\EY/L\WRG&W;R?I3_ #SYD:>5)\XS
MNQPOUIW$2T5#]H.V4^3+^[[;?O?2@W! B/D2_O.VW[OUH JVS@ZQ>C#<I& 2
MI .-V>?QK0J(3DR2)Y4GR#.['#?2F?:3Y22?9YOF.-NWD?6FP+%%1><?/,?E
M2<#._'RGVIGVH^09?L\W!QLV_-]:0%BN/TOPM&FJZMNO[HVKS BW1RB\C/./
MKVKJS,1,D?E2?,,[L<#V-9FG7L;WFJ%%=F24?(!R>,<52;5Q-7+UGIMEIZ[;
M2UBB]2J\GZGJ:M5"9R#$/)E^?OM^[]:!.291Y,OR=]OWOI4C))"5C8A2Q Z#
MJ:JZ6LD>FP1RQM&Z*%*M4OVD^7&WD3?.<8V\K]:=YQ\UX_*D^49W8X/L*8$;
M?\A&/_KF?YBK-9S71^U12_9YN4(V;?FZ]<5>$GSLI5@ ,[B.*& ^BJ4VIPQ&
M,JK2QLP4R1X*KDX&?_K4RWUFTGM9+AG\F-'V$R$#GM_.BS%<T**J1ZI8S2)'
M'=Q,\A(50W)QUI%U6R>[6U2X1IBQ78IR00,D&BS'<N4444@"BBB@ HHHH X'
MQ+9B3Q*TQ52 J_?7<.G<56MK9YM=L9697V.H&U-H ],5UVHZ<;F[:3;G(%16
MVE&.YC?;]U@:BVIP2H-S;\S>HHHJSO"LG6?^/K2O^OL?R-8OC.[GMIH@+NXM
MU^R3/;>2Y7S+D%=BG'WN^%/!YIWBVZUB"*R>SLXI&6561O,RV[:<_)CG'UH
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MM9:@]T;@,&B$94+C)&.>OMVH;TW#Y&M1114%!1110 4444 8FIZA]GO6CW=
M*@M=3\RZB3=]Y@*Y[Q9?&#7Y8P>B+_*J&D:B7UBS3)^:4"@"3QS+K\GBCR+1
M==?3Q'"&33'0 J2^_.3D,2$P?0&NX\,&_/AG3O[3$HO?(43"7&_=_M8[UQWB
M;3;R\\8WDVE:K)#/:6T%Y-"MCYPS&7V -N&2<M\OM7;:#>_VCH-E>?:1<F:(
M.91'Y>X_[O;Z4 :-9.L_\?6E?]?8_D:UJR=9_P"/K2O^OL?R- &JY(0E5W''
M SC-0V@D6V19$V,HQC.:GHI6UN.^E@JM;EOM-QF-U!8$,1P>,59HH:NT"=DP
MHHHIB*UW_P L/^NRU$/^)?+M/_'HYX/_ #S8]OH?TJ6\95\C<P'[Y>IJ=T61
M"C@,K#!![BLG&\FUN:J5HI/8=15*%VM)5MI6)C;_ %+G_P!!/OZ5=JXRYD1*
M/*Q&W;#LQNQQGIFJNFP7%M:"&X,192<&/.,$Y[U:()! .#ZU!9M(UL&DD+L2
M>2 ._M3YM>47+I<L5GWM@[RB\LW$5X@QD_=D']UO;W[5H452=A&!#K=G-X@M
M;::007ODR(UO(?F#94X]\@$CUK?KEKWPIIEWXQMM1E1_,\MI&0-\K,I4 G\_
MTK;U6(/92R[Y$>-"RE'*\_A5.VEB5?J7J*;$28D)ZE13J@HY7QIX6&NV8N+9
M0+Z$?+_TT7^Z?Z5X_)&\,K12HR2(<,K#!!KZ*KF_$G@ZQU\&8?Z/> <3*/O>
MS#O712K<NDMA-'B]%;6K>%=7T9F-Q:L\0_Y;1#<O_P!;\:Q3P<'@UV)IZHD,
M"BC-.CC>5PD:,['@!1DF@0VM#1M&N]<U!+2U0\\O(1PB^IK>T3X?ZIJ3+)>*
M;*V[[Q\Y'LO;\:]/TG1[+1;,6UE$$7JS'EG/J3WK&I64=%N4D.TG2[?1M-BL
MK9<)&.3W8]R:NT45PMWU904444 %%%% !1110!@>,I/*\.2M_MI_.O-?MQ]:
M]#\>?\BK/_UT3^=>39/K0!Z'X#N#-?W8STC'\Z[RO-OAL<ZE>_\ 7(?SKTF@
M#!\8:A-IWARYDAM+RX+HT9-FNZ2+*G#@=\''YU5\$SWDMC<+=R7;[6&W[3IP
MM#R.< $[OK6[JDT]OI-Y-;&,3QPNT9D.%# '&2>U<M\/O$%_K-I=+J5W%++&
M_P"[!:+S",G)*H2,?=P?K0!VA&1@]*YF3PQ,)(A;S01PEW\Q?+Z(9 XV8Z'C
M%=-10!S-SI5I9^+]*NH4D$TQGWEIG8'*CH"2!^ KIJQM3_Y&/1/K/_Z"*V:
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MRZ2%@"LIW*PQW[_C6Y5:V_X^+K_?'\JF=&G>.G]6*A6J6>O]7(1J+0G9?0F
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M(1M+-&"2,8QGZ4/86<DR3/:PM+& $<Q@LH] >U6**5P($L[6.$PI;1+$6W%
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M0O64S2+&(T 48557VY_.@#99@BECT R:Q(O%FF3&,*+D%Y#&P:%AY9! R_\
M=&6')]:VW7>C+DKD8R.HKG(O",:2B5M0G>1Y"]P=J@3#*G! ''*CD<GGUH G
MU":*3Q-HR)*C,IGRH8$CY1VK=KG+S3K*V\6:3<06L,<TIG+R(@#-\HZFNCH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &NRI&S,<*!DFH-/=9+&(J<@
M+@_6K-%3;WKE7]VP44451(4444 %%%% !1110 4444 %%%% 'E'C>9X/%\LD
M9PPC3!QGM6;HMQ)/XATP2%<), H50H&3Z"K_ (\_Y&J;_KFG\JR_#_\ R,.G
M_P#7=: /;J*** .;\4^%YO$!MY(=3GM9(&4HJJI0_."3@J?FP, __7J75[-5
MU;2KKS9R_P!I5=ID.S[IYV],UOUDZS_Q]:5_U]C^1H UJ*** "BBB@ HHHH
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M$@;1UYZUH^1XI_Y_=,_[\/\ XT ;U%8/D>*?^?W3/^_#_P"-'D>*?^?W3/\
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M@ HHHH **** "L'4?"6FZGJT-_,A#*<R(O27TS6]10 BJ%4*H 4#  [4M%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img105269759_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &$ Y0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /$?CDQO_ !9X*T2Z8C3;FZS,,X#$
MNB_H"?SKJ_B'XBTCPUI4.A7?A6[U/3+JW8-'9PCRXE7 Q_LGN".F*T/B1X!B
M\>:'';I<"UU"U?S;6X()"MW!QV/'TP#7%SV/QNN=-;19)-'\IT,+W^]=[*1@
MD]\X[[<T 4[O5M#U;]G;6V\.Z9-IVGP2^4L$TF\[MZ,3G)Z[JB\%^-O'.G^#
M-)M-.\ 2WUG%;JL5R)L"5?[V,5T,7PMU#2/@SJ?A*TNHKS4;R3SBQ_=QABR9
M )[83J:[CP1I%UH/@G2-*O@@NK6W6.0(VX9'H: /-_CIKS2Z3HGA994M9]6F
M22Y+MA8HP0/F/8;CG_@!K%\*7NC^"/C;_9FC7]M<:%K-ND:&"4.J2XXR0>NX
M'_ONNIN/AE=^*?BGJ.N^++6";15A\FRMQ,22!@*3C&/XFZ]35?QQ\%;"73+6
M?P3806&K6URL@8S, RCW8G!!P10!S_C37'\.?M#P:G'IMSJ+1V*@6UL,NV48
M<<'IUIP@USXE?%71-;A\+W6B66F,CSW-RA5I-K;L$X&3V &>M==;^#O$4_Q@
MTWQ=>0VT=NFGK%<A)LE9?+(8 =QDUZA0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444  HH%% !00""",@]0:** /FOQOIFM?#
MGQ9?:1X:<)IWBQ!%#%G'ENS %5]"-Q /HWM7L.A>$K7P7\-KC2;?:TBVDKW$
MH'^ME*'<W]![ 5D_$;P5K'B;Q;X3U'3E@-OIER);@R2;2%\Q&X'?A37?ZG;O
M=:3>6T6/,E@>-<G R5(% 'Q]IVL^([CX;WNAZ7:3#2+:<W>I7$7\0;:JJ3V'
M&<=^_ KZ>^&_]@-X"TU_#D0BL7CR5)RXD_CWGNV>O^&*R?A7X)O?#/@:[T37
MX+=FN;B1G1&WJ\;*JX)_ UF_#OP1XF\!^*=3LD,-QX7NG9XB9OWD9_A;;ZX^
M4_0&@#,_9X_Y!7B/_K_'_H->JZ_XATSPQI;:EJ]S]GM%8(9-A;D]. ":\8\+
M^#?BMX+6^AT6+1O)NY_-;SY-QST'IVKT;PWIOB76=,O;3XAV.DW,9D1H(H4#
MH0,Y+ YYSC% &1K_ ,9?#L/A.[U#0;Q;V]WBWMXBC)F5AP3N X'4_EWKS3P[
MIEMX:^,GAJ2\U>"ZO+FUDNM1NC<*R"=Q)E=V<<<#W_&O9=4^%O@S5K:*WFT.
M"&*-RX6US#EB,9.W&:X.]^!&G'Q]I\EGIZCPRL!^UQM=-O,GS8QWQ]SOZT 2
M>!U6_P#V@/&=Q<A9)(8S'&6&<+N5>/P %.^!+>3J?C.QB&+:'4,QJ.B\N/Y*
M/RJ]KW@KQ;H7CVZ\5>"/L,YOX/)N;6[; 4X W#D9^Z#UZYZYK?\ A=X'N?!>
MAW/]I3I-JNH3?:+IHSE5/90>^,DY]30!W5%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444  HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BB@G R: "BH;>ZM[M6:VGBF53M)C<, ?3BB&[MKEG6"XBE:
M,X<1N&VGT..E $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%1RW$%OM\Z:./><+O8#)]
M!FEEEC@C,DLB1HO5G8 #\: 'T4U'61 Z,&5AD,IR#3J "BBB@ HHHH ****
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MBJ3^/"? =CXD@TIY)[Z2.&"Q,P5B[OL"EB,#UZ4 =E17(#Q?J=AX=U/6M>T
M6-O9QAXQ!?)<&;G&!@ +S@<^OM4NB^*-1N-?31=;TB.PNYK4W=N8;D3HR @,
M&.!A@2/8]C0!U5%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XO=@
M>)/%GBM[OPI-XB:RG^R1JTRQI:PJ@/[K<>9&)8\<].:O6$>F>*=8\(:1)+/J
M6A1:3+>+'>\M+(KK&HE'1BGS#![UTMWX9\0Z;KFJ7WAB_P!/CBU8K)<17T;-
MY,H7;YB;>N0!E3W'6H!X#O=&M-!F\.WT U'289(&-XA,=TDAW.&V\J=_S#'2
M@!_@:%-(\2>*_#]J"FG65Q#-;19RL(ECW,B^@R"0.V:Z(>*_#K3"%==TPREM
M@0729+9QC&>N:I^%/#UWHYU*^U2ZBN=5U.<3W+PH5C4!0J(@/. !U/7)K-\?
MZ1ID'A&YGBTZTCE%Q;D2+ H8'STYSB@#M:*.U% !1110 4444 %%%% !1110
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!-<ZG]G>0Q1MT6(!3^\([GA>O)KT=5"@!0 !V%+0!Y='HU[J,>B7O@N32Y=
MTV%Q;V^H+,I^T9(:4C +-C.">Y)K+T:*,?"O0/\ A,-,-QI<5Z'!M=X^SKEL
M23+U*[B0<<8(->RT=: /%YD4VGBV;P3!)_PCSVD",MO"6C:4N?/:%&&"1$><
M#&?>M3PE'H4'CFR_X0N:>ZL&L7CU*1R\B1A<>4-[\JY);*CMU'%>IA0H 4
M= *%55SM &3G@4 +1110 4444 '2DW#U'YTR=MD1;W'\ZH?:/>@ERL:6X>H_
M.C</4?G6;]H]Z/M'O2N+G1I;AZTM9\4^7 SU(_G6A3*3N%%%% PHHHH ****
M "BBB@ KEOB)_P B5=?]=[;_ -'QUU-<M\1/^1*NO^N]M_Z/CH ZGM11VHH
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M !1110 5RWQ$_P"1*NO^N]M_Z/CKJ:Y;XB?\B5=?]=[;_P!'QT =3VHH[44
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M"_N%9LW;7 +S98D,PSP<=<<4 >^6RE;6%2R,0@!*#"GCL/2I:BM@%M80(C$
MB@1G^#CI^%2T 8WB?Q/IGA'1GU3592D"L$54&7D8]%4=S_A46N^*[71%L8Q:
MW=]>WY/V:SM4#22 #+'D@  'DDUY1\0]1U6\A\2W.J^&=7\J&)K73IA&IMX(
M]PW3$YSN?'7' P.YKK;&]>\^(WAB]NK.>Q^T:+<1Q070 =761,C@XR5 /TH
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M?VI(B>8MQ/U&3S0!Z)X1\51>);6X1K*^L;ZR98[FVO8PDBDC(;C@@CD&NBK
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M]Z%_?O=O$S9_A"J0,?4FI.>7-RVLM/7R_P Q-#_Y#MA_U\)_Z$*]VKPG0_\
MD.V'_7PG_H0KW:K@=^6_#(****L],1_N-UZ=NM>"Z-I9T[35M;_X.3:A<(S;
MKN4QEYOF)#-D'G'7G%>]U0UK49=)TBXOH;"XOY(5!6VMAF23D# 'XY_"@"U;
M_P#'K%^Z\KY!^[_N<=/PJ6J&D:A/J5GYMSIUS83*=K07&TD<9R"I((Y_I5^@
M HHHH *Y;XB?\B5=?]=[;_T?'74URWQ$_P"1*NO^N]M_Z/CH ZGM11VHH **
M** "BBB@ HHHH **** "N6U__D>?"7^_=_\ HJNIKEM?_P"1Y\)?[]W_ .BJ
M .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\L^)/\ R,$'_7LO_H35ZG7EGQ)_Y&"#
M_KV7_P!":IGL<68?P3D[.:>WO8)K7/VB-PT>%S\PZ<=ZW_[5\1&-H_[-38[;
MF7^SEP3ZGY>O-<[ TJ7$;P%A,K QE.N[MCWKL%FOW4'Q!)':@C_6BX:*?Z[$
MSD_4#-9H\JC>S2;7Y'+:G<7=W?R37RE;@@!@4V8   X[<8KL?AC_ ,?]]_UR
M7^=<=J30-J,QMKB>XAS\LLXP[#'>NQ^&/_'_ 'W_ %R7^=..Y>%_WA>IZ52.
MZQHSNP55&2Q. !ZTM8WBV"XNO!VM6]K&\EQ+8S)$D?WF8H0 /?-:GOE'1OB)
MX3\0:L=+TO6K>XO!G;& PWXZ[20 WX58T?3_ !':ZA/-JFN07MK)(^RW6U$?
ME)GY,,.21T.>OM7C4;ZW!9^"HX/A[K$4^@2(]Q*L"@S +A@#[GGFO;/#>M7.
MNZ8UW=Z->Z3()"@M[P .0 /FX['/Z4 ;%97B'2'US1Y-/6_FLDE9?-DA.':,
M$%D!ZC<.,CUK5K!\8:%>>)/#D^E66IMIS3D"294W$IW7J.O3KTS0!YM?3P:%
M#XHU/P7YMOHUIIC6\DL<C-#)>%P T62<E%)RPXR0.U= NB6?@SQ9X5.D>=&N
MI-+:7JM,SBX(B+B1LD_,&7K[FM"Q\%ZN=)N=$U?6[6YT::T:V6UM=/6W\K/0
MJ03T]*L:3X4U==9L+_7];CU :9&\=DD5MY7+#:9)#DY;:,<8')H O:]XLT?2
MOM-C>7$R3^23M6VE<8(..54C]:/ G_(A:#_UXQ?^@BMJ]XL+C_KDW\C6+X$_
MY$+0?^O&+_T$4 =#1110 4444 %%%% !1110 5SWCO\ Y$+7?^O&7_T$UT-<
M]X[_ .1"UW_KQE_]!- &W9_\>-O_ -<U_E4U0V?_ !XV_P#US7^534 %%%%
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M44 %%%% !1110 4444 %<MK_ /R//A+_ '[O_P!%5U-<MK__ "//A+_?N_\
MT50!U-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7EGQ)_P"1@@_Z]E_]":O4Z\L^)/\
MR,$'_7LO_H35,]CBS#^"<I8I<O?VZ6>?M1D BP<'=GBM-M>\1"&6<WUQY<;^
M6[\8#<\=/8U2T6YBL]<L;F=ML44ZNYQG !YK8:/23I%[9?VY#NN+I9PWV>3
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MXY-24R%&CA1'<R,J@%SU8^M/H **** "N6^(G_(E77_7>V_]'QUU-<M\1/\
MD2KK_KO;?^CXZ .I[44=J* "BBB@ HHHH \\^(/_ "%+;_KC_4UQ]=A\0?\
MD*6W_7'^IKCZ8@HHHI@%%%% !1110 4444 :7A__ )#]E_UV7^8KV&O'O#__
M "'[+_KLO\Q7L-)C"BBBD 4444 %%%% !1110 5S_CK_ )$+7_\ KPF_] -=
M!7/^.O\ D0M?_P"O";_T T :NE?\@BR_ZX)_Z"*MU4TK_D$67_7!/_015N@
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ML?X4 9'_  G'A7_H8=,_\"5_QH_X3CPK_P!##IG_ ($K_C6O_9]E_P ^EO\
M]^Q_A1_9]E_SZ6__ '['^% &1_PF_A7_ *&'3/\ P)7_ !KRC4]=TB75+ITU
M2T9&E<@B48(R:]N_L^R_Y]+?_OV/\*7[%:?\^L/_ '[% '@O]M:5_P!!*U_[
M^BC^VM*_Z"5K_P!_17O7V*U_Y]H?^_8H^Q6O_/M#_P!^Q3N!X+_;6E?]!*U_
M[^BC^VM*_P"@E:_]_17O7V*U_P"?:'_OV*/L5K_S[0_]^Q1<#P7^VM*_Z"5K
M_P!_11_;6E?]!*U_[^BO>OL5K_S[0_\ ?L4?8K7_ )]H?^_8HN!X+_;6E?\
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M[Y%&Q/[B_P#?(I_5_,7M?(]\_P"$V\+?]#%I?_@4G^-'_";>%O\ H8M+_P#
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M%%( HHHH **** "BBB@ KG_'7_(A:_\ ]>$W_H!KH*Y_QU_R(6O_ /7A-_Z
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MG3)\[OP3%=Q14RGS=!J-CE?^%AZ#Z:G_ ."RX_\ B*/^%AZ#Z:G_ ."RX_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%S+-<<$-)@ DDC)/;&!6I967B/7O$6AW>MZ3%IMOHRR2,1<K*;B=DV H!T0
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MI\R5CH[*/Q%]CA-KJD<<&P;$-^B;1Z8)X^E4]975Q'%_:5\MRNX[ +I9<'Z
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M7_7>V_\ 1\==37+?$3_D2KK_ *[VW_H^.@#J>U%':B@ HHHH **** "BBB@
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MN;QYLG8,M(#U(<#!Z@5KV.F^)=:\0:+>:]I]K80:.KN/*N?--S.R;-P&!M4
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M\= '4]J*.U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN-&L_%5W;>&[AV9]/$",ZHQ):-93R%))[=Z .XTG4$U;1[+48T*)=0).JGJ
MR@X_6KE16MM#96D-K;H$AAC6.-1_"H& /R%2T %%%% !7DOQ)O[RU\2HD%W/
M$GV=3M20J,Y/I7K5<OXA\#V7B+41>7%U/$X0)MCQC SZCWK2E)1E=D33:T.)
M^'.H7MSXJ6.>[GE3R7.UY"P[>IK;^,3.OAC2FB@$\@UJT*0D@"0[CA<G@9Z5
MLZ!X%L?#^IB^M[JXD<(4VOC'/T%7/%?AH>)[&RMC=&W^RWT-YN";MWEG.WJ.
MOK15DI2N@@FEJ9^C7^KR7[-J?@R'2K>.-I/M*W44I!'8!0#SSS7*Q:[XWO\
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MA>"]CU"Y43,TO.<J3C;R< =* ,^.Z\9>*=0U>71]:M=+L],N6LX8WM!*;J1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img105269759_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &8 [$# 2(  A$! Q$!_\0
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MGJ,&LFY^+/@FTULZ3-KD0N5?RV8(QC5NF"X&W]: .THI%8,H92"I&01T-+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%'
M>B@ HHK@+SXT>!;"^N+.XU659[>1HI%%I*<,IP1D+ZB@#OZ*YWPSXY\.>,!*
M-$U)+B2(9>(JR.H]=K ''O6QJ6HVND:9<ZC>R&.UMHS+*X4G:H&2<#DT 6J*
M\Y_X7G\/_P#H+R_^ <O_ ,36]X7^(/AOQE=3VVAWKW$L"!Y T#I@$X_B H Z
MBBBB@ HHK,U_7]-\,:/-JNJW @M(L!FQDDDX  ZDT :=%9^G:U8ZIH<&LV\V
M+&:'SEDD&S"8SDYZ5RUM\8/ UWJRZ=%KB><S[%=HG6,G_?(Q0!W-%-9U1"[,
M%0#)8G  ]:P_#/C'1?%Z7CZ-<M.EI+Y4C&,J,^V>H]Z -ZBBB@ HH[T4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2?'?69_P"Q
M--\*6!)O=:N50J#SY88<?BQ7\C7.^$[0?"SXU?\ ".^8W]EZQ;1K"[GJ^/E/
M_?8=?^!"I=3\%ZE\3?B[J4VK0ZCIVC6$7E6LX0H7VG V%ACDEF^F*I>.O@M+
MX>TB#6?#5YJNHZC:W"-Y4A$C!<_>4 9R#B@#7\?QQZC^T!X2LKN,3VT=OY@A
M89#,#(W3W*K^0JIX?N[;7OCY%J-[:?\ "-W-M;E(=/G0I+=L589/&WH3W_A'
M6LOQAJ>LWOQ7\&ZK8:<W]KMIL<_V&?\ =DN#(7C.>A.& _"M6Z.O_$?XJ^';
M^/PS?Z/:Z.ZM<3W:%3PVXC.!GI@ 9ZDT >Q2^*- @NFM9=;TZ.X5MC1-<H&#
M=,$9SFO+?B/J%UX]UJ[\(Z3,R:5I,#W>KW*=&=5)6(>O(_/_ ':ZJ^^#G@_4
M=<GUBXM;DWDTYN'(N& +DYZ?6N3U#X$I:6NJ7=CXGU99)5DF,$0 $K8)"G!Y
MST_&@";X0Z'!XD^",^CW4T\5O=W$R2/ P5\94D D'KC'3I6)\4M+\+^&_!NG
M>!M'LH[O7994\DK&IG W?>=@,Y;. ._T%.^'>BZ_X(^'NJ>(H[;5)=5E5K>W
MTEXFVJQ88DV]?<\=!7.>#;SQ/X8U:[UN_P# 6IZQK=RY;[;<!P4!Z[1M/)]?
M3@8H [_QY97(\,> _!%Q+YEU>W-O%<DG.Y(E&\_3)'Y5<^(FI7?BG6[;X<:!
M+Y9F42:M<)TM[<?P?4\<>X'<T:=_:'BKXNZ/JE]I<]G#INBB8I*C!4N)1\R@
MD $@-C\*9JGP1AOO$&IZS!XHU2SFOYGED6W 7J<[<@\@4 <I\*[F31_A'XZN
M+9F$EL\YC;N"(N#5/0_#FEW'[->J:A+90-?%Y)Q<% 9 5< 8;KT&,>YJ_P#"
MCX;:B^G>(&U234+(3QSV*VLZ%4E5TQYI!ZD5DPCQEH_@&^^&O_")WTMW/<%8
M[R,$Q>66!)W8QU'7/0^U 'L?PGO9M0^%V@SW#EY! 8]Q.20C,H_0"NSK!\%:
M"WACP;I6C.P:6U@"R%>A<_,V/;)-;U !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 44=Z* "BBB@ HHH[T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 '>BCO10 5\O\ A/Q-X4\-^/?%[^*;
M1+B.:\D$ >T$^")7SUZ=17U!7B_PK\-74'CKQG/J^CNMO/<EK=[FW^5QYCG*
MDCG@CI0!SWP]-KKOQONO$'AC37L/#T$3^<2FQ.4QT' RWS8]LU[C'K_AW5G^
MP1ZKIEXTP*_9UG23>,<C;GGBM#[%;"S>T2%(X'4J4C4*,$8/2N,T+X0>$?#F
MM6VKZ=:W*7=N2T;/<,P!((Z'V)H \_\ C5H^EV'B3P;'9Z;9VZ2W9$BPP*@<
M;X^&P.>_6O5M9LY/#N@WEWX1\.6,NJLH6.**-(0W/5B,9 ZXSS7"?&;1M3U3
MQ'X0EL-/N;J.WNBTS0QEA&-Z<G'3H?RKH_C!9:_??#ZX@\/"9KCS$,Z0'$CP
M\[@,<GG' [ T <!J_P 0O'W@NXTRZUW4]#O4NI L^G6^WS8!W!QR#[\C/K79
MZSXWU>S^,FA^&;=H1IE[;"64-'E\D/T;M]T5Y!K_ (>DU7PGIO\ PC?P\U.Q
M>UD7[9=31DRROC&%!^9ESDDXXXKN_B'8ZSIGQ%\,^-K'1KO4;*WMD2:*!"9%
M(W<$=1P_YB@#H]?\;:QIWQFT/PO;M --O( \H:/+Y._HW;[HKEOC+X,U.ZTK
M6_$NJZW++:6IC_LW3X^$BW,JDMZGD_X]JC:+Q)XC^-OASQ'<^&K[3]/$>Q/-
M7+(@#\R8X4DD\>F*] ^+EC=ZE\,M6M+&VEN;B3RMD42EF;$BDX ]J ,O3;%-
M2_9[@LY+V.R272 #<2G"(,9RWMQ@UXA/K%MJ/P[TCPV?#\%B%O K:_)&1$W)
MR=VW/?GGH.GI[=_PBVI:U\ K?P_'&]OJ+:?&!%+\AWJ0VT^F<8_&O.[W4?%&
ML?#FT^'4?@C4(M0C,<3W#QD1!4;.X'& 3CDYQUH ]3\3^"]3\4Z5HVE6WB*2
MUT6. +?-#R]V,+MP>F#@^W/0UR/[.L:PZ9XCB3.U+U5&?0*:]7\-Z6^B>&=,
MTN63S)+2UCA=^Q*J <>U><? O1]2TBS\0KJ-A<6AEO0T8GC*;A@\C/6@#UNB
MBB@ [T4=Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#CM5\ PZI\1=+\7MJ$D<EA%Y:VPC!5_O<[L\??\ 3M78T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 '>BCO10 4444 %'>BCO0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 =Z*.]% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 '>BCO10 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@ H[T44 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/ALPH.1$S'=]<U:\,?\ (S:=_P!=T_G1U""M45NZ/<****W/I@HHHH ****
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MRL;NZA$\FHW3?N[:(]"H_C<]AT[FLF5_#NE6O@_5='U".ZT73]3E6]OM^_\
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MK!8Q/$T88GH 2,4 =S1110 4444 %%%% !1110 U_P#5M]#7-_#S_DG^B_\
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M<$_/QFF>&/\ D9M._P"NZ?SIFL+K >+^UWG9L'R_-?=QWQS3_#'_ ",VG?\
M7=/YT=0_Y>KY?H>X4445L?1G >._"VMWWB#2O$F@0Z?>7=A&\+66H#]VZMSN
M4]F%<KJVF>,O&4T/AO5](\-:,LQ6=Y(Y0]P(U8$M& 2>O&?>NH^)?P_O?&$4
M%YI6K3V>H6J%5A$K)%,N<X..0?>O,-!\'6NJ_$JSTJ[C\1Z;/#8R/=+<7)9E
MD5ACRY0/FC(.: /H]%V(J@DX&,FEI , #TI: "BBB@ HHHH **1W6-&=V"JH
MR6)P *S-*\1Z+KLDR:5JMI>O"<2+!*'*_7'\Z -)_P#5M]#7-_#S_DG^B_\
M7N/YFND?_5M]#7-_#S_DG^B_]>X_F: .FHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"*Z.VUE/HIK"-QR>:V;\[=/G/HAKD#<<GFDS
MGK2LT:OVCWH^T>]9/VCWH^T>]*YA[0UOM'O6[:MNMD/KG^=<9]H]ZZ[36W:?
M"?4'^=-&U&5V6Z***9TF+XP%L?!FM"[GDM[<V4OF2Q#+(NPY('K7B/A\6/\
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M (NC_A:47_0N:K^<7_Q=<7118#M/^%I1?]"YJOYQ?_%T?\+2B_Z%S5?SB_\
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M^%OV7_0!U3_R%_\ %UL>&+6VDUWQ4KV\+*FHJ%!0':/)CX%=-_9]E_SYV_\
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M 4444 %%%% !1110 4444 9NOG'A^_/_ $P;^5>.F7DU[!XC./#>HG_IW?\
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MGV(/XUI4 %%%% !1110!ROCG_4Z#_P!AJU_F:ZJN5\<_ZG0?^PU:_P S754
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M>^\$2V-I8Z;%))>@XO+EF$$)SCYL#GUZUP^F6&J^._'D&E>(_%XU*P-A]O\
M*T>79 &WA0AQU]>>: /7?".I:_J5A,WB#0TTB:.0)%$DXEWI@<Y'3GBNAI
M  .@I: "BBB@ HHHH **** &O_JV^AKF_AY_R3_1?^O<?S-=(_\ JV^AKF_A
MY_R3_1?^O<?S- '34444 %%%% !7 ?$+_C]L_P#KF?YUW]<!\0O^/VS_ .N9
M_G30'%T444Q!1110 4444 %%%% !7:_#S_C[O/\ KFO\ZXJNU^'G_'W>?]<U
M_G28'?4444AA1110 4444 %%%% !115>]@FN;*:&WNFM9G4A)T4,8SZ@'@_C
M0!SWA3_D8/%O_827_P!$QUU-<EHO@_4](U>:^;Q3>7*W$WG7,+VT2K*VT+U
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MEAK=S;03A8D8!1L!QP/:O0*\G\6?\C+>?[P_D*: F_X336O^?A?^_:_X4?\
M"::U_P _"_\ ?M?\*YZBF(Z'_A--:_Y^%_[]K_A1_P )IK7_ #\+_P!^U_PK
MGJ* -:W\1:C;:A>7T4H%Q=[/.;:#G8,+QCCBK?\ PFFM?\_"_P#?M?\ "N>H
MH Z'_A--:_Y^%_[]K_A1_P )IK7_ #\+_P!^U_PKGJ* .A_X336O^?A?^_:_
MX5TW@_6[[5YKI;N4.(U4KA0,9)]*\XKMOAY_Q\7O^XO\S28'>T444AA1110
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MT6Z,Y1=A!(&,=<\T =+;O');1/" (F0% !CC''%24  # X%% !1110 4444
M<KXY_P!3H/\ V&K7^9KJJY7QS_J=!_[#5K_,UU5 !1110 4444 %>3^+/^1E
MO/\ >'\A7K%>3^+/^1EO/]X?R%- 8E%%%,04444 %%%% !1110 5VWP\_P"/
MB]_W%_F:XFNV^'G_ !\7O^XO\S28'>T444AA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<IXNCWS6YQT4UU=8'B*/S'A..
M@I/8QKJ]-HX[[/[5?\ZU_P"@3;_]_'_QJ;[/[4?9_:I.!1:*-R(IBIBM(X,=
M0C$Y_.I]'@VZM;''21?YBI_L_M5O38-NH0G'1A_,46'&'O)G844459ZAYK\2
M8_"EUX@T*PU?0)M:U6\;RH(H793%%GYG.#T'7\#6)XI\)_#[P=JNEK>^#I6T
MZZD"2:BDTACMW)PH8;N_^<UTGCK2->M/$^D^,?#MDFHW%C"]M<6+-M:2)N<H
M?4'-<]K=YXP^)MM%X>;PC<:'ILDR/>7E[)DA48-A!@9/'O0![",!1CICBEI$
M4(BH.BC I: "BBB@ HHHH **** &O_JV^AKF_AY_R3_1?^O<?S-=(_\ JV^A
MKF_AY_R3_1?^O<?S- '34444 %%%% !7 ?$+_C]L_P#KF?YUW]<SXH\.7.N7
M$$D$L2"-"IWDCO["A >945UW_"O]0_Y^;;_OH_X4?\*_U#_GYMO^^C_A3N(Y
M&BNN_P"%?ZA_S\VW_?1_PH_X5_J'_/S;?]]'_"BX'(T5O_\ "*W7_"0C1O.B
M\\VGVK=D[=N_;CIUS5__ (5_J'_/S;?]]'_"@#D:*Z[_ (5_J'_/S;?]]'_"
MC_A7^H?\_-M_WT?\*+@<C7:_#S_C[O/^N:_SJ#_A7^H?\_-M_P!]'_"N@\+^
M'+G0YYWGEB<2* -A)[^XH Z6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH R_$G_(M:E_U[O\ RKPT]:]R\2?\
MBUJ7_7N_\J\-/6LY[GCYE\<?0W-$N]6\IK31[2,S\N]PL2F0#_?/"BJNK6&K
M6\@N-4CF)D/$SOO#'TW D?A5R))9O!;)9!F9+LM=I&,L5VC82!U7K2Z;'/;^
M&]7>Z1TLY(U2)7& TVX8*@]P,Y-2<O+>*B[[7\C KVOPC_R*MA_N'^9KQ2O:
M_"/_ "*MA_N'^9JH;G3EO\1^AMT445H>R4=:U./1=#OM4EC>2.T@>9D3JP4$
MX'Y5Y'_;GCO3H&^(-WX=\/\ V*6W1YDB)%U]F."/GZ' (./TKV#4K1M0TNZL
MUG:!IXFC$J $ID8R :\M;X(W+:9'IK>.=8:QC(*6Y4%!@Y'RYQ@'M0!ZO;3K
M=6L-P@8+*BN PP0",\U+7-^$O#-]X;CNEO?$5_K)F*E3=_\ ++&>!SWS^E=)
M0 4444 %%%% '*^.?]3H/_8:M?YFNJKE?'/^IT'_ +#5K_,UU5 !1110 444
M4 %>3^+/^1EO/]X?R%>L5Y/XL_Y&6\_WA_(4T!B4444Q!1110 4444 %%%%
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M_)/]%_Z]Q_,UTC_ZMOH:YOX>?\D_T7_KW'\S0!TU%%% !1110 4444 %%%%
M!1110!RY_P"2J+_V!#_Z/%=17+G_ )*HO_8$/_H\5U% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &7XD_P"1:U+_ *]W_E7AIZU[EXD_Y%K4O^O=_P"5>&GK6<]SQ\R^./H;
M%G9:;#I":CJ7VF199FACC@(7&T EB3]>E5=7T]=,U.6U20R( KHY&"58 C/O
M@U8M=8MHM*CL+S38[I(Y&D1FE9""P /3Z5)J>N6>I^8[:1%'<,BHLJSN=H
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M*V/_ ($)_C1_;ND?]!6Q_P# A/\ &JG_  AWAG_H7]+_ / 1/\*/^$.\,_\
M0OZ7_P" B?X4 6_[=TC_ *"MC_X$)_C1_;ND?]!6Q_\  A/\:J?\(=X9_P"A
M?TO_ ,!$_P */^$.\,_]"_I?_@(G^% %O^W=(_Z"MC_X$)_C7E_BF_LI?$5V
M\=Y;.I88*RJ1T'O7HO\ PAWAG_H7]+_\!$_PI1X0\- 8&@:9_P" B?X4 >0?
M:[;_ )^8/^_B_P"-'VNV_P"?F#_OXO\ C7L'_"(^&_\ H :9_P" B?X4?\(C
MX;_Z &F?^ B?X4[B/'_M=M_S\P?]_%_QH^UVW_/S!_W\7_&O8/\ A$?#?_0
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MI;_]^Q1]7?</:KL?27]LZ5_T$K/_ +_K_C1_;.E?]!*S_P"_Z_XU\V_8+/\
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M:*3G)Z-ARKL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #-=50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYFNJKEH? &BQ7EM<M+J<SVTJS1K/J$TBAUZ':S$&NIH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRX'.2/2LSQ!XMFM_B'X>O-(AO-6M[W2)7@M+1\+,Q8%6.3@ #/)Z5RT'@_\
ML.&[TF_\ ZEK%\LTGV:\M;IEM[A&8E2Y#@)UP>.U=-<V6L>%_$_AR^L?#$MU
M9V6CO;7,%BV\0DN#M0L<L0>W<9H Z"U^).F?V#JFH:I:76FW.E.L=Y8S*&E5
MV^X%QPV[L>]-TSX@RS:Q9Z?K?AS4-$_M!BME-<LK)*V,[3M^XQ'8URUYX8\0
M^)H/$7B,:8;&^NY;-['3[I@'9+9MW[S' +'./2M*\N==\=ZQH%LWAB_TBTT^
M^2_N[B^VCE,X2/!.[)/7TH ]-HHHH **** "N$\;>,=1\.ZK#;6:0-&\(<^8
MA)SDCU'I7=UYUX^\,:MK>LP3V%MYL2P!2V]1SD^I]ZTI6YO>(G>VA7\.?$#5
MM6\06=C<1VHBF<JQ1"#T)]?:ND^)$\UK\.-?GMY9(9DM&*21L593Z@CI7'^%
MO!FN:;XEL;NZL]D,3DNWF*<#!'8^]=I\0K*ZU+X?:Y9V4#SW,UJR1Q1C+,?0
M"G64;^Z$+VU//-#B^'NH6^FPMXQU-]1N$C4Q+JTV3*0,C&?6NVUCQS)8:S+H
MFB:#?:Y>6D:M="!U18 1P"S=6(YQ6UH.E6UOH6F++80QW$=M$&S$H96"C/;K
MFN/=]8\$^,M?O8O#U_K&GZR\=Q')8!6>*14VE&4D<=P:R+-&7XFZ<WAZRU"R
ML+RZO+RZ:RBT[ 259UR61R3A<8Z_2K%CX]B_LS5;K7=)O=%ETN,27$5PH<%3
MT*.O#YZ<=ZXR;PQJ@\+75WK/A4:F=4U>34+O3H9OW]JC#"&(@CYQ@9Y[U4M/
M#&M7GAKQ/9I_:6F:');Q_88-?N 66=7#$YS\J' ')[T =;;_ !-G%YIL.I>$
M]5TZ/5+A(;.:4H5?=W;!^0XYP:FU#XC2)J-];Z-X:U+6;;3G,=Y=6Q141QRR
MH"<N1W KFM>\3:WK%WX3M+[PO=:6B:U;&::XD0J\@SA8L'+#J<^E7=+NO$'@
M*76=*3PM?ZO'<WTUY975GM*-YASMDR?E(/4^E &WJ'Q-TVWM=#GT^PO=3&M(
MYM$ME&XLN/E()X.>#Z8-59/'<&I^'O$MOK&CZEI=YIEH9;JT$H$AC920T<BG
M'.#SVK'T+PAK&B:GX"CGM6D-H;Z:]DB^:.!Y1N"Y],G'X5;\4Z)JEWJOCF2W
ML)Y4O-"B@MF5<B60;\JOJ>1^= &K=^/8],N-/T;3M%U#4[ZXTZ.[MX8W7+(>
M/G=CQC')/K6>?BWYFF37UMX5U::*Q9EU3[J_8RI^8<GYR.O':I]&TC48?B)I
M-[+93);1>&H[9YF7Y5E#@E"?6JUMHNJ+X$\>VC6$XN;V\OGMHBOS3*ZX4KZY
M[4 ;FK^/([66QM-%TJZUK4+VV%W';VY5 L)Z.[-PH/:N>\6?$*ZF^'&LWFE6
M5]8ZO9RK;74+[1)9,2#N/8J1T(]:Q-2\(3VUYHFK:CX9OM8LVT:WLY[:TE9)
M[65!UVAAD'.#Z&K3>%+FY^&_BI=,\)R:3/?B/[/:RW#27$ZH0<ODD*>N!F@#
MJ+CQ_/:P:;8V_AW4+W7KJV^T/IRL@:% <;I')VC)Z4O_  LW3H_#&IZO=6%Y
M;3Z5*D-]82J!+"S$ >Q!!R".M8ZW6MZ7XCM_%D/AC4KJTO\ 3H[.YLU0"ZM9
M(V."5)P5.>QK)UC0/$.M^'/&&MRZ+/;W6LRV:VVG<-,(H77YG XR>3CL!0!V
M&F?$)[KQ!9:7J7AW4=*340QL+BY*D3;1NP0#E#CG!KMJXKQ1IE]=^*_!%Q;V
MLLD-G=2O<.JY$0,1 +>G/%=K0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <;XD\57VD:LUK;I"8PBM\ZDGG
M\:;X=\5W^JZO':SK"(V#$[5(/ SZU#XJ\/:EJ6M-<6L&^,HH!W =![FF^&/#
MFIZ=K<5Q<V^R(!@3N!Z@^],!?BK(5T/28C>36D,^K6\4\L,QB(C).[YAT%<G
MXFATKPLMA>>%?%5]<:RUY#'%8G4S=+<*S ,I0D\8R<^U=I\1]'FUO3-'M8[%
MKV(:M;O<1!=P\H$[BP],=:VM-\)>'='N?M.G:)86L_0210*K#Z'%(#EM-\0_
MV-J7CJ_OFN[BWL[Z(1PQ@R-S$F%1?<FKFF^/[J77[+2M:\,:AHS:@6%G+-(D
MBR%1DJ=OW3CM6#JFF^*K:#QO-HMO<Q7%UJ,,D3QX626$1J',1/&[@@5A:9H-
M\_CCPWJEKX=\20VUO=,+JZU>Y,LGS(0,)D[5!ZM[T =G>?$TI<WCZ;X:U/4]
M*L)6BN]0M]NQ67[VQ2<OCOBK>I?$#;?I8>']$O==NQ ES,L#+&L,;C*[F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !574=.M-6TZXT^^@6>UN$*2QMT8&K5% '(Z/\-] T;4[
M?4$-]=36H(MA>W;S+!GCY%8X!QQ77444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 A 8$$ @\$&N)7X4>%UN0XBO3:"7SAIYNW^RALY_U><=><=*[>B@!
M    !@#H!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img105269759_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '5 C$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O!OVDXGG7PS%&NZ1Y)U4>I/EXKWFO#_P!H+_D(^#O^OJ3^<= %WX9>
M-9-=\ :OH&J,RZQI-I+$RR?>>(*0"?=?NG\/6N(\(^(IO#WP#U@V]I<SR7U]
M/:^9!_RPS"OSL>PK<^,&@7O@_P 21>.]"7;%=*UO?Q@?+N9=I)'HP_4 ]ZJ_
M#W_DW;Q=_OS_ /HM* ,KX7PZ1-X1UQO^$?N5U2'2[R3^U7)\I@5*[%'3.#_.
MO0?V=?\ DG5U_P!A*3_T7'5?X=?\FYWW_7M>_P#L]4/@3XJ\/Z)X#N;;5-:L
M+*=M0D<17%PJ,5*( <$].#^5 'N=%9>E>)-$UUY$TG5K*^>( R+;3K(5!Z9P
M>*U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO$
M7@[0O%<EE)K-F;AK)R\!$KIM)QG[I&?NCK6[10!3U32[+6M+N--U"!9[2X39
M)&V>1]1R/K6/IW@/PYI7AN\\/V=@8],O"QGA\YVW;@ ?F)R. .AKI** ,73?
M">BZ1X:D\/65H8],D61&A\QFR'SN^8G/.3WKE_\ A2'P^_Z C?\ @7-_\77H
M5% '-^&/ 7ASP=-<3:'8&V>X4+*3,[[@.1]XG'6NDHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME:C:WL<;;7:WE#A3Z'%7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM?\ T<E '56MC:6*LMI:P6ZL<L(HP@)]\5/110 4444 %%%% !1110 4444
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MC7'?$[_D3&_Z_+7_ -')0!V-%%% !1110 4444 %%%% !1110 4444 %%%%
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M  L"_P#^?:W_ "/^-%@/1**\[_X6!?\ _/M;_D?\:/\ A8%__P ^UO\ D?\
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MW\':]IF[A;G3YO*&?;G;7K/PU\?Z1JZ0^&E_M6+4+:'<O]J >;,H/7<.I&:
M/1Z*** "BBO*]3\;ZIJ7Q T"#2)/*\.G4&LY9QC_ $R55)8+_L+TSW.?2@#U
M2N.\>_\ 'SX3_P"P[!_Z"]=C7'>/?^/GPI_V'8/_ $%Z .QHHHH **** "BB
MB@ KC_B#_P @VT_Z['_T$UV%<?\ $'_D&VG_ %V/_H)H \\HHHJA!1110 44
M44 %%%% !1110 4J_>'UI*5?O#ZT >TZ=_R#+7_KBO\ (59JMIW_ "#+7_KB
MO\A5FI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %</\ $S_D%6?_ %V/\J[BN'^)G_(*L_\
MKL?Y5,MCFQG\"1YC6K9V&FW%HDEUK:6TG.8F@=MOXCBLJNET&'0H;/[7>WL#
M7^3Y<%PC&-.>K8'S?2LT>'2CS2L[?,2?PO:Q:.^IKK,;0@'R]\#)YI]%SUKF
MZZ#5HXKXR7=QXDMKF95.R-8G'T51C KGZ&%513]U6^?_  6>K?#C_D79?^O@
M_P#H*UV%<?\ #C_D79?^O@_^@K785K'8]W"_P8^@4444SH"N8^(>D:CKO@/5
MM-TIRMY-#A #C?@@E<^X!'XUT]<UX_UN^\.^!M5U738O,NX(LQ_+N"DD#<1W
MQG/X4 >5:EXXUS6/!C>#XOA[J"7\EN+3#1$0QD#&X<<8ZCGCUK=T#0O$4GQ)
M\/\ ]HVK^1H&D"">_.<3RNG*@G[V,_H:S9O!GC:S\,OXH_X6-=->);?:S&S'
MR"-N[;G.,=NF*]3\':M=Z[X/TG5+Z'R;JYMUDD3&.?4#L#U_&@#<HHHH P?&
M>FZOK'A2]T[1+R.SOKA0BS/D!5)^;D<@D9&:\CUS2/'.CZEX+TYIO#T7DW9C
MTY+>)PB,$/W\]1CT[U[U4<EO!,\;RPQN\1W1LR@E#ZCTH I7MA=:CHOV1[^:
MSNG10]Q9D*RL,9VY!XS7 >(O#=SI&K>%;B;Q%JVHJ=:A7R;R160$J_/"CG_&
MO4*X[Q[_ ,?/A/\ [#L'_H+T =C1110 4444 %%%% !7'_$'_D&VG_78_P#H
M)KL*X_X@_P#(-M/^NQ_]!- 'GE%%%4(**** "BBB@ HHHH **** "E7[P^M)
M2K]X?6@#VG3O^09:_P#7%?Y"K-5M._Y!EK_UQ7^0JS4C"BBB@ HHHH ****
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M9OAK\1-9TMHIOB$MS97<7S*ROMD1A_(BO4_">C2>'O"FF:/-*DTEG;K$TB#
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MPZ7,EW>Q/&[M<94;NIQBN9H8ZO(OA\SU;X<?\B[+_P!?!_\ 05KL*X_X<?\
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M._N=3T.SOKRR>QN)X@\EM(?FB)_A- &A1110 4444 %<=X]_X^?"?_8=@_\
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M4$&[3T^M6/\ A+/#O_0>TS_P+3_&C_A$_#G_ $ =,_\  1/\*/\ A$_#G_0
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M %%%% !1110 4444 %%%% !1110 5\]^)/\ D9=2_P"OF3_T(U]"5\]^)/\
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M"6(0WEG/C;.!T(SQV'''3@T 7_BM8^(?[#CUWP_K+V,VD![AX /EG7 R#ZX
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M^_\ UJ/^%:^'O^>=Q_W]_P#K5U]%'M)]PY8]CD/^%:^'O^>=Q_W]_P#K4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<_* >E>>^)?&7ASQ#JOA6TTG6+:\N%UN!S'$Q)"A7R?IR* /3J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&LZ+IWB#3
M)--U2V6YM)""\;$@$@Y'3W%><Z[\&- FU?0WTK1+9+..Y+:@IE8%XMO &3SS
MZ5ZK10!%%;PPVT=LD:B&-0BH>0 !@"@6T 8,((\@Y!V#@U+10 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img105269759_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Z!94# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M79FW2<GLJYX]Q7NGP)\3G7? @L)Y2]UI;^2=Q))C/*$D_B/HM &]XX^)>C^
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M 4444 %%%% !1110 4444 %%%% !7$?%_P#Y)3K_ /UQ3_T8M=O6)XP\/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Z+(C(ZAE88*D9!%8)\">$2<GPOHQ_[<8_\ "@"QI&L^'9M.=-&U'39+*QC
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MZ"*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHJI=ZG86#*MW>00,W*B20*3^=
M%NBF0S17$2RPR))&XRKH<@CV-/H **** "BBB@ HHHH J:K%)-H][%""97MY
M%0#J6*D"O"/@YIG@_7M#U#PSK.D0RZY')(9FE@RX3./EDZJ0?<?C7T%5&#1M
M,M=2FU*WT^VBO9QMEN(X@KR#_:(Z].] 'SAXJLO$7PIL-8\/8DOO"^KQ,EM(
MQXA<^_9O4=#UKV#X-?\ )+-'_P!UO_0C6YXZNX]/\#ZQ>26=M>+!;-)]GN4W
MQOCLP]*SOA7=Q7WP[TRY@LH+)) Q$$!;8OS'IN)/ZT =E1110 4444 %%%%
M!1110 5R?Q-_Y)GXA_Z\GKK*Y/XF_P#),_$/_7D] %[P5_R)&B?]>47_ *"*
MWJP?!7_(D:)_UY1?^@BMZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB/\ N7#_ .CQ7HU><C_DXC_N7#_Z/% 'HU%%% !1110 4444 %%%% !1110
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M\V!G]:M445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH HZV2N@ZB02"+64@C_=->.?
MW5O"FB^#))K[4],L]3N+E_--Q<HDC*/N\,<@=:]KN[=+RSGMI"0DT;1L5Z@$
M8.*\E_X9R\)?]!#6/^_T?_Q% &K\2?$WA'5OA[K5M'K6CW=P;<M#&MS&[%QT
MVC.<_2M+X/2O+\+=%WG[L;*/H&-<!KWP=^&GAF#S=9\2ZA:#&Y4>XCWL/]E1
M'N/X"O3OARFCQ^![!- ENI=,7<(9+H#>PW'DX [^U '54444 %%%% !1110
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M.%50,DDGH*2W_P"/:+_<'\JY/XJ:D^E?#'7[A$#LUMY&#Z2$1D_@&S0!H?\
M"=^$/^AHT;_P.C_QK>CD2:)98G5XW 964Y!!Z$&O#=)UOP!H^AZ9%JO@2[^R
MQQ10OK-SHB>3*< >86/)#=<XSS7M]J8&M(3:^7]G*#RO+QMVXXQCMB@"6O.1
M_P G$?\ <N'_ -'BO1/,3^^OYUYTI!_:(R"#_P 4X>G_ %W% 'H]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(ZY&:^D=-TRRT?3X;#3[:.WM85VQQ1C  KY_G^%OC[P-KD&M^&K^+6'M4\M
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M>N:W*\2\%:_XT\)_$>U\$>+;Q-1BO83);W#2[RO#-D,1N()5EPW<#''7VV@
MHHHH *X#XU?\DDUO_MC_ .CDKOZKWMC::E:/:7UK#=6TF-\,R!T;!R,@\'D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "O.1_R<1_W+A_]'BO1J\Y'_)Q'_<N'_P!'B@#T:BBB@ HHHH ****
M"BBB@ HHHH ***BNEF>TF2W<),T;"-ST5L<'\Z ,Z?Q)I=O),CSN1 VR5TA=
MTC/HS $#\^*TXI8YXDEB=7C<!E93D$>H-<WH6L:1IWAZWM[BZM[6:WCVSPR,
M%<./O94\DDY^M7_#,;1Z*N8'@C>622**3ADC9R5!';@CBKE&Q*9L4445!044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ KSD?\ )Q'_ '+A_P#1XKT:O.1_R<1_W+A_]'B@#T:BBB@
MHHHH **** "BBB@ HHHH **** *\MA9SW,=S+:P23Q_<D:,%E^A[58HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y[54_M3Q%!H
M]Q,4LOLQN'B1BIG.[;@D?PCKCW%-*XFSH00>AS17,-9P^'M;TV+328K>]D:.
M6UW$KPN=Z@]",8/U%=/0U8$PHHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!>3T 7O!7_ ")&B?\ 7E%_Z"*WJP?!7_(D:)_UY1?^@BMZ@ HHHH ****
M"L^]T6ROK@7$BR1W 7;YL$K1L1Z$J1D?6M"BFG;8"M8V%MIMOY%K%L3<6/))
M8GJ23R3]:LT44@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BN:MUNO$5Q>R?VE<VEM;W!@BCM]JDE>K,2"3R>GM5W1;NZ:ZO].O)?/EM
M'7;/M +HPR,@<9&"*IQ%<V****D84444 %%%% !1110 4444 %%%% !1110
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M %W% 'H]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;U8/@K_D2-$_Z\HO_016]0 4444 %%%% !1110 4444 %%%% !1110 4444
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M#/?%;]   P!BBANX)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45#<W=M91&6ZN(H(QU>1PH
M_,T6UU!>VZ7%M,DT+\JZ'(/XT#L[7)J***!!1110!7ET^SGO(+N:T@DN;?=Y
M,S1@O'N&#M/49'!Q5BO._$W@SQ5KGCVVU"S\37.FZ&D(62&VN75_, 8@A,%"
M-VW.>HS78^'XM8@T.VBUZXM[C4D!6::W4JDF"<-@]"1C/;.<<4 :=%%% !7
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M:)_UY1?^@BMZ@ HHHH **** "BBB@ K'OM3NGU5-*TT1?:1'YLTLP)6),X'
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M*)'%K9P%BEM<7217#AMN$/;/;)P/QK/\3:-IUAI4=UI]I#;WT4R&V:*/EGR
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M %%%% !7G(_Y.(_[EP_^CQ7HU><C_DXC_N7#_P"CQ0!Z-1110 4444 %%%%
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M%MVR"D(\R7';G/Z@BNPM[:"UA6&WACAB485(U"@?@*EHLWN'MX0_AP^;U?\
ME^!REC\/M&MY_M-[YVI71.YI;MRV3].A_'-=/!;PVT*PP1)%&HPJ(H4 >P%2
M44TDC*I5G4^-W"BBBF9A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7E?QPBU&+1=&U>SLOMEOIE\+BYA(RI4#@L/3/?MFO5*Y3Q_XWM/
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MW_[OS8STXKU"N6U_X<^$_$U^+_5M&BFNL -*KM&SXZ;MI&[\<T <Q\+7CO\
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M=^X\_ATK4T&[N+[0K*ZNXRD\D09P?7U_'K^--K2Z$F:-%%%2,**** "BBB@
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M6FMEE9@,B0$<\E<H&P2>1]*][H **** "BBB@ HHHH **** "O.!_P G$?\
M<N'_ -'BO1Z\HUX73?&C4!99^T'PJ^S;USYPZ8[^E-*[ ]'&NZ2;O[*-1M?/
MW;=GFC.<XQ]?:M"N=DD\/-X//,!TPPD #&2<=!GG?G\<UJ:,+A=$L1=;OM @
M3S-YR=V!G/O3:$F7J***D84444 8LWAR%YY)+>]OK-)CNEBMYMJL<Y)Z':3W
MQBM.SL[?3[2.UM8A'#&,*H_SR?>IZ*;;8K(****0PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH YNTN[73/$6K#4IHH)IW22&67"!X@@ 4,>N"#Q4NCRP
MW>OZE>6*DV3HB&4'Y)95SN*^N!M&1UQ6U<6T%U'Y=Q#',F<[9%##]:D1%1 B
M*%4#  & *IR%86BH;N[M["UDN;J58H8QEG8\"J=OKVGW-TEJLDD<T@S&DT+Q
MEQ_L[@,_A2LQW-*BBBD!SMD-6UJS:_&I/8I-DV\442,%7)P6+ Y)]!BM#1+^
M:^LY!<A!<V\KP3>7G:64XR,]CUJFFDZKIX:WTN_@2S9B42XA+M"#V4AAD9Z
M]*TM,T]--LEMUD>5MQ>21S\SN3DL?J:N35B5<N45%<7,%I"TUS-'#$O+/(P4
M#\37,7OQ!TB*?[-IZ7&IW1) CM8RP)'OW'N,UFVD;4Z,ZGP*YUE0W-U;V<)F
MN9XX8EZO(P4#\37("?QOKF##!;:);,00TG[R7&/3I^! -26WP\L9)5N-:O;O
M5;@#&9Y"%'/8 Y_#.*5V]C7V,(?Q)_):O_+\22]^(6DQS&VTV.XU2ZY CM8R
M1D>_<>XS5<2^.-<.8X[71+9B""_[R7:1Z=/T!KK;2PM-/B\JSM8;>/KMB0*/
MTJQ19O</;4X?PX?-Z_AL<?:_#S3VE%QK%W=ZK<XP6GD(7\!G/X$FNIM+*TL(
M?*M+:&"/.=L2!1^E3T4TDC.I6J5/B84444S(**** "BBB@ HHHH **** "J&
MKV$E_:H()A#<PR":%R,@,,]1Z$$BK]%"=@,&XM-9U58K:]6TMK4,KS&"0NTF
MT@@#*C:,CWK>HHIMW%8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "JD6J6$^H2V$-[;R7D*AI($D!= >Y7J*35YI+
M;1;^>)MLD5O(Z$=B%)%?/G@-(?#WPN\0^/VO9#J]TLMLOFM\A8L,'CG<2?6@
M#N;6Z^'OAWXI:AJ;>*%&L7^4EA=P88R<<;PN >.A:O55974,K!E(R"#D$5\T
M^'_AEI-]\&=0\3:JLB:I(DEQ!</*<(J].!P<\YSDUZO\%M2N=3^&.FO=%BT)
M>!6;.653P: /0**** "BBB@ HHHH **** "N3^)O_),_$/\ UY/765R?Q-_Y
M)GXA_P"O)Z +W@K_ )$C1/\ KRB_]!%;U8/@K_D2-$_Z\HO_ $$5O4 %(RAE
M*L 01@@]Z6B@#$_X133 VW%S]FZ_9?M#^3G.?NYQU[=*V@ JA5   P .U+13
M;;W%:P4444AA1110 4444 <]IJVT_B356O 'O8G A$JCY8=HP4]B2<FC1ECA
M\1:M!9!!8J(R50_*LQSN '0<8S53Q5_96H7MAIMS<6B2/+B5V9?,10,[0<Y7
M<0!^-.O=(M/#:VEWI$<D#&YCB>%)"5F5C@@@DC/?/7BM>GJ0=51116184444
M %%%% !1110 4455O=3L=.0/>WD%NIZ&60+GZ9ZT#2;=D6JR=6U&>"[L]/LO
M*^UW9;#2@E411EFP.O8 9'6L2?XBZ=)(8=(L[W5)]N0L$) _'(R/R-4I[?QG
MKU[!>I9V6D-;Y,+R/ODPPP1T(_,"B,E<VEAJB5Y:>NGX;FZU]J.B75JNJW<%
MU:7,GE^<L7EM$Q&1GD@KQCMBHM1\>^'M.)47HNI< B.U'F$Y]Q\OZUBZ?X O
MKR\:?Q1J37Z+G9"LSD9/N<8^@KL-.T+2])4"QL(("!C<J#<1[MU-$KL(JC%N
M[<OP_/7\#FAXE\4:LVW1_#IMHMP'VC4&V\'OMX/Y9H_X1'7M5 .N^))MA!#6
M]D-BX/;/&?Q%=K14\O<KZSR_PXI?B_O9SVG>"/#VF8:+3HY9,#,D_P"\.?7G
M@'Z8K6U&Q2_TRXLMWEB:,IN4?=]ZMT52TV,9U)5'>;N<Z]QXCD@:P.FPK,5V
M&]\\>5T^\%QNS[8_&MNQM5L;"WM48LL,:Q@GO@8J>BFW<S2"BBBD,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** .)^(GP]C\<VME)!?/I^J6#F2UN
MD!.TG!P<$'J <CD8K*^'GPJ;PCJ=UKFJZF=4UJX0KYS XCR?F.6)+$X'/'>M
M/XB?$RP^'T-LMQ97%Y=7:L8(XR%7Y2,[F/3KV!KS+6M=^+?BO2;_ %&*U;P]
MHUM!).V#Y4A5 6QN/SDXXR  : .B\$>!4T#QZNK>+_$EMJ'BB?=]CMDG+, 5
M8%^<$_*& &,#\L>QUXC\$OA]I\FG:=XZNKNZN-4E:8HK-\B?,T9)[L<;N<]^
ME>W4 %%%% !1110 4444 %%%% !7G(_Y.(_[EP_^CQ7HU><C_DXC_N7#_P"C
MQ0!W(T?31=?:AI]K]HW;O-\I=V?7..M7:**+@%%%% !11535%G?2;Q;7=]H,
M#B+:<'=M.,'ZT 5W\1:/'?"R?4;<7&<;-_0YQ@GH#GM6G7.V-QX?3PDN3 FG
M+%ME23&0<<AAUW9_'-7?#:W2^'+ 7F[SA$,[@00.P.>^,9JFDA)FK1114C"B
MBJ<FK:=%=?99+ZV2XR%\II5#9/08S18"Y1110 4444 %%4[_ %.TTT1_:9"'
ME.V.-$+NY]E&2:;8:O::D\D<#NLT6/,BEC,;KGIE2 <>].SM<5R]1112&%%%
M% !1110 4444 8/B56C;3KV16DL[2Y\RX14W8&T@/C_9)S_^JJVLZE8ZN;&R
MTZXCNKLW,<JF%\^4JG+,Q'3C(YZYKHYYX;:%I;B5(HE&6=V  'N37+WGCW0[
M2<VU@)=0NF) BLX]VX_7H?PS3YTMRX4:E3X%<ZRHI[B"UA::XFCBB499Y&"@
M?4FN.%YXWUP VMG;:+;-@AYSOEQWXQ^A ^M2P?#ZUGE$^N:A>:K.,_ZV0J@Y
M[ '(_/%1=]#;V$(?Q)?):O\ R_$FO?B#H\,_V6P$^I71)58K2,MDCW[CZ9JH
M+KQOKF/L]K;:);-@AYCYDN._']"!]:ZRRTVQTV+RK*TAMT[B) N?KCK5JBS>
MX>UIP_AP^;U_#;\SCK?X>V<LJSZW?WFJS@$?OI"J#GL <C\\5U%GI]GIT/E6
M5K#;Q]=L2!?Y59HII)&=2M4J?$PHHHIF04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 R:&.X@D@E7='(I1U]01@BO#[O\ 9^NGOI+*
MT\430>'9)?.-H59BI[#&=I..-QY]J]NN;A+2TFN9,^7$C2-CK@#)KQ*\^-/B
M'Q3=-I_@'PW-*V0IN;A=Q7(ZE0=J\]V8CVH W/B%\/M0U+2-*TK3->M]&\,V
M,&R[6:0J"!C#$# ;Z$@9KN/!EII.G^$["RT6Z2ZL+=/+2=#D2$'DY'7G-?/H
M\+^*/%OQ.L_#/CG6[DR20&[DCBD#",;<[5 ^13QU (^M?1GAW0++PQH5KH^G
M^9]FMUVJ9&RQYR230!J4444 %%%% !1110 4444 %<G\3?\ DF?B'_KR>NLK
MD_B;_P DS\0_]>3T 7O!7_(D:)_UY1?^@BMZL'P5_P B1HG_ %Y1?^@BMZ@"
MO>WUMIUJUS=S+%$O4GN?0#N?:H;'6+'499(;>4^='R\4B,C@>NU@#CWK+UIH
M[;Q'IE[?<6"(Z!V/R12G&&;L.,C-17MW;:GXCTC^R[B&::!V>>2(A@L6T@@D
M>IQQ5J.A-SIZ**0,#T(/TJ"A:*** "BBB@ J*Z\P6DWE9\S8VS'KCBI:* .7
MTVST.Z\(!+A8C T>Z[>0[6$@Y8L3R&!S2>&-%A>PM+ZYFN[ETR;=;ER1&N2%
M(7CDKCDUL3Z!I-U>?:Y]/MY)\Y+L@Y/OZ_C6B!@8%6YZ:$J(4445!045'/<0
MVL32W$R11J,L[L% _$US=]\0- LY/)AGDOI]VT1VB;R?H>A_.DVD:0I3J? K
MG44=*XK^W/&&L$#3-"CT^$Y'G7S'/L=O!'Y&@>"M4U09\0>([J=67YH+7$:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBM8LH."P!/;-#5AIBT444@"BBB@ HHHH **BDN;>*5(I)XTD?[JLP!/T%2T
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M,,JRG((]13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-(NY[>Z@9AN1C(S _3DC/L:])KC/$'PK\(^)=4;4M0TUOM;D&22&9H_,Q_>
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MUW)(D4;R2.J(@+,S'  '4DUC:KX?\.^+[!/[0L;/4;=T_=RX#$ ]U<<CZ@T
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M0M]3\5:W?>(;Z @Q"XD;RXR.>A))P??'M7J%% !1110 4444 %%%% !1110
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MN\MT9&(]0& )%:-<UJEY9:AJ>E0V$B7%XEPLN^!P?+B'WRQ'8CC'?-=+3DK
MF%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH K7VH6NFV_GW<HCCW!1P26)Z
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M#.%Y7S$#8^E/M;2WLH1#:P1PQ YV1J%'Z5-11< HHHH **** "BBB@ HHHH
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MM-(O;F/'F0P/(N1W"DBO O #W&E>!/$OQ)N]3EGU*Y26%8Y&P-V1@[NI.2,
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M;;W!)(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK1;/5/"V87@CA_MJYT@+;SR!0"V\C<<G/.*]Q@6)+>-8 @A"@($^Z%QQCVH
MDKSD?\G$?]RX?_1XKT3S$_OK^=>=*0?VB,@@_P#%.'I_UW% 'H]%%% !1110
M 4444 %%%% &)+I5_:7MS<Z1<V\:W+!Y8)XBR[^A92I!!.!D>M6M+TQK%[FX
MGF%Q>7+AI90@4<#"J!V %:-%/F8K!1112&%%%% !1110 A /4 _6EHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH CGF6WMY9G!*QH7('7 &:YNQTZ_UG3[?59-;O8+B>/S8TAVB*,-R
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MGXMTWQAI)O\ 3_,0HYBF@F&V2%QU5AV- &[14-W=06-G-=W,@C@A0R2.W15
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M*)KR^OT79%<7TYD:),8VKT &/;-;\WAW39_$EOK\D3G4+>%H8WWG 4]1MZ4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)+8&5SP<L.  > 10!]!45XIX(\1^-O#?Q'MO!/BZX6_2\@,EO/O#%<!FW!L
ML#M92&YR!CCK[70 4444 %%%% !1110 4444 %><C_DXC_N7#_Z/%>C5YR/^
M3B/^Y</_ */% 'HU%%% !1110 4444 %%%% !1110 4444 -=%D1D=0R,,%6
M&014-K8VEBA2TMH8$)R5B0*"?PJQ10 4444 %%%% !7.:G@>+]-:^V?8?)<0
M%\;1<9'Z[>GXUT=17%M!=PF&YACFB;JDBA@?P--.PFKF%?&(^+M+^Q;/M063
M[5LV\0X&-W?[V,?C7156M-/L[!66SM88 QRPC0+GZXJS0W<$@HHHI#"L>]\.
MV]U<R7$%U>64LO\ K3:R[1)QC)'(S[CFMBBFFUL#5RM8V-OIUL(+9"J9+$DD
MEB>I)/)-6:**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <UJWA%=7\::-K\]ZXBTM'\NT"\-(W\>[
M/IQC%=+02!U.*3<N<;AGTS0 M%%% !1110 45A^+?$]EX0\.7.L7N62(8CC7
MK(Y^ZH^M1>'_ !#=>(/ UKKUO8K]JN;8S1VHDX+<X7<?7'6@#H:*\NOO'7Q$
MTRQGOKWP%:P6T"%Y)7U6(!0/QKK/ OB*_P#%?A>#6+_35L#<$F*(2;]R=FZ=
MZ .EHHHH **** "BBB@ HHHH **** "BBB@ HJ*ZN$M+2:YDSLAC:1L=< 9-
M>!6_Q8^(%_+=>*K/1HW\*6C[)8BBCY,\MN)W%@/3@>E 'T%17S=<>)OBCK.E
MWGC[3[X6VC6LC>5:?* 8L\G81A@.Y)SUQ7N?@O7W\4>#]-UF6)8I;J+<Z(<@
M-G!Q^5 &]1110 4444 %%%% !1110 5R?Q-_Y)GXA_Z\GKK*Y/XF_P#),_$/
M_7D] %WP4H/@G1"0,_8HN?\ @(K?K!\%?\B1HG_7E%_Z"*WJ "BBB@ HHHH
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M&6X558L$F;C!/&&%?0E8]EX3\.Z;=I=V.@Z;:W,>=DT-JB.N1@X(&1P2*V*
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M51T '05Q/AO0M9C^)?B;7M4MTCMYUCM[)@RG?&O?@DC\<5W- !1110 4444
M%%%% !1110 4444 %%%% %#7/^0!J7_7K+_Z :^8-"^(^D:9\'M2\(S6]ZU_
M<^;LD1%\L;B,9.[/;TKZEU&9+?2[N:2(2I'"[M&W1P%)(/UKS'PS=^"M=^']
MUXMN?!&E6L%L9-\$=K%*Q">A*K0!YQ9_%;0K?X.2>$&M;\Z@UH\'F!$\O<22
M#G=G'X5[#\&O^26:/_NO_P"A&I/"VD^!?%N@0:Q8>%--CMYB0JS6$088..0
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MS[6/A'I#>._#TNG>';<:(BS?V@ X SM^3()R>?2@#TK6=8M]&T"\U>9@T%M
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MM7I%>3_#+Q;X'\4:J8K#PS8Z-KENK.B+;1@E>A*.%!Z'D8'7OS7K% !1110
M445XU\8M>\62Z'JUMIEA)I^B66U;O4)'VO<[F0;(@.=N7Y/?!&1T(![+14=O
M_P >T7^X/Y5R7Q.\37'A7P/=7M@ZKJ,SI;6FY<_O'../<+N(SQD4 =CD9QGF
MBO&=<^'.H>$_#5QXHT7Q+J\NOVD0NKF2>XS'=!<%PR^F 2 2>F*]7T/5$UO0
M=/U6)"B7EO'.JMU 90<?K0!?KSD?\G$?]RX?_1XKT:O.1_R<1_W+A_\ 1XH
M]&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5_R)&B?]>47_ *"*WJP?!7_(D:)_UY1?^@BMZ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PSXR>3;_$
MWP9=ZWM?00V'1^5#!P7+#TP4SZ@5[9;W-K<6T<MM-#)!(H9'C8%64]"".U9O
MBCPMI7B_19=*U: R0,=RLIP\;]F4]B,_XUX_/^S8AN)#;>*98X-QV(]IN95[
M D. 3^ H FU"XT[4/VFM&;0G@>2&!EOI(5RN\))NR1P3M*C/K@=17N=<9X#^
M&FB> H9'LO,N;^90LMW/C<1QE5 ^ZN1G'7U)P*[.@ KAM0^&OV_4;F\_X3+Q
M9;^?*TGDP:CMCCR<[5&W@#H!7<T4 <MX;\%?\(YJ+WG_  DGB#4M\1C\G4;S
MS8QD@[@,#GC&?<UE?&K_ ))+K?TA_P#1R5WU8_BCPY:>+/#MUHE])-';7.W>
MT) <;6##!((ZJ.U &I;_ /'M%_N#^5><?'"WE;P/:WR*&BT[4H+J?)_@!*\>
MO+"O0[BU$^GRV@EEB#Q&,21-M=,C&0>Q'K69:^%[-/"K>'M0N+O5K1T=)9-0
ME\R60,2>6XZ9X/; ]* *'C[4+6T^&>NW4TJK#)I\B*PY!9UVKCZEA5KP-;RV
MO@#P_;SHT<T>G0*ZL.5(09%<S:_!O1(7M([O5]=U'3[1P\6G7EYOMP1G:-@4
M<#/3^E>C  # & * /,6^'OCHL2/B=> $\#[ O'_C]4?^%2>*_P"VO[8_X6+<
M?VCY'V?[1]@&[R\YV_?Z9YKURB@#S#_A7GCO_HJ%Y_X +_\ %T?\*\\=_P#1
M4+S_ , %_P#BZ]/HH \P_P"%>>._^BH7G_@ O_Q='_"O/'?_ $5"\_\  !?_
M (NO3Z* /,/^%>>._P#HJ%Y_X +_ /%T?\*\\=_]%0O/_ !?_BZ]/HH \P_X
M5YX[_P"BH7G_ ( +_P#%T?\ "O/'?_14+S_P 7_XNO3Z* /!?B#8>.O F@0Z
MJ?B#>7OFW26_E_95CQN#'.=Q_N]/>NIC^'WCMXU?_A9]X-P!_P"/!?\ XNI?
MCGI>H:MX'M+?3;&YO)EU*)S';Q%V"A7R<#MR/SKTB $6\8(P0HR/PH \T_X5
MYX[_ .BH7G_@ O\ \71_PKSQW_T5"\_\ %_^+KT^B@#S#_A7GCO_ **A>?\
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M*N!\7Z?>W/Q,\#W4%I/+;VTMR9Y4C)2(&/ W$<#)]: ,[_A7GCO_ **A>?\
M@ O_ ,71_P *\\=_]%0O/_ !?_BZ]/HH \P_X5YX[_Z*A>?^ "__ !='_"O/
M'?\ T5"\_P# !?\ XNO3Z* /,/\ A7GCO_HJ%Y_X +_\71_PKSQW_P!%0O/_
M   7_P"+KT^B@#S#_A7GCO\ Z*A>?^ "_P#Q='_"O/'?_14+S_P 7_XNO3Z*
M /,/^%>>._\ HJ%Y_P" "_\ Q='_  KSQW_T5"\_\ %_^+KT^B@#S#_A7GCO
M_HJ%Y_X +_\ %T?\*\\=_P#14+S_ , %_P#BZ]/HH \P_P"%>>._^BH7G_@
MO_Q='_"O/'?_ $5"\_\  !?_ (NO3Z* /"+33/'5U\0]0\)_\+"NU^QVR7'V
MG[*IW[@#C;NXZ^M=1_PKSQW_ -%0O/\ P 7_ .+JQIFFW\?QXUS47LKA;*33
MXD2X,9$;, N0&Z$UZ/0!YA_PKSQW_P!%0O/_   7_P"+H_X5YX[_ .BH7G_@
M O\ \77I]% 'F'_"O/'?_14+S_P 7_XNC_A7GCO_ **A>?\ @ O_ ,77I]%
M'F'_  KSQW_T5"\_\ %_^+H_X5YX[_Z*A>?^ "__ !=>GT4 >8?\*\\=_P#1
M4+S_ , %_P#BZ/\ A7GCO_HJ%Y_X +_\77I]% 'F'_"O/'?_ $5"\_\  !?_
M (NC_A7GCO\ Z*A>?^ "_P#Q=>GT4 >8?\*\\=_]%0O/_ !?_BZ/^%>>._\
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M<1V^'BE0JRG<>"#R*ZR@#S#_ (5YX[_Z*A>?^ "__%T?\*\\=_\ 14+S_P
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MCO\ Z*A>?^ "_P#Q='_"O/'?_14+S_P 7_XNO3Z* /,/^%>>._\ HJ%Y_P"
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MT >9^#_#WCKQ7X5L=;_X6->6OVM"WD_8U?;AB.NX9Z>E;G_"O/'?_14+S_P
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MX +_ /%T?\*\\=_]%0O/_ !?_BZ]/HH \P_X5YX[_P"BH7G_ ( +_P#%T?\
M"O/'?_14+S_P 7_XNO3Z* /,/^%>>._^BH7G_@ O_P 71_PKSQW_ -%0O/\
MP 7_ .+KT^B@#Q#QKH7CKP?X3O==/Q%O+O[-L_<_9%3=N<+UW''7/2M;3?!'
MCK4-,M;W_A9EXGGQ++L^PJ=N1G&=U=#\7K&[U+X8ZM:6-K-=7+^5LBA0N[8E
M4G ')X%=/X?CDA\.Z;%*C)(EK&K*PP5(49!% ' _\*\\=_\ 14+S_P  %_\
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M0CLJC)_05\V^%M,^&6HZ-97/BS5I$UN_EE>0?:'  ,C;=Q7A,C!^8CK0!],
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M-6U?_B>3VZ-.%NW$?F$<C?\ <!SQC-?06GV,&FZ=;V-L"(((Q''N.3M P.:
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M')V*@S@ <=0:[7X8ZU?:UX-B_M-VDO[*:2RGE)SYC1G&[^5 '8T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "$A1DD#ZTH((R#D5Y1-HD?Q)^(VM
MVFNSR2:+H1CAAL8I619)'7)=BO.1R.O]:M>"89/"'Q!U+P5%?2W&D_8UOK))
MV+-!EL&,'N.I_P F@#TVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***Y;QAJ/B>(6^F^%],2:ZNPV^^G?;#:*"!N(_B// 'IWH ZD$'H:0L%ZD
M#ZUYI\$5GC\,:Q'=7#7$Z:S<+),W5V 7+?B>:S-/T"W^*/C#Q#?>(#>3:/IE
MT;&QM!.R1[E&'8A<'.<'/O[4 >O]:0LH."P!],UY/X3U5_ VM^*_#-[=W=QI
MVEVHU"R><[V2';\RYZX!P /8U1\*_#NQ\>>%AXH\175]/K6I;I89UN&3[* Q
MV",9QCOSF@#V>BN)^%VL:AJOA-[?5I&EU#3+N6PGF+9\QHS][/?@@9[XS7;4
M %%%% !1110 4444 %%%% !1110 4444 %%%% "$@#)( ]Z 0PR"#]*X+Q)X
M*O\ QCXQ1=:G?_A%8+<&.TM[@IYTV>3(  <8Z8/;MDUA:9I<?@'XMZ=H/A^Z
MF.DZK;2376GR.TBVQ4'$@).1D@#G_# !ZT65>I ^II:\<T/PW8_%76M?UKQ'
M//=6=I?26-C9I*T<<*J!\XP?O'(_+OVT/!^KWGA.W\9:%>SS7]OX:43VLLCY
M<PM&76,G'8+U]_04 >I%E!P2,^F:6O&O#7PTM?&'A./Q)X@N]0?Q#J*FYBO%
MN&!MLDF/8HP ,8./RQ76_"C7[O7O!$7]HR/)J%C,]G<._P!YF0\$^IVD9/KF
M@#N**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!DL:S0O$V=KJ5./0UYF?@-X/9B2^IY)S_Q]'_"O3Z*
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MB-D&'SGI@@UV->>7_P &_#=[?W$T5QJ=E:74@DN=/M+G9;S$'/S)C^1&.V*
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M##*+C;R/RKTRN7\*^ M(\)W%S>6SW=WJ-U_K[Z]F,LT@ST)X'Y"NHH ****
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M:SZJUV'MD9$\B;8,$Y.?RKGX/@5X1M[B*='U+?&X=<W1(R#D=J],HH *\_\
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ME:?!86,*PVMN@CCC7HJB@"S1110 4444 %%%% !1110 4444 %%%% !1110
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MENO#UO>[]5M5W30>6PVCC^(C!ZCH: -NBBB@ HHKDO$WQ*\*>$IS;:IJB"[
MS]GA4R./J!]WKWQ0!UM%<AX8^)WA3Q;=BSTS4O\ 3"I86\R&-B!Z9X/T!-7?
M$WCGP[X/DMX]=U#[*UP&,0\IWW 8S]T''44 =%17G_\ PNSX??\ 0>_\E9O_
M (BNQFUK3[?0FUJ6X"Z>L'V@S;3_ *O&<XQGI[4 7Z*P?#7C/0/&$=P^A7XN
MEMRHE_=.FTG./O >AJ3Q)XKT7PC917>MWGV6"63RT;RV?+8)QA0>P- &U17
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M/# 'J#6C0 445@ZMXRT'0];LM'U&^\F_OBHMXO*=MY9MHY ('/J: -ZBBB@
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MOY:[PPST!Z<"M/XJ'66^#6F-KUE9VE^;] 8[0?)L",%/4\XQ4G[0X)\->%L
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M5\8:EX1\46\ U"S5B)H%QDJV&#<X/48(%9_PQ4_\+H\>DC_ELV#C_IH:I>$
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MXBMG=39HS()CGY0#@A?0YQT/6NN\4Z5!I_[/D4EMI-SI:W>H1SBUGG\YE!R
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M\R*TL '8,2/EQ@=F))&5''0UTW@R)[C]G;Q9:P0R/<)*=\:J2W!0]/8#/X4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^]M&?SIK6MN[%F@B9CU)0$FI:* (EM;=&#+!$K#H0@!%2T44 %%%% !1110
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MQN ZC-7** ,3PIX>7PSH4=AYYN9R[S7%P5"F65R69L#IR>GI6#\6_#^I^)O
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0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img105269759_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y!/$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZAJ(/V6(;I#Y5LX ]3L&0/>O1O!WC6V\0>#EUO4)+>R\ES#=,\@2-7&.<L>
M=R]?7'-><W^C?&#7K1]/U)L6LHQ(#+;("/0^7R16UX@\*CP?\#=3TTRK-.SQ
M33R*,*7,T8./8  ?A6DE%I)VO?H7))V6E_(]&'B'1&D@C&L:>9+@ PJ+E,R
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M;<[?L_VA/,SZ;<YKPSPAXNOM/^&_BJV@GE(LEC-H['YHQ*_EG'IC((]\UN>
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M_$PST/2O3Z*:JR33[ INZ?8\J\8^$/%,7Q @\6>&H8+N554>5(ZKM(78<AB
M01Z'/-9=SX0\=W?C31O$VI6MO=3)/&\T%O*BBWC1A\HW,,G!8\$_6O::*:K2
M2V!5&CS#6O"6N7?QBL->@L=^F1&+?/YJ#& 0?E)W?I3?C=IR'P_I^LQR"*[L
MKD*C X8AN>#Z@J#^=>HUYWK_ ,+&\2>(7OM0\17CZ>9?,6PVDB/ID*Q8A<^R
M]Z<*GO)R=K#C+5-]"7X0:'_9/@B*ZD7$^H.;AB>NSH@_(9_X%5?57^*5EJUP
M;&WTK5;!R5CC950!?<%E.>Q^8BO0[>"*UMHK>! D,2!$0=%4# 'Y5)4.I[SE
M;<7-K<\N\">!-:M?%UQXHU^*ULYW5O+M+7& S#!)VY &.V3DG/U;X&\(>(=&
M\9^(=0NK1;6&[286T[.D@+-)N4E5;.,<XXKU.BFZLG?S!S;/++F3XM0-<6TF
MF:1JL$C':[>6%4>P+*<=_F!K1^&7@6^\*B^O]4>(7M[@>1"<K&H)/;C))[<
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MZ0@\13VTU^223;IM51V!]3[@"M>BE*IS=!2E?H%%%%02%%%% !1110 4444
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M5;S4_M0LKNYLRD(U2VC ^T(03C/MCD#CD?4U_'E]9QZKX=L[]U%H;LW$^X9
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M84445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!$+EDV&8(-Y7KC/7'M4U% $4=K;Q7$T\<$2338\V14 :3 P-QZG Z9J6BB@
MHHHH **** "BBB@ HHHH \X\4_\ (QW?_ /_ $!:]'KSCQ3_ ,C'=_\  /\
MT!:]'K6?PHF.["BBBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *YCQI>W4=K8:78S&"XU.Y6W\Y>L:=6(]\8_
M.NGK(\0Z"FO6D*"YDM;FWE$UO<1=8W'?'<>U &.G@JPT*[M]5TRZN+0VN7NL
MLTOVE .0V6P#[_I69HOABT\5Z4=?\02S2W-WNDC"S%5MD!.T+CC@#OFMNS\-
MRV5W+J^KW]QK-XD1C3]R$"(?O!4!QDC\ZYL:%,EL^FV>L:RNC2$M':1V@+21
MDDL4D)R%'/!&3Q@'<,IR2W+A1G-7BBFUS>:SX-\-Z8URSS7.I%$N'&28XV;Y
MN>N./RJ]<>%K>'QS;:7I]U>P1SV+S:A(MPQ>==V!DGIDC!Q6JMM9QZGHUQ9V
M]X+73(I%M;9+;/G*PPT@8GMCH1D\8SN&;%O)#%XGO-:6*]G:Z@2*");8C,:\
MLZG/(SV(!Z8!W#*YX]R_JM7^7^OZ_7LS*T1+?PYJ7C!M/+1Z=8Q1LD;,6'F"
M,LV,\]>/QK-C\'VD'PX_M2^N+C[?%:M=02"8J(2<NJ@ XY)&3UR:LZN;:R\/
M:O;--=F;6[W?%-]E(WAV& JYY P1S@G.0#D9D.B^>(;*?4=8O-%C8/;V'V4#
MS8U[[^I5<=" 3QC[PR<\>X?5:O\ +_7]?KV8Z!;CQEJ5EI>HSS)96FFP7%W'
M&Q4SS2*#ACUQ@U>T&Q@T'Q[=Z/ILL@T]]/%RUNSEQ%)O &">F0<U'JEK]JU=
M=5T6XU'3[UHO+#16@E2XB'\05B!\OO@GY<#D999Z3IL>F:A;SQZIJ%SJ:_O;
MMHL/,@_B3^ZJ^AY/& <K1SQ[A]5K?R_U_7Z]F<^FD6T,YMO$(O\ 3=?FG)AU
MHNSQ2,6R ,$ <8X/YCI70WPBN_%VJM?CS[?2]%,<QY0,S@LQX/&5ST-4QH]S
M<Q6UE?:OJM_ID3*\%LMBJ&9%_BWYR0,=#@GC'WA5Z2R@GA\0)F_E?6FW(\=K
M@^4HQE<GD*/7!/&!\PR<\>X?5:W\O]?U^O9G/PV#^'_!6E#2;=UUO7"L;R)+
MM9D.7PI8X4X*C./UJ>S\/:U9:I876F^%Y].FCG0W$[:LLPECS\P9<C/'I^5:
M\UB+[P[::;<W&I7%W:R+-97L%H(VVKP&5<]%'8D$\8SD4[3K5DU.+4M5N]3U
MFYB!-F/L@CCV]&D5 <9 ]<$\8!RM'/'N'U6K_+_7]?KV9W5>2WFEVL.HWP\4
MQWUKJ$]PQM-:1V:%,_<'! 4#T/YBO3#]GUO2YXF23[+<H\1+#:70C!([X.3C
M\ZYC_A!;^2Q32KKQ-<S:.NT?9?LZ!BJXPOF9SC@=JI,QE%IV9%)82^)O$LFB
MZC=R3Z=I%M#]H5"8_M4SKG<V#G& 3C/'K46J:9=>#].GM]%OY$BU6[AM;2!\
MG[*[Y#%6)[@'Z<5LZCX4N)-6?4M'UB72YY8EBF"PB59%48'!/! XS36\#V+^
M'I-,:XG,\DWVE[TG]Z9O[^?Z?_KH$<_XA\,6'A32[?5M,GN4U6*XB43-*S&X
M)8 JPS@\9.!Z5<N=+'B;XAZC'/)(+"QM(K>9(WV^86._82.<>N/0"M*U\'W,
MNI6UYKNMS:J;0[K>)H5B16[,0"=Q'K6KH^BC2KO4[EKCSI+^Y,Y.S;L7&%7J
M<X]?TIA8\WBL;K7;BY>/PU+J>D6TC6ME"NI"WCB5./N]2QZDDUVG@RSUK3]%
MN[:_MF@*S,;.*>X$Q5".%+KU /XU%+X-O8;N\;2/$-SIUI>2F::W2%7PQZE&
MR"OX5T.DZ5:Z+IL5C9J1%'GECEF)Y+,>Y-($B/0=.;2-"LK"1E>2&,"1EZ,Y
MY8C\2:P?$:SZYXHLO#0N)(+(VS7EX8FVM(H;:JY],]?_ *U=?6!KOAI]4U"V
MU*QU&73M1MU,:SH@<,A_A93P10!A6^CV?ASQU8:;I32QVE_:R_:;4R,R@*/E
M;DY!)R,^Q]:9\//#VEA+C7(;39(UW,MHWF,=D.=H')Y[\GFMO3/"9L7O;VXU
M*6\U>ZB,1O94 \L8X"H#P,X.,]NU:>@Z2NA:'::8DGFBW3;OV[=Q)))QDXY-
M 6,/Q5)/J6M:5X;AN)+>&[WS7;QG:QB4?=!]SFJUSX?MO!<=WKND3R06\-J_
MFV3%I%F?'RL26XYQ_P#6K9U[PZVKW-I>VE_)I^H6A;RKA$#C:>H*G@BH+#P?
M#'%?MJEY+J5W?Q>3/<2 )\G]U5'"CO0!SK^#K)_"<NMZK=W+ZNUL;HWGGL/+
M?;N 4#C'0?RQ2P37?B^?1M&O+B6.V&FI>WVPE&G).U5)].A_'Z5HCP)=S6\6
MGW_B2[N=(B(VVGE*A*CHK.#DCC_#%4/%MSIFG>(;:0:E>:%>6]L(H[I;3S89
M8LYV #K@^HQ3 6ST:TT?XB0VUI/(NG6%C)>>2[EQ S_(<9R>1@_G67I?AJSO
M_!-_XAUEYY&F6XNH8O-*K$<DAL#JQ([Y[5I^$-%N=0MO$-\]Q<@ZDOV>WN[J
M/]XRA2"^W(X)/ [8Q72W?AH3^#!X=ANO) @2'S_+SG:1D[<CK@]^] ',8N+S
M3? NE7+&26>1;N3<<DI&FX9_ C\J9HFE:7:WGB7Q.+92;&ZG^RL9&(!1#N/7
M!R2>N?:NO'A]!XBL]4$_[JTLS;16^SH2?O;L^G&,?C61#X*NH?#^J:.-;9K>
M\;=%NME_<Y;<V<'+$].HQZ4!8Y_2K&XU"TT#PN9I(+66R;4[XQ-M>56<[5S]
M2,__ %JU;73+/PMX\T^RTF22&TO+65KFV:0LJ[1E7Y)QD@\^Q]:V-6\*?:[B
MQO--U"73;ZSB\F.9$$@,?]UE/!IEAX0-JNH7-SJ4MYJUY T)O94 \L$8&U >
M!G!QGMVH Y+1_#EGK'AK5/$6L//+'/)<W<,0E*(F,_/@8^;Y>_8"NU\%?:#X
M,THW3N\K0!MSG)*DDK_X[BD?PS_Q10\.PW9C_P!'$)N/+SG^\=N>_/&>_>MF
MTMUM+."V3[D,:QK] ,4@2.#\5W%MJWB,6#P:GJMO:(!-8V,96-7/(,D@89.,
M<8]>>HK/T*].FZ#XQ:*&XM+*W0);VLTN]H9"A##/^\5KJ+OPE>_VO=WVD:]-
MIJ7N&N(E@60,P&,J2?E-5XO 7D^'=0T9=4=H[V[%P\TD.YRN5.PG/)^7KQU/
M%,#F-3\)VND?#^#4)I+F36=L/D/YS#RF9A\J@<# )_$9KHKNRD\5^++C2-0G
M<Z9I4,1GAC8IY\SC(+8YQC-=#K>B?VT-/1IQ%%:W:7+)LW>9MSA>HP.?>L_5
M/"MS<:X^K:5K4VF7$T8CN L(D$@' X)X..](+&'X>T:&S^)5]#;S2R6FFV@2
M%'<MY)<@[03VY;\ZT_B5!!<>$7CEB\R=IXUMAN(Q(3C/'7Y2W6K_ (9\+KX<
MDU"4WLEY+>R"1Y)5PW&>IR<G))SQUJUK6BG69=-+7'EPV=VMTT?E[O-*YP,Y
M&.OO0'0YB/0[#3?&6@Z-I\&R&UBFOYAN8[G($88Y)QR*MW5Q'+\2))W.8M(T
MMI']G8Y_]!J]JWAF[O-<&K:;K4NG7!@^SRX@64,F<\;ONFJ]IX)^Q6FN11ZG
M*\VJQB-IYH][H-I!).?F)R3V_2@#D;'PQ92_#VZU[5WGEG>*6X@02LJQ$D[2
M .I)YR?45KJM]K;>'O#=S=S)"=-2]OV1MKRKPJJ3UZ]?6NEU+PV+[PBGA^.Z
M\B-8HHC+Y>253';(Z[?6FZUX9DO[ZUU#3=2DTR^MHS"LJ1B16CZ[2IX-,+&5
M=^$M/\/V6K75M.\6DO8N)M/9F968#(8,6R#VQ[U@/H%MI7P^T^V@@"7^NRVT
M,[[B2VYMX')P,#@X_&NJ7P5&VC:G:W&HS3W^I*!/?2*-W'0!<\*/3/\ 2IT\
M,7$AT,WNJ&Y.EN\C'[.$\XD83H<+M_'/M0%C&M](A\9ZWJDFJ-(^EZ=<&RMK
M1)"B;D W,V#DGD?Y%9;W1T;PYXRTRWN9);.U=8+7>=Q4R#:R ^Q./S-=+=>$
M+Q=3O+S1M>GTQ;UM]Q$L*R!F[LN2-I/K3F\$6B:';:7;W+I&EVEU<RNN][@@
MY()R,$\<\XQT- '+ZUX2AT'0=*N$FN'UQKFW@CG\YOE8_P "KG&T 8'TKU&L
MG5M$_M74-*N6N/+CL)S.8]F?,;&!SGC'T-:U( HHHH&%%%% !1110 4444 %
M%%% 'G'BG_D8[O\ X!_Z M>CUYQXI_Y&.[_X!_Z M>CUK/X43'=A11161044
M44 %%87C'^UO^$9N?[%W_;/EQY?W]N>=OOBLKX=_\)#_ &5<_P!O?:?]8/(^
MU9\S&/FSGG'3&?>K4/<YK@=E1114 %<GKVN:[#XKM-$T:/3BT]L9RUX'P""0
M>5/H/2NLKC;_ /Y*UI7_ &#G_FU ,9?:[XN\/Q?;=6T[3+JP0CSFT]G#QCUP
M_6K/BWQ7<:3X;L=5T=(+@W<Z(GFJ2"K(S# !!SP*W=<\O_A']2\W'E_99=V>
MF-AS7F%WYG_"JO"WF9W?VDN,^FZ7'Z8IB/2?#>K_ -O>'K/4BJJ\R?O%7H'!
MPP'MD&N=N/&EX/B#!H5O#;M8M)Y+RLK%RX7<P!SCC('2DT2]B\,:AXFTVX(6
MWM2=1@7/_+-ADJ/H<#ZFL.TLI+;5/!-Q<#_2[^XNKR<GNT@0C],4 ==J?B2\
M;6SH>A6D5U?(@>>69RL-N#TW8Y)Z<#UJI=^(]>\.2PS>(;2PETZ5Q&US8%QY
M)/0LK9R/I_\ 6J+P1G_A(_%WF?Z[^T.<]=F7V_I777PLC9R?VAY'V7C?]HQL
MZC&<\=<?C2 G!#*&4@@C(([UR-[K?B"?QA=:)I*Z8J06ZS[[M)"3G (^4^_I
M76QE#$ABV^7@;=O3';'M7 3C5S\4M1_L=K$3?8(]_P!L#E=N5Z;3G.<4 R[J
MNM>+?#MF=1U"VTBZLHV7SEM/,6103C(W$CO77VUQ'=VL-S$28Y461"?0C(KS
MC5I]<U76X?#'B6[M;"TNB"CV43%;G!SL#,25.<=OZ9N>-+LP:EHOAZ..]_LY
MHR\\5BA:61$&%0 <XXY_^M3 ] HKRZ,)IFLZ;<>&= UZR!G6.[AFMI!%)$>"
M3DG!'K6I::?!XQ\4ZVVL;YK/3YA;6]J'94!&<L<'D\?YXI!<[VBO/M>L[OP7
MX<O5TO49?)O+B.*VC?)-IN^]M8GO@_3C\9]6\"Z;IOA^XO=/DN(=4M86G6]$
M[;W91D[N<8.* .ZHKS6_EF\47/@=I)9(7O8KCSVB;82 B;P".F=I_ TE]X;L
M['QWIVCZ<]Q9V%_;.UW##,W[P+DXR3D9P ?;/K0%STNBN#L=/M_#GQ*M]/TL
M-!97EBTDL&\LNX$X(R>O'\ZI>%/"UAK]OJLVJB6XC34)XH8O-95CYR6 !'S$
MGK["@+GI-%>:>#O#5IXE\-M-K,MS=M'(]O;[YFQ"B]"H!ZY)Y/L*SD\0ZBWP
M[T.U\ZY+WETUM)+ "TQB5ONKW+8( ^F* N>N45Y-?0V]A#%=^%_#WB.SU.%U
M8,]K*5F&?F#Y)SD9[5MZIIBZ[\2[:"X,L=NVC+)/$KE"Z^:?D)'.-Q&?I0%S
MOJ*X.RLH/#/Q%BT[3/,BT^[L6FDMMS.H=2>0#DYX_4U7\+:!9^+]+EU[6_-N
M+RZE?RF$S+]G4' "@'C&._M^(!U/AS6+C5_[6^T)$OV/4IK2/RP1E$Q@G)//
M/_UJVZ\\\,0/:^$_$UO)JQLWBU2XC>_?DK@("W4<GZ]37/ZH/"8T*:31X=3N
M-2ACW+J,:2CYAU9F8@ =:87/2->UU](O=(M8X%D-_=+ 68_<'&3CN>:M23:J
M/$$4*6T1THVY:2<GYQ+GA0,],>WXUP7B&RM=8_X0B]O81+/?>1'<,6/SH5#$
M?FQ_.MJ6*'3_ (D:=#"FR"WT9E1%YPJL0 /P%(#M**\[\+Z!9^,-+?7=>$EW
M<74K^6IF8+ @) "@$8Z']*I27%S!X6\8Z%-<27$>F%1!)*V6V.<A2>^-M 7/
M4:*\WU'PE86W@0ZMNN#JT5JMP+SSFW!L X'. .P&*[G0[F2]\/Z;=3',LUK%
M(Y]6* G^= RKXBUF32K:WBM(TEU"\F$%M&_W=QZLV/X0.346O^(O[$2UM8H#
M>ZI=G9;VT9V[SW8Y^ZO^?4UF3,;WXM6T3?<L=,:5 ?[S-M)_)A^50S[_ /A<
M5KYWW/[-/D9]<G./?K0(N2W7CBV@^U/8Z-<JHW-:P/()<>@8\$_YYK9T'7+7
MQ!I4=_:;@I)5T;[T;CJI]ZTJ\E35IM$T[QQ=V#;/^)@(X'3&%9F8,1^']* /
M6JQ+G77A\866AK I6>W>=Y2>1C(  _"LC_A76G+81FWN+B#5U"M_:(E=G+CJ
M2,X(]JRM2\/:=<?$[3X+RW6?S[(S7#9*^9(,C=@'CH.!0!Z/7'6NO>(]?DNY
MM"M=-BL8)6A22^+EIBO4@+T'UKL:P?$?B>'1%2V@C-WJMQQ;6D?+,3T)]%H&
M5=-\8QS:#J5]J-N;6YTQFCNH%.[YATVGW/ _R:H2>(_%=II":[=:;IQTTA97
MMXW?STB./FR?E)P>F*QM?T&[T7X::I)=R^;J%[<)<7C+T!+CY1[ X_$^E=UK
MGD_\(AJ6W_4?8)<=?N^6?Z4Q%'6O$\MNNEP:/;)=WNJ#=;>82J*FW<6;'.,=
MOKZ55&OZ[H^L6%GX@MK![>_D\F*XL2XV2'H&#<\U:\)7,=GX!TVYO)5BBCM@
MS.YP%7M^F*R;8W'CCQ#9:D(G@T'39/,MRXPUS*#PV.RC_'UX0&A<:]K.H:_>
M:7H%M9A;$*+BYO2^W<1PJJO/KS[?G-H.OWUYJ=]HNJVT-OJ=HH?="2T4B'HP
MSR.HX/K6AKVOV7AZP^TWC$LQVQ0IR\K>BBLCPKI.H'4+WQ%K"^5?WP"I;CI!
M$,84^_ S]/4F@#1\/:S+J<=W;7J1Q:C8S&*XCCSM]59<]B.?SK:KC239?%O:
MGW+_ $T-(/\ :5B ?R7%;NA:!:^'K6XM[229TGN&N&,I!(9@ 0, <<"@9JT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'G'BG_D8[O\ X!_Z M>CUYQXI_Y&.[_X!_Z
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MM&ME8;6NH$D,N/4*> ?\\593P;IT?A*7P^"_DRC,DQ^^TF0=Y]\@?EBNBHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%<1PB5HL3J%;( /8GCFC4"M_9/BO_H:;7_P5#_XY1_9/BO\ Z&FU_P#!4/\
MXY72447 X?6QXLTF&S<>)+63[1>P6O\ R# -OF.%S]\YQGI_*M3^R?%?_0TV
MO_@J'_QRCQG_ ,>FD?\ 88L__1JUTE%P.;_LGQ7_ -#3:_\ @J'_ ,<H_LGQ
M7_T--K_X*A_\<KI**+@<W_9/BO\ Z&FU_P#!4/\ XY1_9/BO_H:;7_P5#_XY
M725A>)O%VE^%+>"34&E:2X;9!! F^24^P_$?F*+L"#^R?%?_ $--K_X*A_\
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M.(\0CQ9HF@W6HCQ):RF!0=G]F!<Y8#KO/KZ5I_V3XK_Z&FU_\%0_^.4>/_\
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M_P#@J'_QRM?1O^0'I_\ U[1_^@BKM%P.;_LGQ7_T--K_ ."H?_'*/[)\5_\
M0TVO_@J'_P <KI**+@<W_9/BO_H:;7_P5#_XY1_9/BO_ *&FU_\ !4/_ (Y7
M25S=WXVTFS\8VOA=A/)J%P <QJI2/() 8DY!P,\ ]11J ?V3XK_Z&FU_\%0_
M^.4?V3XK_P"AIM?_  5#_P".5TE%%P.9?2_%:1LW_"46IV@G']E#_P".5?\
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MB+;LM(<[Y,L%., G@$GIVK4HI >!:9XTUJW^)>M:Q'X/OYKRYMXTETY2_F0
M+& Q_=YP=H/*C[PKUG4]6T;1](A\4:S90VMT(%(WQ SJS+_JE) .>2,<=\XJ
MS:>%K&R\6ZAXDCEN#>7T2Q2HS+Y8"A0,#&<_(.I/>N/\?>!O$?BOQ):7=M/I
M;Z;:*OEVEY+* S9RQ8(O?@<'H*NZ;$5?A;#J.M>)=<\97=O]GM[\>5 N/O#(
MZ>H 4#/<Y]*[3QOHE_XC\)WFDZ=-!#/<;07F)"[0P)' )YQCI5?1H/&D:SP:
MF/#T%NMLR6W]G+*"DO&W(<8V@9[>E54\/^+-0\&3Z=J_B+R=9,Q>*]L?D 7
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M7?ZE(DBBXM+QVD65#U*Y4;375VFHS:1XJU^TO;B:6W^SC4;?S)"=J $.HST
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M8=*M]+D+#S;UKA)E [[4Y//O_P#7H ZJVG6ZM(;A00LJ*X![ C->=:KJR?\
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MG^*:JB[:@?*=%?9WV6W_ .>$7_? H^RV_P#SPB_[X%7[3R%8^,:*^SOLMO\
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M)_C7CGEI_<7\J/+3^XOY4: >Q_\ "<>%?^ABTS_P*3_&C_A./"O_ $,6F?\
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M_P# I/\ &KGV:"Z&/(CANXO]@?Y(_P _4^S070QY$<-W%_L#_)'^?J: 4_\
MA./"O_0Q:9_X%)_C1_PG'A7_ *&+3/\ P*3_ !JY]F@NACR(X;N+_8'^2/\
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M**D#RCXE_P#(X:?_ ->#_P#HP5RU=3\2_P#D<-/_ .O!_P#T8*Y:FP"BBBD
M4444 %%%% !5&Y_Y"]A_NR_R%7JHW/\ R%[#_=E_D*: O4444@"BBB@ HHHH
M *GAM)9I(%V[%G?8DCC"DY //MD9K8L/"USJ/AV74[<F242A$@3DD=#^/(_
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M?Y^I_P ??_3&[B_S^(_S]3_C[_Z8W<7^?Q'^?J '_'W_ -,;N+_/XC_/U/\
MC[_Z8W<7^?Q'^?J?\??_ $QNXO\ /XC_ #]3_C[_ .F-W%_G\1_GZ@$<W^E0
M2?\ +*[B4_R_4?Y^M#P)_P B%H7_ %Y1?^@BK\W^E02?\LKN)3_+]1_GZT/
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MT&<\T) ;5%4<:K_?LO\ OAO\:,:K_?LO^^&_QHL!>K<TCPIJNL;7BA\JW/\
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M_P!,;N+_ #^(_P _4_X^_P#IC=Q?Y_$?Y^O.[/&5U)_Q\:#%<1'_ )X3 _\
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M3[]$NL>+I71]VB+(O1EAES]/OT?6:/\ ,'M(]SMO^/O_ *8W<7^?Q'^?J?\
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MFDQ7WV/[5YDXAV>;LQE6.<X/]W]:YH_%98Y(9I] O(M.E;:ETS?>]<#;@_\
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M *8W<7^?Q'^?KX=;ACK6C!" W]I6V">Q\P5[C_Q]_P#3&[B_S^(_S]7T /\
MC[_Z8W<7^?Q'^?J?\??_ $QNXO\ /XC_ #]3_C[_ .F-W%_G\1_GZG_'W_TQ
MNXO\_B/\_5 '_'W_ -,;N+_/XC_/U/\ C[_Z8W<7^?Q'^?J?\??_ $QNXO\
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M^09:?]<4_P#015FJVG?\@RT_ZXI_Z"*LU\[+=G$%%%%2 4444 %%%% #9?\
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M-N;7(WF7:1G;UP6YS[UK?"ZVGMO!<1G4J)IGDC!_N' 'Z@FM ^ O"YN_M/\
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M4\[<^_/K7'ZGJD^J:I-?RG;)(> I^Z,8 'X5E_:[;_GXB_[[%'VNV_Y^(O\
MOL4@)J*A^UVW_/Q%_P!]BC[7;?\ /Q%_WV* )J*A^UVW_/Q%_P!]BC[7;?\
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MZ'%8MT54_M33_P#G^M?^_P O^-']J:?_ ,_UK_W^7_&ERR[!8MT54_M33_\
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M;N+_ #^(_P _4_X^_P#IC=Q?Y_$?Y^I<#+'AO0KI2HT73H;F/J/LJ8_ER/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^@&M"L_7O^1=U/\ Z])?_0#5P^) MR?3O^09:?\ 7%/_ $$59JMIW_(,M/\
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M-N#8!P.< =@,4 >D45YGK^M75_#X8T^<7TEO>V:75XEBA:6;Y =H YQG.?\
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M[UVRB\O4Y28//!.<&0 'T&!722^ =-CT!KA);A=76'S?MXN&+F3&<YSC&?\
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MH;JS")J7AG5HY%+37".PD]58EN0?4XH"YZ#<ZZ\/C"RT-8%*SV[SO*3R,9
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MOK^TTRSDO+ZXCM[:(9>21L 5B:/X]\+Z]?BQTW5XIKDYVQLCQEOIN S^%'R
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M>!?%4KNFS25=>JM=29_]%UZO_P ??_3&[B_S^(_S]3_C[_Z8W<7^?Q'^?J7
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MK*Q6$\]I-IMI*)8].FOF 4YS@L(LE<GH/7WKO3<^,+J3 TO18KB+O]OD!_\
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MZ'J FL=.6(VTF\K=.2!M.<#9R:H^"KB)]8UI8&W0R2"2,]/EW-V_$5TNO?\
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M77C7P]9231W&HJDD,K0NGE.6#+UX"Y('J.*RM2@MX_BMH<D:(L\EK,92HP6
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MB@#J]/U"UU6PBO;*7S;:4$H^TKG!QT(!ZBK-16]M!:0)!;0QPPI]V.-0JK]
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M0:%90W,?5?+X_P#KC_/U- .B_P"/O_IC=Q?Y_$?Y^I_Q]_\ 3&[B_P _B/\
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MO#6BV\%D8=-MT+WT$;$+U4N 1^(K5_X1+P__ - FU_[XJGCH<J=F/VJ/2?\
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MU]%8O_")>'_^@3:_]\4?\(EX?_Z!-K_WQ7F6I]W]W_!,=#:HK%_X1'P__P!
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M$8 ^'VF&)+:2_P!5EL$8%;&2Z)A&.@QC./QK<U31;/5=%DTF93':NBH!%@%
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M% !1110 4444 %%%% !1110 4444 %%%% &#XM\,IXJT=;%KEK<I*)E<)NY
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M\Y:W/^/O_IC=Q?Y_$?Y^K8!_Q]_],;N+_/XC_/U/^/O_ *8W<7^?Q'^?J?\
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M"/\ \(PR3IT=;Z/_  Z43>+M8E"/_P (PR3IT=;Z/_#I1[:G_,OO#GCW.O\
M^/O_ *8W<7^?Q'^?J?\ 'W_TQNXO\_B/\_7D)O%VL2A'_P"$89)TZ.M]'_AT
MHF\7:Q*$?_A&&2=.CK?1_P"'2CVU/^9?>'/'N=?_ ,??_3&[B_S^(_S]>/\
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M!B^+/^17OO\ =7_T(5M5B^+/^17OO]U?_0A6U6C_ (:]7^@^@4445F(****
M"BBB@ K/U[_D7=3_ .O27_T UH5GZ]_R+NI_]>DO_H!JX?$@6Y/IW_(,M/\
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M+7H]><>*?^1CN_\ @'_H"UZ/6L_A1,=V%%%%9%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'G'BG_ )&.[_X!_P"@+7H]><>*
M?^1CN_\ @'_H"UZ/6L_A1,=V%%%%9%!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'G'BG_ )&.[_X!_P"@+7H]><>*?^1CN_\
M@'_H"UZ/6L_A1,=V%%%%9%!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '&:[X>U&^UFXN8(E:)]NTEP.B@?TKLZ**IR;20D@HH
MHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img105269759_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (C!98# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC8]%% %A/ACX1CU<:FNE*)A+YZQ^8WE"3^\$SC-2ZS\.O#&O:F^HWVGDW,@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[]56ZMXML@5L@')[UTU%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 45GZU/JEMIKR:/90WEX& 6*:7RU([G=@UE>"_$EYXDL+R34+&.SN
MK2[>UDBCE\Q<KW!P* .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH) &2< 4 %%0_:K?\
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ME0![!17C_P#PF/Q<_P"A(MO^^_\ [*C_ (3'XN?]"1;?]]__ &5 'L%%>/\
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M7-HJ?/(BR,3\O<\@X[XKU>B@#RC5)3XEN?$&LZ7IMU%9+HCVGF2P&-KB4G(
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MP'_T%I/_  '?_"@#T2BO._\ A=_@/_H+2?\ @._^%'_"[_ ?_06D_P# =_\
M"@#T2BO._P#A=_@/_H+2?^ [_P"%'_"[_ ?_ $%I/_ =_P#"@#T2BO._^%W^
M _\ H+2?^ [_ .%'_"[_  '_ -!:3_P'?_"@#T2BO._^%W^ _P#H+2?^ [_X
M4?\ "[_ ?_06D_\  =_\* /1**\[_P"%W^ _^@M)_P" [_X4?\+O\!_]!:3_
M ,!W_P * /1**\[_ .%W^ _^@M)_X#O_ (4?\+O\!_\ 06D_\!W_ ,* /1**
M\[_X7?X#_P"@M)_X#O\ X4?\+O\  ?\ T%G_ / =_P#"@#T2BO._^%W^ _\
MH+2?^ [_ .%'_"[_  '_ -!:3_P'?_"@#T2BO._^%W^ _P#H+2?^ [_X4?\
M"[_ ?_06D_\  =_\* /1**\[_P"%W^ _^@M)_P" [_X4?\+O\!_]!:3_ ,!W
M_P * /1**\]3XV>!)'"C5F!/K X_I2'XW> P<?VL_P#X#O\ X4#L[7/0Z*\[
M_P"%W^ _^@L__@._^%'_  N_P'_T%I/_  '?_"@1Z)17G?\ PN_P'_T%9/\
MP'?_  I[_&KP*@4MJK_,,C]P_P#A1<:3:NCT&BO//^%V^!!_S%9/_ =_\*#\
M;O 8_P"8L_\ X#O_ (4!9GH=%>>?\+O\!X_Y"S_^ [_X4G_"[_ ?_06D_P#
M=_\ "@1Z)17G?_"[_ ?_ $%I/_ =_P#"C_A=_@/_ *"TG_@._P#A0!Z)17G?
M_"[_  '_ -!:3_P'?_"MOPS\0_#?B^]EL]&O6GFB3S'4Q,N%SCN* .IHHHH
M**** "BBB@!K\(W.W@\^E> :YXIO;%+F:Q^*<=U<)+A;)+(;F^;&T''45] ,
M<(QQG Z>M>"2>/&MKJ]OQ8^&4*9DMK/R5$X*R[2C'&?,(Y% 'N]JS-:0LQ)8
MQJ26&"3CN*\JU[3]:M?&NN76C:'IGB%+^...59Y )+-@N &!_A(YKU-;D"Q%
MU(K*OE^8RXR1QDC%> ZGKWA/6/%^M:I%XTUC1W8HG^C(P68!?3&1@\<T >S>
M"M$N/#OA#3M+NW5[B"/]YL^ZI))P/89Q6_7,?#VY-YX'TVX,UY.'5B);TYE<
M;C@FNGH **** *FI:I8Z/9M>:C=1VULI ,DAP 3TKCOA?<P7EGK]S;2K+!+K
M$[1R*<AAQR*[>XMK>[A,-S!%-$>2DB!@?P-<7\-(TBA\11Q(J1KK,X55& !Q
MT% '<UYG\3?^0C9?]<C_ #KTRO,_B;_R$;+_ *Y'^= '"4444A!6]X-_Y&JQ
M_P!_^AK!K>\&_P#(U6/^_P#T- 'M-%%%,84444 %%%% !1110 5CR>*-%BU8
M:8^H0BY*EMI<8!!VXSZY[5L5P-S\,+6Y\?)XI-[()E^?&T</GCC&,8R/6@#I
M[SQ/HUAJ,=C<ZA!'</NRK.!MP,_-Z=>*-0\3Z-I=S%;W=_#'+(0 I<?+D9!/
MH,#K7,^(?AC:>(/&%KK\UY(DL)S@*/EP/EP,8//7.:=XN^&EKXLURQU.XO)$
M>V(  4<*!VXY.<'GB@#N8Y$EC62-@R. RL#P0>].J.",PV\<1;<44+NP!G Z
MX%24 %<[KGC/3- OA:7:3F0H'^101@_C[5T5>/\ Q/C=_$T95&(^SKT'N:TI
M14I69,VTKHZO_A9^A?\ /.[_ .^!_C1_PL_0B?\ 5W?_ 'P/\:\?\B7_ )YM
M^5*L,N\?NWZ^E=/L(&/M)'TDC!T5QT8 BN7\4^(M5TO5](TO2+2UGN-0,GS7
M,A54"#/:NEM_^/6+_<'\JX?QMHT>M^,_"MO<P326@:<R-&S+M^08RPZ5Q'0:
M.E>(]87Q)'H>O6%I#/<0-/!+:3%U(7&0P/(Z]:T;;Q=H%WJ9TZ#4X'N@2 @/
MWB.H!Z$CVKC]+\.#PIXLU+38())8M6M7-C?R%G>%@#F)F/0=Q6?:2)>Z)X<\
M.6NDW4.KV-Y$TY:W*B (V7<OT(;V/.: .NT'Q]I>L6>K7DTJ6UOI]RT+.Y(!
M4' ;D=3Z5IP>+-#N=*N=3BU&(VEM_KW.1Y?^\#R*\SU&RNWT[4X(H[N-K'Q$
M;RX6&#+&%L[74$8?'7%+J=G_ &EX:\67MI-JFHM-9QP&:XMA$LI#@X50 6('
M?% 'INE^*M#UJYEM]/U&&>:)=[*#@[?[PSU'O3=/\6Z#JE^UC9:G!-< $A%/
MWL==I[X]JY/Q%HUQ<ZGI\.G6_E3R:)<P+(B[0I*KA21TJC:7$.KQ^%-*T[1[
MFVOM-E5[EGMS&+540AP6Q@[CZ=: .TM_''AJ[O8K.#5K=YY7*(H)Y8?PYZ9]
MJGOO%>A:9J*V%YJ4$5R<90G[N>FX]!GWKS>+2I$^$]DJV#K<C64E($6'_P"/
MGEO7IW]*@U.SFM=2\4:?J5QJT9U"Z:2&"ULQ*MW&P 4*Y'!'3DC% 'M ((R#
MD&J=KJ=K>7UY9PL3-9E5F!&,%AD?I45I8$>'H+!I)XL6ZQ%M_P"\7Y0.OK7)
M^'O!$^G>+-4OIM0U0P&6)H"]SD3 +SO'?!XH V?%NO:CH[Z7;:7:V\]UJ%SY
M"_:'*HORDYR/I4NDWGB)9)Y/$$&EVUI''N$EO,S$$=<[N@Q61X^TI-8U#PS:
MS0RR6YU#,OEDC:-AYR.12Z[X/M[#P7K-GHEO,\MS&&:)IF<R!3DJ-Q.,C(H
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MBZ "BBB@!\7^N3_>%?=^C_\ ($L/^O>/_P!!%?"$7^N3_>%?=^C_ /($L/\
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M-2@ MXY;R3[-)SEER0I]<?TH ^>Z*]@\=PZ5?>!+B^DDLIM1M[_RX)[&S:%
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MTGP-9Z7?6US)J&HWPL\BTBNYMZ09XR/4XXR:ZFBB@ ZT444 &!1110 4444
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M8U;>2^>5Q32C ?[-$3;6(/?C-3@A5VMR*;;0H1C-=B"10NTC.".]>Q_LX?\
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MXCO;B[D\4^(/[6NEO]%FM$TX1S%%VL%).SOOR:]7UGP)X<U_4UU'4=.66Y
M9@[*) .@< X8#WI;_P "^&]3UF#5;O3(GNX=N&R0K;?N[E'!QVS0!2U+Q=K%
MA=K;P>$-3U!/+1OM$#($8D9(&?2L_P"%5Q)=Z=KMQ+;26TDFKSLT$ART9XX.
M.]=_7$?#C[OB3_L-7']* .WKS/XF_P#(1LO^N1_G7IE>9_$W_D(V7_7(_P Z
M .$HHHI""M[P;_R-5C_O_P!#6#6]X-_Y&JQ_W_Z&@#VFBBBF,**** "BBB@
MHHHH X3X@>)=3T&YLDL)EC65&+90')!'K7&?\+%\1_\ /TG_ 'Z6MSXL_P#'
MYIO_ %S?^8KSBNVE"+@FT<\Y-2.DN/'.N7-Q;3RW"%[9R\9\L<$C'\C4_P#P
ML7Q'_P _2?\ ?I:Y2BM/9Q[$\S[G6#XB^(B0/M2?]^EKV33IGN-,M9I#EY(4
M9CCJ2 37S@OWA]:^B]'_ .0+8_\ 7O'_ .@BN>O%)*R-:;;W+M%%%<QJ%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC[OB3_L-7']*[>N(^''W?$G_ &&KC^E ';UYG\3?^0C9?]<C_.O3*\S^)O\
MR$;+_KD?YT <)1112$%;W@W_ )&JQ_W_ .AK!K>\&_\ (U6/^_\ T- 'M-%%
M%,84444 %%%% !1110!Y;\6?^/S3?^N;_P Q7G%>C_%G_C\TW_KF_P#,5YQ7
M?1^!'-/XF%%%%:D"K]X?6OHO1_\ D"V/_7O'_P"@BOG1?O#ZU]%Z/_R!;'_K
MWC_]!%<V)V1M2W9=HHHKD-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOG1?O#ZU]%Z/_P @6Q_Z]X__ $$5S8G9&U+=EVBBBN0V"BBB@ HHHH ****
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M/??P]%^HZ7[Y.[=GG-(&P!@#(.<TW/&**UL;WUT'.Y<Y/6FTY5RK'(&.QIM
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M SG-<)\+=<MKW2_$U]##<^4-3FGPT1#%2,X [GCI0!Z57F?Q-_Y"-E_UR/\
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M(Z$_6L R--G+8;'YUC1DI*_5:/U-^=<G(B+<=NWM7UK\"O\ DEUE_P!=I?\
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M)F&U5;9&O]U1P!5KPY(C:Q;[]\C;6X3C!QQ61=9-PS,V\ECS7.M:]WT7YO\
MX!@XQ>(YET7YO_@$% !(.!P.M/\ +R 5Y]O2K5O',T<T,:@LX'&.OTK>4K(Z
M53;W*-%*RLO48H )( ZU1 OS(<'(!ZBFGKQ2L23\QR124 [=!>.*.AHXQ[TE
M A<<\5[-^SA_R.&I_P#7G_[,*\:&<_+WKVC]G,!/%VJ*<%OL8_\ 0A2N.Q]*
MT444Q!1110 4444 <OX^U&32_#$EQ#H']MS>8JI:>7O&3_$1@\"O$M+B%YJZ
MZOXL\%:S>7*M^YL[2Q$5M",\<#EOQKZ5HH C@(:WB94,8* A",;>.E2444 %
M%%% 'EOC#X=:EJGB'5+W3K?3;B/5K>."26[SOM&7^-/6H=4^'.OM)J>EV-S:
M/I&L-;O=SS,?-B,8 ;:.^[%>L44 <]?>!?#.IW(NK_1[:YN-JH99%)8A1@5B
M?"ZV@LK+7[6VC6*"+5YUCC7HHXX%=Y7$?#C[OB3_ +#5Q_2@#MZ\T^)I_P")
MA9#_ *9'^=>EUYG\3?\ D(V7_7(_SH X7)QC-)DXZT44A"Y([UO>#"?^$JLO
M]_\ H:P*WO!O_(U6/^__ $- 'M-,F_U$G^Z?Y4^F3?ZB3_=/\J92W/CF[_X_
M)O\ ?/\ .H:FN_\ C\F_WS_.H:\<_1EL%%%% 'T+\$C_ ,47-_U]-_(5Z57F
MOP2_Y$N;_KZ;^0KTJO4H_P -'PN8_P"]5/4\M^+)/VS3?^N;_P Q7G&:]'^+
M/_'YIO\ US?^8KSBO3H_ CR9_$PS1FBBM2!5/S#ZU]%Z1_R!;'_KWC_]!%?.
MB_>'UKZ+T?\ Y MC_P!>\?\ Z"*YL3LC:ENR[1117(;!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?&
MGQ9_Y*AKW_7Q_05Q==I\6?\ DJ&O?]?']!7%CJ* .HN+^[M(;=+&U!A,8(;9
MG)[UE:E?WUW"B74010V0=F.:U7FUZ"!&B\J6+:,&-0<5C7^J7MZBQ76,*<@;
M<'-<-"'O)I)^=]3ZC-*[5-PE.:NE:+BE'\]BG%_KD_WA7W?H_P#R!+#_ *]X
M_P#T$5\(1?ZY/]X5]WZ/_P @2P_Z]X__ $$5W'RY\Y_M$G;XWTYO2S!_\>->
M.L^]P7Z9YKV7]HD9\86/_7D.?^!&O&#E\G'2IW9IJDD:$EU&EN4C/WACBLVB
MBB,%'8NO7E6:<N@4H!/2DJ0$ <<9Z4V915R.K%K<"W9]T>\,N/I[U7HH:35F
M.G-TY*4=S2M[Y)9%AU/S)8>@8?>3W%/OM,D@'F1OYEJ>4DQU'^-9[MRK[]SX
MYR.E;.E:IC3;C3+H*8[IAY<K_P#+%O4>U<]12A[T/FO\BDHPDV[V[?U^1DRB
M&(J8SOSZ]JKGDUHZII]YI>VUN[<*?O))V=3Z'TK.K:G)2CS)W)G4A.SA:WD2
M$JP4* "!R?6D)505 !_VJ$\L(V[.[^&F>U40WS/4**4G)S0%9CA023V I@Q*
M<5(4$]#TJ_;:!JUVX2'3[AB?]@C^==7IO@-DM#<^(+B.PA!X4D;FKEK8RC27
MO2^6[^XY*V-H4?BDO3=_<</%!+.X2*-G8]E&:]2\!>$3:-]HU.(/))@I#C(0
M>I/K[57DU3PCH-ND%M*USQED@'WC[MUK8N_&D-MX+34=/A\AIG\J-#SM/<UX
M^.Q6)Q$%3I0:4G:[T/&QV+Q6(C&G1@XJ3M?;_AAWC_X@SZ6/[*T@JD@&))!_
M![#WKA/#.J>5XJLKRYP#+)EY#W8]ZI:LJ78^WH68LX\[=U)]:P_-990RL?E.
M5]JZ\'E]&GAG2BM6M7U/=CED</1<):RDK-_UT['UA!,)8RRL,C'6DO[OS;?R
MR1QU)KSGPMXLD;PI=WS!I9K.++*1U]*X6[^(VL75E=0O* 9FRH48V#VKY6CD
M=>K5E%6]UV/GJ&$Q56,J4O=Z/S-'Q=X O8+]KRT(EM[EBP., >M< Z""=D;Y
MBI(-7XO$>K1JB&_G:)3Q&S9'O4D\%MJ*FYC9+9@,N&/!/M7V6&C6HQ4*\KKN
MOU/HZ<YTJ:C4UMU_S7ZF02">!@>E;9U:9=.MXK5F CXDQWK(E\L$+'SCJWK2
M1R;!@@GG/6NJ<%-*ZV.F,N5VZ!.Q:=V8$$G)S4T4222IC+#'(STJ$MYLQ=NY
MR<FK19(MIBR)'!# C@#_ !IRT5D:QBG)R>JN-O93/*O\*+\H7T%577:Y .14
MDBLH#$YSQ41ZTX*RLC*IN[GKWP2O--\G7--U-HC!-&':.7HRCK7GGBR+1D\1
M7/\ 8$K/8,V4##[OJ/I6*DCQDE'921@X.*;7%2P/L\74Q*D_>MITTZF=Y;-Z
M#L $[\CCBOK3X%?\DNLO^NTO_H5?)1))R:^M?@5_R2ZR_P"NTO\ Z%7H#;['
M*?M*_P#('T+_ *^)/_017SI7T7^TK_R!]"_Z^)/_ $$5\Z4"'(5&[=Z<4@!8
M@#K00,#!Y[U-:VLEU(5C'3DDTFTE=FD(2J24(J[(2"#@TE2SP/;OM>HJ$[JZ
M)G%PDXR5F%%%%,D**7:=N['%)0%K!1110 H&X@#O3VMY5.&0@TSM[U,;N4@!
MCG P*EWZ&L%3L^>Y!1115&1H:1*J7?EL!B0;<GL:[C3_  E/=*;AK4R!Q^[=
M.0*\WKZ7^#&BW^G>$3/J (6Y?? C]53U_&O!SW%/!T/;1>KTMW+474M%'EWB
M_P (S:-X>BN;OS-V?D#>]<'8:?<:C.8K=,[1N9CP%'J37UCXW\*0>*="DMI
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M4/8QG>4NFQH#5[<A1)I=NVTY!!(K>T+Q)I>G7CW2:!%++&NX-NSM/T-<:6)
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MX=2:.)MT:R84^HS7W1H__($L/^O>/_T$5\(1?ZY/]X5]WZ/_ ,@2P_Z]X_\
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MTGF/C&XXK14*K24JC^22_0KV$KOFJNWDDOT.Z34?!T"%;?0Y[ICSOG?%4/\
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M&G1C+]YU\B.5A&Y4 8%=_P##N]:ZTO5-&<C$L3/&#W;'2O.I',DC,>YS76^
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M6NHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /C3XL_\ )4->_P"OC^@KBZ[3XL_\
ME0U[_KX_H*XN@#H+/4+N_MVM(88O.\O:92<';67=WSSV\%ML")",<=SZU=L[
M;4],E\Z.U\S>F..1@U1NM/NK:(3SQ&-7; SUKEIJFIZ6MT]3W<5/%RPRYU*]
MFI76G+=-=.^_<KQ?ZY/]X5]WZ/\ \@2P_P"O>/\ ]!%?"$7^N3_>%?=^C_\
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M?8L?^/"G<7*FKKH?2E%%%,@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M24WH=#A*C%IK^NA?\.W'V?7+<D\2'RS]&XJE>P?9K^> _P #E?UJ.-WAE24
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M >*]Q_9J_P"0MKO_ %PC_P#0C7B+1RO!YIY1#LSFO;OV:O\ D+:[_P!<(_\
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M1- &G>(([+57,IF8BT6) W;"CT]30!S=SXHM7^),USIUM:7*C09+N&]5V)<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/LWJ^K[?(JT44\.H7!7)KT3XQ*^XRBE W$"D(P<4P\R3SI%78KL%] :1I9&
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M?XFB[O=&LQ-#;6[7[(^(KF8X&/7%<;?[QQLV_P"NIW5L7[&E&='WKZ-+H_\
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M\$ -C\:]H_9U*_\ "8ZGM.1]B'_H0KM5SYF;C)-VL?2M%%%48A1110 4444
M%%%% !1110 4444 %%%% #/)C  \M, Y VC@^M*$4,6"@,>IQR:=10 UD5QA
MU##K@C- 15SA0,]<#K3J* ()[2*>SFM2NR.5&1M@QP1@UG>&O#=EX6T.VTFR
M,CPVX8(\I!?DY/./>MBB@!IC1F+%%)(P21V]*011J00B@@8! [>E/HH 9Y,6
MT+Y:;0<@;1C-!BC.[,:G=][CK]:?10 WRTRIV+E>AQTH\M-^_8N_INQS3J*
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M[RXGN"^)%EZ!<?2N.AF-.M/DC&6]MM%ZF%/%1J2Y4G]QS$7^N3_>%?=^C_\
M($L/^O>/_P!!%?"$7^N3_>%?=^C_ /($L/\ KWC_ /017H'2?./[1O\ R.FG
M_P#7D/\ T(UXW7LO[1AQXTT_C.;+_P!F->-4 +CN.E)WI<X7 )]Z0=>:!L!3
MMW&#R/2FTK*5QFD"NM@ R:D,1V# R3357GYN@JTP!B8JXV@?K4RE8VI4U).Y
M/J]A+I0M[65@6:,2G;T&ZJT,YAC*KU(SUJ"2>29@TKL[ 8!8YP*:G)/TJ8P?
M):>K,\/.=.SZ^1HZ5"+_ %)%G.(OXV)^ZO<TNMZI_:%RD47RV=L/+MT]%]?J
M:T)I;+3?"D5O'&W]J73$ROV6+L![FN;K.DE4FZC6BT7^9C)JK-3>MMO5[O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&U0OR+VI._0TIJ.\G8@"D]!FDJ92N\$Y4$]:21EW,JXQGK1?43@K7N15];?
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MG;C@?8Q_Z$:\=)";E4@@]\4B]6M6,HI0"Q %3/;%(P^:&T@C3E)-I;"K'$J
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M=*^L_@<,?#&S! '[Z7I_O4+30)VDN9')?M*_\@?0O^OB3_T$5\Z5]%_M*_\
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MI7\+:]O.S0]3V]O]$?\ PK[GHH'?2Q\+'POX@[:'J?\ X"/_ (4?\(OX@_Z
M>I?^ C_X5]TT4"/A<^%O$ _Y@>I?^ K_ .%)_P (OX@_Z >I?^ C_P"%?=-%
M 'PM_P (OX@_Z >I?^ C_P"%'_"+^(/^@'J7_@(_^%?=-% 'PR_AGQ$Y!.AZ
ME_X"O_A36\+:_GC0]3_\!'_PK[HHHL-N^Y\+?\(OX@_Z >I?^ C_ .%'_"+^
M(/\ H!ZE_P" C_X5]TT4"/A;_A%_$'_0#U+_ ,!'_P */^$7\0?] /4O_ 1_
M\*^Z:* /A;_A%_$'_0#U+_P$?_"C_A%_$'_0#U+_ ,!'_P *^Z:* /A;_A%_
M$'_0#U+_ ,!'_P */^$7\0?] /4O_ 1_\*^Z:* /A;_A%_$'_0#U+_P$?_"C
M_A%_$'_0#U+_ ,!'_P *^Z:* /A;_A%_$&/^0%J7_@(_^%.7PQKP5LZ%J1)Z
M?Z(_^%?<]% T[:GPM_PB_B#_ * >I?\ @(_^%'_"+^(/^@'J7_@(_P#A7W31
M0(^&1X9U_9C^P]2_\!'_ ,*9_P (OX@'_,#U+_P$?_"ONFB@;;9\+_\ "+Z^
M1_R M2_\!7_PI/\ A%_$'_0#U+_P$?\ PK[IHH$?"W_"+^(,?\@+4O\ P%?_
M  H_X1?Q!_T ]2_\!'_PK[IHH ^%O^$7\0?] /4O_ 1_\*]O_9WT+5--NM:N
MKZPN+6)T2-?/C*%CDG@$5[U10!Q7Q5\-ZAXK\"76F:6J/=-(DBJ[8#!3R,U\
M]_\ "CO'7_0.A_[_ *U]<T4 ?(X^!OCKOIT7_?\ 6@? WQUWTZ'_ +_K7UQ1
M0!\D#X'>.2#NTZ('MB=:;_PH[QU_T#H?^_ZU]<T4 ?(W_"CO'7_0.A_[_K4D
M7P0\;H^9-*A<>GVA17UK12:N.,G%W1\H7GP1\8.Z-:Z6B<?,K3KUIUM\%?&@
M.+C38R/]F9:^K:*GD5K&_P!9DJGM$EZ6T^X^3;GX'^,V<F'38P/0SK4'_"CO
M'7_0.A_[_K7US15)65C*<^>7-:Q\D-\$/'CG+:?$3[SK0/@?XZ# _P!FQ<?]
M-UKZWHIDW=[GS#%\*?&\,:@:5$Q QS,M4/\ A3GCM;QKA=,A).<!IUP*^K:*
MRC1A&]EN=M7,<1445*6VQ\GW'P4\<RE3]@B;'8S+37^"?C:61 =*@C08#;9U
MS7UE15J*1Q\VMSY+D^!_C57?R=.CVY^7=.N<4UO@AXYVJ%TV+/<^>O-?6U%.
MP.5VSY/N?@MXWF$8CTB"(*N#BX7YCZU6_P"%'>.O^@=#_P!_UKZYHH225D.I
M-U)<TMSY*@^"7CN&99!IT65.?]>M:<OPA\9R(?\ B51[SSGSUX-?45%3*G&3
MNS>ABZM&+C#9GR1_PI'QX&)&G0\G/^O6G#X(^.6!+Z;$6QQ^_6OK6BJL<ZFS
MY('P0\>*P8:?$&'(/GKQ0?@AX[=R[Z?&23DGSUYKZWHHL3UN?+%M\(O'ED3]
MGTU!E<'-RO6HY_A-\2;C[]K&!Z"=17U714>RA>]M3L>/Q/)[-3:CV6B/DAO@
MAX[9MS:=$3W_ 'ZU*/@KXZ6-4738L!MW_'PO-?65%6TF<G,SY'/P.\=$D_V;
M#S_TW6D_X4=XZ_Z!T/\ W_6OKFBF(^1O^%'>.O\ H'0_]_UKTKX+_#SQ'X/\
M1WUWK%HD,,MMY:,L@;+;@>U>WT4 %%%% !1110 4444 %<YX[U%M*\'7]XL%
MK</&%VQ7:YC8E@ &_.NCKGO'-]'IW@[4;B6Q@OD"!3:SMA9=Q VY_&@#SAM<
M\2>&]63.A^$TF^QO>?Z(2K-&N-ZAAT./P->EZKK.GKX3:^O;R*P@NK;*R3-@
M*63('N>:\C6%_#<TUI<?#O3X5NK,SS*-0+N\"$%E4GT]*]=U.WTK6/![FZT^
M.ZL&M?.6W=1T"Y 'H: //O"NM:C8R:+9-\0-%U"TED6*.!(,SR*>BYSD'W->
MNUX]X,M;L7NE7=KX7\(VEJV-LL=P&ND0_ARU>P]!0 45Q.D?$%-7\4:QIJ6$
ML-GIUKYZSS*5:7!() /\/'!K,TOXF33^&;_7[Q=/,%O!YJVEO(QG!+;5# \
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR9_$S]!PW\&'HOR"BBBI-CWSX&?\BS?_ /7R/_0:]3KRSX&?\BS?_P#7R/\
MT&O4Z].A_#1\/F?^]S]3Q#XA_P#(Y7?^ZG_H(KE:ZKXA_P#(Y7?^ZG_H(KE:
M]:G\*/&ENPHHHJR3;\(_\C;IG_7<5[]7@/A'_D;=,_Z[BO?JX\1\2-Z6P444
M5SFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ@=?7BLSQ;X#\0ZKX2T[3[+4$CNK4 2O'(^9OF!_B/\ P+GOTKTYV*(S!2Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU<>(^)&]+8****YS4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_"EO#G_/[J__ (&-7HL<4<,2Q1(J1H,*JC  ] *=0!P:_"O3D0(NN^(551@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img105269759_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1L\CJB*,EF. !3JS/$$]M;:)<37>GRZA$@!^RQ0^:TAR, +WYQ["@"VU_9K
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M:WBD1FW%70$$^N#WI7MH))HYG@C:6+/ENR LF>N#VJ6B@")+:!)WG2&-9I
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MMV\0L9;2V$4S^6C!Y A(+-@DD_7-4+YOM'B( <QVVTGWD/3\A_.NDH ****
M"BJ-_J]GIS+'-(6G?[D$2[Y'^BCG^E4O+UC5?]:YTNU/\$9#3L/=NB?AD^]-
M1%<N7^LV>GNL4CM)<M]RWA7?(W_ 1_,X%9&IQ:UJFF3F:[CT:V9<84>;)@_W
MCT'T'YUMV&F6>FQE;6$(6Y=SR[GU9CR?QJW332V"U]SC/#.GZMINBQ?8-4BO
MXE_Y=9XR@48SM5NH/U!%;UKKMO+.+6[22QNSTAN!C=_NMT;\#6K4-U:6][ T
M%U#'-$W5'7(IN5WJ)*VQ-16)_9FH:9SI5WYL(_Y=+MBRCV5_O+^.14UMKUN\
MZVU[')87;<"*XP Y_P!ENC?@<^U+E[#OW-6BBBI&%%%% !1110 4444 %%%%
M !1110 4R7:(7+,57:<L.H'K3Z1L[&QP<<4 >5?#K2H--URTF&I+-#?V4MSI
M\<5H8C)&3$&>4[CE_E0X[DL>^*]6KRWX8SV9UJ]@BL-"2]6(_:+JPN79I</U
M5&0*$)SG8=NZO4J "BBB@ K,US_CR@_Z^[?_ -&K6G69KG_'E!_U]V__ *-6
M@#3HHHH **** .5U+7["U\2I;FVEEN%&W*D8+G&WJ?\ .:L:BZI&)-8D\R1_
M]1I\ +9/TZN?<\"N"\2VEW-\17M(;Y86N)HGC8 GR^!WQUXZ?3UKO!X2M(3-
M=27VHS7+IB25KEE+8'3Y<8'L.*$^Z-I4HQ2;EN1:=IL^JESJ9,=L,$64;?*W
M_71A][_=''UKHS);VR!"\42*,!<A0!7-Z;X=TR<R>=#++C'W[B0_^S5JIX;T
M6,Y&EVI/JT88_K0VV2HTUU?W?\$FDUK2HO\ 6:E9K]9U_P :R-:\::9I^DW-
MS9W4%U<1IF.-22&/N16W'IEA#_JK&V3_ '8E']*+[3[74=/FL;F(-;S+M=!Q
MD?A2U*@Z2DFTVCD/"OC^76XKDW>G2^9$RA19PO(""._I70?VW=/_ *G0M1;_
M 'PB?S:I-$\.Z;X>CFCTZ QB9@SY<L3CIUK5I).VI=:I1<VZ<=#'^W:Y)GR]
M%BC]#->#^2J:3_BI).VE0C_MI(1_Z#6S13L9>T72*_KU9BOI^NRQL'UJ%,@C
M$5F!^K,:X+P;X%U>QUV6:^$UI!Y3+YD$H5F)(XR.U>KT4G%,VIXNI",HJVOD
M8_\ PC&EO_KXYKD^MQ</)^A.*M6^BZ7:D&#3K6,CNL*Y_/%7J*=D8.K-Z-L0
M *,  #T%+113("BBB@ HHHH **** "BBB@ HHHH **** (+Z6XAL+B6U@$]P
MD3-%"6V^8P'"Y[9/&:\>T8_VUXB2<:+XJTT?VJ[7,0M8WA9O,23YG."@#C)Q
MGCC.*]HKSF3XA:@OB=[<0Z9_9Z:J-*-JTS?;F8D#S0O39SG']T9S0!Z-110>
MG% !17$V>M>(-3O#I@FLK2[$]UNF6(R*J1% J@$C)/F#)XZ< 9J!?%NK7^F7
M&J6IMK>+3K.*XN('C+>>S E@&S\HPO!P<D\]* .]K&\/_?U?_L(R?R6KEYJ2
M64<3M;7<PDZ""!I"/KCI6=X7G%S'JDRQRQAM0D.V5"C#A>H/2@#>HHHH ***
M* "H+RZ2RLY;AQD1KG [GL/Q/%3UF7?^FZK!9CF*#%Q-[G^!?SR?P% &=%;O
M;/&LQS.Y$DI]78Y/^'X5J3BY_M6!4NV2%U9C&$4_=QWQGG-5K[_D)#ZK6%K>
MJZI<^,+:PTV.X6TA!BN;B&,,5+8)QGT&WZ9JHJ[$W8ZF_P!6L]-"BXE_>O\
MZN% 6D<_[*CDU1QK.JG_ *!5H?HUPX_]!3]3]*NV&D6>G%G@C)F?[\\A+R/]
M6/-7J+I;!8I6&E6>FAOLT.)'_P!9*Q+.Y_VF/)J[114MW&%%%% !1110 5%<
MVL%Y T%S#'-$W5'4$&I:* ,3^R[[3?FTB[W0C_ESNV+)]%?[R_J*EM]>@,ZV
MU_$]A=-P(Y\;7/\ LO\ =;^?M6M5:_%D;.0:AY'V;'S^?C;^.:J]]Q)/H9EP
M^ECQ- LC0_:BAX)^;=E=OXXK<KQ>?Q1=V?C86NDW_EZ>)1;P[R9$5&*Y(W>_
M\J]1%AK0'&N(?]ZS7^AI)J74Z*^'G147);FO6?JJRF.%HKF6$F5$/EXY#, >
MH-0?8]='_,7MC];/_P"SK!\32^*K..T%KY5[F=7;RH-F,$8!)8]3Q51C=[G,
MWH=HHVH%+%L#&3U-+3(9&E@CD:-HV902C=5/H:?4%!1110 4444 %9'B768]
M!T22^FA$T?FQ0LI?:,22*F2?;=G\*UZK7^GV>J64EG?VT5S;28#Q3(&5L'/(
M/O0!POP]T[39)1?0ZK/=?81/86-I++&WV:!9=IQL +9V+@MVQ]:]#K(TOPMH
M&BW+7.EZ-8V<[)L,D$"HQ7TR!TX%:] %'4M8L-(6$WUQY7G,4C 1F+D#) "@
MGH":AD\1:3%<V]O)>*DMPJM&K*PX;A=W'RY/ SC)JMXETU[U+2:*RFNI;>1B
MH@O3;.NY2I(88SUZ9']*P!X=U\64]C<+#=/J4=N+B\,O,+)@-D8R_ &".^<X
MH ZRWUS3+K4I-/@NT>ZCW!D /)7A@#C!(SR 3CO3-<_X\H/^ONW_ /1JUB:;
MHFIPZAIUO/!$EIIEQ/.MT) 3/YF\*-O4'YR6SW'&<\7-6TF* 07(N;UF^VP-
ML>Z=DYE7^$G&/:@#HJ*** "BBB@"I)IT$EZEVQE\U.!B0A<<=NG85//_ ,>\
MG^Z?Y5)4<_\ Q[R?[I_E0!GZ1UE^@K4K+TCK+]!6I0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UPQ1@A ;'!(R
M:\\T[PAXP?7!J6JZMHGFK>;S<V^FC[0T (_=B0GY5(R,<D ]37HM>37=KJTG
MBF]O]"UFW\.VO]HM:2M)=-=K>7)Z PGY(R21T.: /6:*J:8U\VEVK:FD*7QB
M7[0L))0/CG:3VS5N@#'N?#&EW0;=#)&YF>;S(9GC?<X ?YE(." ,CIQ23^%M
M'N'@+6I5(8TB$<<C(CHARBNH.& /(!S6S10 5C>'_OZO_P!A&3^2ULUC>'_O
MZO\ ]A&3^2T ;-%%% !1110 R:5((7FD;:B*68^@%4M(B<6SW4PQ/=-YK@_P
M@_=7\!BF:G_I=Q;Z:/NR'S9_^N:GI^)P/SK3Z#VH YS7KI[2?="H>YD98X$/
M\3GI^ ZGV%-MHQI5]:V@N[0R#)D\PMYDKN06;TZCBJT<G]J:VVI_\NZ'RK0>
MHSAI/Q(P/8>]<WXC\=:IIOC9K&W2W>&"18U&PEB&"DCKUIRER*QMAL/*O)I=
M$>I45B_\)) O^NT_5(?]^S<_JN:4>*]%!Q)>&(^DT3I_Z$!4W0O8U/Y6;-%9
MT6OZ/-_J]4LS[>>O^-78[B"49CFC<?[+ T[D.$ENB2BBHKFX2TMVFDR57L.I
MH$E?1$M%4+?6+*>P-Z9A#;CJ\Q"#]:I_V_)>_+H]A->#_GN_[J'_ +Z/+?\
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MUQN9%_DU8GBOPE+=^'YX;*^OY'RI$4T[2(0".V":[2BDXHTAB*D9*5[V.!\
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M_P#$T?\ "1:?_P!/?_@'-_\ $UJT4 8\7B?2YXEEB>YDC<95EM)2"/;Y:?\
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MI9F"J!DDG  JABS2^.J&\B"2PK"I+C:0&)R#WZ_I0!'_ &M<_P#0$U#\XO\
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MH(!ZC- '#:)'=Q:MX<=]4FNHY;.Z#(DQDA&&4J,_Q$9V[C_=^M=S0 !T&**
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MFL+V(RVTXVR(&*[AZ9!!J>&&*W@C@AC6.*-0B(HP%4#  'I0 ^BBB@ HHHH
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M(U*RBLFMQ;V:S)-);VH6))RARJN .5R <>PK<H **** "BBB@ HHHH ****
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M(ZF0+SN4'.T9Z#/8<=:TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,>E. "@ # ' H&84EO?L-*ENI)S/'=?O%5AM((;EMH /:LQSY3ZM-:I<1((
MXWJZE9U;(R6)#$GN.,8'<5V-->-)0 ZA@"& ([CD&@!5R5!(P<<BEHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img105269759_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &$ G # 2(  A$! Q$!_\0
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M/^UY-PO8I6DW;$S@JP&.E,UJYGO]7\4RW'BB[T@Z(B&TA@F$: &(/YLBD?O
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M^/=$L;?Q1?:I;76GSW,T5Q<B7+?)B3CHIR<#H.<5Z-0 4444 %%%% !1110
M4444 %%%% !17DWQ6M]=;5[:X@L]9O-.CMT-O'IA)5+D2@LTJCD@IP.V:ZWX
M?IJ@T>]GU&"]MH[B^EFL[>^?=-%"Q!"MZ?-N('8$4 =91110!5U&UEO;"6VA
MO)K.1QA;B$*73GJ-P(_,5R.L>!YM0OM4:":&)+[1OL33%<.\^\MO< #.1C)K
MN** .1TCPQJ$FDZJFJW36-WJ=X+ESI4[(8<*B@*Y /.SGCN16+>>'%T/QYX.
ME&L:Q?>9=7"[;^[,RK_HTAR 1P?>O2*Y'Q1_R.W@G_K]N?\ TEDH ZZBBB@
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MZE$HQY;MD$C(.5'>NIIM6$@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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MW2__ .OV7^E:=8VE0W :\VW( %V^1Y8YZ9K9H4^?6UBZD;2W"BBBF9A1110
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M[!>FNC9R7_"7:S=?\@_P;JCCLUV\=N/U)/Z4?:/'UYD)8Z)IZGO-,\S#_OD
M5UU%'M8K:*_'_,/:);11R/\ PC_BR['^F^+S"IZI8V2)C_@39-'_  KZRGYU
M+6-;U ]Q-?,JG\%Q7744>WGTT]$D'M9]-#G+7P%X5LV#1:':,PYW2IYA_-LU
MQGC+X52:UKD^I65S!:V_E*!"L0 7:N.QKU:HKK_CTF_ZYM_*I^LUH7E&3O\
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M5Q! U^9YA/)%-;,I^](N?G5R.@ X]:]$J))+8I.X5'/_ ,>\O^X?Y5)4<_\
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M^YP/XL<\5(GB.^CFOHI]*=_L.//>$G'*[LKN W<>F?3K7245I]7:^";7SO\
MG<R]O?XHI_*WY6,2/Q18M'')/#=VRR ,IE@8 @C/44]?%.CO#>2K=96T!:0!
M#E@%W?(,9;CTSSQ6Q52?3+&Z_P!?9P/[E!FCEQ$=I)^JM^*?Z!S4'NFOG?\
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M/91P>6WV:0[LJ>>.,5ZE7(^*/^1V\$_]?MS_ .DLE '74444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
MD#K14<L$4X EC5P.1N%)WMH-6OJ0V1'^D<C_ %[5:JLMA:*<K;Q@YSPO>K-3
M34DK,J;3=T%%%%60%%%% !1110 57C_Y"$__ %S3^;58JO'_ ,A"?_KFG\VJ
M);Q]?T9<=G_75%BBBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK6HG2-#OM26!
MK@VL#S")6"E]H)QD].E7JJZEIUKJVFW.GWL?F6US&8Y4R1E3UY'2@#E=%^(=
ME<>#[CQ%K7E:?:6]QY#RQLTJ-RH!&%#=6QR.H/:L.3QUX;\7>/O"%OH>IK=R
MP75Q)(HB=-JFVD&?F4=Z[O1/#MAH-E+;6HED$TIFEDN)#*\CX RQ/7@ ?A6'
MXEBCC\;>"2D:*3>W.=J@?\NLE '8T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 -DC$B%"6 /=6(/YBJPT^$,6#3;B "?.;G'X^]6Z*F4(RU:*4Y1T
M3$5=JA1G &.3FEHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,C.,\T5YWXB\/:J
MWB#Q'<:6MXSWVA&-)6E)7S?,/[M"3A?EZ8QUS0!Z&"&&001ZBN2\4?\ ([>"
M?^OVY_\ 262LWPYI.M1^%M6AT-)- ,]]YFGQ7\7F&"+:@8%"3C+!R.>^:YW7
M='^($?BCPNESXJTZ2YDNIQ:R+IX B80.6)'?*Y'U.: /8J*\^_L+XG?]#GI?
M_@K'^-']A?$[_H<]+_\ !6/\: /0:*\JU9/B7I5[I%L_B[3)#J5W]E4C30-A
M\MWR?7[F/QK4_L+XG?\ 0YZ7_P""L?XT >@T5Y]_87Q._P"ASTO_ ,%8_P :
MPO%%Q\2O#%MI\TOBO39Q>W\-B NG*NTR$@,?88Z4 >O45Y]_87Q._P"ASTO_
M ,%8_P :/["^)W_0YZ7_ ."L?XT >@T5Y#XKN/B5X5TN&^E\5Z;.LMU%;!5T
MY5(+MC/X5N_V%\3O^ASTO_P5C_&@#T&BO/O["^)W_0YZ7_X*Q_C65XE7XE^&
M_#UYJ\GBW39DME#&-=-4%LL!U_&@#U:BO/O["^)W_0YZ7_X*Q_C1_87Q._Z'
M/2__  5C_&@#T&BO+/$,7Q+\/^'=0U>3Q=IDR6<#3&-=- +!1G&:L:9I_P 3
M=3TFSOU\8:8BW4"3!#I@)4,H..OO0!Z717GW]A?$[_H<]+_\%8_QJCK=K\3-
M%T'4-5?Q?IDB6=M)<%!IH!8(I;&??% 'I]%>7Z):_$S6]!T_54\7Z9$E[;1W
M C.F@E0ZAL9]LU?_ +"^)W_0YZ7_ ."L?XT >@T5YIJ>G_$W3=*O+]O&&F.M
MM \Q0:8 6"J3CK[56\.Q?$OQ#X=T_6(_%VF0I>0+,(VTT$KD9QF@#U2BO/O[
M"^)W_0YZ7_X*Q_C1_87Q._Z'/2__  5C_&@#T&BO*?#2_$OQ)X>M-7C\6Z;"
MERI81MIJDKAB.OX5J_V%\3O^ASTO_P %8_QH ]!HKS[^POB=_P!#GI?_ (*Q
M_C6%X4N/B5XJTN>^B\5Z; L-U+;%6TY6R4;&?QH ]>HKS[^POB=_T.>E_P#@
MK'^-']A?$[_H<]+_ /!6/\: /0:*\A\+W'Q*\3V^HS1>*]-@%EJ$UB0VG*=Y
MC(!8>QSTK=_L+XG?]#GI?_@K'^- 'H-%>??V%\3O^ASTO_P5C_&LO2D^)>JW
MVKVJ>+M,0Z;="V9CIH.\^6CY'I]_'X4 >JT5Y]_87Q._Z'/2_P#P5C_&C^PO
MB=_T.>E_^"L?XT >@T5Y#IES\2=2\6ZYH"^*]-2325@9I3IRD2>:I88';&*W
M?["^)W_0YZ7_ ."L?XT >@T5Y]_87Q._Z'/2_P#P5C_&CP9JWB;_ (3C7/#W
MB'4[:_\ L5M!-')!;"(9?)[4 >@T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5DZA;Z1<Z]I+7=S$NHVK236<)F"LV4*,0N<L-K'Z5K5Y[K7A;5+OXA1:A
M%I\$]K)/9SB^:50UJL!?>@4_,=^X8QQR<T >A4444 9&K0Z1<:CI/]HW445U
M!<F:RC>8(SR;&4X!/S<.>*UZX/QCHUYJ/BO2I8/#1O;5/+:YODGB610DF]$4
M.V54-\S%1DC %=Y0 5C>(](TG5[6R76)!'%;7L5Q"QE\L><IP@SWR3C'>MFO
M/OB-X8\2^(+S3)M)ELI+6SGAF%M.64B42J3)D$ @*,8/."V.2* /0:*09P,X
MSWQ2T 8?BG3M$U73[>UUVXCA@^U1O%OG$6Z53E0"3R<]N];E>??$CPUK>M7>
MFW6CPQW)@CFB,,@B*!G*%682 @I\I#;?FQTKOXPPC4/C=@9QTS0 ZLCQ/;Z/
M>Z#/9:[=16]A<[8W:2<19.00 Q(YR*UZX3XG^'=4\0Z;81Z99BY:&60N%>-9
M%#1,@V^9\F,MSGG'W>: .[!! (.0>A%%4])MI+/1K&UE2-)(;>.-UC)*@A0"
M 3SBKE &=K-GI^KZ?-HFH2+LOXGC,0DVNZX^;;WXSVI=&DTT:;%::7=0W%O9
MJ+8>5*)-FP ;6(/4 =ZP=;\,R7?C33=7LX%1_LEU!<W6_P"9-R*(\ GUW=/Q
MJG\//#VHZ*;I[[3(=.!M;6U$44BN)GB5@TWR\?-N'7GCF@#NJH:O;V.HV$VD
MW\JK'J$3V_E^9M:12I#!>^<9Z5?KF-:\/&[\9>']:M[17DM9)%N)RW*1F-P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M $D 9/6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBLC6-4N[*]T^SLK6*>:]:10992BIM7
M=DX!)Z4 :]%8"^(IG\(_VU'I[R3 '=;(2V"'V-R!D@8)X&<#I6?:^)KK4Y[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2%( P".".11JV@F;PC=:-9LS-+&45IY68L2<DECDYZTO_"'Z%_SYO_X$2_\
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M#0!H0^';&WN[>YA,T<D$LTJ[9.#YIRZD=UR!QVP*UJP_^$/T+_GS?_P(E_\
MBJR-%\,Z3<W6L+-;RNL-\8XP;B3Y5\M#@?-ZD_G0!V=%8?\ PA^A?\^;_P#@
M1+_\56=_9G@W[0EOYD7G27#6J)]LDRTJC+(!NZ@<XHT ZVBN,MK?P->3"&VN
MK>5RAD&V]DQM R3G=CIS].>E7-.T'PKJUJ+JP47$!)7?'=2$9'4?>HT Z>BL
M/_A#]"_Y\W_\")?_ (JLG1_#&DW%_K*2V\C+#>".,&XD^5?*C.!\WJ2?QHT
M[*BL/_A#]"_Y\W_\")?_ (JLYM,\&K.L#21"5KDVBH;R3)F"[MF-WWL$'%&@
M'6T5QMM:^![RX6WM[F"65E+!5O)#D#.>=WL3]!FK6G:'X4U:!IM/"W,:ML9H
M[J0X/7'WO0@_C1H!U%%8?_"'Z%_SYO\ ^!$O_P 547ANUAL=3UVUMPZP1W,>
MQ&D9MN84)QDGN30!T-%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0\]JT? ^CWVD:)-_:H8ZI=W#7-Y*75A)*P&2N.B@ *!Z+5O^R=9_Z&6X_P#
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M4;M[LK\ER"FYAP3TSBNSK#^T^)_^@9IG_@:__P ;H^T^)_\ H&:9_P"!K_\
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M419+:M)*((E5 @,:C);CKN9F.?85T-8?VGQ/_P! S3/_  -?_P"-T?:?$_\
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M 7K+T366L4OQ/I&L S7TTR8LG.59L@T6 ["D(R",X^E8G_"31_\ 0)UG_P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img105269759_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (_!98# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY+F;_6.1]X^I'K72T4 8=MX0T.SDTUX+%$;359;4C_EF#UQ3]=\*:'XE$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S!5+
M,0 !DD]JY&_^*/@O3;HVUQK]KYJG#!"6VGW(KAOC]XKO=.TZQ\/:?*T4FH$M
M,R'!* X"Y]S5_P *_ [PK::!;MK-JU]?2QAY9'D90I(Z* 1TH ]'T?Q#I'B"
MW,^DZC;WD8ZF)\X^H[5#J_BK0M N;>WU74[>TFN/]4DK8+\XX_&O,=!^$FJ>
M$OB(FJZ!JL<6C[OG@E<EW0]4/K[&L7X__P#(X>%O\_\ +04 >_@A@"#D'D4M
M<+X[^(MOX!MM+,]A)=?;/E&Q@-N /7ZUN>(?$T7A_P 'S^(9+=Y8XH5E,2G!
M.<<9_&@#>J*&ZM[AY4AFCD:)ML@1@=I]#Z5Y;K7Q1^W?"2;Q%9:==1M=M):H
ML;9:$X(WDCL*X[X">,)+>ZET&6QN;B2_N3,UYG*J0O1CZ\4 ?1%%>4Z_\;;2
MQU^?1]$T6[UB>W)65X.@(ZXP"3]:U? 7Q6T_QMJ$^F&RGL-1A4N89><@=<>X
M]* /0:*\HNOCGI=GKNIZ3-I5VUQ:.8HEB^=IW!Q@ =*JZ;\?]):\N;77-*N]
M+DB4E58;BQ_NXZ@F@#V&BO'['X]6;Z]!8:IH5[IT%PP$4TW7!. 2,=/I78>.
M_B)I?@2Q@ENDDN;FYSY%O%U?WSV% '84R66.&)I)75(U&69C@ >YKQVW^/D4
M%];Q:WX:O].MYR-LS^GK@@9_"L+]H+Q;.Z6.AV@N8H& N'G1B(YE8<+[XZT
M?0$<B31+)&X='&593D$>M.KSCX=^/K74/!$MU>V<VG6ND6\:22S]' 7[R_E7
M.R?M PM))<6GAF_GTN)MK70Z#WZ8'YT >TT5C^&?$NF^+-$AU72Y2\$G!###
M(PZJ1ZUL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y[\
M:O\ DG,__7U!_P"ABN\L_P#CRM_^N:_RK@_C5_R3F?\ Z^H/_0Q7>6?_ !Y6
M_P#US7^5 $U17,1GM980VTNI7=C.,^U2T4 >>>$OAA%X7\47NL)>LYF;Y5('
M((YSZ<^E1R?"N.3QZGB0W[;@"Q&T?>SP,8QC'XUUNIZ5JUW=F6TUR2TBQCRE
MB5AGUR:YTV_B,>*UTC_A))/*-H;C?]G3.=V,?2@"'QG\,H_%NO66I27K1F&0
M$J% PH]/4Y]:[RT@^S6D4&[=Y:A=V,9Q[5E:;I.K6EX);O7)+N(#!B:%5!_$
M5MT %%%% !1110 4444 %%%% !1110 4444 %%<'\2[F>WM].,$TD19WSL8C
M/ KS[^TK_P#Y_;C_ +^&@#WVBO AJ5_N'^FW'4?\M#7N]H2;* DY)C7)_"@!
MMU?6MEY7VJXCA\V01Q^8P&YCT ]Z=-=6]O)#'-,D;S-LC5C@N>N!ZUPWQ3TR
M+6;?PYITSO&EQJ\:^8APR'8^"/H:P;SQ!=-?Z!8:PH_MG1K]Q<*.//01,4E7
MV8#\\T >NT5YG!J?BFRL=*\3W6M0W-I?W$:2Z:(%5(XY&P-CCDL..O7FJ<FK
M>*QHEUK*Z\,G4OL5O;&W78J^;MW,>I.* /6**\TE_P"$O_MO5-#7Q2 MK:+?
M+=?8T\PEMP\O'3;E>O6LNZ\7:_J]M9K8ZE=1W0L$FD@TRQ$[&0YYD+<(IQD"
M@#UDW=N+P6AF3[04\P19^;;G&<>F:FKS+PIJMQKGC/1=3O%47,_A]C+M&!N$
MV#]*[SQ!/<6OAW4KBT!-Q';2/'C^\%.* &S>(M&M[\6,VJ6<=T3@1-,H;/IC
M-:=<7H/A;P[=^!K5;BQMI8[FU$L]PX!=F899R_7.<\]JS;236?$%]=6/ASQ$
MEEIFDPQ1P2^6L[W+E<Y<M_#T''7F@#T:F--&DJ1-(HD?.U2>6QUP*\LTK7_$
M_C'5;"UM=732DDTLSW)B@63,JRF/*;N@./RJOI4^M>(/$_A.^NM7:*>-+N&4
M10KMD\I]I//3< ,^G:@#UZHKFZ@LX#/<S)%$I +N< 9.!^M>7V>K^*[G3;:[
M&N1K-JE^]C C6Z[+90S?/ZLV%Z'BH/%-SJ]EI>M^'=6U$:FL<-K>0731+&X!
MG52K <=1D&@#URBD3[B_2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G[
M]HG3YX-6T+7%0M#&#$Q X#!MPKTN\2'XD?#E(M)U86QNHXR9XSDQD8)! /'I
M72:]H.G>)-(FTS5+=9[:4<J>H/8@]B*\>N/V?+BVGD&B^*;FUMG/,; @X^JD
M9H \^UG2KWP?\1-)TE/$TVI S1-(R2L I+?=(R:[/X_?\C?X6_S_ ,M!75>%
M/@3H>A:A%J.I7<VIW<;!UW_*@8=\=3^-;'C[X9KXXUC2[\ZD;3[#_ (]V_Y@
M?7CI0!PG[17RV'AIS]T.^3^ KL_B7<1+\$[MRZ[9+.%5.>I.W%;'CWP!9>.]
M"AL+F=X)K=M\,ZC.TXP<CN#7$P? VZN=&;3M9\5WMY%$A6TA&?*A/9MI//TH
M A^'J[OV=M1&,GRKK%._9S9$\&ZK(^ $O,DGL-@KN_"?@6'PWX'?PQ-=&[AD
M\P/)LVDA^O%<GX.^#=WX0\2I>P>(Y9--5RS6FP@29!&&YP>M &)I?B_7O%?B
M75(?A[H6E6$43;9[^= '<9."<>O)Q6#\.HM0M_V@KV+4[J*YOE683S0C".VT
M9Q79_P#"D[W3->N[WPWXJNM*MKLGS(HURP!.< YYJ_X;^#</A;QI!K]AK,[J
MBE98ITW-(6&&);/<\T </\/+:&?]H36WEC5FB:=TR,X.<9IOCBS@NOVC=+AE
MB1HW: NI'#8!Z_E7I7AOX8KX?\?ZAXH&IF8W>_\ <&/&W<<]<T:O\,5U7XDV
MGB_^TVC-OL_T?R\[MH]<T <'^T1&BZKX:<* VYAD#MN%=!\1O&=IHUQH6CVV
MA6FJZW<1QM!]I0%8LX"_CFN@^(?PV7QY<Z;,=2-I]B).!'NW9(/KQTJ#Q[\*
MK?QD=/NX-0DL=2L8Q&DZKD,!TSZ$'O0!Y'\8(/&PTC3+GQ;=Z?M>9A!:6J\H
M<<DGOZ5O?&X$_#3P@V.<+D_]LA6_J?P-N=?L@^M^++V]U),+'/(N4C3N N>_
MK73^*/AK'XI\#:?H%WJ#+<V"KY5TJ=2J[>5]"* .5^)QGC^ NG^0,(T5L)<<
M?+M']<5S_A"'X@S?#:&#2X= _L*6!PS3D!MISN+^]>A^$_AG)I'AO4M$UW5I
M-7M;U!&$?($2@<!<GC_ZU<N?@5J=M!/ING>,KN#1IV)>U*GD?0'!H UO@AX;
MU'PWI&I0W5W97-O-*KQ&UG$@!Q@YQTKU6N>\&^#M-\$Z&NF:=N8%M\LK_>D;
MU-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4R5F2%V5=S*I(7U/I3Z9*Q2%W49*J2!ZT
M>"3?$7Q??;Q:7)B>R=GN1]D)#,7VI#^7>O>+2226SADF39*T:LZ^A(Y%>4:/
MJGBC7('OT\3Z#8!YV#6IB7<F&QACZUZS;[OL\>]P[[1N=>C''6@"2BBB@"EJ
MVK6>B:=)?7\OEP1CDXR2?0#N:Y>Q^)FDWG@JY\4O!<0VD4[0+&P^>1@<  >I
M)KL+B&.:$K)&L@'(#+GFO$[7PUK-S\([RWBL)?MEOK;WJV[C:TB+)G@>XZ4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q_$_B2S\*:'+JU^LK6\3*I$2[FR3@<5L4R6*.9"DL:R(>JL,B@#R[_
M (7]X3_Y]]3_ / ?_P"O1_PO[PG_ ,^^I_\ @/\ _7KTK^S;'_GRMO\ OTO^
M%']FV/\ SY6W_?I?\* /-?\ A?WA/_GWU/\ \!__ *]'_"_O"?\ S[ZG_P"
M_P#]>O2O[-L?^?*V_P"_2_X4?V;8_P#/E;?]^E_PH \U_P"%_>$_^??4_P#P
M'_\ KT?\+^\)_P#/OJ?_ (#_ /UZ]*_LVQ_Y\K;_ +]+_A1_9MC_ ,^5M_WZ
M7_"@#S7_ (7]X3_Y]]3_ / ?_P"O1_PO[PG_ ,^^I_\ @/\ _7KTK^S;'_GR
MMO\ OTO^%']FV/\ SY6W_?I?\* /-?\ A?WA/_GWU/\ \!__ *]'_"_O"?\
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M_A1_9MC_ ,^5M_WZ7_"@#S7_ (7]X3_Y]]3_ / ?_P"O1_PO[PG_ ,^^I_\
M@/\ _7KTK^S;'_GRMO\ OTO^%']FV/\ SY6W_?I?\* /-?\ A?WA/_GWU/\
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M>O2O[-L?^?*V_P"_2_X4?V;8_P#/E;?]^E_PH \U_P"%_>$_^??4_P#P'_\
MKT?\+^\)_P#/OJ?_ (#_ /UZ]*_LVQ_Y\K;_ +]+_A1_9MC_ ,^5M_WZ7_"@
M#S7_ (7]X3_Y]]3_ / ?_P"O1_PO[PG_ ,^^I_\ @/\ _7KTK^S;'_GRMO\
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M9MC_ ,^5M_WZ7_"@#S7_ (7]X3_Y]]3_ / ?_P"O1_PO[PG_ ,^^I_\ @/\
M_7KTK^S;'_GRMO\ OTO^%']FV/\ SY6W_?I?\* /-?\ A?WA/_GWU/\ \!__
M *]'_"_O"?\ S[ZG_P" _P#]>O2O[-L?^?*V_P"_2_X4?V;8_P#/E;?]^E_P
MH \U_P"%_>$_^??4_P#P'_\ KT?\+^\)_P#/OJ?_ (#_ /UZ]*_LVQ_Y\K;_
M +]+_A1_9MC_ ,^5M_WZ7_"@#S7_ (7]X3_Y]]3_ / ?_P"O1_PO[PG_ ,^^
MI_\ @/\ _7KTK^S;'_GRMO\ OTO^%']FV/\ SY6W_?I?\* /-?\ A?WA/_GW
MU/\ \!__ *]'_"_O"?\ S[ZG_P" _P#]>O2O[-L?^?*V_P"_2_X4?V;8_P#/
ME;?]^E_PH \U_P"%_>$_^??4_P#P'_\ KT?\+^\)_P#/OJ?_ (#_ /UZ]*_L
MVQ_Y\K;_ +]+_A1_9MC_ ,^5M_WZ7_"@#S7_ (7]X3_Y]]3_ / ?_P"O4EM\
M=_"MU=0V\=OJ6^5U1<V_&2<>M>C?V;8_\^5M_P!^E_PI1IUB""+.W!'((B7_
M  H LT444 %%%% !3)B@AD,G^K"G=],<T^F3,%@D8J& 4G![\4 >%NNAF.77
M8_A^K: LYWWHGPY&[!DVYZ9KW&S:%K*!K?\ U!C4Q_[N.*\4T.#P'K:R7%UK
MDNGP_:F,NCO>8B#AO3T)YQ7M$I4:8YMB0GE'RS&,\8XQ0 ^:[MK;_7W$47_7
M1PO\Z?'+',F^*1'4]U8$5X6EMH<D\LFJ>$_%>K7+,2\MR"03GL < 5UW@SPW
M837:ZMI$&M:&(9-LEG=.=DJ_[IZ4 >DT444 %%%% 'GOQJ_Y)S/_ -?4'_H8
MKO+/_CRM_P#KFO\ *N#^-7_).9_^OJ#_ -#%=Y9_\>5O_P!<U_E0!-7BOC/_
M )&Z_P#]Y?Y5[57BOC/_ )&Z_P#]Y?Y4 85%%%(05L>%/^1KTW_KK_2L>MCP
MI_R->F_]=?Z4 >WT444QA1110 4444 %%%% !1110 4444 >?_%#QGJG@^VT
MZ33%@+7#NK^<A;H!C'(]:\W_ .%V>*O^>>G_ /?D_P#Q5>D_%#P9J?C"VTZ/
M36@!MW=G\UL<$#&/RKS?_A2?BC_GK8_]_3_A7)5]KS^[L?18#ZA]77MK<VN_
MJ"_&OQ46 \O3^3_SQ/\ \57T!9RM/8V\SXW21JQQTR1FO %^"GB@,#YECP?^
M>I_PKW^SB:"QMX7QNCC53CU Q5T/::\YRYI]5M'ZO;K>QSOC'4+Y)-*T73+H
MVEWJLYC-R%!,4:KN<KGC=C@?6L-M+@\,ZY9+9>-YQ=^:@N;/5KP2+/&QYP#R
MK>A%=1XGT"76[6WDL[K[)J5E*)[2X*[@KXP0P[J0<$5R^H^$O$GBF:WBUQ-#
MM8(IHY9;FTB9YYMC!@ 6^Z"1[\5T'CDO@SQ'<"2#3KHRW#WFH7X661\F-8Y.
M%^F#BJOB'Q?K<NN:5;:5:!8DUO[%-F8+YV$)P>.G?\*FB\&Z_IJV=[IL]BU_
M:W]W/Y4^[RY(IFSC(Y!'%,7P7XBCAANFN[&?4HM:_M+!!6-U*[2OJ, G'TH
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M *"Z_P#?A/\ "@#Z]HKY"_X79X\_Z"Z_]^$_PH_X79X\_P"@NO\ WX3_  H
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M2Z.T+[!;RLI./7"]* .@HHHH **** //?C5_R3B?_KZ@_P#0Q7>6?_'E;_\
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M.7_COP[I?V87FH"-KB-957RV)53T9@!\H^N*Z".:.6%9HY%>-P&5U.00>^:
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M4"QV<*B7)88'S\<]<UN7^@WDOPXU&W73)&N9M<$QC\KYG3[0IW>XV_I7K=%
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MKR;1?B!XBO?B$^EW%D$LB OF[&V8S]X#MGWH ];HHHH **** "BBB@ HHHH
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MZK/,(TSRX' J&%-\R)_>8"DF 69P.@) J7KH$9)33:O;H2SE%E?RV#1L<9J
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M%1112$%;'A3_ )&O3?\ KK_2L>MCPI_R->F_]=?Z4 >WT444QA1110 4444
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MK*]RN>7+RWT/IBBBBF2%%%% !4<_%O*?F^X?N]>G:I*9,,P2#:6RI^4=^.E
M'SUHNB&^MS=?\(/;:ENN7(O+C4=DC_-U9<\&O>BA&AF,1M&?L^-D9R5^7H#7
MB.HZ1I^DF:\N?AOJD5NLV7F6_.WEOO$ ]*]UL=OV"WV+L7RUPN<X&.F: /"/
M 8\/Z+XD;4-1UVPLC#YD;02PM#-*2?\ EJ6X;\*]"T;Q3X/C\1&R\.1FXNKY
M@TS6<9,2X_B)Z#\*ZN^T'2-3;=?:;:7#>LL08U/9:;8Z='Y=E:06Z>D2!?Y4
M 6J*** "BBB@#SWXU?\ ).9_^OJ#_P!#%=Y9_P#'E;_]<U_E7!_&K_DG,_\
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M !1110!\7_%/_DJ'B'_K[/\ (5B:-)J)D:&P8#/+$C@5M_%/_DJ'B'_K[/\
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MNQ.C">D[OYFS_P )$)6_TC2=.D3T$6S]13_[8TB5&5] B4_WHIF!'YU@EB0
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ML'F)C:50S,?ND?7L:Z77]!LX?"$<-Q<+',CMY08X!^GK7%:3JT]K%&KW;\C
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M2:2@!2S, "<X&!2444P"O9OV</\ D<-3_P"O/_V85XS7L_[.'_(X:G_UY_\
MLPH ^F**** "BBB@ HHHH **** "BBB@ HHHH **** //?C5_P DYG_Z^H/_
M $,5WEG_ ,>5O_US7^5<'\:O^2<S_P#7U!_Z&*[RS_X\K?\ ZYK_ "H FKQ7
MQG_R-U__ +R_RKVJO%?&?_(W7_\ O+_*@#"HHHI""MCPI_R->F_]=?Z5CUL>
M%/\ D:]-_P"NO]* /;Z***8SY4\?_P#(^ZS_ -?)KFZZ3Q__ ,C[K/\ U\FN
M;KR9_$S]!PW\&'HOR"BBBI-CKOAC_P E#TK_ *Z'^1KZAKY>^&/_ "4/2O\
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MU?$-WI6H:W+;RO/;F,[/.SO4D>HZXS6!=Z5<VKC $\3?<EA.Y6H59-1NYI&
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M/_?L5SO#0;N>Q#.\1"*BDM/7_,^,!>1%R@64L.JB,Y%+]I7_ )YS_P#?IO\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q?\4_^2H>(?\
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M&G5?^ON7_P!"-95:OB;_ )&G5?\ K[E_]"-95 !4L,S1$X/48J*BDU<:;6J
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M8N5I/0="G[2<_>2LEOU]#,HHHK8044H8@''>D)S0 4444 %% &3@=:",'!H
M*Z'1_LD,MO(]T"\ORL".4K!,3B,2%?E/>K.F6AO+K8)DBVJ7RWM6-:*E!W=D
M4L.Z]Z*6LM%T^?\ PYK1:-<66K3')46[Y9\X^7L1ZUL>#V6?XJ:+(LBR-]LC
M+,O0_2L[Q6[.MC>PS-LN+=58 \9'!I/AR3_PL;0.?^7Q*QPW-42JR>NW^84,
M6JF"A32L[W>O5::+9'VO7*_$I2_PWU]1U-HW]*ZJN5^)6/\ A6VO[LX^R-T_
M"NQDL^,0I9Q"N5).#GBD>/;)Y6\8'?M5^V6[F01K9K(/O!MN6_.I'T::XW-
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MVL)7LW[.'_(X:G_UY_\ LPKQFO9OV</^1PU/_KS_ /9A70=!],T444 %%%%
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MG7RG+$%<L9$P3_"<U]6_ @J?AA:[1@?:)?YTT[C3N>ET'H:*#T-,9\*^)O\
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M(S!0ZEB,@ ]O6A71P2C*P!P<'/-?-L_ALZ5IO@'4++5]3BOM9=8+J<7+$[&
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M@@4/ _[^+'.[HQ4^_6N"U*9WT^]*!4+2"".4\$[N3]*\K 2JQFU%V2T7E?\
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MO!UUJCWTFG/\\GFO;K,PA9O4ITK4U3QOI6FPZ<T27-]+J2;[2&TB+M(N,Y]
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MPJ@8 J TYP#M*@\C'U-2I9R%=TA6)/5SC]*]5<L4>TG&*[%<5.H)M" %)+\
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M/%/O=GVEO+4!.H J5I*Q/+:6VY7KZS^ W_)+[7_KXE_G7R97UG\!O^27VO\
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M*%7H"YP%J6[*[+IPYY<JW>WJ-FM9;=4=T^5QD'L:A((.",5<#F*[,#W&8D.
MV,CCH:@N;B2YF,DA!;ID#%*+;W-JM.G%-JZ=[6T?KK^6@R(1F51*2$[XI&VB
M0[>5SQFFT55M3"^EK"L<L3C'M2D@ !2<8YIM%,5PH'7FBB@0^1E8C:,4RB@=
M: "BES24 %/C4NX"@D^U,K8\//!#J2S7*YA48=O[N>!45)<D'(SJSY(.5KFK
MI,"VD-K/,"5FD"LA7 ('O[U]!?"O4K34I9I;>*-'V%7V]<@]*\[U&WTO3O";
MWMQY<EP &4G[H/\ " /6M+]G]WCUV_2=BT]S;_:""?NC< /SKP\,UBZJK:KE
M?WGE4*OM<0YX>H^6Z3MHI=6K>7F?05%%%>^>R%%%% !1110 4444 %%%% !1
M110!!? FPN0!DF)N!]#7SI#IUVWP0TNW:RG,G_"0!FC,1SMW'DC'2OI*DP/2
M@#S._M9?^%[:!,EN_DKI,BEPAV@Y/&>E:_Q1L].O?">S4]/U&[MUF5]^GC,L
M!'_+3'H*[;%% 'BG@R_U]=?NM.L]6U#6?#2V#M+<ZA;&-H6VG:JLW)-<=H'B
M)_\ A4-YX5A\/7UW>:A<2);31P[HG)<<ENQ6OIB>%9[>6$G"R(5)';(Q6)X/
M\*6O@W0$TBSGEGB65Y \N-V6.3TH \^GT>\TWQ]\.+66*20VEB\<TBJ2JL%[
MFLC1]/N%^&'Q%1K*4337TY13$=SC/&!WKW?%&!Z4 >'3ZIJ^F:7X*L9IM1TW
M1)--7[3=6-L6G$H'$><$KVK+\-VEPGPR^(MJ;2^6625I(TN(V\UU(X)]37T+
M@48'I0!S7@"-XOA[H4<B,CK9H&5A@@X[BO(M(T^Y7X+>.(S93":2]D*J8CN8
M;AT&,FOH*C ]* /'=2LIEU7X6>7:2!867S-L9Q'\@Z^E9]IJUQ\/-4\6:;JG
MA^_O9-4N7GM+BW@\Q9PP("L>V,_SKW+ ]** /G?4_"VM>'_A3X8>ZL9Y)+35
MOMUQ;Q+N:&-CD+@?YYKH+S6)-!^(D7CJ?2-1NM'U;3DCC9("TMJP_A9>V<?K
M7M%% 'S_ #Z3J=U\/_'NOOIMQ:1:U,DEI9LAW[0?O%1TS7L/@B(P^!=#C:,Q
MLME$"I&"#M':M^B@#S34+61_V@-)N#;NT*:5)^\V$JK9/?IFN&E\-ZKJ_A?X
MAVEE:3>?_:Z3QQ["IE5<DA?6OH3'-&* /#O" LO$OC/1;F1/%4MWIL>5DO(5
M2&#C!4G R*Q(=0U'PYH_COPS-H&I3W^H7$TL+10DQ^6PY8MZ <U]&44 >$1V
M%RUW\)]UI,5BC/F9C.$X_B]/QK=\9"[\+?%>P\8SZ7<ZAI)LC;.;:/S&MW]<
M?Y[UZU@>E% 'AEE9ZAK%A\1/%:Z9<65EJEBT5K;R1E9)=JGYROJ:9J^GSCX:
M_#F*.SEWQWT#2(L1RG7)([5[M1@>E 'A_C2VTZS\:ZI?6=YXB\/ZNR!O/M[=
MI8+TXXP%S[#FO2?A]=Z_?>#+*X\2P^5J3@[@4"$KGY2RCH2*Z? /:B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+_ (I_\E0\
M0_\ 7V?Y"JOA?QE=^&8Y[=+>*XM+@YEBDR,\8X(Z5:^*?_)4/$/_ %]G^0J_
M\/=)\,ZI;W::VT7VD./)1Y=A(QV_&N/'RI1H-UHN4>R,,2X*FW-71J:+J?@F
M\6^%NTND7=];M ZRG=&-W<&N!U_16T+4S9FZANEVAUEA.58&O2]0\/>&].RS
M^$M3FB SYD#[U/Y&O-O$;Z<^JM_9EE/9VX4#R9R=P/?K7GY;.,JKE2<N5KK9
M^FMVSFPLDYMPO9][/\=S1^'/_)1_#W_7]'_.OMBOB?X<_P#)1_#W_7]'_.OM
MBO</0"O#/VCD62QT-&."9)2I]\#BO<Z\'_:3)%IH!'_/67^0I-:":NCYY8%6
M((P1UJ2.=XL%3@@Y!J>Y1Y#'-(5!=>6Z=/6H"$CY'S^_:I34EJ0FI+4F9/.F
M#,1\_P VX"I7MP@!N9QY7\ 7EOR[55$C,"7.$'8< FHV)9BQ.<TN5]PLVE'8
MM+>^2Q$$2QC^$GYB#ZU5=W=RSL68]2:3.>M/\F39O*D)_>/2J45$:C&.HA!.
MT 9XXQ75:E8R:;X<CL[9B&($EZ5ZECT4^P':H;"SM=*L$UJY82J#MMXL8\UQ
MW.?X16)<:G=W3S-)*?WSEY . 37*W*M-<NT7][_X'YDT)T:U2]1-QC?R][IZ
MVZ^?H0-&5@60YPQ(''%1@D CUI[32-"L)8F-22%]#4==:OU.B?)=<OE]_4**
M**9 4N:.U)0 44H!)P*" #C- "5;>18K5?FW3..3_<7T^M+%%;QV3SR.?M!8
M"*/';NQJHS%F)/)-1\3]"+\VG3\RS=7TEU!!$Z(!$NT$#DU!#"\\JQQC+-1'
M&97"+U/2KLEL]E;JDB$7,_W5/\*__7I-Q@N6)=?$2J2O-WD_T_R(Y952S6!-
MAPQW$=2?6JT05I4#G"D\GVJ6YC(((A,: !<^IIMO;R3R*D:EF/04*RC<B#4%
MS/U+,\5J]T\EN&%J@&<]33K&ZF.HQ,BL<.,(M)/,D<(LXP-@.9''\;?X"M'P
MT\=IJ4>I!&D-I^]90.!CI^M8S?+3;:OII_7F%6HJCE5DK+?33[OT07]XMM=N
M+A9#.Y(E4M_ >U49=-#*7LI5G@8\=F7ZBC6]4.K7\ERT"Q.SDMCOFJ]@YBN!
M(254#)[9HIPE&FI;/L15HJFVZ<^;S[_J2Q:->22!3'L4_P ;= /6IKBYM].#
M6UBPEDZ/<D=?9?0>]=%MFFLWU=[D%8X]L4,8X;ZURMQ&DQ,D2 .Q^ZOK["HI
M5'5?O[+\PG2J1Y75>C6W^94RV6P2<]?>MW2]34:<UOJBO)9?<B<??A8]2OM[
M5E):K 5>\+(I&0J_>/\ A44L_F!4 VQK]U1VK><(U5R_C_D34A&LN7\?\O,M
M:AI4MD0Z,)K9^8IDY5A_0^U9]:>EZG/8R& *LUM-Q) _W6_P/O5G4-#'EM=:
M>6:('#PO]^(^A]1[U*JN#Y:GR?\ 6P1G.&E7;H^GS[/\_P #.-_)]B6U"H I
MSN ^;\ZFU9X96M7A7:3 H?W(J@\;QXWJ1GIFK6HQ&"6*,MN_=*?S%7RQ4U;S
M-ZU656I!R=[*R]"G7UG\!O\ DE]K_P!?$O\ .ODROK/X#?\ )+[7_KXE_G6H
MSTR@]#10>AH ^%?$W_(TZK_U]R_^A&LJM7Q-_P C3JO_ %]R_P#H1K*H *,T
M44 %%%% %FUL+F]+"WB9]O)([57961BK A@<$'M73Z7K4&E^'I%3:]PS?</\
MZYRXG>YN'FDQO<Y.*PISG*<DU9+8[L10H4Z%-QG>;U:Z)?YD5%%%;G"%%%.C
MV;QYA(7OCK0"&T4'&3CI10!966'[$\1C/G%@58>E5P.<=*%)!R.HJ_\ V<\T
M#W"3(X5=S=C[U#:AOU-8PG5TBMBK<0B!PHD5\J"2O;VJ&BBJ6VIG)INZ5@HH
MHIB"MW1M+&H:7?CR6,RH'B;''!K"KH](\17,$268"<_*I(_G7/B?:<G[O<[<
M#+#1J.6*=HV?2_\ 7<ZW3+-IETR_\ID#VCVTR^A'&37F=Q$8+B2)ARC%?R->
MP>#%OM6TZ\M=CI.$^1F7"@YZ"O/O&6DRZ9KTJR(5,@WX]^_ZUY>7U[8F=&3U
M_I_J?+X&I&&,JTHOW;OE]$VU^#_ YRI8+>:YD\N&-G;K@5%5[28[V2_06.1+
MW;H%'<D^E>U-\L6SW8RIQ:=7X>OH4Q&[2>6JDOG&T#)S6FNAW2QJ]VT5HAZ&
M9L$_AUJ:[U"*Q:2+30"^2);O'S,>^WT%4OMS30^5,B/Q@.WW@?7-8\U2:3BK
M+\3&'-5>CY5TNKO_ ('XEG.BVPV!;BYD'64_*GX+U-,FN7$3):R*4;[WEIM(
M'I526V,=LDI=<N?N]P*KJS(P9201T(IQIIZWOZDO#.+]YW?GJ!))R23]:D6=
MU '4#IFI&472ETP)1]Y1QN]Q5;IUK56>YHK2T98CN3'('4;&!R"!TJ:^F\V1
M&6X\T[><C&T^E4@"2 .II71HW*.I5AU!I<BYKFBNH-=!<-R<Y]:Z7X<_\E&T
M#_K\2N8!(.0<&NJ^')5_B+H+-PWVQ.G?FJ(V/M2N4^)@+?#77P 23:-@#\*Z
MNN6^),C1?#C7G0X9;1B#38WY'QM$L5K&YN1ND.-L7^)[5#<7$MTYDE;IP .@
M'L*B+,S%B22>2:;4*.MWN2HZW>XI)/6K5A.T,^ H8-P<_P"-5* 2.E5**:L5
MMJB:ZD$L[E1A<\5$, \TE%"5E85C8T74#I]R+IB.?W8!'8\9_"NINO&.I:4(
MH-T;QS( TH7+;1QC\J\_))[]*VYYA=>&T 5GEAD#,_H",5PXC#4YS4IJ_3_(
MYVYT:JJ4W;FT=NW0FU+R9MM]9EHK:4[67'*FL-Y"AVHN O&2.35O3+U(3);3
MKNMYP%;)^Z?6DO/,MC+;NJD@XW =1V-;4XN#Y'_2+IRESN%1^G]?@4-Q/>DH
MHKI-AP*;""#N['-:EAI]E=6$TLMUY<J G;65L8*&VG:>,XH4GD X!ZU$XN2T
M=CHH584I\U2"DK;/\]"2&<PAP%4[ACD5'C')JW'(MO!%*+?)WY+MR&QVJ&[G
M-U=23%%3><[5Z"A.[V)G&T%>6O:W1ZD-%%%68A1110 4444 %%%% !1110 4
MN">U3VGV<W*"Z+"'/S%1S5F^EMIG*P@I"OW"1RU0YVE:Q7)[CFW_ )_<9U%*
M<9XSCWI#C/%62%%%+@^E "5?9/LXAA+%\X>5%['TI(XULHTGG0-(_,<9/3_:
M--BDFN9$B5/,:1QPH^9C]:RD[[;(Q;YGY?U^1TFH7,^JP6$1.W3(TW28/"L.
MN3ZXKT3X 2/>>-M7O,8B-J$0'L PP/RKS:=;:Q\.W^D&;-VLBS-M.5SW3WP*
M]"_9VF8^+M1A#?NTL^!_P(5S86*UY5HMO3>_S.; QCK9:*]O/K?Y_H?25%%%
M=QWA1110 4444 %%%% !1110 4444 %%%(S*BEF8*HZDG % "T4R.:*;/E2H
M^.NU@<4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ^+_BG_P E0\0_]?9_D*L>!/ T'BN&YN;B[DBCMW"[(P,MQGJ>E5_B
MG_R5#Q#_ -?9_D*YFVU"\LU9;:ZFA#<D1N5S^5<^*IU:E)QHRY9=S*M&<H-0
M=F>X6>EZGX;1H]!T)Y2>/,N[[.?P[5Y7X[?5I/$KMK4$$%V8U^2'[NWM63_;
MFJ_]!*Z_[^M_C56XN9[J7S;B9Y9,8W.Q)KAP67U*%5U:C3;6^M_O;9ST,-*G
M/GDTW\[_ )G1?#G_ )*/X>_Z_H_YU]L5\3_#G_DH_A[_ *_H_P"=?;%>L=H5
MX/\ M*$BRT''_/27^0KWBO!OVE?^/+0?^NDO\A0!X 'WV[@MC:0P7%+'!.+<
MS^6?(SM+$<46^)'$0"@L",GO0UU,+86OF'R@<[>V:S=[V14/9WDIWVTMW\_(
MBDX( ^[V/K31GM3DPPVD^X-6!']B&ZXA#/)'F,$_=ST:J;MH9.5M.I&R1Q(C
M!]TIY*X^[_C4L7VC4[^*#.]Y7"@ ?A53DG/)KI?"]LUG;WOB"6,F&R0K%Q]Z
M5N!^595I^S@Y=>GJ]D95Y>SIN2UET]7LAGBV5&U0V,##R+%5AC0=.GS8_&N<
MJQN:9I'8EG?)/UZYJ#-.A#V<%#L/#T_94U3["444IXK8W$HIRJ6#,,87GDTV
M@!3T%&,=:>!MC)*\GIFA8)& 8C"GHS< TKH5TB[!_9KZ>XF+I<CE2.GTJ/3X
M4+O<3[##"-S(S8+^PJ 2+'M*J"Z]STHR<"5]K;F.5K/E>JON;5<0Y<G+%+EZ
MI;^O<2XF\^=I,84GY1Z#L*BHI<$D8'Y5HE96,A8Y&BD#KU'2NDLM8CN8!#J5
MI'(JKB&;_EHOL/45@QQ-&V2I/'.!G%2P^0DJ/,[,X/W4XQ]36%:$:BU.6O3A
M46OX;FM=7'VM#;V[+)%)RJ,,%*S;N5X!Y$ *@K\\BC&_Z>U2-?80E(E*N=@P
M><?_ %ZJ_:Y8Y&90L8+9"@=,=JBG3:Z%.56JTZCO;O\ UT'6=H\^]P$\F+YG
M9S@?2M6Q%K=SR65B[0QNN3OZN1SCZ5E3WQND82KR3G<O'YBKGAUE@UZW<,DB
M Y8-QQ154G!R>ZV%-.47[1V7]:^91O[.XLKDK/$T9;YAN[BJI8D\DUU'B/4+
M'5#Y\;22%&(# 8 _#TKESC/%:8><IP3DK,VC*,K\E[>:M^!KV-P5T>YMHSOE
MF(X_N =ZJ>:+:,QQ[?/!R90>GL*;;GR;=W8#]Y\B>H/K54@@X/44XP7,PD_:
M2L]D.<,6RS;BW.<TFQBN>,?6D&"1GI2NH1RH8,/45KY%\KM<?$?+=6)'/(]J
MTK?59[/4O/DD+!AA\>E9%3LI>U23/*G;43A&7Q=12E+EY&]'^?0Z+4-.-]9-
M<686:+.X,O4>U8=_"YU%X(PSLH"^O05J^$+R>WUJ*, M;NW[Y>P'K4^MZK>6
M.HW""VM8S(Y;S$C'[Q#T.:XX2J4ZOLEKIH<,J^(>(<&E+2]]OO.=EMC  9#@
MGHO<U]6? ;_DE]K_ -?$O\Z^6W\J_0NI\NZ'5.S_ $]#[5]2? <$?#"V!&"+
MB7^==L&WON==.3:UW/3*#T-%!Z&K-#X5\2@GQ3JH')^UR_\ H1K*(P<&MCQ#
M*T/BS5'7&X7<N,C_ &C60268D]3S2UN5IR^8E%%%,D**5E*G# @^])0%K!FB
MBG(F_/(&* &T4I&#BDH **** "BBB@!14S 1V_$Q+$_<'3%0@%C@=:2DU<I.
MW0****9(44K;<_*21[TE !2@D'(I** /6OA!KD&FZE?2ZA+MCEC58=[=7ST&
M:L_%.*#5H9;VU*R-;,#+L_@8\$?RKSW1Y$@N8'DN4!+JGDL,C'K7K5AH*S64
MDUO&"5 0GKD'J?>OE,;3AA<:L7?5V].QA6P>(]A*I%1M"T]];:JWSL_P/%;3
M1[F\N&15V0H-TDS\*B^I-27VI0I ;#34\NV'#R?QS'U)]/:NGUC2KV^SIEM&
M;>""0[2<A)_]HGU]JXBXA-O.\3$$H2#7O4*BKOFD]NGZO^M":4)5HJM-6CT7
MZOO^2]2,,5Z4]2A/S9&?2HZ*[+'0T7+CRUMU&_+[OND=!ZU3J>Y_Y9'N8Q4%
M*"T!.Z0 D'(.#4VX3C#$"0=&/?ZU#13:N#5QS*T;8(((H=VD8L[$D]S3EF.W
M8_S+^HIKH%/!RIZ&CU!2>S&UU/PX_P"2BZ!_U^)7+5U/PY&/B-H'I]L3%,9]
MK5R?Q-_Y)IX@_P"O1OZ5UE<G\3?^2:>(/^O1OZ4 ?%H8@$ \'K24HQD9Z4Z7
MR]Y\O.WWI#MI<'";5VDYQSFFG& !U[TZ)-\@!Z=_I36P6..E'D)N[!3M.< _
M6DIZ(K*Q9L8Z>].F6)67RG+ C)R.AHOK8OE?+<BJ_8W@@M;F(DC>O  ZGWJA
M3XRV\!3@GC-*<5)69E)70TG)S5NXEW1P2C.=FU\G.<53/!Q4T,Q5&A9L128W
M<>G2B2ZBFKV832(^T*@7 ZCO4-/>,IZ$'HP[TRFK6T+YN;4NP7T@2..0*\,7
M(4BJTL@>1BJA5)S@4S/&*2DH).Z-)59SBHR=TA=Q(QDX]*<D3R;BBYVC<?84
MRC)%5Z&;N%%*01U!'UJ2W@:XE"*0/4D\4FTE=A;H.6$&(/NY]*@/!JU+;+"K
MGSU)'9>]5CR<THN^II4@XM)JS$I0 2!25)'&KJY+A2!D ]Z;=B(J[L)@,/E'
M-,H[T8IB;N%21023/LC4EL9P*8&(! [T!F4Y#$'U!I._0<;7UV'J "<#+#UI
MKA@WS=3S3PZ^24V#>3G?W'M08D$ ?S06)^Z.U*^I2@FKHBHH )Z#-%40%68?
M]&99I%R>J*>_N?:G6EN#&]U,/W$7_CS=A4<<<]]=K'%&TDLAPJ*,Y]JAM.ZZ
M=3.4D[KHMQ9;F6XE#.=[GC[O6MF)GT >9-%']O9<A<<Q ^ON?TJ2*S71+AGW
M)+>QIO8@92#_ !;^58$UQ)<SO+(Q9FR22>37.K5M%\/Y_P# _,Y^7VR5E[GY
M_P# _/TWUM/CCU&Y,7ELL]P&P2WRCN*]0_9VA,?C#4B65LV?8]#N%>1VER+8
M,SAL8 &.OYUZY^SUM_X3G5R@PIM,@$YXW"M()J;[&T(.,KIZ/^O\CZ3HHHK<
MV"BBB@ HHHH **** "BBB@ HHHH *JZGIUMJ^FW&GWB%[:X0I(H8J2#[CD5:
MHH \K^%VG6VC>-O&NF60=+2VN(DB1G+;1M]37JE>:^ O^2E^/O\ K[B_]!KT
MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^+_BG_R5#Q#_ -?9_D*Y"NO^*?\ R5#Q#_U]G^0KD* "BBB@#I_AS_R4?P]_
MU_1_SK[8KXG^'/\ R4?P]_U_1_SK[8H *\&_:5_X\M!_ZZ2_R%>\UX3^TC%)
M-9Z"(T9R))2=HSC@4-V$W;<^>%;8X*]14LJ;YP47:).0.U7++3T\U&NR%B)P
M0&&16B^G0*OVJ*4-!;2;7YR,'H ?6N>=>,96)FXQIJKS+>UKZ_<13^'9--LO
MM\\T;J,;%'1R>U9$Y\P^=R<\$$]#_A6KK6NMJA6(CRH$ "*HX]R:RHXL-@G,
M;<%AV]Z5'VG+S5=RZSI>U<J5^7I??;7\2.-'FE6.,99S@ 5U_B)KJSTRP\+6
MH)$*>?<*G\4A]?H*7P1H$=QKMK-=R!8U;<!V..^:L>(]%N8]?NH3EKGS24NE
M;Y2G;/X5QUL33EB53O\ "K_/;\#*DG/$PE)VII/K;F>UEYVON<9!MAD#3#(S
MM=.A^M131-#*4/X'U%=(-%\^-9)9(A(K%6>5PJ8_K3S;:.L!BNKU)U7^*VC)
M9/H>XKI^M1O=:^AA4QE)3?L[M>AR@ISC#8]*W5TO0VG &L21QD\-);GG\JDN
MO"[2#SM,O8+U&YVH<,/P-7]:IWL]/5-#^N4DTI77JFOQ:.<[5I6.DR7-I)>L
MZ)#$>=QP3]*C%B\%P1?QR0(GW@5PQ]AFG7.JR7%JEKY:)"AR HY(]ZN<I2LJ
M?WGH8:=!MNIJK:>O37\0O+Y9G!3+G&"74 ?@*HM([JJLQ(7H">E.DVRRDQ1E
M0?X>N*0(!]X\^@JXQ458SG\6KN(BE\\$@=2.U.DP7X4*!Q@5;BLYG:-2C+$V
M-Q Q_.M&;1["V@5IKHH2<MTSCT ]:SE6C%V81AS4Y5;JT?/7Y+J9T6EW$]L;
MB*)VB'\?0#US4(,8= C'(Y8MZ^E:(U2T2VDLH89D@8Y#&3DGU(Z5ELL(E78Y
M*D\Y'2B#FV^96[&49\UKQ:_7[AUQ*0[1I(2A_6F*"L1D]3MQZTZ?RUE8#+')
MR<\4IPJQA@< ;C6BV0+96&LVU4Q@%>F.OUJ/(*G=G=V/K2,=S$T@&3BJ2+2L
M.!&WW]:NZ/C[:S-T6)S^E43Z5>TF<07OW0P=&7!]Q45?@=B*JYH->1221X\[
M3C(P:0B@\$@]:D@ ,@9QE%Y:K>FI;LM1UP[?NH\C]VH Q^=0L2Q).23WJY'%
M!<QW%Q+.L3#E(P.IJE4Q:V+=*4(1D^H44459(58C.+-_4,,57J<1$6I?<,,X
M45,B9=#?TN:.+0Y?)D$%QNPTG?Z55UV?[79V,_4JK1$^N#5.V)CLKS<W& -O
MJ<]:= 1-I%Q!D%D82H._H:Y%349\_G^9A*Z:O]F3_%?H9H)!!!P17UM\"Y3-
M\,K9V #&XER1WYZU\DU]9_ ;_DE]K_U\2_SKLMU.BRO<],H/0T4'H:8SX5\3
M?\C3JO\ U]R_^A&LJM7Q-_R-.J_]?<O_ *$:I7$,4:H8IQ)E02,8(/I2;L[%
M*+:;70KT444R1S.SG+')QBFT44#;;U8444H4GI0(2CM5[3K2UN+L1W=R(8\'
MY@,\^E5K@!)F16#*IPI'I4J:<N4KE?+S]-B*BBIXK2>?_4QF3V7K3;2W(<DM
M60@%B !DFE>-XG*.I5AV-;6F>&]3GG5S;,J#DDG!KU'2?A#!KVAQWNI7S6MT
MWRQA,,,#IGUKSL7FF&PMG4EIY:G/'$1G55*G[S\CQ-6*,&4X(H8Y.?6NUUKP
M#+H]XUN97D96*Y*\&L>ZTM[1?WD2XQU%;T\91JI2@[W)CCJ4O=BS!HIS@!R!
MTIM=9UA12BDH ***M79MBL/V<8&WY@>N:3=FD7&%XMWV&,2T22]U.TG^5>W>
M$]:=/!IO\>;!'+&F>ZD=2:\4LV7]XKIO&-P4]R*T(O$^HVUL;2UE,5J3EH1T
M->9F.">+@J:Z/\!T*R@I4I+W9;]U;56_(]6\7W!C\*:E/'(9&G48'95)SD5X
M\V[4HMP&ZZC'S8ZNOK]17K_@;4+._P#!4T>IM&\:!]V\\K&.Q]J\QU:]TQ';
M^RK?R5W':0V37#E3=*52ARN\7OT.&MF=;&8BTX^]&RNMOG_7Y& $9FV@'=TQ
M3W14.T-EAU]*>]W,X^9N>YP,FHHUWR*OJ:^@UZG1KNR:[&)$7T11^E1I"[H[
MJI(3[Q]*)WWSN0>,X%"3.@8 \,,$>M)7458=/1*Y'10:*L8H!8@#DFIF1X&:
M&92._P!*8A" 2*V)%.0,5:O+B?491/*%#$ 9 P*AMW\C1QI*DW)^]I;TZE7R
M6/*_./45UGPXMIO^%@Z$^W""\0\U@V]FK72VXR9B,X8[5'UKJ?A[/*GQ T-(
M[=-INU5G SCGL:AU'>R,)1JJ*DEI>US[$KD_B;_R33Q!_P!>C?TKK*Y/XF_\
MDT\0?]>C?TK8L^+1QS244JC<<"@$KEJV@E>VG>.,N0N#CL.YJJ!6C#.VGF)@
MK%&0[QT#9JC.ZR3,Z($4GA1VK.#;;[%*,.3F3U&9XQ25:L+47<Y1MV I/R]:
MK,,$CT-4I*]@Y&HJ0E*"5((ZBM"WT^.;29KD3?O(S]S%9X!+ =R:(R4KI="I
MTI0492V:NB2X_P!<3C&><5%3Y>)6'H<<U:TO[']L'VTD1X_#-)OEC<FC!SE&
M">_<K([@;1R.N*5U!&Y1M/<?X58GXEEGAE7:K;5XP2*I[B3DT)WU'4I*#L2K
M:R/(J( S$9X-1NAC<HW!!P: [*<JQ!]J0DDY)R35*_4&XM:+42E!P<TE%,@E
MGN'N&#/C@8&!3_,M_+0&-@X^\0>M5Z4J0 2#@]#4\JV-'4DVY/5ON)1115&8
M4444 %.7OSVIM*.AH 2BB@#/2@!RJ6R!UJZVCWZV7VO[-(8!U<#(%4XB1(.,
MUJ6>M7^DL5@NGP3\R]4(^AK*HZB^"WS,*KJK^':_F5K6*:W82R6TAA(Y(7M5
MG3=%FU>:9+>-E5>02IX%>G>#=6LKRPN;QXH7,8S)'M  '?(-37GC33+?3[F?
M3;%%:,;F4 +GWKQ:F95_:2IPI:Z*]]"<SK8BCA*<J45+F_!]5Z?@><2:!=-"
MGGL+#3HR2)+DX9CW(7J345EJ-K:3&WL6-NC*5DNV'[QA[?W<UFZIJ4^J7KW4
M\CLSDG#-G'L*I5ZL*,I0M5?RZ?\ !_K0,/2=DZ]GY=/GW_K0N"4K8SJI+*[C
MYC5:*-I'V*,DBI<XT_&WK)P?PIT,92+<5;S)?EC'MW-;;)FMTKM=QLR(J*HD
M!/7CD5[7^SY$!XIO)!&4!L ,G^+YAS7CC-!:2MNB$D@ "J3D+[GWKVOX!VMV
M/$]Y>73?ZRQ 12.0-P_*HYM49*?O1_JY]"4445N=(4444 07MY#I]A<7MRVV
M""-I)&]% R:\YB^*NH:J(K;1O".H/?W2^=:+=$1QRP_\]-W;Z5Z#JK6:Z1>'
M4,?8A"WGY&1LQS^E>767Q$^'WAGP@^G:=K-S=QP1.L*D,90&S\JL1QC/'TH
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M@HZFKUI,EM?122!)$C/*D\&O8O\ A;OP^ P/A_%_W[B_PH_X6Y\/O^B?Q?\
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M'OTKHE&,X^IO6A>+A(\+Z4H]NM>[W?Q3\ 6TV&\ Q.&&Y7$46&![]*A7XO\
M@!#E? ,:GVCB_P *M.ZNAI\RNCRNWTIGTR#[6ZVT7FEV=SSMQV'6K(GTZ$KY
M-M->WL@VQ(QVK&O;@=Z];?XG>"7AWOX%1E\L2D-''QD\#I52+XP>!EN/]'\"
M#S6XRB1 G]*Y/9<]VY?I_P $X?8^TNW/]%_F>6-/#8SA#;VJW?5B%W+#]?4U
MZI\ =9O-0\6:G!-.9(EM=PR.IW#FN7\=^/\ PIX@\/R:=H_A9-.NS*KFX5$'
M ZC@9K6_9P_Y'#4_^O/_ -F%:PH13YGJS:GAH1:D]6?3-%%%;G2%%%% #719
M$9'4,C#!4C((KQKXF^"M-\-Z!?:IHLJZ<E\Z6]S;>2)(GWG&X#JA]Q7K&M:A
M_9.AW^H[-YMH'E"^NT$XKRO3]7\27USX:_X2U=-U+1O$;YCMEAP;9P-Z<]Z
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MQG^=?=GD1?\ /)/^^12^3$.D2?\ ?(JFNPW'JCXE'@[4H462^46J'D!@2Q_
M5=L])CTX"[^P33E#A?.C. ?[Q'I[5]FF&,G)C0G_ '108HSUC3_OD5A*C.:M
M*7W:'-.A4FK3G]RM_P '\3XJFU.^+R.;:XFED^^_E$9_2L^2:^<,!82@L<Y\
MMC7W)Y$7_/)/^^11Y$7_ #R3_OD54:%..R-8X>G%)6V/AD'5<86.7'IY1&/T
MI$L[V?:AMW4]!^[85]S^1%_SR3_OD4>1%_SR3_OD5?(NA7LX]-#XU.C:[8>'
M&NX[.>)A-QY:DE5QU^E8\=QX@BQL:^!7..&XS7W)Y:8QL7'IBD\F+_GDG_?(
MK*%!*_/9W\C*&'2OSV=_(^'HK[7XR!_IC+G[I5N:U++4;PKFYM[Y1&,189OE
M]<\<BOLWR8O^>2?]\BD\B+_GDG_?(ISPU.2V*>'A?FBK/R/D&\U28VRR-HFZ
M)F !9&;/N*Q)+J6\<K>Z?.R]%FCB*NH]/0BOMKR8L8\M,?[HI/(B_P">2?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQQ]:](KQSPO81ZEX\TK4- \'W?ARSLHI%O99D\L39&!'M'WL'G->QT %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 'V:V?"EU</XJTU6GD(,XR"QI/#V5[C56_0]YHHHKF-0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1^(YM8FLE9;2,Q"-(R1@L0.K8[UW5 'CFO:%;Z5\=O"UZDT\MQ?M/)*TK[L
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M:\(_\C9IG_7<5BUM>$?^1LTS_KN*F7PL:W/?Z***\TZPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBL6MKPC_ ,C9IG_7<5,OA8UN>_T445YIUA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img105269759_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0!+4# 2(  A$! Q$!_\0
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ME3Z* &>3%_SS3\J/)B_YYI^5/HH :(HU.510?4"G444 %%%% !1110 4444
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MR8O^>:?E3Z* &>3%_P \T_*CR8O^>:?E3Z* &>3%_P \T_*CR8O^>:?E3Z*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-BDYVC/KBEHH 0@$8(!
M'O0 %&  ![4M% ";%)R5&?7%!12<E1GUQ2T4 %%%% $<L$4Z[98U<>C#-'D1
M%0OE)M'0;1Q4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 A8*"6( '4FJ US2FF\D:C;&3.-O
MF#-0^(='?7---FEW);!C\SQG!QZ5PNN^!/"6F:%<2/=^5=Q1DK-YOSEP./UH
M ]0!!&0<BBN/^&MUJ5WX.MGU+<7'",_5E[$UV% !13=Z!PFY=Y&0N>:=0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5[
MVW>ZLI8$D,;.I =>HH AEUK3()_)EO[=)>FQI #5U75U#(P92,@CO7G%U\._
M#5EIMR^I7IDN]K.9Y9<,#[59^$]S?S^'[B.[D>2&*8I;R/U9* ._HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+J]M
M;&/S+JXCA3^](P J9V"(S'H!FO';;[+XZ\4ZG>ZW>B/2+%_+B@9]JL?6@#UR
MUO+:]C\RUGCF3^\C BIZY'PKX9TO2+V:\T:_:2TE7'D"3<JGU%==0 44C,J*
M68@ =230"& *D$'H10 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'O7;5Q-Q_P E>M/^P>]=M0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7CWBSQCX"_M6ZL;C2FNM0C<K($CQS]:]AK%A\)Z'#>37@TZ!KB
M9MSR,N230!\^W-OJ>KW(/A;1M1L5SP[2-MKVSX=6'B/3_#YC\2RK)=%\H0<X
M7WKK8X8H4"11JBCLHQ3Z "BBB@ HHHH *X6Y_P"2QVG_ &#V_G7=5PMS_P E
MCM/^P>W\Z .ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-K# '>OH*KA+F1Y>.PT</-1B[Z!1115G$%%%% !1110 4444 %%%% !1110
M4444 %%%% !114%Y=)96DMS(&*1J6;:,G% $]<*GQ0TMO$=QI!M+I3;OLDG*
M?(#3K/XL>%+L,1>F,J2I$@P<BI] \5^%O$6LW-EID227"C=(_EC!_&@#KT=9
M$5U.589!K-\1:L=#T"\U(1F0P(6"#O6F    , 5A^,YG@\(ZE)'")6$1PA[T
M ><6?CKXDZG:K>6/AJ%[:3E&YY%>@>"]1\0ZEI3R^(]/6RNPY"QKW7UKRWPU
MI/Q,FT.&;2=6MH+.3+)&W.WVKU#P5:^);329$\3W<=S>&0E7CZ;: .FHHHH
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M-X?,?1116IXH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>_\
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M&3ZUQ4OQ4U)];MX;[PWYHCB"O;R0[I';U!]*V[/XC13ZA;0_\(#+$9) OF&
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M7T!6]+8^>S?^,O0****T/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6'*LL0!!R*Z#PW_R+6F_]>Z?RH U**** "BBB@ HHHH **** "BBB@ HHHH
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M]1'_ +H_E6U+J>'G&\/F/HHHK4\4**** "BBB@ HHHH **** "BBB@ HHHH
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MZ\.W;WL:M$"B?(QZ9KN/A9HE[HWAE_MZ&.6YE,WE_P!T'M0!W-%%% !1110
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M9.U=_0!Y+\0D2Q\;V6J:O;-/HRPE,;=P5_4BN TB\369M.TS2H7:=+TR[E&
MB9KU3QKXU@T7Q38Z/J*6CZ9=+^^\WEE'K5S2-?\ A[IMPJ:9>Z?%-*VU=G4D
M]J!G;Q@B) >H S3J0$$ CH:6@04444 %%%% '$W'_)7K3_L'O7;5Q-Q_R5ZT
M_P"P>]=M0 4444 %%17,WV>VDF"%]BEMHZFO.[/XKV]UXHETL6<A4+A%'WM_
M<&@#TFBO-M0^*\-EXFM],-E( RXD4_>W=@*T?&'Q 7PSIJ3-9N)94#1[^G/8
MT =Q17 S_$N"/PS_ &N+&;88_E<XVEL5H^"?&J>+K)9%MG1E7]X_\.[T% '6
MT444 %-?_5M]#3J:_P#JV^AH ^:-2_Y#%]_UW;^=5JLZE_R&+[_KNW\ZK5RG
MVL?A04444AA1110!T7@/_D=;#\:^@*^?_ ?_ ".MA^-?0%;TMCY[-_XR] HH
MHK0\H^>?$7_(S:C_ -=C6;6EXB_Y&;4?^NQK-KTH[(Y'N%%%%4(**** -?PK
M_P C9IW_ %TKZ!KY^\*_\C9IW_72OH&N/$?$C>EL%%%%<YJ%%%% !1110 5'
M<!FMI0APQ0X/H<5)4-V,V<XW;<QMSZ<4 ?/-GI/A"74M1'C'6)1?I.=I60XV
MYKT/X;Z?X)M-3O'\+W\ES<,@\T,Y.!7%>#4\!++J</B&:UFNEN&(FF)PPSVK
MTWP>G@A;RX_X1<V?VC:/-\CKCWH&=C6)XOU&YTKPKJ%[:#,\41*?6MNLW7KN
MWL=#N[F[@,]NB$O&.K"@1X3!:PVFIZ/K,FK/+=7T#O.[2_ZL^GM7I?PJU6[U
M70;J2ZF>8)<,L<CG)9:YVS^&/A/Q3##K-K=7,%O*2P@\S 'J*]/T;2K'1M-B
MLM/15AC&/E[T :%%%% !1110 5PMS_R6.T_[![?SKNJX6Y_Y+':?]@]OYT =
MU1110 444V21(8VD<X11DGT% #J*Y>/Q]H,NMR:8+H;T4-YG\))[#WJ77/&V
MCZ"T:7,^9'D5"B]5SW/M0!T=%<YJ?C?0],T]KQ[M9%&,*O5OI5NW\3Z1<Z?]
MN2\3R !N;GY2>QH V**YW1?&FCZ[/+!;3@2QR&,(>K8[CVKHJ "BBB@ KP?X
MD?\ ([7'_7,5[Q7@_P 2/^1VN/\ KF*SJ;'J93_'?H<K1116!]$%%%% !72>
M /\ D=[#\:YNND\ ?\CO8?C3CN8XG^#/T9[]11174?'A7C/Q._Y&M/\ KB*]
MFKQGXG?\C6G_ %Q%;8?XS.K\)QM%%%=QSA1110 4?Q)_O#^=%'\2?[P_G2 ^
MCM,_Y!=K_P!<E_E5JJNF?\@NU_ZY+_*K5>:]SL04444@"BBB@ HHHH ****
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MK;#_ !F=7X3C:***[CG"BBB@ H_B3_>'\Z*/XD_WA_.D!]':9_R"[7_KDO\
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MO=/Y5PWB[XA:%J'A34;2$W?FRQ;5W6[ 9R.]=SX<&/#>G _\^Z?RH U****
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M,M_??_OHT44 =U\.L^5>Y8GYAU-=S7#?#K_57O\ O"NYJ1A37_U;?0TZFO\
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MUM^$=7U&[\0)%<7;R1E"=IKDZZ#P5_R,J?[AI >IT444AA7@_P 2/^1VN/\
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M=-JA!1110 4444 =U\.O]5>_[PKN:X;X=?ZJ]_WA7<U(PIK_ .K;Z&G4U_\
M5M]#0!\T:E_R&+[_ *[M_.JU6=2_Y#%]_P!=V_G5:N4^UC\*"BBBD,**** .
MB\!_\CK8?C7T!7S_ . _^1UL/QKZ K>EL?/9O_&7H%%%%:'E'SSXB_Y&;4?^
MNQK-K2\1?\C-J/\ UV-9M>E'9'(]PHHHJA!1110!K^%?^1LT[_KI7T#7S]X5
M_P"1LT[_ *Z5] UQXCXD;TM@HHHKG-0HHHH **** "O%/B1]J\1_$2S\*VXA
M@\V(.;@IEJ]KKROQO\-M=U_QC'KVD:M'8O'$$4X^8&@#DK30KGX=>-],TR^,
M&HVE^=JM)'S7NUIIEC8NSVMI# S#!,: 9KQ>\^$7C34;J"ZO/$Z33P',4C Y
M3Z5W'@7PQXJT*_N9=?UXZC#(@$:<_*?6@#NZ\^N-0\1F77H;B;36C"D6,4CC
MD^C"O0:\F\;?#+1(+75?$4MW?^<<RE5D. ?I0!FQ:S\3XHE1/['15& JR* *
M]"\"W?B"\T>1_$1MC="0A?L[ KMKR[0OAMH>J>#?[7EUN<7#1LX(FP%QT!&:
M['X+K;Q^%)T@EDE"W#!G<YR?:@#TFBBB@ HHHH *X6Y_Y+':?]@]OYUW5<+<
M_P#)8[3_ +![?SH [JBBB@".X_X]I?\ </\ *O$I/]?+_OG^=>VW'_'M+_N'
M^5>)2?Z^7_?/\Z: ;1113$%%%% !70>"O^1E3_<-<_70>"O^1E3_ '#2 ]3H
MHHI#"O!_B1_R.UQ_US%>\5X/\2/^1VN/^N8K.IL>IE/\=^ARM%%%8'T04444
M %=)X _Y'>P_&N;KI/ '_([V'XTX[F.)_@S]&>_4445U'QX5XS\3O^1K3_KB
M*]FKQGXG?\C6G_7$5MA_C,ZOPG&T445W'.%%%% !1_$G^\/YT4?Q)_O#^=(#
MZ.TS_D%VO_7)?Y5:JKIG_(+M?^N2_P JM5YKW.Q!1112 **** "BBB@ HHHH
M *\?^)>@>'QK"WMYK_\ 9QG(\^)>3)7L%>.>(/"]W=^.M9N+G3#>QS6Q-J7&
M54@?SH =I6H>$=6\7Z,MEK._[)&([>W"8RWK7L-> >#H8;OQ3I$>G^'GMKBS
M)^V3.A 'N*]_H **** "BFB2,N4#J7'50>13J .=\>?\B/JW_7'^HJ]X;_Y%
MK3?^O=/Y51\>?\B/JW_7'^HJ]X;_ .1:TW_KW3^5 &I1110 445RNJ?$#1-*
MU2WL)ILR2L58CC9CUH ZJBL#5?&&DZ3I@OII\HR%XP!C>/:H+?Q[H4^F)>_:
M@JLF_:1TXZ9H Z:BN8TOQ[H>J:>+M;CRQSN4C)7'K1H/CO1O$%Q);VTI$JR&
M-5/.['>@#IZ*** "BBB@#P;XB_\ ([77^Z*Y:NI^(O\ R.UU_NBN6KFENSZ_
M"_P8>B"BBBI-PHHHH FLO^0C:_\ 75?YU],P_P"HC_W1_*OF:R_Y"-K_ -=5
M_G7TS#_J(_\ ='\JVI=3P\XWA\Q]%%%:GBA17(>._$U[X;MK62RCC=I7VMOK
MB_\ A:.N?\^]M^5:QI2DKHAS2=F>QUYAXI^+5QX:UZ?3CX=NIXXR LXX5R?2
MLO\ X6CKG_/O;?E69K7C74M=MXH;J"!5BE692HY)'2G["8O:Q.]\$>/KKQ=?
M7%O/H5SIZQ(&#RCAO:NYKQM?B?K:C MK4?04O_"T=<_Y][;\J/83#VL3V.BO
M'!\4=<+H/L]MRP'2O7K61IK2&5OO.@8_B*B=-PW*C)2V):***@H**** "BBB
M@ HHHH **** "BBL+Q<->.A2?\(X8QJ.X;3)TQWH O:MIEEJ=C)%?6T<\84G
M:PSVKA/A7'IUU!?3PZ3#:R0SM&&"\D UR]UKWQ1L]6MM*FN+,WEQ]U @Z>M.
MDU;XA^'=8TZVOVL;>WNY@',<8 ///XT >X44U"3&I/4@4Z@ HHHH **** .)
MN/\ DKUI_P!@]Z[:N)N/^2O6G_8/>NVH *CN/^/:7_=/\JDJ.X_X]I?]T_RH
M \2E_P!?+_OG^=-ITO\ KY?]\_SIM4(**** "BBB@#NOAU_JKW_>%=S7#?#K
M_57O^\*[FI&%-?\ U;?0TZFO_JV^AH ^:-2_Y#%]_P!=V_G5:K.I?\AB^_Z[
MM_.JU<I]K'X4%%%%(84444 =%X#_ .1UL/QKZ KY_P# ?_(ZV'XU] 5O2V/G
MLW_C+T"BBBM#RCYY\1?\C-J/_78UFUI>(O\ D9M1_P"NQK-KTH[(Y'N%%%%4
M(**** -?PK_R-FG?]=*^@:^?O"O_ "-FG?\ 72OH&N/$?$C>EL%%%%<YJ%%%
M% !1110 4444 %%%% !4%Y:07]I+:W"!X9%VLI[BIZ\LUGXLW^DZM>68\+WD
ML5NY7S@#M8#O0!C:[\//#.D:_9Z?+JNH0"_8^7;Q'Y/H:]8T'0;'P[ID=C81
MA(E_4^M>*ZG\1DUW4+'6)?"UX_V$DI(N=HKU7P+XN/C+1GU V3V@60H%;O[T
M =31110 4444 %<+<_\ )8[3_L'M_.NZKA;G_DL=I_V#V_G0!W5%%% $=Q_Q
M[2_[A_E7B4G^OE_WS_.O;;C_ (]I?]P_RKQ*3_7R_P"^?YTT VBBBF(****
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MG30#:***8@HHHH *Z#P5_P C*G^X:Y^N@\%?\C*G^X:0'J=%%%(85X/\2/\
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M<5NT44 <[X\_Y$?5O^N/]15[PW_R+6F_]>Z?RJCX\_Y$?5O^N/\ 45>\-_\
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M "BBB@ HHHH *" 1@C(HHH S9/#^DRZFNHO80&[5=HD*C.*NBUMP<B"($?[
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M@Z1_T#;3_OT*<-#TH#C3K4?]LA5PFX.Z%**DK'S5_:MG_P ]3_WP:/[5L_\
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M6\.7Q6-PQX["O7$\<W:QJO\ PBNK< #[E=K1344MCFQ&*J5[<_0XS_A.KO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45SFL>.-"T.Z^S7=TQF[K$A<CZXH Z.BLS1O$&FZ_;F;3KA957[PZ%?J*TZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6BKM\J)5(]\5Q=EIM['\8;B]:UD%HUH5$V/ESZ4"._BBCA0)$BHH[*,"N/\
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M?]\UL>%-#U:W\56,TVGSQQ*WS,R\"NV37*]3G2=SVZO+?&L8\8>-K'PQP]K
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MRW6FW2JMS&!EU;^]0!J7OBO6=1U^71O#MO"\EJ!]IGE^X#Z"F:-XMUV7QN=
MU2TAB"P[]Z_Q'U'M5&--2\%^*+_4(M.EO=.U(AR(AEXS[BJFE:A=:I\7_M%S
M:FV(LP$0]=OO0!ZO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !377>C(3@,,<4ZB@#@[KP
M9X@+S06?B1XK"4G=$R;F /8&NHT#0[;P_I:65L"0.78]6;N:U** "BBB@#D]
M:\-:Q<:FU]HVMM9.XPZ.NY3]!3_#7A#^Q[R;4K^[:]U.;AIR,8'H!74T4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img105269759_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (' RX# 2(  A$! Q$!_\0
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MA$,AN+LLW[J96QY>,?7GVKJ/%?B0>&/#DNM_8Y+R"$H95C;!6,D OTYQG.*
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MP;>V^S0C3]/6%I3WED8Y.\CC ('6NI7Q1I+' N2#[H13SXBTP-M\\DXSPI-
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MIK=)7_[X-.37].<X68D_[IH TZ*RG\1Z8A(,YX.#A":;_P )+I9.!.Q_X :
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M.X?.,&,T ;=%8\WBC28-H>X.3V"$D5K@@@$=#0 M%%% !1110 4444 %%%%
M!1110 4444 4M7&[2+H>L9K@?G:4I$OF''.1C KOM8&[1[L9Q^[-<%(TP\E@
MRQ9&,KU"^] $0E:RDDW;&.0/Q]JD\Y/L82,?.YVA@>A/K1;20V]RS7 +A>$V
MC((_QJI,QDNF<)LC8=&&": -&;3Q:V320RE!MR1GBJN'>UBB252K$<8Z'WJ%
M8Y)T+HI=5!/SDDG%+YPEC"!<;0!E>,'W]Z +UW:26\<;/<;F<@;,=CUJ-9+O
MR))+<H(V.W+C[U5S(TS?Z5<89/D48SQZTX7,JV?V?8C(.CANGX4 5;8?;=\6
M )023SQ]!5EHI[=D0L!(RD#8>0!ZTD,<$,#+(KQ9^8-GEC3H;*YF!DB8Q*1@
M9^\10!6@19;7>\I#+T .-M,@D9X$D /WR"PZXJ.XMWAE*3KEB,[E_B%+Y'DQ
M(0P.>3M;.* +90S7"H/F+'"NXQCUJ1$>WGFB<*Y:,XP/Z5#-YUP8H$()49+$
M4L;-;QS1M&?.*Y+YSQ0!4@8I&0J9W?P;.GXU?6QN8=LD+@>8/F4C.*KND953
M!]].6?/%3)J%W(NV"/<%ZL>] "W%C:00+YLC&7..#WJMY"HZ)"QWOSN;M22R
MR>=^^1DD/W=O0FEEE<,CJ55XAA<# (H L-I4> 9)&\P]3FJJQ_8[K8S$QL.>
M>U3R7S2H"(7+?I52<L%#R.K.Q^;!Z4 ).4+!H%E ]:2S,1O%WAB>^ZMF-[=H
M5"-&V!TK-G,,LZB$?.IP6'2@"S<7KS3>1$H/;)%-;3[J+$B.-QZC%0V4\=O=
M2"<;<G@^E:YNX%!8S+C'8T 94DEQ?%(63$L7(]Q4YOIK8[)8<GU'%-6[\N66
M[*8)&V,4L=G=3[7DFY/O0!&LTT8FFV[6?@<5:^QW MMZE&)'(89 J&:":*9(
M7E+ _,,]B*?-;7<MOODN,Q8R,\9H ]%TP$:7:@XSY2].G2K=5-+&-)M!Z1+_
M "JW0 5QVK+_ ,32<X_B_I78UR>J#_B8SG_:_I0!0*D?-VI" Z_+UI[*Q4TQ
M%*Y).* &>6P&33ADC!I6E4+\S 56DND7.T$F@":1BHXJ($DY-4VU-22!&QQ2
MPZ@CL%V,"3B@#25LCFK,7S8"GI67->+;CYB"W]T5)]J#VH=?E!ZD"@#81BO
M(:E,BIP3C/K7.O<R#+1[MH[GUI\=U-(A$A&0=I?% &U(D.]9#&I)/WJ9=WB+
M;.(QDX[5G&]%I"1.VY6^XO<CU-.79<Q!X.AZJ: ,Z%1)%+(!EEQC^M$IAW%D
MR1Z8(-/F:>VE*A2N3P,=:F,+*\2+EIOO/SP* 'G3$N8U ; QDFJAMDM[P_:2
M67U%:Z-(!C!SCL.AK(DCD7.]9?-S][L: %?+0L(B$0G@'K1"?LT"SQN">5(8
M=Z<R39$C1;AW%1[ 9<.0K'D+GI0!,S1F.!B-Z@L2/4T^:[CNH%#VS;Q]UE/
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MT 9LD;1L%!5CG[X/;TJX(K>=%;&<<8-0N;6%3Y3EF'3/2EAMMU@]PK'S$.<
M]* +<;Y'E[,(.V*SP2DCA 5A9@#FMF-XOL*7#$ D<^]9LH\Y/M'*QO)M"^U
M#YX+>.6"*/AY&SDGGZ"IMBAF&=PZ=:AN8TMD#H27)"[FY('M3;3/ELW\)/&:
M "62*)RJ\@#G:.E,\T7$D4;/LA/.ZK.FRQPSR03J/GY!-074$=O=>4N"C\[<
MYVF@"&9[8DQPQX(./,/4U<BF!B."6*#D&JD<4B2%XRJ^Y'2EA>1$EECQA3\Q
M(ZT 2>?.Z[OM4<8/&W'(JQ!;M(A,=Z=P'X4CS6T=OY[0KC .U>IJNTML\ZJR
M20.XRH(X84 +;QB?.Y,LK<GL:LW-K%(03C&.M01+YEP+:)S&IZGUI+N"6SD"
MB7>AZ9H EN(E>V\J,@ 8SZ509F'[LD,G^ST-2,3,GE[B :9#%=1R;$7) P&[
M?A0!,+JYM0LAVJA. G>I&=(;X23'S%<#<IZBF+ITBRAY6W=\9IBQG[0TK R*
MI!+#I]* +=P;6?(MX4..LC#"CZ4VT"(OEK*"?:H9+B.2?B-FB7H@XS4D2M*P
MGD41HOW% QB@"2Y@9XRH/4?G3()FM+?RH[;Y^['I]:=/,=BG.T$X) Z"JIN$
MBN1Y99HQ]YCWH 'DR?,>0O-V;L*<D4ETCN\BJB#[S#K3;: 7MP45@H)J>XBA
MLV$3NTF.=HZ"@#9\*)$M\S#_ %C19Y],UV%<5X6<2Z]*ZCY?(P!Z<BNUH *P
M/&3,GAV4AV3YT!8#.!FM^L+Q>H?P_*I<H"ZY(^M '%O=PV&GQI:J'>3ICG-5
M9TU/RC-,0T>!E?04Z336DL4:U;F(]CS^=(\U_/&8&*(K##'N* $=EEM/M",[
M-N"N3R56I+@6'V?;;J7F;D;#D@^N:GB@@LK,CS5V8RW/7ZU6CO!"K2V]E\G\
M3$8S0 ^*XNY+</$J,(^"6ZG'6J,DLC317F65&;)XZ8JX\6VTDN8IRD,GWD6J
M\<D[6>53%NG^<T 32N=3O(V7BWBY+,,#-7+AK5H7:)HY9<<8YQBLT3&Z$2.5
M2/&2.@:I;L6ZSQ"U3$P(SM[#WH DLGLEM-\SJ96'SD]2:K!$?3]IG"!7+1JW
M<>]2RS1) \B6L:E@=K Y(/N*=9VMH\2R2'?(W))Y- "2"XOK9"7B\N+YOE.2
M<5"9YS )?M0RPX7 R3VJ6W\JVNKU@?W*C\,U5CAE\EKR*-(D49&5Y- %N9[B
M1$68Y.T#:&QS[U49XSMA\AI)UX;:/YU8M;@R1++*"=QW,H[>]2Z7M?SQQO+D
MDT 5KB>9%0O"8BG1AR!]:D*JB1O(3(L@+,R_Q'L*N74JP6[F4!AC 'K[5GV\
M;RF.T=RL87<5!QUZ"@!WEV\T2>9<A9A]WYLE?:HF2;>4FE:6)#D]O_UU=;3;
M40/&$PP[U4M&26V8S<R X!+8! H MZA,PAACP5B)Y/M4*.F93"F(<#!/&/6M
M",PR6I:5FE4'/[Q@2/\ ZU4[JYAGL7C@C!<$%4'&X ^M #9G\\1SSP2;!@!S
MZ42"W6\C4;EA9>>>IJ0ZBC0F.6&0$C&TIR?:H[>WC>P\BX(+*">O*@]J +%U
M##:W5N("59B>_45499$S%L.\G[P/:F0HT$<=R8I'B3A26Z+6A]I:\N&$2QJ$
M Y89)S0 Z-Q!'&TN,+V[D^@J-S+)=N$_=&8<B09'X&GHDMW-LQ&KP]\<<^GH
M:)K.:&UE=L-L_P!6 >0#U/UH 680QO:^4RR")QYF#GGIFO3E^X/I7E5I/!;S
M(Z@-'L 8=UY[^]>JIRBGVH 6BBB@ HHHH *Y+XF6KWO@#4[>*RGO)'50D,)^
M8G<,'Z"NMKG?'6NS^&_!NHZI:INN(D CR,@,2 "?89S0!PFF^++R);*VD^&%
MTA&R,RA4"KT&[IG'>O7:\=G3Q1X*72-?N?%LFKQWMQ%%<V3J-K"3C,>/3->Q
M4 <]XTO]+T[PW--K&FOJ-JSJGV9(?-+L3QQ_6O+_  YX0\1S^)[;5="TV;PO
MI E5YK>:Y+-,N>1L[ C\J]%^(]OJESX/FCT:UEN+_P V,Q"*38RD-G=GV]*P
M=*\9^.KB[M;6Y\%J(_,2.XG6Z!V#H6(Q^.* /2J*** *6L!3H]V&("^6<DUY
M[;G_ $AH+8##'Y9&&<#U%>@ZP=NCW9)  C/7I7GLRK<31^3(5&,8QC/TH GN
M+(6DL;+-YDCM@J><^]26L%C(DK7$ZI,&(P6(--LHX/-90XWC@L33!:17=_,A
MEV(AP #C/O0!&LEQ]JDCMG:3/ .."M2P)O1VESD.$<]< 5$IB@FG>*5Q'%@
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M ,:SMRN(;K#>STRUF+':[#<,C-6#I]MC8J@\=13([:*&!\@(1U=J )I6S\G
M&."3UJC;L+5\M;F1@2584^.-R#)Y:3YX#DY _"I%_P!%MW!.]\\#MDT 12)+
M=2^?.<=@!VJ=)< YZ 53F\^+#R2@D]4!Z56\Z61'+DA&X!H O->QJV.7'?;T
M%)/<;R-KD($SQWK.=W=BL?$8. N:O6\<44/F2C>PY [4 .1V)$.]5./G=OX?
M;%)&VR20J=Z*OWL8J*68RREG503Z#I3<N"" T:G^(T =#X3F>6_D+,H'EG"
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M,YP*9!=/:1B":*1F7H5&<T /AEDMIGMY]C/MRDF,&JUO%+J$3RRW#AAG:H.
M*0S^;>^;*/*"C&UNI]SZ4@MF1O+CO@BDY QZT 1M=R?8_*)VLKA7([BG3PV4
M=ONA<B8CY0AR2:LHEO!"UOM\S<?F8CK22V9B :WCVKU8C@X]* (97G;[+:N_
MEEUR[=ZG&G6JM\RL_N3566-I47=)MD0_*Q;./8U.)+Z0>6J1AB/O[L_I0 RS
MV1:PR6^1$!AN>]2:F/-($13ALE"<;JB=#91FVC?==R'+28Z5'<V"16AD&YI
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M)@N>O% &7<2EY6F!P&[YYI8F=%+ #]XP )'ZUH+:6:1-(9%)ZY-(\4$\0 G
M Y#8QB@#,O()Y)0'0[P.=O6G6J)&NR17"GKBM&!X;57F:4RR$[>>]02YG+R0
M]6.&4]J (0L1N2)2RQ_P =#5G3V^2:/!"ACC!ZU&$ A$+KNR>OI2+,889$B7
M:!T/<T 7L,S8 &!TIZ+*&'.!3-,LY)X#+,[JY/%6(V)E:-CDH: (FC_>-NR:
M8\(CA:54W'-1ZC?M;,$0#<>2?:J<-U/<RA(VVY]30!+]JG:+S=NR+.TD'I4M
MU;3:A:"*-_G4[@N?O532)Y3(AE(&[D+T-6X3%*YC:X\N-!C@X+&@"32["XL8
M)6G.&?I&#FG3IOR'QM-0B<0&?8Q>$?=.>IJJ;AIVP^0H()QZ4 3NELJ$( 2!
MS4#-&(ANVA/05)>W5JS1K;1%%7JYZFJ\\;!$=BNWJ : !K=IH@+91@]2.N*L
M^21"L*JQXP?:J:G]W\K'D_-CTJ4(5MF=F8+NXR>HH F%LRD%67*GCFDE?S9,
M7$X.WL.PIJF%I08<A%7YF]338[<LS2&&1H\DB@#HO"\4S7QG9 D9B(4#TSWK
MK:Y'PO.\FI,@=C&L.,'L<UUU !6'XN:)?#TS3+N0,IQ^-;E8GBU86\/3K.^Q
M"5Y]\T <!'#>^2;F +"@Y$8'45+;M)<@746T,3M>,GJ1W%58#-<J+3[3B/UP
M02*U3:Q6D"K&3@#GW- %![;]X?,R Q_U<?0_6IH+L,7M@A20 [0>AJ56VDX'
MS$=344-O)-<!V7:0, +Z4 1;8TA*RK*+GJ&Z\_X4B3R>8P,JH44%B1GFB0Y?
M;N^=2=_/2J[@HWF&/(R,<<'ZT 31/.L#N(D=9"<EOX2:(;=E4DG* @LOK2V\
MLASNP W8<XH29E_NX)P5S\P]Z )9KB(6Y:)<2=,D<#WJO.KP1JGVEG6;C).>
M?:G^7)"7$IW+V4U''$K.6*G(['M]* *SVWE1Q12QQQD'F49W,/I4BM'ERI9C
MO!#]P*LEY$E\QHRZ8P W) J"*,M,\P4QM_""* )=TANC<6T9E)&'4\$&F32W
M%RIB98DW'! ;D4RX,RH\F\9.-^SC J62"S%AYJD XSN[YH =J2"(0DR@87;@
M]OI4$,=O.%6&7?.#D+)T/M33*6EM9+@;DVXYI]PD7VZ'[-@,>210 Z6:7S8C
M*BY4D*B=6_&F;+>>Y59(VA<]@?O"GM)''>R/<,00?D.,C%1F;S[B-E7Y(SG=
MC'- ">7%/>-'C;'&,!1QS3;V*)8%\M IW  CM4DB0W-T3;7 64CD=C4#Q22.
MT4DX+H#M4#J?K0!+>3K/$J(Y?809%'<4R1X[H1I##M((+,5P !44DAAD5T@,
M>%VC<,?-5C[(67=<7#<\GG H 9+!-!MBW[D=LA,]?K3;B"6.54FD ##) Z*!
MZ4V"U%R73S2%5\QL3T-/F@E61=S&25LX+' 4"@ W2R((FD^53RV#DT\KY:2%
M6(3'*X]*B8N-X?(F!PPS^M/CD.S$@)X^8=>* %(E2:-]V<X)!/'7I7LB?ZM?
MH*\>B$7GJ% PI!R>?I@5["G^K7Z"@!U%%% !1110 5C>++S3;'PO?SZO%YUC
MY>V6(#)<'C ]\FMFL;Q7H(\2^'+K2_.,+R@&.3&=KJ05/Y@4 >0VNG>$/#7Q
M MD>VUF\6)HBTMPX,-D[C]VK#J3VYZ5[O7F%O\.=;ETEX=2U.VFO+[4XKO4)
M44@&./[JI^0KT^@#SWQ3XF\+^(?!&J_;#?FRAN1:RM#;MYD<N>&4=\'O7 >'
M=8TF\\3:3_;7B'6]76VF5;&WDT]HT5SPK.3UQZUV/Q1O_%NGQI#H.EI_9[S1
M,US#@N9"WW2OH>YJ%(OB-K.KZ9'<Z)8:/9PW*S3SQ2HQ9!U7 ]:!GJU%%% C
M/US)T2\P<'RC@UPJZM>*!%Y:;@ ,ENAKNM<)&AWI'7RC7'6^B0-:+OR96&<Y
M[T -LK<?:6N+JX9I#TQVJ*YN);_4A:[VAAZ*!U;\:A25[1V@F4[<X#8JW]D:
MZE2:V8&1.0">M %B71K>*V;#'S ,[B>1^-4;*UN+B$W5O<&*0\,,_>QWJ>ZA
MO98B;IT6)?O+&>35*"":[EVPL%5>"?2@"R]I?W*GS[@-".6.:9:6<NH,2LKI
M;KPJCC-1S6TUADR.61N"15K2M4BMX!!<#8P. 2.HH AN[:YM('BD+26Q.<YY
M!]:6W:ZLH5=&$T!Q^%7-3U2%;9DB97D?A1UQ67'!).!;LSXC P@.* +*12ZC
M?F94\N,)]X]2:K[8U56G!5"Q))Y+=L 5-_9UQ;1_:(I,,O5<\4D$Z76I0W$N
M-K+M [!J *?GRPC;!)*L7HR]*OV,4:312R3F5%X7C(%:LX@2)]X!!''%<_;Q
M//YJI@(LA(!; 'O0!T%]<6L>#*0%(XS6*)[0W.<D)GC(QFEU!U9K<*0^S&YQ
MR":JW#?+M;[W.1GK0!NI%#+;R2@_(1R36;,M@%W(I+'LO %-,SKI21=,X!^E
M.DB:!;>-  TQ^\1TH A^S731;US&G;)Q421,L@D:3'J<UIM8W4$8ECE,@[JW
M(-16\D-QJ0:09#+A1CC(ZT ,BD2:9R"<CA%0U#Y<K3-]GW!Q]XJ<#-:U]IPD
MA)A4"4'@XQ5&RNTMIVDE.%;N1W'44 4V(5&!C8S@='JU&UE'IP#89QUX_G4W
MFKJ-ZFP!8E;=D\%J@NHO-N!!'&F\#);KUH @@AF&RX@)9NZ^HJ]+J%P\+1B"
M17(QG'05&='F2#S(I6\P<G)JWI]W)+:RHZAMHQUYS0!EQP2R*6M\A(^K=R:<
MLTFUDB8*3][TSZCWJS"]S DD:1 AB<$G&,^U1FW5(3')NR!D8'5O>@#O],&-
M+M1_TR7^56ZK:<,:;;#IB)?Y59H *X;4;NVMO$MRTLN,'D>AQ7<UYKXCLI3X
MAN72-6:1LKD\=!S0!/$Q:RN&C96:3. 3CBH[4I'%Y8.6QELBLZWM9Q(=S$ #
MJ>A-73<H"07#2MU8?RH 9+)(LFR/]VI_BJ-B!(1$VY@<9SRU)(TMPCF,YVG[
MOJ*="D,[ J&C=1R* )I[5[6%':4^8YP%%1/F7]ZR B/@Y[FGDI%+OFG+A?NK
MGFJIERF-QR#G:1C\: +(1Y+K>T)93]U2<"I4MRH<R%8QG( .<53:1@482,03
MU)QG\*GDF:Y12R#:AYQWH L_95E0+O.<Y#4D1 ;[/;?-(WWF/:EM2(H&<G:F
M?K2V<Q@FDE@*-CEED7I0 Q5N(KAXGY91Q[U)8P.;E5=._(-%M=+->-+-G>XX
MP.*MS&2WECDC7=ZX]* -9W$4))4#:,US^FEQ+/.XX8U;EO)+C,:C:G?/4U7N
MI?(M\HO% #+JWBO)06)# =JKM91Q,JKDLW11U-5S*Q)9B=W;FK:7(AG\\IND
M*C:3VH :[26D@C>(*3S@&E$T:R1+]E4F;.USTR.Q]*9=!C(':3S#(-Q/]*B7
M&[&30!8EE4P_O8C&K<9'2J22&&8X!;(Q5N<A; Q2-\[N-J^U5]LYN5C4KO(_
M(4 (;64G<Y^5S@''-6K,6YNRMT2 @PH8=*+RWFLO+$DP?=U3N*55>1Q*X!RH
M7D=<4 27#+=2GR80J X#],U494)E#L_F*<*IZ59B\ZZN3;1815&2:8W^C74B
M,1($')/K0 ]XU15^=0^/NU/%?S1VWD+'\XX!Q56",S3N9.&(#$"M6U41$W%P
MH"K]T>M &AX:LC;RO-,W[Z5<X]!725R'AN\DO-=E=WR/*.$ X49&*Z^@ K!\
M8%1H+%@"!*G!^M;U8?BP0'09%N/]6SH/QS0!P.IR0/$OE,&G4_($ZUJK,BVT
M0E R5[]:2VLH+4%D0,<<9K)VB]O)S,22IPN#P!0!K!XI"%*CZU4O9&DE2U1C
M&IY)'<51N(/L:K-%*<@X*L<YIUQ,US$I*!8$;!8?>!^M $]REO'-;I'&N\YW
M,O?ZU [.P55SMSQ@8PWI34C$<,DT+@+T&[DM4N6=1#QC[VT'G/K0 Q%FC)6(
M+)+G<%8Y!'>IYE$ACDD4QKNYQR15?<D3.Y9EGS\H X(H/SJRN&,Y.=^>!0!*
MRL&$K-B,/\F\X)J=U83F25U ( ^3D&J]KY5S(9;F91@$+&>WUJ&%E$1BP7)<
MA#G _.@"9[M/-\M,<'J1D5&&:0N%< @9;!IKP2 E0KYX+ ?W?:I&5+HQQVR$
M>7G<6&/PH 2W;$F7Y&,!6'44PVT D+1J6V\E2?E%#)-;LHE)*@Y4'K3FQ+MQ
MCH3Z$T +.H> >:%56(]]OO42);Q1% 5#,W#'C</Z4Z/,,Q8LK+P3NJ.-/M!D
M"X*H2S'/WJ +L,15SYP54/12>_M5+40$*Y&(MPSM[BH4M1<QF5I&$A.1STJ>
M":3S&L[H*Z%<A@.E $-XD.U?LY_?<$!>U)+ \95@Y/.2,XQ3K>+SF<6^$09Y
MQR:BD:1&>!BTBJ023UQ0 [$=VLJK*%8C(4D\8]ZB,K.BI-)B,=U!YJ255N&W
MP*P^0J21@?A3TN$\GRVC;S ,;<4 ,*QFX6-FQ"1\I4\&@*#(4:<[(Q\KCKGT
MI@YMQ'Y;'RS\S _RJ59(XBDD8#;AM"D=#0  12AU,I 09W9Y;W-*A.%)?&0,
MC'6GPO$3*LBE9#\W*_RIAW,A8;2%.0V>30!*6_>*>P(Z?6O8D_U:_05XPFXI
MN4*%W#ENK<_I7L\?^K7Z"@!U%%% !1110 5@>--=F\.>%;S4K9%>>/:L8?[N
MYF"@GVYK?KG_ !M<Z;:>$-0DU:V-S9F/:\*\%R2  /?)% '#ZGX[\16_B*>X
MMY+-M%TR:WM+R,+EII9<9*GM@GI7K%>(L_A[0=2M/#\>B7\FEVEY!<WUY)<9
M*7#CY%?^\!P/:O;J .-^*&H7^G>")Y-.F:"66:*%YUZQ(S ,WM@&O+[6QL]/
MU^$#Q=JMQ<VVL16RV;2Y:9, [\>A/Z5Z9?>(=>N/#>HS-X.:>>*[\A+*:48G
MCS]_..E<Q8WNLS^++34[CX816]VSK$U[YXW1IT)QCG H&>NT444"*&MJK:)>
M*S;5,1R?2O/HM2NH J),D@'&&'->A:P&.CW>T9/E' KSYKF":U,93S)]N.%Y
M!]: +37UU/$5ELUD##"[1WJO!:S+=);S2-"'YPIJQ9W=U:0"UA ,O5F<9V^P
MIEU%>S,)Y_F*GATX(H ?J-@]G TL<[L .0S9S52!KJSG#^4?F'(]15C9=7\*
MQB4.@;.3UJ599XYEB9V9@.5< #&.30!7G>>_*K)M@AS_ !'FK]_+:KI>ZWC2
M1UPFXCC/K5>QL!J1,\X)0<*,]JCU+3S8H=C'RG(#+GH>QH 9%IEW&IE C_%:
M(+B:.;[7Y99&&U]HS@BK#2:A!9^6R ;A@2$]!5:Q2]D7;;$+$.Y[T 6;G4GN
M8&@MX)"SC'W<4HTU;;3T28#</F8@\CZ4Z+4);>2:*X5?,C7=E1C/I6<TL\QR
M\K^8X+%1T'MB@!_V;?+L:6<#&0'/.*A3=(YMMZQQ+P%Z%OK4\+^:<%'WIS(0
MWY4MVZF *I5Y.CX&2M #WTW9 )(<;AU'8TRTMSJ$3QQJD<B=<#OZ&EGOQ/;1
MVL)=%Z/(1@XJ2VFBTR)UC&Z20<F@"M*"A$6<[!R:+FXFFC@,T?EJH_=N/YFH
MYB?L\G(WM_#GD"MR)(+S3(EP" HYH J)JKQVI21"TF.@'!/K54/&D));_22^
M\!1TI;:81&YA4(4+?*S\X^E$?^CW1N F]"<-WVGVH 5-0OKI3"LJ1JHY)&&I
M'N!'9>4JXRV Y'4=S4.I3PSSI(H:*$+C)'+$TNGS"[=;9W01H<@D<G% &@-,
MADM/,C8M(>=Q-9L,DL$HN?OJIV-CO[U(0P+-$98[=CAB#U'KBFVD"WDQB$NQ
M5SM0'D^] &K)J\;Q;8 7D88P%XS6=&LT-N[*0%R<Y/)-/DAN--N8WD(>,MCI
M@FDF=&F\TG)D.0B] WO0!(LTAA9A( 4&=OJ*5KEFB5]VW'4<$;?\:@^SO'&S
M-&V#DY4\4I/FP+$L:97&6 QQ[T >B6#!M/MV (!C4X/TJQ5;3U*:=;*>HC4?
MI5F@ K@_$*1G5+A\GS <#GVKO*X74=/-WKMX[L0JO@#/M0!E+%(]LV6)D;M[
M4R."21TC:-5 .?<U+;ED$I/(0D"H%=YG,P'3W[4 75L2KNRL$11DGTI(7@4M
MAMY/4]Z29C/:*P[G)7/6J3S1*K-N*RMQQT H E:TW,SQR#CD9-- FGEC+1A=
MG4^M10)(.5QAAU-68[IEWHQ5ACDCB@"#8GV@EWRH/.T<4XG;*<H3GH.E1QO&
M["(2,$'(4C&:EFN764*$&/[Q% %F!8Q+&L\@1%&\@]S3+N5G,LB'".=J^NVE
MMY=[E7P^T @D=*7[0CO\RD*3@-B@"2UMPEH)F)\P]R>@IO\ :#K*HB8OCJ#4
M;6\OGM))+MA'/'<>E6(W$D$NW8IW8R1B@")[MG<DXSWVCBI99$>TYSM_7-,#
MNEM]G6%#GJXZFDFA:*W0CG!S0 TI9E!F1PW=<<DTQ[R-&,/EC*CHPJVM]$T@
M>*T!FQC+=*CN+%;A'NB^)^X[4 /\ZTN+42%"K+Q@57ECL1C;*X)]*2VA_=LA
MD!4C.3ZU-(CM"B&)0%Y+#O0!46*/S H.6_O,:EMD>VN)/,4F1R K]@*L1K9C
M2RSN/-YP!US20G;"!(Q.>@[F@"Y>0VT5L%1@\KD9;.3BJ,F.6.1@]?Y"I6CE
M6/S&BPGUI)0+A50=>P% #;258)I)23NV8 'K1%83W"&1>6+9.>]7;71R"K3.
M .NVM=(P@"J.!TH I6&GI:[G=MTC#G-6A"AR7.0/X:<2%))JM-=*ORIR?K0!
MIZ3'$ETYCC5,KV%;-<WH,QDU*1=V1Y?]:Z2@ K!\81^;H#*<_P"M3I]:WJQ?
M%,CQ:&[1J&;>N 3CO0!S)XB4+Z5@W,7V1VDCGV[CRAYR:T;6Z%Q&9,$$$J1Z
M&JM_ ZWL4ZJ7 Z@=: (+1(9Y=\LS2%?FV'C\:CD8W,Q-I&?+SR';"DCVIKRB
M6\W-MB*J54 ]2?4TZVG-O'Y30OO!Z@=: )8$\UWS'LN(^=@.5^HH,W[P,Z?.
M."XXQ2#S9;A[AD\M2 H7UJ1K6,LT?G+OQP/>@"-IBV^13NQW]OI3XMT4Z";8
MY*Y !SB@"<W*AA&C,O?I@5.JK:3JC;&#@DD#&* (A"LK O&2Q8[_ )>,>U2R
M)&T6P@!!TQQ4L@(4&,%D89R#WJ%6#1EBK,$SN*]!_C0!!*%24'YR2.<-U/:F
M++=7$QA#)&4P,GJ?>GL/M$F(,E5Z ]Q[TK*\J"X#QHT!ZGN/>@"&2WD2Z2)G
M>5F&6W'^52JJJ[(2-RCN>]0Q7D:R/-*7+.-JOMPHI1$\JQHD>6S_ *P<@CWH
M C<#!9@"R\@$_>%)!(9)G &QF& O3-2W2""5 \P\Q1\HVYQ]:BD264JSD*6&
M RG/% #(IGAB,9A<L.X%1P,\!9Y$W.>6R>@IS!8I8UC=M^<G)[5(6+_,=CD\
M# X% $0DCB9A'.44GD+R*?"LLHD^SL O]YN2344EM,L2P[5*MS\IY-('$:Y6
M7RLG!7K0!-')/):NBX$BD@D=\5$X!1'02!@W+-_*G##,(8I.!\Q/I3<-(Y;S
M#Y:]#ZD>U !NFB:4$A%)^;/49]*;N13%Y624/W6&,TX2(MQ&9,B/GYCZTZZ>
M"7Y(>6)Z^E "23.\H9TP%XQZ?6E7>[';A<?=P.IHD#.-Z E <L"<9([BHG"<
M?.P#=!US0!+ P9T)4L^_[N?EZ]:]J3_5K]!7BP9$\MA(000!@8/6O:8_]6OT
M% #J*** "BBB@ K&\5:/;:]X:O=/NY_L\3IN\[./+*G<&_ BMFN7^(FGWVJ>
M ]5M-.R;EXLA5ZN 02H^H!% 'G7A^ST+6@=#3QG;ZAJ=SJ4=Y?/L*_:!'T1,
M_05[;7@\^IZ-XG7P]H_A?P]-9ZQ:743R2_9]GV15^^&;OGI7O% '&_%*._D\
M!WG]GB4LCQO,L6=[1!@7 QWQ7):CXPL/%^M>%++PM-=R7EM=++/PP6*(+AQ)
M[X]:[GQYK=WH/AO[59-&D\MS% ))!E4#L 6/MBN!C\2:K;^+9=4T^6R31%U6
M/2C:P0*IG9A\TFX<D@\T >R4444 4=8*#1[LN6">6<[>OX5P%@\$=T[8(0K\
MOF'G/O7H.K9_LFZQ@GRSC-<7I*6CVA,X42-W)&<T 5K><-J$[N>6Y'TK02]@
MC0HY8$]R.!6:]A"^I30PG  !!SP#5.6WW+NVS-&O\6[(_*@"Y"9PTES$[);M
M(<8Z_6I9XY$1IY\;7 <G'S >E57FN(88X(F*K(< GH*?,)X8/)\P2&7L3D_6
M@!UAJ$EKO6-2\0Z \$9_G3[F_?4@D*Q,B[@S,_M399''E30PLC1)\Q;O5BVT
MN*YM'N9)6>8C(P<<T 7-3NE>VBM54#<@RV.1GI5.VU5+*W^S/"ZR)QA5Z_C5
M:WE>YEC5"//3(9FYP!1,TU]<0B:38&R"R\;L&@"9+.;4[MYW C4IM )YQ4#&
M:&4*T :<_(L@Z5+?V:647FQ32%@0!ECS4<44^J2.QD92G"J#@"@"!X2)TMPQ
MD<MNE(XJ?4(HK:6W6%0.22>]02VTL-[&LLQ#L.&7@U(\21 R,SR2GNQS0 R>
M0RMO8'<W8#C\JNVS6=L"+ELRMT&,X^M1VL!%O-=2%00OREO4U75]UJ8VAS)R
M?,8XS[T .B2'R;EF(60/D$]?;\*;;1W#G;%.(DF^]VQ]*=$DMU"KR%(XT&0Q
M')I4$;R0-,N$(/..-WO0 C6QA=XUZ1C(.>OO1&_F,B.VV%<@E>F?6DN55;@I
M'*OE*-V[KM]JDM)X4(67?L;U7 S0!$2#/!]H&Z,9VY'Y5H:O;6L-FDT*A9"0
M 13+ORF0.PRJC@CJ/I5?[-,<3R)(8P/ER<D?A0 GF>5 (M^Y&'S87)7VS5:.
M1XK@R0@#=QR,UH0SQBP\M8<N1CIA?KFH?LZ0JKR'! ZT /N/M=TJ,YBQ&,C!
MJL\L;KU8'C&>WOFE,O[DJ&;DXP%P2O?ZU9DN+>2Q$:J!,>-H'2@!R:DTE@UO
M)$6D/&XC 'O4*,PB6124.&PWJ!3,L(HRY)7 VC/6F73OY0A57VCMQP/KWH ]
M'TP[M+M223F)3D_2K55-,_Y!5IQC]TO'X5;H *X/6!<_VO>*DFV-G[=>@KO*
MXC68)9-4N3&X7#]^_% &>42* Y;@=>:H.B1QEXBQ.<%2*D(VEQGGC/L:F@C+
M7?,@< ?>'2@!D:LUKLD8ANQ':LJZM)UDW-R.U:$SO).5B.!GBA51+@&:0LW8
M#M0!E"XG0;-Q'L14T-XJ!A(N<C!QWK1NI8!(4DC#\=1VJE]DA!#;MJ'A0: '
M1[!#YD:G)./FJ82D*WGX95X4#N:D5(]HB8\=L4ES A11"#CI@]CZT +#Y=Q&
M8XLQO]>M65:5D$3K&$4CD<=*K0V,B'=O7/;)[5)C#%?,#<= : $D5IYRL4RD
M>F:DACC:=4=_E0\^]+#'MZ(%/KBIC81F"24J_')P: ([M8O,F:W)$8 ''K2"
M-%,024LQ/*@YP*:KL(BL:CR^]+9[1(3Y?3GI0 [*XD#J^\_=V]*:MI<2*C!R
M I[FI[JZ/F1QIM0R'!)'2K1TNV6+S);H@^NZ@"@+5XW,KJ6C#<[:DA#EY-I(
M0] :3+1JXBD8H3\NZDCW%AE^1V]: '"W0L?D^;N:DB80.2T7F2'[I/05$K1N
MLAEF9)0> .]6M/LY+EE:3(4'O0!+';W%\0'?;&.<#I6E#9P0?*BC<.YJ=(A&
M-JC@4-A06.![T 5I%)=@23CI4,]X+:$!CCV[FH9]4"DQP#?)TR> *IJWVJTN
M'=/WJ?=/8T ,?4II3)Y8^4#/)QBJT-S+.DC!<D>M1[VW&&95\PC(VU9MBK)L
M"@%>#[T :?A-)AJTK29QY1Q^8KLZYKP]$5O6<@_ZO'ZUTM !6%XO)'AZ4KC.
MY>IQWK=KG_&84^'G#G"F5,_G0!QFES0+'Y(?<Y)+$C'-:$\2/"RC@L.HK(U,
MVXAC:!AYJ_=V]:V83^XCWC#;1D"@##WF"%[>2#<W0'''US4<5Z5MB@B9T'!?
M%:.KJ[6@"+D;@6 ':JOVZT2-8T0D8^Z!SF@"$Y:P>XB<DKP!Z4+#:-:K)N(;
M&2^>:+:7[.6W(2TI)\H=A2;;-Q([1N'7DQDX% #H7>>P7S1N <A7(YQ20B)[
MR..0<8RV3U_^M5B.*YFA#M,J ]$4<"F0F.6!EG0,ZOA"O&XT .@^::40EO(!
MP![^U.;9;[XOM*I&?O*!DCU IZ;)+66.%3'(@((]Z+(VPLUW*H(^]NQF@"M<
M30L\*J66VQ@E>Y]S39+:":X:.T;Y63YL=!Z5)')%&]PR*&B<_*#T)I 9894\
MMU+MU0+Q0 C+<B'[(8XCVW$X%1(CQA[?[0(]@Z_WO>I(UBN(Y9;V0[U.-N<8
M_"HH>8O*1-TC-A"XSM% #U2=4^T!/-\Q>0>Q_P *@61H8S&0K;>JGN3Z5>62
M>TG$4CB16&1GM5>^(,3M&%+'J5Z@4 0S&T^41E$DZD'D?2FO&\4@>5-Z'JJ\
M#/:FL]M);>7%%F4CEL=*D>(@*NY9?EP,-T- $<4.]BLA*(6RJ[N12!H[6=UE
M3CL0,\4X;45EE5FD(VK]*B(<$K('+]B.GTH !$OD9(QSQ_L@U*D:HS('#(%R
M#GH:3>-H&"#[]Z1E$D.T$*0<CCB@"(/"D3%0,C "=A[U)()$B!Q&-QP-HZTB
MMF8[T#L5QM3L/6A/F4J9"%0YVD<CTYH ?L(R 2$(YP>*ARLKC *E1Q[U*S94
MMG)/''%1$*@W'@_SH =Y96,8Y(93^M>VQ_ZM?H*\0BE)FC*N,[QG/UKV]/\
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M0!56>XC4LL@=1ZFGK<+-'OQ@C[PI\D43 L8B.>AJ %8PVV/:/7UH 6*]4L4
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ML\,44 *)GYB!3;6>.,&-$('J15R"6*YCW 9!]:B>!(HRKS*B'KQSB@"&SE$
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M$MO+L"_+^[.,5ZW10!X^D%T]J_[F8QA_NE3DBFA)PY,,$ZAL*O[L_B:]BHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[9IMD++S)H Z2(!UVYX.>:T;OP0W]H^'KW3KU+1M(1HC&(04E1P XQVSC]:
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M.7P]81K':&-T19?W@&XD\YZ\FN6\(_#)]!UV/4[Z^2Y,$+0PQ(K%<-USN)_
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M4K>&/'1\)7]D/$B_VE+>&6&;'W8MV=N>WT_"@#T6BH;2.:*SACN91-.J 22
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M*_>V,#BK%<#\.@!<:A@?PI_6N^I %%%% !1110 4444 %%%% !1110 4444
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M7/RD-(>,')P!]*])U#4-9M[PQV6AB[@V@B4W:QY/<8(H I^"?^0!)_U^W/\
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M_P"0#>_]?1_]!%=_7 ?"?_D WO\ U]'_ -!%=_7GU?C9U0^%!1116904444
M%%%% !1110!'/C[/)EBHVG)';BO$O"D*+X@\-0DZ<D,%S,T%_;ONGOBV[AUZ
MKCON]*]ODR(GPP4X/S'H/>O%O"LGABV\=VKZ5K%_-K$]P\=Y,UF?(NLY)"GH
MF.Q% 'M=%%% !1110!SGB#_D9/#/_7U+_P"BFKHZYSQ!_P C)X9_Z^I?_135
MT= %#7/^0%??]<'_ )5XTOW1]*]EUS_D!7W_ %P?^5>-+]T?2FA"T444P%'W
ME_WA_.O;XO\ 4I_NBO$!]Y?]X?SKV^+_ %*?[HI,!]%%%(84444 %%%% !7G
M/Q;_ ./#2_\ KL__ *#7HU><_%O_ (\-+_Z[/_Z#6E'XT14^%GEM%%%>@<P5
MUWPT_P"1SB_ZX2?TKD:Z[X:?\CG%_P!<)/Z5G4^!E1^)'M5%%%>>=04444 %
M%%% !7D'C>Z:3Q[=6EQ=^)I+>.SC=(-$X,1.<EO7->OUXA\2C:OX[FBMM+::
M]-JOG3/J;VRD!20 %]J /8])P-'LMOVC;Y"8^T_ZSH/O_P"UZ^]7*S?#[B7P
MYIKJNT-:QD+O+X^4=SR?K6E0 4444 %%%% '.>"?^0!)_P!?MS_Z-:NCKG/!
M/_( D_Z_;G_T:U='0!YO\0/^0Y;_ /7O_P"S&N4KJ_B!_P ARW_Z]_\ V8UR
ME,04444P.V^'7^OU#_=3^M=[7!?#K_7ZA_NI_6N]J6,X;XKC/@Y?^OJ/^M>*
M[1_DU[5\5_\ D3U_Z^H_ZUXM6%3XCZ7*O]W^; #'3/YTFT?Y-+169Z)O>"%'
M_";Z1_UV/_H)KZ$KY[\$?\CMI/\ UV/_ *":^A*WI;'S^;_Q8^GZA7SAJ/\
MR%;W_KXD_P#0C7T?7SAJ/_(5O?\ KXD_]"-=N&W9X=7H5J***ZS$*]W\"_\
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M#4?^0K>_]?$G_H1KMPV[/#J]"M111768A7N_@7_D2M+_ .N7]37A%>[^!?\
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M1WO_ /=C_P#017-5Z4/A1Q2W844459)ZS\)_^0#>_P#7T?\ T$5W]<!\)_\
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M[+:65UOFC!(!0J' ."5)'S#/<4S5?%NCZ->BTO;EEEP&;;&S",'H6(&%'UH
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M?_[L?_H(KFJ]*'PHXI;L****LD]9^$__ " ;W_KZ/_H(KOZX#X3_ /(!O?\
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M_P"OJ/\ K7BU85-SZ7*O]W^;"BBBLST3>\$?\CMI/_78_P#H)KZ$KY[\$?\
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M^OK_ -E%73^(X,S_ -V?R/1:\Y^+?_'AI?\ UV?_ -!KT:O.?BW_ ,>&E_\
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MC7PR!DZW9_\ ?RN Z3>HID4J31)+$P>-U#*PZ$'H:?0 4444 %%%% !1110
M444R:58())6^ZBEC] ,T /HK@(/%6NI86'B*Y%H='O;A8A:HI\R)';:K[L\G
MID8[UUE[XBT;3;DVU[J=K;S@!C')(%.#T.* ,_P3_P @"3_K]N?_ $:U='7#
M>$/%&@VNB/'/J]G&YN[AL-* <&5B#^5;W_"8^&_^@W8_]_A0!R7Q _Y#EO\
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M_/PGZU[1X-\4Z#:^$=-@GU>SCE2+#(\H!')ZBL,0TXHTI+4[BBL3_A,?#?\
MT&['_O\ "KVGZQINK"0Z?>P70C(#^4X;;GIG%<AN7:*** "BBB@ HHHH ***
MP_&6HW.D^$=1O;1MMQ''\C8SM)(&?PSF@#<HK@[2VD\.^*-!@M;^[N(M3BD%
MRD\QD#,J;A(,].>...:IZU)<ZA<^*-1:^NK:71-HLXXI2JC"!]S#HVX\<]J
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M4OV>#_GC'_WR*DHH C^SP?\ /&/_ +Y%'V>#_GC'_P!\BI** (_L\'_/&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @NK*TO5"W=K#.JG
M($L88#\ZE14C0(BA548"J, "BB@!)8XYHVCE19$88*N,@_A3+:TMK*/R[6WB
M@3.=L2!1GZ"BB@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img105269759_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )^ GP# 2(  A$! Q$!_\0
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M3RI9!$QBC?\ NLX& ?Y4 =G17)>(?B3X9\+ZI_9VIW<J71@6=$CA9]ZDX&W
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_B7:&[\<^
M4:W:: WTRRC867:0@.[VKTRB@#YYTWPWJGA?XX:!HCK-+HMK-<3Z=(5)"1RH
MQ*EO9AC]>]9T=E+I5OK7A/7YO$D;7>H.3:Z?IL4R7:LP*R+(R[L\9Z]N.]?2
M]% 'DECI)MOCIHT9CGDBL_#B1I-,G.X97+'H&P3GZU1^+MKJ^A:__:^@P22O
MK]BVD7(0'Y6)&U^!UVY'X5[310!XQX^\)W6@>%?!8T]+IK309U-VUG"LLB9
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M[2+[Q#>RRO)J]V\\2.Q(2('"!0>G S0!W-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 -DC2:)HY$5XW!5E89!![&N5L/AOX9T[4H[V"SDS"YD@A>9FBA;U
M1"< UUE% '-V/@70K!+-8K9V^QW<EY"9'+%97SN/TYZ57L?AOX:L=06\%HT[
MJ966.Y?S$!D.6.T\9R*ZRB@#E+GX=>'+EKT_97A2\EAFEBA?8F^(Y4A1P/?U
MKJ@,  =J6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HZSJL&BZ5/?W 9EB7A$Y:1NRJ.Y)XK#3QJD^D:3<VFFW
M$][JB%X+)74, OWBS'@ 5-XFT+5-5O;"YL+^"%;/>XAG@\Q6D(P&ZCD#./K7
M+Z)H^NZ%8>'=5N;*2\GLX)K:>T@4+(B.05(!."01SST- '=Z)K$&N:?]JA1X
MF5VBFAD&&BD4X93[BM&N<\*Z7>6NFZA/>J;:YU*[ENC$I!,(; 49Z9  /UJ'
M5-#OK?1[V9?$NK;H[=V!W1CD*3_<H ZFBJ>D.TNBV$CL6=K>,LQ.225'-7*
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M?]>L?_H(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>/2M5@BWRV=IJ$\5F <YC7&%4GJ <@?2EUC7KQ]#OU/AS5$#6T@)/E<?*?\
M;KI+.SMM/M([2TA2&WB&U(T& !5?7/\ D :E_P!>LO\ Z : %T7_ ) 6G?\
M7M'_ .@BLC2M<TV;Q'J%O'=*TL\BB-<'YMB8;\B#6OHO_(!T[_KUC_\ 017G
MVE:U>VWB.ZD.DVUUAY/EMX LB?-@$'Z=?4FFD&G4]/HKGG\6P0Q"2YTW4H?7
M-N2!^-);>+[6].VSMY)6_N[T4_D319A<Z*BLG^T]1;[FC2\]-TR"E^V:PP^7
M2HUS_?N!Q^0I :M%9/G:ZW2SLE^LS'^E+_Q/F_Z!Z?\ ?9H U:*R?(UT];VS
M7Z0D_P!:46>L'[VJQC_=MQ_4T :M%9/]F:@WWM:G_P" Q**!H]P?OZO>D>Q4
M?TH UJS-8GAB%FLDJ(S74>T,V,\TW^PHV^_?W['OF<C/Y5DZSX6LI6M)&FN2
M?/5#OD+9!/OTH ZO('4TTR(.KJ/QK-'AW3/XH7;_ 'I6/]:7_A'M)_Y\D/U8
MG^M %]KB!1EIHP/=A43:A9J<-=P ^\@JNN@Z4IR+"#/^[4BZ1IRC L;;_OT*
M  ZQIJC)OK<?]M!3#KNE#_E_@_!LU8%A9J>+2 ?2,4];:!?NPQCZ(* *!\1:
M4/\ E\4_12?Z4G_"1Z;VED;_ '8F/]*TPB#HJC\*7 '04 9?_"069&5CNF]-
MMNW/Z4?V[&?NV.H$_P#7N16K10!E?VVQ^[I>H$>OE ?UJ"\UF^2RF>#1KHR!
M"1OVX_0UN5!>W M;.68QR2!%SLC7<Q^@H R_"EU<7>@0M<0>45RB_P"THZ&M
MNLGP_>?:-.2$V]Q"\"JK>=&5R?;UK6H **** "BBB@ HHHH **** //_ (FZ
M'<RZ7)K=E>ZRMQ;A$,-C<LJB/?\ .^P?>(!/Y5G?#UH)?&-\VCZEK6HZ.MBH
M,U_(Y1)RW*J& R<?E78>-I+:/PS,UW<ZI;P[TR^E@F?KT& 3CUKC_AX[R>,+
MW[#<>([C219#YM7#*%FW\@!@,\=_K0!ZC12,P1&8]%&37FVC>*Y-6U"UOI_$
M?V,7%R5BL1:YAV;B C2$?ZP@9Z_A0!Z56$?^1^'_ &"S_P"C15S4=<T_294C
MO)9$9QN4+"[\?\!!K&T[5;/5O'3/9R.ZIIN&W1,F"9?]H"@#JJ*** $90RE6
M ((P0>]<[-HMYHTSW?A]E\MCNETZ0XC?U*'^!OTKHZ*31<)N.VQF:5K=IJZN
MB;HKF/B:VF&V2,^X]/?I5BXTNPN\_:+*WESW>,$U6U;0K;5"DX9[:]B_U5U#
MPZ?XCV-4;?7+G3;A+'Q B1,QVQ7T8Q#+['^XWL>*+M%NG&>L/N_R[DS^$M(R
M6@BEM6/\5O,R?R.*3^P;Z#'V37[U .BS!91^HS6Z"",CD45?,S"R,+R_$]OD
MB?3KL>CHT9_3(H_M?6(,"YT&1_5K:=7'Y'!K=HHYNZ"QA?\ "5V$9Q=0WMIZ
MF>V8#\QFK=OK^D77^IU*V8^AD /Y&M(C(P:IW&E:?=_\?%C;R^[Q@T>Z&I+<
MW(@LIKA%$OEH7"A@-V!G&3P*Q_#WB8Z]<7$7V!K;R0,EID?)]/E/Z]*KZMX4
MTI=*O6MXI;=_)?\ U+OZ?W0>?I7(> ]!NH[V]-O?W5FPC4!C9% XS_MC].M7
M&,7%LEMW2/5J*PC9^)(C^ZU2SG _Y[6Q4G_ODT&Y\2PG#:=8W ]8IRN?S%1R
M^95S=HK"_MW4(SBX\/WH]3$R2#]#1_PE=@AQ<07UOZF6U< ?B :.5A=&[163
M#XFT2<X34K<'T=MO\\5H17EM<?ZFXBD_W'!_E2::W"Z)J***0PHHHH ****
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M/XL<1^$-8=EB8"SE)67[A^4]?:O-OA[JUO-?:-;IX]M;QS"!_9@L$1^$^[O
MS\OKWQ7K[^6W[M]IW@_*W<=^*P-5U33] O[&)=&GFDN2P$EI:AO* ')8CH*
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M!;_XUKVTBRVT;I,LP*C]XO1O>I:7-+N.R,/_ (1>V'W+[4T'HMVU'_",0_\
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MK"/_ "/P_P"P6?\ T:*W:PC_ ,C\/^P6?_1HH W:*** "BBB@ HHHH ****
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MK'@_0(M#OW338PRVTA!W-P0I]ZZJJ&N?\@#4O^O67_T T +HO.A:=_U[1_\
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M-?2S.EHK"\)""7P_;7<,\DYN(PSN\K/EAP>IXK=IHSG'EDX]@HHHH)"BBB@
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MG9@1YO?<!755A'_D?A_V"S_Z-% &[1110 4444 %%%% !1110 4444 %%%%
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MZ=_SPU+_ , )O_B:W:* ,+_A+=._YX:E_P" $W_Q-'_"6Z=_SPU+_P  )O\
MXFMVB@#"_P"$MT[_ )X:E_X 3?\ Q-'_  ENG?\ /#4O_ ";_P")K=HH PO^
M$MT[_GAJ7_@!-_\ $T?\);IW_/#4O_ ";_XFMVB@#"_X2W3O^>&I?^ $W_Q-
M1Q^--)F,@B2_<QML<+8RG:WH?EZ\BNAK)T2TN+6?5FGC*":^:6/)SN0H@S^8
M- $'_"6Z=_SPU+_P F_^)H_X2W3O^>&I?^ $W_Q-;M% &%_PENG?\\-2_P#
M";_XFC_A+=._YX:E_P" $W_Q-;M% &%_PENG?\\-2_\  ";_ .)H_P"$MT[_
M )X:E_X 3?\ Q-;M% &%_P );IW_ #PU+_P F_\ B:/^$MT[_GAJ7_@!-_\
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M)H_X2W3O^>&I?^ $W_Q-;M% &%_PENG?\\-2_P# ";_XFC_A+=._YX:E_P"
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MJD]V$T995MR),,?,4J22!UY.,8H K^"_'$OBJYECDMK2 +&'"1W.Z5.?NNA
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M\OFOG>&4*1(PP0.,%<=CFM70="LO#FD1:;8*X@C+-EVRS,QR23[DT :=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M LXI;QKW.ZZ8IN.W!&T<=?4UB:/XMUQ]=\1:Y/JEG!9"PMKA+>Z#[(O,4[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK)USPQHWB2&./5["*Z$9RC-D,OT88(K6HH Q(/"&@VT-A#!IL,4=A-]HME3(
MV28QN]S@]\UD>(O %EJYMA:QP0QG55U&^23<1<':58>Q(Q^5=E10!F:)X>TG
MPY:O;:391VT;N7?:22S>I)Y-59_!OAZYNK^YFTN%Y;\ 7).?WF.AQG@^XYK=
MHH YUO OAQK 6;:?F(2>:"97WAL8R&SGIQUJ27P9X>FL+2Q?2X?L]I+YT"@D
M%'[MD'))[YZUO44  &!BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#!O/%NF6/B2+1)3)]H:"2>20+\D2*N[YCZD=JATOQE::E>PV
M[V5Y9I=(TEG-<H%2X51DE>>..<''%4/&>B76LZI806T3!9+6\B>91\J,T>%W
M'W/%4$AU'Q)+HEA)I5WIXTQ&-U-,NU=_E&,+&?X@2<Y':@#=T_QI9:A?P0"U
MNX;:[=DM+R5 (KAESD+SGL<9'.*Z6O.-/LM3N[7PYH$NEW-N^CW*2W-RZXB*
MQ@A=C?Q;LCZ<YKM=1T=-2F21KV_MRJ[=MM<&,'W('4T :5%<OIEC_9OC2X@6
M\O+A&T]'_P!)G,F#YC#C/2NHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHJM-?VMO<QV\LRK++]Q3U- %FBJ#:UIR)*
MS7<8$3;7YZ&I1J-F;I+87"&9UW*N>2* +5%%% !1110 4444 %4]4U.UT?39
M[^\<K!"NYL DGV '4FKE0W:>9:3+MW$H<#&><4 <R/'=K-96,]GIE_=S7=L+
MLV\2 O%%G&YLG Y[=371:=J%MJVG07]G)YEO.@=&QCCW'K7GGAV/4O"J6E_/
MH]]<I=:9% T<,>Z2*:-FPK#L"&ZUT_AO0)[7P;!IM[+-;SR%I9/L\NUHRSEM
MH8>F<4 =-17&Z]H@TZSMKF/4]5=EO;<;9;QF4YE48([BNRH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#"7_D?)?\ L&)_Z-:MVL)?^1\E
M_P"P8G_HUJW"P7J0/K0 M%'6B@ HHHH **** "BBB@ HHHH *YZ:_P!>5;[R
M[%28V @X^\/SKH:;)YGE-Y6WS,?+NZ9]Z ,>*\UEKYDDLT6$0[@W^WZ=:M:/
M/?7%EOU" 0S;B-H],TNFW-W<^?\ :1"!'(8QY>>2.IYJ_0 4444 %%%% !11
M10 4444 %59].M;F[ANI8@TT/W&STJU10!S-T?#4%W/83KB::12Z;'.6.,<X
MQ6T-+LQ>1W8A'GQIL5LG@54O[VUBUS387GC64E_E)YY7 K7H **** "BBB@
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M_P"1\E_[!B?^C6K=KEM+U.#5/&]Q) DZA-.12)H6C/\ K&Z!@,UU- !1110
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M2%AD)O;."%R<8Z\5V-%% &$O_(^2_P#8,3_T:U;M82_\CY+_ -@Q/_1K5NT
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M7FTV-+J)&B$6[S7+C:01SD>G0]Z *WPTC\*VMS?0:#;:L+J11+//J,#JS#/
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M;;"37;.I_>KU!ZUVE8/B[_D#P_\ 7[;?^C5K>H **** "BBB@ HHHH ****
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M@##\7?\ ('A_Z_;;_P!&K6]6#XN_Y \/_7[;?^C5K>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWUE;ZC9RVEU
M'YD$HPZ9QD4W3M-M-)LDL[*(16Z9VH"2!GZU:HH*YG;EOH%%%%!(4444 %%%
M% !1110!6GT^RNI/,N+.WE?&-TD88X^I%+;V-I:,6MK6"%F&"8XPI/Y58HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $O_ ,31_P )98_\^FJ?^ $O_P 36[10!A?\)98_\^FJ?^ $O_Q-'_"66/\
MSZ:I_P" $O\ \36[10!A?\)98_\ /IJG_@!+_P#$T?\ "66/_/IJG_@!+_\
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MG_@!+_\ $UNT4 87_"66/_/IJG_@!+_\31_PEEC_ ,^FJ?\ @!+_ /$UNT4
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M6/\ SZ:I_P" $O\ \36[10!@GQ;8@9^R:I_X 2__ !-:UC>P:E8PWMJ^^"9
MZ,01D'V-3MDHP'7%97AFTGL?#5A:W,?ESQ1!77.<&@#6HHHH **** "BBB@
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M_H_AJ2PU+^T;_4YM2NTA^SP/)&J>5'G)&!U)P,GVKH* "BBB@ HHHH ****
M"BBB@ HHHH Y3Q?>ZS97VAO8W,4%C)?Q17(VYDD#-C:.P'J>M=769K.CKK$=
MFC3-%]FNX[D%5SN*'./QK3H **** "BBB@ HHHH **** "BBB@"AJUI>7MF(
M;/4&L6+#?,B!FV]P,\ ^]8_@V_O+Q=4BFNVO[2UNC#:WKJ TP &[..#ALC(Z
MU>\3:+=:_I#Z?;:K+IPD(\R2) S,G=>>@/M3_#^E7.C6 LY[U+F-,+"J6RPB
M-0.F >: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"CK&FG5M,ELA>W5GYF/W]I)LD7!SP>U>6>#+F^T_P]K_BB[UG5=0?2I;J)
M+6XNB8G5#P2,=>.M>PUS%KX&TZT\.:OHD<]S]GU22:29RPW*9/O;>* .?NOB
M==6EIIPGT>&WOK^ W4<,]ZJH( !\Q?'WCGA:L:A\22FB6&K:;I\$]M<VK73"
MXO%A8!?O(JGEFX/L:U]3\":9J5OIJ^=<6]SI\ MX;F)AO\O !4Y!!SCTJOJG
MPYTG4YXYC/=0R"S^Q2&-E_>1^^0<'G.1B@#!M?'6NW/C"ZDCLHVT1=%744C:
M4!@A!8.>,Y)&W;VQFDA^*&M2Q63'PLH>_L'O;4?;5PR(,ONXXXZ=S70CX>Z:
MDUK+'=WL;0Z=_9K[9 !-#M( <8Y(SFGQ> =-B&EC[1<D:;I\FGQ98?-&ZA23
MQUP* ,2_^*T$%GIDEK8QM-=V U"2.XN1$$C/\()'S.><"IKSXBWLMU!%H6B#
M4$GTD:HK/<"+:F[!!R*O2?#;239:9##<W<$VGVPM$N8V7>\0_A;(P?KBM,^$
M;$ZN^HB682MIQT[:"-HCSG/3[U ')Z+XWUS7?'>E1VUFB:+?:6+ORWE&Y5W8
M,G3.0?EV^G-==XP\0MX6\+W>L);?:6@VXBW[=VY@O7\:R5^'5C:PZ>;&^OX+
MBPL&L8G2;;YD9R0'P/4YXJ]-X274O \7AO5;ZXG/EHLMRK?.Q5@V<GW% '.7
M/Q&URUGU2V?PJ!<Z?;+>R+]M7:(#GDG'WN#P*FF^)5S,EQ=:1H$E[I]C!'/?
M3&=4:,.@?:JD?,0IR>E;]WX,L+R^U6[>>X$FI6"V$P5A@(,\CCKR:S+CX8:/
M.$1+S4;>%H([>ZB@GV+=J@"KY@QR<#J,4 9=_P#%&[A;5KBPT+[7IFF)!--<
MFY"'RY%#9"D<GGI6/XR\7^)H]4\0VEH!!I\>B"[AD24!XLGB4'&<]MOMFNWN
M/A_I,]KKML))XH=9CBCF2-@!&L:A5V<<<"H];^'>F:Y,\LMW>P-)8?8)O)D
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MJM)[I+<.TBV6Y3$K-G..,XYZ9H R?^%B7QUP:7_9-MYERTL-GLOT=C*@)"R
M#Y 0.O-8WACXA^*+C3M$M9]%BU"_U);EX91<K'O$38RPQA?3\,]ZZ33OACI&
MF:CI]W!<WA73YWFMH692J[P003C)')ZFI]%^'FFZ'JEE?6UY?/\ 8?/%O#+(
M&1%E.64<=,\T 8^F?$^YO#H]Q=:$UMI^H326IN/M 8K,@;=A<<K\IYIEC\6K
M>\N8LV4*VUWY@M"MR&D+*"1YB 94-C@\UNVWP]TJVLM*M%GN7BTV\DO(@S [
MV?=D-QR/F-)I_P /=,TR:7[-=7BVK)(L=J64I%O!!QQGC/&3Q0!A6/Q)UG4(
M+#_BG4@;5;&6XT]C=@AWC7<0W'RC'0UO?#?6-7U[P59:AK*)Y\JY696'[Y<_
M>( ^7TQ[5+9^!=-LAH(2:X9=%@D@@#,/G5UVMNXY.*JV?@5M'BTFTTK5[V.S
MLKQK@QR39_=D?ZH#'W<^O2@!WB/Q?J6E>)(=%TS1EU">:QDNP6N!$%VM@@Y%
M8EG\6U:&&[U#19+6QGT^2]@D68.S^6P5EVCIEC@5V5UX;M;OQ)%KCRS"YCLW
MLU4$;=C').,=>*QK?X::)#;:?;2-<3P65G-9".1@1(DK;FW<=<]"* *T'C[4
M(7E@UC0?L%Q)82W]FHN!(LJ(N2K$#Y6Z>O6LIOB3K=S8*J^'UM9[_2Y+ZPD-
MTK A5RQ88XP#D#O706/PZTVS%R9;[4;R66T>RBENIM[6\+#!5..*L)X$TM7T
MHF6X9=-T^33XU+##1NH4EN.N!0!PUEXJ\5W-UX)N1;FYO+VPN'>T6Y$<=SA5
M*R-QA3WQVS6O_P +79[/294TE8FO/,$K7-P(XD='V,BOC!;(R,XXK?TCP%8:
M/=:1/'>WLS:3'+%;":0-A) !@\= !Q5-_AEICZ/'I0U'4ELPTAEB$HVS!W+L
M&&/4]1@XH [6-M\:OQ\P!X.?UIU1V\$=K;16\2[8HD"(/0 8%24 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)I#% \@C:0J
MI(1.K>PH ?16&/$-Q_T =4_[]K_C7*OXQU<:_L$9$8EV?9#'\V/3ZT >C45A
M_P#"0W'_ $ =3_[]K_C6?XCUB;29=%UJ1YK>RW/'=0.<#YD)7</4, /QH ZR
MBO,]#U/6+^YTS0;W4)_MHN9+JZ=&VL;<IO0?3YU'X5L>%M/D7Q'K7F:IJ=PE
MC<K%#'/=,Z[3&I.1WY)H [2BN=U#Q.;+Q+9Z6+&\=)5D+NELS#(VXVD<$<G/
MIQ3M7\3KHM[<0W-O\BVAN+=PW,S X,8'KDK^= '045Q3>/E35OLC6:[8IDM[
M@*[-(LC 9VJ%P5!89.1WJEIWBG5+32W2[B,BRF^^SW9EW.6B+L 5QP,# ^E
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M&021B:=G"84J%&3]W#'BK.F:#9Z3*S6KW&TKM2*29F2-?15)P!6G10 4444
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:UZ* "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img105269759_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' C\# 2(  A$! Q$!_\0
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MW''7UJ/1?B'_ &OXQ\1^'_[-,7]C([>=YN?-VG'3''ZT =Q17DOAOXPZMXM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI? $5[;W?B:"_P!0DO[F/4L/.XVY)BC.%4<*HS@#TH [6BBB@ HHHH ****
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M0 4444 %%%% !1110 5X7\2?"=OI'B_PSK3WEW>7^H>((MSW$F5BBW@K&B]
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M_P"!Z5R&N?\ )T'AW_L%M_Z#/7L-2XM]3:%6,59P3^__ #.-_MWQO_T*-O\
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M8&U2O!'?(]: .]HHHH **** "BBB@#Q[7/\ DZ#P[_V"V_\ 09Z]AKQ[7/\
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M44 >/:Y_R=!X=_[!;?\ H,]>PUX]KG_)T'AW_L%M_P"@SU[#0 4444 %%%%
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M]5_ZX'^8K6\92U6Y%FEN:FF:C#JVF6]_;AQ#.F] XP<>]6ZP?!/_ ")>D_\
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M6E;2=)L[)I?OM!"$+?4CM6I0!\]Z/HFM:#^T+H%IKNN/K%VUE)(MPX.50I,
MO)/<$_C7T)7CVN?\G0>'?^P6W_H,]>PT %%%% !1110 4444 %%%% !1110
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M^P6W_H,]>PT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8@T\F\\LL?S'/8X%=#X9TW5)_$VK>)=5LQI[7D,5M;V9D5W2./)W.5XW$L>
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MLP?8P!7Y1P<,#^?I68WBZ/5+_2FCM[N*)];FL('BN=J3^7&^7<8^9"RL /4
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M'=P3;VMG$"AIT0X+!1&>G?&<5Z=\+]9CU[PO)J$&@VVBVSW+K%!!C# 8!8X
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MC_#]_HMX+JU6P>)I C)A@DQ(PP!Z$5[O0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2-G<_F [B6R<\\YILO@S1)+>UACMY;?[+&T4<EO.\;[&.64LIRP)Y.>_- '
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M/+7_ ,&L?^-'_"4_%#_HGEK_ .#6/_&@#TFBO-O^$I^*'_1/+7_P:Q_XT?\
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MS_RSDKTVZUK3;+4[33;F]ABO;S=]G@9OFDVC)P*KZUXHT+PZ8AK&JVMD9O\
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M+9P6:1K<$P[A/L4!<C/3(SCZ>E/T'P9XDM4FL-?\2PZEHLEHUK]ABL4@"@C
MP5Z8&: /-(M&\0_"[0M-U/5[7PYJNF?; MPOV<23C>Q.X2D9)!Z>G%?0J.)(
MU=3E6 (^E>5V?P<NU^Q:9J/BJZO?#=A.)[?3FA"DD'(#.#R.3^9Z9KU8# P*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img105269759_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '0 \\# 2(  A$! Q$!_\0
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M)BT*=@L64&=PR,9[?C7?67B6YL_%LOAA("UK9Z&EZDMPS-.S9VX<YYZ<]\T
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M^&UMI@\)A-2F?_A'?/\ +S&!YWF]=WICVJ)_A=9G29;5-5NX;L:K)JMK>1*
M]O*YY '0CZ]:[VB@#@[KX:M?>&Y-.O/$FIW%ZUZE\M_*5+1RKTVI]U5]A3YO
MAE8W[ZZVJ:A<7?\ ;$%O%,=JHR/","12.Y(STQ7<T4 <1IOPZ%O<7E[JFNWV
MK:A-9/80W%PJCR(6'(51P3SR3UJ2Q^'EO8MX49=1F;_A'4D2,&,#SMZX^;TQ
M[5V=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5FZ]K=KX=T6YU6\#FWMUW/L&33?#VO6GB70[;5K(.+>=<KO&#[_K0!J4444
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MY]3_ -_7_P : -"YM8+RW>"YA26)QAD<9!I+6TM[&V2WM84AA085$& *H?\
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MUE_] -6[?_CVB_W!_*JFN_\ (OZE_P!>LO\ Z :MV_\ Q[1?[@_E0!)1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9-E_P C
M+JW_ %RM_P"3UK5Q\OBP6WQ&7P^NCRG[1"&>^ .TXZ G';)'U(IFD>.Y-4U;
M7+-M'N(5TQ2RNV<38'0<=_\ "@#LZP[36-5O;2&ZAT5?*F0.FZ[4'!&1D;:Y
M5?B?</X)NM?_ + NA+#.81;$'<>3\V,=..?QKN=(OO[3TFUO?(:#SHP_E/U3
MV/O0!6^W:U_T!8__  ,'_P 31]NUK_H"Q_\ @8/_ (FM:B@#)^W:U_T!8_\
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M8M '90.9+>-V^\R G\JYSQKXM?PCI]M<IIL]\9IECV0\E1D9./Q_/%=%:_\
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MA0!IT444 9$?_(WW'_7A%_Z,>M>LB/\ Y&^X_P"O"+_T8]:] !1110 4444
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M^+[:1[?7AJ8U$M=7LEVITY[3>?E5,_W, #&0>]>Q4 %%%% !7$_%W_DE.O\
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M>4__ *'%0!J4444 (WW#]*S?#O\ R+>F?]>T?_H(K2;[A^E9OAW_ )%O3/\
MKVC_ /010!IT444 4-=_Y%_4O^O67_T U;M_^/:+_<'\JJ:[_P B_J7_ %ZR
M_P#H!JW;_P#'M%_N#^5 $E%%% !1110 4444 %%%% !1110 5F>(+07NB7$7
M]GC4&4"1+4S>5YCJ0RC=VY K3HH ^?=%EL9/$6GBY\(Z58:P=14SS2Z\"8SY
MG.( Y;=TP/7MBOH*O%?#WAWP_>ZGIU_IVO:7;RQ7[BX@GAB%V[1SNR@'=D,<
ME2>=RXKVJ@ HHHH *XGXN_\ )*=?_P"N"_\ HQ:[:N)^+O\ R2G7_P#K@O\
MZ,6@#L;7_CTA_P"N:_RJAJG_ "$M'_Z^F_\ 13U?M?\ CTA_ZYK_ "JAJG_(
M2T?_ *^F_P#13T :E><?%/5=3TJ;2CIVH7%KYJ3;Q$^ Q4I@G_OH_G7H]>6_
M&+_6Z)_NW'_M*IEL=.#BI5XJ2NCSZ/Q-XJ2Z><Z[/F0*K8<YP,_XFO8_AMJ-
M[J?AB2>^NI;F5;J1 \AR=H P/UKPZO:/A1_R*,O_ %^2?R6HIMMZGIYE0ITZ
M*<(I:_YG<GI69X<_Y%G3/^O6/_T$5IGI69X<_P"19TS_ *]8_P#T$5J>&:=9
M6N_ZNP_Z_H?_ $*M6LK7?]78?]?T/_H5 &K1110!D1_\C?<?]>$7_HQZUZR(
M_P#D;[C_ *\(O_1CUKT %%%% !1110 4444 >+>)_ 7B#4/%.IWEOHPG@GG+
MQR>;"-PP/[S ]J7PMX#\0:=XKTR]N='$$$$^^23S83M&UA_"Q/<5ZS-KFDVT
MSPSZI912H<,CW"*RGW!/%$&MZ3<S+#!JEE+*YPJ1W",S?0 U'(KW.SZ]4]G[
M+2UK$'B"PNM4LX;*W<1Q23H;B3C(C4[L 'KD@#Z$UB:?H^K:1JL+"W%Y:VWV
ME(6614;9(R. 0< 8(<?3%=7=W4-C:375PX2&%"[L>P%5[;5[&[-H()@YNX3/
M#P?F08R?;[PJSC,)=&U!/$ O+2&2Q#W0EN"EUO@G3'.Z(])",#(QR,Y-:EUH
MTESXALM4%_.B6\<B& $;6W;?;_9YJ9-<L7O?LJR.7\TP[Q&VSS ,E-V,9]JT
M-PW;<C<1G&>: .;US0+F_P!8MY;?R_LER%BU%6."T:-O7'J2<J?9JP[GPAJE
MS]KCD59/,D8O(9% G5IU< @#)PH/4\=!UKK+CQ#I]K<SP2M*/(9%FD$3%(RP
M!&6Q@=15J'4K6>\DM$D_?QJ&9",<$L!_Z"?RH XZ;PKJBWLCQ11-:+-(ZVWF
M[5DC,\<FS'0 A6XZ=CP:2\\,:C-J#W4-C%#:$Q'[$LB'("RCN-O!<''N<=*[
M@7-N9!&)XBYZ*'&3^%0OJ=FEQ;P&X0O<;_+P<@[1EN>V!0 FDVTMGI%I;3N7
MEBB5'8MN)('K@9^M7*:CI(@=&5E/1E.0:=0 4444 %%%% !1110 444R:)9X
M)(7+!74J=I(.",<$=* /);WR?^$TU*_U?X>W&J36]Y_HFI6T*;?+ 7&_+ $@
MYY/;%>I:CIUMJ^G265XKFWF $B*Y0D9SC((-?/>KVFCZ-J.HV*G7+ZVBO99+
MJ.?6B@>&/RP[,@'+%G 4'EL5]'+C:,# QQ0!X#::AX=O]<M-.A\&^'Q:F[%M
M<!5/VA=\S1QJ&'/F (78>E>\65G%864-I!O\J%0B;W+' Z<GDUX]X:U"UO\
MQ%]KN/'.F6=])JDA?2H;* %F#E H<C<Q9?XNOS5[10 4444 %<)X@_Y+!X-_
MZ];[_P! 2N[KA/$'_)8/!O\ UZWW_H"4 =W7A?@9B/#CX)_X_;G_ -&M7NE>
M%^!_^1<?_K]N?_1K4 =)N;^\?SK%U<D^)_!V23_Q.8__ $%JV,C.,C/IGFL;
M5O\ D:/!W_89C_\ 06H$>UT444#,O0/^0?-_U^77_H]Z3PS_ ,BUI_\ UQ%+
MH'_(/F_Z_+K_ -'O2>&?^1:T_P#ZXB@#5HHHH **** "BBB@ K)\,*5\,Z>K
M*5(A&01@BM:B@ HHHH *A@M8K9YWB4@SR>;)DYRV O\ )167XBOM>L;>%M!T
M:#4Y6<B1);H0!%QP02#GFN2T3QQXSUK4;NVB\'6:K8WGV2[?^U!^[88+8&WY
ML YH ]'HHHH **** "BBB@ HHHH **** "O./BE)J,PT[3H=)BN(;F=4MKI=
M1^RS17!#_=..FP-]<XQ7H]<5\3H;2Z\-16U[JFD:?!)< &35(?,1B 2 O(PW
M?(/8T 4_A7 UC:ZOIMQ9_9[RTN(XYG:^^U/)^[7:2^!@!< #MBO0:\Y^$;PQ
MZ?J]C:W.F7=M:W2K'<:;;F.*3<@8DDD[FYP>3TKT:@ HHJ.*>&;=Y4J2;&VM
ML8'!]#[T <W\0/\ D5A_U_6?_I1'745R_P 0/^16'_7]9_\ I1'744 %<)X>
M_P"2P^-/^O6P_P#0'KBK#7/'&M2:A<0^+OLD45_/;QPC3XGVJCD#D^U,M]+\
M66FL7NK0^,RM[>K&EQ)_9T1WA 0O&<#&3TH ]SHKR/P]K?BRU^(6B:7JGB/^
MTK.^CN&>,V<<6"B9'*\]3^E>N4 97B+_ ) [?]=X/_1R4W7OO:5_V$(_Y-3O
M$7_(';_KO!_Z.2FZ]][2O^PA'_)J ->BBB@#*UK_ %VD_P#7\G_H#TLW_(TV
M?_7E/_Z'%2:U_KM)_P"OY/\ T!Z6;_D:;/\ Z\I__0XJ -2BBB@ (R,5%:VT
M5G:16T((BB0(@)S@ 8%<]XJNO%UGB?P[;Z-+;1PL\_V^217R.?EV#'3UK*\#
M:]XS\26]AJVI6FAPZ/=PF4?9I)3./[O!^7KUYH [NBBB@#/UW_D7]2_Z]9?_
M $ U;M_^/:+_ '!_*I" 001D'J#2T %%%% !1110 4444 %%%% !1110 56U
M 7C:?.-.>%+S8?):=24#=MP'./I5FB@#YV\/WD<GB33K.Z7PU]MCU(":[M-&
ME>5V$G*B7;LZ\;NU?1->+^']3N;'6Q9V?C'41I$>HJ@C;1(U@D\V5_E63.X(
M75EW8QD\5[10 4456U&^CTW3;F^F5VCMXFE98UW,0!G  ZF@"?>A<IN7>!DK
MGG%<7\7?^24Z_P#]<%_]&+7&?#O6Y;_XEZU>W-WY^H:CID<Z6VUE6$AF(A!(
MXVKM!/<DU+\1]9\;W/P]UB'4_"5G9V31*);A-360H-Z\A0HSSB@#U^U_X](?
M^N:_RJAJG_(2T?\ Z^F_]%/5^U_X](?^N:_RJAJG_(2T?_KZ;_T4] &I7EOQ
MB_UNB?[MQ_[2KU*O+?C%_K=$_P!VX_\ :53/X6=>!_WB!YA7M'PH_P"11E_Z
M_)/Y+7B]>T?"C_D49?\ K\D_DM94MSU\W_@KU_1G<U#:VT5E:0VL((BA0(@)
MS@ 8%-NY+N.,&TMXYGSRLDNP ?7!JIHVH7FI6D=U<64=M%+&LD>V?>>>Q&T8
MK<^=-.LK7?\ 5V'_ %_0_P#H5:M96N_ZNP_Z_H?_ $*@#5HHHH R(_\ D;[C
M_KPB_P#1CUKUD1_\C?<?]>$7_HQZUZ "BBB@ HHHH **** /*->\!Z_?>(=0
MN[:WM'@GG,B,T^TX('4;?:DT'P+X@T_Q%IMY<6MLL$$X>0I<!B!M8=,#U%=_
M=>+/#UC=26MUK5C#/$=KQO.H93Z$4MIXL\/7UU':VFM6,UQ*<)''.I9CUP!4
M>RC?F.?ZM3Y^?J/U[39]6M(+..7RH6G1YV!^;8IW8''<A?PS6-8Z%JND:I%+
M$([RV@-P(M\NQPLK(^#QCA@P^F*Z>]O(=/LIKNX8K#"A=R!DX'H.YJM9:W8Z
MA););R,S7-M]ICRA'R9 Y]#DCBK.@QUT&\&O+?P(EBQN/-G>"=MEPF,;6C/&
M[I\WMFM*70UE\20ZQ]KN 8H&B\D.=AR5.<?\!Z>]/@UZSN;W[-$LY!D:%9_*
M/E-(N=RAO4;3[<&M'S$\SR]Z[\;MN><>N* .6U+PQ>75YJ-U%<<S7$,J6[2'
MRIE15!1Q[X//TJG;>%=3M-3COU-N[13B41F0C<"\Y(SCTE'Y&NFDUJRCU@Z5
MO9KP0&<1JI.5] >F[VJI;>*;.YF,9MKV'%P+7=-#M'FG^'_/% '/VOA/4S;)
M;7<5L&AL6M;:XBDYC=T(:0\9)Y '/ SW-,O?!>I7TC2Q&VL59=H@A8E5P@7/
M3^+&#QT ZUVT%]!<3W<*,=UHX27<, $J&Z_1A6:/%VB'2_[2%ZIM#<&V1PI_
M>2!MN%'4\]QQCGI0!+X?TV;3;*9)\*TL[2A%;(0'''  [9X&.:UJQYO$^FV\
M]S%(\H\A7+/Y9VL4&653W89Z5H6=U]LMEF\B:$-_!,NUORH L4444 %%%% !
M1110 445!>WD.GV,]Y<L5@@0R2,%)(4#)X')H XG4M3^&]IXNGM-0_LT:U<R
M1"<O"6RX(,8=L;0<@'DCH*[VO _$6HJ]YKVEV_B338-/U6[%Q)!+I,[N"=IP
M7 [X&?3MBO8;2U\0OX:D@O-2LX]796\NZMK<^6G]T[&//'7F@#RG3=3G;QE:
M_P"F;M>?5VAN-!_LU!'!;!R/,#[,C"@/OW<YKW&O%] O]=BUG3])\0>.IK2Y
M6[!^R7&F&&6Z <D*LQ/S*>!]#BO:* "H[BX@M(&GN9HX8DY:21@JCZDU)7G?
MQ,2VN=<\&66IB-M(GU)A<I,<1NPC)0-V/.>#0!Z%')'-&LD3J\;#*LIR"/4&
MN&\0?\E@\&_]>M]_Z E9/@*^U+3O!.J?V#I8U2*#6[F&QMQ<K$HM]_!5FR,
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M^'#2/$YCD"1Q':P['G@X[5?*;>Q\_P SZ*M=9TN^F\FSU*SN)<9V0SJ[8]<
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M-O%;VT*[8XHEVJH]A7&>(/\ DL'@W_KUOO\ T!*[NN$\0?\ )8/!O_7K??\
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MB<DF%23^E<-H&G6+?%SQC$UE;F-+:Q*J8EP,H^<#%=MK&G'5M*GL5O;NR,H
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MC Q@J !@\8^E',R_:3[EWPKH7_",^&;+1_M)N?LRE3,5VER6+9QVZUL444B
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ML4T9C<QN48 C!PPY!]Z /'-3M=+F\7ZV_B#0?&E_.;T_9[BRBG\@184*J[6
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M'745R_Q _P"16'_7]9_^E$==10 4444 %%%% $<]O%<Q>5,@=-RMM/J""/U
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M).3D=L5ZT,X&1@]Z %HHHH *YCQUXO7P;HUO>BWCN)KBZ2UBCDF$2EFSR6/
M  )S73$$J0#@XZ^E>>:QX?\ $=G8PRW4=KXU$=VLIM;V".%XDP1F+^$MS_%0
M!UGAC5KO6]$BO[RTM[9Y&.U;>Z6X1E[,'7@YKG/$'_)8/!O_ %ZWW_H"56\*
M^!+G_A#KS3]4DN](^VZE)?1VNFW6QK1&(VQ!U[<9(''-9B>%X/#7Q=\*K#J6
MJWOGVUZ2=0NS.4PB_=STZ\_A0!ZO1110 4444 %>$^+/%>N1?$/7]/3Q@^D6
MEHT(@AVQ8(:,$_>&>O\ .O=J\ UW3[*]^*7BTW=I!.4DMMOFQAL?N1TS2D[(
MWP\%.HHLR+K4;F]O[*_N/B")+JQ9VMI-L \LLNUN ,'(XYHU7QGX@L-*GN;3
MXAO<31@%(52#YSD<<"J^K^$WN=9T^?3X-/AM(B3*AME_,_WL],=NM2>+='TR
MW\+:A-!IUK%(J JZ0J"/F'0XJ.8[I8=<LO=2MZGTG9.TMA;2.<NT2LQ]20*\
MK^(0S\4M%Q_T"I__ $,5ZEIW_(,M/^N*?^@BN;\5_#W2_%^HVU_>7>H6UQ;Q
M&)&LY_+^4G)SP:N2NK'D5(\T6CB=I]#2A3D<&L'7_A=XGCNKBWT*RU22%9!Y
M-Y-KX^=.,YCVC!/(Z\5L>'?A3=W\UP-=BUO28T ,31:Z+C>>X("C&.*P]BSC
M^J2[G4?!C_DG</\ U^7/_HUJ] K&\+^&K+PEH<6D:>\[V\;NX:=]S$L23DX'
M<ULUT':B*Y_X]9O]P_RKC?A!_P DIT#_ *XO_P"C&K1\1Z'XDU2\5]'\5?V3
M;>5L>#[!'/N;)RVYCD<$#'M69X,\$Z]X26RLV\6&\T>U5E6R-@B9SDCY\EN"
M<T#.YHHHH QO$7ABP\3V\,%_)=HD+EU-M<O"22,<E2,USUG\)?#5A=BYMY-5
M23S1,W_$PEP[@]6&>>G>NZHH **** "BBB@ HHHH **** "BBB@ KQ[XJW.B
MV_C#2VGMM6.LK;YM)K>*.:'&YOE9)/E)Z^_2O8:\Z^(K>,+G4;33-%TW3[O3
M9XB91-+$LTC\Y5!)D8"X.0IZT 3_  E;6(O"K:?JFGRVL5G)LM'FA\IYHS\V
MXKDCJ2.*[ZN'^&&G2Z;H-Q#)I36 \[@'5!>B0C@D$<+@C!4 5W% !6=IVOZ/
MJ\TD.G:G:7<L8RZPRARHSCG'O6;KMYK\=\;>UTV)](>W<SWJS_OHCM;[D6/F
M/3'/.:XOX>7$MMJ']AZ!J)U+2(M(#K=7%F(FM;C=A8VP 3D9)4Y(QUYH Z_X
M@?\ (K#_ *_K/_THCKJ*\K\36?CN+2H'UG5]%GL!?6GFQV]HZ2-^_3&"20.<
M5ZI0 4444 %%%0WA*V-PRD@B-B".W% $U<+\/?\ D-^-_P#L.O\ ^BTKR+P_
M;ZAJF@VE[<>)?$'G3*6;9J+@=2.!5R#PZ;5YGM]=UV)IW\R5H[]E,C?WFQU/
MO4\R.N."JR2:L?1=<]X\_P"2?^(?^P?/_P"@&O.?AJ][:_$VYT^35M2O+8Z.
M9]EY=-* _G*,C/M_,UZIXCTR36O#6IZ7%(L<EW;20*[C(4LI&3^=4G<YIP<)
M.+Z'@^EW.O'P_9)!I=N!]E01RF\&?NC#8V_CBHM!@\5Z59R0WD$%^S2%U=[L
M#:#V^[7:V?P\\96=E!:I?Z"R0QK&"4FR0!CGFLWPUH_BWQ/I3:A;3:'"BW$L
M!6192<HQ4G@]"17/R2['G.C/561H_")[B3QCXQ:Z@2"8K9;HTDW@?(^.<"O7
M*X;P'X-U7PWJ^MZEJMU932:D( $M5<*GEAA_%ZY%=S6\=$=L%:*3,G5_"^@Z
M_-'+J^D6=])$NU&N(0Y4=<#-0Z;X.\-:-?+>Z;H=A:72@@30P*K '@\BMRBF
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !69X@MM5N]#N;?1+V*RU!U
M BN)4WJG/)Q],UIT4 >8^%O WB[P_J:7<VI:)>2RRAKN\F@E>ZE3/(#L>..@
M'%>G5XO%X:\51>++"YN[G5;II;T/.#JP%O"%F8G,6>4:/9M Y!!!KVB@ J.=
M'D@D2.0Q.RD+(!DJ<<'!]*DJ"\MEO;*>U>22-9HVC+QMM901C(/8T >;^$]1
MNE\=W]EI^KZEK.D6%B1J%S<-YBM>;LXB]#C.57BLGXC_ !"L]7^'NL6$>A>(
M;=YHE ENM-:.-?G4_,QZ=*[[PQX(LO"2QQ:=J6IM:QJP6UFG5HADY)P%'.>^
M:H?%W_DE.O\ _7!?_1BT =C:_P#'I#_US7^54-4_Y"6C_P#7TW_HIZOVO_'I
M#_US7^54-4_Y"6C_ /7TW_HIZ -2O+?C%_K=$_W;C_VE7J5>6_&+_6Z)_NW'
M_M*IG\+.O _[Q \PKVCX4?\ (HR_]?DG\EKQ>O:/A1_R*,O_ %^2?R6LJ6YZ
M^;_P5Z_HSS[Q/_R-NL_]?;?R6L2[_P"/*X_ZY/\ ^@FMOQ/_ ,C;K/\ U]M_
M):Q+O_CRN/\ KD__ *":YY_&SX"M_&?J?2%K_P >D/\ US7^59^N_P"KL/\
MK^A_]"K0M?\ CTA_ZYK_ "IMU:178B$N[]U*LJX./F4Y%=Y[I/1110!D1_\
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M22.-S$%B!QS785R7@+5WU>PNY'\46WB I*%$MO:>0(N/ND=_7-=;0 4@ &<
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M3Q!_R6#P;_UZWW_H"5W=<)X@_P"2P>#?^O6^_P#0$H [NBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N:\2>&[C6KA9(_$E_IB! /*M_+VDC)+?,IYP?TKI:\<^*VCW^K>(95M
MM$OM3<:8BVCVTP46TAE8NQ&X?>4 9P?2@#T'PAI:Z;83&/Q!-K4<TF5GD:-@
MN!@@% !715PGPXL);.XU^5/#\^A6%Q<Q/;64H5=N(@K$!20,D9KNZ "BBB@#
ME_B!_P BL/\ K^L__2B.NHKE_B!_R*P_Z_K/_P!*(ZZB@ HHHH *@O038W
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M<D^M>6UWOPT_X]]6_P"OA/\ T6M*I!):'?B:,(0O%'=4445B< 4444 %%%%
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M!)LC#.)&)7UZ&NNH X3_ (6G9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\
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M<TSXB:)J>J3MI>@O'JE_]KG_ -,DS'D*I"_+SPM>H44 %%%% !1110 4444
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M/T;1+'0+%K/3HC% TKS%2Q;YG8LQR?<T 8_]A^*_^AQ'_@KC_P :/[#\5_\
M0XC_ ,%<?^-=110!R%[I?BRTL+FY'B]6,,32!3ID?. 3CK5?1+/Q;JV@Z?J3
M>+4C:[MHYR@TR,A2R@XZ^]=G/"ES;R02C,<B%&&<9!&#4=C9P:=86]C;*4M[
M>)8HU)SA5& ,GV% '/\ ]A^*_P#H<1_X*X_\:/[#\5_]#B/_  5Q_P"-=110
M!P?B2'Q;H7AO4-53Q8DSVL+2B-M,C ;';.:TDT7Q6\:M_P )B.0#_P @N/\
MQKH-2TZVU;3;C3[Q"]M<(8Y%#$94^XJRJA5"CH!@4 <Q_8?BO_H<1_X*X_\
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MFW%_=%Q;V\9DD*(7(4=< <FK5>>^.?'DNEM;6>C7-J));B2UEGEB,JI.J@K
M0" &;<.20 ,T 4O$OC'3-2O+*70[R6WOQ\FGZO+$6L'D<!C S9QN8 #)'&>N
M:A\,^%-0UJW0W%U=Z;I$>I&[GT:XM_WD5RC[V6.;/,1?Y@<>V>M2^#_#D.KV
MMVX2T;P_J!D34M**$PK=J0&DMF[(2#^617IL420PI%&NU$4*H] .!0 _I117
M+>+_ !1/HSV>E:7##/K>I%EM(IY/*C^4$DE\8SZ+U)- $GBKQ%=Z7)9Z7I%K
M'<ZUJ(D^R),^R)=BY9G/XC@<FO/M"L+'QS/?:5+:RV36TYN@(ROFZ-?J_P"\
M12>L;L-Z]OO#L*3P]H$WBHPQSW5_>6D<I_M"&_N6COM)O5'+Q2#G:W]WI@@U
MVO@[P.WAW49]1NIX9+AH!:PI;JP580Y?+LQ+22$G)8_A0!U=M:06D92&*--Q
MW.50+O;NQP.IJ>BL7Q3XCMO"N@S:G= L%(CC3H&D;A03CY1GN>!0 _Q+X@@\
M-:3]NFB>9GEC@BB4A=\CL%4$G@#)Y)Z5YC'.VM>+;CP]XETB%;^_18=5L87W
M1RI@F&[B)YROW6[@8/:H6MM9\1:OJ-CJ)=M7=MUWH5U<%K*[LB1M>W?'RLG7
M<.<]:ZW1_ANNF^)H+][OS+*RD,UJKL\EP\ACV9EE8Y*@9 5<#UH Z3PYX;MO
M#^F6]MO%U<0Q" WDD2++)&#\JL0.0!@?A6U16'XDUJ;2[806:QB_N$?[*]R"
M+?>,861Q]TMG ]30!JWEW%96[32DG .U%^](V,A5'=CC@=Z\>U/Q#J^N:COU
M(6.DZII>J6TNEZ==AG$PFC($<FW)WX.<@?*?SJ;6/$5QXJM[FWU#1KJZL!MB
MFLK./_3](O5!VOP?F5CR'''X9KKO"/@PVMQ;^(O$*Q77B=K989;D#A5 P..@
M?& Q'7'% %KP=X9GT>+4;K4HK-;O4+TWK6]J"8;=MH7"$@$G R6P,DFNJHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&(52Q. !DFEKC?$
M_CF+2=-O1:!(K^"XC@<7BD+$CL%^T,H.3$,]1C..U "^(/B'IVE:78WNFB'4
MQ?&3R"EPL<;",9;YB#\W0!0"23BM_0M9AUW2H[V)&B8DI- Y!:&0<-&V/XE/
M!KSBQ\)V'B#7;A+2:VN;".=&U6.+='";KRPPN+1D8F-\D!AG!S7INEZ79:+I
M\5A80B&WCSA<DDDG)))Y)))))Y- %RBD) ZD#MS7$>+?%EQI@OK6*ZM8XIT-
MK;WL3;OL5R5.!<'/R!C@*<?6@"IXK\>7=A;ZII\%E=6>J6CI( $65Y;/< \\
M(/#D#.5/W>]:/PY\07^O:)*;Z87C0.%6^10J3;ANVC  8KD*Q  )SCI6%X=T
M*37#96EYHFI:;:Z<HN/M5W,QN?MNX;C%+N):,J#GL<BO3@ HP  !V% "TR2:
M*'9YDB)O8(NY@-S'H!ZFGUY?XVU?0->U$V'V]YUL1NNX(F((3/\ KX6'62%@
M"<=!N!H T/&OBR6.>RTW3=:M-)ANS,IU>8!XXYHB/W/. "><D]@<<UK>!?%Y
M\5Z4YNK8VNI6P07,6#M(9=R2(3U1AR*Y_P &>!=2M$O(M:U6XOK)YWD1&:*6
MWO%<;EDV%28V!.3@\GFNUT+P]8>'K62&S$KO*V^:>>0R2RMC +,>3@8 '0 4
M :M,>6.-E5Y%5FSM!."<=<4YF5%+,P55&22< "O)/$>HZ1XLUW=8ZU(GD.L"
M7*'!L)S_ *N=,_>ADR8V['Y: -#Q?XWO8M2$&CZMIUA#!9KJ,$MWRFI %@T*
M-T X'3)R1BNS\+^(H/$^BI?Q02VTJNT-Q;3##P2K]Y#]/U!%<CX0\!7T7AN.
MP\17ETYA1HHH',4@MV!XF@?9N3(Z ]*[C1]'L]#TY+*R5A&"69Y&+O(Y.6=V
M/+,3R2: +]9^MZH=&T>XU$65S>"!=[0VRAI"N>2 >N!DX]JMW-S!9VTES<RI
M#!$I>21VPJ@=237E>O>+/^$CDM;[3[_7K706AFCAN=+@8N;Q'P!(H!.PCD X
M!SS0 FL_%"Y3Q) VFWMJ=)\J.XC1H=QO8B/FV,6!\P,0@0#.<YKUB-S)$CE2
MI8 [6ZCV-<CX-\*II]K'JE[!Y6H7D<<]S:;5\J*XQ\\B+CY&;^( XS784 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16?>ZWI^GZA8V%Q<
M!;N^<I;PJ"S-@9)P.@'J>*XSXBZ?XSO[^U_X166YAA6VD^ULERL8D7<OR("#
MB0C.'Z"@!OQ(UK7["SG%IHU]Y%LT5S;7UFXD#LA!:.6,?,$(R,\BIO#/P]TJ
MUN[;6;:XO5LI'6_M].F "P2LO&3C<0H8X4G R:[NW#+;1!@X8( 0[;FSCN>Y
MJ2@ IKNL:,[D*JC))["L_7=;L_#VE2:C?%_+0JBI&NYY'8X5%'=B2 !5+1O$
ML.LQFUN(SI6JL&Q87$T;3JO9]H)X[T #ZOIGB:SFT_1O$"1W4UL)TFLW5WC0
MG < Y'48YKG=#\%:O%XBUA_$;Z7JNE:A#&9!]GVF69. [1G*AMO!(ZX%:/@S
MX?VG@NZNY[2_N)VO44W(E5?GE!),@P/ESG&T<5V% $5M;06=M';VT,<,$:[4
MCC4*JCT '2I:*X'Q'\1H;/1M5:P62WO]/NDM[I;J$DVT3,%^T;!RZ8Y&.O%
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M7P_J=B=90,QTN8C?<J5. A[..H'\6,5SNB^'[CQ6UK?G59+ZT1=]MJDBJMW
MV0);2:/&'0\\$<?E6;X>\/WOCQ(_$=MK,"&=PE^-A+0W40$;30$8 +(HQG[N
M\D<U[-%#'"I6-%0$ECM&,D]2?>@"&QT^STRU6UL+2"UMUY6*&,(H_ 59I"0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?@SPL=-T+2VUJTMIM8LXVCBN'59988BQ*1^9C)VJ0,B@#K< =!1110 4444
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M< GG'3TK9C5"J.(PIQD#&",\FI* "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCS@_IDUM444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"ZNV\06KW<FGW(@TF>63[EJF&C"[<'(+$'/7'I7I= #8T2*-8XU"(H"JJC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img105269759_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ Z@# 2(  A$! Q$!_\0
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ML_\ Z%7.:EXTTWP5\<_$-WJ4%Y+'/8P1J+6(.0=JGD$CCBN_^&7A:_\ !_A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]!V ]R3VJW'(LL22(<JZA@?8U\V:M?ZIXA^ NIW&JZG?33:7K!@3S' :5,H
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M))F*+:[#*+C@G//K6=\4=?TJX^)'A_1-7$LFDZ>C7M['%"TI=V!"*54?YW4
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M3)[@YVXQUYKM: "BBB@ HHHH **** "BBB@ HHHH */2BCTH **** "BBB@
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MGH5Z?BG+X%CC']B:EJ,>N28/W8PI+KCT+C'Y5[M=7"V=E-<LCLD,;.5C7+$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$D;CHRD9!_*I:Q_"7_(G:)_UX0?^@"MB@ HHHH **** "BBB@ HHHH ****
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MKP.>M:MKI]I937,UM;I%)=2>;,RCF1L!<GWP /PJK-XCT.WU)=-FUBPCOF(
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M* (K>WAM+:*VMXUCAB0)&B]%4#  J6BB@ HHHH **** "BBB@ HHHH ****
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M)!"^ VW9C/'^T:#.K45*#G+9'IE%?-__  EGB7_H8-2_[^C_  IT7BKQ(UQ
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M G[Q^M)2G[Q^M)7IG(%%%% 'KGPF_P"1<O\ _K_;_P!%1UWM<%\)O^1<O_\
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MJ?ZM?H*=7FG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )&RQ_Z\3_Z,->PUX]\6/^1LL?\ KQ/_ *,-;4?C1[D_A.'HHHKO.<*ANO\
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M"H+W_CPN?^N3_P C4]07O_'A<_\ 7)_Y&@#Z$HHHJ1GSIXV_Y'G6_P#KY_\
M9$K!K>\;?\CSK?\ U\_^R)6#7GU/B9];A?X$/1!1114&YT'@;_D?-$_Z^&_]
M%/7T37SMX&_Y'S1/^OAO_13U]$UVT/@/G<U_CKT_S"OF#4/^0I??]?4W_HQJ
M^GZ^8-0_Y"E]_P!?4W_HQJUD?+9Q_"CZ_H5Z***@^>"O0OA!_P C+?\ _7F/
M_0Q7GM>A?"#_ )&6_P#^O,?^ABFMSORW_>8_/\F>RUB^,/\ D2M=_P"P?/\
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MKVB>&_#RZIK5I%=F&939P.H):?G;MST(Y.>PS75U#<V=M>($NK>&=5.0)4#
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MM>?4^)G3'9!1114%!1110 4>E%'I0 5D>(M(NM:TU;6TUF[TF02!S<6NW<0
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M^G?\]I/^_+_X4?V_IW_/:3_OR_\ A7UUM7^Z/RHVK_='Y4OJ\2_[6K=E^/\
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MF>@?*)\3:3D_Z1)_WY?_  H_X2;2?^?B3_OR_P#A7U=M7^Z/RHVK_='Y5O\
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M_P#@.M%P.F\Z+_GJG_?0KGO'<L9\!:Z!(A/V*7^(?W34/_"M?!/_ $*^E_\
M@.*/^%:^"?\ H5]+_P# <4AIV=SP LN3\P_.DW+_ 'A^=?0/_"MO!7_0KZ7_
M . ZT?\ "MO!7_0KZ7_X#K7-]7\SV?[8_N?C_P  ^?MR_P!X?G1N7^\/SKZ!
M_P"%;>"O^A7TO_P'6C_A6W@K_H5]+_\  =:/J_F']L?W/Q_X!B_!^6-?"%R"
MZ@_;Y>I]EKT#SHO^>J?]]"N9_P"%:^"?^A7TO_P'6D_X5KX)_P"A7TO_ ,!Q
M71%65CR*D^>;GW9B?&"2-O"]CAU/_$P3H?\ IG)7CFX?WA^=>_\ _"M?!/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4>E%'I0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %'I11Z4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img105269759_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q Z0# 2(  A$! Q$!_\0
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M'/*;95\MD! *@'&,'&.V.M=5)HDG_"'_ -@V]ZT+BQ%FMT$!*X39OVYZ]\4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ=:\ANM%\0Z/IWBOPPOA*;5)-;NY9;?4T*F/;)T,A/*E>OU_.M2YTGQ!X/\
M%7AG4H-&N]<BM-#&FS&T8;A*#G)ST'3F@#<\3_%O0]"T:WO[1C>&:]-H!L90
MI0@2$\?P@].^>*[FPOK?4M/M[ZU<O;W$:R1L5(RI&0<'D5XBOAKQ(OPNV2Z%
M<-J,/B/[?)9H 7:,-D[?45[9IUR][IMM<RVLMI)+&KM;S8WQDC[IQW% %JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 $ C!&1Z4@50<A0#C&<=J6B@! H484 ?2EHHH **** "BBB@ HHHH ****
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MH@X Z<=\5!H/PVO]&U_0]6FU>SE72K:2V%O;Z>(5=&7&[AC\_<D]<=!7HU%
M'D'@+1HM9^*6N>++>SOK?28R3:)>0F+-Q(JB9E4_[O)_VJ])\3:!!XG\/7>C
MW$TT"7"@"6%L,C @@C\0..]:U% '":#\/;JVU2?5/$>OS:U?/9'3XG\H0"*
M]<!3RQ_O55T+X876GZIICZGXDN-3TW1W:33;-X50QL>[N#E\=O\ (KT6B@#A
M/ ]C-<>*_%_B26)XX[V\6UMMZE2T<*[=P'H6SCZ5W=%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7#:1X+:"3Q=HM]#NT+5[DW4+))AOWJ_O4]1@C@^AKN:* .(TWX3^%-
M,OK6[%O=7,EH0UNMW=/*D9'0A2<<5>U;X>^']9U2ZU"ZAN5EO(A%=K!<O&EP
MHX&]5(!Q74T4 >9^./!&H:KX<TCP9HVGPMHT;1^9>W%Q^\ME0]%7JQVDC/\
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M "O/]._Y+OK7_8%@_P#1E>@5Y_IW_)=]:_[ L'_HR@#T"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#F_%W@Z#Q:ED);^[LI+.1I(Y+;9G++M.=RD=*YO_A44?_0U:U_W
MS!_\;KTBB@#S?_A44?\ T-6M?]\P?_&ZZ#PIX*B\+7-W.NJWM^]PB(?M(3Y
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MO+1EP_S<<G('/I5'4OA_H^HWMW<"?4;-;TYO(+.[:&*Y/0EU'<C@D8S7544
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M\0W-_>/YUZ3\-"3H5]DY_P!.?_T".BPSLZ***0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MG^G?\EWUK_L"P?\ HRO0*\_T[_DN^M?]@6#_ -&4 >@4444 ,>:.-XT>15:1
MMJ G!8X)P/7@$_A33<P 3$S1CR/];\P^3C//IQS6-K?A+3=?U*QO[SSO-LFW
M1B-]JMST8=QC(Q[FJ#?#K0V&J _:?^)D<S?O3\G.?D_N\8''H.] '4?:(<Q#
MSDS-_J_F'S\9X]>.:EKE#\/=%+:4Q-SG3!B+][]_G/S_ -[OU]375T %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7:3_P!$2UD5K^$_^1ST;_KM)_Z(EI >S4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E?QJDD2'P^J2.JM<R
MA@K$ _N^]>6[F_OO_P!]&O>?'7@EO&<%@D>I_8'LY6D#>0)0VY=N,;A7'?\
M"E+W_H;%_P#!:/\ XY2:/*QV$KUJBE3=E;N>;[F_OO\ ]]&O2?@X['5M94NQ
M400'!8D9W24G_"E+W_H;%_\ !:/_ (Y75^!_ <O@^ZOIYM7^WM<I&@ MA%L"
MECV8YSN_2DDR,)@\12JJ51Z>IV=<59_\EGU7_L"V_P#Z-DKM:Y;5?!LE_P"(
MWURRU_4=,NI+9+:06RQ,K(K%A]]&YRQJCV#+UN-+/XP^%Y[-0EQ>VMU%>;!_
MK(E4,I;Z-T/O7&>#A-X.T*S\86PD?2[JXF@UJ <[ )W5+@#_ &> WM]*]/T3
MPE;:1J4VJSWMYJ>J2QB)KR]<,RH#G8@4!57/. .:L:%X:L]"\/?V(C/<VI,I
M;SP"6$C,S X&,?,1]* /)[^?/A+Q-<6RBXSXP22)4< 2?O8R &Z<^M=7XDMO
M%7C?16T*;PNFE0S21L][<7T<IA"L&)14R=_&!TZUH6/PPT?3?#LNAVUS=K:/
MJ*7ZY92R,K*P0''W?E YY]Z[:@"O<O/:Z?*]M;M=3QQDQP[PID8#@;CP,^IK
MS73_ !3XM?XAZM"WAB[=5L[<FQ.IP[8,E_G'.T[O;GY>:]2JNEC:1WTM\EM$
MMW,BI),%&]U7. 3W R?SH JZ_D^&=4)&#]CER/3Y#7 >%=5\43?#S2+"U\&"
MXA?38HH[BXU"$1.OE@!F7EMIZXQFO2KVU2^L+BTD9E2>)HF*]0&!''YU7T72
MHM#T.QTJ!WDALX$@1Y,;F"@ $X[\4 ><VFDZ[H5[X3\%VVORVD1TZX>ZF@C1
MBS*RD;"ZG&"V!QT[5!<^++Z^U[5;)];URQ@TN;['#_9VDFY,SJ!NDE81L.3_
M  C;Q]:]'N=!M[GQ-8ZZTLHGLX)8$C&-K!RI)/&<_**S+_P6DVJW.HZ9K.I:
M1/=X-TMFR%)B!C<5=6 ;'&1@\4 <S:>)_$>OP^'-&=YM'O[_ .TM=W1M=DAC
MA( ,:2#Y2^0>0<"EAUC7M%U_Q1I^H^(X9+?3]-AFM;N\A4+'N+#=($ W-QCC
M&<#CFK?B?PZVEZ?HL>FZ?J]V+&21AJ%E=![VW9ARV).)0Y)# ^W%9_ASP-)K
M,WB2YUR'5$M-7A@@4ZA*HNG,>29"$^6/YMN%'3;TH I6OBC5K/Q+X?\ L^KZ
M[J%GJ-W]FN#J6FK;P-E208CM5@>,@<\=ZL>'=*UV^G\7W&G>(I=-C@UFY,$4
M4$;AY!@DR;@25Z# QWYKHS\/$GOM,OM0\0ZO?W6FW"S6[SO'M4#JNU5 .>Y/
M/'6D;X<0"YU.2UU_6+2/5+EY[R&"5 LF[JHRI*\<9!!QWH PI?&ESK&B>'YY
M-9N--EOK0S2VNE61N+J5P=I9?E8)'D'DCOC-8=[KVJ:I\/O%UAJ<UU,=.OK>
M.&2]@6&<HSQL!(J\9YZ^E>AW?@.S-S8W.DW][HT]G:BR1[,H0T .0C!U8'!Y
MSUYJHGPRTR/3=9L1J&H-'JTL4\[RR!W$B$$L&(YW$#.?PQ0!B^)?$VLV-O\
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M_7:3_P!$2UD5K^$_^1ST;_KM)_Z(EI >S4444AA1110 4444 %%%% !1110
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M:33;5FOU"W9,0_?@=-_KCWK150BA5 "@8 ':@"M!9)9:7'8V.((X81%!QN"
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M(P$/&,=Z]%2"*.W6W2-5A5=@0#@+C&*99V5MIUG%:6<$<%O$-L<4:X51Z 4
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M\=:3D_QR_P#HIZ]VKPGP%_R/6D_[TO\ Z*>O=JXJ_P 9T4_A"BBBL2PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,O
M'.G^(==\66EI-H5W>^%;,+,\-M/$ANYAR ^YA\B^G<C\JM[X/UV?6+[3H].'
M]FZEK<&KO?-.H$**%+QE,[BVY,#'&#UXKU>B@#C==^&VC:[JMSJ=U>:LDTV"
MRP7SQH,*!PHX' JC\$^/A/I ]&G_ /1SUWS_ .K;Z&N!^"?_ "2?2/\ ?N/_
M $<] 'H%>(:W_P C'J__ %^R?TKV^O$-;_Y&/5_^OV3^E- 4:***8@KTGX:?
M\@&^_P"OY_\ T".O-J])^&G_ " ;[_K^?_T".DP.THHHI#"BBB@ HHHH *:S
MHF-[*N>F3BG5P'Q?BCE\(6_F1H^+V/&Y0<?*U!%2?)!S[*YW?GP_\]4_[Z%8
M^OS1%])Q*G_(0C_B'HU?-_V6V_Y]X?\ OV/\*/LMM_S[P_\ ?L?X5/,>1_;,
M?Y/Q/JCSX?\ GJG_ 'T*//BSCS4_[Z%?*_V6V_Y]X?\ OV/\*V/"=K;_ /"8
M:+_H\/\ Q^Q_\LQZT7+I9M&I-0Y=W;<^E*Y[QW_R(NM?]>K5T-<]X[_Y$76O
M^O5JM;GKGA#?>/UI*5OO'ZTE>D<@4V3_ %4G^Z?Y4ZFR?ZJ3_=/\J0'T;HG_
M " =._Z]8O\ T$5>JCHG_(!T[_KUB_\ 015ZO-.L**** "BBB@ HHHH ****
M "BBB@ HHHH *\_T[_DN^M?]@6#_ -&5Z!7G^G?\EWUK_L"P?^C* /0*\Y^)
MW_'_ *-_URN?YPUZ-7G/Q._X_P#1O^N5S_.&@#B****H05K^$_\ D<]&_P"N
MTG_HB6LBM?PG_P CGHW_ %VD_P#1$M(#V:N=\> 'P%K@(R/L<G\JZ*N>\=_\
MB'KG_7G)_*I>Q<?B1\YFVM]Q_P!'A_[]BD^S6_\ S[P_]^Q4Q^\?K25YUV?8
M\J[$7V:W_P"?>'_OV*1[:W\MO]'A^Z?^68]*FIK_ .K?_=/\J+L'%=CZ9\/(
MJ>&]+5%"J+2+ 48 ^05I5GZ#_P B[IG_ %Z1?^@"M"O2/C#YN\4_\C=K/_7]
M-_Z$:R:UO%/_ "-VL_\ 7]-_Z$:R:@^.Q7\>?J_S"BBBD8'KWP;_ .0)JW_7
M\/\ T5'7I->;?!O_ ) FK?\ 7\/_ $5'7I-6CZ_!_P"[P]$>5_%W_D(:+_UQ
MN/\ T**O.J]%^+O_ "$-%_ZXW'_H45>=5W4/@'4^(****V(.C\!?\CUI/^]+
M_P"BGKW:O"? 7_(]:3_O2_\ HIZ]VKBK_&=%/X0HHHK$L**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_^K;Z&
MN!^"?_))](_W[C_T<]=\_P#JV^AK@?@G_P DGTC_ '[C_P!'/0!Z!7B&M_\
M(QZO_P!?LG]*]OKQ#6_^1CU?_K]D_I30%&BBBF(*])^&G_(!OO\ K^?_ - C
MKS:O2?AI_P @&^_Z_G_] CI,#M***XOQEX^/A/4K>S73!=F:'S2QN/+Q\V,?
M=.:EM)79I"$IRY8J[.THKQR^^*<>H,C3:#*I0$#RM5>/\]J#-9I\?)]O$O\
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MBB@ HHJO=W]G81K)>7<%LC,%5II @)/0 GO0!8KS_3O^2[ZU_P!@6#_T97H
M.1D=*\_T[_DN^M?]@6#_ -&4 >@5YS\3O^/_ $;_ *Y7/\X:]&KSGXG?\?\
MHW_7*Y_G#0!Q%%%%4(*U_"?_ ".>C?\ 7:3_ -$2UD5K^$_^1ST;_KM)_P"B
M):0'LU<]X[_Y$/7/^O.3^5=#7/>._P#D0]<_Z\Y/Y5+V+C\2/G@_>/UI*4_>
M/UI*\T^S"FO_ *M_]T_RIU-?_5O_ +I_E3$SZ;T'_D7=,_Z](O\ T 5H5GZ#
M_P B[IG_ %Z1?^@"M"O2/BSYN\4_\C=K/_7]-_Z$:R:UO%/_ "-VL_\ 7]-_
MZ$:R:@^.Q7\>?J_S"BBBD8'KWP;_ .0)JW_7\/\ T5'7I->;?!O_ ) FK?\
M7\/_ $5'7I-6CZ_!_P"[P]$>5_%W_D(:+_UQN/\ T**O.J]%^+O_ "$-%_ZX
MW'_H45>=5W4/@'4^(****V(.C\!?\CUI/^]+_P"BGKW:O"? 7_(]:3_O2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img105269759_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %R \T# 2(  A$! Q$!_\0
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M_P _<_\ W\-']H7O_/W/_P!_#5:B@"S_ &A>_P#/W/\ ]_#1_:%[_P _<_\
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M=I5D5@>?F)P1C.13L!UO]H7O_/W/_P!_#1_:%[_S]S_]_#5:BD(L_P!H7O\
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MU0%C'JIJO_'E#_UU;^0KH_[.M_[K?]]5%/I%K<1K&X?:K%AAN] 6.*HKKO\
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MNO\ O[_]:C_A7FA^MU_W]_\ K4 >5UK0^(;JW<M''%DV8M.0> .C?[PKOO\
MA7FA^MU_W]_^M1_PKS0_6Z_[^_\ UJ //(M:NH)[26(1J;:W^SA2NY9$YR&!
MZYS3[G6VEM);:UL;2QCFXF^SJ=SCT)).!["O0/\ A7FA^MU_W]_^M1_PKS0_
M6Z_[^_\ UJ .'_X23,D4QTFP:ZB142=PS$;0 #C.,\57M];:.">*[L[>^$T_
MGL9RV=^,9X(KT#_A7FA^MU_W]_\ K4?\*\T/UNO^_O\ ]:@#SU]64&X^SV%M
M;+<6Y@=8MV,$@[N3UXHT_69;"!83!#<11SK<1K+G]VX[C'KW%>A?\*\T/UNO
M^_O_ -:C_A7FA^MU_P!_?_K4 ><VNK7-M?R79/G-*'61)"2KAP00?SJ'[8_]
MF+8[5\M9C,&[Y*[<?3BO3/\ A7FA^MU_W]_^M1_PKS0_6Z_[^_\ UJ .!BUN
M,6=M;7&DV=U]G0HCRE]V"2>Q'<U5AOQ!JT=_%:0KY<@D2 9V CIWSUYKTC_A
M7FA^MU_W]_\ K4?\*\T/UNO^_O\ ]:@#SBTU2XM;R6X)\[S5=)$D)*N''.:N
MKXA 6W,FDV$T]O$L:32AF.%'!(S@UW7_  KS0_6Z_P"_O_UJ/^%>:'ZW7_?W
M_P"M0!Y?<7$MW<R7$[EY96+.Q[DU'7JG_"O-#];K_O[_ /6H_P"%>:'ZW7_?
MW_ZU 'E=%>J?\*\T/UNO^_O_ -:C_A7FA^MU_P!_?_K4 >5T5ZI_PKS0_6Z_
M[^__ %J/^%>:'ZW7_?W_ .M0!Y717JG_  KS0_6Z_P"_O_UJ/^%>:'ZW7_?W
M_P"M0!Y!XI^]I/\ UX+_ .C)*P*][O\ X;:#J)MS,;L>1$(4VS8^7<6YXZY8
MU4_X5+X;_O7W_?\ _P#K4[DM'A]%>X?\*E\-_P!Z^_[_ /\ ]:C_ (5+X;_O
M7W_?_P#^M1<+,\/HKW#_ (5+X;_O7W_?_P#^M1_PJ7PW_>OO^_\ _P#6HN%F
M>'T5[A_PJ7PW_>OO^_\ _P#6H_X5+X;_ +U]_P!__P#ZU%PLSP^E1VC=71BK
MJ0RL.H(Z&O;_ /A4OAO^]??]_P#_ .M1_P *E\-_WK[_ +__ /UJ+A9GF4GC
M"X=Y+I=+TV+4Y%*O?I$1(21@L!G:&(SSCO44?B2$V5I;W6@Z=>&UA$*2S&3<
M5!)&<,!W->I?\*E\-_WK[_O_ /\ UJ/^%2^&_P"]??\ ?_\ ^M0%F>2Z9KTN
MD:W)J5G:6ZAPRFU()BVGMC.< @$<]12:9KCZ?-?/-:07RWJ;)TN"V&^8-G@@
MYR*];_X5+X;_ +U]_P!__P#ZU'_"I?#?]Z^_[_\ _P!:BX69Y8GB2*VU"TO;
M+1-/M);=RW[HO\^5(P<L>.<\51T[59M.@O+<1I-;7D7ES0R9VG^ZPQT8'D&O
M8?\ A4OAO^]??]__ /ZU'_"I?#?]Z^_[_P#_ -:BX69Y@WB>">. 7?A[3+J6
M&%(1+(9-S*HP,X;'2LW3]4;3=:CU."VAWQ.TD<1SL0G.,<YXSQ]!7L/_  J7
MPW_>OO\ O_\ _6H_X5+X;_O7W_?_ /\ K47"S/'K#5[FQ>Z)/VA+J!X)HYF)
M#*W?KU!P1]*UO^$P_>07#:%I;WL$21I=2*[,-BA5;!;&1@=J]+_X5+X;_O7W
M_?\ _P#K4?\ "I?#?]Z^_P"__P#]:@+,\3GGENKB6XGD,DTKEW=NK,3DFHZ]
MP_X5+X;_ +U]_P!__P#ZU'_"I?#?]Z^_[_\ _P!:BX69X?17N'_"I?#?]Z^_
M[_\ _P!:C_A4OAO^]??]_P#_ .M1<+,\/HKW#_A4OAO^]??]_P#_ .M1_P *
ME\-_WK[_ +__ /UJ+A9GA]%>X?\ "I?#?]Z^_P"__P#]:C_A4OAO^]??]_\
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M>+Y/J:,GU-']EQ_F#ZDOYCVC_A8'A;_H+Q_]^W_^)H_X6!X6_P"@O'_W[?\
M^)KQ?)]31D^IH_LN/\P?4E_,>T?\+ \+?]!>/_OV_P#\31_PL#PM_P!!>/\
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M/_OV_P#\37B^3ZFC)]31_9<?Y@^I+^8]H_X6!X6_Z"\?_?M__B:/^%@>%O\
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MY$9-']MZ=]F^T?:1Y>=N=K9S],9K!R?4T9/J:GV, ]G$WGUO3HX$G:Y'EO\
M=PK$_EC(I9M:TZ 1F2Y'[P97"D_G@<?C6!D^IIKRK$A>218T'5G; 'U)H]C
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M.?PI(];TZ6&25+D;(_O95@?R(R?PKGS( RH7 9L[5)Y..N*7=D ALCUS1[&
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M_P"+HY*O</;^9W:Z';K=&8SW#*?^6)8;!^F?UI(="@BDD9I[B4,#A7887Z8
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M_P ]K+_P&/\ \73OB/YG]X?6)=V:O_"K-%_Y_M4_[_)_\11_PJS1?^?[5/\
MO\G_ ,165_PFOB#_ )[67_@,?_BZ/^$U\0?\]K+_ ,!C_P#%T7Q'\S^\/K$N
M[-7_ (59HO\ S_:I_P!_D_\ B*/^%6:+_P _VJ?]_D_^(K*_X37Q!_SVLO\
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MOB#_ )[67_@,?_BZ/^$U\0?\]K+_ ,!C_P#%T7Q'\S^\/K$N[-7_ (59HO\
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MR?\ Q%=S11]8J_S/[P]I/NSAO^%6:+_S_:I_W^3_ .(H_P"%6:+_ ,_VJ?\
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M(1AAOKD&E?0[=[E9A/<(HQ^Z5AL/UXS^M:=%'M9]PYY=S+70[<71F,]P5/\
MRQ+#8/TS^M$6A012N[3W$@;.$=AA?I@"M2BE[6?<.>7<RHM!@BCD1KFYD+C
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M4MCK@$Y.*9I=@+^Z=)':.&*-I974<A5';WS@5M6FN6+I(;^1I(VEDD-H]L'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH<<] R@MT[9HB\1:;-82WJ2S>1$</FVE#9XZ*5W'KV%/V\NP>S1YG_9&J_\
M0*O_ /OP:/[(U7_H%7__ 'X->F-XBTU=.6_,D_V=FV _9I=V?]S;N[=<4EQX
MBTRUM(+F66;RIQE-MM*Q_%0I*_B!1[>78/9H\T_LC5?^@5?_ /?@T?V1JO\
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M.@HKG_\ A-O#W_/\W_@/+_\ $T?\)MX>_P"?YO\ P'E_^)HY)=@YD=!17/\
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M'E_^)H_X3;P]_P _S?\ @/+_ /$T<DNP<R.@HKG_ /A-O#W_ #_-_P" \O\
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M_" Z1_SVOO\ O_\ _6H_X0'2/^>U]_W_ /\ ZU5[> O9L\\HKT/_ (0'2/\
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M**]#_P"$!TC_ )[7W_?_ /\ K4?\(#I'_/:^_P"__P#]:CV\ ]FSSRBO0_\
MA =(_P">U]_W_P#_ *U'_" Z1_SVOO\ O_\ _6H]O /9L\\HKT/_ (0'2/\
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M(_Y[7W_?_P#^M1_P@.D?\]K[_O\ _P#UJ/;P#V;//**]#_X0'2/^>U]_W_\
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M3BX/E84445!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4A( ))P!UI:PM=C6YOK%/M846Y-PUNIY<_=0G_9!+'W./2FE=@1KJ^H7L%R/
MLYT_)VV[,0\@'=F7H/89/OZ5$)-1_LXVYU:X\\MN^U"*(,!Z;=NW'X9IU%:6
M1%V-FDU"2QA@35KF*5#\UPL<1:3Z@IM'X 4MU)J$ZP"+5;FV,:X<QQQ-YIXY
M.Y#C\,=:6BBR"[%GFOI;Z.>/4IX8DQNMTCC*O@\Y)4L,^QH\^^_M+[5_:4_D
M?\^GEQ[.F/O;=WOUI**+(+L6WFOH;V6>34KB>)\[;=XXPJ9/&"%#''N:;:R:
MA DXEU6YN3(N$:2.)?*//(VH,_CGI2T46078V*34([&:!]6N99G.5N&CB#1^
MP 3:?Q!ZT&34#IPMAJUR)PV3=>7%O(],;-N/PIU%%D%V-G?4);."&/5KF&6/
M[\Z11%I?J"A _ "ENI;^=X#%JEQ;", .L<<3>:?4[D./PQ2U0U746T^"$0P>
M?=W,HAMX=VT,Y!.2>R@ DGVIV079H33WTFH)<)J4\4*XS:K'&4;ZDKNY]C0D
M]\NI-<G4IV@/2T,<>P<>NW=[]:P_[2U#3KZ"#5DMI8KE7,<EDCY5D7<4*DDG
M(!P1Z=*R++Q7JFH2:?'%9K&^H2.\1>TEVQVZ_P 3'/S$Y7D8 S1RH+L[*VFO
MH+F:674[BXC?.V%XX@L>3V*J"<=.2:;;2:A!!/'+JUS</(,)(\<0,1]0%0 _
MCGI5'4M0DM+W2[6%$9[RY,;;L_*BH68CWX'YU)?:G!IYC61+B620$K%;P-*Y
M ZG"CH*+(+LM1R:@FGR6[:M<O,S96Y,<0=!QP $V_F.]#R:@VGI;C5KE9E;)
MNA'%O8<\$;-OY#M6%=>*+:&\TX0[[BUNK:6Y+0PO(^Q< $*.>I.<^E6I_$>F
M0)&XEEG5X1<9MX6EV1'^-MH^5?<^AHL@NS3N)-0FMH(HM6N8)(QAY4CB+2^Y
M!0@?@!3KF:_GGADBU.XMTC WQI'$1)SW+*2,^V*SH-2:YUR:SB\MK:*TCF,@
MY)9R=H';&T9_&M&BR"[%DGOGU%;E=2G2 8S:B.,HWXE=WZT13WR:B]RVI3R0
M-G%JT<81?H0N[CZTE%*R"X6LM_!+,\NJ7%RL@(1)(X@(_<;4!/XYIMO)J$-K
M/%)JUS/)(/DF>.(-%] $ /X@TZBBR"[&K)J TYK8ZM<M.6R+HQQ;U'IC9M_3
MO1))J#V$5NNK7,<R'+7*QQ%WZ\$%-H_ #I3J*+(+L;=2:A/% D6K7-NT:X=X
MXXB93QR=R$#\,=:?<S7TUW%-%J5Q;QIC= D<963!YR64D9Z<$4E%%D%V*TU\
MVHBY&I3K!_SZ"./9TQUV[O?K6=?77B>*6::UU*V>V"EUB:U_>#V!!P?R!K0H
MII(+G'P^-M;N(4EBOH&1QD'[,/\ &I/^$QU__G\A_P# <?XU5\1116FN+%#;
M+$D\)G+(,!GW8;(]>0?>LVNB,(-7L9MM/<W/^$QU_P#Y_(?_  ''^-'_  F.
MO_\ /Y#_ . X_P :PZ*KV<.PN9]S<_X3'7_^?R'_ ,!Q_C1_PF.O_P#/Y#_X
M#C_&L.BCV<.P<S[FY_PF.O\ _/Y#_P" X_QH_P"$QU__ )_(?_ <?XUAT4>S
MAV#F?<W/^$QU_P#Y_(?_  ''^-'_  F.O_\ /Y#_ . X_P :PZ*/9P[!S/N;
MG_"8Z_\ \_D/_@./\:/^$QU__G\A_P# <?XUAT4>SAV#F?<W/^$QU_\ Y_(?
M_ <?XT?\)CK_ /S^0_\ @./\:;'H7G^&#JD+LTZ,Q>+C!0'!([\<5?M_"]K/
M=7<'GS#RK>.1#QRS@\'CIG%0_9KH/WBE_P )CK__ #^0_P#@./\ &C_A,=?_
M .?R'_P''^-31>'8#HME=RRRB>>:-&08PJLV,].N!3IM#TN:>\L[&ZNOMML&
M.R91M?;U (H_=]@]XK_\)CK_ /S^0_\ @./\:/\ A,=?_P"?R'_P''^-&GZ%
M'>Z+)=M*ZW+!S;Q#HX0 M63:6TM[=1V\ #2R'"@G&3348.^@KR-;_A,=?_Y_
M(?\ P''^-'_"8Z__ ,_D/_@./\:K#0-0,SQ;(<Q@%V,R[5). "<XS[4R#0]0
MN)9HUA"-"P1S*X0!CT&3U-'+3\AWD7/^$QU__G\A_P# <?XT?\)CK_\ S^0_
M^ X_QJI#H6HSM*JP!3')Y1WN%R_]T9/)^E+:Z%J%W#YL<2!/,,1,D@3#CMSW
MHY:?D%Y%K_A,=?\ ^?R'_P !Q_C1_P )CK__ #^0_P#@./\ &HAH,PTBZO)6
M$<L$OEF%F /'7\?0=ZAN-#U"TM6N)H0$0 R*'!9 >A91R*.6F%Y%O_A,=?\
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M[O7D19()?+\O>O;KSGKZ#O1:GV'>1-_PF.O_ //Y#_X#C_&C_A,=?_Y_(?\
MP''^-4X=-$FDF\9CYDEPMO @. S=23[=*G?PSJL>[=#%\C8?]\OR>[<\#ZT<
MM/L%Y$O_  F.O_\ /Y#_ . X_P :/^$QU_\ Y_(?_ <?XU3_ +$O_MLMH8E6
M2)0[LS@(JGH=W3%.CT'49)KB(0HK6^#)OD50 >AR>"/>CEI^0KR+7_"8Z_\
M\_D/_@./\:/^$QU__G\A_P# <?XU!+X=U2%)7>!,1KO($BDE?[P&>1[U"^BW
M\=B;QXE$002$;QN"GH2O4"CEI^0[R+O_  F.O_\ /Y#_ . X_P :/^$QU_\
MY_(?_ <?XU7E\/:E#;O.\*;$C\T@2*6V>N.N*N-X;\J>Q1G,PN(#(RQ2(&#
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MW--M=3TLVFEI>QS.UGO5HU7Y6#'.<Y[<<=ZK?\(MX@_Z!,G_ '_B_P#BJ/\
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M_OZO^-']LZ7_ -!"U_[^K_C5;\J/RH]I/R_KYA[.GY_U\BS_ &SI?_00M?\
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M_P!!"U_[^K_C5;\J/RH]I/R_KYA[.GY_U\BS_;.E_P#00M?^_J_XT?VSI?\
MT$+7_OZO^-5ORH_*CVD_+^OF'LZ?G_7R+/\ ;.E_]!"U_P"_J_XT?VSI?_00
MM?\ OZO^-5ORH_*CVD_+^OF'LZ?G_7R+/]LZ7_T$+7_OZO\ C1_;.E_]!"U_
M[^K_ (U6_*C\J/:3\OZ^8>SI^?\ 7R+/]LZ7_P!!"U_[^K_C1_;.E_\ 00M?
M^_J_XU6_*C\J/:3\OZ^8>SI^?]?(L_VSI?\ T$+7_OZO^-']LZ7_ -!"U_[^
MK_C5;\J/RH]I/R_KYA[.GY_U\BS_ &SI?_00M?\ OZO^-']LZ7_T$+7_ +^K
M_C5;\J/RH]I/R_KYA[.GY_U\BS_;.E_]!"U_[^K_ (T?VSI?_00M?^_J_P"-
M5ORH_*CVD_+^OF'LZ?G_ %\BS_;.E_\ 00M?^_J_XT?VSI?_ $$+7_OZO^-5
MORH_*CVD_+^OF'LZ?G_7R+/]LZ7_ -!"U_[^K_C1_;.E_P#00M?^_J_XU6_*
MC\J/:3\OZ^8>SI^?]?(L_P!LZ7_T$+7_ +^K_C1_;.E_]!"U_P"_J_XU6_*C
M\J/:3\OZ^8>SI^?]?(L_VSI?_00M?^_J_P"-']LZ7_T$+7_OZO\ C5;\J/RH
M]I/R_KYA[.GY_P!?(L_VSI?_ $$+7_OZO^-']LZ7_P!!"U_[^K_C5;\J/RH]
MI/R_KYA[.GY_U\BS_;.E_P#00M?^_J_XT?VSI?\ T$+7_OZO^-5ORH_*CVD_
M+^OF'LZ?G_7R+/\ ;.E_]!"U_P"_J_XT?VSI?_00M?\ OZO^-5ORH_*CVD_+
M^OF'LZ?G_7R+/]LZ7_T$+7_OZO\ C1_;.E_]!"U_[^K_ (U6_*C\J/:3\OZ^
M8>SI^?\ 7R+/]LZ7_P!!"U_[^K_C1_;.E_\ 00M?^_J_XU6_*C\J/:3\OZ^8
M>SI^?]?(L_VSI?\ T$+7_OZO^-']LZ7_ -!"U_[^K_C5;\J/RH]I/R_KYA[.
MGY_U\BS_ &SI?_00M?\ OZO^-']LZ7_T$+7_ +^K_C5;\J/RH]I/R_KYA[.G
MY_U\BS_;.E_]!"U_[^K_ (T?VSI?_00M?^_J_P"-5ORH_*CVD_+^OF'LZ?G_
M %\BS_;.E_\ 00M?^_J_XT?VSI?_ $$+7_OZO^-5ORH_*CVD_+^OF'LZ?G_7
MR+/]LZ7_ -!"U_[^K_C1_;.E_P#00M?^_J_XU6_*C\J/:3\OZ^8>SI^?]?(L
M_P!LZ7_T$+7_ +^K_C1_;.E_]!"U_P"_J_XU6_*C\J/:3\OZ^8>SI^?]?(L_
MVSI?_00M?^_J_P"-']LZ7_T$+7_OZO\ C5;\J/RH]I/R_KYA[.GY_P!?(L_V
MSI?_ $$+7_OZO^-']LZ7_P!!"U_[^K_C5;\J/RH]I/R_KYA[.GY_U\BS_;.E
M_P#00M?^_J_XT?VSI?\ T$+7_OZO^-5ORH_*CVD_+^OF'LZ?G_7R+/\ ;.E_
M]!"U_P"_J_XT?VSI?_00M?\ OZO^-5ORH_*CVD_+^OF'LZ?G_7R+/]LZ7_T$
M+7_OZO\ C1_;.E_]!"U_[^K_ (U6_*C\J/:3\OZ^8>SI^?\ 7R+/]LZ7_P!!
M"U_[^K_C1_;.E_\ 00M?^_J_XU6_*C\J/:3\OZ^8>SI^?]?(L_VSI?\ T$+7
M_OZO^-']LZ7_ -!"U_[^K_C5;\J/RH]I/R_KYA[.GY_U\BS_ &SI?_00M?\
MOZO^-']LZ7_T$+7_ +^K_C5;\J/RH]I/R_KYA[.GY_U\BS_;.E_]!"U_[^K_
M (T?VSIG_00M?^_J_P"-5ORH_ ?E1[2?E_7S#V=/S_KY&E#<P7 )@FCE Z[&
M!_E4M84EI!*P<QA9!TD3Y6'T(YJWI]Y*)C9W3;Y-NZ*7&/,4=<_[0[^O6KC5
M=[21$J*M>+-*BBBMC **** "BBB@ JMJ7_(+N_\ KB__ *":LU'<0BXMI822
M!(A0D=LC%3)7BT5%VDFSE4_U:?[H_E2UHC0;@  7Z8 Q_P >_P#]E1_8-Q_S
M_I_X#_\ V5>>J-2WP_E_F>DZU*_Q?G_D+H/_ !]7O^['_)JH:OX<?5_&EK=3
M&\BLXM.DC\ZUNW@/F&1"%)1@2, GTXK;T[3FL6F=YQ*TNW.$V@8S[GUJ_7;0
MBXP2EY_F<->2E4;CMI^1Y]K>B:J-6U&WM=+EN[:^DT^1;GSDPBP2+O#[CN+8
M&1P<YZ\5E_\ ".ZQ8V=Y%:^'G8SV6H6&V)XD&Z24O'(?F'R%3C/4%<8KU6BM
M3$\UO/!M]+HVK/#8A;V:^MI&*B,R3V\<<(9 6RO5&^5OE)'/7-=)X(TF;2M+
MNEEANH!/<M,D5SY(90549V0@(F2"=HSUSGFNFHH XS5M%U"YT_QO%';%FU%
M+4!@/-_T=$]>/F!'.*PM8\&WR75T-.TYHM-6YM9S;6J0YF"PNCE4DRA8,4.&
M'.WKD"O4** /.]'\)74$]G-+IN\V]A=_9A?&)O)EDF5D&(P G )^0?*,@&N5
MG\-ZCI^F7,]UHTR6\ME;6TL4IMXEDF%U$=BK%_"02 S$D]SZ^W4R2*.9-DL:
MNF0=K#(R#D?J* /,KGPIJ]Y'>MI^F_V5'=+>?9[<NB_9]\,2#(4D*79&.%R!
MG)[U73PA=MI5V_\ 9.JJ&FMV$!-DC!HP^76%%\IP-P&'/S#TVBO6** ,3PE;
MWUIX;MH-0MH+:="X$<,:Q@)N.TE5)56(P2%) ).*VZ** "BBB@ HHHH ****
M "BBB@ K(OSYFKQ(>D4)<#W8XS^0/YUKUE:HODWEO='_ %; PR'TR05)_$8_
M&LJWPFU#X_O&T445B;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!2UB:2WT:[FB<I(D9*L.H-8\>KW4EK8Q/(T=VEU'%.!_&I&0?
MH16YJ%J;[3KBU#A#*A7<1G%4KK0TN+NQNEE"2VVT.=O^L"]*YJT:CE>&VGYG
M51G24;3WN_R"77"GVB6.RDEL[=RDLX<#!'7"]P*?)K44/VWS$P+>-94(;_6J
MPX(].>*BDT24K<6\-[Y=E<N7DB\O+#/4*W8&I+_1(KVXLY _EI!A63&?,0$$
M+^8H_?V=OT_JVS[C_P!GNK_KY?CNNQ'=:\+9EC-N#*(1+*C3*FP'L,_>/M3K
M:_:ZUR,12L;62R$RH>F2W7ZTZ]TEI[]KR"6%)'0(XF@$@XZ$9Z&IHM.,6IK>
M>8N%MQ#L5-O.<YXX'THM6<M=KBO14--[>?\ 7H17.K2PW\UI!9-.\40E)$@4
M8_&D&M"9+06EL\\US&95C+!0JCJ2?KQ4W]GG^T[J\\T8G@$.W'3'?-58=$EM
M8;-K:[5+JVB,6\Q[E=2<X(S0_;7\OEWZ?+N"]A97W^?;K\^PKZ\H@A=;61I7
MN/L[P[@&1_Y&I[35%F^TK=1BUDMG"2!Y 5YY&#4"Z'M6W/V@M*EU]IE=E_UC
M8Z =JG32HC=7TMP$FCNF1O+9>%VC'XT1]M?7].W^82]A;3]>_P#D,O\ 5FM$
M\V&V$\ 3>91,JJ1Z+ZFHY-;;SEBMK)YBUL+D'>%POOFFW6@"6=VMYHX(GA\D
MQ^4&V#_8_NYSS4MOI#0S"1IU;%F+7 7'3^+_ .M2?MW+LOE_7WC7L%&^[^?]
M?<,M]<-Q+; 64B)=(S0,SCYB!D@CM]:DM]96X73_ "X29+LL"F[_ %87[V?7
M%-@TAK<:6?/#?858'"_?R.WI5?1;0'5;V_$<J0%BL"RJ5//+$ ]!FA.LFD^O
MIV3?ZH'&BTW%;>O=I?H_O$T_5YAIUN'5[N\GFD6-=P'"GJ3V %/NM8+6C92:
MWN(KF.*6-7&1D^N""#3HM">"WMQ%=!;FWD=TDV94ACRI&>E+)H;2V\GF76ZY
MEN$GEE*8!V]% ["I2K\MO+R[??>_R*;H<]_/S[_=:WSN1:IK$_V74?L=O($M
MLH;D.!M?V'<"MFW8O:PLQRS1J2?4XK*NM$FE6]B@O1%;7;%WC,>XACUP<]#5
MVW2ZCO3&S9M4@15^7'SC@X/4\5I#VBFW+]/,SJ>S<$H6_'R_KL5;G6)8;N[M
MX;%IC;()'82!1M(SW[T\ZQYK6\=E:M<330B;:7"!%]R>]/.FDW>H3^:/]+B$
M8&W[N 1GWZU!'H\UL+62UNUCN(8! S-'N611[9XI/VU_+Y=^GR[C7L+>?S[=
M?GV!M>4QVK0VLDDD\K0F(L R..H/:I[/58YXYS<JMJ\$OE2+)(, ]>#WJ&+1
M!"UDRSEF@G:>1F7F1F'/TJ:+281+>FY6.>.YF$H1TX7 Q1'VU]?ZT_S"7L+6
M7]:_Y%==1NG\0_9XT62T\CS!L<'(S][W],4^WUEI+T6L]H87>-I$'FJQPO9@
M/NFG2Z0?MPFMIE@B-N;=HU3HO^R>QJ"RT*2UN;:5[J-U@C:+:D.S<I&,DYY/
MO2_?)_/RVT^8_P!PX_+SWU^1-'K0DL].N/((^VRB,+N^YUYZ<]*EO;F0:E86
M43E#*Y>0C^XHZ?B:IPZ#/$+.)KY6@M)O,C3RL$CT)SUJS?1.FK:=>JK,J,T4
MF!G 8<'\Z:=3E][R_2^PFJ7/[GG^MMS+M=8NDNK^&YD8QLTJVTAQ\K+_  _E
MC%63>7<V@Z;'#.POKP*HE[CC+-^7\ZE?04ET^[M9)06FG:='"_ZLGI1'H$;&
MU6[=9X;:#RDCP5^;/+=:S4*RT_7S-7.@]5^79?U=%2[U.\E\.V<]M(4NVF6%
M\=V&00?J14T&J27^I6*Q2-$DL$OFQC^&0<<^XIP\/[-T<,ZI;_:DN$CVD[,=
M1G/>K"Z,D>OG4XY H92'BQU8]P::A6NF_*_RZB<Z%FEYVT[]/Z[%".WU$ZT]
MB=:N2J0K+NV+DY.,5I:?<RM>W]G,Y=H) R,>NQAD#\.E2K8E=8DOO,&'A$6S
M'3!SG-0:=$[:AJ-XRE1+((T!&,JHQG\\U<(.$EZOKTU_X!G.:G%[;+I;73_@
MCM2U*6PRRVAEC5"[2&54'T&>I]JB;67>Y@@M+)YVGMQ.OSA<#T.:2_T:2\O9
M)TN5020^2RO$'*CU4]C51;"\AUBTCMYMC0V.SSC%N1B#T(_7K2G*JI>7R_K[
MRH1HN/2]O/\ K[BS_;X>.T,-G)))<2/%Y>X HZ]0?\:237_*MG9[-Q<13K!)
M#O'!;H0>XJM/I<MK/I,-O*YD$TDCS[,@,1G)'IVJR=#=XV,MT'N)+E+B239@
M';T4#/%2I5W==?EV7Z_(IQPZL^GS[O\ "WS)GU.X$XM8[ R78C\R6,2@",9X
M&[N30=8,ME#<VMJTH?<&WR+&(R.H8GO3[G3YVOVO;*Z$$SH(Y \>]6 Z'ZBJ
MIT#RQ:?9[D P!]WFQAPY;DMCH&JW[9-V_3^MM[_(S7L&E?\ 7^M[6M\R1-<6
MX@M#:VKRSW(8K$7"[0O4D^E17>HWBW.EE+>:)IG=7MBPRV!QSZ=\TL.A2VT%
MIY%VJW-L7"R-'E65CD@C-6/[-G>>QFGO/-DMG=F)3&[<,8&.F*5JTE:6^G;R
MO^OD5>A%WCMKW\[?IYD)U^-+.266W*3I/]G,)<8W_P"]TQ[TT^(X5M))3$/-
MCE$+()5*@GD'?TQ[TZ701*ESF<!Y+K[3&2F0IQC!!ZBI?[,N#9/%]HMUE9PQ
M*6JA"/[I7N*/W_\ 5OZ_0/\ 9_ZO_7ZEFPNWO(#(\'E$-MX<.K>X(ZBK59^E
M:8--2?YT9YGWL(TV(O&, =JT*WI\W*N;<YJG+SODV"BBBK("BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "H+IO+^SS#[T4Z$'V)VG]&-3U
M"Z_:+RVM5Y^<32?[*J<C\VP/SI2VL5'>YNT445V'"%%%% !1110 4R61887E
M?.U%+''H*?5?4/\ D&W7_7%_Y&FMP,4^-=)!(_?\?[(_QI/^$VTG_IO_ -\#
M_&O-W^^WUI*[/80,/:,]=TO6+75XY'MM^$(!W#'6K]<AX!_X\KO_ 'U_K5_5
M-1U.?7H]$TA[:WE%M]JGN;B(RA%+%554#+DDALDG@#OFN6I%1DTC6+NKG045
MST.O75@8K+6[=/MQ@N)]]J<QO'$5^8 G*E@P^7G'/-46^(-H+:YNDTO49+:V
MA@EEE54X,RHR(!NR6^<=.!Z]*@HZ^BN1N/B#IUEJ*6-[;36\JF-;G?-#_HS2
M8VJ1ORW522@8 $9/6JM_\0Q'IE]-::/>B6."Z>U><((YW@;;(!A\X'7G&0#C
MF@#N**Q]1EU6;0%N[&:*PNA%YSK<P>=CY<E,*X&<]P37-6_B?7[.U\.SW<<>
MJ/J\+3?9[*V\IT'DAPH+R8ZGJ2/I0!WM%<;<_$O0[?[._P"]:"2"*XED+QIY
M"2?=RK,&8]R%#8%6I?&L,<6H3#2KYH+.Y-IYQ,:))*#@X+. JC^\V!VZ\4 =
M117'1_$2QN;2WGL],U&[,L,TS) L;&-87"29._!P3QM)W=LTZ?Q[86BR-EKD
MRW/EVJ*8X=Z^2DA.^1PN,..20<D#% '7T5R=OX_TV^O;&VT^VN;LW4*3DHT:
MF-69E^ZS@N05;=L#8Q764 %%%% !1110 4444 %%%% !3)8HYXGBE0/&XPRG
MH13Z*-P3L8S65Y:?+$/M< ^Z"P$BCTR>&_0_6F>;-WL+L'_<7_&MRBL/8+HS
M=5WU5S#\V;_GQN_^^!_C1YLW_/C=_P#? _QK<HH]B_YA^W7\IA^;-_SXW?\
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M=_\ ? _QH\Z;_GQN_P#O@?XUN44>Q?\ ,'MU_*8?FS?\^-W_ -\#_&CS9O\
MGQN_^^!_C6Y11[%_S![=?RF'YLW_ #XW?_? _P :/-F_Y\;O_O@?XUN44>Q?
M\P>W7\IA^;-_SXW?_? _QH\V;_GQN_\ O@?XUN44>Q?\P>W7\IA^;-_SXW?_
M 'P/\:/-F_Y\;O\ [X'^-;E%'L7_ #![=?RF'YLW_/C=_P#? _QH\V;_ )\;
MO_O@?XUN44>Q?\P>W7\IA^;-_P ^-W_WP/\ &CS9O^?&[_[X'^-;E%'L7_,'
MMU_*8?FS?\^-W_WP/\:/-F_Y\;O_ +X'^-;E%'L7_,'MU_*8?FS?\^-W_P!\
M#_&CS9O^?&[_ .^!_C6Y11[%_P P>W7\IA^;-_SXW?\ WP/\:/-F_P"?&[_[
MX'^-;E%'L7_,'MU_*8?FS?\ /C=_]\#_ !H\V;_GQN_^^!_C6Y11[%_S![=?
MRF'YTW_/C=_]\#_&CS9O^?&[_P"^!_C6Y11[%_S![=?RF'YLW_/C=_\ ? _Q
MH\V;_GQN_P#O@?XUN44>Q?\ ,'MU_*8?FS?\^-W_ -\#_&CS9O\ GQN_^^!_
MC6Y11[%_S![=?RF'YLW_ #XW?_? _P :/-F_Y\;O_O@?XUN44>Q?\P>W7\IA
M^;-_SXW?_? _QH\V;_GQN_\ O@?XUN44>Q?\P>W7\IA^;-_SXW?_ 'P/\:/-
MF_Y\;O\ [X'^-;E%'L7_ #![=?RF'YLW_/C=_P#? _QH\V;_ )\;O_O@?XUN
M44>Q?\P>W7\IA^;-_P ^-W_WP/\ &CS9O^?&[_[X'^-;E%'L7_,'MU_*8?FS
M?\^-W_WP/\:/-F_Y\;O_ +X'^-;E%'L7_,'MU_*8?FS?\^-W_P!\#_&CS9O^
M?&[_ .^!_C6Y11[%_P P>W7\IA^;-_SXW?\ WP/\:/-F_P"?&[_[X'^-;E%'
ML7_,'MU_*8?FS?\ /C=_]\#_ !H\V;_GQN_^^!_C6Y11[%_S![=?RF'YLW_/
MC=_]\#_&CS9O^?&[_P"^!_C6Y11[%_S![=?RF'YLW_/C=_\ ? _QH\V;_GQN
M_P#O@?XUN44>Q?\ ,'MU_*8?FS?\^-W_ -\#_&CS9O\ GQN_^^!_C6Y11[%_
MS![=?RF(J7T_$5H81_STN&&!_P !!)/Z5HV5DEFC?,9)9#F21NK'^@]!5JBK
MC247?=D3JN2LM$%%%%:&04444 %%%% !5?4/^0;=?]<7_D:L4C*&4JP!4C!!
M[T(#Q9P=[<=Z3!]*]>_L;3/^@?:_]^5_PI/[&TS_ *!UK_WY7_"NOZPNQC[-
MG/> O^/.[_WU_K6MJ^@R7U]#J-CJ,VG:A%&8?.C17#QD@[65A@\C(/!'/J:T
M[>TMK12MO!%"&Y(C4+G\JFKFG+FE<UBK*QR=QX(\V& Q:U?1W@\\7%T0CO.L
MV/,&",+]U=NT#;BI(O!5M#I-UIXO)BEQ]ERQ497R%C4?GY8S]37445(SF+SP
M9#<^(9-5BO7@$[QR7,0@C8R,@ !5V4LF0H!P>0.QYJ.?P-:SZ?#9M>SA(X[U
M-P5<D7));_OG=Q^M=710!42TD.DBSN+@RR&'RGFV!2QQ@M@<#Z5GP>&H8/[!
MQ<R'^QX#!'D#]X#&$RWX#/%;=% '%1?#JVMS:_9M1EC$<$4$Y-O$[3"/A2&9
M24;!P2O;'<9J[?>#(;NP:!+UXY!J+ZC'(T22*KONRI1AAAACC/?![5U%% '
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MW7R[Q+=X4N$8'!VMT(((-'BK7M6B\0Z5X<T,V\-Y?J\KW-PNY8D4=E[DX/\
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MK]DGE\F*;S!M=^1M!]>#5#Q)XG32K:>.QN-.?4(&C\R&[N/+5%8\$GMGM3U
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MIEACUNP:1H_-"^>OW<9SU].:+L#*L_ 5O!JLNI76K:A?7,]F]G.UPRG>C>F
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M\32^9]KMDVA!C8Y&=K'W&?T'I71T478'*ZIX&MM2UVXU2/4[^S>[A$%W';.
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MMNQ\R)PCKYPR&)QC\^*VJ0!1110 4444 %%%% !1110 4444 %%%% !1110
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M1_Q8QU->I44^8#A/AM9F--8OD:[:"\N0ZF>T%LCD Y=$!X!R.H'2N[HHI-W
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M/?+:R6EFSR20JQP&,GW<^WZ>AX;U?6M.\1>-=1U2>VFL[$EIT0OORJDHL>>
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MM<2);ZL-35WC!9B!]TGOZYK5N?!MI>Z_JFIW4SR1ZC9"REM]N %XY#>O%.Z
MX/5[[Q'J5QX)O=:BT];>[U.&> 6VX-&#@A6R2#P<Y'I7L-<%!\-I$DTG[3XC
MOKJ'2;A);2&2- J(O\)QR3P!D] .!7>TFP"BBBI **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@<*  <\>IP6 [>BL?2_$5M>VTK7>RQN()VMYH991\KK@G!XW#!!!]#VK)O\
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M:6C7BI97RSHZ @$%@!M8$C@COP:T+V^OK.P/B"^MI819P2EK&WF,GF@[=I/
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M5=.U%Y$LK^UN7CX=895<K]<'BL?5_&5CID^JVJ!9KS3[,731>8%WCGY1U.0
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M7$L<YB##;,^YT9>XSC'(/ J2Q\)Q65Y8W?VR66>":>XF=U&9Y)0 Q./N@8&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4$9ZT44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img105269759_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105269759_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +C!J\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**X^X\1W\=S*BF/"N0/E]Z .PHKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**
MXO\ X2;4?6+_ +XH_P"$FU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^
M^* .THKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**XO\ X2;4?6+_ +XH_P"$
MFU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^^* .THKB_P#A)M1]8O\
MOBC_ (2;4?6+_OB@#M**XO\ X2;4?6+_ +XH_P"$FU'UB_[XH [2BN+_ .$F
MU'UB_P"^*/\ A)M1]8O^^* .THKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**
MXO\ X2;4?6+_ +XH_P"$FU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^
M^* .THKB_P#A)M1]8O\ OBC_ (2;4?6+_OB@#M**XO\ X2;4?6+_ +XH_P"$
MFU'UB_[XH [2BN+_ .$FU'UB_P"^*/\ A)M1]8O^^* .THKB_P#A)M1]8O\
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M_P +O\8?W[+_ ,!__KT?\+O\8?W[+_P'_P#KT<C ^EZ*^:/^%W^,/[]E_P"
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MA_?LO_ ?_P"O1_PN_P 8?W[+_P !_P#Z]'(P/I>BOFC_ (7?XP_OV7_@/_\
M7H_X7?XP_OV7_@/_ /7HY&!]+T5\T?\ "[_&']^R_P# ?_Z]'_"[_&']^R_\
M!_\ Z]'(P/I>BOFC_A=_C#^_9?\ @/\ _7H_X7?XP_OV7_@/_P#7HY&!]+T5
M\T?\+O\ &']^R_\  ?\ ^O1_PN_QA_?LO_ ?_P"O1R,#Z7HKYH_X7?XP_OV7
M_@/_ /7H_P"%W^,/[]E_X#__ %Z.1@?2]%?-'_"[_&']^R_\!_\ Z]'_  N_
MQA_?LO\ P'_^O1R,#Z7HKYH_X7?XP_OV7_@/_P#7H_X7?XP_OV7_ (#_ /UZ
M.1@?2]%?-'_"[_&']^R_\!__ *]'_"[_ !A_?LO_  '_ /KT<C ^EZ*^;[+X
MU>+9[^WBD>R*/*JL!!V) ]:^D*EIH HHHI %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><7?_'[/
M_P!=&_G7H]><7?\ Q^S_ /71OYT 0T444""BBB@ HHHH **** "BBB@ HHHH
M ***Z:Q:*V\."Y^RQS2!B,,O7F@#F:*Z>YB@O]!ENVLUMI8^1@8S4>A*BZ1=
MSFW2:1&RJLN<\=* .<HKK;,1ZG'-'=:8ENJKD.%Q65X=BCDU8HZJZA&X89%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\XN_P#C]G_ZZ-_.O1Z\XN_^/V?_ *Z-_.@"
M&BBB@04444 %%%% !1110 4444 %%%% !746=W)9>%A/%C>'(Y'O7+T[S'V;
M-[;?[N>* +M[K%Y?Q^7*X"9SM48S6IHLSV^@7TL9PZ'(/X5SE.$CJI4.P4]0
M#P: .IMKM]=TJ6V,ACNE'\)P&%9_AM&CUID<$,J,"#VZ5C*[(<HQ4^H.*!(X
M<N'8,>X/- '3RP>(3,^R3Y-QV_,O2LK3ICIVN W)P0Q5SZ9JA]IG_P">TG_?
M1J,DL26))/4F@#H;S0+BYU-I8BAMY6W;]W05FZK;6UI?>3;2%U'WLG.#Z536
MXF5-BS2!?0,<5'GG- '6:UIEU?K:M;H&"I@Y;%<]<V%Q83QI<*%+<C!SWJ'[
M1/\ \]I/^^C3'D>0@N[,1TR<T ;GBC_C_@_ZYC^=7M2OVT_4[.3_ )9M%M<>
MHKE6=W.79F/N<T,[OC>S-CIDYH ZCQ&L:Z3 (<>67RN/?FJTG_(G)_O_ -:P
M#([*%9V*CH">!1YC[-F]MO\ =SQ0!T&E%-0T.;3@ZK,#E03U[U'#H @MIIM2
M?RE4?+M89S6$K,IRI(([@T^2>648DE=P/[S$T :_ANW5KR2Z?B.!2<GUK1L]
M7TQ]2+QQS++.=I9NA_6N561U4JKL >H!ZTT$@Y!P: ->XL_L7B..,#Y#*K+]
M":OZWHU[>ZDTT$:E"H&2P%<VTCLP9G8L.A)YI_VF?_GM)_WT: %NK66SG:&8
M ..H!S4-*S,[;F8L?4G-)0 4444 %%%% !1110 4444 %%%% !1110!S/C__
M )%"[^J_SKQ2O:_'_P#R*%W]5_G7BE:PV ****L HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *]8^$U]9ZCH&O\ A"YN$MY=00M;
MNYX)*X(_0&O)Z579&#(Q5AR"#@BDU<#U;0_@U=6]S=W'BR:.RTRWC8B2.8$N
M>Q'H/K61\*E@3XLV2VK,UN&G$3/U*[&P3[XKB[C5M1NXA%<7]U-&.B23,P_(
MFJ\,\MO*)8)7CD'1D8@C\12L^H'J?BSX4^+-5\6:I?VEE$]O<7#21L9U&03Z
M9JK\)+&?3/BI]ANE"SP1RQR*#G! YYK@/[9U3_H)7?\ W^;_ !JNEW<QW!N$
MN)5F/617(8_C19VL!Z7X,_Y+Y-_U^77\GKIO!_B.VN_&.N^$-8Q);3:A+-:;
MS]V02;L#TY&1[UX:ES/'<?:$FD6;)/F*Q#9/7FD$\HG\\2OYN[=OW'=GUSZT
M.-P/1?B[_P E5_X!!5WXZ.8_&.G..JVBD?\ ?1KRZ:XGN)?-FFDDD_ONQ)_,
MT3W5Q=.'N)Y)F P#(Q8@?C0EL![;XQT&?XGZ!HVM^')(9YX8?*GMVD"LIXSU
M]#FN1\8^ ],\'^$K%[R]+>()F^>"-P4 S^? P,^M<':ZA>6+%K2[GMR>IBD*
MY_*F3W,]U*9;B:2:0]6D8L?S-"30'MO@LZ7X&^%<VK:U%,W]L/L9(>)&0@A0
M.1VW'\:T-!O/"WC7P3J_A30+:ZMUBB,L<5T03NSD%>3W _.O Y+NYFA2&6XE
M>)/NHSDA?H*2WN;BU<O;SR0N1@M&Q4X_"CE ]8^!<,D?B/6H&7$BVNP@]CNQ
M6'=?!_QEYTTOV"'9N9L_:$Z=?6N%AO;JWD:2&YFC=_O,CD$_4BICK.J$8.HW
M>/\ KLW^-%G>X%(C!(/:BBBJ **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"UIG_ "%;/_KNG_H0K[4KXKTS_D*V?_7=/_0A
M7VI6=084445F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &=(VK^8WEI:E,_+N)SBF[M:_YYV?YM6G1
M0!F;M:_YYV?YM1NUK_GG9_FU:=% &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O
M^>=G^;4;M:_YYV?YM6G10!F;M:_YYV?YM1NUK_GG9_FU:=% &9NUK_GG9_FU
M&[6O^>=G^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G10!F;M:_YYV?YM1NUK_GG
M9_FU:=% &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G1
M0!F;M:_YYV?YM1NUK_GG9_FU:=% &-<7.M0*A\BT?<X7AB,9[\FIMVM?\\[/
M\VJ/Q BO#9;DM7Q=QD?:7*@'/5<=6]!6O0!F;M:_YYV?YM1NUK_GG9_FU:=%
M &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G10!F;M:_
MYYV?YM1NUK_GG9_FU:=% &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O^>=G^;4
M;M:_YYV?YM6G10!F;M:_YYV?YM1NUK_GG9_FU:=% &9NUK_GG9_FU&[6O^>=
MG^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G10!F;M:_YYV?YM1NUK_GG9_FU:=%
M &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G10!F;M:_
MYYV?YM1NUK_GG9_FU:=% &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O^>=G^;4
M;M:_YYV?YM6G10!F;M:_YYV?YM1NUK_GG9_FU:=% &9NUK_GG9_FU&[6O^>=
MG^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G10!F;M:_YYV?YM1NUK_GG9_FU:=%
M &9NUK_GG9_FU&[6O^>=G^;5IT4 9F[6O^>=G^;4;M:_YYV?YM6G10!F;M:_
MYYV?YM1NUK_GG9_FU:=% &6\NL(C.RV2JHR22W K%MO#YU*!;V.^A=9LN&C&
M5.3V.:ZFY.+68D@81N2,@<>G>J6@,'T*S998Y08^'BB\M3]%[4 9'_")2?\
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M )^U_P"^/_KT?\(E)_S]K_WQ_P#7KIXY8Y5W1NKKZJ<BG4 <M_PB4G_/VO\
MWQ_]>C_A$I/^?M?^^/\ Z]= =1L02#>6X(Z@RK_C4D-S!<9\F:.3'78P./RH
M YO_ (1*3_G[7_OC_P"O1_PB4G_/VO\ WQ_]>NIHH Y;_A$I/^?M?^^/_KT?
M\(E)_P _:_\ ?'_UZZFHXIX9]WE2I)M.#L8'% '-?\(E)_S]K_WQ_P#7H_X1
M*3_G[7_OC_Z]=-++'"F^61(U_O,<"FM<P)LW31KYGW,L!N^GK0!S?_")2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCJ!W^E1:.YDT:S=I))"T2DO)'Y;-QU*]C[4 7J*** /'_B82/BCX0 )^^/\
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M;=,W0 $T1<L<'A?[I]ZU:RM8E:.XTT+--'NN0"(X0X88/#'^$>]:M !1110
M4444 %%8/B'QGH7A:2"/6+S[.TX)C'ELV0.O054TCXC>%-;ODLK'5HVN9#A$
M=&3<?09 R: .IHK(@\3Z3<^(IM!BN=VI0IO>+8>!QWQCN*UZ "BBB@ HHHH
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M %%%% !1110 5R/Q/_Y)SK/_ %Q'_H0KKJYWQUI=WK7@O4]/L8Q)<SQ[8T+
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MH\'@[P_/9SQ3!I;@1>6 ,C!./3&<UZ+\0/"NKZ[XO\,W]A;"6VLIU>X8N!M
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MN(UX#;L<>O?ZU1\1!#X?O1)]EV^7S]JSY7_ L=JNVF/L4&-F/+7&S[O3M[4
M34444 %%%% !1110 4444 5=2CAETN[BN)A#"\+H\A;&P$$$Y[5X/;:;XH\*
M:#=6D.DZ;X@\.R%V:6(!BR]R&4Y'ZXKWN\M(;^RGL[A-\,\;1NOJI&#7EL?P
MN\4:;:SZ5H_B[R-'F+9B>(EE!Z@?_K% '$^*GL]3\#>'+S0GDL=/^V^0;%CO
M\J8Y._<>O_UZ[7Q;=ZOHEIHNFW7C1+11$3/-'"6N9SDX(0=N@ZUH:C\)HI/
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M1H;3S%M"!=1D?:6*@'/\/^UZ"M:LG7Y5BALRTT$>Z[C4&:+?GGH/0^A[5K4
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M#QZ=JIZZ7&AW9C>X1_+X:V3?(/\ ='<U<M<_9(<ER=BY+C#'CN/6@"6BBB@
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MWK;_ )&C%]ZV_P"1H LT56Q?>MO^1HQ?>MO^1H LT56Q?>MO^1HQ?>MO^1H
MLT56Q?>MO^1HQ?>MO^1H EN 3;R@!B=AX4X)X[>]5-%5DT:U5XYXV"<K</OD
M'^\>YIUPMX;:4-]G92AR.1GCU[5FZ+)/!H]M%!#;Q1*F%02&3:/][/- &_16
M?]IO/2#]:/M-YZ0?K0!H45G_ &F\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ
M0?K0!H45G_:;ST@_6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?\ :;ST
M@_6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ0?K0!H4
M5G_:;ST@_6C[3>>D'ZT :%%9_P!IO/2#]:/M-YZ0?K0!H45G_:;ST@_6C[3>
M>D'ZT :%%9_VF\](/UH^TWGI!^M %B_)&GW!#.I$;?,B[F''8=S46DL6TBT8
MR2R$Q+EY4V.W'4KV/M52_N+XZ?<!0A;RVP(LA^G8^M1:3<7XTBT#KA_*7(N"
M3(#C^(]S0!NT5G_:;ST@_6C[3>>D'ZT :%%9_P!IO/2#]:/M-YZ0?K0!H45G
M_:;ST@_6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ0?
MK0!H45G_ &F\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ0?K0!H45G_:;ST@_
M6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?\ :;ST@_6C[3>>D'ZT :%%
M9_VF\](/UH^TWGI!^M #-69EGT_$T\>;D B*+>&X/#'^$>]:=<WJT^H&?3]B
M2$"Y&[[.Q  P?O\ JM:GVF\](/UH T**S_M-YZ0?K1]IO/2#]: -"BL_[3>>
MD'ZT?:;ST@_6@#0HK/\ M-YZ0?K1]IO/2#]: -"BL_[3>>D'ZT?:;ST@_6@#
M0HK/^TWGI!^M'VF\](/UH T**S_M-YZ0?K1]IO/2#]: -"BL_P"TWGI!^M'V
MF\](/UH T**S_M-YZ0?K1]IO/2#]: -"BL_[3>>D'ZT?:;ST@_6@#0HK/^TW
MGI!^M'VF\](/UH T**S_ +3>>D'Y&C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M
M &A16?\ :;ST@_6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?]IO/2#]:
M/M-YZ0?K0!H45G_:;ST@_6C[3>>D'ZT :%%9_P!IO/2#]:/M-YZ0?K0!H45G
M_:;ST@_6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ0?
MK0!H45G_ &F\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ0?K0!H45G_:;ST@_
M6C[3>>D'ZT :%%9_VF\](/UH^TWGI!^M &A16?\ :;ST@_6C[3>>D'ZT :%%
M9_VF\](/UH^TWGI!^M &A16?]IO/2#]:/M-YZ0?K0!H45G_:;ST@_6C[3>>D
M'ZT :%%9_P!IO/2#]:/M-YZ0?K0!H45G_:;ST@_6C[3>>D'ZT :%%9_VF\](
M/UH^TWGI!^M !KBL^BW:I'/(Q3A;=]DA_P!T]C5NV!%K""&!V+PYR1QW/K6%
MKTMS+H=XDMM!<(T>#%YACW^VXD8K3M1>BS@"BW0"-<+DG''3/>@"_15;%]ZV
M_P"1HQ?>MO\ D: +-%5L7WK;_D:,7WK;_D: +-%5L7WK;_D:,7WK;_D: +-%
M5L7WK;_D:,7WK;_D: +-%5L7WK;_ )&C%]ZV_P"1H LT56Q?>MO^1HQ?>MO^
M1H LT56Q?>MO^1HQ?>MO^1H LT56Q?>MO^1HQ?>MO^1H LT56Q?>MO\ D:,7
MWK;_ )&@"S15;%]ZV_Y&C%]ZV_Y&@"S15;%]ZV_Y&C%]ZV_Y&@"S15;%]ZV_
MY&C%]ZV_Y&@"S15;%]ZV_P"1HQ?>MO\ D: +-%-C\S8/,V[^^WI3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O
M7(?.BM!Y EVW4;8,WE[<'K[X].]:E9&O^7Y-GY@M"/M<>/M1(&<_PX_B]*UZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDY!P?N?[5:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E^
M(A&?#]Z)1:%/+Y%VV(NO\1]*W;/'V&WV[,>6N/+.5Z=O:L'Q)((O#M\[310A
M8\^9-%YB+SU*]ZWK([K"W(96S$IW*N >!R!VH GHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,K7
M658K3=-%%FZC ,D/F;CGH/0^_:M6LO6Y7BBM"DEPF;F-3Y$8<D9Z'/1?4UJ4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<
MY(MY2"P.P\H,GIV]ZQM(9GTJW9WN'8KRURH60_[P'0ULW )MI0 Q.P\*<$\=
MCVKR^R^*GA73K1+.YN+V.>#,;I+&TC @\@MW^M4HN6R&DWL>B45P?_"X?!__
M #^7'_@,W^%'_"X?!_\ S^7'_@,W^%/V<^P^678[RBN#_P"%P^#_ /G\N/\
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MY<?^ S?X4?\ "X?!_P#S^7'_ (#-_A1[.?8.678[RBN#_P"%P^#_ /G\N/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4V218HV=CA5&33JHZPQ739<=\"L<14]E2E471-E0CS24>Y3'B
M&/S,&%MGKFM6"XBN8P\3!A_*N)!!Z$5:LKR2SF#H?E_B7U%?+X3/:T:EJ^L7
M^!Z=7!1<?<W.QHJ."9+B%94.585)7UL9*24H[,\MIIV845!>)-):NL#;9#T-
M,L(YXK4+</N?/7/:LO:OVOL^5VM>_3T*Y5R\URU17*0>-H]4UNXTO1;)KV2V
M_P!=,9 D:\XZ\YK>L[V::5H+FU:WF5=V-VY6'L:Z'!K<EIHNT45F_P!M6_\
M;7]F;7\S;GS,?+NQG;GUQS22N(TJ*RKC6)(]0EL[?3YKEXE5G9&4 9SCJ?:I
M[#5(K]Y(O+DAGBQOAE&&&>A]Q[T68KEJX -M*" 04/!. >/7M7QCJ8"ZK> *
MJ@3N JMN ^8\ ]Q[U]FW6/LDV=N-C??^[T[^U?&.HX_M.[P8R/.?!C^[U/3V
MKIPN[-J6[*U%%%=AN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:WRV,UA!ON+@KN$4THRY( /(! JQX^:2X\':%-_:0UI4DE634\\[CSY>#\W
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MU236M9N]2EC6.2YD,C*O0$T04KW8)/J4*Z_P!_Q_W?\ US'\ZY"NO\ ?\?\
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MX@\&Q03W=O="*:1(G@D,BA,\+N/7'(H ["BBB@ HHHH **** "BBB@ HHHH
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M\UT8><8MW9I3:6YYE17IG_"D/$G_ #]Z=_W\?_XFC_A2'B3_ )^]._[^/_\
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MFC_A2'B3_G[T[_OX_P#\31[6'<.>/<\SHKTS_A2'B3_G[T[_ +^/_P#$T?\
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M^/\ _$T?\*0\2?\ /WIW_?Q__B:/:P[ASQ[GF=%>F?\ "D/$G_/WIW_?Q_\
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M7<3@5T#ND4;/(RHBC+,QP *Y?4/&5NFN:)8Z;-:7D5_<-#,Z2;C'A<\8/\Z
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M,5E90)!;1#:D:#@"N8M/&IU#Q%X?L[6!/L>JV3W6]\[T(&0/2KWBSQ#/X?\
M[)\B&.3[;?Q6K[\_*K'!(QWH Z*BN+O_ !-XBO-?O=,\-Z1:S)8!1/<7DK(K
M,1G:H _6M/PGXH7Q'HLMY/;_ &.>VE>&YB9LA'7K@^E '0T5QGA7QU_PE/BC
M5;"WMPMC:(K0S'.Z7)P6^G'%=G0 4444 %%%% !1110 4444 %%%% !1110
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M10 44U75D#JP*GOGBD2:.1B$<,1UP:3DD[-A;J/HHHI@%%%% !1110 4444
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M\7O_ $ X/^_Y_P */85.P>SD>W45XC_POB]_Z <'_?\ /^%'_"^+W_H!P?\
M?\_X4>PJ=@]G(]NHKQ'_ (7Q>_\ 0#@_[_G_  H_X7Q>_P#0#@_[_G_"CV%3
ML'LY'MU%>(_\+XO?^@'!_P!_S_A1_P +XO?^@'!_W_/^%'L*G8/9R/;J*\1_
MX7Q>_P#0#@_[_G_"C_A?%[_T X/^_P"?\*/85.P>SD>RZ@VW3KEMX3$;'<5W
M <=<=_I4>CMOT>S;S%DS$IWK'L#<==O;Z5XU-\=+Z6"2-=&AC9E(#K.<K[CB
MFVOQRO[>UBA?2(IF10ID><Y8^IXH]A4[![.1[I17B/\ POB]_P"@'!_W_/\
MA1_POB]_Z <'_?\ /^%'L*G8/9R/;J*\1_X7Q>_] .#_ +_G_"C_ (7Q>_\
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M_P#"^+W_ * <'_?\_P"%'_"^+W_H!P?]_P _X4>PJ=@]G(]NHKQ'_A?%[_T
MX/\ O^?\*/\ A?%[_P! .#_O^?\ "CV%3L'LY'MU%>(_\+XO?^@'!_W_ #_A
M1_POB]_Z <'_ '_/^%'L*G8/9R/;J*\1_P"%\7O_ $ X/^_Y_P */^%\7O\
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MY)&K16<-5S_RR_\ 'JD74,_\L_UI>SD@Y67:*K"[S_!^M2+-G^&IY6*Q+12
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M7$F+J,D02B,@9ZGU'J.]:M96N(CQ6F^&&3%U&1YLWE@'/4>I]N]:M !1110
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MO?>/7WKIPN[-J6[*E%%%=AN%%%% !1110 4444 %%%% !1110 4444 %%%%
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MOA;2-9\(>)[W4+19YXC(L3,3^[PI.1Z'-9]Q+))^S_:AV+!-4*KD]!UQ^IH
M]_36K&VAM(]0U"SANIH1)L:91NXY*\\CKS3(?%&@W%M-<0ZS8O#!_K76=<)]
M>:\A\86$&J>._ UE=+O@FLHED7.-PSTI(?".BR?'6?1_L2#35M_.-L,A"0@Z
MCTR<T >U6&JZ?JML;FPO8+J$'!>&0,!]<56M_$NAW=\;*WU>REN@<>4DZEL_
M3->!V<MQHND_$.VTMGBCBD6-0A/R)YI4X_#BJK:+<R>"])N[72M.T^3S T6J
MM?A7D;T(/0^W;% 7/8-9^(]GI?CJQ\.YMQ')S<W,DH"Q<'Y?8].OK75ZAKFE
M:3&DFH:C:VJO]TS2A=WTSUKQ;6=&L+OXQ:##J%M"PO;6.6[&?EDD*G)S]15K
M3=.T[Q+\9M=M/$BK+':H4L[:5L+M& ,#O\O/XYH ]DMM1L;RS^V6UW!-; %C
M+'(&4 =>15&3Q9X>ACCDDUS3U24X1C<+AOIS7D'A,)IWB[QMI.DR%]&2TF*J
M&W*I XQ^9'X5G^&?"VD7GP7U?6+FT62_0R&.9B<IMQ@#T[T ?0L<B2QK)&ZN
MC#*LIR"/4&G5Q7PFE>7X;:478L0KJ"3V#G KM:!F7KAD6*T\MKL'[5'G[,NX
MXS_%Z+ZFM2LW68VDBM0L,\N+E"1%+LV\]3ZCU'>M*@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &E 9 _\0&*=11222 ****8!1110 4444 %%%% $=P-UM*,%
MLH1@'&>/7M7QCJ:[-5O%*E<3N-I;<1\QXSW^M?9MSC[+-D*1L;(8X'3O[5X=
M#\%8M3C^W?VVD?GL9-D$0=%R3PK;N1710G&#?,:4Y);GC-%>U?\ "AH?^@^_
M_@,/_BJ/^%#0_P#0??\ \!A_\571[>GW-?:1/%:*]J_X4-#_ -!]_P#P&'_Q
M5'_"AH?^@^__ (##_P"*H]O3[A[2)XK17M7_  H:'_H/O_X##_XJC_A0T/\
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MC-N"5/ID-1[>GW#VD3QNBO:O^%#0_P#0??\ \!A_\51_PH:'_H/O_P" P_\
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M6BO:O^%#0_\ 0??_ ,!A_P#%4?\ "AH?^@^__@,/_BJ/;T^X>TB>*T5[#=?
M_P A[=8]6EF$D@1R( -@_O<MS5G_ (4-#_T'W_\  8?_ !5'MZ?</:1/%:*]
MJ_X4-#_T'W_\!A_\51_PH:'_ *#[_P#@,/\ XJCV]/N'M(GBM%>U?\*&A_Z#
M[_\ @,/_ (JC_A0T/_0??_P&'_Q5'MZ?</:1/%:*]J_X4-#_ -!]_P#P&'_Q
M5'_"AH?^@^__ (##_P"*H]O3[A[2)XK17M7_  H:'_H/O_X##_XJC_A0T/\
MT'W_ / 8?_%4>WI]P]I$\5HKVK_A0T/_ $'W_P# 8?\ Q5'_  H:'_H/O_X#
M#_XJCV]/N'M(GBM%>U?\*&A_Z#[_ /@,/_BJ/^%#0_\ 0??_ ,!A_P#%4>WI
M]P]I$\5HKVK_ (4-#_T'W_\  8?_ !5'_"AH?^@^_P#X##_XJCV]/N'M(GBM
M%>U?\*&A_P"@^_\ X##_ .*H_P"%#0_]!]__  &'_P 51[>GW#VD3Q6BO:O^
M%#0_]!]__ 8?_%4?\*&A_P"@^_\ X##_ .*H]O3[A[2)XK17M7_"AH?^@^__
M (##_P"*H_X4-#_T'W_\!A_\51[>GW#VD3Q6BO:O^%#0_P#0??\ \!A_\51_
MPH:'_H/O_P" P_\ BJ/;T^X>TB>*T5[5_P *&A_Z#[_^ P_^*H_X4-#_ -!]
M_P#P&'_Q5'MZ?</:1/%:*]J_X4-#_P!!]_\ P&'_ ,51_P *&A_Z#[_^ P_^
M*H]O3[A[2)XK17M7_"AH?^@^_P#X##_XJC_A0T/_ $'W_P# 8?\ Q5'MZ?</
M:1/%:*]J_P"%#0_]!]__  &'_P 51_PH:'_H/O\ ^ P_^*H]O3[A[2)S/@/_
M ) LW_7<_P A77ITK>\._#&ST.P>VDOYKAFD+[E4)C@#&.?2MD>#K ?\MKC_
M +Z'^%;K&4E%(M5H6L<>E1:EIPU.T$'FM$0ZNK@9P0<BNX'A*Q'_ "UG_,?X
M4\>%K(?\M9OS'^%1+%4I*Q+JP9P+:/=75J]M=ZG)-'(5W#RU7Y1U''K5B/P_
M D%_;)(R6UX/]4HXC..2*[D>&K0?\M)OS'^%/'A^U'_+27\Q_A63K4B>>!PO
M_"/S206I;4I/MEJ3Y5P(UX4C&TCH15W^Q);BU@CN[]YI(KE;C?Y:K]W^' [5
MV T.V'\<GYC_  IXTB ?QR?F*S=6F3S1.6DT5WU"[OH+R2">XA2(,J@[-I)S
MSUZU GA%9;2\2XO7DGNY8Y))1&%'R$$ *..U=F-,A'\3_G3Q81C^)JS<XLER
M1R5SX5DDO;R>QU6>R2^ ^TQHBL&.,9!/W3BM.P\-6UAJEG=V[LJ6MH;5(L<$
M9SDGUK=%J@[M3Q$H[FLVT2VBAH>DIH]K-"DK2"6XDG)(Q@L<XK3I ,4M02%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB")IM!O(TBFE
M9H\!()1&[<]F/0^];EHI6R@4JRD1J"&;<1QW/<UA>(E1_#]ZLD4,J&/E)Y?+
M1N>[=A[UN68 L;<!54"-<!6W <=CW% %#Q)XAM/#.CR:C=AW4,$CBC&6D<G
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MP.NSAH$V(?H.PK<N#MMI6R5PA.0,D<>G>L71Y#-I-M(TKREDR7DC\MF^J]J
M+U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 5M0 ;3KD%48&)OE=MJGCN>PJ+1E":-9JL<<8$2@)$^]1QT![CWJ:_Q_
M9]SN,87RVR91E1QW'I46D;?['L]C0,OE+@P+B,\?PCL* +M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E:PBO/II:&"3;=
M@RR["O!Y7U/M6K67J^SS].WO:J?M(V^>N23@_<]&K4H **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^%'VN+TD_P"^#_A0!/14'VN+TD_[X/\ A1]KB])/^^#_ (4 3T5!]KB])/\
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MP!9@6\E.",?Q9'W?I5[[7%Z2?]\'_"@">BH/M<7I)_WP?\*/M<7I)_WP?\*
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M[]M_A0!9HJM]NA])?^_;?X4?;H?27_OVW^% %FBFQR"1 ZYP?48IU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5
MKB,\5H%AEEQ=1DB.;R\<]3ZCV[UJUE:[$DL5H'CMWVW4;#SY2@!SU&.K>@[U
MJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$5R ;28$*04;AS@=._M6'H2+'HEHB+;JH3A;9BT8_P!TGJ*W+D@6LI)4 (>6
M&0..XK%T619=&M71X9%*9#0Q^6A^B]A0!?HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ^BF>;'_ ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= #Z*9YL?\
MST7\Z/-C_P">B_G0 ^BF>;'_ ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_
M )Z+^= #Z*9YL?\ ST7\Z/-C_P">B_G0 ^BF>;'_ ,]%_.CS8_\ GHOYT /H
MIGFQ_P#/1?SH\V/_ )Z+^= #Z*9YL?\ ST7\Z/-C_P">B_G0 ^BF>;'_ ,]%
M_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= #Z*9YL?\ ST7\Z/-C_P">
MB_G0 ^BF>;'_ ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= #Z*9Y
ML?\ ST7\Z/-C_P">B_G0 ^BFB1"<!U)^M.H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R_$4
MAB\/7L@F:$K'GS%A\TKSUV?Q?2MVS.ZQMSN+9C4[BNW/'7';Z5C:[N_L2[V&
M[#;./LF/-_X#GC-;5KG['!G?GRUSYGWNG?WH FHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S6C
M((K7R_MG_'S'G[+C.,_Q?[/K6G67K<+316@6!Y=MS&V$F\O;@]3Z@>G>M2@#
MS7XLV4.HW/A6SN$+P3:F$D4$C*D 'D5M67PO\(6-W'<QZ2KRQG<OG2,X!^A.
M*ZV2&*4J9(T<H<J67.#ZBGT >7^*=<NE^(/]DS:O'X?L4M!(M[Y2[YR>JAR.
M /3VKF](F@EO_'?D:A=7\;Z6"ES<YW3  @D>V>E>VW-C:7FW[3;0S;>GF(&Q
M^=*+2V&<6\0RNPX0?=]/I0!YEKD07]GN%$7;_H-OP!W++5;PM;R?#KQ':VUU
M(T^EZ]%&R7<@^:.?'W6/H<\5ZP8(6A\EHD,6,;"HVX^E$EO#*JK)$CJIRH90
M0/I0!XGJ2D^!_'((/.M]/^!+76?$Y /#GA\*OW=4ML8'3@UWYM;<HZ&",JYW
M,-@PQ]33I(8I559(T<*<@,N<'UH \AU?^QE\8ZQ-'K=]X5U5&!=V?]U=C'#A
M>A^E57U74KO1/"OB36(C+:Z?J<HFFCAVAHC@++M].#7L5SI]G>,K7-I!,5Z&
M2,-C\ZF,,1B\HQH8\8V;1C'TH \Q\2:S8>+_ !=X6L]!F6]DM;O[3//""5BC
M [GW]*N_#1 +/Q2=N"=6N,\=:[VVL;2S!^S6T,.[KY:!<_E4D<,4081QH@8Y
M;:N,GU- '%_"<8\"Q#&/]*G_ /1AKCK^32(-:URZLO$-[X7U..=C+:S-NCN#
MV<+T(->RQQ1PILB147KA1@5#/IUE=2B2XLX)9%Z,\88C\30!A^ M3U'5_!MC
M>ZI"(KJ0'(";-P!X;';(KD[S7M,\/_&?4+G5;M;6%]-B17<$@G/3@5Z@ %
M  '0"H9;&TG??-:PR/TW/&": /,O$NNVGQ!U/2-"T#S+NWCNTN;RZ$;+'&B\
MXR0,FH=2^S#Q'X_-[837MJ;:V\R&$X<CGD?3K^%>K0V\-NNV&&.,>B*!_*E$
M,0=W$:!G&&;:,M]?6@#Q6UU9]&OM%C\,>*9M:@N+A(SIEPOF/$AZG/5<?A3-
M.BBT?Q3XCM-7\37^@2R7;3QE"%2=#T()')KV>#3K&VE,L%G!%(>KI& 3^(I;
MFPM+PJ;FUAF*]/,C#8_.@#QJ'4'T7P1=ZAI/VHPW^K*'OM1B5]JXP9@N.G'>
MJVN7-N_B;PP8_%-UKKK?HTKG'DQ9Z8VC )_D*]R:WA:#R&B0Q8QL*C;CZ5#'
MIMC#&(XK.W1 =P58P!GUH \AO7T>+Q!KES::]>^%=3CG8RP2MNCN3_?"]"#5
M75KG5-3TCP;X@U>:XL88I)HY[JUCVF($@))MQP"!Z5[3/IUE=2+)<6D$KKT:
M2,,1^=3/#%)$8GC1HR,;"H(Q]* /)=-CTS4?B#H_V77M4U^:U#R^?N4Q0#'1
MCCOZ"O7:@MK*ULU*VMM#"#U$:!<_E4] !1110 4444 %9'B;4Y-*\/WMU \2
MW$<1:/S#CFM>O"?%%]+?Z_?;Y6>,2LJJ6R !Q6^'H^UE:YSXC%K"\LW&^NQP
M\EZ^HW$ER\QFEE8LSDY))KVOX:ZE<6N@"QO@=D<A\I\YPIYQ^=>,MI=E8W<!
MC>422R!5CW9!Y_E7IEIXEDM@EN=/ C08#(_&/QKQ.(\3B<$X1PUG?77LCZ7$
M\1X7,,)&FXM._;MV/7 0P!!R#2UGZ+J,.IZ9%<0@A?ND'J"*2'5!>M+]AB\]
M(G,;2;@%+#J!ZXKT:,O:TU-=4>%==#1HK/N=4%I87=Q- ZM;1&5D_O #/!JO
MX8\01>)M%CU*&%X4=F78YR>#6O)+EYN@KJ]C8HHHJ1A1110 4444 17(W6LP
MV[LHPQG&>/7M7QKJ4LR:I=IN=-LSC;YA;;R>,]_K7V5<X^RRYVXV'._[O3O[
M5\9:EC^U+O:(P/.? C.5^\>GM75A=V:TMV0^?-_SU?\ [Z-'GS?\]7_[Z-1T
M5V&Q)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!
M)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W
M_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_
M^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1
MY\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_
M #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?
M_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU
M'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!
M)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W
M_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_
M^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1
MY\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_
M #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?
M_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU
M'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!
M)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W
M_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_
M^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1Y\W_ #U?_OHU'10!)Y\W_/5_^^C1
MY\W_ #U?_OHU'10!TG@::5O'.B@R.0;M."Q]:^J*^4_ O_(]:+_U]I_.OJRN
M+$_$C&KN%%%%<QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!F>(HVE\/WJ+#),S1X$<<WE,W/0/_#]
M:W+,%;&W!4J1&HVEMQ''3/?ZUA^(E1_#]ZLB6SH8^5NI/+C//\3=A6Y9@"QM
MP @ C7 0Y4<=CW% $Q( ))P!U)JG#J^FW%QY$-_;23=-B2J3^6:R/'MCJ>H^
M"]0M=)W&[=1A4;:SJ&!90?4C(KS)G\"7UA!ICV5QX7UE"GEW4\#(R.".K]\^
M] 'MK3PK.L#2H)6&50L-Q'J!1+/#!L\Z5(][;5W,!D^@]Z\P\5ZQ%X?^)?AN
M\O#/=(FFR*S6\9=G).,@"J/B_P :Z?XCN_#EK:6VH0NFK12$W%LT:D8(ZGOS
M0!ZY/<06L?F7$R1)G&YV &?QI[2(D9D9U" ;BQ/ 'K7G'CV >+/$]AX3$VR"
M*"2\N6#8P=I$8_[Z.:DT?67U;X1ZI'<-F]L;2>TN!GG<B$9_$8- ';KK.ELP
M"ZC:$GH!,O\ C4]Q?6EJBM<7,,2O]TNX4'Z9KQ/0I_ABO@BT&J):MJ7V;$NR
M-_-+^Q ZUGW!:W\+>"&\1PSS68OIB8I4+.T'&T$=3Q0![LFL:9(ZHFH6K.QP
M%$JDD_G5VO+M%NOAO=ZU9P:?H$D=XTH\EVL74*PY!R>G2N^\127<7AW4'L50
MW"P.5WL5'3DY% &D&##(((]12UY)X5\6ZKI/@?0+-;**\U'469+%/-/S*"2S
MR$],&NGL?%FK6VO-HGB#3[>"ZDMGN+66VD+1RA1DKSR"* .TJ)KJW21XVGC#
MHN]E+#*KZGVKSBU\?>*+GPT?$PT&T_LJ+)D7SCYK*IPS*,8P/?TJJ^IVUYXU
MU_4DC%Q:R^'4F$;$@.IYP<=* /5(Y$FC62-U=&&593D$4ZO-D\97>F:-X1L]
M&T:%VU6WQ% 92%BPH(&3V'?/I5^V\<WVFWFK6?B>R@MIK"T^V![5RZR1],#/
M?/% '=45YL?B#K=G86VMZEIE@FD3,NY8KG=/$C'AF'0_2N_O;^"PTR>_F;]Q
M#$96(] ,T 3RS101&6:18XUZLYP!^-.!# $'(/0BO'O&'B/Q-K'P\N+^?1K>
M#2+WRS&RS$S1J74JS#I@X'YUU]WKNO13V>FZ/I<+*MHDLEY>L4A''W5(ZF@#
MLB0H))  [FEKR#Q-XNU;7/ &K*+>W@NK&]2WNS%.2I&004(ZY/%=;=:[XH@^
MP6%MH]LUY)"9)[F21A;1 '  ;')/'% '945R?A#Q5=ZY>ZIINHVUO#>Z>ZJ[
M6TF^-PPR"#764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!DZ^$,-GOCM7_P!+CQ]HDV@'/5?5O05K
M5DZ\R+#9[Y+9,W48'GQ[P3GHOHWH:UJ .+^('B/6-!_L:#11:_:-0N_L^;E"
MRC(XZ$5EZCKOQ!\,6K:GJUGI-_IT/-PMGO61%[L,GM4GQ-_Y"W@[_L++_2NE
M\;:A::=X,U::[=51K61 "?O,RD #\30!>@US3IM$AUAKJ.*REC$@EE8* #ZD
MT_3M9TS5XGETZ_M[I$^\T,@;;]<=*\1NK?5!I_@#1FLHKJ-[=Y_LES)Y<<KY
MR Q]@>GO6[I^FZQ8_$.QN9-,TG11-;R)/:VET"9TVG!V8'0XH ](D\5>'XFB
M5]:L%,IQ&#.OS<XXY]>*F_X2#1_[2&G?VI:?;3P(/.7>?PS7D'A[PUI%S\'M
M=U*XLH9;QOM3K,RY9"A.W:>W2I=;T'3-,^%>@ZG:VD<>H":VE^U!?WA9B"26
MZT >NZEK6EZ.J-J6H6UH'^[YT@7=],T\:IIYT_\ M 7MN;/&?/\ ,&S'3[W2
MO(IHM4U;XH>(&CT33]8DM5CCBBOYMHB0CJJD'.?7_&J4]C?:=X*\;VMQ'9VL
M!:)ULK6X\T6[EQN'M0(]BA\1Z)<:A]@AU:SDN^GDK,I;\LUC0>.+2?Q]/X;\
MRV5(H PE,HW/*3]P#U [=:XWQEX<TG1/ ^A7NG6,-O>0W5L5N(UPY)ZY/4UI
MZ=IUB?CAJ;&T@)73HYE/ECAR1EA[^] SK=#U6XDTZ\NM7O-/VPW$BB2WD&Q$
M!X#'/#>M6].\1:+JTS0Z?JEI=2J,E(I0QQ]*\@@N--3P=<VM_:W-[)<>()1;
MV<#[//<-P&/]VIIX;^T^(GA*:Y\/:=H9DN"BI:2AG=<8.[  QS0(]LK(D\5>
M'XKW[%)K-@MSG;Y1G7.?3KUJUK%S;V>BWUS=2O%;Q0.TCQ_>50#DCWKPZ_M&
MF^'ES-I_@ZSMM*\LR)J-[< W##/## SD_6@9[E=ZMIU@^R[OK>!MADQ+(%.T
M=3SVI--UC3=8B:33;ZWNT4X8PR!L'WQ7E3:?;:_XM\!PZD@N(FTCS'1^0Y"9
M&?7FK&HVR>'/'7B-=$@6VW: TXBA7:OF#(! '?B@#L?$WC/3]+TC4S8ZE8R:
MI:PLZ6[2!CN'8J#FM?P_?2ZGX=TZ_G"B:XMHY7"C R5!.*\NF\->'I/@@=0-
MM ;HVGGFZ('F&7_>Z]>,5Z1X._Y$O1/^O*+_ -!% '*7&O\ C34O&FM:1H3:
M4EOIYCYNHV+'<H/4'US5O2?%FO6'B:VT#Q996L<MX";2[M"?+D(ZJ0<X-1^%
MO^2I^,_^W?\ ] %1>.IH[WQQX.TZV8/=Q7WVF15.2D:]2?3.* .SU'7]'TB1
M(]1U.TM9'Y59I0I/X&IY=2L8+6.ZEO($MY2 DK2 *Q/3!Z'->,Z/;:OK'B+Q
M+=KX<TS6)?MKP.U]/M:)!T4*0<#'>J5YI]U#\.)--O)+<P#78TCBM[CS1"I)
MRF?:@1[3;^)=#NGG2#5[*1H 6E"SJ=@'4GGI4^G:QINKH[Z;?V]VJ'#&&0-M
M/OBO-/%'A#0H_&W@^RATZ"&WF:1)DC7:)55=P#8Z\CO5;5HE\-^.?$PT2!;3
M_B0&81P+M <'&X =Z!GIK>)-#74?[/;5K(7F=ODF9=V?3&>M6+O5M.L'*7E]
M;V[!#)B60*=HZGGM7ANGZ'J=Y\.T9/#6BF"6'S3JDMYME#==Y.."#VS6ZFEI
MKGC7P;;ZX(KPKI+22X;>DK*.#GN.] 'IB>)-'GTRXU"VU*TFMH 3)(DRE5]B
M>U<S8>-[C7O"%OJFG7&F6UXURB317$V5C0L1@\CYB!Q63#H^GV/Q.U[3K>SA
MCL;C2%EDM@@\LMD\[>G:N<AM+:#X,://#!&DLVHP^:ZJ 7Q*<9/>@1[+J6N:
M5HX4ZEJ-M:;_ +OG2A2?IFI[*_L]2MA<V-U#<PMTDB<,/S%>::RT%]X_U!-*
M\,C7=1@A2.X>]F58+<'D!00>33OA(LL&J>*K62&"W\N\7,%LVZ*-L'(7VH&>
MHUYWXH^'[SW#7FD8W.V7A8]SW!KT2BM*=65-WB8UZ$*T>69\[7/@Z^TWQ)YV
MISKOA8-'&@R,=N:UJ])\6^'+C5Y(;BS"&51M8,<9':N/D\*ZS&X4V;')QE2"
M*^1SA8ROB7*HFTMK+2WR,'2Y/=2T-KP%>/YUS8'=L==X(_A/2L.TB^('A"2X
ML-/L(K^R,K/&Y&>ISZBO1M T2+1; 1@ SOS(_J?3Z5:\^[A)62V,P!^5XV R
M/<'I7T>4QJ8;#*G42?D^ANH/E5V>?V?C/4-7TS7-'UO3OL6HPV4D@ ! 9=OH
M:@\$633?"R:?[5/')&)FB,3E=A'.>.O-=5?>'9]1GU34I$1+N>R:TMXMV=H(
M/+'U)_*J_A7PYJ&D> 9='NEC%VRR@!6R/FSCFO5=2')[NFJ!1=]2AX1\5BZ\
M!1W^NZAY)28Q&;HSXZ#ZU0\8:]+H=[HU[I%S=1K/+ME@GW;9$..<-5(?#?6C
MX*M+(M"+ZTO&G$7F?*ZG'&?7BMKQEX>UKQ3%I!M[*. VL@>5991GMG&.W%6O
M9*K=/1M^@O>Y;%>TU/4;[XMWVEO?3+8+"&\E6P!\BGCTY-/EUF\\/?%&#1UN
M99=.O(@WE2MNV,<]">>U9UAY\7QMU$PH)'2W&4SC<-B]#ZUO)X8O]7^("^(M
M0B2VMK:,1P0EPSL1GDXX'4TI<D7[VW+^(*[V[E'PKX@?Q3?ZU<W]Q,D,4GE6
MT,9("#GGCJ>E:GP^U+6[J"^M=9CG_P!'EQ!-,A4NG/YTWPYX;OO".LZE]GB%
MUIEZ_F)L8!XFYX(/4<UV%N\\FYI8Q&,_*N<G\:QK3AJHK1VMY%03TN+<G%K,
M20,(W+#(''<=Z^,M2(;5+M@RL#,YW(NT'D\@=A7V=.<6\I!880\J,D<=A7QE
MJA+:O>DL[$SN=SKM8_,>2.QHPN[.JENRI11178;A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 7-(M$O]:L;.4L(Y[A(
MF*]0&8 X_.NH\4:3X=TZ\NM+T[3]6CO(KCR$N+F=/)8@XS]T=?K7-Z%/';>(
M=-GF<)%%=1N['H &!)KM?&T]WK-Y=O\ \)A8W>FR76^&U^T,2@)P#C;@8!]:
MSDWS(E[G*W/A+6;,WXN;3RA8LBS,S #+?= /?.>U7+OP!XBLK2>XGLU @3S'
MC$JEPG]_;G.WWKK?%&O:3KGA^+2+74RTNC20A)9#_P ?X "EA[@]/:K^KMIN
M@^,]:UZXUJWE+630BQ&[S?,:(*%(QC;WSFIYY$\S.)U/PPUQ)X>M='M&>YO=
M/6>0!NK;FRQST&!5&\\&ZU97%G"\$<@O)/*@DAE5T=_[NX'&:ZRRU[2?M&F6
MTM^D*S: UB\_)$$C,Q&['^>:33[[3/#EAHND2:K:W<O]KI>S2P,6C@11CJ0.
M3G-'-)#NSF9O NNV]]'930P1SLC2,K7"#RU&,E^?EZCK5S2?A[J5YXGM='O7
MBMEN(S,LZR*ZLG/*G.&Y':I-%DT6_P#%^M3ZI-;OYGG/9M=,PA>0M\N\CG&*
MZ>7Q!H]KXG\&.;ZQ,5E'+'<M: B*(L3C&><<T.4M@;9P47A#5KC5KC3H$AE>
MW3?+*LRF-%]2^<#\Z>?!.O?VS#I2V8>ZGB,L.QP5D0#)*L.#TK>TM=/MM-\1
M^&IM9LHY;TQ2P7BL3"VPDE"V,CKZ5J:?K>E:1>Z+IO\ :L,_]GV%VLEVA.SS
M)%8A%)Y..!3<Y= NSA]4\)ZMH]K+<W441ABD6.1HI5?:S#(!P?8U0U'2[O2I
M8HKR/RWEB695SD[6Y&?2NP^&HM]6U&_\/:@S?8]0B\QG'.QHSN#?D"/QKF_%
M.JC6O$M]>KQ$TA6(>B+PH_("J3?-9C3=['9?\(;X9GO;;0XFU.+5)]/6[6X9
MT:'<8]Y!7 ('7O5.^^']W>Z+H5UH]K&7N+,O-NF ,L@8_=!/)P.@I?%?C>[!
MM[/2+R$6S:=##+)%&N\G8 RE\9_"@:W9#4_ CB\398Q1BX.[B(^82<_A6:Y]
MR=3F]*\*:IK"R-;)"@27R3Y\RQY?^Z-QY-/M/!^LW<]Y$+=(39R"*=KB58U5
MST7).,\5U.DOX>E6_NS<:8+_ /M-W9[_ '%1;]0T8'4YS6D=6LKWQ3KC'5-(
MET6[O%:>VO"PWJ /WB$#KU%4YR'S,X33_!^L:DDKPPQ*D<I@W2S*@>0?PJ2?
MF/TK(GM9;.]>UNT>*2)]DJD<J0>:],M]5T>XT--/TJXTF/[#?3/$NJJ?FB9L
MJRGUP.:X+7;J35?$]U/<75O(\TV'GA!$9Z#<!UQ51DV]1IMG0OHGAC5/#&JW
MVC?VE#<:8L;,]TRE)@QQP /E/MFL7PIH">(-6>&><P6=O"UQ<RJ,E8UZX]SD
M"NK\1V^GVOA<:1H6O:2;"(":X_>MY]W*!W&W&!V&:Y_P-JUCINJW=OJ4ABLM
M1M)+228#/E[L$-CTR!4IOE;0E>Q9CM_!^HZKIUMID.IQR/>Q1/'=.K++&6P3
ME0"IJ/4_#T AOQ9V,WFKJYLX9?-&P ]$P><^]2V^C:9X?UC3;U_$=A=E+Z(A
M+;<V(PV2S$@8QZ<UIMK>F_9[A?MD>6\2K= 9ZQ<?/]*+OH'H<[J?@77](LI[
MN[M$6.W($RK*K-'DX!90<@'UJ:\\*7-WK%O8Z3IT\9:RCN9!/,I !4$N6Z*I
MSWK6FUNQ?6?'$IO$:.]@=;=B>)3YBD8_"M9M=T>^EO\ 3#J4-O\ ;]#M;:.Z
M;.Q)4 )1B.F>E+FD%V<5_P (9K U%[)DMU98A,96N$$>PG ;?G'6M#2/"CV^
MLZA8:U;#?%ILUS%M?*DA<JP(ZBK6BZ7H-A>7MM=:IIE]>+;*ULTS.+82;OF4
MGO@<^F36WJ.NZ0-=5H[ZS:-/#TEJ6@!$?FX;Y5!Y[BAR>P-LX7PTFA37HM]:
MM[Z7SG1(C:RJFTDX.[(.>U;7B'P]I!\2MX;\.6FH/J4=PT):XG1DDP"> %&.
ME<KIDB0ZM9RR,%1)D9B>P!%=G%K-@GQGEU;[7&+$WDCB?/RX*L :J5T[H;W,
MMO"5QIEOJBZG9L]Q!:"=#!<(1"=^W+C],=:JMX,UE=,>_P#)A:-(A,\:3J9%
M0_Q% <@5:T74K:*P\5"XN%$EW:E8MQYD;S >/PKK[6Z\-Z9I]X]C=Z5';S:4
MT2?>-T\I3D-G@<_TI.4D)MHX?Q)IEI8:9X?FMH]CW=B)ICDG<VXC/Z5SU=)X
MGOK:[TKPY';S+(]OIXCE"_P-N)P:YNKCMJ4MCH/ O_(]:+_U]I_.OJROE/P+
M_P CUHO_ %]I_.OJRN3%?$C&KN%%%%<QD%%%% !1110 4444 %%%% !1110
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MN_+K3[BZM[1-]S/%"G3=(X4?K0!X[#X7NI=.M=+C\!V\.I*52>^N"&@VCJP
M.23Z5ZMJ^EC4_#]WI>X()[=H00.!D8%7T=)4#QNKHPR&4Y!IU 'D6IQ^,+OP
M"OA(>&Y#<0I'"]T)5\MXT(P5YSD@#]:L:SH.I-XJ6XU71+O6M*^QQ1VT$$P"
MPR #=N7(SSGFO5:* /&[?PAKH\)^*K,:*MI+=745Q:VT;@J5&#M!]1BKVLV6
MKZQK=AJ6K>&]0N]+-IL_LZ.< PR@_>8 @$$?SKU:B@#SOX?:#J.D>(]<N;G1
METRTNUC:WBC8,J #&TX[^M>B444 %%%% !1110 4444 %%%% !1110 4444
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MI6G0!R.K_#S2M4U674HKF^T^ZG&V=K*<QB4?[0%3GP%H0\/V^BQPR16D$ZW
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M4 %%%% !1110 4444 %%%% !1110 4444 =!X%_Y'K1?^OM/YU]65\I^!?\
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M;^VN;B&%H;>"U0B- PP3D\G@FJ5IX6\9^';6YTC0;_37TN5W:"2Y#"6W#')
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M %_QH_X5OX1_Z EO^O\ C7544<\NX<S.5_X5OX1_Z EO^O\ C1_PK?PC_P!
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M7_A6_A'_ * EO^O^-'_"M_"/_0$M_P!?\:ZJBCGEW#F9RO\ PK?PC_T!+?\
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M/^%6:* *WVZ#U?\ [X/^%'VZ#U?_ +X/^%6:* *WVZ#U?_O@_P"%'VZ#U?\
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M2Z=>JQ2AB/PK2H **@N;RUL_+^TW$4/FN(X_,8+N8] ,]34] !1110 4444
M%%02WEM#<PV\MQ$D\V?+C9@&?'7 [U/0 4444 %%%% !1110 4444 17)VVL
MS;@N$8Y(SCCT[UB:)*)M&M9!*LH9,[TB\L-]%[5N7&1;2D%@=AY49/3M[UP5
MKXUL+.V2WF%]++&-K/+&%<GW&>#6=2K"FKS=C6E0J57:FKG8T5RG_"?Z7_SQ
MN?\ OD?XT?\ "?Z7_P \;G_OD?XUE]<H?S(V^H8G^1G5T5RG_"?Z7_SQN?\
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MZ&CF0O9R[$U%1?:%]#2B93V-/F0N278DHIGFCT-+O%%T*S'44@;-+3$%%%%
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M% !1110!'<9-M+@,3L/"G!Z=CZUX+<AA=2AEE5@YRLK;G'/<]S7O-R-UK,N
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MM[::ZD\N",N^TM@>@&32202Q)&\D;*L@RA(P&'M3L[7%=7L1T444AA766/\
MQXP?[@_E7)UUEC_QXP?[@_E73AOB9C6V+0ZT\4U" X)4, >A[UTNFVVC:@FW
MRC'-CE#(?TKT:=/G=DSSZ]94ES--KR.>%/%:>I:'-8DR1YD@]1U7ZUF"G*#B
M[,4*D:D>:+'"G"F=*K?VMIZPPS&\A$<[;(F+##GT%"382:6Y?%.%0&Y@2X2!
MI5$KJ65">2!U-58=?TB:80QZC;-(3@+Y@R3Z523(E)+=FF*>*C9E12[$!0,D
MGL*HV_B#2+I]D&H02-@MA6SP!DU239$FEN:@IXZ5G1ZQ8RRV\<<X8W$;2Q$
MX95ZG-6[6Z@O;9+BWD$D3C*L.AJK,BZ>Q9%/%,%/%6B&.%/%5KJ[M["U>YNI
M1%"@RSGH*L(P=593D$9!JT8LD'6GBF9 Y/2J-IK^DWMX;2VU"WEN!G]VK@DX
MZX]:M&<F:@Z4X5EW&OZ1:7@L[C4;>.X) \MG (STSZ4^\U_2-.N%M[S4;>"9
ML81W //\JM&3:-44X5!)<0P6SW$LJ)"B[FD8X 'KFEL[NWOK6.YM9DF@D&4D
M0Y##VJD9,LCM3Z8.U/JT9L****9(4444 %%%% !1110 4444 %%%% !1110
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M'Y0[C(Y.:R[+6+JPB\N#R@025<Q@LI/H:<YTU5OTMV7_  PJ=.JZ-M;W[O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:_;S:[J<-EI<L/DQ138W'8OWOR_6NT\6^&/^$GL;6*.^DLKBTN%N8)T0-M8
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MKZY;=//;(\C>K8Y-;-9^A:4NAZ%9:6LIE6UB$0D*X+8[XK0H&%%%% !1110
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M_D>W_:6%_G_,XFBNV_X5Y-_S_I_WP:/^%>3?\_Z?]\&CZAB/Y?R#^TL+_/\
MF<317;?\*\F_Y_T_[X-'_"O)O^?]/^^#1]0Q'\OY!_:6%_G_ #.)HKMO^%>3
M?\_Z?]\&C_A7DW_/^G_?!H^H8C^7\@_M+"_S_F<317;?\*\F_P"?]/\ O@T?
M\*\F_P"?]/\ O@T?4,1_+^0?VEA?Y_S.)HKMO^%>3?\ /^G_ 'P:/^%>3?\
M/^G_ 'P:/J&(_E_(/[2PO\_YG$T5VW_"O)O^?]/^^#1_PKR;_G_3_O@T?4,1
M_+^0?VEA?Y_S.)HKMO\ A7DW_/\ I_WP:/\ A7DW_/\ I_WP:/J&(_E_(/[2
MPO\ /^9Q-%=M_P *\F_Y_P!/^^#1_P *\F_Y_P!/^^#1]0Q'\OY!_:6%_G_,
MXFBNV_X5Y-_S_I_WP:/^%>3?\_Z?]\&CZAB/Y?R#^TL+_/\ F<317;?\*\F_
MY_T_[X-'_"O)O^?]/^^#1]0Q'\OY!_:6%_G_ #.)HKMO^%>3?\_Z?]\&C_A7
MDW_/^G_?!H^H8C^7\@_M+"_S_F<31793^ 98())C>A@BEBJ1DDX]!3;3P))=
MVD5PMYL610P62(JPSV([&CZAB/Y?R#^TL+_/^9Q]%=M_PKR;_G_3_O@T?\*\
MF_Y_T_[X-'U#$?R_D']I87^?\SB:*[;_ (5Y-_S_ *?]\&C_ (5Y-_S_ *?]
M\&CZAB/Y?R#^TL+_ #_F<317;?\ "O)O^?\ 3_O@T?\ "O)O^?\ 3_O@T?4,
M1_+^0?VEA?Y_S.)HKMO^%>3?\_Z?]\&C_A7DW_/^G_?!H^H8C^7\@_M+"_S_
M )G$T5VW_"O)O^?]/^^#1_PKR;_G_3_O@T?4,1_+^0?VEA?Y_P SB:*[;_A7
MDW_/^G_?!H_X5Y-_S_I_WP:/J&(_E_(/[2PO\_YG$T5VW_"O)O\ G_3_ +X-
M'_"O)O\ G_3_ +X-'U#$?R_D']I87^?\SB:*[;_A7DW_ #_I_P!\&C_A7DW_
M #_I_P!\&CZAB/Y?R#^TL+_/^9Q-=98_\>,'^X/Y5:_X5Y-_S_I_WP:U[?PM
M)#!'&;E3M4#.VMZ&#KQ;O$RJYAAI+27YF0.M/%;7_"./_P _"_\ ?-+_ ,(Z
M_P#S\+_WS75]7J]CG>-H?S&,*>*UQX>?_GNO_?-.&@/_ ,]U_P"^:KZO4[$O
M&4/YC(%.%7+K3OLCVZLTC^=((P8XRP4^K>@]ZMC0F'_+<?E35"IV)>,H_P Q
MEBG"M/\ L1O^>P_*G?V*W_/8?E5>PJ=B7BZ/\QF"GBM'^QV_Y[#\J4:0W_/4
M?E35&?8AXJEW,\4\=*O?V4W_ #U'Y4[^RV_YZC\JI4I]B7B:7<I"GBK?]FM_
MST'Y4X:>1_RT'Y52I2[$/$4^Y4%/%618'^^/RIPLC_?'Y52IR[&;K0[E<=:>
M*F^QG^^/RIPM3_>'Y5:A(S=6'<B'2G"I!;G^]3A!C^*J460YQ&BG"G"+'>E$
M?O5),S<D [4^FA<4ZJ1FPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,[7I'AT.[D26XB94R'MXP\B_[JGJ:V[0EK.!BSL3&I
M)<88\=QV-8?B!'DT&\2-+EW,> MJX24_[I/0UN68(LH 0X(C7(<Y;IW/K0!5
MUK5DT6P^UR6UQ<+YBQ[+=-S?,<9QZ"KX.0#ZUQ_Q-O+FQ\(B:TGD@E^V0+OC
M8J<%QD9%<_\ V;>^)_B1K^G3ZWJ5MI]M# XAMIRF6*#OV'4T >HUSFN^,[#0
M]0CTX6UY?7[IYGV:SBWLJ?WCR !5#X;W=Y/HM_:7MU)=-87\MJDTIR[(N,9/
M<\U<\1:KH?A)Y=9F@5M3NE$$:1C,MP1T4#TH DT_QMHNH:'=ZL)W@@LR1<I.
MFUX6'9E]:JZ/\0--U;4X;!K._LI+E2ULUW#L6<#^Z<UP'B#1-1L/!%_JNKA8
MKO6M5MYKB!.D4>[A3[],UV'Q 58V\*O" )4U:!8\=<'@@?A0(MZA\1M+LKVZ
M@BL=2O8[1MMS<6MOOCB/<$Y[=\5TMAJ5GJ>FQ:C:3K):2IYB2#IBN.\0ZM9:
M(DOAGPU8I-K.H%V,$0RL>_[TDA[5SVLW-OX2T+1O DFI+:B:/=?WK9 6,DE@
MN.['('M0,] \.>+-.\4F_.F^8T=G/Y#.P #G&<KSTK=KROX4:EHR:OXCT[3K
MB/9)>F2UC4'YH@H&17JE !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &;K,;R16H2.Z?%RA/V=PI SU;/5?45I5DZ\F^&S_<)+BZC.
M'F\O;SU'J?;O6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 17.#:R@@$;#PQP#QW/:L71%5=&M0D<4:A.$BD\Q1]&[UM7.
M/LLV=N-C9W_=Z=_:L/0MIT2TV&V*[.#; B/_ ("#VH T:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O06L9PHD8F-
M@!&<,>.Q]:CTM632[56696$:@K.VYQQ_$>YIVH#=IUR-@?,;?*6V@\=,]OK4
M>CKLT:S7RUCQ$HV+)O"\= W?ZT 7:*** "BBB@ HHHH **** "BBB@ HHHH
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M^V_NR?\ ?UO\:/[/MO[LG_?UO\:M44 5?[/MO[LG_?UO\:/[/MO[LG_?UO\
M&K5% %7^S[;^[)_W];_&C^S[;^[)_P!_6_QJU10!5_L^V_NR?]_6_P :/[/M
MO[LG_?UO\:M44 5?[/MO[LG_ '];_&C^S[;^[)_W];_&K5% %7^S[;^[)_W]
M;_&C^S[;^[)_W];_ !JU10!5_L^V_NR?]_6_QH_L^V_NR?\ ?UO\:M44 5?[
M/MO[LG_?UO\ &C^S[;^[)_W];_&K5% %7^S[;^[)_P!_6_QH_L^V_NR?]_6_
MQJU10!5_L^V_NR?]_6_QH_L^V_NR?]_6_P :M44 5?[/MO[LG_?UO\:/[/MO
M[LG_ '];_&K5% %7^S[;^[)_W];_ !H_L^V_NR?]_6_QJU10!5_L^V_NR?\
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M;_&C[%!Z/_W\;_&K%% %?[%!Z/\ ]_&_QH^Q0>C_ /?QO\:L44 5_L4'H_\
MW\;_ !H^Q0>C_P#?QO\ &K%% %"]LX%L9V(48C8_O9&V=._/2H]+M+=]*M6
MC(,2G-N[>7T_AYZ5:U!MFG7+%PF(V.XKN XZX[_2H]'<2:/9N)%E#1*=ZQ[
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M?[%!Z/\ ]_&_QH^Q0>C_ /?QO\:L44 5_L4'H_\ W\;_ !H^Q0>C_P#?QO\
M&K%% %?[%!Z/_P!_&_QH^Q0>C_\ ?QO\:L44 5_L4'H__?QO\:/L4'H__?QO
M\:L44 5_L4'H_P#W\;_&C[%!Z/\ ]_&_QJQ10!7^Q0>C_P#?QO\ &C[%!Z/_
M -_&_P :L44 5_L4'H__ '\;_&C[%!Z/_P!_&_QJQ10!7^Q0>C_]_&_QH^Q0
M>C_]_&_QJQ10!7^Q0>C_ /?QO\:/L4'H_P#W\;_&K%% %?[%!Z/_ -_&_P :
M/L4'H_\ W\;_ !JQ10!B>(+:WAT"\D:40A8\F216E5?<I_%]*V[.PMFLH&&Y
MLQJ=P=E!XZXSQ]*S?$#.N@7C1R7,;B/AK6/?(/\ =7N:W+,DV4!8N3Y:Y+C#
M'CN.QH C_L^V_NR?]_6_QH_L^V_NR?\ ?UO\:AUS6;3P_H]QJ=ZQ$$"Y(49+
M$G  ]R2*Y*3XBWMA#%?:OX6U"RTN0@?:BRML!Z%E'(IV [/^S[;^[)_W];_&
MC^S[;^[)_P!_6_QJLNK22:U#91V,SVLMOYXO1_JP<\+]<<UI;AGJ*0%;^S[;
M^[)_W];_ !H_L^V_NR?]_6_QJR2!U(%8_B?Q!%X9T5]2EA:9%D1-B'!^8XH
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M%8O_  E6D?\ /R?^^&_PH_X2K2/^?D_]\-_A1R2[!=&U16+_ ,)5I'_/R?\
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M\-_A1_PE6D?\_)_[X;_"CDEV"Z-JBL7_ (2K2/\ GY/_ 'PW^%'_  E6D?\
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ML'UN/4T>2-H[ V"1)C:(S_6HX_!ME'X(/A43S&T,1B\SC?@G/THN!R=G:_\
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MHT445 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &5KL*S16@:&*7;=1L!)-Y>W!ZCU/MWK5K(
MU]D6&SWFS&;N,#[4"1G/\./XO2M>@ HIK2(F-[JN3@9.,TK,%4LQ  ZD]J %
MHI%8,H92"#T(I: "BBB@ HHHH **1F5%+,P51U). * 00"#D'H10 M%%% !1
M110 4444 %%%% !1110 44U75\[6#8.#@YP:=0 4444 %%1O/#$<22HA]&8"
MG)(D@RCJP]5.: '44W>A<IN&X#)7/-.H **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<D$@@\#WQ0N8-"Q>:);QZ9)>0)=Q&)U!%PH&\'N,=*A\2.T?B*5U.&780?\
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MPLSG**Z/_A#-2_OP?]]4?\(9J7]^#_OJCGCW"S.<HKH_^$,U+^_!_P!]4?\
M"&:E_?@_[ZHYX]PLSG**W9O"E] T:O+; R-L7,F,GVSUJ;_A#-2_OP?]]4<\
M>X69SE%='_PAFI?WX/\ OJC_ (0S4O[\'_?5'/'N%F<Y171_\(9J7]^#_OJC
M_A#-2_OP?]]4<\>X69SE%='_ ,(9J7]^#_OJC_A#-2_OP?\ ?5'/'N%F<Y17
M1_\ "&:E_?@_[ZH_X0S4O[\'_?5'/'N%F<Y74>"/^0E<?]<OZBHO^$,U+^_!
M_P!]5L^'-!N])NY9;AHRKIM&TYYS43G%Q=F-)W.EHHHKF+"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M,\0QK-X?O8WBBF5H\&.:;RD;GNXZ?6MVS 6QMU"JH$:C"MN X['O]:P/$K*O
MAR^9VM541\F[4F(<_P 0'.*WK(@V%N04(\I<>6/EZ#I[4 <7\74,G@5HU8J6
MNX &'4?..:RKK0XO!_BSPO-IMU>$WLKPW8EG:03?)G)!/7/I7=>(_#]OXETH
M:?=2RQQ^:DNZ/&<J<CJ*34_#UMJNHZ5>32RJ^FRF6)5QAB1C!XII@>.6(OO$
MNFWVKW.DZ]=ZA-+(8+RVN0D<&"=H5=PZ=\BMO4M0GOM)\,VOB*74IKYXF,VE
M6 )DN2. [,IX'&?SKJ9_AQ 9;M+#6]2L+"\<O<6<#KL8GKM)&5S4][\/K%VT
MV;2[VZTJYTZ$P0RVY!)0]0P8<U5T!PFE//9R^,],2UO;&R_LAIX[.[F\QHR5
M/.<G&?2I(M"L;[6/ #3K,3<6+>9MF9?N(I7&#QU[=:[6T^'=E;7&I7#:E?SS
MZE:-:W,DSJQ;/\0XX([#I4M]X$M;JTT6.#4;VTFTE=D$\)7<5( (.1CG%*X'
M#Z)X1L]9T[Q5J%U<W@EAOKG[.(IV18BO.[ /))]:DM=5U"TT7P3XMGN99(Q_
MH5^2QPR,2H9O<$#FO1=+\,6NE:?J-G%/,Z7\TLTC/C*E^N,"N5\46-IX?\ )
MX1MK.^U![B)H;8K%N^?=D%F P,$Y_"B]P+O@VXGU[Q-KWB!I'-F)196:Y^4J
MGWF ]SWI/$,TGA[X@:1K+3LNGW\;65RK,=B./F1L=NX_"NB\+Z,GA_PS8:8@
M&8(@'/JYY8_F32>)O#EGXJT272[UI$C<A@\9 92#P1FE?4#R^ZU74KKP_=:U
M#=S6X\0ZNEI#(&(,-L,@%?0G'ZUKZUH\?@36O#UYHMU= 7EVMI=02SM(LRM_
M%@GJ.O%=G=>$=*O/"L/AV6-Q9PQHD94X="O1@?7O6=I_@.*#5+;4-3U>_P!5
MEL_^/5;DKMB[9P!R?<T[@<+IT\L/AK1O+D=-WBEE;:V,CS.AKK_$-Q*GQ4\,
MPI*X1K6Y+(&X/ QD5<D^'VFR>''T;[3=*OVMKR.=6 DBD)SD<8XING> (;37
MK76[O6-0O]0MT9 \[+@J1C& .,<T70' Z'X;CU7X>:KKMW?W[7]N]PULXN7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP_6M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC!).!D]*+ >V4445(!1110 4444 %%%% !1110 457-V ?\ 43_]\4GVP?\
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M_OB@">BH/M0_YXR_]\4?:A_SQE_[XH GHJ#[4/\ GC+_ -\4?:A_SQE_[XH
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M]3Z"M>LK77C2&T\QK10;J,#[2A8$Y_A]&]#6K0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 17./LLV2H&PY+#(''<>E8NB%
M&T:U,;P.FSAH$V(?HO85MW!VVTI!(PA.0,D<>G>L319#+H]M(99)2R9WR1>6
MQ^J]J +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 5M04-IURI5&!B8%7;:IX[GL*BT9!'HUFBI'&!$H"1/O4<= >X
MJ:_(&GW)8QA1&V3*,KT[CTJ+2&5M'M&0PE3$N# NV,\?PCL* +M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E:S&LEQII:*
M!]MT"#+)M*G!Y7U/M6K67J[HL^G!VM03<@+YZ;B3@_<]&]ZU* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\2>7_PCM]YK6JIY?S&[7=$.
M?XAW%;MEC[#;[2A'E+@QC"].WM6'XAF\CP_>RB8P;8\^8(?-*\]=G\7TK=LV
MWV-NV[=F-3NV[<\=<=OI0!-1110 4444 %%%% !1110 4444 %%%% !1110
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M@A"B5@!"<H.?X3W%?5-R0+68DJ $;EAD#CN*^5M28/JETZO&X,K$-&FU3SU
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M*UM2:^C@\737>J0RV=W$6M(Q<!MXW@@JN> !Q7EE&32=)7N 5W_PD_Y&B?\
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M3RW329F:4='W>M=A10!PT_PRM;Y8#J6N:O>RV[J\#R2K^[*G/ QCMU-6]1\
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MU:^MUU>":]M8#<^0L9^:+@YW=C@YQ1:> KFZM[4&[V7EU#YT,/D,5Q@D!GZ
MG%1R^+89-=U#4!:R!;JP-H$W#*G8%S].*G_X3*"YTZUCNCJD5Q;0"$"TN_+C
MD Z$CL?I1^]L!7LO!T-Q:Z=)<ZQ%;2Z@66"$Q%CN#8P2#P/>GMX=TV#PC=7-
MW=F+4(+XV[8C+#(4_)U[D9S5)?$48_L#,#G^RV+/\W^LR^[BII/$5A>:?JMI
M=VDY6ZO&O(&C< HQR,-GJ.:;YP.9KO\ X2?\C1/_ ->Q_F*X"N_^$G_(T3_]
M>Q_F*=?^&P1[!J) TVY):-0(FR9!E1QW'I46C$-HMF5>%P85PT"[4/'\(["I
MKYMMA<,'*8C8[@NXCCKCO]*CTI_,TFU<R-)F)3O:/86XZE>WTKR"BY1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9.LLJW&F
M[I+9,W0 $R%B>#POHWO6M6;JLACFL )GCW7 &%AW[^#P3_"/>M*@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$+F/P_>NLS0D1\2)#YI7
MGJ$_B^E;EF<V-N2Q;,:_,5VYXZX[?2L772ZZ'=F/[7O"<?8\>;_P'/>MNTR;
M. GS,^6N?,^]T[^] #KBWAN[>2WN(UDAD4JZ,,A@>QKC3\+]%VM!'>ZK%8L<
MFR2[(B^F.N/;-=M10!B7'A/29]/T^Q6 PVUA.D\"1': R],^O6IKW0+.]UNR
MUB0.;RQ1UA^;"_,,'([UJT4 >(ZEH37-IJ-F?"NL0ZG<NX$%M,?L+.3Q)UQC
MH<>M=['X!LKG1M'CNI;BWU&PMEA6ZM)=CCCD9[C-=C10!S%OX#T:WT6_TS%Q
M(NH?\?5Q)+NED^K5HVWARPM=9CU6/S?M,=H+-<M\OE@@CCUXZUK44 <7XD\,
M0VVEZY=V&E_VG<:FZ/=6LLF X7CY,="!R*Y'3?#7]H^*M$FT_2M;MX;&7S9[
MC59"=B@<1H"?7^5>Q44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !574=/MM5TZXL+R,26\Z%'4]P:M44 >1?\ "I_$>GP3Z;HW
MBZ6WTB8G= P.0#U''],9KIK'X8Z/:>!KCPR[/(MR=\MQT8R#D,/I@<5V]% '
MD?\ PJ?7[NTM]&U+Q4\VA6[@I L>&P.@S_\ KQ71W'P]!\;:+K=I<I#::9 L
M"VVTDD+G'/XUW-% '(:=X,EL?B-J7B@W:-'>0>4( IROW><_\!KF+OP3+X4\
M'^-KF2\2X&H0O(JJA&SJ<>_6O5J9+%'/$T4T:R1N,,K#((]Q0!X3X3\!:_X@
M\!6D-MXD-OI%X2\UHT><$-S@^AQTKN-=^%EE?Z)I-KIMW)8WFE+MM[D<D]SN
M_'FN]M[>&UA6&WB2*)>B(N /PJ2@#SC1OAOJ3^)K?7O%6MG5;FT ^SHJ;54C
MH3_/ZTS4/AQK,7C.\U[P]KXT\WP(G5HMY&>N,\>]>E44 ><^'OAE/H>D>([%
MM4%P=63:LK(<KPW+>OWJMVGP_FMOAA/X1-]&TLH8?:-AP,N&Z?A7=T4 >;ZM
M\+6U#PKHEC#J/D:II"@0W2J<'G/3J.<57MOAEK<WBC2O$&L>(A>W=I("X,6
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MPIT?]!<_]^O_ *]'_"G1_P!!<_\ ?K_Z]>IT4?6:O<+'EG_"G1_T%S_WZ_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** ,W53()]/V?:\?:!N^S],8/W_\
M9K2K-U6+S)K ^0\NVX!RLVS9P>2/XA[5I4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6OO7^\/SJN=.LFZVD)QSR@I?L%G_ ,^L/_? H GWK_>'YT;U_O#\Z@^P6?\
MSZP_]\"C[!9_\^L/_? H GWK_>'YT;U_O#\Z@^P6?_/K#_WP*/L%G_SZP_\
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M]\"C[!9_\^L/_? H GWK_>'YT;U_O#\Z@^P6?_/K#_WP*/L%G_SZP_\ ? H
MGWK_ 'A^=&]?[P_.H/L%G_SZP_\ ? H^P6?_ #ZP_P#? H GWK_>'YT;U_O#
M\Z@^P6?_ #ZP_P#? H^P6?\ SZP_]\"@"?>O]X?G1O7^\/SJ#[!9_P#/K#_W
MP*/L%G_SZP_]\"@"?>O]X?G1O7^\/SJ#[!9_\^L/_? H^P6?_/K#_P!\"@"?
M>O\ >'YT;U_O#\Z@^P6?_/K#_P!\"C[!9_\ /K#_ -\"@"?>O]X?G1O7^\/S
MJ#[!9_\ /K#_ -\"C[!9_P#/K#_WP* )]Z_WA^=&]?[P_.H/L%G_ ,^L/_?
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MY!Q_">XK6.G61&#:0_\ ? H&G60&!:0@?[@H K[E_O#\Z-R_WA^=6/[/L_\
MGUA_[X%']GV?_/K#_P!\"@"ON7^\/SHW+_>'YU8_L^S_ .?6'_O@4?V?9_\
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MP_.K']GV?_/K#_WP*/[/L_\ GUA_[X% %?<O]X?G1N7^\/SJQ_9]G_SZP_\
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MO]X?G4'V"S_Y]8?^^!1]@L_^?6'_ +X% $^]?[P_.C>O]X?G4'V"S_Y]8?\
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>atha-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-22T16:05:44.6943+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://athira.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:atha="http://athira.com/20231231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue" id="Role_DisclosureFairValue">
        <link:definition>995475 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>995485 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1" id="DisclosureAccruedLiabilities1">
        <link:definition>995495 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements" id="Role_DisclosureSignificantAgreements">
        <link:definition>995505 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995515 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995525 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995535 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995545 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>995555 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>995565 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>995575 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>995585 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueTables" id="Role_DisclosureFairValueTables">
        <link:definition>995595 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995605 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>995615 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995625 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995635 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995645 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995655 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>995665 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>995685 - Disclosure - Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995695 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" id="Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
        <link:definition>995705 - Disclosure - Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" id="Role_DisclosureFairValueAdditionalInformationDetails">
        <link:definition>995715 - Disclosure - Fair Value - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995725 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>995745 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" id="Role_DisclosureSignificantAgreementsAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Significant Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails" id="DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails">
        <link:definition>995775 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD" id="DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD">
        <link:definition>995785 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails" id="Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails">
        <link:definition>995795 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" id="Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails">
        <link:definition>995815 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>995835 - Disclosure - Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails" id="DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails">
        <link:definition>995845 - Disclosure - Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails">
        <link:definition>995855 - Disclosure - Stock-based Compensation - Summary of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails">
        <link:definition>995865 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails">
        <link:definition>995875 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails" id="Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails">
        <link:definition>995885 - Disclosure - Income Taxes - Components of Income (Loss) Before Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2" id="DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2">
        <link:definition>995895 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>995905 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>995915 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails" id="Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails">
        <link:definition>995935 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995955 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="atha-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="atha-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="atha-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="atha-20231231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="atha-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="atha-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:href="atha-20231231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="atha-20231231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue" xlink:href="atha-20231231.xsd#Role_DisclosureFairValue" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="atha-20231231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1" xlink:href="atha-20231231.xsd#DisclosureAccruedLiabilities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements" xlink:href="atha-20231231.xsd#Role_DisclosureSignificantAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="atha-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="atha-20231231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" xlink:href="atha-20231231.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="atha-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="atha-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:href="atha-20231231.xsd#DisclosureSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueTables" xlink:href="atha-20231231.xsd#Role_DisclosureFairValueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="atha-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:href="atha-20231231.xsd#DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="atha-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="atha-20231231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="atha-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="atha-20231231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" xlink:href="atha-20231231.xsd#Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="atha-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="atha-20231231.xsd#DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails" xlink:href="atha-20231231.xsd#DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD" xlink:href="atha-20231231.xsd#DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails" xlink:href="atha-20231231.xsd#Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="atha-20231231.xsd#DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails" xlink:href="atha-20231231.xsd#DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:href="atha-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:href="atha-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails" xlink:href="atha-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="atha-20231231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="atha-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2" xlink:href="atha-20231231.xsd#DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NumberOfClasses" xlink:label="atha_NumberOfClasses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShortTermInvestmentMember" xlink:label="atha_ShortTermInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceThreeMember" xlink:label="atha_ExercisePriceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EntityReincorporationDateOfReincorporation" xlink:label="atha_EntityReincorporationDateOfReincorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmployeeBenefitPlansAbstract" xlink:label="atha_EmployeeBenefitPlansAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_FollowOnPublicOfferingMember" xlink:label="atha_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BothellWashingtonMember" xlink:label="atha_BothellWashingtonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="us-gaap_LossContingencyLawsuitFilingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_WangVAthiraPharmaIncMember" xlink:label="atha_WangVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LongTermInvestmentsMember" xlink:label="atha_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_RoyaltyObligation" xlink:label="atha_RoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_StockOptionsToPurchaseCommonStockMember" xlink:label="atha_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CommitmentsAndContingenciesTable" xlink:label="atha_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IncreaseDecreaseInUnbilledGrantReceivables" xlink:label="atha_IncreaseDecreaseInUnbilledGrantReceivables"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" xlink:label="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AthiraPharmaIncVDrKawasMember" xlink:label="atha_AthiraPharmaIncVDrKawasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmployeeStockPurchasePlanMember" xlink:label="atha_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AccruedProfessionalServicesAndOtherCurrent" xlink:label="atha_AccruedProfessionalServicesAndOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="atha_IncreaseDecreaseInAccruedLegalSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" xlink:label="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncome" xlink:label="atha_GrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShortTermInvestmentsMaturityTerm" xlink:label="atha_ShortTermInvestmentsMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="atha_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NationalInstitutesOfHealthGrantMember" xlink:label="atha_NationalInstitutesOfHealthGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="atha_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DescriptionOfBusinessLineItems" xlink:label="atha_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsRightOfUseAsset" xlink:label="atha_DeferredTaxAssetsRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PaymentOnAchievementOfDevelopmentMilestone" xlink:label="atha_PaymentOnAchievementOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LaboratoryEquipmentMember" xlink:label="atha_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_FurnitureFixturesAndComputerEquipmentMember" xlink:label="atha_FurnitureFixturesAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DescriptionOfBusinessTable" xlink:label="atha_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" xlink:label="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_MilestonePaymentsAmountPayableUponMarketingApproval" xlink:label="atha_MilestonePaymentsAmountPayableUponMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncomePolicyTextBlock" xlink:label="atha_GrantIncomePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="atha_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceTwoMember" xlink:label="atha_ExercisePriceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="atha_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" xlink:label="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AggregateGrantIncome" xlink:label="atha_AggregateGrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" xlink:label="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LongTermInvestmentsMaturityTerm" xlink:label="atha_LongTermInvestmentsMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_OperatingLossCarryForwardsExpirationPeriod" xlink:label="atha_OperatingLossCarryForwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LaboratoryAndOfficeFacilitiesMember" xlink:label="atha_LaboratoryAndOfficeFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LicensedProductsMember" xlink:label="atha_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" xlink:label="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SlyneVAthiraPharmaIncMember" xlink:label="atha_SlyneVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantsReceived" xlink:label="atha_GrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="us-gaap_InsuranceRecoveries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_UnbilledGrantReceivableCurrent" xlink:label="atha_UnbilledGrantReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfDefendant" xlink:label="us-gaap_LossContingencyNameOfDefendant"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" xlink:label="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_MilestonePaymentsAmountPayableUponTrialInitiation" xlink:label="atha_MilestonePaymentsAmountPayableUponTrialInitiation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_WashingtonStateUniversityLicenseAgreementMember" xlink:label="atha_WashingtonStateUniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NonVestedRestrictedStockUnitsMember" xlink:label="atha_NonVestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" xlink:label="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NetSalesExemptFromRoyaltyPayment" xlink:label="atha_NetSalesExemptFromRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_OperatingLeaseExpirationMonthAndYear" xlink:label="atha_OperatingLeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" xlink:label="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" xlink:label="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:label="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NumberOfSubclasses" xlink:label="atha_NumberOfSubclasses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AdditionalGrantIncome" xlink:label="atha_AdditionalGrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" xlink:label="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AtTheMarketOfferingMember" xlink:label="atha_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CommitmentsAndContingenciesLineItems" xlink:label="atha_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceOneMember" xlink:label="atha_ExercisePriceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" xlink:label="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_JawandhaVAthiraPharmaIncMember" xlink:label="atha_JawandhaVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NumberOfClasses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of classes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NumberOfClasses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Classes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NumberOfClasses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of classes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current and long-term assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShortTermInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-Term Investment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShortTermInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShortTermInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_LitigationCaseTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price $20.55 to 29.41</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Net of Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SettledLitigationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled Litigation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SettledLitigationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settled Litigation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EntityReincorporationDateOfReincorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity reincorporation, date of reincorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EntityReincorporationDateOfReincorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Reincorporation Date Of Reincorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EntityReincorporationDateOfReincorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entity reincorporation, date of reincorporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserved shares of common stock for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transaction Remeasurement Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Outstanding and Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, additional term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise price per Share, Forfeited/expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions taken in prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmployeeBenefitPlansAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee benefit plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmployeeBenefitPlansAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefit Plans [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise price per Share, Expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options and restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Unit Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options and restricted stock unit granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bothell, Washington.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bothell Washington [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BothellWashingtonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bothell, Washington</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyLawsuitFilingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lawsuit filing date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyLawsuitFilingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Lawsuit Filing Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_WangVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wang V. Athira Pharma Inc.,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_WangVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wang V Athira Pharma Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_WangVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wang V. Athira Pharma, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term Investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease initial term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan reserve increase on January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_RoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_RoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_RoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share Equivalent, Non-vested, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share Equivalent, Non-vested, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of common stock options and vesting of restricted stock unit shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock options and vesting of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Unit Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued common stock, share under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Debt and Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IncreaseDecreaseInUnbilledGrantReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Unbilled Grant Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IncreaseDecreaseInUnbilledGrantReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in unbilled grant receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IncreaseDecreaseInUnbilledGrantReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unbilled grant receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase three clinical trail initiation of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase Three Clinical Trail Initiation Of License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 3 Clinical Trial Initiation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Available for Grant, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Available for Grant, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for future grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 38,172,603 and 37,877,387 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AthiraPharmaIncVDrKawasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Athira Pharma Inc V Dr. Kawas.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AthiraPharmaIncVDrKawasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Athira Pharma Inc V Dr. Kawas [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AthiraPharmaIncVDrKawasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Athira Pharma Inc V Dr. Kawas</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, maximum percentage of payroll deductions for qualifying wages or statutory limit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Payroll Deductions For Qualifying Wages Or Statutory Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of payroll deductions for qualifying wages or statutory limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock purchased by each participant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions taken in the current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Accrual, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal settlement (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AccruedProfessionalServicesAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued professional services and other, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AccruedProfessionalServicesAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Services And Other Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AccruedProfessionalServicesAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued legal settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Accrued Legal Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual minimum royalty payments after first commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Minimum Royalty Payments After First Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual minimum royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_LitigationCaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShortTermInvestmentsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investments maturity term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShortTermInvestmentsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Maturity Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShortTermInvestmentsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments effective maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NationalInstitutesOfHealthGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institutes of Health Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NationalInstitutesOfHealthGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NationalInstitutesOfHealthGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National institutes of health grant member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock options and vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of common stock options and vesting of restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PaymentOnAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment on achievement of development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PaymentOnAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment On Achievement Of Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PaymentOnAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments on development milestone achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_FurnitureFixturesAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture, Fixtures, and Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_FurnitureFixturesAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture Fixtures And Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_FurnitureFixturesAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture, fixtures and computer equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Percentage Of Number Shares Of Common Stock Issued And Outstanding On Immediate Proceeding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_MilestonePaymentsAmountPayableUponMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments amount payable upon marketing approval.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_MilestonePaymentsAmountPayableUponMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Amount Payable Upon Marketing Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_MilestonePaymentsAmountPayableUponMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments payable upon marketing approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters&#8217; Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and restricted stock units forfeited, cancelled, or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options and Restricted Stock Units, Forfeited, Cancelled or Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options and restricted stock units, forfeited, cancelled or expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Present value adjustment for minimum lease commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Equivalent, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise price per Share, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant income policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Income Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Non-vested, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise price per Share, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price $8.93 to 19.94</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tow Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tow thousand and twenty employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining weighted-average period expected to recognize unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Expected to vest (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase two clinical trail initiation of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase Two Clinical Trail Initiation Of License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 2 Clinical Trial Initiation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AggregateGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate grant income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AggregateGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Grant Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AggregateGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issuable Upon The Exercise Of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term and Long-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity incorporation, date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash equivalents, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and accretion of discounts on available-for-sale securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Ownership Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material interest and penalties on uncertain tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Legal settlement expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LongTermInvestmentsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term investments maturity term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LongTermInvestmentsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments Maturity Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LongTermInvestmentsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments effective maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_OperatingLossCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carry forwards Expiration Period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_OperatingLossCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry forwards Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_OperatingLossCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LaboratoryAndOfficeFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory and office facilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LaboratoryAndOfficeFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory And Office Facilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LaboratoryAndOfficeFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and Office Facilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant-date fair value of restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Non-vested, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensed Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensed Products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed Products [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Capitalized research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Insurance recovery receivable related to legal settlement (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance recovery receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Settlements Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments and Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments and Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of convertible preferred stock and common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock And Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, other than options grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investments, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SlyneVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Slyne V. Athira Pharma Inc.,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SlyneVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Slyne V Athira Pharma Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SlyneVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Slyne V. Athira Pharma Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_GrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceRecoveries_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Insurance recovery related to legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceRecoveries_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Insurance recovery related to legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceRecoveries_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance recovery in operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceRecoveries_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Recoveries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Non-vested, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, Non-vested, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price ($)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_UnbilledGrantReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unbilled grant receivable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_UnbilledGrantReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Grant Receivable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_UnbilledGrantReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled grant receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfDefendant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Name of Defendant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfDefendant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of defendant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents accumulated gross unrealized loss before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash equivalents, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited, cancelled, or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Forfeited/expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National institute on aging of the national institutes of health.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institute On Aging Of The National Institutes Of Health [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institute on Aging of the National Institutes of Health</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_MilestonePaymentsAmountPayableUponTrialInitiation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments amount payable upon trial initiation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_MilestonePaymentsAmountPayableUponTrialInitiation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Amount Payable Upon Trial Initiation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_MilestonePaymentsAmountPayableUponTrialInitiation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments, amount payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_WashingtonStateUniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Washington state university license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_WashingtonStateUniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Washington State University License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_WashingtonStateUniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Washington State University License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Name of Plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NonVestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NonVestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-vested restricted stock units member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NonVestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangement Shares Available For Grant Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based compensation arrangement shares available for grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NetSalesExemptFromRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales exempt from royalty payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NetSalesExemptFromRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Exempt From Royalty Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NetSalesExemptFromRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales exempt from royalty payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_OperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_OperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_OperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit carryforwards, expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Tax Credit Carry Forwards Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss and tax credit carryforwards, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Grant under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future grant under the employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Grant Under Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms of award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Options exercisable (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Non-vested, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise price per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reserved shares of common stock for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Reserved Shares Of Common Stock For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reserved Shares of Common Stock for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NumberOfSubclasses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of subclasses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NumberOfSubclasses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Subclasses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_NumberOfSubclasses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of subclasses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AdditionalGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional grant income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AdditionalGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Grant Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AdditionalGrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional grant income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share Equivalent, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Income (Loss) Before Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation maximum annual increase in number of shares that may be issued under the plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Maximum Annual Increase In Number Of Shares That May Be Issued Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation maximum annual increase in number of shares that may be issued under the plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Common Stock Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expenses and others</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Exercise of Common Stock Options and Issuance of Common Stock Under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of pretax compensation eligible to defer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies line items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise price per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise price per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Insurance recovery receivable related to legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Insurance Settlements Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash, Cash Equivalents and Restricted Cash [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price $0.16 to 4.22</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_ExercisePriceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share Equivalent, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Grant under 2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future grant under the 2020 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Grant Under Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_JawandhaVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jawandha V. Athira Pharma Inc.,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_JawandhaVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jawandha V Athira Pharma Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="atha_JawandhaVAthiraPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jawandha V. Athira Pharma Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Ownership Plan, shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NumberOfClasses" xlink:to="atha_NumberOfClasses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShortTermInvestmentMember" xlink:to="atha_ShortTermInvestmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ExercisePriceThreeMember" xlink:to="atha_ExercisePriceThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_EntityReincorporationDateOfReincorporation" xlink:to="atha_EntityReincorporationDateOfReincorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_EmployeeBenefitPlansAbstract" xlink:to="atha_EmployeeBenefitPlansAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_FollowOnPublicOfferingMember" xlink:to="atha_FollowOnPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_BothellWashingtonMember" xlink:to="atha_BothellWashingtonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyLawsuitFilingDate" xlink:to="us-gaap_LossContingencyLawsuitFilingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_WangVAthiraPharmaIncMember" xlink:to="atha_WangVAthiraPharmaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_LongTermInvestmentsMember" xlink:to="atha_LongTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_RoyaltyObligation" xlink:to="atha_RoyaltyObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_StockOptionsToPurchaseCommonStockMember" xlink:to="atha_StockOptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" xlink:to="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="atha_CommitmentsAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_IncreaseDecreaseInUnbilledGrantReceivables" xlink:to="atha_IncreaseDecreaseInUnbilledGrantReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" xlink:to="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AthiraPharmaIncVDrKawasMember" xlink:to="atha_AthiraPharmaIncVDrKawasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_EmployeeStockPurchasePlanMember" xlink:to="atha_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AccruedProfessionalServicesAndOtherCurrent" xlink:to="atha_AccruedProfessionalServicesAndOtherCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_IncreaseDecreaseInAccruedLegalSettlement" xlink:to="atha_IncreaseDecreaseInAccruedLegalSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" xlink:to="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_GrantIncome" xlink:to="atha_GrantIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShortTermInvestmentsMaturityTerm" xlink:to="atha_ShortTermInvestmentsMaturityTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="atha_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NationalInstitutesOfHealthGrantMember" xlink:to="atha_NationalInstitutesOfHealthGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" xlink:to="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="atha_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="atha_DescriptionOfBusinessLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_DeferredTaxAssetsRightOfUseAsset" xlink:to="atha_DeferredTaxAssetsRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_PaymentOnAchievementOfDevelopmentMilestone" xlink:to="atha_PaymentOnAchievementOfDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_LaboratoryEquipmentMember" xlink:to="atha_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_FurnitureFixturesAndComputerEquipmentMember" xlink:to="atha_FurnitureFixturesAndComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="atha_DescriptionOfBusinessTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" xlink:to="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_MilestonePaymentsAmountPayableUponMarketingApproval" xlink:to="atha_MilestonePaymentsAmountPayableUponMarketingApproval_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_GrantIncomePolicyTextBlock" xlink:to="atha_GrantIncomePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="atha_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ExercisePriceTwoMember" xlink:to="atha_ExercisePriceTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="atha_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" xlink:to="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AggregateGrantIncome" xlink:to="atha_AggregateGrantIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" xlink:to="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_LongTermInvestmentsMaturityTerm" xlink:to="atha_LongTermInvestmentsMaturityTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_OperatingLossCarryForwardsExpirationPeriod" xlink:to="atha_OperatingLossCarryForwardsExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_LaboratoryAndOfficeFacilitiesMember" xlink:to="atha_LaboratoryAndOfficeFacilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_LicensedProductsMember" xlink:to="atha_LicensedProductsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" xlink:to="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_SlyneVAthiraPharmaIncMember" xlink:to="atha_SlyneVAthiraPharmaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_GrantsReceived" xlink:to="atha_GrantsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_UnbilledGrantReceivableCurrent" xlink:to="atha_UnbilledGrantReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNameOfDefendant" xlink:to="us-gaap_LossContingencyNameOfDefendant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" xlink:to="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_MilestonePaymentsAmountPayableUponTrialInitiation" xlink:to="atha_MilestonePaymentsAmountPayableUponTrialInitiation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_WashingtonStateUniversityLicenseAgreementMember" xlink:to="atha_WashingtonStateUniversityLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNameOfPlaintiff" xlink:to="us-gaap_LossContingencyNameOfPlaintiff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NonVestedRestrictedStockUnitsMember" xlink:to="atha_NonVestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" xlink:to="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NetSalesExemptFromRoyaltyPayment" xlink:to="atha_NetSalesExemptFromRoyaltyPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_OperatingLeaseExpirationMonthAndYear" xlink:to="atha_OperatingLeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" xlink:to="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" xlink:to="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:to="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_NumberOfSubclasses" xlink:to="atha_NumberOfSubclasses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AdditionalGrantIncome" xlink:to="atha_AdditionalGrantIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" xlink:to="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_AtTheMarketOfferingMember" xlink:to="atha_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:to="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_CommitmentsAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:to="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_ExercisePriceOneMember" xlink:to="atha_ExercisePriceOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" xlink:to="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atha_JawandhaVAthiraPharmaIncMember" xlink:to="atha_JawandhaVAthiraPharmaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_UnbilledGrantReceivableCurrent" xlink:label="atha_UnbilledGrantReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="atha_UnbilledGrantReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncome" xlink:label="atha_GrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="us-gaap_InsuranceRecoveries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="atha_GrantIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LitigationSettlementExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_12"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IncreaseDecreaseInUnbilledGrantReceivables" xlink:label="atha_IncreaseDecreaseInUnbilledGrantReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="atha_IncreaseDecreaseInAccruedLegalSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atha_IncreaseDecreaseInUnbilledGrantReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atha_IncreaseDecreaseInAccruedLegalSettlement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmployeeBenefitPlansAbstract" xlink:label="atha_EmployeeBenefitPlansAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_EmployeeBenefitPlansAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncomePolicyTextBlock" xlink:label="atha_GrantIncomePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="atha_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atha_GrantIncomePolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atha_EmergingGrowthCompanyStatusPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:label="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" xlink:label="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DescriptionOfBusinessLineItems" xlink:label="atha_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DescriptionOfBusinessTable" xlink:label="atha_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EntityReincorporationDateOfReincorporation" xlink:label="atha_EntityReincorporationDateOfReincorporation"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_FollowOnPublicOfferingMember" xlink:label="atha_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AtTheMarketOfferingMember" xlink:label="atha_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" xlink:label="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="atha_DescriptionOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="atha_EntityReincorporationDateOfReincorporation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atha_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atha_AtTheMarketOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="atha_DescriptionOfBusinessLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" xlink:label="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NationalInstitutesOfHealthGrantMember" xlink:label="atha_NationalInstitutesOfHealthGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantsReceived" xlink:label="atha_GrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncome" xlink:label="atha_GrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AggregateGrantIncome" xlink:label="atha_AggregateGrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AdditionalGrantIncome" xlink:label="atha_AdditionalGrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_UnbilledGrantReceivableCurrent" xlink:label="atha_UnbilledGrantReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atha_NationalInstitutesOfHealthGrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_GrantsReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_GrantIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_AggregateGrantIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_AdditionalGrantIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_UnbilledGrantReceivableCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShortTermInvestmentMember" xlink:label="atha_ShortTermInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LongTermInvestmentsMember" xlink:label="atha_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="atha_ShortTermInvestmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="atha_LongTermInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShortTermInvestmentsMaturityTerm" xlink:label="atha_ShortTermInvestmentsMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LongTermInvestmentsMaturityTerm" xlink:label="atha_LongTermInvestmentsMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="atha_ShortTermInvestmentsMaturityTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="atha_LongTermInvestmentsMaturityTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LaboratoryEquipmentMember" xlink:label="atha_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_FurnitureFixturesAndComputerEquipmentMember" xlink:label="atha_FurnitureFixturesAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atha_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atha_FurnitureFixturesAndComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="atha_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AccruedProfessionalServicesAndOtherCurrent" xlink:label="atha_AccruedProfessionalServicesAndOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="atha_AccruedResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="atha_AccruedProfessionalServicesAndOtherCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_WashingtonStateUniversityLicenseAgreementMember" xlink:label="atha_WashingtonStateUniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LicensedProductsMember" xlink:label="atha_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" xlink:label="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PaymentOnAchievementOfDevelopmentMilestone" xlink:label="atha_PaymentOnAchievementOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" xlink:label="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_MilestonePaymentsAmountPayableUponTrialInitiation" xlink:label="atha_MilestonePaymentsAmountPayableUponTrialInitiation"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_MilestonePaymentsAmountPayableUponMarketingApproval" xlink:label="atha_MilestonePaymentsAmountPayableUponMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" xlink:label="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NetSalesExemptFromRoyaltyPayment" xlink:label="atha_NetSalesExemptFromRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_RoyaltyObligation" xlink:label="atha_RoyaltyObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atha_WashingtonStateUniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atha_LicensedProductsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_PaymentOnAchievementOfDevelopmentMilestone" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_MilestonePaymentsAmountPayableUponTrialInitiation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_MilestonePaymentsAmountPayableUponMarketingApproval" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_NetSalesExemptFromRoyaltyPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_RoyaltyObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_WangVAthiraPharmaIncMember" xlink:label="atha_WangVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BothellWashingtonMember" xlink:label="atha_BothellWashingtonMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CommitmentsAndContingenciesTable" xlink:label="atha_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LaboratoryAndOfficeFacilitiesMember" xlink:label="atha_LaboratoryAndOfficeFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CommitmentsAndContingenciesLineItems" xlink:label="atha_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="us-gaap_LossContingencyLawsuitFilingDate"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_JawandhaVAthiraPharmaIncMember" xlink:label="atha_JawandhaVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SlyneVAthiraPharmaIncMember" xlink:label="atha_SlyneVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfDefendant" xlink:label="us-gaap_LossContingencyNameOfDefendant"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AthiraPharmaIncVDrKawasMember" xlink:label="atha_AthiraPharmaIncVDrKawasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="us-gaap_InsuranceRecoveries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_OperatingLeaseExpirationMonthAndYear" xlink:label="atha_OperatingLeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NumberOfClasses" xlink:label="atha_NumberOfClasses"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NumberOfSubclasses" xlink:label="atha_NumberOfSubclasses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_WangVAthiraPharmaIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atha_BothellWashingtonMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atha_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atha_LaboratoryAndOfficeFacilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyLawsuitFilingDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_JawandhaVAthiraPharmaIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_SlyneVAthiraPharmaIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="srt_LitigationCaseAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyNameOfDefendant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_AthiraPharmaIncVDrKawasMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceRecoveries" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LitigationStatusAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="atha_CommitmentsAndContingenciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_OperatingLeaseExpirationMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_VariableLeaseCost" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_NumberOfClasses" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_NumberOfSubclasses" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" xlink:label="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" xlink:label="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" xlink:label="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" xlink:label="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="atha_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" xlink:label="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atha_TwoThousandAndTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceOneMember" xlink:label="atha_ExercisePriceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceTwoMember" xlink:label="atha_ExercisePriceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceThreeMember" xlink:label="atha_ExercisePriceThreeMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="atha_ExercisePriceOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="atha_ExercisePriceTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="atha_ExercisePriceThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsRightOfUseAsset" xlink:label="atha_DeferredTaxAssetsRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="atha_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="atha_DeferredTaxAssetsRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="atha_DeferredTaxAssetsOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_OperatingLossCarryForwardsExpirationPeriod" xlink:label="atha_OperatingLossCarryForwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" xlink:label="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="atha_OperatingLossCarryForwardsExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmployeeBenefitPlansAbstract" xlink:label="atha_EmployeeBenefitPlansAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_EmployeeBenefitPlansAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atha_EmployeeBenefitPlansAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_StockOptionsToPurchaseCommonStockMember" xlink:label="atha_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NonVestedRestrictedStockUnitsMember" xlink:label="atha_NonVestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmployeeStockPurchasePlanMember" xlink:label="atha_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atha_StockOptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atha_NonVestedRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atha_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" xlink:label="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" xlink:label="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DescriptionOfBusinessLineItems" xlink:label="atha_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DescriptionOfBusinessTable" xlink:label="atha_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EntityReincorporationDateOfReincorporation" xlink:label="atha_EntityReincorporationDateOfReincorporation"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_FollowOnPublicOfferingMember" xlink:label="atha_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AtTheMarketOfferingMember" xlink:label="atha_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" xlink:label="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="atha_DescriptionOfBusinessTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="atha_EntityReincorporationDateOfReincorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atha_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_DescriptionOfBusinessTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atha_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_DescriptionOfBusinessLineItems" xlink:to="us-gaap_InvestmentsAndCash" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" xlink:label="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NationalInstitutesOfHealthGrantMember" xlink:label="atha_NationalInstitutesOfHealthGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantsReceived" xlink:label="atha_GrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncome" xlink:label="atha_GrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AggregateGrantIncome" xlink:label="atha_AggregateGrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AdditionalGrantIncome" xlink:label="atha_AdditionalGrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_UnbilledGrantReceivableCurrent" xlink:label="atha_UnbilledGrantReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atha_NationalInstitutesOfHealthGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_GrantsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_GrantIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_AggregateGrantIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_AdditionalGrantIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="atha_UnbilledGrantReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShortTermInvestmentMember" xlink:label="atha_ShortTermInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LongTermInvestmentsMember" xlink:label="atha_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="atha_ShortTermInvestmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="atha_LongTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShortTermInvestmentsMaturityTerm" xlink:label="atha_ShortTermInvestmentsMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LongTermInvestmentsMaturityTerm" xlink:label="atha_LongTermInvestmentsMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="atha_ShortTermInvestmentsMaturityTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="atha_LongTermInvestmentsMaturityTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LaboratoryEquipmentMember" xlink:label="atha_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_FurnitureFixturesAndComputerEquipmentMember" xlink:label="atha_FurnitureFixturesAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atha_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atha_FurnitureFixturesAndComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_WashingtonStateUniversityLicenseAgreementMember" xlink:label="atha_WashingtonStateUniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LicensedProductsMember" xlink:label="atha_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" xlink:label="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PaymentOnAchievementOfDevelopmentMilestone" xlink:label="atha_PaymentOnAchievementOfDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" xlink:label="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_MilestonePaymentsAmountPayableUponTrialInitiation" xlink:label="atha_MilestonePaymentsAmountPayableUponTrialInitiation"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_MilestonePaymentsAmountPayableUponMarketingApproval" xlink:label="atha_MilestonePaymentsAmountPayableUponMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" xlink:label="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NetSalesExemptFromRoyaltyPayment" xlink:label="atha_NetSalesExemptFromRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_RoyaltyObligation" xlink:label="atha_RoyaltyObligation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atha_WashingtonStateUniversityLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atha_LicensedProductsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_PaymentOnAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_MilestonePaymentsAmountPayableUponTrialInitiation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_MilestonePaymentsAmountPayableUponMarketingApproval" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_NetSalesExemptFromRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atha_RoyaltyObligation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CommitmentsAndContingenciesLineItems" xlink:label="atha_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CommitmentsAndContingenciesTable" xlink:label="atha_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_WangVAthiraPharmaIncMember" xlink:label="atha_WangVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_BothellWashingtonMember" xlink:label="atha_BothellWashingtonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LaboratoryAndOfficeFacilitiesMember" xlink:label="atha_LaboratoryAndOfficeFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="us-gaap_LossContingencyLawsuitFilingDate"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_JawandhaVAthiraPharmaIncMember" xlink:label="atha_JawandhaVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SlyneVAthiraPharmaIncMember" xlink:label="atha_SlyneVAthiraPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfDefendant" xlink:label="us-gaap_LossContingencyNameOfDefendant"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AthiraPharmaIncVDrKawasMember" xlink:label="atha_AthiraPharmaIncVDrKawasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="us-gaap_InsuranceRecoveries"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_OperatingLeaseExpirationMonthAndYear" xlink:label="atha_OperatingLeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NumberOfClasses" xlink:label="atha_NumberOfClasses"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NumberOfSubclasses" xlink:label="atha_NumberOfSubclasses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_WangVAthiraPharmaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atha_BothellWashingtonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atha_LaboratoryAndOfficeFacilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyLawsuitFilingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_JawandhaVAthiraPharmaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_SlyneVAthiraPharmaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="srt_LitigationCaseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyNameOfDefendant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="atha_AthiraPharmaIncVDrKawasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceRecoveries" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atha_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LitigationStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_OperatingLeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_NumberOfClasses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atha_CommitmentsAndContingenciesLineItems" xlink:to="atha_NumberOfSubclasses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" xlink:label="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" xlink:label="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" xlink:label="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" xlink:label="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="atha_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" xlink:label="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atha_TwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" xlink:label="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceOneMember" xlink:label="atha_ExercisePriceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceTwoMember" xlink:label="atha_ExercisePriceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ExercisePriceThreeMember" xlink:label="atha_ExercisePriceThreeMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="atha_ExercisePriceOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="atha_ExercisePriceTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="atha_ExercisePriceThreeMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_OperatingLossCarryForwardsExpirationPeriod" xlink:label="atha_OperatingLossCarryForwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" xlink:label="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="atha_OperatingLossCarryForwardsExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_StockOptionsToPurchaseCommonStockMember" xlink:label="atha_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_NonVestedRestrictedStockUnitsMember" xlink:label="atha_NonVestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_EmployeeStockPurchasePlanMember" xlink:label="atha_EmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atha_StockOptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atha_NonVestedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atha_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="atha_UnbilledGrantReceivableCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_UnbilledGrantReceivableCurrent" xlink:label="atha_UnbilledGrantReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="atha_GrantIncome" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_LitigationSettlementExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_InsuranceRecoveries" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_GrantIncome" xlink:label="atha_GrantIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries" xlink:label="us-gaap_InsuranceRecoveries"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atha_IncreaseDecreaseInUnbilledGrantReceivables" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atha_IncreaseDecreaseInAccruedLegalSettlement" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="13" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="14" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IncreaseDecreaseInUnbilledGrantReceivables" xlink:label="atha_IncreaseDecreaseInUnbilledGrantReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="atha_IncreaseDecreaseInAccruedLegalSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="atha_AccruedResearchAndDevelopmentExpensesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="atha_AccruedProfessionalServicesAndOtherCurrent" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="atha_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_AccruedProfessionalServicesAndOtherCurrent" xlink:label="atha_AccruedProfessionalServicesAndOtherCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="atha_DeferredTaxAssetsRightOfUseAsset" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="atha_DeferredTaxAssetsOperatingLeaseLiability" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsRightOfUseAsset" xlink:label="atha_DeferredTaxAssetsRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="atha_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="atha-20231231.xsd#atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="atha_SlyneVAthiraPharmaIncMember" name="SlyneVAthiraPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" name="ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_OperatingLeaseExpirationMonthAndYear" name="OperatingLeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_IncreaseDecreaseInAccruedLegalSettlement" name="IncreaseDecreaseInAccruedLegalSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_BasisOfPresentationAndSignificantAccountingPoliciesTable" name="BasisOfPresentationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_GrantIncome" name="GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" name="SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember" name="TowThousandAndTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_EmployeeBenefitPlansAbstract" name="EmployeeBenefitPlansAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_IncreaseDecreaseInUnbilledGrantReceivables" name="IncreaseDecreaseInUnbilledGrantReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" name="ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_OperatingLossCarryForwardsExpirationPeriod" name="OperatingLossCarryForwardsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_LicensedProductsMember" name="LicensedProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" name="ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" name="ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_UnbilledGrantReceivableCurrent" name="UnbilledGrantReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_AthiraPharmaIncVDrKawasMember" name="AthiraPharmaIncVDrKawasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_NumberOfSubclasses" name="NumberOfSubclasses" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="atha_BothellWashingtonMember" name="BothellWashingtonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" name="SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_DescriptionOfBusinessLineItems" name="DescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" name="IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" name="NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_PaymentOnAchievementOfDevelopmentMilestone" name="PaymentOnAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" name="IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_ExercisePriceTwoMember" name="ExercisePriceTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_NationalInstitutesOfHealthGrantMember" name="NationalInstitutesOfHealthGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" name="ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" name="PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_LongTermInvestmentsMaturityTerm" name="LongTermInvestmentsMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_WangVAthiraPharmaIncMember" name="WangVAthiraPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_MilestonePaymentsAmountPayableUponMarketingApproval" name="MilestonePaymentsAmountPayableUponMarketingApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_ShortTermInvestmentMember" name="ShortTermInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" name="NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_NumberOfClasses" name="NumberOfClasses" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="atha_DescriptionOfBusinessTable" name="DescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_AccruedProfessionalServicesAndOtherCurrent" name="AccruedProfessionalServicesAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_FurnitureFixturesAndComputerEquipmentMember" name="FurnitureFixturesAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_EntityReincorporationDateOfReincorporation" name="EntityReincorporationDateOfReincorporation" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_GrantsReceived" name="GrantsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_RoyaltyObligation" name="RoyaltyObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" name="PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_LaboratoryAndOfficeFacilitiesMember" name="LaboratoryAndOfficeFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_NetSalesExemptFromRoyaltyPayment" name="NetSalesExemptFromRoyaltyPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_ShortTermInvestmentsMaturityTerm" name="ShortTermInvestmentsMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_JawandhaVAthiraPharmaIncMember" name="JawandhaVAthiraPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_DeferredTaxAssetsRightOfUseAsset" name="DeferredTaxAssetsRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_MilestonePaymentsAmountPayableUponTrialInitiation" name="MilestonePaymentsAmountPayableUponTrialInitiation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" name="SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" name="AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_NonVestedRestrictedStockUnitsMember" name="NonVestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_WashingtonStateUniversityLicenseAgreementMember" name="WashingtonStateUniversityLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_AdditionalGrantIncome" name="AdditionalGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems" name="BasisOfPresentationAndSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" name="ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="atha_AggregateGrantIncome" name="AggregateGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="atha_StockOptionsToPurchaseCommonStockMember" name="StockOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ExercisePriceThreeMember" name="ExercisePriceThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ExercisePriceOneMember" name="ExercisePriceOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756856800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 19, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Athira Pharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001620463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3368487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">18706 North Creek Parkway,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line2</a></td>
<td class="text">Suite 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Bothell,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">98011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,326,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">Portions of the definitive proxy statement to be delivered to stockholders in connection with the 2024 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December 31, 2023.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762043840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,584<span></span>
</td>
<td class="nump">$ 95,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">56,835<span></span>
</td>
<td class="nump">104,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_UnbilledGrantReceivableCurrent', window );">Unbilled grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,682<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance recovery receivable related to legal settlement (Note 7)</a></td>
<td class="nump">1,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">154,729<span></span>
</td>
<td class="nump">207,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">160,245<span></span>
</td>
<td class="nump">258,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">18,343<span></span>
</td>
<td class="nump">8,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Accrued legal settlement (Note 7)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,840<span></span>
</td>
<td class="nump">21,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,057<span></span>
</td>
<td class="nump">23,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 38,172,603 and 37,877,387 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">439,739<span></span>
</td>
<td class="nump">428,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(349)<span></span>
</td>
<td class="num">(1,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(309,206)<span></span>
</td>
<td class="num">(191,534)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="nump">235,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 160,245<span></span>
</td>
<td class="nump">$ 258,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_UnbilledGrantReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled grant receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_UnbilledGrantReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753543872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">38,172,603<span></span>
</td>
<td class="nump">37,877,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">38,172,603<span></span>
</td>
<td class="nump">37,877,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756863936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 93,790<span></span>
</td>
<td class="nump">$ 61,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">33,304<span></span>
</td>
<td class="nump">32,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recovery related to legal settlement</a></td>
<td class="num">(1,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">125,466<span></span>
</td>
<td class="nump">104,016<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(125,466)<span></span>
</td>
<td class="num">(104,016)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_GrantIncome', window );">Grant income</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">5,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">7,637<span></span>
</td>
<td class="nump">3,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(117,672)<span></span>
</td>
<td class="num">(95,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to common stockholders</a></td>
<td class="num">$ (116,065)<span></span>
</td>
<td class="num">$ (97,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (2.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic</a></td>
<td class="nump">38,020,182<span></span>
</td>
<td class="nump">37,733,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted</a></td>
<td class="nump">38,020,182<span></span>
</td>
<td class="nump">37,733,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756605088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 321,084<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 417,363<span></span>
</td>
<td class="num">$ (388)<span></span>
</td>
<td class="num">$ (95,895)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,379,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of common stock options</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(1,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(95,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,639)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 235,137<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">428,623<span></span>
</td>
<td class="num">(1,956)<span></span>
</td>
<td class="num">(191,534)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,877,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of common stock options, shares</a></td>
<td class="nump">128,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits', window );">Issuance of common stock upon exercise of common stock options and vesting of restricted stock units</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares', window );">Issuance of common stock upon exercise of common stock options and vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(117,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,672)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 439,739<span></span>
</td>
<td class="num">$ (349)<span></span>
</td>
<td class="num">$ (309,206)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,172,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of common stock options and vesting of restricted stock unit shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of common stock options and vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756642864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (117,672,000)<span></span>
</td>
<td class="num">$ (95,639,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,623,000<span></span>
</td>
<td class="nump">10,606,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">969,000<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">214,000<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and accretion of discounts on available-for-sale securities, net</a></td>
<td class="num">(1,414,000)<span></span>
</td>
<td class="num">(422,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_IncreaseDecreaseInUnbilledGrantReceivables', window );">Unbilled grant receivable</a></td>
<td class="nump">1,227,000<span></span>
</td>
<td class="nump">1,109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and long-term assets, net</a></td>
<td class="num">(113,000)<span></span>
</td>
<td class="num">(1,257,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable', window );">Insurance recovery receivable related to legal settlement</a></td>
<td class="num">(1,628,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">7,367,000<span></span>
</td>
<td class="nump">2,101,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_IncreaseDecreaseInAccruedLegalSettlement', window );">Accrued legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(326,000)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(100,753,000)<span></span>
</td>
<td class="num">(72,469,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(27,671,000)<span></span>
</td>
<td class="num">(95,288,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of available-for-sale securities</a></td>
<td class="nump">123,064,000<span></span>
</td>
<td class="nump">154,093,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(304,000)<span></span>
</td>
<td class="num">(1,141,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">95,089,000<span></span>
</td>
<td class="nump">57,664,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(5,171,000)<span></span>
</td>
<td class="num">(14,151,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">96,386,000<span></span>
</td>
<td class="nump">110,537,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">$ 91,215,000<span></span>
</td>
<td class="nump">$ 96,386,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_IncreaseDecreaseInAccruedLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued legal settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_IncreaseDecreaseInAccruedLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_IncreaseDecreaseInUnbilledGrantReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in unbilled grant receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_IncreaseDecreaseInUnbilledGrantReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759759280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (117,672)<span></span>
</td>
<td class="num">$ (95,639)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756597680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249761322112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1. Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc. (the &#8220;Company&#8221;) was incorporated as M3 Biotechnology, Inc. in the state of Washington on </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">March 31, 2011</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and reincorporated in the state of Delaware on </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">October 27, 2015</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since the Company&#8217;s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company&#8217;s inception through December 31, 2023, it has raised aggregate net cash proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">407.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million primarily from the issuance of its common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">147.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in cash, cash equivalents, and investments and had not generated positive cash flows from operations. Since the Company&#8217;s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company&#8217;s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based upon the Company&#8217;s current operating plan, it estimates that its $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">147.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million of cash, cash equivalents, and investments at December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the date of the Company&#8217;s Annual Report on Form 10-K.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">At The Market Common Stock Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In January 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the Company entered into a sales agreement with Cantor Fitzgerald and BTIG to sell shares of our common stock having aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, from time to time, through an &#8220;at the market&#8221; (&#8220;ATM&#8221;) equity offering program under which Cantor and BTIG are acting as sales agents. The Company has </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> sold any securities pursuant to this ATM offering.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762748560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">factors </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Restricted cash consists primarily of collateral pledged in connection with the Company's corporate credit cards. </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.</span></span></p><div style="font-size:10pt;font-family:Arial;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.883%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.883%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">90,584</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,966</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">631</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">420</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">91,215</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">96,386</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Short-term and Long-term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment consist of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment, excluding leasehold improvements, are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life, generally </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_b400847d-1662-41db-b50c-4bdbe2ef14f7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of their useful life or the remaining lease term. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess of the asset's carrying amount over its fair value. Gains and losses from asset disposals and impairment losses are classified within the consolidated statements of operations and comprehensive loss in accordance with the use of the asset. There were </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> impairment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">losses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">in the years ended December 31, 2023 and 2022 as there have been no events warranting an impairment analysis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Grant Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2020, the Company accepted a grant from the National Institute on Aging (&#8220;NIA&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company&#8217;s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer&#8217;s disease. The Company recognizes income related to the NIH grant in the accompanying consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred. As of December 31, 2023, the Company has recognized aggregate grant income of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in connection with the NIH grant, equal to the total grant amount approved. The Company will </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t recognize any additional grant income in connection with the NIH grant in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recognized grant income of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, which is included in unbilled grant receivable on the consolidated balance sheets. The Company received cash of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million related to the NIH grant during the year ended December 31, 2023, compared to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the year ended December 31, 2022.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company&#8217;s proprietary drug discovery platform (&#8220;ATH platform&#8221;), the Company&#8217;s drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company&#8217;s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. </span></span><span style="font-size:10pt;font-family:Arial;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Accounting Standards Codification (&#8220;ASC&#8221;) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Topic 842 - Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> effective </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company&#8217;s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company&#8217;s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company&#8217;s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company&#8217;s lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company&#8217;s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company&#8217;s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company&#8217;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In assessing the Company&#8217;s ability to realize deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future income, tax planning strategies in making this assessment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company accrues interest and penalties related to unrecognized tax benefits in its provision for incomes taxes.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comprehensive Loss Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders consists of net loss and other gains and losses affecting stockholders&#8217; equity that, under U.S. GAAP, are excluded from net loss. The Company&#8217;s comprehensive loss attributable to common stockholders is comprised of net loss and unrealized gains and losses on available-for-sale securities.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Foreign Currency Transaction Remeasurement Adjustments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at the balance sheet date. Income and expenses denominated in foreign currencies were translated into U.S. dollars at the average exchange rate for the period and the transaction remeasurement adjustments are reported within other income, net in the consolidated statement of operations and comprehensive loss. The functional currency of the Company&#8217;s Australian subsidiary is the U.S. dollar.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has determined that it operates and manages </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4a281260-fb9a-463b-8549-038a2ea1ba92;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ASU 2016-13</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> effective </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and it did </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t have a material impact on its financial condition, results of operations or cash flows.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756888832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Fair Value</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Inputs are generally unobservable and reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The determination of a financial instrument&#8217;s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following tables reflect the Company&#8217;s financial asset balances measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">56,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,002</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">64,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,392</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Long-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All the commercial paper, U.S. government debt, and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from the respective balance sheet date. Those that are designated as long-term investments have an effective maturity date that is more than </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, but less than </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, from the respective balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of December 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized gains (losses) for available-for-sale securities were recorded in other comprehensive loss.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759372608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">4. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture, fixtures, and<br/>&#160;&#160;&#160;computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,322</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,421</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">969,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">845,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249761296176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Professional services and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,882</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759297040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Significant Agreements</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">WSU License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is party to an amended and restated exclusive license agreement with sublicensing terms with WSU that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2020, the Phase 2 clinical trial milestone had been reached and a payment of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to WSU was recorded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company may also be obligated to pay the following if the related milestones are reached:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8211; At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; and</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8211; Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of net sales being exempt from royalty payment, and annual minimum royalty payments of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> beginning after the first commercial sale of a licensed product. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> sales of any licensed products had occurred and the Company had </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t incurred a royalty obligation under this agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based payments received, and low twenties of net sales based sublicense royalties. As of December 31, 2023, the Company has not entered into or incurred any liability from a sublicense agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762724512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Securities Class Actions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 25, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, plaintiffs </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fan Wang and Hang Gao</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Company&#8217;s former chief executive officer Dr. Leen Kawas, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang v. Athira Pharma, Inc., et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Company&#8217;s business. Specifically, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects were materially misleading. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wang </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys&#8217; fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">That same day, on </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 25, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, plaintiff </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Harshdeep Jawandha</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company&#8217;s then chief financial officer, certain members of the Company&#8217;s board of directors at the time of the Company&#8217;s initial public offering ("IPO"), as well as the IPO underwriters, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha v. Athira Pharma, Inc., et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00862. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933 ("Securities Act"), alleging that that the Company&#8217;s IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas&#8217;s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Company&#8217;s efforts to develop treatments for Alzheimer&#8217;s disease, and that the defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects were materially misleading. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys&#8217; fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Also on </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 25, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, plaintiffs </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Timothy Slyne and Tai Slyne</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company&#8217;s then chief financial officer, and the same members of the Company&#8217;s board of directors and underwriters as in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jawandha </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne v. Athira Pharma, Inc. et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:21-cv-00864. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas&#8217;s doctoral research at WSU should have been disclosed in the Company&#8217;s IPO registration statement. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Slyne</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> plaintiffs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek unspecified compensatory damages, reasonable costs and expenses, including attorneys&#8217; fees, and injunctive and other equitable relief.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Company&#8217;s then chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering ("SPO"), and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas&#8217;s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs&#8217; consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">August 12, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, defendant </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Dr. Kawas</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> filed a motion for partial reconsideration of the court&#8217;s July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On March 10, 2023, following a mediation and the parties&#8217; agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffs&#8217; motion for preliminary approval without prejudice, citing the motion&#8217;s failure to satisfy the court&#8217;s questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffs&#8217; renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024 proposing a date on which the court may schedule the final approval hearing, among other things. In its order, the court preliminarily approved the proposed settlement and certified a class and two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a result of the foregoing, the Company recorded a legal settlement expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in operating expenses in the fourth quarter of 2022 and an accrued liability of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million on the accompanying consolidated balance sheets. Additionally, the Company recorded an insurance recovery of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million on the accompanying consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by the Company's insurers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Shareholder Derivative Actions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Company&#8217;s board of directors, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bushansky v. Kawas et al.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, No. 2:22-cv-497. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that the Company&#8217;s board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Company&#8217;s public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint seeks unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys&#8217; fees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Houlihan v. Kawas et al</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">., No. 2:22-cv-620. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that certain of the Company&#8217;s current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Company&#8217;s public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint seeks unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys&#8217; fees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. The Company believes it has adequate reserves related to this matter as of the latest balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Government Investigations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice (the "Demand"). The Demand seeks documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH, and our receipt of a NIH grant in 2020. The Company is cooperating with the Department of Justice with respect to the Demand.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2023, the Securities and Exchange Commission ("SEC"), sent the Company a subpoena seeking documents and information relating to, among other things, the Company's former chief executive officer's alterations of images in certain research papers. The Company is cooperating with the SEC with respect to the subpoena.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company cannot predict the outcome of these lawsuits or government investigations. Failure by the Company to obtain a favorable resolution of these actions could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date the Company has not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company enters into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">August 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The initial terms of the leases range from </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and the Company has </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">options to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> the leases for an additional </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> that it is not reasonably certain to exercise. As of December 31, 2023, the Company was not party to any finance leases.</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table reconciles the Company&#8217;s undiscounted operating lease cash flows to its operating lease liability (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">509</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Present value adjustment for minimum lease<br/>&#160;&#160;&#160;commitments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.143%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.429%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating lease expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">353,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">368,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively. Separately, variable lease expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">186,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for operating leases during the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756849008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Common Stock</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Company&#8217;s board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception.</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.568%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.557%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.716%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares issuable upon the exercise of outstanding<br/>&#160;&#160;&#160;common stock options and the vesting of<br/>&#160;&#160;&#160;outstanding common restricted stock<br/>&#160;&#160;&#160;units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,130,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,269,861</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the 2020<br/>&#160;&#160;&#160;Equity Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,158,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the<br/>&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,128,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">916,640</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,417,782</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,440,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,230,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, (2) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company&#8217;s board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">646,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, (2) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company&#8217;s board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Effective January 1, 2023, the Company&#8217;s 2020 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,893,869</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">378,774</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Effective January 1, 2024, the Company&#8217;s 2020 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,908,630</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">381,726</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759297040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. Stock-based Compensation</span><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock&#8209;based compensation expense recognized was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,620</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,623</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The fair value of each share of common stock is based on the closing price of the Company&#8217;s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></div></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of each stock option was estimated using the Black&#8209;Scholes option&#8209;pricing model with the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.218%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">99.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">92.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.84</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.02</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The grant date fair value of restricted stock units is based upon the fair market value of the Company&#8217;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of options granted during the years ended December 31, 2023 and 2022 were $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively. The fair value of restricted stock units granted during the year ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Changes in shares available for grant under the 2020 Plan during the year ended December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.24%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Available <br/>for Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for grant at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2020 Plan reserve increase on January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,893,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options and restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,834,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options and restricted stock units forfeited, <br/>&#160;&#160;&#160;cancelled, or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">845,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,158,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A summary of option activity for the year ended December 31, 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.643%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.643%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>price<br/>per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in<br/>thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,033,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,696,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">128,534</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Forfeited/expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">780,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,820,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.24</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected to vest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000,554</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.72</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options exercisable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,820,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The total fair value of options granted that vested during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock underlying all options that were in-the-money at December 31, 2023. The aggregate intrinsic value of options exercised was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the year ended December 31, 2023 and 2022, respectively, determined as of the date of option exercise. As of December 31, 2023, there was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1.99</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years. The Company utilizes newly issued shares to satisfy option exercises.</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options outstanding and exercisable consisted of the following at December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.2%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-family:Arial;min-width:fit-content;">Exercise Price ($)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Exercisable</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.16</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.22</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,709,593</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,005,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.93</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.94</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,759,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,615,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.55</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.41</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">352,248</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">198,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,820,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,820,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Stock Unit Activity</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A summary of RSU activity for the year ended December 31, 2023 is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.879999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Share<br/>Equivalent</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">236,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">138,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">64,252</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Arial;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the ESPP, eligible employees can authorize payroll deductions for amounts up to the lesser of </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of their qualifying wages or the statutory limit under the U.S. Internal Revenue Code. The ESPP provides for offering periods of </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">six months</span></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in duration with one purchase period per offering period beginning May 18 and November 18 of each year. </span></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Participants in an offering period will be granted the right to purchase shares of our common stock at a price per share that is </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the lesser of the fair market value of the shares at (1) the first day of the offering period or (2) the end of each purchase period within the offering period. A maximum of </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">10,000</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock may be purchased by each participant at the purchase date during the offering period. The fair market value of the ESPP options granted is determined using the Black-Scholes model and is amortized on a straight-line basis. Stock-based compensation expense recognized during the years ended December 31, 2023 and 2022 associated with the ESPP was $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, the Company issued </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">166,682</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock to employees under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759262576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">10. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Components of Income and Income Tax</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company did not record a provision (benefit) for income taxes for the years ended December 31, 2023 and 2022. Net loss is attributable to the following tax jurisdictions (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">United States</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">117,440</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,778</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Net Loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">117,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The provision for income taxes differs from the amount expected by applying the federal statutory rates to the net loss before taxes as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">State taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-deductible expenses and others</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Deferred Tax Assets and Liabilities</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">31,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development tax credit<br/>&#160;&#160;&#160;carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,327</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,781</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,564</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,756</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,021</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">42,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Deferred income taxes reflect temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes, and operating losses and tax credit carryforwards. The Company considers a number of factors concerning the realizability of its net deferred tax assets, including its history of operating losses, the nature of the deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible, all of which require significant judgment. As of December 31, 2023, the Company has recorded a full valuation allowance on its net deferred tax assets as the Company has concluded that it is not more likely than not that such losses or credits will be utilized. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">28.3</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">20.4</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At December 31, 2023, the Company has federal net operating loss and tax credit carryforwards of  $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">9.5</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively, which expire over a period of </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">14</span></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years. Net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">138.7</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million were generated after 2017, and therefore do not expire. As of December 31, 2023, the Company also had state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">3.3</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, which expire over a period of </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">18</span></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">20</span></span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in years beginning on or after January 1, 2022.  Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software, or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. We have included the impact of this provision, which results in a deferred tax asset of approximately $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">25.2</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million as of December 31, 2023.</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company files federal income tax returns. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years prior to 2016. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">were generated and carried forward and may make adjustments to the amount of the net operating loss or credit carryforward amount. The Company is not currently under examination in any jurisdiction.</span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A reconciliation of the beginning and ending amount of unrecognized tax benefits for uncertain tax positions were as follows (in thousands):</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions for tax positions taken in prior<br/>&#160;&#160;&#160;years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions for tax positions taken in the current<br/>&#160;&#160;&#160;year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023 are recognized, there will be no impact to the effective tax rate due to the valuation allowance. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated financial statements. At December 31, 2023, there were </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> material interest and penalties on uncertain tax benefits. The Company does not anticipate any significant changes to its unrecognized tax benefits in the next 12 months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762724512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_EmployeeBenefitPlansAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">11. Employee Benefit Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has a 401(k) Plan for all of its employees. The 401(k) Plan allows eligible employees to defer, at the employee&#8217;s discretion, up to </span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of their pretax compensation up to the Internal Revenue Service annual limit. The Company made matching contributions of $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_EmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_EmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759307616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">12. </span><span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.248%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.777%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.777%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,820,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,033,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested Restricted Stock Units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">236,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,148</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,134,451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,275,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756585008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">factors </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Restricted cash consists primarily of collateral pledged in connection with the Company's corporate credit cards. </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.</span></span></p><div style="font-size:10pt;font-family:Arial;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.883%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.883%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">90,584</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,966</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">631</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">420</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">91,215</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">96,386</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term and Long-term Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Short-term and Long-term Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment consist of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment, excluding leasehold improvements, are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life, generally </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_b400847d-1662-41db-b50c-4bdbe2ef14f7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of their useful life or the remaining lease term. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess of the asset's carrying amount over its fair value. Gains and losses from asset disposals and impairment losses are classified within the consolidated statements of operations and comprehensive loss in accordance with the use of the asset. There were </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> impairment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">losses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">in the years ended December 31, 2023 and 2022 as there have been no events warranting an impairment analysis.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Grant Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2020, the Company accepted a grant from the National Institute on Aging (&#8220;NIA&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company&#8217;s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer&#8217;s disease. The Company recognizes income related to the NIH grant in the accompanying consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred. As of December 31, 2023, the Company has recognized aggregate grant income of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in connection with the NIH grant, equal to the total grant amount approved. The Company will </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t recognize any additional grant income in connection with the NIH grant in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company recognized grant income of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, which is included in unbilled grant receivable on the consolidated balance sheets. The Company received cash of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million related to the NIH grant during the year ended December 31, 2023, compared to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million during the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company&#8217;s proprietary drug discovery platform (&#8220;ATH platform&#8221;), the Company&#8217;s drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company&#8217;s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Accounting Standards Codification (&#8220;ASC&#8221;) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Topic 842 - Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> effective </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company&#8217;s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company&#8217;s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company&#8217;s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company&#8217;s lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company&#8217;s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company&#8217;s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company&#8217;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In assessing the Company&#8217;s ability to realize deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future income, tax planning strategies in making this assessment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company accrues interest and penalties related to unrecognized tax benefits in its provision for incomes taxes.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comprehensive Loss Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders consists of net loss and other gains and losses affecting stockholders&#8217; equity that, under U.S. GAAP, are excluded from net loss. The Company&#8217;s comprehensive loss attributable to common stockholders is comprised of net loss and unrealized gains and losses on available-for-sale securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transaction Remeasurement Adjustments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Foreign Currency Transaction Remeasurement Adjustments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at the balance sheet date. Income and expenses denominated in foreign currencies were translated into U.S. dollars at the average exchange rate for the period and the transaction remeasurement adjustments are reported within other income, net in the consolidated statement of operations and comprehensive loss. The functional currency of the Company&#8217;s Australian subsidiary is the U.S. dollar.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has determined that it operates and manages </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operating segment, which is the business of developing and commercializing therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4a281260-fb9a-463b-8549-038a2ea1ba92;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ASU 2016-13</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> effective </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and it did </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t have a material impact on its financial condition, results of operations or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759179088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.</span>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.883%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.883%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">90,584</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,966</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">631</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">420</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">91,215</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">96,386</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759400928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following tables reflect the Company&#8217;s financial asset balances measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">57,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">56,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,002</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">64,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,392</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">104,378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Long-term investments:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government debt and agency<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759216832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture, fixtures, and<br/>&#160;&#160;&#160;computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,322</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,421</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759299520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Professional services and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,882</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762729952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table reconciles the Company&#8217;s undiscounted operating lease cash flows to its operating lease liability (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">509</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Present value adjustment for minimum lease<br/>&#160;&#160;&#160;commitments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.143%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.429%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759292256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock', window );">Schedule of Reserved Shares of Common Stock for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.568%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.557%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.716%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares issuable upon the exercise of outstanding<br/>&#160;&#160;&#160;common stock options and the vesting of<br/>&#160;&#160;&#160;outstanding common restricted stock<br/>&#160;&#160;&#160;units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,130,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,269,861</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the 2020<br/>&#160;&#160;&#160;Equity Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,158,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the<br/>&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,128,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">916,640</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,417,782</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,440,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reserved shares of common stock for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249758675440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expense Recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock&#8209;based compensation expense recognized was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,620</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,623</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of each stock option was estimated using the Black&#8209;Scholes option&#8209;pricing model with the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.218%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">99.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">92.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.84</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.02</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock', window );">Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Changes in shares available for grant under the 2020 Plan during the year ended December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.24%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Available <br/>for Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for grant at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2020 Plan reserve increase on January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,893,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options and restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,834,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options and restricted stock units forfeited, <br/>&#160;&#160;&#160;cancelled, or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">845,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,158,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A summary of option activity for the year ended December 31, 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.643%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.643%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>price<br/>per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in<br/>thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,033,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,696,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">128,534</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Forfeited/expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">780,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,820,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.24</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected to vest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,000,554</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.72</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Options exercisable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,820,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Stock Options Outstanding and Exercisable</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options outstanding and exercisable consisted of the following at December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.2%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-family:Arial;min-width:fit-content;">Exercise Price ($)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares<br/>Exercisable</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.16</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.22</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,709,593</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,005,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.93</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.94</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,759,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,615,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.55</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;to </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.41</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">352,248</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">198,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,820,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,820,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A summary of RSU activity for the year ended December 31, 2023 is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.879999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Share<br/>Equivalent</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">236,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">138,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">64,252</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation arrangement shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756539680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Income (Loss) Before Income Tax</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company did not record a provision (benefit) for income taxes for the years ended December 31, 2023 and 2022. Net loss is attributable to the following tax jurisdictions (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">United States</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">117,440</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,778</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Net Loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">117,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The provision for income taxes differs from the amount expected by applying the federal statutory rates to the net loss before taxes as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">State taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-deductible expenses and others</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">31,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development tax credit<br/>&#160;&#160;&#160;carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,327</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,218</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,781</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,564</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,756</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,021</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">42,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A reconciliation of the beginning and ending amount of unrecognized tax benefits for uncertain tax positions were as follows (in thousands):</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions for tax positions taken in prior<br/>&#160;&#160;&#160;years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions for tax positions taken in the current<br/>&#160;&#160;&#160;year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759181088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.248%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.777%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.777%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,820,869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,033,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-vested Restricted Stock Units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">236,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,148</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,134,451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,275,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762091648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation, date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_EntityReincorporationDateOfReincorporation', window );">Entity reincorporation, date of reincorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 27,  2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants', window );">Net cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents, and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atha_AtTheMarketOfferingMember', window );">At The Market Common Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued and sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atha_AtTheMarketOfferingMember', window );">At The Market Common Stock Offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate proceeds from issuance of common stock</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_EntityReincorporationDateOfReincorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity reincorporation, date of reincorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_EntityReincorporationDateOfReincorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible preferred stock and common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atha_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atha_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756617376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,584<span></span>
</td>
<td class="nump">$ 95,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 91,215<span></span>
</td>
<td class="nump">$ 96,386<span></span>
</td>
<td class="nump">$ 110,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753680816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_GrantIncome', window );">Grant income</a></td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="nump">5,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_UnbilledGrantReceivableCurrent', window );">Unbilled grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atha_NationalInstitutesOfHealthGrantMember', window );">National Institutes of Health Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_GrantsReceived', window );">Grants received</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_GrantIncome', window );">Grant income</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_AggregateGrantIncome', window );">Aggregate grant income</a></td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_AdditionalGrantIncome', window );">Additional grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_UnbilledGrantReceivableCurrent', window );">Unbilled grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_AdditionalGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_AdditionalGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_AggregateGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_AggregateGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_GrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_GrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_UnbilledGrantReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled grant receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_UnbilledGrantReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atha_NationalInstitutesOfHealthGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atha_NationalInstitutesOfHealthGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753580576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 90,584<span></span>
</td>
<td class="nump">$ 95,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">57,154<span></span>
</td>
<td class="nump">105,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Unrealized Losses</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments, Fair Value</a></td>
<td class="nump">56,835<span></span>
</td>
<td class="nump">104,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Short-term Investments | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">6,431<span></span>
</td>
<td class="nump">36,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments, Fair Value</a></td>
<td class="nump">6,427<span></span>
</td>
<td class="nump">36,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Short-term Investments | U.S. Government Debt and Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">50,723<span></span>
</td>
<td class="nump">65,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Unrealized Losses</a></td>
<td class="num">(315)<span></span>
</td>
<td class="num">(784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments, Fair Value</a></td>
<td class="nump">50,408<span></span>
</td>
<td class="nump">64,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Short-term Investments | Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Long Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Long Term Investments | U.S. Government Debt and Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">59,290<span></span>
</td>
<td class="nump">78,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Unrealized Losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">59,260<span></span>
</td>
<td class="nump">78,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Cash Equivalents | Money Market Fund | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Cash Equivalents | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">59,227<span></span>
</td>
<td class="nump">78,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Unrealized Losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">$ 59,197<span></span>
</td>
<td class="nump">$ 78,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=atha_ShortTermInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=atha_ShortTermInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=atha_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=atha_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249758692032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional Information (Details) - Recurring Basis<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_LongTermInvestmentsMaturityTerm', window );">Long-term investments effective maturity date</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShortTermInvestmentsMaturityTerm', window );">Short-term investments effective maturity date</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_LongTermInvestmentsMaturityTerm', window );">Long-term investments effective maturity date</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_LongTermInvestmentsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term investments maturity term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_LongTermInvestmentsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShortTermInvestmentsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments maturity term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShortTermInvestmentsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249758666672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 5,722<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(2,334)<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_FurnitureFixturesAndComputerEquipmentMember', window );">Office Furniture, Fixtures, and Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 4,322<span></span>
</td>
<td class="nump">$ 4,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_FurnitureFixturesAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_FurnitureFixturesAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249758690064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 969,000<span></span>
</td>
<td class="nump">$ 845,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756610208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 11,916<span></span>
</td>
<td class="nump">$ 3,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_AccruedProfessionalServicesAndOtherCurrent', window );">Professional services and other</a></td>
<td class="nump">1,882<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued Liabilities</a></td>
<td class="nump">$ 18,343<span></span>
</td>
<td class="nump">$ 8,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_AccruedProfessionalServicesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued professional services and other, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_AccruedProfessionalServicesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756455184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements - Additional Information (Details) - Washington State University License Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_MilestonePaymentsAmountPayableUponMarketingApproval', window );">Milestone payments payable upon marketing approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale', window );">Annual minimum royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_NetSalesExemptFromRoyaltyPayment', window );">Net sales exempt from royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_RoyaltyObligation', window );">Royalty obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atha_WashingtonStateUniversityLicenseAgreementMember', window );">Licensed Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atha_WashingtonStateUniversityLicenseAgreementMember', window );">Phase 2 Clinical Trial Initiation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_PaymentOnAchievementOfDevelopmentMilestone', window );">Milestone payments on development milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atha_WashingtonStateUniversityLicenseAgreementMember', window );">Phase 3 Clinical Trial Initiation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_MilestonePaymentsAmountPayableUponTrialInitiation', window );">Milestone payments, amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual minimum royalty payments after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_MilestonePaymentsAmountPayableUponMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments amount payable upon marketing approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_MilestonePaymentsAmountPayableUponMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_MilestonePaymentsAmountPayableUponTrialInitiation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments amount payable upon trial initiation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_MilestonePaymentsAmountPayableUponTrialInitiation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_NetSalesExemptFromRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales exempt from royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_NetSalesExemptFromRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_PaymentOnAchievementOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on achievement of development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_PaymentOnAchievementOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_RoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_RoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atha_WashingtonStateUniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atha_WashingtonStateUniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atha_LicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atha_LicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249754034704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recovery in operating expenses</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance recovery receivable</a></td>
<td class="nump">1,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Accrued legal settlement</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=atha_WangVAthiraPharmaIncMember', window );">Wang V. Athira Pharma Inc.,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Lawsuit filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 25, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Name of plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fan Wang and Hang Gao<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=atha_JawandhaVAthiraPharmaIncMember', window );">Jawandha V. Athira Pharma Inc.,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Lawsuit filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 25, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Name of plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Harshdeep Jawandha<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=atha_SlyneVAthiraPharmaIncMember', window );">Slyne V. Athira Pharma Inc.,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Lawsuit filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 25, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Name of plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Timothy Slyne and Tai Slyne<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=atha_AthiraPharmaIncVDrKawasMember', window );">Athira Pharma Inc V Dr. Kawas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Lawsuit filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">August 12, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfDefendant', window );">Name of defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dr. Kawas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryAndOfficeFacilitiesMember', window );">Laboratory and Office Facilities | Bothell, Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_OperatingLeaseExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, additional term of contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryAndOfficeFacilitiesMember', window );">Laboratory and Office Facilities | Bothell, Washington | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease initial term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryAndOfficeFacilitiesMember', window );">Laboratory and Office Facilities | Bothell, Washington | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease initial term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_OperatingLeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_OperatingLeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLawsuitFilingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States the date the complaint was formally filed in a court of law, in arbitration or mediation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLawsuitFilingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the named defendant in a lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the plaintiff in the lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=atha_WangVAthiraPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=atha_WangVAthiraPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=atha_JawandhaVAthiraPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=atha_JawandhaVAthiraPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=atha_SlyneVAthiraPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=atha_SlyneVAthiraPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=atha_AthiraPharmaIncVDrKawasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=atha_AthiraPharmaIncVDrKawasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryAndOfficeFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=atha_LaboratoryAndOfficeFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=atha_BothellWashingtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=atha_BothellWashingtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756146128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">Thereafter</a></td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment for minimum lease commitments</a></td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net lease liability</a></td>
<td class="nump">$ 1,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249763615632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756866672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="nump">11,417,782<span></span>
</td>
<td class="nump">9,440,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember', window );">Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="nump">7,130,956<span></span>
</td>
<td class="nump">4,269,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember', window );">Shares Available for Future Grant under 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="nump">3,158,094<span></span>
</td>
<td class="nump">4,253,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember', window );">Shares Available for Future Grant under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="nump">1,128,732<span></span>
</td>
<td class="nump">916,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753471904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="nump">11,417,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,440,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atha_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan', window );">Share based compensation maximum annual increase in number of shares that may be issued under the plan</a></td>
<td class="nump">3,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding', window );">Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atha_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,908,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan', window );">Share based compensation maximum annual increase in number of shares that may be issued under the plan</a></td>
<td class="nump">646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding', window );">Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation maximum annual increase in number of shares that may be issued under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atha_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atha_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759733184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 10,623<span></span>
</td>
<td class="nump">$ 10,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,003<span></span>
</td>
<td class="nump">3,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,620<span></span>
</td>
<td class="nump">$ 7,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753903360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue', window );">Fair value of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period expected to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,623<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issued common stock, share under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the ESPP, eligible employees can authorize payroll deductions for amounts up to the lesser of 15% of their qualifying wages or the statutory limit under the U.S. Internal Revenue Code. The ESPP provides for offering periods of six months in duration with one purchase period per offering period beginning May 18 and November 18 of each year. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Offering periods</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of fair market value of common shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit', window );">Maximum percentage of payroll deductions for qualifying wages or statutory limit</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares of common stock purchased by each participant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, maximum percentage of payroll deductions for qualifying wages or statutory limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, other than options grant date fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762116992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.54%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.18%<span></span>
</td>
<td class="nump">92.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762146864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Beginning Balance</a></td>
<td class="nump">4,253,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">2020 Plan reserve increase on January 1, 2023</a></td>
<td class="nump">1,893,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted', window );">Options and restricted stock units granted</a></td>
<td class="num">(3,834,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired', window );">Options and restricted stock units forfeited, cancelled, or expired</a></td>
<td class="nump">845,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Ending Balance</a></td>
<td class="nump">3,158,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options and restricted stock unit granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options and restricted stock units, forfeited, cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249748574944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Beginning Balance</a></td>
<td class="nump">4,033,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">3,696,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(128,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares, Forfeited/expired</a></td>
<td class="num">(780,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Ending Balance</a></td>
<td class="nump">6,820,869<span></span>
</td>
<td class="nump">4,033,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Expected to vest</a></td>
<td class="nump">4,000,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Options exercisable</a></td>
<td class="nump">2,820,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Beginning Balance</a></td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Granted</a></td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Exercised</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Forfeited/expired</a></td>
<td class="nump">6.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Ending Balance</a></td>
<td class="nump">7.97<span></span>
</td>
<td class="nump">$ 11.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Expected to vest</a></td>
<td class="nump">6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise price per Share, Options exercisable</a></td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 2 months 26 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Expected to vest (in years)</a></td>
<td class="text">8 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Options exercisable (in years)</a></td>
<td class="text">7 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">$ 387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753633376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding</a></td>
<td class="nump">6,820,869<span></span>
</td>
<td class="nump">4,033,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Exercisable</a></td>
<td class="nump">2,820,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceOneMember', window );">Exercise Price $0.16 to 4.22</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding</a></td>
<td class="nump">3,709,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Exercisable</a></td>
<td class="nump">1,005,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceOneMember', window );">Exercise Price $0.16 to 4.22 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise Price ($)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceOneMember', window );">Exercise Price $0.16 to 4.22 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise Price ($)</a></td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceTwoMember', window );">Exercise Price $8.93 to 19.94</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding</a></td>
<td class="nump">2,759,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Exercisable</a></td>
<td class="nump">1,615,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceTwoMember', window );">Exercise Price $8.93 to 19.94 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise Price ($)</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceTwoMember', window );">Exercise Price $8.93 to 19.94 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise Price ($)</a></td>
<td class="nump">$ 19.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceThreeMember', window );">Exercise Price $20.55 to 29.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding</a></td>
<td class="nump">352,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Exercisable</a></td>
<td class="nump">198,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceThreeMember', window );">Exercise Price $20.55 to 29.41 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise Price ($)</a></td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceThreeMember', window );">Exercise Price $20.55 to 29.41 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise Price ($)</a></td>
<td class="nump">$ 29.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=atha_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249759748464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Equivalent, Non-vested, Beginning Balance | shares</a></td>
<td class="nump">236,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share Equivalent, Granted | shares</a></td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share Equivalent, Cancelled | shares</a></td>
<td class="num">(64,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Equivalent, Non-vested, Ending Balance | shares</a></td>
<td class="nump">310,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Non-vested, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 15.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Non-vested, Granted | $ / shares</a></td>
<td class="nump">3.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Non-vested, Cancelled | $ / shares</a></td>
<td class="nump">7.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Non-vested, Ending Balance | $ / shares</a></td>
<td class="nump">$ 11.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249762060224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income (Loss) Before Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (117,440)<span></span>
</td>
<td class="num">$ (95,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(232)<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (117,672)<span></span>
</td>
<td class="num">$ (95,639)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249757721040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">State Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses and others</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(21.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753782992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 31,342<span></span>
</td>
<td class="nump">$ 24,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">9,327<span></span>
</td>
<td class="nump">4,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,564<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">25,182<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">71,756<span></span>
</td>
<td class="nump">44,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_DeferredTaxAssetsRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses and other</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(1,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(71,246)<span></span>
</td>
<td class="num">(42,985)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_DeferredTaxAssetsRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_DeferredTaxAssetsRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249748520352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 28,300,000<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">138,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Material interest and penalties on uncertain tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets</a></td>
<td class="nump">25,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod', window );">Net operating loss and tax credit carryforwards, expiration period</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_OperatingLossCarryForwardsExpirationPeriod', window );">Operating loss carryforwards, expiration period</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod', window );">Net operating loss and tax credit carryforwards, expiration period</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_OperatingLossCarryForwardsExpirationPeriod', window );">Operating loss carryforwards, expiration period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and tax credit carryforwards, expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_OperatingLossCarryForwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carry forwards Expiration Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_OperatingLossCarryForwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249756770800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">$ 722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions taken in prior year</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions taken in the current year</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 3,109<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249761300416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atha_EmployeeBenefitPlansAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of pretax compensation eligible to defer</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atha_EmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atha_EmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140249753020144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share</a></td>
<td class="nump">7,134,451<span></span>
</td>
<td class="nump">4,275,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_StockOptionsToPurchaseCommonStockMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share</a></td>
<td class="nump">6,820,869<span></span>
</td>
<td class="nump">4,033,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_NonVestedRestrictedStockUnitsMember', window );">Non-vested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share</a></td>
<td class="nump">310,087<span></span>
</td>
<td class="nump">236,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">5,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_StockOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_StockOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_NonVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_NonVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atha_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5&; .=(,",+R9SER$,.H&.&4W/2*/XAJ:O7T4:VIG<(!.)4#<(YR /MIX(&
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M7_P$W]*@92Q'0^2:W#*!QAGE9"$U<_7U[6JEC<(J^SYDM>4>#W/;+^]2-[2
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M03-&$Q(CCF-PS\6'F#:< ;H2=S1ZVM DQ@7[!02?MX1_!6/P<+\$%V_>@C>
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M'5=J5ZJCMT:[/$'9!UF1B@- ?;.HE[17I"R_M<YG5Q.,9Y;";[&+0D?@&^E
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M($R OE]SKG:&2=!OYO0W4$L#!!0    ( /2!5EAD.J)K0P(  (H&   8
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MI Y5--:#K].+G$HRY&+41^)/]:55N0IW\=2);%2 X"?RMG49U%XB$K2)(2?
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M0+ ZW-;S;TR'/*Q'J ?M 3[MV)HZL(E$&,*>J<UF_P<[17KM25B!SF;^#0(
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M=D?M\S%F@_;_L$,23P-([8II;J$5("FM+0U3K:BG%*@;1V8=L_@QVN.M!]7
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MHGN.5O"QB\KO2NCT;/@BX8)PRL60R-;ZD.N"'AT6]NRXD52DOG=SL";HAP&
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M'N273=B-)P6Z+IXV& (TS3!^PO7NRJ$0#$)VBH)"]*:$DVVP)1F;)G=&00_
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M7%E: 5ZL:>>B=@YT7REECXI+T&_QY1]02P,$%     @ ](%66+.4\61U!0
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MM)=4M'T(MHXWXH4-N%_'GR7^T)#C#7B_M#9L']A!]Q=I]@]02P,$%     @
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MJFV)WWG=+HFWN9X7QK.3$%QJ/&) U%99US0F9S71"KJL.] $>_ ;IS)=X4'
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ME_QS:=!G-O0 [B]JE!'^#UH@?KG^_'\!4$L#!!0    ( /2!5E@KPJ!\KP0
M &4,   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;-5766_C-A!^SZ\@
MO.@B 51;EZ\<!I)LBFZ!+8S-MGTH^D!+(XL-12HD9<?_OC.4XFASN%@4+5#
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M9>V1]4<EM\R5P P5*G.::05LHQT,V1?<+K7,P=@7:@3%I=4,E!-.0DZJ!C+
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M$!M8M 1=:N)-42NM7*1*Y-4BU7'J9,#"5"^5*&*MLE@5CC#3%&3@)&2-IT!
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M>XNW&OO\Q>LZ-Y42'^2=<F=''A+I^5$>=[\,N[,'=J>9^,/4?NG$J[I0Q;Z
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M/SV"CK2ZN=)'S_[YC\79R8\3V#X*V#Z:@O[LN6I-F]7K[!W!KJPBN1Y#\BO
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M\D_'Y,2*C 0:^(M,9K]&AFD!"XP;7;(0I\RBS2 =U::F4Z[8E'0M_;TU -_
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MH;A-*IRN!JUL8G2&#;U@Q'U#SS6$?/0W6IO$,1AQ8B(9S8 /C;OQ-S2Y(_6
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M7-I<[NC@"UOM\=Z2R72*8YHD@V]ER7,DMEIRVVH(2<F?W,2$7L49?E:3<R0
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M%O2JHW8&M)\K9?<3EZ#[GS#[ 5!+ P04    " #T@5985SJ%\^ "   \!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R5E6UKVS 0Q]_G4P@/Q@9:
M_9RG)8&F75E?%$K3;2_&7BCV)1:U)5>2D_;;[R0[7@II8! 2/=S][G^2[C+;
M2_6D"P!#7JI2Z+E7&%-/?5]G!51,7\@:!.YLI*J8P:G:^KI6P'+G5)5^% 1#
MOV)<>(N96[M7BYEL3,D%W"NBFZIBZG4)I=S/O= [+#SP;6'L@K^8U6P+*S _
MZGN%,[^GY+P"H;D41,%F[EV&TV5B[9W!3PY[?30F-I.UE$]V<IO/O< *@A(R
M8PD,?W9P!65I02CCN6-Z?4CK>#P^T&]<[IC+FFFXDN4OGIMB[HT]DL.&-:5Y
MD/OOT.636EXF2^V^R;ZU'28>R1IM9-4YHX**B_:7O73G<.0P#MYQB#J'R.EN
M SF5U\RPQ4S)/5'6&FEVX%)UWBB."WLI*Z-PEZ.?65S)JL+#61F9/9%/CVQ=
M@OX\\PVBK8&?=9AEBXG>P801N9/"%)I\$SGD;P$^:NJ%10=AR^@L\1JR"Q*'
ME$1!%)_AQ7VBL>/%[_"^/3?<O)+?EVMM%+Z%/Z>2;!'):82MCZFN609S#PM
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M9QMJH]+>7+8!EQ0PDJ->&+T&.?1@LZT>;ZO'=]5[%))R]?EH)H7 *FN!26E
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M'D'5L":BHU'I6$%  J'MNR@<41XM#748%$V\!E#,./"0%6D&$@-&=A V'H9
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MN#9@Z[+D9G4A"KT\ZT2=S1\W<KYP]$=_<EKQN;@5[KZZ-OC6;[WDLA3*2JW
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M2=UK../&K%#&2VYR6B'02YPP'+"D&XY9<(/)<9,M/,1</."YI\)3C/-^&V7
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ML2AUQC@\2*+*/*?R\PPRL9MXH??2\8&M-]IT^/&XH&MX!/VQ>)#8\AN4E.7
M%1.<2%A-O&EX,P][QL#.^(W!3AU\$T-E*<23:=RF$R\P'D$&B380%/^V,(<L
M,TCHQZ<:U&O6-(:'WR_H/UCR2&9)%<Q%]CM+]6;B77DDA14M,_U!['Z$FM#
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M.\+]*ZLRK&IH4=A*9BDTUD7V<X.E*T@S <=7 J_QNF$6:(KA^&]02P,$%
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M:/4\2_&#^^_4RW%+.B:GZ12J")>J")N%R9+KK9!\1DKQ(/B>T#C]*)<(\)(
M!=1K+G8S: \] ^%-W_069LMCTRU5#C:KG#ORM+?Z6U4R;:'5\RR5#'XO)8-;
M53)MH=5I*I4,-BN9(ZO?##HP5'^KW\^ZE?.@$+B?'I,)E+[3[%"EN%L<Q<W2
M ZB=^W/[:I$=J)4PV?G>'>$^C00*P%.0UL5(35^>'9EE%Y+%Z:G3FDG)PO3G
M!H@+7 ]0SSW&Y,N%=E <7$[_!U!+ P04    " #T@598&%S><$(&   H+0
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M_*9N=#N_!*]?_09>@2@%7]9\*]0X,1E*%5'NUW!Q\/YB[SWJ\/Z2+<X AF\
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M>D*)#C,C;*QJ?-O-E<4F]LL*QRQH%X#?%TK9[<9=T WN_!=02P,$%     @
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MA#E!_S[),O6\8RK8?$(Y^@]02P,$%     @ ](%66*.3(N_8 @  = <  !D
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M*%W5/;Z>&%E4?74A#7;I:ICAM0C*;L#UI91F.[&MNKUHX]]02P,$%     @
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MAK@AP[#B%Q"M#^#]I3&TG_BN[-_4_!=02P,$%     @ ](%66(TB@:-W P
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MYOBX Z$-<'W-N7H:Z.=#]UQ,?@)02P,$%     @ ](%66$6(*S?L!   SR$
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MQ81\(%=1Q/0AC<E=6E:8OO$V $59+-]ADZ?'@+Q]\XZ\(2PEGQ8\ES2-Y,5
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M+O#W'6:,16F'\"L:C178I4<,ND)K<]4X1==N%:?HA7$?U+X'YW6FWQHD5+R
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MU^WC59)5EZLF6I2V4<R%QK9CAQE^&( T!KB_$$+O)^: YE,C_@-02P,$%
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MN"0X)$PUD._GE(K]@W)0WA^/_P=02P,$%     @ ](%66&G:#.3[!   ^20
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M:&5E=#4Q+GAM;*V66V_:,!2 _\I1-DV=5,@- NT "7K9*FU35=3M8=J#FQS
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M"W7+-Y^Q]3,T?"DOI/V%39OK.9#64O&R!6L%)67-ESRV==@!^-$K@* %!/N
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M2N]TI&LEFD[;!(I7MEDMN-*MSPYS_3BA, EZ?<FYV@9F@^ZY2_X 4$L#!!0
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M    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*V747.C-A#'OXJ&WG3N9NJ
M!#8XM9G)V=-I9JYM)LFUSPK(MB: J"3;23]]5T"P#8++0UYL!+O+;U=H_]+B
M*.2SVC&FT4N>%6KI[+0NKUU7)3N64W4E2E; DXV0.=4PE%M7E9+1M'+*,Y=X
MWLS-*2^<>%'=NY/Q0NQUQ@MV)Y':YSF5KU]9)HY+!SMO-^[Y=J?-#3=>E'3+
M'IC^7MY)&+EME)3GK%!<%$BRS=*YP=<K'!J'RN)OSH[J[!J95)Z$>#:#VW3I
M>(:(92S1)@2%OP-;L2PSD8#CWR:HT[[3.)Y?OT7_K4H>DGFBBJU$]@]/]6[I
M1 Y*V8;N,WTOCK^S)J&IB9>(3%6_Z-C8>@Y*]DJ+O'$&@IP7]3]]:0IQYH"#
M 0?2.)#W.OB-@U\E6I-5::VIIO%"BB.2QAJBF8NJ-I4W9,,+,XT/6L)3#GXZ
MOBT2D3/T2%^80A.T$GDI"E9HA<0&K=F&2<E2\QC=*,7@-BU2](W3)YYQS<'G
M\YIIRC/U!;R_/ZS1YT]?T"?$"_2X$WL%UFKA:@ UKW.3!NIK#44&H-8LN4(^
M_@41C_@6]]7[W<FENPOE:6M$VAJ1*IX_&*\I@X8RT*H,U[:DZBB!/8I9C]>J
MI E;.K#@%),'YL0__X1GWJ^V%#\HV$7"?INP/Q8]_A/:!S0*234OMB@32J&$
M2OD*7>-(I7U&ZXAA%='TCD/L8S^ \A_.L^I;D<";GZPN<(,6-QC%O8<"4)GL
MJF\S90?H325T&EW-5P(3Q_6/^>M73,_(YCX)._A]HX#@R$X_;>FGH_0W22+W
M\'%EIT5EXYOV7DTB$G7X+$9AA.U\LY9O-LKWH$7R/#&M,D70*T _%#4=V 8Y
MZ[]_.@LZD'TC/ MG=LBPA0Q'(?\Z?:T,2-MBOMHHPQZ [_L=R+Y-X 5VQJAE
MC,89]8Y)&T_4+TCD=7@L-F1@8N<MSWR49T5+KFG&_X.)E0-+R(8[MTPRCKHK
MO6^%O9#,[<C8.\F5-PK]* #9Z'2W(UM5QNM!A#B<SCJH%K,@\(;*B\^D%;]?
M-\Z6MU4\FE@?I!X?%>TR\Y-@XE%YBJO=H-E![&$M5O-C39GTZCXA9V5O4K%9
MS<*!R3E)'![7N#O)2LI3Q%Y,1V/UQD8,+=$FV 5$..V26HR",ZM+TI.ZX7%Y
MNRT.3&FS&NT?>5^4)@1WFZ[5:C[0T?!)N_"X>%F6XP]T#/<U:C+%W79GL\*>
M/Z 2^*1E>%S,OC'8RQQHMJ?U(2*#8PPM$F8E[0O5),0DZ+4/BUU YM'0Q)\T
M#8^+FMF&O;?3A;V-5:^D8R8UH7MVCC"'N#^HW/)"@:9NP,>["B%'69^+ZH$6
M976T>!(:#BK5Y0[.DDP: WB^$4*_#<QII3V=QO\#4$L#!!0    ( /2!5EA!
M([F>=00  )<:   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;+59VV[C
M-A#]%4(MBEU@&XGT-:EM('&Z:("Z#3;=]J'H R.-;6(ETB7I2X!^?$G)D:Q$
M9F*#RD,LR9PS<X8SXP-QM!7RFUH":+3+4J[&P5+KU548JG@)&5478@7<?#,7
M,J/:W,I%J%82:)(;96E(HJ@?9I3Q8#+*G]W+R4BL=<HXW$NDUEE&Y=,-I&([
M#G#P_. +6RRU?1!.1BNZ@ ?07U?WTMR%)4K",N"*"8XDS,?!-;Z:DKXUR%?\
MR6"K#JZ1I?(HQ#=[<Y>,@\A&!"G$VD)0\[&!*:2I13)Q_+L'#4J?UO#P^AG]
M<T[>D'FD"J8B_8LE>CD.A@%*8$[7J?XBMK_ GE#/XL4B5?E_M"W6]@<!BM=*
MBVQO;"+(&"\^Z6Z?B ,#W#]B0/8&Y*5!]XA!9V_0R8D6D>6T;JFFDY$46R3M
M:H-F+_+<Y-:&#>-V&Q^T--\R8Z<G=SP6&: _Z X4^A%=)PFSZ:4INN-%D=AD
M?[@%35FJ/IHE7Q]NT8?O/XY";=Q;D##>N[HI7)$CKC!!,\'U4J&?>0))'2 T
M<9?!D^?@;X@3\1;B"]3!GQ")2*<AH.G[S8DCG$Z9RTZ.UWDSEVAJB#*^ !X_
MH;]_->O0G89,_=.4M0*TVPQJV_A*K6@,X\#TJ0*Y@6#RPW>X'_W4Q-@36(U_
MM^3?=:%/IDMJ*"/&T8:FZZ)R:&H&!>4Q-#$OX 8YG)TWFPD9=B+[-PHWAZP:
M%D;=^L):Q+TRXIXSXM_,G#0345*[62@52J&82OED*G]+9:*:@BX0>P>QX,YP
MT!2UT_>9>]$OF?6=S&94@V2FC1DW%Z THCQ!9OC35#/3ZF9KUF97I&EKCK2I
MV$?@,&>ZD7+_%>675)W!G$EU4%(=.*G>PARDA"1OO&NEH)G$X!4)TB--V^;T
M=B:78<EEZ.3R&1)3C6E3_$[#4\>$)[ :Q\N2XV4;8_+2)W]/8#7^.*I^<R/O
M8V</>5B_E[VF\G7[/I?;@9[ 3FYV6V/3C4R_@Q-^/4M)MY&4T^FYI$A%BCA)
M/6@S3AL9..U.K4I?:'66E7S!K>@7[%7 ^$*KYZ"2,-BM8<YJS=?RI-,H8]R^
MS^56B1WL5CLSQEFVSM!_R/$SX\8X>3?;T$"X$D&XWTI%>Y(S^QRT(8YPI8ZP
M6QXU5+25@OK(G/Z$8+=BLE#OQHR)I#%%;J=#] 14-G7+U&UY;CHJ@87="JMJ
M@N-#W:O4\H56YUN)+=R*VL)>Y98OM/I;@DIO$;?>^MTQT-]9[V]XP(Z"=YN>
M2[X29,0MR&9T]_;4=V.<NMV^T.J,*[5&2!LE3[QJ.5]H]1Q46HXX=5)+4_\-
MI[CKZ((V=!VI=!UQZ[JJ"XZ.?3?"R?O?AM8CE=8CO59ZP*OZ\X56ST&E_HC[
M'9B/L>_V0")'P7N5?>'!*_X,Y"(_^3"<Q)KKXH5Y^;0\7;G.SQ1>/+_!5]/B
MC*2"*8YL9E0N&%<HA;F!C"X&9O=D<0I2W&BQR@\2'H76(LLOET#-;XI=8+Z?
M"Z&?;ZR#\BQJ\C]02P,$%     @ ](%66!-F=S'I @  '@@  !D   !X;"]W
M;W)K<VAE971S+W-H965T-38N>&ULK59M;],P$/XK5IC0)L'RTC8=HXW4%Q#[
M,*E:&7Q ?'"3:V,ML8/MM!N_GK.3AJY-.P1\:?QR]_AY?.>[#C9"/J@40)/'
M/.-JZ*1:%]>NJ^(4<JHN10$<=Y9"YE3C5*Y<54B@B77*,S?PO-#-*>-.-+!K
M,QD-1*DSQF$FB2KSG,JG,61B,W1\9[MPQU:I-@MN-"CH"N:@[XN9Q)G;H"0L
M!ZZ8X$3"<NB,_.M)W]A;@R\,-FIG3(R2A1 /9G*3#!W/$((,8FT0*'[6,($L
M,T!(XT>-Z31'&L?=\1;]H]6.6A94P41D7UFBTZ%SY9 $EK3,])W8?():3\_@
MQ2)3]I=L:EO/(7&IM,AK9V20,UY]Z6-]#SL.?GC$(:@=@GV'[A&'3NW0L4(K
M9E;6E&H:#:38$&FL$<T,[-U8;U3#N(GB7$O<9>BGHQL>BQS(9_H(BKPE<\R2
MI,R B"6YYQ)BL>+L)R3&@(R!PY)I13!Y<#<&J3%-[-9,*&;"HLCY%' U4Q>(
M=C^?DO.S"W)&C%DJ2D5YH@:N1N+F>#>N28XKDL$1DGY ;@77J2(?> +)<P 7
M%3>R@ZWL<7 2<0KQ)>GX;TC@!9T60I,_=P].T.DT4>A8O,Z+42!3IN),J%("
M^39:*"TQT;^W75F%V&U'-(__6A4TAJ&#KUN!7(,3O7[EA][[-KG_">R9^&XC
MOGL*/1K#BG'.^ K?8T8QK=K45A!]"V$JTSKRNUXX<->[*@Z-^B8\ZQ9RO89<
M[R2Y49+4B6V27F. BB;5-7T ;E*[D PWGX#*-NK5 ;U=ZE?!'O.3)/[R_L-&
M8OCO$G4*6(ZD!*Z/"@T/A?8"?T_IH5%XU6V/4;\1T#\I (O""]G3/TB,CN^]
MVV-V:/0LQ2IJ[DZIS4&N; =2)!8EUU7Y:5:;)C>RM7UO?8S-K^I5OV&JSGE+
M)3X(13)8(J1WV<?+DE4WJB9:%+:@+X3&]F"'*39PD,8 ]Y="Z.W$'-#\)8A^
M 5!+ P04    " #T@598UOQY.I("  "H!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6RM55MOTS 8_2M6F- F07/I!3322+T,L8=*U:;! ^+!3;XT
MUAP[V%_;[=_C2QJZJ:T \=+8SG>.S_EJGZ0[J1YU!8#DJ>9"CX,*L;D.0YU7
M4%/=DPT(\Z:4JJ9HIFH=ZD8!+1RHYF$21:.PIDP$6>K6EBI+Y08Y$[!41&_J
MFJKG*7"Y&P=QL%^X8^L*[4*8I0U=PSW@0[-49A9V+ 6K06@F!5%0CH-)?#T;
MVGI7\)7!3A^,B76RDO+13FZ+<1!90< A1\M S6,+,^#<$AD9/UO.H-O2 @_'
M>_;/SKOQLJ(:9I)_8P56X^!C0 HHZ8;CG=Q]@=:/$YA+KMTOV;6U44#RC499
MMV"CH&;"/^E3VX<#0#PZ 4A:0/(:,#@!Z+> OC/JE3E;<XHT2Y7<$66K#9L=
MN-XXM''#A/T7[U&9M\S@,+NI&RZ? <@4!)0,R9)3H<E[,BD*9AM-.;D5_K38
MME_. 2GC^LJ4/-S/R>7%%;D@3) %X]P4Z#1$(\N2AWDK8>HE)"<DQ E92(&5
M)C>B@.(E06C\=*:2O:EI<I9Q#GF/].-W)(F2_A%!LS^')V?D]+L>]QU?_^]Z
M_'VRTJC,.?YQK&>><G"<TM[M:]W0',:!N;P:U!:"[.V;>!1].N;W/Y&]<#_H
MW _.L6=+4#D(-)% 9$G,!DB?2"YKDT/:GRG@;,U6' A*>P-!'>N'WR3VY]AF
MTS:+TW![Z/*LCG]T.>Q<#L^Z7%#,*R;6QIE Q58;/'49/,_HP$?4&[YR<JQF
MT-5X@>'!I:]!K5T6:K/_1J"_*MUJ%[<3ES*OUJ<FAGUJ_J;Q&;Z@:LW,2>50
M&LJH]\'H4CX7_01EXZ)E)=$$E1M6YE,"RA:8]Z64N)_8#;J/4_8+4$L#!!0
M   ( /2!5ECZP]UHQ ,  ),0   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;-58VV[C-A#]%4(%BA;H1E??4MM ;HM=8'=CQ-CVH>@#+8TM(A2IDI2=
M_'U)2I8M6Q::0@_9%XND.(<SAW,HCJ<[+IYE"J#02T:9G#FI4OFUZ\HXA0S+
M*YX#TV_67&18Z:[8N#(7@!-KE%$W\+RAFV'"G/G4CBW$?,H+10F#A4"RR#(L
M7F^!\MW,\9W]P!/9I,H,N/-ICC>P!/4]7PC=<VN4A&3 ).$,"5C/G!O_^LX/
MC8&=\0>!G3QJ(Q/*BO-GT_F<S!S/> 048F4@L'YLX0XH-4C:CW\J4*=>TQ@>
MM_?H'VWP.I@5EG#'Z9\D4>G,&3LH@34NJ'KBNT]0!30P>#&GTOZB7377<U!<
M2,6SREA[D!%6/O%+1<21@3^\8!!4!L&I073!(*P,+'-NZ9D-ZQXK/)\*OD/"
MS-9HIF&YL=8Z&L+,-BZ5T&^)ME/S;SI3OG IT0($6J98 +I12I!5H?"* E(<
MW?$LTX0O%8^?4TX3$!)]0,MRWQ%?HWM""[,9: EQ(8@B(!&\Q+1(($%KP3,#
MD6M NW%[ _WN?R[^RSTH3*C\5;LAC96<NDIS82)RXRKNVS+NX$+<?H"^<J92
MB1Z8=K,)X&H2:R:#/9.W02?B/<17*/1_0X$7A"T.W?UW\Z##G;#>V-#BA1?P
M;I@B2<O&/.PWYN/IQCRNT0,6C+#-\8;\]44#H\\*,OEW&\VE%U&[%^80NI8Y
MCF'FZ%-&@MB",__Y)W_H_=Y&44]@#<*BFK"H"WW^6"BI,$MT_%56F53-N0+-
M)*;T%=5TR@.=.] <-9-=I8#B9L*;H:1*>J:3GIJDSS7'=J$V6DM?!]97<Q1O
MYR,_C**!/W6WQXR=SXN"T<#S)O6\!AF#FHQ!)QE6;^@Q-P%(H\-%(>)4'Y<-
M0;8YWHG[UGSH":Q!P;"F8/@N!#3LD[">P!J$C6K"1C^0@$9GPAB. V\\G)P(
MZ'Q>Y(7AP)S!;0(:UV2,.\GXQMF'+4CC[Y-^"!*;9BFK[XRHUD]6)^1;4Z$G
ML$;TDSKZR;O0SJ1/PGH":Q#F>X=[F/<#J:=R]E@6H>]YX]&)>EKF!>$P#"]\
M?ORC:ZG?2<=#EE/^"E!)IO[\+"AFK0YWPKTU%?I":P8?'((/WH5\*C?Z(JTG
MM"9IA_NNWWD[?&\""L\%%$T&I_(YGS7PH_&)>-RC\BX#L;%5K]0^%DR5]4D]
M6E?6-[:>/!F_-16W+1L/,&6Y_A6+#=$W/0IK#>E=C;1+HJR RX[BN2TB5USI
MDM0V4\"Z'#,3]/LUUT17';- _3_$_%]02P,$%     @ ](%66/9;SUHV P
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MU-U[/AM^(+EZ!5!+ 0(4 Q0    ( /2!5E@'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ](%66#-O
MB<#N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ ](%66)E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #T@598;J(JA/X(  !?
M-P  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ ](%66'=KQQ_H!0  7A@  !@              ("!01$
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /2!5EANTA7H
MBP(  "\'   8              " @5\7  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #T@598]/-&>(@$  !W$   &
M@($@&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ](%6
M6(Q=-F'H!0  ["<  !@              ("!WAX  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( /2!5EA5R+U8#P8  %\9   8
M      " @?PD  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #T@598J"];14P"  "E!0  &               @(%!*P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ](%66&0ZHFM# @  B@8  !@
M             ("!PRT  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4
M Q0    ( /2!5EB].0"H4P8  *8.   8              " @3PP  !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #T@598;K9:<R$8  !Z
M2   &0              @('%-@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+ 0(4 Q0    ( /2!5E@GIAB[8@<  ($2   9              " @1U/
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ](%66)D9
MGA_O @  @@8  !D              ("!ME8  'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"% ,4    " #T@598@6J_7Z<"  #1!0  &0
M    @('<60  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M /2!5EBSE/%D=04  "X-   9              " @;I<  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ ](%66*TDVID4$P  Q3X  !D
M             ("!9F(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #T@598*\*@?*\$  !E#   &0              @(&Q=0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /2!5E@$1&"Y8PL
M !\>   9              " @9=Z  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ ](%66)8.9\"3"0  B!@  !D              ("!
M,88  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #T@598
M6<$VF,0"   L!@  &0              @('[CP  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /2!5EB=>8&A*0,  /4&   9
M      " @?:2  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ ](%66-K\&KYV&0  85,  !D              ("!5I8  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #T@598O]N(M;D"  !R!@
M&0              @($#L   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( /2!5EC+M9R!Z ,  + )   9              " @?.R  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ](%66!@>L:3'
M @  &@8  !D              ("!$K<  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #T@598<X$3^;,"  #.!0  &0
M@($0N@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /2!
M5EC[+[ZP70,  #,(   9              " @?J\  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ ](%66%<ZA?/@ @  / 8  !D
M         ("!CL   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #T@598DOL-!D8&   "$@  &0              @(&EPP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /2!5ECRFD.&KP4  #\.
M   9              " @2+*  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ ](%66!_$"9H] P  !P<  !D              ("!"-
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #T@598203&
M3<@#   8#P  &0              @(%\TP  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( /2!5EB_;\ ]J@(  !P(   9
M  " @7O7  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M](%66(4UAY%%!0  Q!P  !D              ("!7-H  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #T@598&%S><$(&   H+0  &0
M            @('8WP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( /2!5ECAF7G IP(  &<(   9              " @5'F  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ](%66 L"<:)< P
MJ0X  !D              ("!+^D  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #T@598RM_HYV<"  #$!0  &0              @('"
M[   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( /2!5E@^
M&K5GM0(  #,'   9              " @6#O  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ ](%66)L,GIP\!   F18  !D
M     ("!3/(  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2!5EA%B"LW[ 0  ,\A   9              "
M@3D' 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ](%6
M6 N"7: @ P  X L  !D              ("!7 P! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #T@598=+'4F%X&   C(0  &0
M        @(&S#P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( /2!5EB#*!#9% ,  '8(   9              " @4@6 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ](%66!76N2CZ @  C <
M !D              ("!DQD! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #T@598'J0:(\D$  !+%@  &0              @('$' $
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( /2!5EAIV@SD
M^P0  /DD   9              " @<0A 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ ](%66-@<G&LV P  W D  !D
M ("!]B8! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #T
M@598NX8*ZZH"  #Z!@  &0              @(%C*@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /2!5EB(WQI\. ,  %L*   9
M          " @40M 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#
M%     @ ](%66')4-X8-!   J0X  !D              ("!LS ! 'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #T@59802.YGG4$  "7
M&@  &0              @('W- $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;%!+ 0(4 Q0    ( /2!5E@39G<QZ0(  !X(   9              " @:,Y
M 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ](%66-;\
M>3J2 @  J 8  !D              ("!PSP! 'AL+W=O<FMS:&5E=',O<VAE
M970U-RYX;6Q02P$"% ,4    " #T@598^L/=:,0#  "3$   &0
M    @(&,/P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M /2!5ECV6\]:-@,  .X3   -              "  8=# 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ ](%66)>*NQS     $P(   L              ( !
MZ$8! %]R96QS+RYR96QS4$L! A0#%     @ ](%66"LVCKFH!   P28   \
M             ( !T4<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /2!
M5E@3)^RZ[P$  *4B   :              "  :9, 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /2!5EAB(^<8V $  $@B   3
M          "  <U. 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !" $(
*!1(  -90 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>120</ContextCount>
  <ElementCount>303</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails</Role>
      <ShortName>Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails</Role>
      <ShortName>Fair Value - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Significant Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails</Role>
      <ShortName>Significant Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD</Role>
      <ShortName>Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Stock-based Compensation - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Income Taxes - Components of Income (Loss) Before Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Components of Income (Loss) Before Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="atha-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="atha-20231231.htm">atha-20231231.htm</File>
    <File>atha-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img105269759_0.jpg</File>
    <File>img105269759_1.jpg</File>
    <File>img105269759_10.jpg</File>
    <File>img105269759_11.jpg</File>
    <File>img105269759_12.jpg</File>
    <File>img105269759_13.jpg</File>
    <File>img105269759_14.jpg</File>
    <File>img105269759_15.jpg</File>
    <File>img105269759_16.jpg</File>
    <File>img105269759_17.jpg</File>
    <File>img105269759_18.jpg</File>
    <File>img105269759_19.jpg</File>
    <File>img105269759_2.jpg</File>
    <File>img105269759_20.jpg</File>
    <File>img105269759_21.jpg</File>
    <File>img105269759_22.jpg</File>
    <File>img105269759_3.jpg</File>
    <File>img105269759_4.jpg</File>
    <File>img105269759_5.jpg</File>
    <File>img105269759_6.jpg</File>
    <File>img105269759_7.jpg</File>
    <File>img105269759_8.jpg</File>
    <File>img105269759_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="451">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "atha-20231231.htm": {
   "nsprefix": "atha",
   "nsuri": "http://athira.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "atha-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "atha-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 260,
   "keyCustom": 43,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 27,
   "hidden": {
    "total": 5,
    "http://fasb.org/us-gaap/2023": 2,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 120,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 551,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 451,
    "http://xbrl.sec.gov/dei/2023": 41,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_b55a09af-5dc9-4df7-b9a8-4abd66541c09",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b55a09af-5dc9-4df7-b9a8-4abd66541c09",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue",
     "longName": "995475 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "995485 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1",
     "longName": "995495 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements",
     "longName": "995505 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995515 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995525 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995535 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995545 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans",
     "longName": "995555 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "longName": "995565 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "995575 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "995585 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueTables",
     "longName": "995595 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "995605 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesTables",
     "longName": "995615 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995625 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "995635 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995645 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995655 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "995665 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
     "longName": "995675 - Disclosure - Description of Business - Additional Information (Details)",
     "shortName": "Description of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "995685 - Disclosure - Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995695 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails",
     "longName": "995705 - Disclosure - Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details)",
     "shortName": "Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
     "longName": "995715 - Disclosure - Fair Value - Additional Information (Details)",
     "shortName": "Fair Value - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_d98123fe-9e7e-4c2e-8b91-5f07a93c8aaa",
      "name": "atha:LongTermInvestmentsMaturityTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d98123fe-9e7e-4c2e-8b91-5f07a93c8aaa",
      "name": "atha:LongTermInvestmentsMaturityTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "longName": "995725 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995735 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "longName": "995745 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "atha:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "atha:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Significant Agreements - Additional Information (Details)",
     "shortName": "Significant Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_69c9026a-c50a-44e3-a00c-4b6fe771b199",
      "name": "atha:MilestonePaymentsAmountPayableUponMarketingApproval",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_69c9026a-c50a-44e3-a00c-4b6fe771b199",
      "name": "atha:MilestonePaymentsAmountPayableUponMarketingApproval",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995765 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_1316502c-52a2-42d4-b1b3-95c55a6319ad",
      "name": "us-gaap:LitigationSettlementExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1316502c-52a2-42d4-b1b3-95c55a6319ad",
      "name": "us-gaap:LitigationSettlementExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails",
     "longName": "995775 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)",
     "shortName": "Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD",
     "longName": "995785 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)",
     "shortName": "Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails",
     "longName": "995795 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)",
     "shortName": "Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1961c4e3-fcb5-421a-969d-a6cea22d51f1",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a3cbf114-5760-4876-a9ac-f26ffd0959d6",
      "name": "atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails",
     "longName": "995815 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4e72d8ea-ec67-44e7-a900-766be31764bf",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995825 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails",
     "longName": "995835 - Disclosure - Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails",
     "longName": "995845 - Disclosure - Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details)",
     "shortName": "Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_224dd772-6aaa-446a-ae9e-b8d743a062d3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_224dd772-6aaa-446a-ae9e-b8d743a062d3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails",
     "longName": "995855 - Disclosure - Stock-based Compensation - Summary of Option Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_224dd772-6aaa-446a-ae9e-b8d743a062d3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails",
     "longName": "995865 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails",
     "longName": "995875 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_a65c107a-c260-47d4-aa36-25401168c1ef",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a65c107a-c260-47d4-aa36-25401168c1ef",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails",
     "longName": "995885 - Disclosure - Income Taxes - Components of Income (Loss) Before Income Tax (Details)",
     "shortName": "Income Taxes - Components of Income (Loss) Before Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "995905 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "995915 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fcc5fd18-8424-4126-b998-8a3ad1ffc264",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails",
     "longName": "995935 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_224dd772-6aaa-446a-ae9e-b8d743a062d3",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b55a09af-5dc9-4df7-b9a8-4abd66541c09",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995955 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1c93451-1f41-49f8-b231-c5cf477afc39",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-02",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r174",
      "r175",
      "r176",
      "r223",
      "r224",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r280",
      "r365",
      "r366",
      "r367",
      "r397",
      "r398",
      "r406",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r803"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r680"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and accretion of discounts on available-for-sale securities, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued Liabilities",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "atha_AccruedProfessionalServicesAndOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AccruedProfessionalServicesAndOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued professional services and other, current.",
        "label": "Accrued Professional Services And Other Current",
        "terseLabel": "Professional services and other"
       }
      }
     },
     "auth_ref": []
    },
    "atha_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses, current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r141",
      "r533"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r71",
      "r147",
      "r529",
      "r555",
      "r559"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11",
      "r23",
      "r423",
      "r426",
      "r485",
      "r550",
      "r551",
      "r791",
      "r792",
      "r793",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "atha_AdditionalGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AdditionalGrantIncome",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional grant income",
        "label": "Additional Grant Income",
        "documentation": "Additional grant income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r572",
      "r800",
      "r801",
      "r802",
      "r855",
      "r874"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r174",
      "r175",
      "r176",
      "r177",
      "r187",
      "r223",
      "r224",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r280",
      "r365",
      "r366",
      "r367",
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r519",
      "r520",
      "r521",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r328"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "atha_AggregateGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AggregateGrantIncome",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate grant income.",
        "label": "Aggregate Grant Income",
        "terseLabel": "Aggregate grant income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r716",
      "r726",
      "r752"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r755"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r720",
      "r730",
      "r747",
      "r756",
      "r760",
      "r768"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r372"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual minimum royalty payments after first commercial sale.",
        "label": "Annual Minimum Royalty Payments After First Commercial Sale",
        "terseLabel": "Annual minimum royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r143",
      "r167",
      "r202",
      "r213",
      "r217",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r411",
      "r415",
      "r451",
      "r527",
      "r598",
      "r680",
      "r693",
      "r816",
      "r817",
      "r860"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r148",
      "r167",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r411",
      "r415",
      "r451",
      "r680",
      "r816",
      "r817",
      "r860"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "atha_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Common Stock Offering"
       }
      }
     },
     "auth_ref": []
    },
    "atha_AthiraPharmaIncVDrKawasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "AthiraPharmaIncVDrKawasMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Athira Pharma Inc V Dr. Kawas.",
        "label": "Athira Pharma Inc V Dr. Kawas [Member]",
        "terseLabel": "Athira Pharma Inc V Dr. Kawas"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r712"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r712"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r712"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Investments, Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Investments, Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Investments, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r275",
      "r526"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r275"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Investments, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r226",
      "r275"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and significant accounting policies.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Line Items]",
        "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_BasisOfPresentationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and significant accounting policies.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Table]",
        "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_BothellWashingtonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "BothellWashingtonMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bothell, Washington.",
        "label": "Bothell Washington [Member]",
        "terseLabel": "Bothell, Washington"
       }
      }
     },
     "auth_ref": []
    },
    "atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Cash equivalents, Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      },
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, Amortized Cost",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r138",
      "r657"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents, Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r105"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r79",
      "r164"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r79"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r173",
      "r223",
      "r224",
      "r258",
      "r259",
      "r260",
      "r266",
      "r267",
      "r280",
      "r395",
      "r406",
      "r407",
      "r417",
      "r418",
      "r419",
      "r431",
      "r432",
      "r442",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r465",
      "r468",
      "r469",
      "r470",
      "r481",
      "r519",
      "r520",
      "r548",
      "r549"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r223",
      "r224",
      "r258",
      "r259",
      "r260",
      "r266",
      "r267",
      "r268",
      "r280",
      "r395",
      "r406",
      "r407",
      "r408",
      "r417",
      "r418",
      "r419",
      "r420",
      "r431",
      "r432",
      "r433",
      "r436",
      "r442",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r465",
      "r468",
      "r469",
      "r470",
      "r481",
      "r519",
      "r520",
      "r548",
      "r549",
      "r777"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r174",
      "r186",
      "r263",
      "r399"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r201",
      "r301",
      "r302",
      "r303",
      "r305",
      "r308",
      "r313",
      "r315",
      "r565",
      "r566",
      "r567",
      "r568",
      "r667",
      "r776",
      "r797"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Significant Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r129"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r687",
      "r688",
      "r689",
      "r690"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r282",
      "r283",
      "r643",
      "r812"
     ]
    },
    "atha_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments and contingencies line items."
       }
      }
     },
     "auth_ref": []
    },
    "atha_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Table]",
        "documentation": "Commitments and contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Reserved shares of common stock for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685",
      "r687",
      "r688",
      "r689",
      "r690",
      "r800",
      "r801",
      "r855",
      "r873",
      "r874"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r586"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65",
      "r586",
      "r604",
      "r874",
      "r875"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 38,172,603 and 37,877,387 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r528",
      "r680"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "terseLabel": "Employee Benefit Plans",
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to common stockholders",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r150",
      "r152",
      "r158",
      "r522",
      "r538"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss Attributable to Common Stockholders",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r118"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r107",
      "r389"
     ]
    },
    "atha_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized research and development.",
        "label": "Deferred Tax Assets Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred Tax Assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "atha_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liability.",
        "label": "Deferred Tax Assets Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "atha_DeferredTaxAssetsRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "DeferredTaxAssetsRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets right of use asset.",
        "label": "Deferred Tax Assets Right Of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesInvestments",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments",
        "label": "Deferred Tax Liabilities, Investments",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses and other",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of pretax compensation eligible to defer",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r33"
     ]
    },
    "atha_DescriptionOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "DescriptionOfBusinessLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business.",
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_DescriptionOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "DescriptionOfBusinessTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business.",
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r330",
      "r361",
      "r362",
      "r364",
      "r674"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r712"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r712",
      "r748"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r189",
      "r191",
      "r193",
      "r194",
      "r195",
      "r199",
      "r440",
      "r441",
      "r523",
      "r539",
      "r659"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r191",
      "r193",
      "r194",
      "r195",
      "r199",
      "r440",
      "r441",
      "r523",
      "r539",
      "r659"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r196",
      "r197",
      "r198"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r380",
      "r402"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r854"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Non-deductible expenses and others",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r854"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r854"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r854"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Taxes",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r854"
     ]
    },
    "atha_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "atha_EmployeeBenefitPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "EmployeeBenefitPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee benefit plans",
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining weighted-average period expected to recognize unrecognized compensation cost",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "atha_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address Address Line1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address Address Line2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity incorporation, date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "atha_EntityReincorporationDateOfReincorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "EntityReincorporationDateOfReincorporation",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity reincorporation, date of reincorporation",
        "label": "Entity Reincorporation Date Of Reincorporation",
        "documentation": "Entity reincorporation, date of reincorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r132",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r175",
      "r183",
      "r185",
      "r200",
      "r262",
      "r269",
      "r316",
      "r365",
      "r366",
      "r367",
      "r397",
      "r398",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r439",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r485",
      "r550",
      "r551",
      "r552",
      "r572",
      "r624"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r716",
      "r726",
      "r752"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r713",
      "r723",
      "r749"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "atha_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price $0.16 to 4.22",
        "documentation": "Exercise price one.",
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price three.",
        "label": "Exercise Price Three [Member]",
        "terseLabel": "Exercise Price $20.55 to 29.41"
       }
      }
     },
     "auth_ref": []
    },
    "atha_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price two.",
        "label": "Exercise Price Two [Member]",
        "terseLabel": "Exercise Price $8.93 to 19.94"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r104"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r59"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r445",
      "r490",
      "r491",
      "r492",
      "r665",
      "r666",
      "r670",
      "r671",
      "r672"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r318",
      "r323",
      "r445",
      "r490",
      "r670",
      "r671",
      "r672"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r318",
      "r323",
      "r445",
      "r491",
      "r665",
      "r666",
      "r670",
      "r671",
      "r672"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r490",
      "r491",
      "r492",
      "r665",
      "r666",
      "r670",
      "r671",
      "r672"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring Basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r448"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r299",
      "r313",
      "r429",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r537",
      "r664",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "atha_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-on Public Offering",
        "label": "Follow On Public Offering [Member]",
        "documentation": "Follow-on public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transaction Remeasurement Adjustments",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "atha_FurnitureFixturesAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "FurnitureFixturesAndComputerEquipmentMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Furniture, Fixtures, and Computer Equipment",
        "label": "Furniture Fixtures And Computer Equipment [Member]",
        "documentation": "Furniture, fixtures and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r608"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "atha_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant income.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "atha_GrantIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "GrantIncomePolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant income policy.",
        "label": "Grant Income Policy [Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "auth_ref": []
    },
    "atha_GrantsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "GrantsReceived",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants received.",
        "label": "Grants Received",
        "terseLabel": "Grants received",
        "verboseLabel": "Grant received"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r712"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment losses",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r85"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r401"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r401"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r281",
      "r609"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r609"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r101",
      "r102"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r376",
      "r381",
      "r386",
      "r393",
      "r400",
      "r403",
      "r404",
      "r405",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r378",
      "r379",
      "r386",
      "r387",
      "r392",
      "r394",
      "r564"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "atha_IncreaseDecreaseInAccruedLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "IncreaseDecreaseInAccruedLegalSettlement",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued legal settlement.",
        "label": "Increase (Decrease) In Accrued Legal Settlement",
        "terseLabel": "Accrued legal settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInsuranceSettlementsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance recovery receivable related to legal settlement",
        "label": "Increase (Decrease) in Insurance Settlements Receivable",
        "documentation": "The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r794"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current and long-term assets, net",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "atha_IncreaseDecreaseInUnbilledGrantReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "IncreaseDecreaseInUnbilledGrantReceivables",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Unbilled Grant Receivables",
        "documentation": "Increase (decrease) in unbilled grant receivables.",
        "negatedLabel": "Unbilled grant receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r720",
      "r730",
      "r747",
      "r756",
      "r760",
      "r768"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r772"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r772"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r772"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance recovery related to legal settlement",
        "verboseLabel": "Insurance recovery related to legal settlement",
        "terseLabel": "Insurance recovery in operating expenses",
        "label": "Insurance Recoveries",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Insurance recovery receivable related to legal settlement (Note 7)",
        "terseLabel": "Insurance recovery receivable",
        "label": "Insurance Settlements Receivable, Current",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-term and Long-term Investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r560",
      "r561",
      "r562",
      "r563",
      "r631",
      "r632"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and investments",
        "label": "Investments and Cash",
        "totalLabel": "Investments and Cash, Total",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r871"
     ]
    },
    "atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock unit shares.",
        "terseLabel": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock units, shares",
        "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Unit Shares"
       }
      }
     },
     "auth_ref": []
    },
    "atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock units",
        "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Units",
        "documentation": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "atha_JawandhaVAthiraPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "JawandhaVAthiraPharmaIncMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jawandha V. Athira Pharma Inc.,",
        "label": "Jawandha V Athira Pharma Inc [Member]",
        "documentation": "Jawandha V. Athira Pharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "atha_LaboratoryAndOfficeFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "LaboratoryAndOfficeFacilitiesMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and office facilities.",
        "label": "Laboratory And Office Facilities [Member]",
        "terseLabel": "Laboratory and Office Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "atha_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment",
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvement",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease existence of option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year three.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "verboseLabel": "2022",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment for minimum lease commitments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, additional term of contract",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease initial term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r167",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r412",
      "r415",
      "r416",
      "r451",
      "r585",
      "r660",
      "r693",
      "r816",
      "r860",
      "r861"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r108",
      "r531",
      "r680",
      "r798",
      "r810",
      "r856"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r137",
      "r167",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r412",
      "r415",
      "r416",
      "r451",
      "r680",
      "r816",
      "r860",
      "r861"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "atha_LicensedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "LicensedProductsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensed Products",
        "documentation": "Licensed Products.",
        "label": "Licensed Products [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Legal settlement expense",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Legal settlement",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Investments, Total",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "atha_LongTermInvestmentsMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "LongTermInvestmentsMaturityTerm",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term investments maturity term.",
        "label": "Long Term Investments Maturity Term",
        "terseLabel": "Long-term investments effective maturity date"
       }
      }
     },
     "auth_ref": []
    },
    "atha_LongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "LongTermInvestmentsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued legal settlement",
        "label": "Loss Contingency, Accrual, Current",
        "terseLabel": "Accrued legal settlement (Note 7)",
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_LossContingencyLawsuitFilingDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyLawsuitFilingDate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lawsuit filing date",
        "label": "Loss Contingency, Lawsuit Filing Date",
        "documentation": "States the date the complaint was formally filed in a court of law, in arbitration or mediation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r88"
     ]
    },
    "us-gaap_LossContingencyNameOfDefendant": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNameOfDefendant",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Name of Defendant",
        "terseLabel": "Name of defendant",
        "documentation": "Identifies the named defendant in a lawsuit."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r88"
     ]
    },
    "us-gaap_LossContingencyNameOfPlaintiff": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNameOfPlaintiff",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of plaintiff",
        "label": "Loss Contingency, Name of Plaintiff",
        "documentation": "Identifies the plaintiff in the lawsuit."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r88"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r325",
      "r517",
      "r547",
      "r577",
      "r578",
      "r629",
      "r633",
      "r635",
      "r636",
      "r638",
      "r653",
      "r654",
      "r663",
      "r667",
      "r673",
      "r682",
      "r818",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "atha_MilestonePaymentsAmountPayableUponMarketingApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "MilestonePaymentsAmountPayableUponMarketingApproval",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments amount payable upon marketing approval.",
        "label": "Milestone Payments Amount Payable Upon Marketing Approval",
        "terseLabel": "Milestone payments payable upon marketing approval"
       }
      }
     },
     "auth_ref": []
    },
    "atha_MilestonePaymentsAmountPayableUponTrialInitiation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "MilestonePaymentsAmountPayableUponTrialInitiation",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments amount payable upon trial initiation.",
        "label": "Milestone Payments Amount Payable Upon Trial Initiation",
        "terseLabel": "Milestone payments, amount payable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r325",
      "r517",
      "r547",
      "r577",
      "r578",
      "r629",
      "r633",
      "r635",
      "r636",
      "r638",
      "r653",
      "r654",
      "r663",
      "r667",
      "r673",
      "r682",
      "r818",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Fund",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "atha_NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NationalInstituteOnAgingOfTheNationalInstitutesOfHealthMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National institute on aging of the national institutes of health.",
        "label": "National Institute On Aging Of The National Institutes Of Health [Member]",
        "terseLabel": "National Institute on Aging of the National Institutes of Health"
       }
      }
     },
     "auth_ref": []
    },
    "atha_NationalInstitutesOfHealthGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NationalInstitutesOfHealthGrantMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "National Institutes of Health Grant",
        "label": "National Institutes Of Health Grant [Member]",
        "documentation": "National institutes of health grant member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeLossBeforeIncomeTaxDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r81",
      "r111",
      "r135",
      "r149",
      "r151",
      "r156",
      "r167",
      "r174",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r192",
      "r202",
      "r212",
      "r216",
      "r218",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r441",
      "r451",
      "r536",
      "r606",
      "r622",
      "r623",
      "r661",
      "r691",
      "r816"
     ]
    },
    "atha_NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss and tax credit carryforwards, expiration period.",
        "label": "Net Operating Loss And Tax Credit Carry Forwards Expiration Period",
        "terseLabel": "Net operating loss and tax credit carryforwards, expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "atha_NetSalesExemptFromRoyaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NetSalesExemptFromRoyaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales exempt from royalty payment.",
        "label": "Net Sales Exempt From Royalty Payment",
        "terseLabel": "Net sales exempt from royalty payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r747",
      "r756"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "atha_NonVestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NonVestedRestrictedStockUnitsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Restricted Stock Units [Member]",
        "documentation": "Non-vested restricted stock units member.",
        "terseLabel": "Non-vested Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "atha_NumberOfClasses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NumberOfClasses",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of classes",
        "label": "Number Of Classes",
        "documentation": "Number of classes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "atha_NumberOfSubclasses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "NumberOfSubclasses",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of subclasses",
        "label": "Number Of Subclasses",
        "documentation": "Number of subclasses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r212",
      "r216",
      "r218",
      "r661"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r679"
     ]
    },
    "atha_OperatingLeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "OperatingLeaseExpirationMonthAndYear",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration month and year.",
        "label": "Operating Lease Expiration Month And Year",
        "terseLabel": "Operating lease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Net lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, less current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Non-cash lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r679"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermineTheOperatingLeaseLiabilityD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r679"
     ]
    },
    "atha_OperatingLossCarryForwardsExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "OperatingLossCarryForwardsExpirationPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carry forwards Expiration Period.",
        "label": "Operating Loss Carry forwards Expiration Period",
        "terseLabel": "Operating loss carryforwards, expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r103"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r718",
      "r728",
      "r754"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r721",
      "r731",
      "r757"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r721",
      "r731",
      "r757"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters\u2019 Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_PaymentOnAchievementOfDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "PaymentOnAchievementOfDevelopmentMilestone",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on achievement of development milestone.",
        "label": "Payment On Achievement Of Development Milestone",
        "terseLabel": "Milestone payments on development milestone achieved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of available-for-sale securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r160",
      "r225"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase three clinical trail initiation of license agreement.",
        "label": "Phase Three Clinical Trail Initiation Of License Agreement [Member]",
        "terseLabel": "Phase 3 Clinical Trial Initiation"
       }
      }
     },
     "auth_ref": []
    },
    "atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase two clinical trail initiation of license agreement.",
        "label": "Phase Two Clinical Trail Initiation Of License Agreement [Member]",
        "terseLabel": "Phase 2 Clinical Trial Initiation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.",
        "label": "Proceeds from Exercise of Common Stock Options and Issuance of Common Stock Under Employee Stock Purchase Plan",
        "documentation": "Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of convertible preferred stock and common stock warrants.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock And Common Stock Warrants",
        "terseLabel": "Net cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of available-for-sale securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r805"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r518",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r655",
      "r668",
      "r681",
      "r779",
      "r814",
      "r815",
      "r819",
      "r872"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r518",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r655",
      "r668",
      "r681",
      "r779",
      "r814",
      "r815",
      "r819",
      "r872"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r149",
      "r151",
      "r162",
      "r167",
      "r174",
      "r184",
      "r185",
      "r202",
      "r212",
      "r216",
      "r218",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r410",
      "r413",
      "r414",
      "r441",
      "r451",
      "r524",
      "r535",
      "r571",
      "r606",
      "r622",
      "r623",
      "r661",
      "r677",
      "r678",
      "r692",
      "r793",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r119",
      "r122",
      "r123"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, at cost",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r140",
      "r534"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r525",
      "r534",
      "r680"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r119",
      "r122",
      "r532"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r317",
      "r325",
      "r356",
      "r357",
      "r358",
      "r493",
      "r517",
      "r547",
      "r577",
      "r578",
      "r629",
      "r633",
      "r635",
      "r636",
      "r638",
      "r653",
      "r654",
      "r663",
      "r667",
      "r673",
      "r682",
      "r685",
      "r811",
      "r818",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r317",
      "r325",
      "r356",
      "r357",
      "r358",
      "r493",
      "r517",
      "r547",
      "r577",
      "r578",
      "r629",
      "r633",
      "r635",
      "r636",
      "r638",
      "r653",
      "r654",
      "r663",
      "r667",
      "r673",
      "r682",
      "r685",
      "r811",
      "r818",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r713",
      "r723",
      "r749"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r849"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r849"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r374",
      "r868"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r715",
      "r725",
      "r751"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r722",
      "r732",
      "r758"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r787",
      "r796"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r93",
      "r530",
      "r554",
      "r559",
      "r569",
      "r587",
      "r680"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r170",
      "r171",
      "r172",
      "r175",
      "r183",
      "r185",
      "r262",
      "r269",
      "r365",
      "r366",
      "r367",
      "r397",
      "r398",
      "r421",
      "r424",
      "r425",
      "r428",
      "r439",
      "r550",
      "r552",
      "r572",
      "r874"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales",
        "terseLabel": "Net sales",
        "label": "Revenues",
        "totalLabel": "Revenues, Total",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r167",
      "r203",
      "r204",
      "r211",
      "r214",
      "r215",
      "r219",
      "r220",
      "r222",
      "r257",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r451",
      "r524",
      "r816"
     ]
    },
    "atha_RoyaltyObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "RoyaltyObligation",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation.",
        "label": "Royalty Obligation",
        "terseLabel": "Royalty obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and restricted cash.",
        "label": "Schedule Of Cash, Cash Equivalents and Restricted Cash [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based Compensation Expense Recognized",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of Income (Loss) Before Income Tax",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reserved shares of common stock for future issuance.",
        "label": "Schedule Of Reserved Shares Of Common Stock For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Reserved Shares of Common Stock for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan",
        "label": "Schedule Of Share Based Compensation Arrangement Shares Available For Grant Table [Text Block]",
        "documentation": "Schedule of share based compensation arrangement shares available for grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Stock Options Outstanding and Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r46"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r91",
      "r92",
      "r93",
      "r144",
      "r145",
      "r146",
      "r201",
      "r301",
      "r302",
      "r303",
      "r305",
      "r308",
      "r313",
      "r315",
      "r565",
      "r566",
      "r567",
      "r568",
      "r667",
      "r776",
      "r797"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits for Uncertain Tax Positions",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r851"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r574",
      "r575",
      "r576",
      "r630",
      "r634",
      "r637",
      "r639",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r669",
      "r685",
      "r819",
      "r872"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r220",
      "r662"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled Litigation",
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share Equivalent, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share Equivalent, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant-date fair value of restricted stock units granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Equivalent, Non-vested, Ending Balance",
        "periodStartLabel": "Share Equivalent, Non-vested, Beginning Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Ending Balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Share Equivalent, Vested",
        "terseLabel": "RSUs vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, maximum percentage of payroll deductions for qualifying wages or statutory limit.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Payroll Deductions For Qualifying Wages Or Statutory Limit",
        "terseLabel": "Maximum percentage of payroll deductions for qualifying wages or statutory limit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares Available for Grant, Ending Balance",
        "periodStartLabel": "Shares Available for Grant, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock available for future grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options and restricted stock units granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Unit Granted",
        "documentation": "Share based compensation arrangement by share based payment award options and restricted stock unit granted."
       }
      }
     },
     "auth_ref": []
    },
    "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options and restricted stock units forfeited, cancelled, or expired",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Restricted Stock Units, Forfeited, Cancelled or Expired",
        "documentation": "Share-based compensation arrangement by share-based payment award, options and restricted stock units, forfeited, cancelled or expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise price per Share, Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited, cancelled, or expired",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Shares, Forfeited/expired",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise price per Share, Forfeited/expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of options granted",
        "documentation": "Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value",
        "label": "Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Ending Balance",
        "periodStartLabel": "Shares, Beginning Balance",
        "terseLabel": "Shares Outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan reserve increase on January 1, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Total",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise price per Share, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise price per Share, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise price per Share, Expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of restricted stock units granted",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options Grant Date Fair Value",
        "documentation": "Share-based compensation arrangement by share-based payment award, other than options grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fair market value of common shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock purchased by each participant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise price per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise price per Share, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation maximum annual increase in number of shares that may be issued under the plan",
        "label": "Share Based Compensation Maximum Annual Increase In Number Of Shares That May Be Issued Under Plan",
        "documentation": "Share based compensation maximum annual increase in number of shares that may be issued under the plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding",
        "label": "Share Based Compensation Percentage Of Number Shares Of Common Stock Issued And Outstanding On Immediate Proceeding",
        "documentation": "Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation shares authorized under stock option plans exercise price.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price",
        "terseLabel": "Exercise Price ($)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering periods",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Options exercisable (in years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Expected to vest (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Future Grant under Employee Stock Purchase Plan",
        "documentation": "Shares available for future grant under the employee stock purchase plan.",
        "label": "Shares Available For Future Grant Under Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Future Grant under 2020 Equity Incentive Plan",
        "documentation": "Shares available for future grant under the 2020 equity incentive plan.",
        "label": "Shares Available For Future Grant Under Two Thousand Twenty Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted",
        "label": "Shares Issuable Upon The Exercise Of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted Member",
        "documentation": "Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "atha_ShortTermInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShortTermInvestmentMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Investment [Member]",
        "label": "Short-Term Investment [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r789"
     ]
    },
    "atha_ShortTermInvestmentsMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "ShortTermInvestmentsMaturityTerm",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investments maturity term.",
        "label": "Short Term Investments Maturity Term",
        "terseLabel": "Short-term investments effective maturity date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r165"
     ]
    },
    "atha_SlyneVAthiraPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "SlyneVAthiraPharmaIncMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Slyne V. Athira Pharma Inc.,",
        "label": "Slyne V Athira Pharma Inc [Member]",
        "documentation": "Slyne V. Athira Pharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21",
      "r132",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r175",
      "r183",
      "r185",
      "r200",
      "r262",
      "r269",
      "r316",
      "r365",
      "r366",
      "r367",
      "r397",
      "r398",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r439",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r485",
      "r550",
      "r551",
      "r552",
      "r572",
      "r624"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r574",
      "r575",
      "r576",
      "r630",
      "r634",
      "r637",
      "r639",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r669",
      "r685",
      "r819",
      "r872"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r200",
      "r518",
      "r560",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r686"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r200",
      "r518",
      "r560",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r686"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r717",
      "r727",
      "r753"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan, shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan, shares",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52",
      "r64",
      "r65",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued common stock, share under employee stock purchase plan",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r65",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued and sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r65",
      "r93",
      "r565",
      "r624",
      "r640"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityDetails",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of common stock options, shares",
        "negatedLabel": "Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r65",
      "r93",
      "r340"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52",
      "r64",
      "r65",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of common stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21",
      "r93"
     ]
    },
    "atha_StockOptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "StockOptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options to purchase common stock.",
        "label": "Stock Options To Purchase Common Stock [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://athira.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r83",
      "r588",
      "r604",
      "r625",
      "r626",
      "r680",
      "r693",
      "r798",
      "r810",
      "r856",
      "r874"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r166",
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r316",
      "r430",
      "r627",
      "r628",
      "r641"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r486"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r486"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r486"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "TowThousandAndTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Employee Stock Purchase Plan",
        "label": "Tow Thousand And Twenty Employee Stock Purchase Plan [Member]",
        "documentation": "Tow thousand and twenty employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r299",
      "r313",
      "r429",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r537",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "atha_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand and twenty equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r174",
      "r175",
      "r176",
      "r177",
      "r187",
      "r223",
      "r224",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r280",
      "r365",
      "r366",
      "r367",
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r519",
      "r520",
      "r521",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureFairValueScheduleOfFairValueOfCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Debt and Agency Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r670",
      "r869"
     ]
    },
    "atha_UnbilledGrantReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "UnbilledGrantReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled grant receivable current.",
        "label": "Unbilled Grant Receivable Current",
        "terseLabel": "Unbilled grant receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r383"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Material interest and penalties on uncertain tax benefits",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions taken in the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsForUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions taken in prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r115",
      "r117",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r679"
     ]
    },
    "atha_WangVAthiraPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "WangVAthiraPharmaIncMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wang V. Athira Pharma Inc.,",
        "label": "Wang V Athira Pharma Inc [Member]",
        "documentation": "Wang V. Athira Pharma, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "atha_WashingtonStateUniversityLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://athira.com/20231231",
     "localname": "WashingtonStateUniversityLicenseAgreementMember",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Washington state university license agreement.",
        "label": "Washington State University License Agreement [Member]",
        "terseLabel": "Washington State University License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://athira.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480637/718-40-25-10"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0000950170-24-018787-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-018787-xbrl.zip
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M!&O*$B#I4>'$WAZ<A#83 ;-#8D4)P$E,0<IW8Y=P%G,_#!TWL89+F*>T%+^
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M6%@5Q5; Y)%!PR1F=$O0D(\ZYC9 PXEMD0C3!!DM<4!^=@+XRQ3$=R/+\LW
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M^Y3>7=L7ENF[Q+( %5W!'%#,..CLU R=V(E-)^!#N](GT-F?R$:-1L;O$JQ
MZ8/K9@D)&#.):X-01 40#AXZMDT3+XS8X,!J%_3]QV'%U(IBV\?X<1M3)3PJ
M2&R'C'BF\#U*J1VSP<I)0U "7TJ<'0U<S%4(B6U&H.J8CL 06IL(D*<#WXX]
M$*Z'!B=/&;7V.-AI>99O>HE-0IEEQ5A,HL2*"'<B3P!E#=W8WX53OY7K]%8C
M=Q3Z5U&<E70^12==#^M_*8 @9]G28[8MG+\VZ^J*$_$#C8N2UD6Y@,<^)0EP
M^T/*TNSQ31M;A#R>@$(6A8)P'UB"*P#I(]#*2.+&%J>6ESC68#UTW]*?W\&O
M59VR TP *Q=CK,#=C/Z!R3S'3D@"(@+0) =H$C=# (\H <4]$DX\V&RF05EO
M#X!& 87 ?Y"8G-/LJJ2Y]N/N"3#W6=)UAF.,3T45BF:?*4#LKI!2WX_<P+8%
M\0(*>K89(,(D,?$8C86=T"1Q!DM*!^;!?IZXX20,F!\GE)B81.Z&L4-BDZ)_
M/ HY8XX @CC8"[RE1LMYBG8,1*V4'^4'=)[6--L5:_^M\ML'=D-/*38\#F$3
M5 C7YS$<<VB"C!B#3NCZ"8DLAU*/"FJ/><W/H#,FB1OQ(,',21.=D@&)0"H#
M3=WS0A8$S!NN<V4(%IWG%PQW4SI[9K?^-FVBKA>YD>,0QFU,_[,YB5U *(?9
M/G>P#$ P6+IV>S/%85/F*7HI#]-+_*="743FE8FR>VMGK@Q(6V@'/@ELRR%P
M/QZA2601Q_%,B]K,#YSA9D4,3$0;@(TA,1W'3RR7",8$<3'W-G1BGX1QE"0L
M$M3AC^Z5N/M)6>;3GQ3U/6:9 24,*R^Y 0<9F#H^L3W7M"P_9)88G.0[P.RT
M+7I*G,2R;(M'H(%X'*1B#P1B-P@(M9+(CTW'M]G@XIT?WZT^:)?9 "@>-06-
M/2\@<2!LXO)0D-BW$N(GW/0\,V2^-;A0ZH&G+O5O%>M?WO)6U_.<'G*K=LQ$
M'$2,V';B BUP0Q+Y(B)F8,&=4A;XT6#%DET*=-NF)!DDE'*+$1&86**-8GXM
M(**@)J<!VC?B,9/IN>W ST.CN26 G5.3^%+6 GV#4 =(MN7YW+(Y?#D\;_R+
M<C8-1@:TPD"$@8WLV\3J,TY(J$<=$CB4ALRS?#'<JE3;,(59WY>/]#J3UV^@
MIR]^H^4?HCYL<CYBS -\": :Q2$H^S3&9#2 :Q++*CW"%&YBA6'B1T/%F%O9
MW-J'/\ MB6F1\:/9O"S.U77MRBUQG]J^[Z&I Q1<-W%=$H:<D= 6(!MQP2UW
ML'3M/@%<NV<'#9@?<,<AE IT_L# D4ABDEB.@YD;L>,/5HT<&<_(>)X>8_R(
M1:;M4\(\U/=< ;ACR@K\?B*"P(JM:+",9Z"&E\>I&9-PT[>I!QQ'F%@1&"VL
M;L*)'P2.YXO89?'@;"FHB0/?X0VK/Y7'HCR'L^\S&G457#^R-30>*%P,0(4'
M8=*V;4X)=RG@N A=$ID10*F@U RMQ++BP<;B#5S,W&;Q;Y<[V,*%.($%ZC/%
M^KN<,6*"YHP]1F+;'!Q-OK&NR%HYD7^\*_].+^ACE]A_)M^M%<8LH#'Q:(+%
M1%A((MNEQ$EL'Y0%$[NU#.WR;F'FU/=X,A5*[OJ4)&)HWBAX=#MWZ#"?!5:(
MW9TL%WBM'Y X"A$+;9ZXOA7RZ-$MG7<]J6>J*>R:81!Q05B$?0J2! [)M4/"
M,'\R-F.7>X/+BWOB5.=/^;>R86]%7%]0B@T+/(X)E\2*L-@"EARFP/)(Y%JN
M)X"84C%8+7ZW\^<?1YXQXYAY/&;$\K SF@AC$H:V1P3C)G=]/T[,1P\HO-OF
M7=FX,=K&YD$"8%'D"Q)YC@!A+DI(F"0@S"6<6<P*J!D,3F\;'(4<#"B[=A29
ME$7$#'W@=S[C)/1@ DYM$/!L;HEPUW-AGBKF?YO>$R])?!Z:A/NRH)*-M\(C
M$F#;,L;LT!ZNV??QNUU\+/)_B*H6?%-DX?<I0' [I ['0DTH0)A6A#58@*C'
M(-D'-$ =;:CP, S+^TLQ?WM.C+E:)O$#WP?*(3NI)C[A/';]Q$*/WN"B59^.
M<CQ7$>_GT64CP1W/H381U,+.TPY(:I1:)'0")V&AZ27>8(VC8X":]&69S#.=
MF#AFR(F;@ Q/1> 2A[IF$OB1&P_7&+']-@X7Q=C$80-HFK<'37.+54,LX3*T
MX7L!!PDUBCU"@;40RIR(NH&9A,/K,#+6&QHHG:.>Y3NVS0CU,/'< DV4>H$%
M_^$N8\(RN3?8,*0AUEW>HB8:)4X<6*!T.#'67?:M@% .FJCC,=-V_9B'?'!7
M<Z/K[CA;Y.)%] .PJ)VXV(7'LN#60'&T"<@3/@F\(+)C^-)V!ML/8&@YM(\4
M?NE2)W)]3I@#>IH+VADPT<@GV,4ALCS;HLFC)WO>55,U_5X?F0>%-D96$)@.
MJ$:>ZL/(5:Y<:'';26AHN8_?]>^^X/G(/:/NI"5)8T;]_AS^<S5L9.V!1T4,
M=Y7*/:B@O!\*%VMJ<=\4(%T"@$0^UFKRO3 P_9 -N&+#K:J3_RIR48+@"<#"
M9Z#45* *H=7B_9/4)W\F<T1H^@+=10'F!;C4CPFEIDM"WPE\DX*>RX8;2#(P
M?C2 Z[1YXB0)=4D@XS?=P,.@+I]8II/8@>?[PA^<>#%J@-_D[]OS85DQ9YZ=
M$,^+L6Z\<$D4!P[A(-K$;N@'[G #L<>Z5;M;M^J@*.>(/>*7(N>[UX/*]  S
ML+"HQ2(71)_())%-8Q+:#G:*9E;H#XY+?B,L_B-5/!&1*:V;6E2?DK\*FM53
M66=@5PB:95/+Q!0(N!B.4<P"Y)?8E3DF5#B!R:+!-<(8\,UL$V>LP'6B!"NX
M<M2C$XM$-!#$B@0+$M"FA3>XFQD2JWDISG%N>V;D6*!WF R=%K9)0B]DQ/+-
M) Y-1U Z.*?%4(IK#<"@Z8O 89CL$R>.#Q(E>@A$"'_%5F(*.PE]/MAZ'0/S
M9S]/ZVB3"M  ?  )"TU^KF>3B >4!)[P+<OC 0^'BW_\7XTBP-5A47X4%_N,
M8;\)('_ 8'/XDRFJ>*6UE'X*],Z< PY77^<<#M"&19K?$M4'0SG=B#,'M'K"
M8RR"YP6<1"*$T6,OHIR&\/=@C;4#"Q/=8IET+JAOFB(F?IPDQ V$2:B;,!+3
M*+ Y#QV?#<XY]]1Y!1?%KN"8Y5B^9]J,>#8%ZFASE\16[)#(8YY'?<<"3!N
M-VC-]'CK(JE;-#V&E(6FR0'038L!-1(8Y CJ&.PJIJ8 PAH.CAK=Z)3^'4#X
M1?BD'3\T@8,(XH46MIUS(Q+R,"!P89R)P&8>&VP@\_T** (!:OV"VBDHN1!<
M,*[H?*>:!H=1$%.+<N+Y6-3402F )0&)7'3>V*$?VKN>+/*D<3I;9!Z!928B
M=%UB!C9H1(GOD5AXC* G/1#4"P:,6 /H[_98;20'0'*Q'@9/F$D<.PI!2(P
M:2-J$=M+/"N*PL3V!@L90S".C7Z8%]7=S?0PNIY;)(YM0)?$$B1FW"%<<#?P
M',<??.C)M@CI8*X$!(O(YQY0L-"1YGV;@)0O4'P4GNU[U#,'%VEPU\"1Y^A
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M?Z1*4#M)<1^G%A5/+.&+("!,>%BV"*3_V$;>#)]]RAR'#S=^=@=J43V3I20
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MWQL]E:E3E_8/3O!G"R!MJ^3QS@2Q X.6M,"_2 %W5!"-[B:'%J513X61I!4
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M:IIS6O+*P+XI*;^N6([S _UQ8TCZW=.8UJ_RNMJ!3NC%81 1.PD#X@:13;#
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MT>EF7$#Q3X)] =*C@MPE0+?HUT,1R3&ZA'5DF:R0V?C &;-%E2J&EV-M2^"
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M5\5K\1F@#DVF2O1]FF,#2TSM'2G%"J6(1DHQ2$JQ.\&> 3W]-U;-2[$"S;G
M#UG[MS9[/R:I^#^]N276_Y_E_'T;N+$?%TW=%GS"L-&1$O0I@3-&DPV2$H0[
M0PC"GN2_K/YY6C7S>2;_IN5C$H*E%'"\+#V*!.&XMX"%\0YTDA'S1\P?/N9'
M.X/YT:FJ$E.=ICGR?'I6"HW]6%CFE#+VJ)&E:G(LN8/X_JZ_ %799E_5L*>R
M8'?>?I25T>"%)>58R@LCB>B3"&\T* R31.R.FA#14]W&HE(Q;ORQ@V$.]'02
MQS]W4XZ8/6+V#F#V[J2)1?%I40+G5W4QTR)_3*3^),O-'BTG&]%Y!9U'>]XP
MT7EW<L(BUHM6Q5@ 6F* .$8& ,CDI_]J'E6-7XK@& J@YL9BECBW\;>F3"N>
MZD8CLG#UYU*<PYM $JJY[D"R-]*$H=*$,=YUC+<;XUV_RWC79PEX'2->=Y"]
M?6<H.,JYO=H'YL[(N99YVK9KJ4Z[=BZGLID+QKV6\^)QY5P]]\1XW_62^:1Z
MR2B3U4%; -[X%=O4H8UZ-$NO2+:^.5*!05*!':HS:/5PO]]S\C%Q?XGP![T9
M1]P><7L'<'MWBJ)8]FE;;^BTN,B!KT[3^:GN='8:BUP\:A"K3C99&)_:N643
M -UH[1></I5>9_6[Y/G+P%<=P7IMJLM(+49JL0/48G<*L%A.1QI*H7HG(LY6
MZI/@I_6CVKU;NO"E/_<*$3@I*4@*RL0]T9$NNMWD$0#*'/LHC2K"2!AV@S#L
M3B47RSV=EVG.TCG-,)1-AXZ=)D)4IYA_ECYJ=-OG=NY^V-JAT W:CN7\8U3+
M<+%^='F-!O?1Y?4]NKS.G\'C]8_1X;5[S.T[0\!1CNW)L;M3X\7R3L7E-(W3
MNMJ4J75:L>GC&KW5W!-C0Z:6<<RF@C?9*,BN";+6B/:#1'M_9[#>Q\A-='?_
M<5HU,WC_4:O\=VW'C6,UV8C/*_A\8Z5_^!<[X<H_A]X5^-Y]GW%SV^U0;CU6
M?W++_M:FKS_CA_4]O4\GYG3L5OYX4/LTW<HU%+]]9:3\IU>:7-^RE]KC-S+7
M%!V+9[0G\VQKN=KT;:V9>E_0</<\Q_GS#=*&?W\\[Z[LZ1#]4U,:;7=,(ZV,
MJHG_!>33J LC;V8"!+_*0)A1%N(FUVXM+'LX,=*<98U,JJBG126,*5Q&AA<B
M."90UU-A5(H6H[>ZGL+XI9@796TP.L>OX3DLRF2;;_N]]_;D=]9;XP0&2(HL
M*RYP#GB;&AJ.U7C"Z(SI>I$7\ (>S$-@ZC[':%S/E/J"*P"/'?YYE2.M@<Y&
MY@.*55F_E4!"4!*KWL2T$AG<VA5P6JX0(37X\Z/#U_5DT-T+/-L*0M^-;"=P
M ]M;;CW-<?5$GL -6T;J";#@=^2S=[!J$LLTUT=]2OSY71BTA/\WT*]J,)A>
M"I^P^C-AQ&DQG])R!E,U4B@U,"J,Y@M520!>2F<I(DNA2HH!D ..  HL]I8
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M?NBUUK\NP:9G4^ZWC5SQUJ(>HCM6;B#E(XT<H7=S2(&6!50K7]E<?7-C];9
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MMR>'CTYZS:*<#\;T&_)I1R/XG9;&%/QQ3V)  6+4* !?=4Q1(YQH3:Z!H"Z
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M_8<^FCL0K'!V(0R4/%@DD?+0E3082[^HW;+:F4X1E^"@"_.Z3"M5_[(N/J1
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MF7)<NEB]AR; &%"ZBE)'3]-$)F=*MB+]-_A9&NF2\!\N&LL_I+[(M-6;A5U
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M/+%-*7R.E,+>-J5P?ZDQ/]*V/OJD- :?)B%M*FXG^3G49AU6MVFS<Q/(+YU
M_A-NR9\^,/X.%I-1TM2#O_\/^L?>[J/]HR?'CY[\O[V=?TY'_P/1J>X_1/B
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MT_F(UB(PT.AW4DZ'/CT\E$MT)H4D%?GG?I3!,H:\06%].9?6?V.N9I57!/X
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MDQD'0^NH[7S)KN*J#3I1+\KD92;$1((<,S_^REL!DJ,),@,"J K<ZS8&RZ/
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MJ0:J%*PT@XYC]<C[&D:,9&$*1O)?DR:RV!B8]>N2+?1P@P?95"15L9'%C&A
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M@Z\U_P*PDDW-\=OETROME#,DJS-5V$Q19]#,E.YB%<^XX^(W$2CUAR^]L5M
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M0@[?%>[G4M:QM:Z\=RY#E6*G>![5? :[44$48AP,@BZ7@4LH+("P%?F;'<:
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MQ$X7Y1Q&D$,<\WK: QK(6AZ(6E*%%!=A$TA*S5JM5OEKLE(<)$3;4T:W%9E
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M5W(:LF0]U'V_9 HDGM4<5:E==#I^<K'S!^\.\,2$>W]AE(@RLVNLO\R372O
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M0@_;<NAYQMW/NY/K\)YG*51"=?,"%0?D6X38+*!TDCD#AE <@IKCLFP2\J,
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M0:[RFRKPLV$^;,,TFU)NP):!%4!Y\K_85D  V0N)\K[ IDCY+@5M93-[MMF
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M_0_R+7GZ>UH!9LLJMRP4^4JNBP<J];JHJ*/BP]UO:B%(\TQJR!A<;4\=<:!
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M4O)H)O]9.C4=$N -@[KPKZH^P(E_VUK<!:M:Y_ "[)P.!]%4%J@5>L4"KJ0
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M M$(<PX2AUGM F=$T)O4]*X\V_&0^)Q>K $W.AV/THQ6N\>BX<<>U4$?NN+
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M=SD-4"/;$\U&9-42/Q_$N[7--0NMX^#TL $,H8=;4?2"M9JZ=X>JYPBRJ;B
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MNU9];EV=[/VC4A]I'XTK\"3*,XQ=1](1< 4:Z2!#$QM^(YI;KAF3]7;ENJ0
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MYW"FO-2O"A2%NZ8FB[B?R&%VXI$,V!W"9/,'_T3>T(>@)VP\C86-R_3,7GI
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MG54:*:8IV)ANL0E=V0BBMBSE#K9,M;KP?H&='"JO]11?$)/852?Q)K%R.[)
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MA@<U01L4^@6#G0N+/7ZPX%2+4,-08"SQS1TO$)N=JR_$3339SKA0VRR9X5V
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MM2D[FK@C^K(XH[":T._)DLTLM(.4[AW%VR[4!3Q8R8*W%'TX^A06JJ"@^96
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MFT% /-0^D<FP/B6^EY#3,^I.+S875C*BL>X$[7$W)3U*?\YE-<I=3BV%<\L
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M Z918T@O $-P:$\[SD4VY7\P0CB.YI%6GHOFSW.L9RDYIJBU6!4MJ04 5<H
MI5CV9BU'+D@/2SZ:7:SOS6CA"=K"W%F-N;>^%=8@M/7!O<Z'UO,X+9MPB;&
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MD"KM,;KPSY A&RZ2'/9JQSN,[5%2%'3DG;IG295PSSV/+3GO0[(M>0$N!'2
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M$,Z(<YA*VK"D"<Y+Q5>'6*#'ZE)]/^V!//?GS_&%V=3= B) +Z39@U W/Z7
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MD"$%]2E&%LHL?+I:_ ND(+5ED&4W19FBN> ZN119M(B.)G(DBU;PH7MS/1>
M:;9W; NVA]"O"2G<6IGFY5HEKQA67<>+U94SS^?>B7(6;BJ\,EQ:B-=$LD<)
M0:4^\C\]\PZZTHB4;_4/G\K:".,]L@Y% XRLYW@*<(;QK&K3RFJW-A;[/7IW
MY:&4\39]W6/CT$X&CJ",R@I,P36C2>?23Z@IXCY9>TOO^UO^K=VWL4:K%[&>
M/PAN&$\#0C[0*D$ 0/D&\2#HT?Z%%S-W]0<5[E+*%3B":MSJ7[2I$"LKKIK
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MQGLN#;B(H; _%X 760.+HY@U3Y$'2@B+@_FO F^OM4T9:T1OB\3/,*K1,=$
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M&!?K3_)W8 EDC\I*%I@B0B]#^[OG=I(/<MMXJ^WTW#[R(QI//SI$ *?Z]+/
M/ICU #;U@]C4Q[[5/EUDU_)^AV*A7X((NQ58($L[+,CNV*]MUQNL4O3:)$1/
M#Z=F'IGT.-T(C34NLN0M\[L(57+9IOV<WN+U?5$<U>.P.EV1KRN)ZN\*W\(T
M,@'U%A,+'BOU,6)M<]CX882-9*AD!7A-TA)GX,VB/Z!^$V$X"9!&21@2S(UU
M'6V&W7K LDD(\.;FN^]UP\#^0?O(*@99;F&($1\0@;[%(C%N? -9ZE;>_SQC
M>Y>'>JF69#*=2OC(-?=BVQPQ=+[L:8NU07QU0OJ&Q#K2M[F@0$E?,YN-Q1$3
MSHA<((5+W#7/;\D<\5L*7A*!U1C30J(O5!1]V81#J#B#$_4!40=";*44B!4(
MPVY+<^]CKXQ:9XIZ>0L[#DB)0%-6LR/7RD ._ATC(RM3--HU<X3*S<)WXXKQ
M+D!@)N'NK[T:YN[]4W3OOYB[]^^U>_^;\=O!RT2GI4C(8[DWW"%*Q85C>^V*
M1V_+U@<5:-M>>VI D*K_=2((CSWH<9=S]TF[:;ALI,)(_NZ*5N)O5$SJ8PFG
MC: &P*([?K"4I5_12V'I($I+ 0Q3=!ISG%'84EJ66G!O1_J^+-2KE0GIP<@5
MEIT]-4$\<JVI74><O./B8@A?L^*:FF:YZ2S62'>X6Y7"0+:*$/LH#]JZO&R8
M&:B*#W^$[I([27K5R>GT5GUO2U_8:%N39X/K6P_[!W^]^2&I^B4-!"%NM!'7
M('RAHZL,@#8;RUNK#:!<Z3,,I2&S.L90 I&[9&8C;EN_HM1U\AB.AHQNE"\_
MV."!R]YK\$,*V9T6RH81"C^Y^P#G$X8K80W2N;LXDC6=VTU!8YPAT26G)5<L
M@O (>'F9NK8P&/?CXH]V'977O*]A3GQP6[/\;B2?>^2KD6A+YGY%6-!(_]RP
MU? REJP77F@2:6#/1"S1N)7'4');3Z#5BKC7J3$J>6)Q?3G^?3RN"(WDT$_@
MCWF]D"E,::*Z9S(N>KG' #2ZTE3QH5&B]==TU  79<AD2"%&K7)BF6Q6ROZE
MLGX=F/A=5B%R=R$T7Q^:LDYEQG.1IS\U/;Q79JF=&;9F;F=N _%CH'+7X4"Q
MV"ES&@[##TQTH(DU:9"T_T$:/'A3G1=-1J.]TJ:A3HRM;?77[WX8>1^-W,4L
M\P49SK9P<E4LH\WES5*@\%SP,C2T+E'[,2#$)ZHZPV:JOPBILE*<V_9 _G<]
M"LR\%\;+L"N86$0M9>(,4)O&SLL^*.KC.ED^*LRH:OG5XCM::KS79^E<G[J"
M4N>QV6=L[O-.RIC;A<D3#.N"7FPP;,(=BJ$\TJC)W+0IFOF,O/-'WTE^I]:>
ML5FX@0PL#W.5HXA+(?;!]#5E3D$T.:LCRE0X=E138'73XYC>T86%X=!!;06^
M([FT3*O]?$:++.]VA78Z<"&0TR!OW7!'*JX#SK_5+!309%EZ4V\;8<RV^P39
M'GO3L-T-RHL*JTB?&EB;N+>"C'A" =[:1F&PS/@<A@/N1@L%ARTLC0)#.L63
M1"\F;":CMHON/'SEO@[AAR^3:5V!GTK2KYNJA7Y8R9#Z>*A2_ [%83\0?5^M
MV)123#9R"7H/YH$#(Z4J+/P/'5RA4#)OM@J#[&GP@F-II;F4O47XW]>&#\/P
M>X2SY&MH$:K1A(-9@.#G5T:1-OLHMZ?K[G]/R(19,Y -P.W*+<H^">=YOEZE
MJ5218G:8@/VAJGKZ[AXLL:?5(/Y$'.>SZ>TPCQ%MGC46I<2$)S(^<$R[>%?F
M1] $&'5 'DIGTM(4-U1N,>D"\U*]@T3J@[Q(%_^*_(]0@O*Z6"O*^.<WC@P;
MW(V@;7Y,NW.CDRY+#QYYTZSZ"453'O5B$R.+[UN<,J]UDDI2*%%>RH7M.MR-
MVB[ 1(P?'1BJ5F@;=@Y>,M'I&]A@5VI9<$Q2U>V0HD[E@[',^]';V=.U+A^#
MS'9\3I8.#/W$ICEOIQ.NU22:K(? 5U'6O2OR;W1QG$DC^>L,"][+#/-F"@C)
MD4'9W5,W,=_5#6;4K9H>"(U<Z$)[FHG*G7D46K#HU(WO_%>04_%F2($8-@E>
MGNG>CS61A1E300D9"O31V,^/W>#?L2NED8]";$$U:P/,->4J-GFH.MOD9&!;
M^<&[%F?L@9W['JOO!963A'52X1I:HP(%[K-]^;L9JC+:I71JMB@U)]8R[=NN
MR>E^*A\W,,_1494V.DQI.OB21\9+UZGA/D+!D@\].(5B G&U^+;GRFN[;YB[
M'(LMOW/C'>>B#R!FD2!@FE7UHG- E'24F9%Y%=D0/A7X'B2;9'YP6*Q-S? U
MLJ#[6C7!993#,-^ [AV.06W(#8G$4O-1X%IMR9L:+^:^#@&R0>#T 43JIC-N
MPOU5D>!3KU#&13A,S4)ZE<==%.\I6(A $O7\<7"@[+K>P;69)-#-J+@;DATY
MF_N&O\6^X9=SWW#N&[Z+Y=!J4Q0YX#\=#W*%6J<FPMHY0:%]F3:/>.0?&HJM
M%C>%HNQ@+!"A[#/&PB5(D^%.^;B-TN6[CW+,48F#VS:2J"<-"N3IN#0M$/2U
M)?QA1HQ;B1V'>&6WB\]B6%,[?_%21 YX%Q<Q O 2!3*UCVD7$$_ZZ'-EXPAY
M\I)XV*GDT-LQZ3& U!7,_GC>C<]<TK]A"G]?G=/HR=< !E'U9*2'+KJBD-%N
M7^T*EHI4A4JF3DS$5F7M>FOU$F1;+F]L(>W3"O9;HWL9YS<OH,,?.K,LL(@S
ML5HD5[;J*KF\;H/S,3PLM#[]C>!!\'JUI^(6Y;(XWC'S:!\J<RP9_-7OXIXR
MRV%<ZEJBO<)2NV2#%>JPQOU193TYK5N>(MU=9@WL-L?LDG&.%5H9-ZRF@7S8
M1F?KFZWO3^:Q' %"W=1L,'?2FT@(^YJD3;@\W>N3V8E+G5D4(#L4OVP^CCY)
M$0U*;%)5F<UQ-L<_&1DZBT^=8EPQ85T:S(^CWF(_&]%L1$ET.FU!Y^%W9SK)
MLX>:C>M)4A_5+)>:RFQELY7!RO9E5^7+HM)P/K9UM$F5)1J+D39)*0+N6FY^
MK,&FNF=V!$Y!^>_Z_;7 =, 9!!/E<6M&]"P;A;6(3(].GYI8=K&>#70VT#^-
MK-'9C.:H.D@0/BB8:.$SR-"54Q\X@-&C3QO+STUK^LJ3YS(YLC"V8+5?(W_G
MD0U!AJ# 63,Z-EDL%2-FP+@MELWEF=FZ+]JZU?VB]G]H8]T$1!7X50&=MT2N
M+(61"BU*5ZQ:FXQE,HIGN^;NHH6O!B"" )A,)M5R" ;Z6=BTXVV =[2? $;G
M5GH8: \#" 9U&GPY</_H](N?(QF-&(@^E/\^/<E=LG$J_&ZE4(N-D67[40;
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MZQ56\&VA-Z /:T@ER;=]6Y*E3 +X.PX&+;'!8F-PJUNPJ-'MZ1'C:9A(*&B
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M$Z),6>1H9!O;)NJG[\' A*)O76Q;(1(<GQ+CD>5^27M*$1ADZJ!Q8FMG=-.
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MC3!US9'.0F^2I]P\S=N0BF7HO@0K%<8>#]9:3N+PC]BTY,T&?R_'I[S6_9%
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MX/U4K- N=39>K'S[DVV>#UP_*^0^-U7)=A$G2)XV?4K6Q_6C(/1H@N'-)2Q
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MPHT6_>DV.X"QX$D_ I[T\8(G7?"D[\F8G@YW>'IBW"TIQ@&DKS-#7J6RWLF
M (GMTK% I/,:N.:.UX/Q"$9L#P5-AV.DOPE$,<L% "?+Z2\/7EOZ:'B],HR1
M..?9;93TV,4/[D/-*I(U3;BY0;(]7-$*W'AO/K7E3<DN\BT<NPTQ=!40.LUC
M.QD!R;M@KSQP0&7\ANKN<IC&$(UL2F].@C+YJL*,!/9Q(_WV?!78*RZ.O!^B
M:1P)U02),/"5^M9GL8ID:3SWXMFQ<]DO(]VVI47)]<_N) 1EO &_C'2ZE]4)
M=)VR+SL*5^4QO"D)#M',3V,ND:(6NN5DU3CR9VI3BC-)QLQMGLTD=.T4WQ)M
M.L=NF*Z1H>Q=%W2Q$;:ID*][WO("6U5Z+>';,:)%P^_#H&FM4%*:>77>M3:H
MI9GLN2;XJ+]G-FTE9(,>G(F6L&D*X##]SZ4]=%$UM8NE5J">B)<O%$3XC]PJ
M$[%\2XR.#7[N'J?>,?S8:\9[0:+WFC>\KRPALK/Y0%"2(<7#=,@&P;J"NYF&
M*HMR4:-V^W?/PY^#H:HDLD\05 Q5[)YSH3YS).2H/3VQ-68YO39*F-A<H-NG
M6<L.7IE&@)M;F_;Z3<3NK\4L)6T/Z%FX?;HTTT[;>(3W!A*VY%?0L5#&F\C9
M,>%^U0\T9-LD@^.+&9VV&;%[L8545,,7U,>)VX6V1Z8#5/^',R^3+_J82 (F
M5JUAN>^!T7G$40-QB(#2 TF(3_U M0?>9!2&RYO%,D_;,I4E98H@;@DI>T@G
M34:DZH(>HMRQ;0WCF>?E6;FW7"_>[\1M3(MR;&.6CR?TD]$4,'G>]X;Q?#&;
MDS2;V#5503:R[V[+AOD+&:*.(]2+(F9\5'E=UDTI3BI2&C5BIE3@8MYCPEJB
M4*-"%(Q,)CD1YQB50C&A/HSI7"RN^;*L4>4*4I6>"LP4-T\9P_14]4%;ZP9N
MH4[EPY[2,/_F2D:TS .\3.E'JIG-9VL99HL(*MDU6="$P0)8>;8T.$,PQY29
MC.^&%*"G=CK30K=MMML;Q0.AE2M0&DHG23M2V*"J]O>NMA9K(1B6-BI;LP^M
M5V<V6LPN!/U IE@I2^)]/+1!_-A&O?L2VCSZ "R"AV: U_Y$:90FD;83!Z?\
MUHJ(IHV_6LJ0I9\]F5.-B]!TEJGO!ZDO>B <5QDS%)8U=:G[VED#%Q1%L2-"
M4)@"$LLR<UT@2.M%GT8) 1(A6VYKEVJ8 ;.E90,HD$@O1<BTO& 0+9\W/%(M
MMN3SJC^*A@*YJ?;6+Y77TV0VY$1*5C@4]=YW!-8\[!;)5>U'ZQ;=BV6W:+LP
MRE(G4[Y:+QY&PK)=UFML8^CYD$$HG4+ZDK73YP%G[&C?IY_-PT;CHOC1]I:G
M#JMH=^3W&VI$]]ASU/8B0%?DO[#"7HK;>9'UNNMIAS40T3DB3+#ZW>U$. =Z
M!QOWNQHO0.93! !3*,D[*6'32PHO(@B RPN!;K'U?=.<4#-%B.E,ZVQ5[+O+
M0$XSM*H"U:F$6U% J6FK+ LU"ELVW?/45O2TM<=*P8;[T5WVJKZHP_.S[Q$^
MT8!JN\<Z<#LL<]J?$-[QI>\WX7R3#I Y#A/:E<'=8NFUG@;NTZNRI>=)]3X:
M. )+">OV;BN[VG<^H9\'6*#QW>ZSEZ [1F_7O;VUX1:FRX9^L_*X9H%V1&]/
MCO$V^.(,'>-=EGMT&P]%:'V6C(Z BQJ$QI%]HD$CV FWM7I_6D1GS_7 ';8@
MAIUL,CI#/&V3!!VT&8&,HPW!,W3NTP%>2.^[;J<(53!31J$W\$?K?2PXL@^!
M(WNRX,@60:N'6,X=%.VF4-27=.B:L<GM1%BRZ$A^+[SOAZ.391SFCG&8WRI;
M?Y'1!I*>I;@=8:=$40JD@^R$#T0U#<_3JHU7/:H%Y=J=LHKG9GD0%3EX-SFI
MA4;R_>UK15(F$T&TA2[[<J?\.Q9OI#4!#Q/?YFHTZ'BE^"#.)2_[[H85,2)2
M2/HFGJZQPS6)=X%1]1 Q.O,):M<;ROM8)C2]+ZLN.K4:R\I5$VECU48V:/L
MJ@=B+&2-L;2O?/W1@0N)T+*#7PPT)/4!L^NV75:OF+G"3:F5P!%AZZ4PQ;MX
M0,N8?].% CHAVDZ["Y),WDHL/U % E!8P[Y/2[N?>E*^UCI#98GW$3ZOU8#N
M>5NZ+D@,E=V]'-WUN8]%C=20F__"0Y8';T\.GRS-Z(H2!$IV!&7)M2C:6"[I
M+O?D04(2@G71U&3=U(P^N7M0RUV(+1I8YBBD#W>*9W:KL*[H!KG^=F'O.ZAH
M3RV5[Z366 Y< @D$,<%;3VS^7D@GV@/O\H(Z!J#JF^*15^@A*K_K:YYYW_..
M+,$<[[Q)JUN<>-\&+LWX$C_8ZP4J&NXSG%:-!T:&1_2IW9WWSL#,S!?XV6FF
M:X=LR.7QY[_AD,9#PF%B]#(NG 6X)[0V(3FJ1[6*I\5P9@*VCHLS;Q<RW5]M
MNUABIK>(F2YB_>@@X]8%JF,O4I;*.-[!M"AR;@&Z;0W@HI(Z-VJN&7SMU(:M
M8;27YMI:;W\GX1883'V(9XKV4ZP$#C3+$NU](M'>,\OG9 8=[N0[=*=JY^O-
M\<0.F4 YN;BH=S>TX;@H3,8$?RPC)]$?:P-([!R5P&#E7)5U"WKF#7U69@XC
M+-&%;65=(54<7ZYY;I9.&/W+P*EF@C\97H"=%TR0'BL ]U[D2?%;>EYUO86,
M!7Y]V60QERI/YG1:IZOFBAV^!AN3=* !R5[&/PD7R:@;.[*\3AZUY@=>.)[U
MX2QZLJI2*7L>#%XN# D#!D;[.%*FO8\P+4VR'/0=-$O;R<@%)P!XW?-:LIS-
MR>1S=.?^G@=6Y^$CW.I(SK0<RYY[!5V[;]QV.U_]O>]0NN"1,?^W09>%^ZP<
MV="7$#U9Z-_LJFI40QAHI!_Z/N4XN??N:] [/Z.CTD-&2X@6U)TPZ]?T7ZT+
M31N$+1?7=3<-?,SK;X>)YGAJF'-?$S;:K<>P[NL][Q1 (Q#B<#L+8_?^.F?C
M[;Z",)CG[<5FBU:@S2R9BF6*L:0+8O#]5 (GDY1ZNULJE-LI[("N:JH>%(VD
M[>JAKTAKARJF,)UM7TZ;J<%T&*Z$?-,'5;:N[DOA/$B.N'F#6*H>&A&DI??"
MGF,S]2(_I_?UV0=$#Y.72&>0D#5P<4^9=\V&\@*ER=A^&'V4X7P7$_==N9'N
MM"4RP)>_23@11%AN5[E=U];#;O VYA[1T P4Q"A0L,B\RP[KZYFL$X>YM.O<
M3<=G!":JE!7@=V<  _7\L06_J,XOSPM#36#_[,N,2FG:!N=8_[KS0X.42+9K
M=]*&']#N<L:W48'W=XH:C;C637GKY_&HVK=J.N>V>B9M2D<1Z4VY>Z)]4^BW
M9L?=Y'"7G.;#JNG^EHB!6S=,%@?6@Z!L?1@D8"82@Y08;_3L=**,1WHP-T2[
M!"FAT[X95\%Z:_:8UO-=\2+ X2:+DZQ-YG J O"$%+KI?'>N:V#Y2DG@JOZJ
MW ^"C8M<J9&%D3SQ?;SW5VQDB:2Q^:Z;HXDKS42^6^)Z/&]=&H@?HH'XU=)
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M['IML*Y43G46UZU?R_Z*W_V\<A(#?Y5;C$7"/.B<MJCTWXU>N&G,^]&);;Q
M=D)'SD.=BBB;"GR*!D,.\Z@OIH1>U6-(O(Z%.:1#^NK?6[@OT#>R@,9P?#&"
M@JI;MP@]''=P[@)DW_$U]T)E^YD<Q3J$9S2 [%_?$8D\+_/[!9Q;28!(IP A
M7J!*2V_\/KF@?XJ>^(^$R;\/Q_YA ?5:PL, (GH@,2%OS@(U8UH+RF7H/IIW
M1WGQ0[GV(\B2XW[]%+=5>M C<T/.C%Q/V[%=Q6GSI6*X=)*.,PDZ4N3LXK_
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M.Q22<;].>MJKPGPL+3];"F*E&/:5W__:%I6Q=['5,$=5WI3]AL$=]"Q7+L&
M*V3J*?FU\_-7[,4/Z2\9M?IH1#PW?9[M/J9 C%FLD7V5[" 1)JHE)N&%:'UP
M8;C:772;V\.C8F$S> LZXF%%*:&3V';NECV/TP'<8&73T,CXFUM]P8DR-/K#
MF8S:<RFKB=V4R!2XE^[/^Y(PUA+_>OY1#K#98L2C 3D9D+:5Y\S//PEY\('
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MSQH<YJZ[J %B%I=42WV0#_TJ8=:D+!Y ^W':5"$#K-X8U5/ZR41)L[I9"KD
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MVW<>HUE"R;<0FO!T'54S5(RFF4M."-EY)#SQE<A._!= B"]#\&*E)S+FF#%
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M%3CRR!1M?/?DR3<^W# +RU_R^-&C]*H?<[/QD.Q&^F'E73D',0%:-O:(^W=
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M]1A68Z /5$P,*T9,/BRJQUPMBS'Q>T8]9NEYOGP,>SE.@?@NR%:&RT $XZ!
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M6%(4D+NBTX:*F5$!2PF*7*_/7A=I!_BZ+O0N8&HKU\U@XJR\*6SK]:0@(77
MV=G43Z>/%16FH;:B"'O52=(5K#:>+E>[: >I,^<H1J>ZN'<V=".T6OYF#L%]
M/AI[2OTA2YV@VC):HABS4LJJB$PVEI$L=)8E/#1N.I3<-HOZ>W^E[ZHJS3E
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M%9H5N6>UP!X3Q-G:,A4!V5-M PR$>' )>)6QG1H)A"ONZ2JSTLU#OVN4_3;
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M\R2/GI\Z);<ZH,8=\XPE+N=O*0*46-V;E,)S!D6?H"5!P9PGC/:OW<2B4O)
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M[6GX\.O/_P_3]7^8(F)-[N3#8Y.W%<\)T<'+]Y5AE<;HSP!>72\H*&KY.WI
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M=IP:N!-\:))0"(>9T:MC X*Y15:*)Y1=)Q3)&.!"37;-"?ZM/_L=/WO'RI
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MI\J&.^4CG;?@-O>"4I(?$&?9^PWPM+^W1[_W&^!I?V^/?N\WP-/^WA[]CF_
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MJ&[H35#/9QX*0>PGG^D?A?V!YS.>SW@^X_G,+9;9#,*CXYLS8#V;\6SF_C?
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MD\/GGO]X_N/YC^<_]U#&-@S[AX>>_WC^XSU<WL-U9;';S7&*1TH+VL$%_XV
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M>14M\/:"XES")H_76_0/\2+>$K\ZYYU JC>;M8<LZSPA$4OJ[E@MC/(_BRZ
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M'HAT,)-P]<3#3[;GX9-M9 9. W9D=;,ZPEZD_6J_6D.VD;!<8,*B^1;O)RC
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M]875L:X*"#4B)C=C-/P=']\]6 U_B/AGQPO2'6SEG^P\9=EE=DK3?T,IQPL
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MW0^HVH)KEEF/C?42::<"XEPJI$DH$?5&1<^IL<[W$NWJ>/1]RZ(]=\*'?&X
MO,,];@"\+0(>49AQ)1V2L4S@)65$AB;P*JWTCOL0&(N]Q*(V"7AT4&+H7[S3
ME#50P&\HX)-9\,N>,1!)!RV2=JB!'(TDXMA2*;U F J,.*5)$BE*4<DH#[S$
M6,>5;GAKJMZ9.Y?BQCUKWVK .+3J +2#XP:TNQ?M!"UY@C6)J" )[00F27U.
M\"5<D(QKPT2YXFA84^_>*-JI@< <P Y\WWNF>H<S,RSJQ0SVXOM?Q]-0R!]
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M [;JXB2\!Q=G<Y'#=W&^GTW<N<G-!\>Q>' ,(=C"D.9XR&F.S\*.9=Q)Q:5
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M$N*2 6E54KZE2H*$$44#71E3?H\]N+#Y>A(2LCS!>R,C!IV%5[4.ROS?P35
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M<8U.TJ;(; :2 L&K<Q1??OAG]V'K,=[LW5VYDRG@DB9I';^^\J:V8@6OZ'S
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MAGV;F]J];6)SJW>]LW#4BYWV[5<"GAKYQZVHS7?HRXYLMC0\<GR_6PED*Q$
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M)LNGLARO.PYFQES#_R621#@5C\=Y3K(PSHF)0F'R/&)R/YCY Q@%P%"NMR6
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M_KU/)A1J5*@YG#+.@N,B#DFN(D&43E2<A4F82_5<A/+^MAU4\;UEDA/ :IQ
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M"!J2V!1@25/-29Z*G,@PBDV>%S07:]VQ,J&R,-0*OD05X;%!V6P,"7DB16A
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M,MJ!\Y([@O&A^+:W-KVR\37])O@WNB"L?K# 9'Y46UK)8KN^WR,,3^Q'*+8
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M9KJ8@^K5EF+6IFTL9(<27?=BH%P2 Q?!#TW:X'*$QT*.M,<G0-6] P7-M44
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M7/NB7V7*-[['KD+#_7Y(.:F2;3G'NQ)+UU*R:_]UJI\B8A!@,( DYM/?U3,
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M4K?D>2W&VQXI9@ :./'(D>6@0KBV%FG $9 UDQAA43.O5HJBB#>,"X)(XJ"
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MG#H?G3(>49IX9FO6R,AH$%9$8&V]DD8=7SN2#J&ZHQA]D1U BE-1H/<4!:-
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MN6-O3,BEQ+"<Y]4F@_WY8EZH<F4_Q;8&!35VW"O;_V*OZ]??_+"T*K,I;_+
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MV3_BD'I;U#N0A5)%(K(8]"'HPP;C"_IP)_3A0U=MH/L8^G  ]A#L%_ [+/S
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MY7-!H\0C3["3JFPPS@K7R/\'00B"L-D8@R#<*KQ_\"CGR9Q9AB()39"$L*V
M'_ #70 "!H@"42 *DK!);,P.2,(>2,*V&V)U) DW10::>SPD_!Q\(&(%006V
M UU0@3NA C?R4X 7L8*@88 ?\*LG?OM6P@TE!( H$ 6BAX8H:,"&T(!]T(!M
M-\1J10,NLP5:EFDOLP6:QM UFW5$^!\\2MGG6(R"/$4<(-($-A]?I G<$?^'
M6,!=I DT;.0);!T- _R 'PB!QA$"0!2( M%#0Q0T8*UI0$D NB  VVZ"U8D
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MIUB_C4B#]8/)!/R '_Q_( I$@2@0!>M75Y)EJZR? =:O[298(U@_<]C?8U;
M9PD#! \('K ]\(('1(F0AL,+'K"]/ SP WY@!!K'" !1( I$#PU1\("UYP%-
M\(!M-\$:P0-:P_X>CP,_(OKO,T]^L'_%238!ZP?6K^GP@O7;">L'>,'Z@76I
MO\D$_(!?G?1P0_U_( I$@>BA(0K6K_:LGP76K^TF6"-8/WO8&S0\^@\\('C
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MR)S*6+IXS#[0XS-!_Z&?!9DF$N&SLWP4!AX[\3Q2-AFAQMX'R;16'-N!2#X
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M-[-KH"IHR\VGK=-N9B.CVPR7_;-[WCWM+A@QPW+T7])F [T'VJR.TPH  D
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M_,!)U9H"D)S4Z<DGK/RMMIR:(X^_H*1.>>CE87%R[U,0_1CQ%$%3A[+^ 4
M" !!4,%, '[ KX7J%?@!/^ '_/9N'8&@J@TA( FJM^_>UWSE;Z9C<"@ [I*A
M>BO&012 H*J#$ -   @ ZP\@"*HZCP[P WXUQ0\.+O #?L"OU?A5UA']+Q^%
M0OW3#WXNOBX45YH?)$6UKB,REO)I=.P'Z2SD\R-Y]29R#B$D.U+Q7/3SSSS-
M@O&\ZI%Z4!.1?SR*KR1X]/S1B(PJD=!KKNYI?AHF_7XDQA[U0B2/=>67W7D
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M#X09\ -^P*_5^(&;JC45(+FILV_O:K[R-],Q.!0 =\E-G24BI1MQ:+@68@P
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M&#3^<G/D8\_^U6W<TSTU8^L$09@@+_A)_KC9>,$JY+^PWV"K^"D*?7K'QHS
M'_<WETU'ZKO$^1P&X7KW#AJ_NV'_\W>I^<C_S@/W/$B\9'?)6$5K[,,WQ&,G
M9??FLH>RCRYEBI2'TGQX#_^/J5F*QI7^Z00NX=2(0N[?WQ6)%,AO8^HN@O_
MOS<1TX\"/G17[ ?QLFC2\.+2\9=;?__WLF[5OB9^E#.E=_YNF:RHIYV&H*MZ
M+ONG>^+X<)#=/E&:Q,KL=6C<,G<?8.Y2,@04VHP2$:0(I_4Z<<,F[MJ)V.,G
MFGA,QKUF,?]FRY0>[S&EY$V.]+>O4[SW%*<_QHO58B-U#K:/GH9K-D)/H)$\
MTZLP;OUP]Z#4L@2^:UP"&1\2KDC&"??K'"\"S%[71,V::)W$VR1<_OX4^BZ-
MXO-_;-DYR)= GQ=;9OS[/69<I?ZOA--_G>1!'_ZI$S]=^.'+7M]X]E++Y/ZP
MQ^0"48)47Z>T44].K8=G-%Y&W@:ZLEB=;&,OH+F]NJUEP^3]^.,/W__P ZC$
MF:V2_2,C S,F";W.5[?YNO4> V_%U!5V6UDNPRV[8 2/U^QS6'JT>MZ:WVB9
MOS^4YD\A1S)Z1!)\G<=N\WCA>-$OCK^EE7.6/6V9GS^6Y@=>)?CNZU1TFXKK
M*&1:8+*#VS]3!S9PFGRB2>7$U+5MF:8_E:9)$N)F DEJ1ABQUWFKF;=L -G&
M$VVI>^4Y#Y[/.D/C#WRZFINTS-*/I5D21(A"Y75V]C^H'B/*=;36 RIKV3Q7
M/[QO/IA2.J_3U6VZV,UW[24X9'CGQE.=!K5:15/[EJG[4)HZA9BXABOD7F>P
M^PR& 5YO:V=,/F^9H>/*&6(*.[[].B$==T 8K!.'L0:S$@WBDONAK6G+-'U7
MW@.!SA%X7+DM2U)ZG;)N4W89L+;TSOE<L^NISULFY_O2Y/"7";[].B'=)N1\
MO?'#':4G-&!]2JY])ZB>F<J&+5-4-DY(*D20(4CG=;*Z31:[NX#)_)I&MT\.
MT\!%5);SP!B$RO$CK*^5\[@OC98I+MLO& ,T[!/&@B /HC(A29@[[ 2?UR6@
MP3S5WTS5T5SU0]D<TF*N(F_D7Z_>O_9K=^,<W<'G$Q>OX5U>:9G4LO&D=5(Y
MX=<IW=<8J<YA2YN622O;4C+#Y.O\Z+%0-LQ6\QO-<_>'LFVEP5KY.IE#S);5
MFV9MNY:)*UM6*@R8KQ.FSS36\ 6VO]4RF=5&F%HSV>NT]K>7M4QCOE7+M)6-
M,NIUXG66M!C1&B:L\866N2O;;.H,:J_SV-^RUC!YY58M,U8VX:A6MM=9,FO!
M:9C)?I1:9EN7->=U7>B($IN[+G;.\97\AC.:.)Z_1P19(Y66]5 V]]1$EX$F
MG/)1TS'(&\'J=2D,-/] @JF[]2F/[(3_@WOBL^,+#?B&QNR[7";L7&;/<LO$
M*(>6);2_<>F(R([(B-,9CSM5>H/J>=8?_OQUJ>DT)N^]^_2GUK*$RJ:N]B7T
MNAMIMEQFFT/Z$]\GE*_R]BF,DCL:K2^#9_9MRKOY51@\%GYM6D>&638OMC^6
M;7.*736_-2D/9&B\TK,9P;X=):P;1.D';EW0O_*3U]79=W7NO5EU>[-EK93-
M@;FU\KH'&;7.9]M#58.FR1]$L&5-E*V*3;;]_(92W?)UP6A:,'MO$GWHM"R/
MLO6R>7F\[B$&G$+9AUY^5G-QZD>D93&4S:%5[J3\'E'I<'I=#1IBYP==>+I1
M:5D/96-K=<S]Z[Y@P_>X]WKH2ZME592-LLU^RM?%H>'0:)C+&[H,V1^^YW!#
MZWW@LM? !L&ZR.$.@L<KZL0T3<&^"_,/Y.:]NW9VY?OPZ+UH69!EJW#;@LQW
M%HXQM;LD[1;!?BE9YN!?*#Y-NTUDOU]7MIZ5_2L%U$CJSI_9B#_2&[IV6'_%
M:@%S"GNAT.9,S.*-D]"[D$T#:^4%].Z)UJRULSW6N)W^M*SVL@&[;;7++A'1
M)Y)V7*Q@Z#J^66HINT^@_[#X4PE(\D0;/H77+Z!_=$JFR4NX5'1T H9&UN@B
MC"ZV";C0XW@+&$=MFH 6XBUKLVP9S\7"Y&\.DC]WXW(X#[4U4Q0([P61W7A=
M5GMNK&(^VU7'_5]K7@I_*MNM"TOA52DT&3!5_>OY9_B3@OK#[G'_I&[C=5('
MX9954K98UP9@-3P2W$G&_G49Z5E&^]L@]B?3LD3*!NR&)?*ZJ9A<#07==LY.
MY36&WL3WK.5E<!XGWAKU0<5!>NXLGY#<0C9EST]\!U41QC7FOU]'WI(]^!BZ
MU-]_@=GN6<N:[9ZHK:CG1U+I5GI/8/:)Q[:X5(""FY<R(<29NDC?@68HR)&0
M1#P[$K(0%.;UL]@G%@J&^*%T&F[7:R?: 8(E[G-0JH%=?TZ?'';_BB\#KMK.
MG]DH0P BTZM_CIP@N0]<&K$[(.!X0\9Q7724#9XM2WF/$&GVB'>- VWB;[)W
M1'0/UK+0]],>HJ:/?21;Z"1>+:&;F(W]NDHU:835RZ:'!MA,J&4]5?@4>JVG
MUU6A=U6H!^%BFT M"2A, Z[FSS1:>C%\J0,6RU[T6]90!4AAIS64/R:57G!?
M=]:/U]6E[V3,HF*Y3:%JW]%%K&7=5* %=%HW2F O7T*ONY"&M" 8[S#@X,#\
M9TCL.*%,&\B:->TX?6FUK)*R@3V78H2&+,$,%H=X^ 88?DLX2^6-UR4R>2_G
M\33<G,=M"[/:NCX)/R<Y?EW=>V^ F2OF?+6B6.4O?0K^MOSL==P)^Q%M7GD_
MEHWYA2U1]>ND?-5=$/V'A>7XNC/J.3S/Z(I&$779@WD<4YYP4!-!J)5BRZHI
M&_<;#U+)%-<+9\MS$UXC"[4LF;UM^5W?;5D&90-^81F\&NT-'BWW091ZQ=@C
M@7,87X31?;"D$1OA@/U\'<8H0M?-8C#]EC53-J W'#AJ%W#SD)U PV+:#7R4
M=N1U>>VAEU>!;>X34[#W^RW+HVR4K@;R?-U<M&TN>^([I!:;,P^*03_36[K<
M1GB(GW]>^EN7NA=1N 8-8)N(NQ0VI>Z>G)IVK,EWNF6=EXWE/?$O<N8L*1W)
MQ"-4R$=63$"B2)B^P)[U!=_X.KXU^!^P).)"](,RZ+H3+>'-&[HBXD_UBTSK
MR'I!\L[UUN]$FW>.[W]#L+ST3T\1774OG?S?E3>A,.V?OXD]MDV*XLP:>L;^
MALIY87#D\A+K/?M92\=TKT.(@QW>Z1P9,WU&%D=KNGZ@4=\.5]$PTMLG1C1:
M;A_H43I(/?O<0*FYY[+;?<^]3G6%59$88>=(DL2^[TW(J$1=*NUVD*<[F9&E
M*92?U2):)4W[<NY3@[6OW/OS,#4.O>J.-HL]@.2XLZT4WM0QL25R9O?49ERP
M;MMI-QJ6Y&BIS;B7/)UH69)+J56XEPRE]RSUM[:@WUZ];Z%B2I:FG/X/;2)T
M>GF$KT$I -?[*RC1L"1'@_=W3VDZ4+(H4UHK;&\9"F_:6D\UY;3V6U"-1"Q)
MDJLRM5?W*]ZTU.?J0DQ[=;Z)A"4I]JY0M)> /:E/03LQH:78TE8Z=D>"%7<]
M0?<@9EL/ZR9*M[?'U<EZ2=*)UACZV;Y+K(W"^!I.K_GI3,^^MM-;GLKW1]5\
M>HG2A91]+:B7*+7O3U.7Z"7C(!YC6F^:HP&&6W:ZT!]9W^@)B*Y%/1G$>PKZ
MJ,;U,YB/;>W.$)1U/V71:&=LCZS&5;47S7%U[(Y Q#I4\+U8C3LJ&M?"  YC
MW%(ZP<OVO\+L07Y,2[2A$V8O^N/?[S2.PD NYK^$<=*XNG]*X_9OU/&WA.RH
M82:L]M2^?60@UF!?LXH6MG96<"<(O7T6VAX$1[4W[0LAI\$NU8_EJ*.D4ZWH
MS6#4$;"."J9A4$?JLP4+E168JLXV*XN]&7>O; %7TK$W=F(QC5'8#TQ(Y^#T
MX3SZ5]D&D:/I<^O&QKXWZ'0O()B^/J,^7.R/14],B+Z#,HC=N"NE*^J!CO6R
M'R_[XZ)1"=V3ZIA?2-_4]N$?RS#.YL^;_?.UNQXQ?2E/TT<_0I:RR7" T<3I
M-[LK)W[ U+]M?/3H.!L^HY2ZZW?GGQ/(,&+<SX/M6J0?77EQ,: <*,4R%;%$
M#X;V'?63&'X!XC&.-HXTL)F$*=0LL-FT;=''PV:@F#_Z(Q_V@#Y"IM.5\T [
M9$[[491[#9)/?SSZ<'STX0\X1E743'3W+DP<7V^?RR2;.^Y#TROVEV@-+&I[
M_QWO 31,J7L)O)"2R7.E\$VS+4C)BT\9A\M<4_9O)PFCMN4+O_S]TQ;RF1>K
M4]]AJEFZ/V G^$NE)N]Z]B"WV\1T^?8Q?'[G4H]O-.R/;'MA__C[?,O.Q3"Z
M\*+UI5OH5_FYEDXU;X'P2]9%\</?KR@;E#K71/K!;MEA]#FY>Z'^,_W(MH>G
MXD@/)C?: ,RC""Q/<O/[Q#29[)<[]E?L+%&/^YA+G2_(O2\52XM0)IYC#U!-
MNZ&;,$HJUF-MT]%F!G61LD4\&]>37=9$K*WYBQ.Y6;1.9MD%-P(8/WX) 1P$
M5B/<<&MFTP;G<8>U9"<J"_=0%*YL6*MSCX(&$;$%OW5\<)(>-PVSY9Z,-NQL
MGZ.[CT[T.TTNMH';O)W4-)[8IRA,]=OD*8S@,HPV>L4&B_=#87FEX!BA-S"S
M3#F@EPE=UYTAAICI';PX2I2!8__*!HW](\N^_YF&CY&S>0+0B/EGKRAS<]O1
MYOLR6$9P=)]1_M_+X#JB&\=SI2U,>&794;=(GFC$[6(U\]F36%_A:S1%MJ"\
M&"(5,V IQK ][:M*I>Q-:[0)+5C_[P,OB6]N[QLWH>9W1A,E/6,O@PT[ *[H
M,_4_- K2](8E18S#_EQO']AJ8)=DITH#*[<9?XPS&T%\QU3V$U_)!*\;Y<IW
MQMS*N D7O\1=FQ2US4<30,8;PP&7J$'']S%=;=E5>U6GQG9Y<S2Q8*GPG=/W
MPQ<>X)7WL_"0@,M@OH:]M$;&O<E8^N OEZM(7/'G2<)V4NSDA>\\5GSY#8U'
MFY^:.SR[V2ZW$2!AU4Q(^WOC:;&I"X?'$>S0)%1URG=Y0[-^4I%64WFHM30>
M;7!Q9,0XM6GXU6W',P&APGG:N*SS;<8SUV5^9] X:Y'*BF:YMM>LJD%SUV6Z
M08SWGD7$3JEGC^W;M1I137.K][DK-G:/N"N?0N0WHWZ6P_U4KG.U34=;-*4
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M[/?N9,YF-O?>LN/!S-MJ'NY/#B\:!U@]7K)- $'V+^PBD3SA'E,?N=?MQ0/
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M?B=W)-!PV;5H:";J'O0UR_Z?S@MC^N1TK\S6\L8$3,( DJ@&2+8:?TLO3/,
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M'6*I4Y3)9D$;Y8%)!2")_CHW(T<8O1D_&W?D-_%?B_.B2RAU2C+)S,4[I-'
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M@E?]"8"-[4)DZ)=6#:+N(J]U) R=(G=QZZ*<AR14._"XE>I:6D52\HQ'$$E
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M7=/CE(GCKBA18N:?U+T/7#:6V<T"#*YQ#AS]!N[7@_PR!61T)&C-PS*!86A
MB4>J)F\+YVP98_IU&&T08BX,H.[M8I7[J>_$(G&,ATY)S8@+D=)L^><XF)[F
MM% P1R[YR,[B;43=17 #7VTDXE#B^R!\B&GT#%?ERX!]K(!($RS9>8V]/-GA
MZZ>^$\>#ECS'ZD4ZUE;Z5(8@%SJ?C8,]\TD)QV8>N%(K8[NW=E-3!7@/5^8S
MGJ.:DXR.1[$^)*\LWW%8+%:,&.0QSD7.V/(7#^Y\17$+*V6!!3!0 0YHGIPZ
M4;1CVU OZ*]B6@HZ4F$YE6%\''"S<E:RM+O==!.# Z#FDNPW!-9S1(R,@K^_
MZ <I9^[;E<(6(<$.4S+%4GE:$&@F4TX0I]I\ 8?LC.Q4*F/NLQ-27$6+Q3"@
MN[%Q#Z=PJKMB[2, (Z\PPJ_"H^H9(X]A'3AD#O!< L5DK,T?X_P21$_"P,UL
M'#J.=$&8 &4+NI1&.?PJ$51[E2TE:V@YB?.L;/UED+!+5NPM<5N<0H$/I7,
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M6"@D=R)6.W6'F-UJJ]W,E(V"I,Q1'9;LB>!O"5W!X@CY^@;G"QJ5?%TS]B_
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MD9OPZ_=0W!'?6G_K@H1#I(W1^,$!8"N97$0 #I_=NF2YODT@/PFQ7Q,7N#P
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M]FXBZZ]0"\$^#$XP!E>EP'W45M:*,5B?DKJI XX,ZY0(_1NIWIJ R-^Z/CX
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MGWE>9A&_[-!7)_P-X75B<H$%'H&E7=C2BEVJ* XSCN@: AIS197<J-5R""O
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M[WN)15SZ2&!IX#>S8J^&<ZVCN=3,N/65Y[8#T?Q"Z]0*\X ^R">^SY!23RN
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M&Z\.$B I@L9O;0?UZIT%LM,9F(4;K0;4"L[9>"ZVIM^%-(7'%-^!,?-I-FI
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MEZS@S#V8>S%4]F<1WR)\@!WO&>]&@M=P+#46@*MC9*O1@G]\1C$^JT2T  A
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M=HS3<'+F^!9JA%R!+)/J;38"*690D$O\)8686#2="!ZD^1,T(&+R-FV!] ?
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MYFV[34+\<H.YR_T&_P&G]*M@?TAB%"IL9)ON]MTGS#JTO4C0Q1@@]UC20;O
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M:7J^:*3];=>H9 VV:<#?HZS>2%,#HIR+Y0ZO/"_)27A)DF0/?^*MH]7P#5C
M8KO -*7T'FPCPO;)^X*P)M\LVEWD3,B TT^<F6&UOP47-D@*-1R^QU(_?J-$
MR+>,YJ$Z@&O0SC,@&6#_]SP6MHZO>?QJP%G(UT %ZB<:T3<2"M[W,9UE#9SV
MEMA[S!((! .M;?H+20+&775[[H^;NZ(N9VH#< OV,'%/U@F'++2#Q_S)TV^B
M,<JY@K3!T>(J7J\/V[J=0JP-ZAYRM!1Q24<P(*I#F0<%SM>)F 0Y&B6"\I@J
M:OB-BKXT\=96^:D\MHD:#VHZT"8@5(0@#:%BAEZ;]CHH6P=%?]/C20MYM/;
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M<90%<*21M^_10\<GIYYCS94IVI8JHT4^_MS0X-S08 8Z+-,-L[TR_T8ZW!H
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M>P$F&B/+7G7U@\-.I=E-H'\QVD0E0@Z!;WX-*G'>N@*'5&)'R6#:51"]D^.
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M5#/W,>L)&#A?YE@<O.@FF7I;NB/__?]02P,$%     @ ]8%66*:\'PN3 P
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MX (SW3+=01B.G,2F(UAQ6Y&1:3"_K>.NK"O!ASDEETSFG F"OZG2>[0T<AV
M:$EM0[WG!LZD;&GJU8#B1;]) ]_[]>6>):A#T#V&#IF&7KGP,^989Z@A"GK4
MT?B!STN/3ZD/%^7$3.!<2V/A.:N;%'ZGH] 27KVZ/(CH#^,=7R.S5N (WC)3
M41&T2AY$W/?2[7=^S^-_S7/O3J?8-Y,%UU1BZ+27$/EM+>^TX!]>"'ZT':5J
M\,%-8:4W#AJV1"_3R-YYK+2H$R96K#/]O>-BXFXK3Y\L)OT]Y]]02P,$%
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M,T ,/G*CJ>+PTDWZ=>ZVWCX (9"B)1K+< WP%"YT .#NI6'%A)I/;V0^4.E
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M>B/SH4J'@G*<G/>K=Y^ZBC8B*U(U%G@Z&B@?8O@MGH$7SY,#;C^,6#<'/D@
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M@/A$0&Q^)T"D##;J&!MTZ1$,WOAPU0"I0"FF F *IJ4&9$4/XRA",(T(O>7
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MN=EMU6VKA:Z?[5)%KE!E3%0A7B3&<R9I! ^#BM9-LFM.VJ')$QEG\A3*V(M
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M FX%7]VVI44 K@!<.\**'7.I R=:B(^4BJXPZP[1PU[JHGF*I9$QUQNC1VO
MR-:OS155L!( 9GF,Y[S%DEN/ZY;)1=BWKD-"2C];@#DZ_)H3P$E;T)A3J=P4
M,P#S'.]!14"$R2I[)(7@,Y&1#Y1E=%*5:U]G%^:5T2...#8ZUII#4R?+#A_
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MDBM46O0(+D&_P0L2"=!72DK\]8@#?&U5.^L4Q^\4-$-8@<\VK0OQ80Z5\N!
M>,HZ?R)VPD#T "K1&\(-1GO0X'>-ZO]:%SM]7V-L?@$I7,$N[\ 90%Z:N>&X
MX)V1(2*5HR.2 #:]MU-QVES-B@L#%*X*O#O65Y=DGMUDHJ^0;U_%8KIT%;WV
M/8,S5(YK,=,H.%P=9;P1F8X+:4?^K5'T:U#[A*_(6%/\A*1*:G6T:<?PDK0-
MOW,NNL,8-*N&Z^0.;V_M6YH"*V",!D 0$+1:KV]P-R?.H2[415%2BZ&.P\'?
MM8._XR4974T&AK-U:N&!RC\%L4378C) >>#39>OR=:NGCZH'$3<H4;(U&*D-
M!X:A3_12#\XKU_V#*S3.1I'>&(#\UF)NZYM.:K1UB9[9/F9$"-XPSKS2%M8@
M345A-U2JWH\S]Z'E="3SB]"EX8[Y<AH;,[&[2WR!Z>4@,-!F'>L<Q(BK:6AU
MBDJ8,U!7+QE:@R!Q%,9V<BU&<%C4JE.RJ"<@+9W6=-9.S,!V[61)B0*;:+I_
MT'0Z@B9"%X"C8;I>KKX*V*48.:74Y]-'MI QARX"+!UKC@/"OKED*>57G.(:
M/K/)'8#[C DO?Y)3%3<2&&TVZ,E7U_7?LZQNYVA-M FB_L1,O&L""0@ZPV%3
M_YQR[],O-@E7[,9G='&<WS<4SN<3%BPZDJ/IJ#=CK#6=8[\9S-FZ2X6KOE%I
M^$QV#^R'BMFXPVXK&'5P<)^-SI\=,C>^$VV!.9^7SEL$@7BC6'4@=75\]<BO
MGJ^"VY3R]ADN@K)3_ 5O&=];S]4QL=(R^C'AOWLN/N\JAKV#1+K]FONU^KJB
MEMWA''$,WQ7Y;D33)GG32 [7^,8M(U%!%S>2D"#=&>_5<[7/7;KBH*FLT]33
M04G",E+?HU Z!=JLJXM.4;@\J3.">)[[FRZRSI0(*"71DC41ET&@-R]W6Y79
M1"_!WC>H1<+WM2Y=Z/*] \[N^\39_7C V>T/SFXG%92'OL:> G:O,^1[**Q>
MM\N<'U!;C5^DN79>M;/$.XELY#'Q%Y.<G_SH%8!?A1F+7-KAV]M4+J,KKO1]
M=G)RUC@P@K31=A)SH_Q<S[!@09-*%]Z2PK\U\LS]1MK[0J940K6I:M$N36"#
M6.ZR-1_XH4H=V*  -:423='8.GF-J@+>\C44=7"WX"5#*WMJI(-D$FB>(F%.
MMH?9/Z&GZ5 &85OD_J931&-EI]N EB +WTQ%KG[S[B2?=7./ C]]K;U<(ET>
M^PQMEUD24A5]GY>8#W9G%P1\@9W+<C  W'W.-5E")[E4="Q"=$)^5S$'\D+[
M5FE,/BG$)V.)9(YZ*]'^Q#77DQ"+%3LMI]FEFJ_"ZLF$&L'F?>XHL2XT#H @
M0Z[Z+)81J+C@&-!/IJK,ND&&O_!ZNRS7.0*::F]]<'B;6@@4,2<K9E[G#VZ
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M-3E?,"YJ<&?LO 58'.N2-]XP!/?@&B2!0" A2/ A$#Q 2'!-<)A@P=W=(8$
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MLT".XULQ4_66,J!<752F>YVSQ%\85NM.\BMY<3)F"HNQT=@#?,*D^!'$KJ%
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M[L]AX;"%^^N9YE,USSDI.D$R_,PHN^ 4":@U.7Q8L6["RGB:)X)'N^Z(YV:
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M!A.Y&6K)"IFR;)F-WHOQW9@'#_-.;<TI=>)Y*FAM:-7K/L7:TZ)V8UUB<J'
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M.#>.SN*X_)P"W2>QA?91"8;?7IE[I79MZ:A!-"X?I@#E-3=<57^OY.7UJ\.
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M')C&-OR9HC>2+*UFSI+E5-BS)Z*RJWW3U?PO!A("W#D%]Q01'(_OL-4>9I"
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M1)FNSM!KY<WH*KH@Q>8XNB<?F*W:OY>/7-,ERTM:HT5"R0T&+IE+(]:%G1(
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M"G[*^(DVI*WH:[\O,HV$E>4YX8D? X1:^P<.PD9!SL [008K\^80.BUN;IY
M:23 ,T[-.XC-02EGUZ"G%#[@*/<.Q)U*NY<!&*T_34TKW!.XRK#+#VN)^1K'
M&CWRAA;%!3^C:6V$;M>?\L<4F10M\-VK;ZZ,[6+E/<?@$NLBU,O+MIJ 9OIX
M=O_TLI'AIRM':%;W,2VM(UWV8BY[DJ0\GO*RN<9^-LJBR_TYAC&M1PE.T=P[
MZ)%YUJ<'7?P>-4NR'[N[[]8CMMUC^2^?JZ*"<E_NL7UR\<+) _'J[!K(4 PZ
MQ1E[EON3([1S.M9*(:F>=@4?WT=.!F^Y_#2=6P\4VFM]@5.W,0)2G[&CNV--
MD&8KCOT<K6#(.9BUWBQ[&OHUPR\E4H\9.#\*?9E?0Q+O3))UY@\I,B_3V]>H
M3Q6(-\S/PB?X4O-;AR/B'FB9;]6<? 75<3&!OS,$\A;0;;H!M@-9#3WEWS5'
M?8@$B0V4"0^XBO:2SWM3M?H3NJA/V/)Q6;"OGHOW,8^@#\O-H@ 0LV"5$B.^
M[320QVN,*>E:3DHT.5"( [EGSO'HN<$4+[G.!#B[[_;=<-)@N=='KB\WX^A2
MY3?XDC"'Y=OM&=BZ5(0Q:88$9P"D/AJVG%L"MW;GTM>7C >^XR^T$GS:%*5&
MEBW3;4Q=!_DBWE<^+P:['KUX;8:KU+8^]G+LSUOS,)>&9//.[EZGND."N::3
MEG(7)3^_L>7/B]@S\MRD;4I4H-!@./7)NVOBQ%H6+E+X=UQ8_3WC>@B"*HIM
M\PH),,V!ZX9N,]A^=3L(WI.DQ";L]=3M,SE-OBG0_@&%8II:18X/NS0;9A'=
M.O6XN_ZK^VB2JJ490H=):-/LINTB&,ZN5B^I2A;:0#JJK1.5_/Z6<Z?V!2A'
MD@E92 #NG7$*6/*Y@KJB($HB"+?KD6/B7HUO4]CLB!8N/B#SQJ3;.Y8YK-O/
MU].GTP.*L6;/2&T9S'BS$/V(PGA:+39Q*8;^:YGE=#C#N SD1#A3/K<27HB.
M9\F\@Q#\CFL@_!"(>#TNT+$PT@'G/_SM;DD)^M"Z?RS$< -#]'"%RH\/5@::
MY;$Z.AWIP1$(H]06R^_6XIRM[3/V.'LO%^3PGM_5Q0O>JJ,7LS>9+;^QP^)Y
M:/I(C.I^W_*BSP1LK9ML(^P.\4 8L5:ZN5A+7(E^WCZ5(^W'<JFG>L)06(?P
MKUD+;P6:5Q@A 3:*!87.P-%]PES/57ZQ_@<KE.D#,;=,N=E,.2I+. RWGCK^
M:"'+[SC]JIK,@<)D?L\)!-KP/.&C3E5T+7 (#Q=3IW"4![OC>V;<!A L^^4X
MIY9TK=A%\$=79+UTB;[^CBN;WVI@I];;T(%[)&K-&#XD^'SE\QGQD"L;=%M,
M40QDKYQ+L$L&#7,X@4QYX8"=?XQ9?-)6@&+%A%43/-F;UHT'B?,F?4!8E'WB
MB))8HZZ=VCPSU5M;/A?<5^Q<):OZ&X-2V2/5?F*G?Z*-L-^%SIX/Q<<7$YFA
MG91]!H!+B9>@*W_R*?\57WK.$STDP#4S5O$G6-*9Q] ]8<U.Z40ED0/_@'O?
M:10Q^@:#5HLVL=7-<"/.9LM791VTB8 <IY=Z)FYT-20P^\44-& EX0E9?,;U
M!EPV;]_+;F13=Q&?ZIL\%"ZJD"80/<=*-]R Z)W&].:YK0UYN8DL*"\$)UQ%
MR:'24<916,*:EM11$-7OGCV5J&,XN.1]4E9P_^YT&U)*_Y7X0Y<K$N#,\LV
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MIV3/.'C= 0-N/+]_?>6>/E-E2]> %:L[/!C_A+3S-F/DM*\KAJRWZWU3ZX\
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MY111!]-"%8_R9]:F<0JP/EJ0S&U<![S'N!1F0AD[O*@FMLF Y;+G61;O$>F
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M7(:QZ0:X[N%?7@96? .O2I\-=KZ2_Z &4'_FJ@7EG])?4K9S(HVU,BP,]ZY
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M)VBT![W49R8N>ODT_WFR$[6[^.![CPB-:TFO<AG<?-,UIJ1^V8UZ-]J36@M
M636&EE2,(TDU1K?IG/H# D*/T/%V$3%HS+2[>BM])'?BY]X6C7T#VA](\;?J
MZ.:/*(=C;]A+Z/(JQAIN^8_7K:QS7I2;?O1;9'5I(=;B'U\@?24.19N?>_44
M>F(N0EN;X!MHN6@?3L;8F/SN!SGM#4=S^CPLW*\$CGYOS[4WD'B;H:>7[>TZ
M[B##Y'(E5[-W0XL-6FH,C_NGK@WSYSWB6L>M2:L)=8U"4TWUM,2N2^>?I2\/
M>2)K"]XW3+@.JM)8S';H^#US2]"$<VW99J5FFP)*5P:MY4CVON=<BTV8CW.F
MB8L;B7Z-?<A)P1J8L",5V[3?-368;PS:O*6IFR!M0=4D#>A."/!HN?LBQ8O<
MVZ&HY@@^5E_-&5JA=2SF&ZW 5BPTR3H9GKMG"1@'*23VFFV0%P='B<0U5/X.
M$)9PS?O%,*ZM7S^9$U,?,8_HMQ-S4:1\^2Y(PEG.J(&V M=N(RXWKI,,1!(:
M[.XK7O0<*C_]X,TSGX[T4L7 )OI!,1V=2X>P4DY7;[F7[$B1:-15Y[O#EG<(
MVE2G.\"CTNCL^$=TL9NO/BOV2#E\#FS=CYY*VZKC;PK+-K"FK(I#/H+HSL,9
M*N*-Z98(':6- !O0^UX"1>A[5$HQ='BBJNF:7[0_]ML\-^$=+_&"K)YVDC8_
M*1ZCT8(D"U?T#_)PLYWNO4Y\/?*#FCI-DG*-(U>"" T,_FVD5>%)F,<C[EEX
M2#]+<;>U*-KQ(BU:*9KW!I7_K*D*F)%SL$IZM-;8SAK*A%5-OAZ8:F#\9"-D
MUW*R0=PS;ZMZJ.#!7&PQAD-]HQQKNA=DL0/G,U(?1:1\@%KXP9^<G[ ">4P2
M\&SU!DQD!+>_ML[4._?K?SUATA!O!5V=D](4=?Q(*AJ'E4<.VW\T;0 Z7^S\
MHN) )\/V\T*3YPG#/2Y\ J_[)N?ZW8)0O[C2;=!)96\0U<4]X02#_0NI$"GQ
M9I9-VP879WXE*G&P=-W8E+JHG<7GR<GD$GCWO$17#=4\4+-QY.3F*5_]N#M^
M"2*H-%'+,HH^Q!\T4C9^/*BC/_96=>1DR^CEQU^]^6HL<G:Q=P!!W F,,1L_
M<:@#RNH8AK]WV]?M(RCXN2Y?&S,UXW#ZM.@.@+ON>4MK3=BSN]O3\8OZRU&E
M\Z7*R6+0+@1V;U^NN38-')'S*W[AWI9(L_+/35\70^/V*'"4),!:W5":@:A0
MX'Q5L[A9%/(P\#LT/3@T*W\;41UQ8@T?E%P9?59K%;_ )6P:[3/9-^T19=1X
M$!J<*>,M8K!]%B]-<G0'*+[B 3:>/#LIN%8H-@(WL4.'=<8@I>=RQ;./',!6
MNQQSM"7^]2A]D;7*H<9<*\3OC_:X_AN'JWZ0:7E-5*\U?0MN!C"C\QXP_YKG
MU\^QU?I1"(WLK';U:SJ#RG'!;RV6N(^Z\$@=;22?\M'<._3NKAJ/%&Z.?/18
MK/PEXJ'<P2J1'F*_P\[-B;$I;CGY@@1E:*X'2S6BX/(<XI(JKIXLK5C$V!1A
M"ONBGD@5/KVP39I8@B(;<"^,=ISIR<"+(\A!)45=R_SP<+[4JSBW;8TI,>-A
M;.Q= G1+7'MK_5Z+7#WDVN&@R!W!?612&E<QAUY(Q\>8_I]W 'Q>1'6#<(DU
M@B,$ L[V<-&+@2U9QR'8*4#+-\-N#%/"R_/O8PLA^T164-3ZSX$W+%4$:Z!2
MD^"IA0#Q2$+4?0OIB,=![2,K4%\!P2-ZG5;#%FJN5N+MAW]])$DBIS=F!YE_
ML:+2B&NW1P8.$1*ZG-QFQI1\,PKCPZ/#X^G@J@IX$CC+]"6M.48+S13"%T<R
MPUY59+?.0MVU[58.--5_IXY%OUP:>DM[T(AN^A6D9X\.271?^*WLM<3EE@5#
M(3@7)6V&^GP;/#D-G4^'?2+W\C,(Q-!YH4/?EYB/4S&EJILK8J7,*WWVNB5%
M/KG4\Z\[>L@:.FB.L?/Y/UK<2C/885P;G"7DPNZY?TH]-7JLCL6+],>P,F+W
M6)^PFS;H$B@^J)KJSO4>O^9?\B5H^S0 M:M_Q$1E!I6=VQ7GW3*D(<88MDK#
M'>/[PYNK3.$-64[TCT6&59.ETT*FY>JPV;:=Y17J.X")WL"29Y[;/@SR^PGB
MD*5&NB.=L1,%3>.*K<_%;JL2 ,Q<.:]$R4=;G\_+KA6+F$ZC.M>(FM=F T3\
M2&IE "Y0_R ^%9$-;:@0S5!1>B4#K%:74($<!2]C;R(XUT1<<(@E1]#'G.4T
M?"&-!N:X3ZACO43ZAT')(O=-&IH5XCUT/C3PV/5=4L9U2.(UB"(5,M,.'YG6
MQMQ[],.WN 47]W+*^/=#ZH!!KI($UH(B?NFVFJ()+_FB9]SOFWXY'WV_E I4
M/:CL#K,;TW@O@5KJ3;RH.S(D(<9(_6&5Z$<S]GQL%S/*RN6GJ+U8RLDU6#:2
M&9/>.,8L=("/2RFJIH=(Z2>^5]S;35%XH]E.DW&"Y;IXYAT@1RZN(G=)U8LS
MRXL2_A_F0(E=XG2J5_X.+Z8?-[#;WZ9CI"^5="*K9>=7:*# \TO\MFH._%EK
M?4;'CZNXG[OSO#I'5WFM!<;X2E^:]7K2'\XT%2$"./_6" WZZA@5.Y^TR,F3
MU]P0>;$;/_,KS!]EZ15V4YN\R6!0:Y2CP=@3WP9?^UO.[7&'',Z^T$B@=O^]
M!?Q<?44[;"K5O\:!BQ,^#&P3?0RH_ULPM]H_(X^V<GX$J51+!;/5/S[P-'[[
M)VSP[M$Q:M\F#T7OD%;+L'0S+ M3_-\:C+T/_5)ZN1^%LBE:.[2?J'B=CL2L
M=- SW24]9Y;[6L,=S2D]CB@3D^;\G+&@M/%-H#N=[_4ZZFSFVEAQKL(.KBZ
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M*=40T8*7Y6%-$Q]T$#6MWSA$G!:*P$D"^T@'7/+KMY"2NL4LQ0U:9;VMF"Q
M^BKK''2!-+C'ZE-GM"V+P,J6>G?N=#MY+*NHJY3[ ]T6BI,,@N>-OK2<3WZ+
M@)[LAT!^CP<;8=7FGMK9[_&8- 1MO)LXCGMX'JP#17:19T.%]V"FB _W ^+M
MN@&!6T;C?XP17:^3]?V21DKY]J<7$\.XFF\^>(QFT5,]#OKC2V(<-QWG!X:+
M2,Y 4&^-H1-B37YKW%+<H[&BEX]/$$&(/OB@(F+V-;;X&RLRR02U?[89S3R2
MWWY1/+A!31 0SLD]M;INCP4;-3!UDHTM[IS-KEE&*_85ZC_#Z'0(RT*9@U/.
MHT%MAX-=E[N.AT9-64Z,_0,6B=IL0ZH*+QI+ETMRG, 9.%1+;G+/#].%V]*<
M+J:BJY+,3=TQ8M8(E9YIQ;E);USHY((\$I5,$C?4[O&1X\9U25*BA>*((EJ%
MY/ L?2&[<3D=:%HRKC;9Y"C5FWHW<<<G+4^<\=@M-^NB1=*^DW0\"[G*ILV(
ME(=(>XW=A'**T[E0*=0\8!,)W(D\MNI'C+\UU%@V=.6S*KY*50?I&LZI8!;I
MOS$WNSW %*,L78Y[(H.T(Q57)#<B=C.?WF *!ATJ)25GE)2:?HAD+B#_LS5/
MTC,/YIJM9VZGZ/(X01E3;FL.0',0]JZSO#%-[^T:TG@7=XS-#59VRS?L!:CW
MKQI%KW2Z0(F2E1RGX2U'Z?=X$ZZZ\RHA[]TM*JK-)'P6CR;O /M9<NF"UR?^
M5YL3KCKORYC^!S&Z,?A[3V1\>\E/0XSQ#^8_F/]@_EO,,0]*:_UN$68>X8<H
M(39?\';DA5I+\Z&X5?/):?I04W$)FUI'M,W>;YO+A>+OQOVGT<7D'-QLL_$H
M#]+>=QI<XW49D3RX 3L/D)15/U#\3!F34_VT6_GL$@X,3P"VGQ71Z8N07^@7
MB-4,_W&88Z\7P&;7@@V(<7RR)D<3YR1%1 A@2,&8@.;AE^;.&7@^69Q5$%2)
M8/ER85$NYFU:L"V!,\'NFMJ%FGBO4?4KWT1/^H2>KJ$WO24)_L0ZSMQIV=?\
ML:?[VY:>GJ78TD6)8PP43(Q5I&4L(R%4"P>OPROPS:_VA\,B[^*\[0P''JIE
MG)5RH8W*R,)N&<_M#P^&72-R>XKAZ"1+AI5GC[-^[S,HMV[IZP_68#E5/W!R
M8<0?Y_3Y;&2QM[V/I&AKQ3M(RRZ2B!@44NS= );HO(KPS]\I)IY111&UT%9N
MT(H'>/SJ.*4E(K(-8F9HJ#69;D6\,;V]%"[@\S4_<?CHE>V.ESQ+I8#B>.@Y
M%R[K_S18BJ9N1T2?"R<?0>B%P7,'B%%S\K6VB9PBX^HH/5.J4??[7DHTDG?^
MH0F[@C(35)5S:JM4+GBD=/5$!.[;"O;'\7C>((=[I!>U%1'YC@V%125-HT:,
ML==;;!TODFE#6KSK2*R8_>5B$G&((MU9;ERHM'R8GJ% LZ(HE@0F4R\6QF+*
M4]QOD&&<,Z*9H.U4GV/#U_$FH1$6)L;()N?J>1:GH62DL&Q,NEVG%GB,PU\>
M>:0QH1??*39^Q,SPJT=-F7)KUT>O2!\\F.D1K%8=M*UD65.9B'@UVD=L5BH6
MQ(Q9D0_=GF?P0'BT9^Z;L_$4;?L6#;'[^"*CTO& 1'@/QZ]8V+Z3#4F 65)X
MF;NXQ&]8BK;=IM+XITX8H@U _<L3WV0[ K8]6[L5 2?RJPI9>O00U_<)YL+W
MWQ8-?NG2\;*(6:82IY(-F=6J[E"GD-?]F1'X9=I].,>X"CUXFNQ9I'>>UH=C
M7<PN,4T[V5_\^;AEV <M13-)LMZ-Q*^V?&\'VP:9!UD3\>SIEKBK$7(O?W.5
M5-S?=UCZ.<[4_+W9"5=6FWX$=^3^X2#Q4PJ+SZ8Q7K]2,,[' W$QL)X=TS5X
M=]'2HP7*#@Z1M[Z4"WAT9_W<Y0/*HP40E@$1DR4_R-3\3MWQVYFM.HDD'!8$
M0[F149F\'! BOVV%6<[ S/ )L&<-[A%30:+T#0X>%F<N+. 444U4UW.K*G[^
M)/U*9!5M: >O1X9+M+ZWRYKE7_WTG:DV7I9T%. (L'56HU;',I=Q]GN"UEJH
M]2ZTKHNI;!"L\RZLUU=H$L3EP>:'__V!X%6;GK1;-HGJW &4XH!67ZRPQ'4F
M&Q_\D:ZDY^?,?OP,+X2<UL>[57BS*683# H0:@ZGI8?S 7>M^#3 IS&O]G<O
M:E_U\0AMRIAOB^QW '%!57E%>EN"EZYB<^QI)Y_)ZG'3)IDZ%B]P/$1OV_IO
M6'/053^L\SQXM:&H20V8F=2CJX$^*<S?&VPO/!?5Y#=ANN!\9'DB][-$[<<
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M9W3L'0%5419NZ-M/UA,8JZ 4/Z[Z@\?G\A[VKYT>R^',/]+I]QB))MD0?D8
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M#W;)/@D 3&.V';F#$=7OSZW=%IY\44D\):_$KF1JKD@3*\\B^H0O=0U6'%=
M5_THF&[ZE3\#TD,(N:N()T-Z:9*?O??-QXR;/.G/03\LQ6]&XNF_2;6@5SW\
M0MK)?1COZ+)OE+=<L,?A(VK*/HEJW$4]671Q.&.0R*PU?"V%CE?*1X#FK:&)
MR1Z[/?SL P>8U\],@K!L-AN RZ/+QK@@:UK_M)$@D+()*1,3YEA@\M\"9Y1Q
MB2M72?TVO>B_=[R/,GB8O,2)8VQ],*^6K:O EN7"7VM*(7Q+G9:P.$<-ZE,
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M0V+:IO+SAY@[@%T0-L59.M[('4 ['$J"E)S;?A@O:/>SY:=\])0_!<#Q9E>
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M'PCM1@ KS9Y9XGU=UG&F1$59N+ ?\%.Y'#S Z#,#A)X.9HN?&(SP[?K#&\;
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M#PA?3<P#7/AW=9[Y%U@X)<95&8Z*!M?A1]4D/!!"0UP\V-S6F\_UX<1+R3
M[A!NNXUG1X-^/*7_M!NZ;R+VR:KA>*AZ/Z1^DGHT#R-$);!,(*KHE7.^DD.>
M92_IRMF0,=H0ZRG 31.6YK]:@: 6;JEU<JD\*R.():=_[&PV&;R8X2UZV*E/
M6EXZZB&7K]ONG">7KT1<+F,#B,9ML#70A11;+I!.>A@LM_Z*SX47IS9/C%UA
M-S7[JQC-&.S*$JSGCZZOE00&0/73J[X+_.R'3UK0\UUL0>4(TC#:_(]4C(05
MF'/I1'ZA0YB>I!P:'J^*%5S9]PU'TBMU)-%D%Y-L1,QH+"6(D7HWTL]2[&SS
M?GQT_<@=1Q&%<2Q[GWXB+A^F8WX',":+)A9T@#70/V=*/J7[#L-H2<=[*H&V
M.&VPV)_C$NXNQ(]]PFFD3?*MZ<6;LNO:3&6DG6W.[+;JLTS>[EP#L37W2!,X
M?IW*67&:W'B\=F7T,D<Q1]M;!#A%H&S&+FK/<J_\_G=7JLA@[=697\[HYC"S
M6JFG^F%3<NKN8].;F-W@96S-^].FYD;&&"G2-H0,5B$1VUW0W:[SDXV:GRO^
MP61"P8EM31N[A:*;V!=5^=Y: 'J]>Z^SNBC=^$/4+:NB&% DQ?#Z+0CTI?^;
ME(EQAVV-V;H80I)ZO=FG9*VFC!(>Q%FRMZ>K@-O\E6%.;GZA9;T,*)!*&M?=
M19:X7IW[M-7=S\[4"%//=XEF7L8Q-H0Y",PQJR6H.@=JS0&,_$2D%-\?T)KP
M%L@K^G:&-!GCN]:&%>O9POH['#Y?DMA%DI\S\\,D,4G2'&#:,U:DP/?E4:XN
MQ</T:O;$]@K["ID[VT6@?A[@'.A+CLN;@21%L%#/.1]:YG]\!4<#PH9T;!38
M0"U7M]M2R6].X8P7K-] OUNF,ATUU&G&BC[^(>+#]K8#UR]:"'O&6]P]%2P(
M&H;T>UVK!7-X@<839]"5][V3?2Y#H?4&KY""(+]._?L58WKO-H[?.J"C=02_
M@(HWAZF/-)&[F([*5%76C\"*.=4>1P]HQ5O;0X5A1]>M0+C?':#*^H 3O#%Z
M0-U8(^7\?,W^_FDG^LM#GZ%N1MJGBY0"7%@\Z:M^VLZ"B?L1W32F!GC;1PL+
MEZ_)LZTY?W*JO-O7]S]:;8U'X4=H@+;3OR[H/E#_P;CD,$GO-NHXB&DP[:$^
M)OJ.\7QC8.-I$&5, Q&\A'Q_5Y+6&>*^0G48JD\1T^'F2"KX:HSQ4_4KW52W
MQ-.0B. FRNK))-EHQ;0J6/=T#X%=L]#N65Z#]%**M"8R(@,93+$_,='!]2U<
M^<17A=JH$0).-S^TMP$I5ECTV?*0:SD=U X(#_%VH%B1/*.O G!UYW7U# PL
MZ7A[YY[:2^6=EL@CNOTX&I3 -//[\VVSTR#YMAF!MIZI'H[33N:.-.Q%E^ZW
MI=5EB?=3%];>=!E*,I"O B9U/*TGA?4Z"Q[3R@-?J+R-"@8<<P6,B-)A02Z?
M,@I[IA>+.3UL"QZ815$,*-Q4GH1-VR,WG1/@)2.-(BWZCVJ/%C\7G^HIRYL*
M$O9HMRE0::.%2Q9S-!&Y9 &; XTF8(&!M)N#:W0O\'.$44+ITA #/)>D3B_:
MH[=UQJJ53G&M"PI3'R3(&6DS'X'$'R)(2SZN%D8\0 8O_"@1S604U!QFM2$?
MP .LTO56B;Y;4E*VRYIW,7IOQ0;CX0]Z&A41_S0\ :-YN5^P%84];GVCY+ 2
M0:3?#BGH3=6UNG_)H)_6%PPXI?Q#JN>?;OFZS>E;:_KU$(%KPTI-C\]/)A=I
M4W;5RD4E'[>;-0#I3FL0Y]&2 ]! NLYMX"G@G>Y@>-6V(P?@D3CDT;3FQ!BT
MNIOB!DM)I< 2HTW_8>+QAG/*WG[332 'X[>6P?$\#*_@$XD %/U$ ,SA.S)Z
M.;L^<4%D5\L+KXNZ9+E[%R2LF>\NV*EGJQ2]/#- Q9(53C2LG2J?CAM!9,[K
M$J@,DH> 8$(V?8U-/#NR#Q,;L[:=9CACP;DZ^=H<0T\Q)G<\=^)#(* 4HC:W
MU&P+L@0[6S2728K-L6N\9O]/;J8Q1;OB='H&;Q'K_5U%PZX9]U@,%T/WV,;<
M5+$+W^GJY]NM4(C3R13(P\Q@.GDU<<02[/Y>QY$B!(G;E6 U7"O9BC'8@&%M
MD+&!=7A:X!M XV^5/26"1,6P@QP[RFH2Y=\QAW\:]DG^WD,]44.N*O;<_)^P
M<:\\:051!165".I0&36^%$-B,9<;4UG6'2FN@L2O<I__T5F4*_(I,-F,VLVY
M!+,&?$'X(E(ACMDEXH.M9V-3[-K&XCU/%5M&%./M_:V,X*.(C/_MEQ9G1B36
M'L"@D\1W@*%.P[&C!27;>T==+8P[I*_"TZG'1Z-#ZD]NOA22L4R[>IE9""EI
M+HPJ?A ?QZQ4GQ5T(J>*OT*1X)6P1\JL" 9-4^O+]2;3GO5!+?5">C@_UR1B
M:H1Y;V&_*4]]TJQ0;,Q!E!2/S^+2CB[G0;GK\HWOL/D&JUG=_R,S*<S*Z:3.
M]OBZGVW-4U%R)+LA4>B 8NT57S=5)@V/5\/[1(]/TTCG=PI<":JZ,M>[!DFB
MM"):8IYY\Y8\1?%J\:P">5WH$9(B[ZN%&R?2[I5*K_.IO3#58<#A$8;D:60.
M.L],7FJ/+V_N76JYSVXZJ*B$MQ9!0-=Y^A<]YC>9#+$<T7)"_*9*G$.6W(.V
M'ZE /XSA'-2C).%/W=;.&&9*C<<YC<,W).8+=&-Y6.D!^]NACOD9DR4K)D^&
M?=OH9WH>?J5!H]D* SHIE+0Z?V3EMYF!ANPU@U(8-9TTA2L4J.EG![,;2HC5
M"!M;'ZH(K62.<NQMU([PBX#>68ZH,*H\-FQ9MK_?_^$.T":7[UG&^;F 2;XA
M]@D S9-;*<:@.7ICP7,K9U$<F(&I,:B/:0#/JM9S=Z/P!%8 FU(6S>X &.J&
M[2J5M:@?9-R543UPG-V&T/T?Y*?;JB$<$N]]V\PY<$L27,\M2*BKUY<V4V\F
M7@,;U]!QP[$CJ9E[A7 G+\?J-(NLBSDT/^A/4/F\E%G:S'%0+1AU"C&82#M2
M8I(M:(BY\83V4UZ=Y:28Y C#8BL%3>VC+AWBGW'?O#8>!^--=.VJ1-U[K&O)
M-/ T42KA+11+.'GTS-.T=Z?-/$ZN+E$'@Z'A$=U7D=!P92O./NVZTI ^O]Y[
MA!H_/Y3';%D,.(Z#3N$F=P <5L>=.H&)BX,[P/*>]9RBY0+5R#)8G-\L8=3K
MO#>RG;G$S1?,,\X%V>H04GS_C"#F.*4%RMJKI[EMC1NW9AYB2_655'ULZ7Q;
MTPQ!FVEGRTXHZFZJ6DY CHG8<3_-VAF-NZUWU;8,TVYVKM^YSKT# +:L5TI'
MSS1'5\MOCW4J/'-=?QC1JM!P]VN4C7!PKI:Z^UW7[&6EC"=[=W #W/&SC7.#
M((R?91DCOMS 4-IS6N2M8I8-PIU[^#;#O6AP:<I/W)7)D9YNX]=N0(O<W.]T
M6K!"%0.MS0L;,']S8/]M2,_1TU([/M6>?G*&@V@5>MJSF&(0%>B,SC3XGDL[
MBW]?)OXAN@4>W-Z&T)9SBO@>YN/B$7S=4 >-DI+-L6<Z9B9,[Y_ZZV)BE)+$
MOHG\"E0TD+9\7R"K ,^NCRTL*KL#1)!+S-'UU@KOLD-7N_ OL(\S<1&\;V9)
M X%1%%%^3Y[X+ 4;<FX^O$\AUN]XI5<=;YQA<9 1;=/H8I#MQK>T<5&V.5F4
MWVV5F/@Z/D8'FI-.[9%UQC"GB0<G"=62V()=_[S9:79\GYCVA7;I&_B!?!W9
MP>*R=F;B-DR34S3$@#<$-S Q)I^#:QC#L^M**XTIV%*?[F@_Z[,/^W%H>#>N
MG[Y_:*@&.9\B.4-E&,,3,'6#!/=2\N;N1'FNN+K;V-SBV3SU0BR4?_++WGX)
M%I?U?D[ QQW9%XM?-K*KJLKBE\=*G**\\WFQ&2);D^[1Z:[4&>R%,!32J/1V
M#D?T<>)K%$0A%16D:H.U9,!MS+$): ->!W9 AX[N:277PRMH%%-(/[/?BNNQ
MB8"K]=EU5<RR:9,!#K!">Y;QD?F;@9)X46J[B%T]HXYHJ>$7EQ1O(L581?3$
M%T:5%>^_#W%487_^<G57*KJ"*N<@Y5SN><X@XT4J;:KL/(/%";<U1(@8I&>I
M59U*4QVB&CV[K\B5PFC)(WGZ"U>H8 49V8#?VD6"#<T-+R,>NHW"3A6I;,N^
M97X\?]%&]PU17S)1DD+A_A)JP!"7I#UF?1H28L&5XQRB1MIL_A[W>6CH$7>?
M%PE\F0LN/WFBJZ<_:&G\R-(FWHH$H_@%/C!$_VBZUD<I]/D3JS('41YYK9\B
M=NU.^YH>_-GZVR<+BI\R[IO.K@.+NE2_[=A[6A[4OAV)3LV.(--5M%@&;2^!
MRY^BP[SM3AYVQU;IJ710^F<)-YQ'@G0Z68O>U'*^.I!3?EE<@&K#5>X"B61S
MX&3BH'6Y]C,*:V0)5LQG$+ CBM2HSS0&)%((G*2202;01XM*!4C3KH.M@$3M
M9A<[;Q7ZM)&RF4=@H\X)MAQI2N V7C\?(@]02T[@*WP]J6B4,VMQ96EQOJ,Y
M3YP1-N?M>0>@["\[<HK/E0^SG+3[#'U!7^N9M2D:NC2>$YJ5$OVR9ZDJK:7I
M>4WM:]ZDD.B#]@T<\4.)6/UQXP!;G.EM"S#UU4"N%24FZR.T2I.I<_3J8M$G
M67H+"@[L/*9:^.R*3PAZVNNYI%7JC\+CW?/%TU=61.)5_5=28M9IL+&S@:;*
M[)LWBA!;TT2S0,[-6/8,N%;M5]G^34SR]TO.#,S;( F\0_!! XT9-8Z"G[W0
MC"S>BOLUY188QE!= =+@'"[8QYRJ(#A0>18FW+;XMC1X8/Q-.ZF4KT-H\AT
MF$$Y5B.BONU7)9[_^+_L7D#\BC3YT3[B*Y#X^)+L\Y>Z.P !3:%3']U'^.SZ
M:J^N*]0YU]:R#4%5Y$7;Z)3(\E[N9W3G1L')6 DTVV;ZL36XQ^2#H4&"EKDH
M! ,^XBUT!P@QC@C4ZI25CZ;&-UC@,+6T1RYVZ%/'R*G@ 74Z(?>#BIGJ\4CN
MMSZ1W W>\U!?/D6(^PA\O<"U*2\7_%98$U9$E;L,')9;EXK:%"'F]+23I%6
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MB%_B'OT2-W(':!.^ YP<-5_T0SSU2XQ25LVAW*'/5ZJZ ]-0[B6W)\J4&'>
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M0Q/KWY[V J1]&70#7]JD#,( &A-5QL/6XI-,59UMER&T?8YSB]Q==ENLR)>
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M<*C2%ETAGR,O46SR A9)RJ/PH>:@F]Y=E7=(].5*OTCGLYOM)B,Y,XG(@1;
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M&WXS=H%!]I'!)W&N&^!!MM2L1"U-C" $9RVX&/>Y+>RLWI9'06)%A1AD6@O
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MRG,70_)*IY'E@RN*@^JTQIC%#%RW[,G8G&EO?EU-\:*E)K:^#FJ:A[F(./\
MRE3=YDE2)C*D8(^=^,ON["@(DRDJ%:?">_;*HY=TYYG5&./U11"EG&9KM#90
M7CXQ'RN2E=B.L-/J$9D(UAY<"Q*H2)I=/M)=[K_>,$Y&H3%TTB]-D>]&#,06
M86R@ ,<$L+ DJR0=W1[=WBGY+PZ["9#/H/81P 7,_G Z>0(HIGZ: F<W-]4U
M34%-(0>?$".$@OI0K\!V6#>!;"]VJ_6E$-X5.]"3ZP;*2D;.]EDT(R1![[',
MK9LBDY/K@2';V6B!H!_SMF<#=R4H '6)D^V)7W4P[Y3RK+,%N6WMY6-X'5\
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MD/03$"(:^LMDY^?XX[XMZ@ \PW((") B $Q\:>PJ&M?%KLU7VZ2A<-Y(B@
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M4)0OM<7.#\#Q=SXBY;2A5]XM*D4,/VD2:C?S^3Y6&V#<V'51O:I-<@ENB'X
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M6!2K.LAUQTY8A=^Z?\;&H7A*247-QL[!R<4M(BHF+B$II?1"645535U#3]_
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M]1Z@2-Z\(M)65]U8TP)-85,EI/)BD=R3UYZN">0JLC+SK=OR.[2-8ZZVGOU
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M),8YIR7&=,C><,>@(?1*RN==W1-_/DCU,#(=9<!_T6#*"3A28;J""E086<H
M=].^+E<\(,WLP9/:X7L GW-<5TZQ]GC+LAE"H&S.-4F]*>[F67_L/> !'E:
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MHZ"TK3/F>U[&M0/EZ7SZ9C1V>_Q8N#>P,%]8%SU9K=#"CO]=6;O>._,!! _
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ML4X6H1-Q ;B V+E&F3I7QD#X.)IQ"Y5=C#Z$UONM_E2=H ++\<5)H!@1*L8
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M]>(#QX_+<_(<-P_06JR=YIV&R:)%7X[4BS],5F^D"!4LQU:UR7P)E<?7?DY
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M+?@\=B$=ZI._6S][:YD#E)3=B#1&O3.8X^%I'>9UO[(B0'+XY @K?](N?_D
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MY='L^CEPCYA\<2J36>\9FVX+YGAKU05:DDQGK=PO\:,_ +S=X74#S9]Q03W
MO?:7SM6QO1O';AYSQJUH:P!#]%)/TY-*S0RV7O\Q]KQE@A=H;E#Q;YB=GACS
MT,WB$.<IQHJ2C(C3Z/#"W;5P)60D$1!EI/'Q*4J[\PT$Q==",N%Y#%O'FQ).
MM]TYEG5+5E_(%9= 2&^REJM.4'-/\41_>Y6.8@I#N5D2 V5<OC$&*HWB(:]!
MI:O-"_Y?S<7!^!;:C3@J2L^"X.MUY4Q??VQ^7_4V/^50CX#71$O.W6X#8:9\
M%>P\AK#6;P>]U)[]MMY-C@7SW8I\RI\53-BZ98T'QSVYW5B;<]SU0R:<)(8Z
M 6C>5K!/G.6+@;V#.E,B)J[%RAL_*<"B:.JZ!8&!*60*ET37(G3)(L_3%3,)
MA%X')] -TKVG++5>XN-FW5!.+$JV2Z;1?\ CGL]U4V8 9V2?V$D:?,MO2D3"
M'J=M?I#0!KB5L]VHBT9E9GDGD[R4SCA: 9EXKS=CC1P:A-8YRJO5[H^UX!$6
M" TRN,[E3YC#Q]4A*ULW(<Y\(-4QW3O>P>@1':,AQ%KJ^6#__.M'4A#IO2KP
M9;N6[PZ_#O-%X[=&7]V!!65*>:%D4[:4B<^OP,0I!F;7+CZR7*TI9507>D<F
MOQHS]#8>+R*4Z<#/\#30W,;;I ^%4Q0;=[Z*.*\U_@&\O+&ZZIR3)D3C7S_F
M[W<1O&?K)(!>S3=ZM0RP6WRAPGHT:P)9)_-T^Q03W4?ZS,C+4A^H#PH*VO:M
M$Y:/I9.NQ>[/J5?C&NQ)8?QBF[L0I9[D]>4Z15[2B%/V&FSP3L9L*4'SJ1:"
MO\SSC2($L UUW3_S3I5VS2=W3_ C8I4)751!DC0\GE=Z'K8]EFN7O-]W!TKO
M_0U=.#13TC9,(3F!O[LJXJ8 MN=G:9E68BPE7C[KO;58RQYK.2AS95O;3"#A
MTMNK>*[P\LSR6K-7//.\7+!&!.NX248D&<JQP'TDSKAY%V4W;&\0:)QA?&O9
M;VZ@[2IWP\:W\OE&)^9WHM3*Y[/F"+.FEP-*KLTGQ"T-N"D" ,<,HU_.,\^Q
M#G)/]S**#$[+!4?LS:%M2#1->SPC4XO%\[*/AA6WCFG69.5I<!7N5'NJ(F6Z
MXN3NTE>='EF99>#*&^B=F8=!@*B3'=FF'9]:/X".U;FM6'VY$DL5J>&EWF_2
M"^GMV.*'2I_E3WC=B>Y@(6Z6._(23JP5^2+)'3_PIEF,=6"FK>&WBOH49Z#R
M FGTBJVZ%][[Z%++5 6YMS\>,8@(OA4*?NBISXW%2TG]LOL'T"Q9Y\+ED5E8
M@E387Y P/#+Y]5)&W)OT,Z'+JRVKX-3P13*;^4E<YL?IZ=+6]:5'*5%ZP:)]
M/P*?Z':8WF@#D$GEC1N6_4<^5:(;A-C!*)_X#!'*O=2I?>O2E]F??P#Y_@\^
M-1[\/FC0P9^%;BSN$!;M3%?&[;709EY&%O95'1&']Y!5=[M!<ZV$W@-YT6\@
MV$"V QG2LVNB5&?8=X5%VQ)1G:^:!30A*&D9V\E_ -9[MIX4UA\>^P95<;HZ
M<<)I8YWW<#R5[=$/4+VBQZ(/UK0>IFEB2Q7JPS[ XR06C3B:5^)$K"J91B?S
M.*B)6KYGTS57_1Y--E&7('VDK>;S*<@DP699RO-PN-RCIGX2?8@+ ]_<:*ZR
M6<!!1ZGW4=& KVE;H![=;3+=.9'OZE*^67.FBL<M [49RFR8R?@M*!U28)T]
MKBB7IV$%88M8^ MS<8+ZC&@J;+XJ4T+TH?5S:O*"A $7F)MZ)*RNJF52'=I>
MI&R4D%W[<KHZ"2U(4N@3^O[-64A00X*R\,@ .,',>8, #D8PCZP-DDW^%L2,
M2A9<GQ- ]=?[1_:DROZ"?-734"[O<W=)=S][B^PR2]V$:X=$/G!9,>WJ!-<%
M'2]@P'?>H#+5]RN,YH +F%B\2T+1,I_[PV Y*.G@1[0LD:T1GG(RTP&<@F;]
MVX;C+YUW/M9?W5)KXX;5#'Y+CRWMK/:,MG97AY2[/9[I^2N<HGJ:SB\S5[5&
MAX4,(5UK+F@U%'RM?F"0K_M.QG>D9:RD(]-UE%@Z>*74.S>@KM[^JVY[?P2R
MAHH-\]IJQY'#-TAY;RX2D9%9:H_%%6^_ZY"Y(1VO3Z624K[/9:1<N+1S^) N
M;*% OB5CW!FUUBC,(36M'J ,%E(,:\C(-%'\#@  G'?U/,6HQ\NLSSL=4?,V
MFAN_]]VMEYH+=CM<58)Y[0BBJA&R5'RDN9ACRLP8XLTQT)HS=O7J**FBB#A?
MK-[<KY6QK:LV1M&Z7\7?8QU5&2M]6)M7PB-;7%[X,J)<S\_<9^P%G,+[ZO.N
ML!OSR/+#J Y=TAW(R):(0L?H99HU]=9P.)!IS(TB=6911_XG6YT%049B 7;*
MJRCIR03R]77$Q+T)N\;>6PKEUY1"\UR=\2_'/;.NRKHDM+'0 :3(]=M$A,D:
MXRVYA7FPDGXL'AE"0'U.' 2@S\+B^C3O6J[#1-7XJL(ESK*P])D5@! 4D%UN
MEY1!/;HUX4BQ$?%!S=WC('=A"B.85[B^#'8J5E<_^0;C*.=#5[51@@^-?FZ>
MY)NH>XF&AS5NFQH5V4R']0>[J!^93W_LJ>T1U@Q(^[):#H15]E\<W-03:K[_
MEA0H*"E(/%/FS8?:(.5_[TZSY<M"?UOX?7QF@AT<,&4;#DV,?#?X'NF)&LGK
MYUIE81#G$^<G%1J[R6E9(:4>!2T%,"XJM.1R*#0$,"PJ-.0LRNZ9*C<$3.+N
MJ4T$I &9;<L;TJ@#&+UU>*W-0]04Q+[4^R,3U_V8 ((QCH'8M?'B!T$!XKBV
MP]_<43ZL^NYJ/9Z.]TLN5#D_N-YH+V+U@J%4B=_W"14I%BOC_$4F[5^Z\ST1
M(VVGB9-)NB>:%%JT"E\M?*)>,4 0SA,](D8J"%)#AR-E/6M[VH#_W4 3(8\@
M]\I#Z6+.A^@#W FQT)[X\O_S;-GG23(0IMA>3(AN_ S6;9!F4WQ7"Q"Z8E$Z
MV3-P2/ITFZ,@UZKA^C]'[PE\^F>@&]A>#RZ+_N^GPV\XEQ]8UT[#7I9UB6V7
M[QKIVKCRD/_X(8IFJ9NK94PD ?!!4D_]65!J,>@FN:]M?+S4[* 9MRWE@*\>
M!($#&^+K<7$LL$_2]]IM%3M*B5%DIW7J*SX2LV>$PEK'>?T)VM]]K1R2T^^.
M.Z1T+\K?Z)S/_413:LZJT-@CJY^JSP,]%>_8+WW]?@2/F[.>J/.^=U[7%'(U
M[X\?%CR_&+ C*U@N?.J0ZD@T6X>@,T];\2@]N;3^K =QUFD0W)GGW2*BU.:Y
M*+<E_[GAPV,@?R)Z'?X"D;VK3W,"=\R))TEV:F^^KB/R;-,T>C$J25<H&MCE
ML9NC++C(1G!9CDT6YE#\:4K.GG4JLL3LQK\]@V DQ:JIGE\C>C426_L--3 T
M'W)GE<FN&'3,A[%KU$2.^O+LIW:XVP =MFQ_WDO=L0(LERWE&D$5#1WK0(-*
MS>H3&8Y^:^C>Y3'6('7>L&U*1,:D^B<>3V:L7AD_4<IWK&K5*=O]N#P-0F]0
MP.I+LT>N:2!OW&@[/ :=>G%<B3MV:@.">(/20A)* F,B;29^Z^Q)XCC^EQSK
M*_;%@D$.GEB;Y'LN7F1$%(N&Z\\HXG=R@?&YGV&^JG3Y&4>8"96OD);JJ4RZ
M^/JW!)!B?Z,5;E1.'(?C'T&HU^M+_83;H<YA8BZYGGU;Z;DXNF4;SO%&2XM\
MVV(:&8O[PY?,GX=+#'O2[C>V]P=]\^&K6H@J\+J8&7,?VUR302>$I)/ U/1%
M:W]#Q9D*Z)T",)>U9RR<A797Y7/BT9N S3W#48[(H5+[%V3L:XV;XXQ*,3 ?
MZ$83.<8]_109E0D-S&<+AF^PD!/ 3S3H_7U[@+FG=RX#7D5T+^XRZOTUQ<1V
MF,\S1B$$]3/13H-0[<P&6!7)!R3H[OZ8S#3X4P!EJFEGPB5>9V9*L8\'7?SM
M OU(TG!6<=6-B_G'ZQ?$VJ0K%ULU'P_49RU<%(#%Q89=UMD'9DBQK9**FM5Q
M\G9:\R(GNOV?>ADP=_HE^[9AWH9T%A&MBV9L\Q<[^)[>7GU#;%TTZ&=F0F04
M-.F>'_S#LQ/2UXRE$XL\Z=(FZUH.00U4=DOEI71)Y/(7#S124=OM/G[]_72)
M9D/^U)>C3*&Y36/K4".XT&F3FVWW**?GC8G<CV\IEA)<;%E30-W#.1SJ*>5Q
M9FHK\= 6'9=D8+)KO6[H?,?6VFSIYNL1OZF+0OM[ 6H]#D]D0DM=#R""X4)?
M]NO8]C:FU/8E,#EW[PL'[=VC8W-T0L;&!'PPO\<RVWA9*4/P<\_;9;(=WR#-
M>7!)LM688]T?@'O@CFU++#S)HSXA[BLV#\%R1?XN>>JR7:B.8\Q;\V$)UF6^
M/#I]*FYM#M2L#4HZR'!+I3?%P;F#@N911C=L_++>\3)Y;@/N5R1.CBBVLV,L
M'.U\F2M=*X; SH3^*F5W<9T?P/[A6N\#*70PQ'_65G:M75O]. 0Y74=-/#2\
MK40T5]DEHB&G48Y'E)7AZ&X/9>TY*1!N3I)2T]/"XOKG5J$"FP.0OKJJLX7"
M& N/8BF@;"FSR'O;RX*O5N$M8,)H9\/664Z)W@T-TC+-N/R,"#S)Z$ZN?G'O
MGKH"1"<)RD;#G-_^<"Y4PDER4/>W9M:VY[I2HAMVU8\S>J9PLQC?,0H-GW:Y
M!O+U>"WW1VYQ\G3WV?BC(1EAI%$EF\KS.CQK(FQ%^]Z%K&CS6-V"3@*ER#/K
M.>@<M'5)X-[&!C=CT6U_.,F+D*![A6WX^$-R!S7;:[P7BE28XMYXXOVU*Q-J
M7*^+F;I,#7E)S..C.:+/'A$#7PN\%J;2$)5[%?U54G'9_0VA&#,3*65V;>2!
MS2<'-MO<!O$O[SP>V/+*&8J%J0K_&0&-&-, #!H@FN,6VU#7BM0EJ!*C"JC:
M U2!69ATM'6D^5ZZW- =WD-3KF>OM^*E^7=9PFE[N7%EA'D#F <9P2P!3W0J
M(25+:JL8./=0* $96NZ4>W<W(90X47/":E#H&Z[+^OSB4CQ$V1YYOOV%2T^2
MPX$?>%Z"W2IBW%4!*O5/<I;_#U[VQ-[$>:U2H3P2N(.<X!38X.NH?ZX!PG^'
M#4?01.44?DS2SKICFHGM1Y%]#FU:[Z;&F5P)+&.'V16^%C,[/\^FC"[UR; 1
MH$-ULM/7ABGO,!$.>;9]IC=Y:=-'%\.9@V1EXJ^_:S? .6:"YM56SA';TN9T
M&PO8P3,$Y>GN$<]%(-N!I>%D%W1[K/MC"N<]JQ;MH-$CPS+A->K2*PXR>_.8
MDEH,5-Q&NW(F%":8=_/4,-$GJ=!7(@-*;Y/HLGO*)\8Z9%S/19-R4\<&X-;M
MU*BU!N\F@%_?5?6=TRN/8GR\@QZ_1M0&2G6@.@>.L 9J/ < =EAL_X:QC-\[
M0R _"#6V4F4LU/98GFXK8.^?86M7I7^L;/)@>5R#3N2=9S?[)HYX>L*<D58K
M>_R8_E,5(N_P5H=O!X])]I-=#+M6TY\?/3&=8PN:LT,23[&P\3^ 28,EFI%#
M$>$\Z0)]O%ATO6'0TS0,:HP:&NS8&,QWV3E2-6%6=I&'R*@' '98%9GAI/^'
MUU\Q</".().#"S3) T@G"<@3BXCS43_:AK?4\G,X6&I_]T>A)+@HCM;SR4@$
MPWMJUL2_^\T2KB;O@(O=D0?(0Z*! _XVRUY61\)^&IK.!8H>/:Y1:E<X1J\2
M+63<3/L[7D5=+'RD/Z(#<B&>VW*#GV.#Q-<\XC!-FR)6VB\;E"WW*TON.,;>
M/CX/NBB*VE$U&PRY][P"BUA\ZHC=L>W>.R_%,[!G#G$R%L1C%8KV.;)_D]42
MK("]X>-)I!GT[0SUB!%>))D''EM:B*.+<*/2S0C0<0A<:Q3UVX#0>Q5(UG7?
M;_@$Z8H3B$T^Q%N=?K%/\E]:KZ3#SG1 :*YV1XI93&W95]:]E0B"DVU&;W;Y
MN)W,6 8DVD8O-\<.LB:*-@1[[/F([1E-TO!:3,>YXW$26J3A::J 4)'Q,)I=
MQ5@FR"EL#C]\5&+S$%FK_3C18XV5D8T.1E@Z&U;1.P^E,D32O]^V*Z2[A$MK
MO1H/S.,V!:\6 < K8\CN3UQ- D=4&:"+GJ>I/3%19(/L#F2%!BHKYL<0L,"1
M"G5@^H!$91$M.PTL@!>,<%2%,, I)U#B?Y3F@-+5PF_[X;AZD</@Z\C0^L*)
M^/M']T&;$O8+F^3L>&Z:GC^ 4JTF]T]S/='N)#B)!)AT5]@]YX-\:SMROQ'B
MK!%X6>6:SRAL772L@J^#1&V_+9U/55DV#OM85O-#@_.%A;VMG;C?V:J@>=28
MF]U?^[]!+\:1+]Q7ST\I6ECP@PJS- W+&B)=,C:(\J\>1.08*:ZCP.6':;YI
MU>-VX^^ITJ%%\+P]R&6L8;]HECU MSA+^ /P+=\THB<FMTKX(JRKG3J!MS]5
M!@MY6,%PC']YN1;-1W)@VI,S)QGD_#JVF17'7"'JJBV)PJE1#KW1UP1WKAME
MF,OULMBEIV#NYP(+*?PJ7!2("YJX;3?PK*VWF7DA"4?EO,'*@UZDFRB/;C>"
MI3YU7A6Q$"4V!A*^JFWVJ:Y45ZO2_ZY(XH-[PI"7%,=;538IAEA4*NEXL0+9
M(+_,E>!"$D$CHG",]/SU!R#L9J*X6O205Y^2YZ8CI'#9ONS>,";CREY2[Z![
M43+(\SYCLVDLKY",?EHR=[?L+M1"$$")YY,\0.34^-'])X0YP ,M4LUK2XV*
MUBPL>][ =;[C^=XT"J8P="IT:Y!0)D ]Q&+OK)2H7[U14'==*0 I,CA34>$C
M$#/0D04+*0WJ'[[26.%U7&)8C;7,)ZQ=;&0F/.](JQG(>GD!_#28MZ9<FLL,
MKB4&$7CSX_=1!I\&)I9NU\9A4ATR*O!%9"9GE6&=/;N8GU[,3-B@43<R"767
M/Z+VTJO:ZI03JX.I@W]]>9-M+/[B_?EW3K.O9<YIIH&7)0_Z[HB&V)C$CSY3
M5K4"U?7+.YA XDKGJT5:[+R^1-F>GD]NI80:,TGS"WN\Z9^X617G<Q(5!0Y<
M!,I?G0:HK^G57,P)7)2F4KUO5R3N%67+/*5JJY^F3WA8^Y;YF4W_K:*GQ)'6
M-YC@G:;Y/ZB?W(I@QM9R2.K ],?EWZ5/DV:@H3.Q0O^PB=S4*N=*M*&"BWEL
MH-^22Z?\/$6<97O7V,/24F"Y$L:1LL^DIN2'LZCKX!IH2'+U/5DG%OM3X>)O
M:(3=2%\>YOM,+N%095<.KW _]I(5M@"YJ:9ACXS2(]O%:U%N*FVSGL&?1&%_
M6V^D]G($.7T5&/Y\&>18(N%DF2Z!@=!(5ONR#HK;W>Z/#^F/#90N5A!>1)H#
M7[^Q+C!2[M; U_H=:RP67)4DJC#HR;_TNEJ9SRO',W81<\44ERTT&.2!I9Z6
M^JT>?Z:99+&0LX&\DD:QU/U:V3>Q-=A5>DUX$?WR0A7W#\#>R&6T8W/^]7Y&
M2O$27G7&&JBU-:9IK.:6---XLL-HGX2DP1Z1$DG,++7>JI+H@D>X;"!!)V^^
M.\UT"^II4A:SAL^[F]=.NXL?^H'=4JT>)G1Y:@MR)M^\V&-#:Q*RK')2E;S?
M_U8U;55=G^3QE23QFZ#F%V4A#BN^1GY^_+>QC0=#&%FEX,G\J77$4,/5I=L#
ML^RS7A24R6@?WM^KL)O/YQKQH18S*7O^#U9UN^ZDY6]0:TE>285M&KOX#>JW
M3GV\Q*N:1XQ&3=%\+^LXYW?\J5W?=8FKXT9.=0_UB&>8KSV>(5(U\X%ZI'XZ
M6RBJY(B_A6[G37 <Y<K;;_>7"ZN2W6E'HASZV_,0VA>/K$>,*XL&3[O6G\HV
M;NQ>3:FG\4E='@A!O_3_'CBY+]M^,%_UOB@CT&RN:YT@UZ"P$:9;KRU?UUS:
MLZ=*T[&5-Q5$J<BFC^$QIKB$;/]:B5??Y?MAYS.>MLIO$3\J5^K*X4V+2Y0R
M<Z@F%&^DW;2?;6,%N&E(34F]P[,U0X2+2!?]K+6SS"][_6V3V]\G"7,KQ?0+
MPQN13C2B0$?6I67VM^OBWO,C('MK=OV/'&YY9(M.>7\ R'\ X5GLRMZPN=V]
MUTL_WF,,+5;INO90CB5H,\@YZPMYN.M9-2966J.85OX!))4_C#[8\6LVO:P,
M7:;Z;*Y@B^9XL .+QYKIDN8,XTVQB>X5OIM:"C*]3M4;FDFEKSS"T+PHG@N.
M34%K+L 2Z,TG$5!@Y\QQX:ND;O]NGB*K^_*R7*EF; K['7B&C)ZBPO=-L_FR
MOI[B88S7.FW@PCK!T )6#;IW\;5+#R?TE#?,BXRB6<:P;FR!9H$3M/2C+(OE
MK&]Z!$LC<C(T/7UP.<SS4:= -)XFR6*A]1COL?*!;<RNJYJBO,+KRY"9$[%:
MZ84(J!IRREHL?QS4@,6<5]*/I?\WZ)67RXO)(DTDB %55 1,5TQ":8F&9-R2
MKA6$D/- SZ"U8'^&*EP5%EZ>_$G@((],I,6$XX<:G=TM/AZ=E;K0/=2,):TD
M,A(7(<I0ZJSIH<P7Q^YDB-]AK:':$.FO]*\2V&90QA"?*>]5JD^&H+Q&CL-\
M^TQWO#O\'U$?QD21+LKNOE.H:[\Z7MB#AR& &IP/P]Z,59:/,]Q]F\#OT3?\
MZ,/KH#&9.& LKG: J5\DIUV@C0ME=RS<V.0FR>O-:I2@/>U\L" 94^%=!$@9
MNNYH34X3^3C+@FWG35Y<>>!C?:LS.86@Z+LR$BB=G#</$=2B+O'5.0\Y6*NN
M9+GFXU& FC+9#!M?6%62'HQ"'< \$GA/O-@J8@3E7!:<DIW&FB0*& 0H0'G4
M<\/4.K+)".NSGO'(_F7'*#10< IJ.^UG%VX,!%F9KW9K@^J+.=T9]L^?8H_B
MY,A>9HED=@>7H9_W.9$&A\L?*)D#%7TC+0F_LY?FB0:]E[LH?>&"(7@-&WPE
M4.IE-Q=91)%.OL004NO]9=V3YKVV*/FXUF3P]95^;.@>TXQ:>:\$)2Y;2^*[
MF ;JB#P0WFIX:#)\F438_CZ(/D44JY+L7L9]O'"1+VYF2$E+KL2K0!-1X2>L
MCO!RQ+NOCJR@]-4Y_N)F#MNE=AOXEAK??#Z!VUX_R&!Q&@;9F& :GBF5GRO(
MOJ"9:J8T?8[%UB>+E::=.AGUK-9#F+>^S,R?^N;SLDZ\<M+YQ]&:'N'/VF+!
MT[)Q](4_9-MB0R4Q7D&V$@5EF!CL4@7Z6?AJZ0?)2BA\PP]$%!B"QT0JC. 9
MZ.;IP>8N?H*H.ENV^I7\_Q ?C&# _2C4RF80R>7]WX2>!') /#!DK16?*<SM
MYVE!IK_@62E'& ==1IK[SV/0I;+&N.RX56MS@APJ6WWX\0Y&?1FH?<YRJ;:(
MAGC?F1 J6=,^VR!)8AY]3 YV-UV6UFQ[I/ CGS-8E+P_-+NX3=:D=O)EOB(:
MU]"8J/7@):Q.^'>]'_]C_T8<OJ0@"1S>#M5\(.!M$3&038L3'(@-#1Q\?VDT
M"%"?^)@UP;Y14R=Q6M>&<3O- E/F#P.^S#6N]]6+LK<R'_D#<)LVVZI$'+(
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MEQ)ZZ^=);@WYI/EAU8AK<:EUZ%;7G,JHTD"PS*3'^'G-:0VDQN67:5UX;9L
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M9ADVP/E*-+#V[I.27@K[T UTTR5!=N+0<7?L:VV:;S E-\6]';+3^B9$@U;
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MX^V/%:B BP]#%J7%P-F0P]E05LQ-BD^*[?WG'.G_I9A[?@%;(B X!;2;,HV
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MD6@T"+4I19N1BJ^,H*#I-*EL%/\1/C1%VC>] $9:X7RE3#D^M%Q1'.LB-&U
M:#EMOLET85J]WP=[/?,?[_G4BNZK7I:0G$-C>>E/1 &ZJ<>49\!OJLJ**KOE
MRSN:_')LNS(7 87PV/1-3R/4&85G@'X]\)/^"A+SFOC7J['&>]AZ>/'?[V9U
ME!*V/+I+^1/I>9'AU)#O_CO&06+T%I48;)#$AN:RI(D1W$1&8AO$D2[$L^+)
M+9U$DA,='9J#X:4JA40-RMDZFC+Z9<'AX]=H0&SYD^5X+0F'.2R=Y7HMD6?
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M&UX\G@'2IIF-(IA)IE< U;<TM(A<G??3!08HU:@C5*#=F,-'V\D#1N=;>LF
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MAO9-PY._Y0O,4'P&G#IMG,SU!CX9_H_K;*-$0B:F/T_$]"%,W3%X&+=!_Y[
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M*ZGB75_VK_/T.K<6I=JH,SYC*VQ.O RDJ^:8)XFYLOMP*JY<OZ$E\KX_G"&
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M6'/1:56*%Y1$6V6/VR';F"V7*[)8LI0JZ&LR/C.70,.*;V5N[E"W\^=N1AD
M5E5%TM,2",2OI E_LD'_5.W$/_A]R 4SDX"FDP& 1)-GVF?@U2X(59;Q*;"8
MKW2CC2M,:JI,&B3SV$V:K-X+($^>TFQN44J0U@77\^=ZW$EW&%RQD9[X>".8
MFN..@:5)5T=_M&E_&OI;DM$H3FP:6'] 1POZ^:(?EIIE^<G6^/.$*\_!V_2F
M:$%=Q_;E#%J6/5]8_T/?YUN+OK+(Y_GR1T41RU0#"/!^WY?Z!MLEKQ@=:*Z
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M]U-_?>L:LDH]LP3;3>W\V$IUD]+:#^9?\K8Q?!CH3!QR$!'^3;TR,-EV]D;
M1)IQ\A'0<#Z ?PHEMF2^.K^#9$_=J7L\ C!&UY>X_QP*5R3[."[&WBN?EPSO
M<=M]T16Q4E-&>!\R+K9R?609MRG9MRCRL,1J/#O_<V1LKVK+$.C^3&T7;'C=
M:B3W7$4%D/R&#9(WPZ/9&^=&@4^>+2P3.:TD\CKMA]>QY13GQCO8(4 KWQT2
M]3#;W.%74>$S:;R96$-[]JRE:#9Y87C89+/_L 3A(TGR45@$XN>T+8+7^F1H
M3+^K*C=(K08Z%HZ4'<#08[B+O#]>L34M"*2":-[?W'.T509B[3^ONO:=_&/
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M,UZ)!AFDWNY_J>HU^$M^L*3(>KZ/.0M[MNIE,D?$N\2?1%(# 1SYU*8\*=2
M6*0&+ZH*$3V0(J$2K7XB$UCYQ*%(SQ]507+2/Z.!+X5.K]MLMZO*=*AXCNM@
M3J\^NT$QI.VN5+NEJGO&@L*-(L+PYZPN[,'/!%F^1J.Z443X<!B/N9P3@UMR
M)$[AH.?Y"UF0\8ZKSB7#625/)&@,NG:FQ_M2B[(IX-!S$MF(<O.***'<M+B^
M1!7['27S5B*N.W0RLE,?O2J!P&<3_#Y?VJ)CKM;;&NJSYL?_W%R)D*&)8\A&
M,X%32]K6NKA]+,(T_58]3ECAM_QBROV4F8$I>'P83[\9!8#;L'+!)#@G5K/
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M@\]9I*LC6Q"LA(^EB0W'\-<PR1LY+(\Y:&&/CT/0(">/]W^PC/\]7/YEY2@
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M8Z->A2+&[ZFS!P'1\N8-2CG_@3+&6-T.C81@&.(CX<Y;XS8P8H';&$^A.BM
M610[TVAN3=RNSI'Z00B#/,3 DRPQL/!/_LOLLU.()]^OD8KQADP' S*6A!F9
MS@"I8M$*^FZS;CUG_)QR&;V& )6CU>@O'@RN;A/3[A:V+^Q@$'.>/]> =(E#
M$C)H8A_/X( CX.&@9Y!$MLK(CR4QDJ,0[HG/--ZZ5A>>1X*=JXN&[HQ+Y46B
MHV%]3NO3(<WW2"*PS<V9_'Y1_R2+?7Q@E@62158PN[FE"K^]!ZS/3:5@(8($
MJ^"*$LHR <>84^>'7R=S OM(V+1C)L(X+):UO"&:]JZ7_<1RGO//61J0GT,3
MJQI@^TZO#O%95^NP<;7P906,X+JX^R_2?@ =J<O\]9,9:OD[Y'\T2"->Z"@5
M*2&8<S?D(RL5N-2K'7-7+-(*L#2Z>#GK"7 Y33T+L%1A<NA6(+OD_%@>6TD6
M(].UXO**A".L[K=3?K%%.6F,YYHTF.)<_727U3,37)B'CBIT$-U_*#5BW !S
M]?*Z%?D]7"+2'*1M_@C7R/ %V9;6UKF_N&-];8U9RE:[XBQ^SFG)<S3?JN_$
MSL"E0J*)51YFY=H<"*''@S @9!SS26&\O?^V*<]?+MX)+;]_BSS"UE$7':<!
M1$VHZX"?3F 9]#U-409(9-,VG!0NZ*444NE@-\&">\#686X,_$<$A_LI[/+$
MDA$OGU\#Q*%FLUA5[6GMS:GJ9V\+Y^WO\!RG[YE][,5?_$514>ZO%*G!A/)Y
MTN!CZ#Z"M-M266T4YR-S>%?P^-3/DK4E]?M3>@>B35+KY44%U?C//^P&8Y2V
MM,Y>!_#BTV1.=BQ]5>U_\V1>WO[K6<Q*Z?X[NVENIT+7'RYQ 44E97=C10]-
MHSG>NI^E*_8OW)MJ*84=MA!NO;R4PQUK[T[$=INY9[[-WWK7E92YXF[+-\Z7
M_# UW31$UW.C >_MH7+_1]R% T_:K@$D/SE"%I173 0RDG$U-TQ2:W<\;(5)
M!,O#E,IM6V%'T&G]<BH?H63J$HW#CXV9"B"N)R !+8$T!',V3$"6;/4]+!48
M9H?]4$=E8AY*.'H+%QIF/SP'-0:40N"0TB0$2(T0"1+12TAZSXF3'!1H?=9H
MXN\8JJ4)ED+0!XIOUNIKPO9>7 VJGN&?RT>%N$MW')#FRR2_-%9+37%>Z/G%
M)KMVE']:GVHAHA.BV\:55>DKW,*\?KCF;J<2NMCTNKJ..@+_+5R3[#V.4^X8
MTH[<_Z<S%LOE.6P;VP#7V7VSF?:EQ82C1I[3ZB865XHMQT."D0]_<-UIUJO7
MVK6_SGSN:9J)7$1Y/>MTY8+O/@D8?@LI5BSJ/%_;>O+H&((E\%ID.<.RR.A,
M3K,Z86F5O5ZUL/^3&IM8XL2C0G#<9WI4N:2/AP.KAN4%TWML!7P7)PTW95:1
MV2D-#]P)'LHY3N.QNH /,Y<#/51E%,;K-8:=TCR'U<IQ,%Y=HE.R* CTRQ'G
MT>+/X-ZZ":L+-2,INH"5LQ^!6"IS)!N&)9!"ZBX78TEHB?E9J%%#@S>/V><!
M8/^%2'>FDM3G+\;M4]:'>]%P<V^_/9>OBES)#7IQW%''*4XD@<;^=9[W!38;
M\RM)XGFB7'M8W@^$!8M8?>=H."WSH&CUGE>I;OH\RFL='55GX-(!(E'0H9?Z
M7/-AU5.3P%NV#?'V@=!P)3<>;Z])$?6&*#ZPP?/C,[=/VI#""I8OZH+C;4["
MQ#(F$8:1):Q[M]*3-M:7_+[9-&J2J;N4.C PC"(23+SY\H06B\E+6XEV1YS"
M8[36P?X&)4M;7G"@I]LMDY+O,(MJD6]2#72O*28$YL):\!P&_9572J1P# _7
MH"/"^N/V!#2SB(?!5=(661&5%9IQK[>N 8O"B.3D\!B^MB7)]YTT>4;FLSTO
M7R@DS,:_)<=]R;_QQ7<''*U!3ZO8.&';D_J*VM^6-M;B+(.T&_U1AJCRX6R]
M9JN#V(S7W*:1%:]6F[&X_")DEOJ6([:S<2DB9ZZ7M38I^LEFA1SACYP_ZKJY
M%1] 3?>;Z5?]K@%D<]LR]E6PN?5QS8<*5/$)0J$FC0_A&8VFFJ5RMQYUUIX$
M5^6\6,O.YTXY-.RN6+LKVIU[#>B=4D@N6;#[@KWVI<ZUCK"*6<:#1X(WD&C<
MI6D4FH4 ^1E0%UQ*H)A@4YLCWHW%C@FJ$YEU33]?;C"%]O8@7]C[BDY?/32#
MHA944A0UE'F9HV&_^VFQE.FK9B^Y?'2V)3Z-M_7V;JF(58BUC.<U'.F_7RZ!
M%M2-.;Z$[]LE0(AR&K#N>'0KY6_/Z7T)^KE'\DM.L,W!Q[.V3C__R5B]4Q36
MOF"@BG]NPY:PP7O[+[/B!9WJ3SJZ[JO4.ILH3&FIB_2^9]EPRG$:^;V*.+/.
MGY/W*3<W*FG):;1[N&%CR<!+@N?-PN2FR)MZ9QMZ)F0\55,1<0V8>WBT:%^V
M'GG915#:&I>S!\ RT\B:?E5@4G.N2#\;K=9'W5^R%D>:[S#LSZIT1E\8Y_QZ
MP.<2WDB@HY&ZDA7_IR* #1E762?8FY V0,KS&J(H*AV:^#0E)WTZA%0.SMW#
MVC J_(5L4^=,F\_1V*$&MN;NBG!36(RYJMEU1](22X0!M2'\_UA_T^Y?M\/]
MUX4Y[1"Y090)Z!.$,(3&\NZX%I08 $R"Z-S55E)GPYB.DSIY_U(2[@NG(X8>
M" -VQ^ V4"&UIP8IGM.G>Z^\"%7O>>A35XA,7S):VZ[2B\S-J*1X.;Y5N-P[
MMVF1  ]Z=\OPSLUK,?[8OP8(G.!? RI,1C/RN-G5$JR'N-MIV&-651W @K&_
MH1R##GY@2/^VQ "G$\OS/F:\6[J_2Q'?OC9#6(=X[27'X'&L0]2%QZIP[&_I
M>6 &NZ$'"391$SYYPH#+<9MTN)":W"<EM'*2GMOFTHE66A*5X9; &V:\GA8V
MA.;*:%ZL+ \D &%TR?#5=6XE8Z,,9I+U]UY>%!G$#\N"Q$G6&XCU?S@4Z1M=
MZ79_CSK1/C@P;B>131X0.BO^?B! Q,;3$]!@=:!OT/E1DZ;KH1$)0DR2M+^^
M9SHO_%L/U=*@0)>E_?E)NIWCR '!MXK#:54D,"7,B/RL %(;LNWMOGOR>]:'
M@#O;:#5F]-9SY9T=,\:.(3)PB\*9N9B#=2Q)Z%G?K_).?^Y1_947^O4_(@S?
M?:.9 UO(S_F%VN*N,-XQ/4N%D"LA7UJ][..HN&!NZ:>RJ@M[\/9)=Q!7(3VN
MO)658X$Q6QF"&\@IK:>M'^9B4+K=_X>@I3T*,AYL2 1 8@=Q"W7Z?I.F'[.>
ML'FRHJ2GY9(B)59 U0"F:.(2<(6RZ**9WK?&P*[WLS4[JD9[/'-WTE,>*L8-
MU"_3;<!_CG+MC&;>'Q!2J;96,:VZ2_CB#%?*WE3WD8R')M*RCK_H,/;=_FNP
MRI4&+94H%7#OVT? .4W,"Q[F',G*+F-]+X&,AKP7QJB5'Z6H&)-UL"WPNUDQ
M8$\5%KX_G-:3 B);3:1X $Q#NLS8<';) "W?A86C525/D-V=VYC)):/86 I8
M5"S"N]KC<1W O"SY1ZFB]*"=<T@]'LA%556V$XF="JPF4C$&00&0,30[!6HK
M6:B 0';_.>!O4LYI;NC<OU$/''7A-75A0(=VC8J]D.S=CX6&>N$4=PB?ZUN8
M&QVY]/\)=NNF6FTQ"G-;8C]L27WKF,!=UG^4D5>A;8 /-7N[Z^T5[IX.WC.7
MT(5HT?5V?*R0BUBQR8"':H('JQXW,3,^LW0H/#P($[X&$)M4>\*,%2]^/-(Q
MN:4W7/+J,:M.[<>:3V^MZNIBP-I!%+*ESVCZ/Y[IGZ3.&'F&'IBQ<X](L]N3
M[$#SGC1E>2ZT>NQTJ8-]'K3$"ADBHO5F-68-0F?BS5=6FD;V2$GG-#0,<_3/
M86O-UGF\V2MF0@.Q# HX1PNPP&!)5:BM7:/C?-+#C0$K5-9DB^:28OK=:D\I
M(AB4@JD-$!KG2Z-F /I 30%T5B0YX,'>%Q.E5S=DCH,]5Y!GYU*#..80]"*Z
M5&%J6K>\\RC8Y]"*SAZ"&[(:78U%,O>D1F1.9/06+910+QJMU6!_[E=/MK*F
MY<3^U%ZET+M-;7CW\3YWQN%[J4_/[!(2S+MUOF\413<P;BPU#B4/[ 1M,7"@
MP-:_+>JO 4_KI1J^*U\&)H/+0P*&(]FLO$-5&B?A[9,4Q&D9RNZJSY/-8?C^
MQV8D_5I)B1^7\MWLSOWR6 SG5\))F)\=EK^>;J]S]3;?D&^,U^H1<U .'@%\
M5Z9ONO*8?5-P*Q\Q6AIC,W!%7I"R="?MH<5;:O_9R8'[VA-8,W S3;7)O4LE
M>'<B<4OWQ2MF0V1 /5KZ_#;0HLRBC'E>&>J#7%K<F<,],CR=NQW=3?O!'6 U
MG3%ASC-Z4,.YQWN24%(XUS!C5)EL$3KRW4S4.(Z'UX92S$?RX<$RWRX!PG"=
MOY!OYO-RCW3GE&<1TKO$9%3A/5MR6*[BIP=L"]9<BAK]$E<42[A%V*AU"ZOW
M1R)O_0JWX'Z&/L\<*^MCW(U(*$YC#&0VD-*_E"8D55?2>3R45JH^']^*^\W7
MHIVZG^#WZW('>4<3.U7H#EW&(_-'/\87JUOXE?B)^^HE-#^/"NE+JN=LWZ\S
M=JI 2LI!/EJ]27W IC-A6W<-,&]T!BU#UN_049R^6RWSTQI_]6KM4UW,\![K
MQ4/-)D+I8THI33HLLXLBNUE%" $2S2N(%\@K^\Y,.NX9G?$ZWM/3'1SB=(YN
M^F[5-E)F<!:X<N> Y-U M+Y\RK[ZQTZ].L<P14:U<S_"O: "[<&?=UC2#Y<B
M_/+MI9GA*UIL/]?4\::&=4.G4660\4MZR6RB>QWB[U@-<%_@)NT3=BMX2/\I
MJ0%6N_%7=D'7>@8H:K.%:5Y *2<3SGI-&TD0?+\B*?)>Y9KW'#'LF%AK5BH7
ME#5F?A7YTWIR3K@ESYF7]M#U->LHV':ZM%D^IP_K2UUD&^N]!'*[OF%!<;KL
M8U@9Y;N*LW>F'S\? 45J/7W]?H_./7[@QMJ2'IM3/I>D/=C>DT9+KVAZ5!")
M&!M^SU:E2F> HQ.D)#EAZA]*#?";?KP2X* C_O-7!-C$CRUKF"*9M:HWJFCW
M\:9/R7ELJ'" PI7JJ>H[OP;1!!.C.1:.BQE1L)?BX55Z3@_SUND%C4XZJQ?O
M#T9/UD3U/F'6]*%-!JJ)ZFM ^",XT0[5YY0[D1/X_=\['#>.@'O/VN>2#X+=
MI:07VOY\R ^ /^/22?MFA\+5K/&LAJQ[U>_&RDR<Q%)ZAQ\KU3=_JOP4TG_$
M)G(TU!))/>#42N?)<#6Y"=16;@K11Z-=7/N-7>XO<,3Z-]/=$!N0P!03NQ94
M;9, PZ/.310.#R949P..VP&$,6H!Q :F @ )R3\0[@2FYPFGWWB1J6]$+#OT
M-F)(X Y<#:6,8 ^JOYRRC>11/PWV<\I[.$:?M^#*=06]7:PQO"KZ-6(NZT),
M^'?:VWN_XHM.I!0W+G=JAWQJFVP]<AT."F?XM2G9#<_Q\ ]XO&H?57Z=Z?"Z
M/>A::+%GHA^.,A'@&&V FTZ8%'GI4]+W"2G82XZOOR.YT0BV'T$^FB8*I^<[
MY7E0WHE%-PC=PMW[C' GS)+GAD_6$S$J#/]]](-H,>5&C6MA*2O8Y6-IF9EU
M02E_DW[$*1*>G^_\%.%"FY'!%;/>\&Y^]':6SR/E:9GVS^W5;^C"XW8&#FT<
MWL51]RQ$_9FX!NQ,<Y1L0\Q^%]V[.KHXUZ4)S_^%^W&>^>IWN>>.[@*12-#Q
MY 5\%Z;UDZO-17"F*)S]F/=9>*!*[G[<4UVZ7A^;_'O?;?'=(XK*?[4M ?PZ
M&) E($.W!B:I9PL7^OT3J5+JG5^?.OCSC=E^JLK6SO1\ET$P\;/UP#R"YB".
M,)J,1?ZI5G$>@*0=$5W;2^R3;+.MW)=>U=5ISPP1AU7HGZ9&A?A.FMYU=F 5
M#@7F0'3"!,,H- W''6M:F#<TFDP[Q"DLQ6.?2'69 ;<-/H[]B+K_T>[U@YJ&
MM-]'LV;X3(%W]2N*A7<VP5+22^>S[QZ[4,7?INIE8:Z?/I-?N>T1/O&B*GDV
MVR<,R2YY#6C:VC,;=$%HE[KDYC)AZ2D &))1L$ZN'Y#*%M^E*15]1NWAAJB)
MI()XV#=^^^UNYH5;J;=^<$W0VC3J<R1O4*06@4*^9;V#M]A*VNR3/LP,4QHI
M*D-4-XI"OP0FGX@4(H8H@C=Q@391J+O:\D BKIJ)\JCX;F>3!)=1O>("9R'7
MSP-/F/TH'[#E03KO[4 F^ 'W<6HTE6-H\57L<$=J\#=$Z;DTR-R4DQ[\5J17
MYXHB@G#V]>UHYMB!Y('HKR$*HU_\4VN0!U;?;)/ZWY*6G_;C/4RV_TD/D(@<
M/'C41'B:'38[Q3W"]&(18&MY^P<+?2I=-4YL/ IJ.A28._OCUO2CI[;]T=F,
MC\WI&:-_-M38?KFOEG>+X!H0D96A'Q>:TN[44[%C/%0>;<'6^0/0ZE^49?@'
MS:&F(KR*[:-7I:Q?>S%N'L;_PK?2/PDD&BIJ-JYMX<S2U]HBE7]66-[*J06@
MP@G"E2@LX6F?%@)GBD@9J,*G'F?VN^PZM%M59:E.54<KIYL&22>?2!#^8*29
MYPU=G>'+Z2]](T'Z^B?R-M@[UR:FH,UX-]7S&C ['50V(4GTD[GQTB!CK@^W
MXEUI#="9Y^#^@T82AW$7^'#NU-I;:N ;C.G$1FL08HGH8N?$EJIV+!(9JPUB
MF5>82W2DM<-Z;W<'XGB*G)<E<\QS5*U-=03(U4:C%06S:BR\?A'=^8#">=F[
MNZ5_7BFIVRK55WH2O,!Q6),PI LUOK";W=-8=EGK8& "!':9R%QA5UP#*%2O
M 00]D3*;3MG7 "R#:P"LO.-5#:>Q_Z!IX5I/N*3<-4#._1IP1OCE4D_4^UFG
MS,FCD6M 4,DUH,O G#*#,L:&#ITO[%(>G>\-.A_!33Z3SF<GH@N!R\S7@".]
M&=R"L)NMQHY67I%= T:_NZ K>(>N0"<BS%\972ZSYPJ;#]T4LR!C;V!#FFM>
M# /PB.,/22KCW]7I='XY$4=71X.I;A:W $M1B$37):_]-?LUX,/<VC4 ,(UN
M>$'L[;/LJPB_[$N<9U=<34R@9>W!CF0ZP\/4M]> 3>^&:T K^!JP6M31+LV)
M+K>^\7>Y\E%"9Z ;_W?%^^A7$0N3V?3!9&7#9%5\(ZF#;N#DR!7630,+@2NJ
MF>@GJ3A[>G-C\>\;LH<1L,!-OW^4*ZD%;HNAGP/]?]_(=#T[D3:]!BR3HQNO
M2XI_5G(5,9!]B8UIHJ]S'J:VP#.Y2SUT;7O3?]6&Z9) V)?-@,9_U%>'O'F!
MF(P&_UM&],/]3\[Z7$R/K%P#5DB/GOTAK7MV=@O]"AD/(\XJKB+F*_[ZOS#.
M=8O^&,:KN^@ZT!URX8'N$'1=7=K_3_69*!RN?RG8=EGXZET5\&3Q,;'3:7%P
ME>@W@2TS=2#$:4VE31X( 2 QNW[]VTX :/[8B1:CLG>4X2!.+*@09C=EC$ 4
M4L:X7MF X4&$:F/*:K+J(B%04*20,IQ8& XPG922TPK5J'9XN\ 5D[X?P#4&
MWL@FXV5W&.#VOGHASSNP,\]<@R3Q857UI Y8*]-F?U4EC].34:Z[05&T\HS"
MW+[NV,A>JX<.*=FK0D+M-YVQ:,ZD%4]Y+*5)5:9)= VP,]W6)$[ZL"% SIHH
M^JS3X /7W=-7JM3'$EF?#4GRBQ:V/?6_[)1;R6TUP8^W_$&KO]EL IZP$[D%
M<[N<%-&VSDUV/E<O-/G $@?,GFIHB08W]PQ>T+_\S(5BOE4]^<YC;0!BY#A#
M%$@II&UT*5X=97-ZZM.W7?(#-O?I,.6M]55Y']UYKU>@N(P+PR[O,-=.ITBJ
M:SIKN%%F8SKCN>[YH\A$I08YO*/G^[=&&T:2LU>?O3+>YQAU+WD#8GM#]9,
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MNK4$E8#;RSJ;;B*+FBS&0,*\\:RA1&U\CJRDG"E/\:G.W QB!=!J2,0XS*Z
M4(X.Y$S01H=QDJ=1OB8\/,VN4"Z;@U;*!S(]0)CC2RG18Y6')*2$[_/GPD
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M!G/*F].44=.[79.L]J8N/O;"E+#Y$)<UI.!H2*OI'2#AC=]JN8"F%6B52S&
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M&NRB9/DOM!@#RVG_L&QCQE8.A&H4)%N SA(N3&CZ/WH#9E2IW0RGI/!,=6$
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M4'=1:,+Z(!\'"H)RWD4I8] 26KB>(LH"97,N;$ZPI_WS9%Z]3FBAEPQ?$Q*
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M^."&00_)<Q(CX7(Y=#QLGUIV"8)<\)[_--3#8*,>( [6$9_3U9"VW/ <;8Z
MU'6#/P<CME5+8)7O<TFW>9@68A>U1^VW^*BY(1"$EGD#78@@MIAM7PE''$]_
M8YF=/'_!%Y/*CNT<R'Z+KZK-2O.09?S**Y9+^7/L[>S;MUW=/R5N5U9.P-]9
M*_L% VC'*C0F/#*IHFQSAT7)??.>VF5+F(=&S'2VL4\[*&O#*G]D-"7.'G-$
MRW3H>9U?X=EBE]IU]V:SP T'7^J_&^+(>F4Q3>EO<.Z21-CUUL]I+,V*9)>/
MT5V0+I:SNE3]&^RS_7.G_0Z1N&RC\E#GHBN>::D[#NT)P/NK;!2C8\;<B6OL
MB*F7*3^*/6$V) *ML(@QX##G[V*\"/%(0*Z?W&U1[(_0VW)9^=V"?$,L<QHO
MZ+Z[X0UW^JRWFK:Q.FF]S=>*="^<9.'Y2DZ6@Z9 2\^'FZ(L-[2G GR7Q,RL
MKI(%S(CLR$9N2@+_33#/OPGJ^:O)@5%!/=36" KZ970Y?NLEI-,8_]>[?[Y[
M^[]M>(PL66GH<?^;FLW*SN+[2[<%0C7EE9ZAHH]WG_URR17EE211"@_]5U%/
M6;&%&;"SS\/>TOO?L66WUGVQ]X0X0X4C)B$Y=,_1,MW/=XH+%ERS>4^3]/)H
M#'40)07W4Y=TKVE/A9+ANB-T-'JTM2%!FE<+;/",3)EXT?I/O?NQ'VO ):=?
M$ KOP[">L&>>A,ZQG'2I'Q9>@47E\9,=\VS.8P0B.^L(I:-KCT&'*K$]ML^\
MI8NE,I\C>FJNCOI<SIF+;9Q4=.49#$#DS1B[ Z^F]$<SB(QF]O,?#+1O=;B9
M2;X% /#?:GQY+RV]FHGNKS^:MR[?\]X\HU @*EE>/Q2< \^_"[",O,U]QW;@
MTN$&8#T:4,^Y7X;^E#;9C7<]CJ2-UUC2/Y>3+74X9OU\+-MSCZ BM(V2)I<^
M<35MFE;$X#ZC#PX-3CTI#65-2+8^XUL/B/\@-:\1GL?+]SOS)>2?;>/VX8[5
M,=%M^4)0U55ESVRRX-<#&U9YF:6Q_@M%4IO"9ACOSH0.T6OJ7]L.7BJZ7545
M&JPY/"%2 *::C<7>.5 UBISM&$33[QZ>M7'J.E YE:&/$AE7+IC@S,Z>!I5B
M>5+7'6WI%&W!)F<%Z=3RH$ TC86<;%F6@S1%12K[MWIM))FF;FBX7X<I3Z7P
M9>>>%?<1=Z[U'TL$QU=?N++O16&]W);XK/N29=PM_HD#%/85JH;R6-O3 ;\"
M&G*F2%V)IM(!>/!'Z>K@VR) I.HT1?JRZ'&1M\FR,X&XW+_L:,RZU%.\K%P*
M!5,^F&:9_-- U%8/G/,P\(O)A,&Z3A1H1H8AH/..Q$ Q!9A8OG+[_6>5U>5#
M LPU8ZKZE/5^ZMQ/$!ZY'ZS-_K":,#EPEK;"Z\_+T0UWY7MF#3XF@HD? F$L
M1#+2?-!(:-\(UR2/:35E#GW<9LN59^5GWJ01XA^Z!N/F,,0^HCU>^403/CV.
MXV+OXNNTHKRL*IH,=+D!;&!OF \_45!\>]#"_MTIPLE !_2*1(JY+O+(::PF
M%*$,KEOI)>;F&9=+DD[UL]M1-U%/>AITK2_#,W%^7-3_Z"M()OIQ,ATXAYK&
M(ND--1O2W\F+U5=T==%LTPSL?LDFH@%[V'RU2LFIY5U>@K7J(PU>"-5B@M?S
M)P''V:N%#&98CM.P5@#;Q$G'A7(:N1M&@>F4E"_=.XV>M1X56G[_<G==5F$S
M5[LJ_^!TFB=7A#-C[?$=[9ZG[:$$-JM%P#/<VE4G_4F?!M,X*IVC2L7%&M&4
MT3"/Z;56C:H$-<VWF79X@M@K8FF_*Z=F<3_-S<M"1_YE,1,_(/YN:\Q<MWN=
M>9V092@>HV6^3Y *WJGSPIZ&'=GBF?^PX[NH+:83&]H7S\R[!//Q&:MKH"FC
MI[#JRZFK H=5B1E1]PJ# 1HP;!#F?X+60S49YC^4'LHQ_'?WB/^W[?:_/#JZ
M^K._1=IN(3E^3!3=A+JP-"M70PU#&3,.=:@RZ<+$C,%YTG9NG.X:K^OJV,=C
M@=L&*QIDUW'MF,*AP =<2Q;J/ FIM"BVWK$NUBXG]^B4VP))SV0_2N?J7JP:
M)+;1-9=SWEMD/6K#:W=;J;(ZE3+P\S9:.GO+\=U8?^;KM!#M6&V_JDHMC,OX
M1WM>MX?NH/C9CE;4LON.><J#YWFMQ<,#SQ::7&1H^CM<'K]V$X_DBZ4NJ*R.
M[$;@[Q4\/F30JD)\#N6+.8>@4QKFAHA*%&[$AU"!HB8GT$[4J-LOSL=5'1WQ
M"IGT%_6&?.]3Y'-6Y;3=C5/LCGTZR '2?/VA42TY@G^/UA_^M"K0>KM]B_Z]
M!?=7PQL B=AM3X&@G(YLZ^/CTE('((GCI>41?ZI%9G&^BWA!?B?#P4C7+:[>
M+EKXR"BEK8]7VVO^QCM<E=/7J[1-]P[/=?8_Y]/H')F$"%10(TQPF<ILN$Q[
M9Z;R;Y7LY3I>21OMCA4R[1[R&'^_%1G!,1/^Q"+]LH!5E8J$@QPJJ.*Z%*ZZ
MI/=X!N-)SRMUILA"I_[](+'N3=:KT&DAJR'#OO3Q]>8'J@^CIF,EA6(#><0*
MXG:='ZGO68Y_;V%X&GN\R1I8 O:R=R8":S>V*L3ZM"+R^EU2"5X-\^67<!_T
M/32\P,Z7ULC:&GEB92(M C2OQ1&"F$]+(SA(-ATL9\@E_&X %.M/"R7NLX3/
MCJWI<MD+E]\  B =='W8<BTN;^DJX\J4Y!R E1ICTI@L3U&^Q^UL=*2ZQ.5&
M91(\S7J,'N>G^!20B[279'_!?5'A"[@,B^.S-$RXLC J0*'\RT<PRTGTX8.:
MDX&SM-YKRN7<LM14EI-A#?T^SM!%WNXS6,1G)<1<$&EHQ->_9!"%)7D#F%<K
M2L,K?X#C>Y_FYY5GW:*'A:7%\K6VJ".[HM]XW5%!4[60%J.&[D<JAT(Y8M_[
M&RH=\E!)%L-U>49+V=_UJ@"\P$_YW/)0]#:!4<P*J$CIQ1N=E0D*>(<LWPN$
MX$7;1VUR/@OCJ'QJG6\9H::.NARU@D?$\1!N)_\1G>RZ/FQ-I<X/RJM/-T(H
M-YX2LQ>$*#\@)A51>ZLKMI!*L3I[#RHPDF,O8'+DT,FS=:HK=]M#M6/PUH>)
MK+WGFJD\8P_*)6<$,$:\#G15N&-@T>5\[S6CE)-/ BZ5S1::N+:.T:6?=I S
MD+W@K[_M?;![ ^B,/C7>Z(FZ+Y#\NNT[SDFFV!."W9+TA1=1_,Y".@#_+9!Y
MZ?;[+7AZE2=^Z-:0ZU#K.S2LLF(#]5WJI'A(GG4-T1I%A G/U'N+:Y@S77TK
MRYPNQZ:%16!$A^=XX(340K]@5;5#?>RG&?(;@(>7;PI;.;R*C0,T;%?(F5$;
M4,\'26T]I[5)SI2_EYGWPNQ=(0_>:U#06S.#S#QWUWTCBHO\?0^H%++K&X 8
M\W"$9CEPCBW@0Z=GCA_/E'N+\N.NY(*\R7>[-774NI=[1LFQ5SG9KVH$= D-
M)6=H!&YI50[!V;%!S/G,OUQDY++-%<^W.';?SJJ&?&WL/M^;K&4Y[)MHU"2)
MN"IQUAZAY77L1HCQ&KHG::U661N)/3&H2*D":]K.- TJ9=1]XN3P9BB;M"$]
M(<5[O10G2XX-P$BQE5+<HPXLP?M>2DXD8M\,RU./,&X2+'H8XF]#Y!IO&T\Q
M;!^[>D$QHOOD!G"W,V(%TM_ZP?6G1.\9[]'&N4Y*9K$>V-5QQE#YHLYW=)/R
MPQ5+UWT9^1YY?3OL*H'/&B */AW,9 0>ET:C@=;!?,+U7 +Z]KEI8M>XMPEC
M?'!:34URU"3)E'.SFM!*$A$O'%:1(OS^X990<0GD;AQ3C$6_#_XL]+N1KXJP
M\'H8MZ).MP;B5M+'4,\]K<U&BVSCF>QJJX#%&X#.RPAK7R6JL8C[TGQ)<0TD
M&YK*3"=/UL+XY.DZ870-/J/L:!+/].N[@IVO\'2W[#JF7UB$O6[7?>A5 +(5
MYQLN?C5=#OCR-1 [N?]K81E9KW,J*[AW0_&$MR XE#JZ 2XUS%S8<L\&(0UC
MJ,>F4&V@2 D(<Z)P"W(Q<AUUP9/5J0WN/V"P]L2?_?:EF+$SMSR7!FP_V3?B
M5#A21U<\L!F)J8J>0#6LE)WQD5KV5@$Z&Y8JC*ORL\%B[0AH>R9#7,][6],_
M<:51M'IK#J)D),_@X)'K),/3MGV8%\>I#E80@#PIV%0LALL7&$FT'CYP@D%7
MG)NDE(8;62".QPD@>&0$W>5BE'OKI77%7G&TAVO<1*W?]#SN\-R37$E;Z0_9
MU@<]3%O9%W$%;2HOHZVD?R$NG#__JZ&,_^K&R '\"Z//"*R,:4>^J&& 40&>
MF)@<I,E%.4*4RJ@;.&]9K5,HA^>3]$U9+V&DFW6?4Y18S??3M6'.?B,VZS:O
MDT@H\E32SN\=JRT,-(\&+K!PRV&BMIQ0 $+\P<P'11P3WF!C2;)S*D?CUU;5
M*>O32=T9VM-BY6P3WHKIT@O41+:DK4X',NT^8]1X'C(?YF9><[QAHRQXI!?U
M=)!K%X(EA-E$Q3??4S!*+B^2 ONT/VZ/@4'<?]K6;C(QIGB[]J>'XWX:[3<Q
MVS?'ZV+BWVP35.@#<&B_U7'A3@C4^3X*YH+[?I<NKWG@F;B4%=_%\=&^C#3@
MDI"*T85#SV/<_H!=^<3B!G!?Y]()UPE\[/KVMM5G-K\AM$E4VORE4EW4[(8R
M=YT&\2!M@*W"ZP)](1Z0>G@0Q4=%*R=*DNF Z=<^MSWMVU:/W25_U/55" W6
ME;"5U]NF5KV;9N"J$9W[:#PXK_><A@2NAOMF7A[1S.9M<<+.3#&!BNMV>.0$
MVM7A:H+O9[6=N-^ZQFS<:I3-M]9582\6'\40;P_4N4@Z$G_71-#NV'U-TT1X
MM4=H=NID3&"^/]O-8=83MZ#&?;IG'$C$JNX]1=X_<8ZCW$!Z[DQJX'J61U:2
M?EC@HJM<22(,:<I;Z0WE]%F?97NGTU"6091T&YBF%<J""KX]A+)89Z._15.4
M_E6^/^XM41P4)/5K)X@*];4JH'9D K\",&#@M.9:SJ= 0CGP<J(T-RX=JK8M
MC"5X,%$G49/(P3]0O,J,GC 'Z*10?:T'"=JA.IA,(<4@UGVL%AV[*'.?U@3$
MK4$H#Y6I+J-AX=9 +I/6"* YJM*B'JI6%(0LC9T76(LZ@C-D?UF)23F#V)8X
M*#)XL:C%*T/.&Q[$;S?C<%M(8759*X85/&*Y<0%7PM%4XF7)\5-+"=(.]-.N
M$A/@,%"HAZ_< +0=[\O,MD)K;XMB<XK06*5=,O@KU\LV-I'>ZWR=5Q VFU"B
M]/Q.NI8IVELQEE;-MT5LNOG:N4^\*+4*A..6O0# 719 KI_>/8!FP /@O)R%
M)50HPSI;VGW:+#;P&<U[74JO.=JR:7[D7L1^$<;9T_>\A8_(1[?F;*$!!+IO
M:UHU0$% -6M=D1T?RC=>_MJA9@C]>-]K[\1W4&&+PZYH!S+FI8]()"'7#?/'
M.(7J;\W7!Z370H7,S0+E@3RI>?R=AJ?X$-;YG<:'><V?'3QL]>]Z>8@%B[&L
M7OIKN0%U"6P1/YSK8%T=YUYK;K@.\:PX!GW;E%6ND:IXWUGXB++*!'OK'S\,
MRJ.+5D9W8RBF.;A6<*FY<J(]OUN\4,$P5,0X!M>Q>#1YSQ3PDTO)N5A)FUQ;
M77V-X1K!>C@] AG.<3(6#'DTYNR>12[K4RCVS PDSE6CJ'IWFC&+A6@)X\XX
M+:=L[CRH/CP(_,5H<GK \N>KJ6APZT:*+VL3'_?TT]WO?@@7UEY/0GU1^N@O
M/R=_7!:^7!58]_6Z#"<:5!ZKDL"1LL7K3&(WYNZ$UWGM^SB-E<R:/ GB"V/J
MZZYI;)9@4+D!.*HJ^9]&*"2=$BC.*B@[?XR^+K)$G.G$W@ "#Z^D5-\-:+G(
M8=*]L$_PI5@))&DTW2QB8TC>.;=^04$,-(I-+FJZ 4B%CZODB,IF-N= 1'?X
M!:Z2:##WQOE].QZ2=@KS/E;+*I9??6,S]N$KR%!#BG,C*/$1/@.81T488TNW
M*I5@8N,#63T^C>B6LR#]9/Q(@:#*177BV(7'A(EN'H)S*[?%XO/>F2"<A.<=
M[>.CBSI$D8C&T-&6L8B%FTMN\()I=_>=*]MT<2KX3VEE5BWP TF%./M/5-%)
MU_RI6'Z'W8_D<6M4"/U9^9(<58J)"M<5E(T4QG6KBO9'G-*%E*LK7=<M9]\C
M%]?'5S4!2K84FQQP$?<K<'UK)>V]PY\5'EXAFIR#.Y9')YULN6/>3\R*/LTN
M"O?Z8^\E47EJ>]ECK>E$3ZD2=3/ZU6!R1'7-ALQM""FPL FQF)2D*1)H;#$4
M>4T7(:; =J)BS?SL=)$B%J6+5D<Y((Z(D$8AJWLM43/I .'V>;U[W._$V+XX
MZQ-^'.$I_7K+DM"PH^OM84@.F)[W:W1460MMD;T)@>9D?:2"@D+_$PN%RNR!
M%6+GT40>48;]N_RU%!Z,X7P/W9I]9&RJHV\ # >Z-X#BEE';,MCED]RU>_W4
MY3T)\;85 O+ *5_<B2DP*84YN7?(E--2W2"U!.M*(.:7]YK54,6=B5Y!&RB+
M^.">T)2/.0=MZ[EEF$T\44--3#E!S.-'J6-YI\E5KO'*T5H7%&71S-5GW8LN
M/<7?3'#7X-9EX-=LG\R%9&8.6%9:$%K1K><:[]E/>(1+'TXJ?0S_J:#M\"GA
MF::!ODMUP9O$,VQWSP'19/86@N]KFMM<L)CC+ P @8+F9%/T\/\S?_@_HRG\
M<MJS_BBY'1<-O*/ 8HTZ;YU 74&CDD7WEA*JX,+(C=?!*/&K%+F<M"A42?/>
M=PVD\E52PT#Z'SY:+2,<?'TO:QN3Z<)D7G>5P!(;AN\L-]I9-2I+2%>;E_@(
M4(5W"_'#]/0Z<O7:P(!V1V9U0]\@467;!56R:>'\9T!*4YWU-M'$[3(#;96[
MST)L\Z9UN1%<V#4AA>ER+_7L'KXJ>#SG/T*Q[BC#)JC\]>"!S4K4NC%>4)NK
M*T#%,G'!C&IP2$"N%;U)A[G=D<$&H T L*7LN=1,#GPD+3J_WV46;<3)9E-%
MA2#YZ<CXLKT#=2SJ%,,=PQ-K>H?^%LV1?_8IKS2,_RX7I&@PJ3UV^O7]5;;T
M#K(OFF!];KW?N+Q\LI@TU.&#%%$RTOM#)2Q6!J)N?0,P9\1%?ONKC!92DK<Z
M&(6C/N%E=0A'^>'110,1R W08Z3(UN[D8-S)@7=G=2"-7S3P4@.5B:&DN2</
M-2?_RZ%#6325>;-/F1 ))),.2%OGJ-K!.<EYBR=4QA<[19PDX_-VW@W 6BOA
M6X2G#Z[5'O9T&9]YTFT18J8UO%^'N7,LN$]96G^=?P!0YR-(EO_(@&<!HZX8
M!P1N#TR>SQ1MSX6[FR!-QF,)OV).7XR?UC5X'G-7RH4A(HG?YN)K?,UFG*X=
MC4:!<&MEP[GYO9(0V.-X<:QFC_@@ZZPS^>.YD=3=SZ?^U^^55:^O":Z9&J L
M,ZXXXBL$2/^C)5AB]?G(#6!G[@:P8'T#>/^SG?:0SL;W9-=WCW]:77K<M&+;
MX0;P3YZ/.%6^?'8#D&3*O0'X8J&*5W0 C?[_['!)C'7?ZTJ LN S"WM.Y(NB
M12'+E?2"H"H@S2C]?[F^^#]HOP.!*%@*-PH+39:-7/%WD2L]+PT39IZ,4AJ.
M\M W+"A4"A,*;=#."_R4NQ"J=NL^+P,/#^>R-@.!IC%YONW/*5!;T>'!;2&,
MQ8L@.$WLCF Q3H<$WMP8Y^2)2@+$SG!I)"(V(J]+RL@=%/D^52AI87)H_TIX
M>T5Z[W;53'G%J^BE2?'S$]I8'RP(CY&!M"/M]$>IB/02$=CU_3O%]/$:(XDO
MI%(Y'SR5""F1AP(#&:#\V,'H>=0!.IQ%0E6]]SX8!+(4?@56W /B1GEIU1:F
M$A6V[(:MTRC$14JVHXV,,VA/2E= ][A".+FHDL4R7U9'>\ME,@9OJ]K4S/E2
MFK@'GANP7;C'#C]A_YCTYI9N@FS!8_*P:G0)BC5Q*OWIGZ>%L\_)3=_?9PM_
MG_*N"11C1J&R84',M.@E(/@+?;&O'/@G!IT%[(A"[:"2IC70?N'1GGZ+0R50
M*\HK_KX_2UWQ5VP*A327!@B@"ETH(+4V '4F C6GD/XE9\!OG8W2W82H!+ [
M*.0\4ORR?^:#A6KN*4+1V]VS.Y#*)V/>[#/84:6#D\70E77:83A"4P."J8;U
M3"61GB[49TD(N#I4K.C"MY/^P=^)"H4>R>Z0KQU"8>B9@8"W*)U9&?@ J2%_
M5YO_=]/E_^,QY_]F#=T<^J<I#?WM$B/7.7*FI+E1X"OUI[B_(5B_@%FHN5!'
M_024,,W?I842)KYA[D 78BL),J:LKP-/=F=R][';2:9^JW&>8>J3K209(UG#
ME4IB7O=1-ND@*W!YQ/BRHS?R^R]@N!IW[:_5\CM]C_OI;^@/T@BA1D/!%%'0
M+A1K@$R@!@P5G_<+^97&A\)+R$,-U94DM;B<[&F)5(EHCY.PTUWXQL<A8+ME
MP<P;@,&#=9\ >9)XJWLW +5BK_BSBK/1_>P]PN^S[3< NXH;0&J>Q,Y<YM:8
M[\$1UM4E<+!TTG>P4.)D4\,G$'[M8W8#:#'_\%QL'DE<^0=QUH5+[N454NOY
MWGZR*9!ZL$5P=0%,-:M"?FSMN^.G,DS@[CL%D5A9)[@X91&? M\ )-1\?WY5
MOB NN;R0N@%X8ZN6@6X @Y42)ZV9,_\"\0W@GU"+=]C> ,2'D/]%CW VWMVI
M1G(X0GNRJW[<IWIV[G]]C6T_4>2[,DE[,:=^S&9R=AQT?0KT2M_!OWB!Y%,*
MQ2?MJS^9S[F"CE_[I-\ FF_3FO_)LFP]#;);T)_=3OW5+>3/;BG_UBW!!>3/
MKT\+^:M;G\ _N^7ZZZGMH$:)K>K4WX+UJ89?OTE#BO/=YS]ZNX**MX'_^&9E
MLO422$&\N@'\D@3S!23UCS%X-P5:#C90(FXQ0XVFY[LS\5MJA7\0L[R9L4**
MS0$IXVM^V@FD,,=H+XZ9+_!R+\_;;@!O.MB>O]GC^D6^_:MO%V3?7U%]2Q]3
MJIX=H3@Q^7/:44PK'E](G%T@)4"PE[EU;')P@N2?%J'^MP41\1>U=5"C\C^A
M]OV+^MW?J/61LUU(BUQ3E1BSC!<^\;^'QSJ%737W7;]!FML6_TL;VK_(U(]Q
M),Z._)%L<0!.0II_OOCSV_'Y_(/^'_1_1W]87Q.S(+3@=-WGK]W\%?DK$"_U
M_5FFWI>MKR QPDK3(:XAP>KZUE@F%JO*<K*?/VQ2?UHHBD5B5&[&:=56[S@_
MYI5@[[PT4"OF/V37_ILT)N;LOTYL.Q@!9'^A5I#^G NP_6^PX>P_<B+R_LDK
MTKQDHV"BR$^S?Z&$I>[_*N,"U%A A0!1*)2,W\5:4+;0TAKA\C'F:HWZT[5+
MNA:?R=GMCB/[99LK6XF0A+;Y9VK3AE.3#[P2%@+NMH*IF <1FKJ$>R2"C.*T
MX4OJ:1 5;KJ>L&RO%;$O&@TLR6%-HTV3I-4I+#$.2G9D;V)92D0N.*-S+Z6'
MX6W&2B\0\1>2(CK?S46]&][.4=T %,8^M$\N%U?,6(/$&H_O=7>7. K)))5@
MF6+XI2P7Q.@*3VN^< Y\%">K%8;V\J4@ #]KG.U).+T]@9Z-0-SGW.9:DA[<
MP5)9)@>W:D$ M$YL+"N%;#1GG.]"X/&4W+6A!DGXBSOR6/3TL-A/AC-0N960
M%R&C",?8%T*W/*$O.KZ3Y)4X\CFR/58S>GLKQ7_#D#3X"$]!XM8J?$U@=W*J
M%]*C%1N9S@!Y%EXP,9;2XNMDGS;15PP6T%0Z?Z\>'"?97?<('U\8ZIWN5-)!
M5JC'OR+.53N4ZV>!/F/'L8AU9;K:>N&OC?4!H<]_MOP63T+>C#8QEX,>L4QV
M'LFB'QBD#.4V]&YF&^-;A>P<0>CN\*W-W#MSH\P.<FQEY_;?"8^="+UW9Q7,
M;Q8"98M0!6YX!F9^F0"#1'EZS!R&$UY^RB"FQE+1.^AZI@8ZA8-&*^-&G%L(
M2F+M[M9=/+]XW7<2)XKON/XFYDROV(TLDWC R+T9.,2W)0G[4<S)3Y=O"VD
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M+_;)P^<C&T,]PV/QX\$^-X [*]"B(L2(@9*7KI&P2+L]7S2E'8#V,WDGKW&
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M(S+V)C73)OX:>T^Z<(QG:M9HIH_=H9L[2LX4;=6'%];$!D3Q,*@_LG.4>L<
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MG-&W^_9[=_3K.VXOQAS\L6I5?=]<<\WZ9E4!? Z^"N#)2\M) PA/  #A\0>
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MJF/GO#N&2&["#1=B^+IY/YP\UIH-4S&+OYT$'T_&3G^''J^U16V(?4S\>DC
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M;HR]9G7.A1#&6K6Z9GWOC2YRO] H+QN7G.]7S@KVIKI&E4E,I/>'?1.M\I'
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MQ#+U<NM*BW5UWNZWOM/HI)NI_C?Z_^RK -7>71>FOCT*$"IB28(#(4FKE7"
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M/A (EJOIQK-*344.MAE^&8I.Z)7M\<3)+_=4UCKQKRV2VE TE7%GRMCI[_R
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M_< *!P949MOW-VXP-EAJ8(\S-<,; SA0'K?#$O5G&]2>AT:Q9:(K_S@X0*.
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M42&6@&EZS0RIP# 0[\Q$GUXK[:TESY2?=9U8]!N[C^P\#YWO(%2S^F&$^E3
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MIDSTJ]D"";3[8:K=@7'0"I.LR%2P(#->?*#DCB"KZ\>LC<2I"]E\26Z1+?]
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M0D7*1."=,Z<0O,7S-3?\$"-Y[8*+:;>BV;,I.1>-NF/AXCIC;N4N X(^F;9
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MS^%]?Q$<$WR?0Q+@\):CSTE@D.--Y( TUY8$%.OHCO'8JQ%SFA4JK'I4TO6
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M [P6,Y^H ;OMH7'U$3 $=,DV,5K;I*;GHX:>"3O>9ZPQKKY$VILP$KD<+B$
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M^T!H47=0"K5SLQC:SEM><WEX+X!VX\X[@A]%-\9 CE8@@* XX_;R61;11PN
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MZ\(2>&,*2/LT8>4T*@-2UI$/@,7*V#5U!'B&:=OM@DBR<.H2@! #_E XVR.
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M4$]-V@MT_J#2N\Z!R975)W2H"3;KPEW:%]:8Q[*+QNOEQ\KA'*>9TF/F;<;
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M(T^1#*OZ]X<LG#G[WEP3RX(=J?G):*?#[4^!(^(OC"9*6"J[X1T1RD_$+@M
MB=EUB'4#Y[X3.?&72<3O"F2U77I!:-O-4;FDX@JVR4YD-35UP<)1NK?J1PF8
MCB/&K57R"$&J;UJ'!&X%+@L/CY0E*=+<O%Y'U)EAN;R/5M5 >W:?X3K+V2PR
M%2&*BJW[4W1NT!.2=&#6BX:D6!'/%L[6Y\#GMI U;76UBB7_@\E]2 (2YX\+
M1Q1UD?L5&5F<]S(KHS[&<L>;HEXR2>:K6TAM7#@NX!*@XZD$>YS,-Q(EL@V(
M?'9D*AZ%>I5M!; 5-H]6(U9G3>GK)7GNG%_>$9E/S)UDNL8J12ZA?_!,W/Q9
MS"$_"9Z/0*Z\*)68E6DT&VIZVL?>&F-S&_'F S%_2MI/7'SNZESGBQ.II%4V
M&?N-+%KD^D!F@(TD21BUY<N@XT.Y@>/,R7>1F]=QJS]YC43D&ZT[<UV?  ?K
M4"'RSW\":/T"^3@D,:-J5U;SG1!1)!E(TQ/@2E<Y+MPU9L>)]WM6,&7DOY\R
M/W*SMR_UX\0RFQ=D<+4H+-"PR'XN3D2U4TNB(JS1&J+?5%?>,CD:,"M?'CV;
M>DV-'16B9\2#XCX&1[R6C&TO\W91=4\+;?(B^;[1*'[$C=H_T@)[*2PM($H+
MI*6ZA@^-QB1.B>+O.U5JCL:PP4TMTUCK60(/\/5]F'OV #EA8GW*!4:;MHR7
M64U[VN_V&^@#P9.7W\W)SD'D#<8T_?2F%:&%MJ[^11:GQ,H3)61UTQ8@0Y>+
M]H+Y'!S->IU,7!Y7WR3 Y;LU3THH0DT/ !ZP63R:K@:XJ[A:75JP=4F9X2W8
MHVJR='$H,C3L1+KJY=KRO6E2RG8.UD9:_)GVH3I->#K#T(<(+TUF^ :H!KAZ
M1TVH/'D9TK_AP:5^_\+TX^Z508S+9?^N9-'N7?.2-1*?VCT"45<8M'6(M^DB
M \F5FEQV\M(M!->XY#+]QY((GQO;?-S#"@_*\VBPS/3F^%I-@-J9E0*!P>I\
M7-.H=D+&KT=(YDQ[/V%EJW;?<*]XI+KLW*=RRKWT!Q&$T58UC":Z=QTTWG.&
MM9X@^WNQ%)0D(R"IK<K4^1^KWBL-[@RF'^RE:1,NX[V3HI:9/OR0ZH!D=C@"
M1FV=C^>CN5MS@+(W^41.JIB>Z^R8>RK3Y8D]RZ))MB?I\:GS?3A.TGL<:<XU
MAQ(0-5@F"$02NT=HV**L\>'V*T_ ;'AU2)>"]"P/Q19[H;"XJ.AVA,78.-)1
MY1G]@V?:Z@'( H"A X"K=E_->M \Q4HLT-30>$P[P@U@9";C^:[G'2G*\U+&
M[#2[&]4TS,9Z9G(!3:SFS&>-P-=Z)UC[2_Y2V8&[]AF$XHXJ^#PB8.$)$,AM
M0#L"LBD4M3+ [!G7PV^(5,%G2S,KK9MT*&3QMD-NW%*%E;?@'0!%<H8MNX"R
M24GM72Y-)&*7.8["DJAQ92<=DL/$R2MG/?M-68]J[ZE:;&:WN<\EBTT6NI>'
MK/+W@;I!(N_X*FF2(TIE) P-NS&CBDWNFA<ZF!_-#DAA2?@,5=G2M5SE]UC?
M50_'-2FKC<Z3RUQ6>J1J#X''3BA@U(+[INP?M;8'%JAYC YB>OY]76'2G+/V
M9::W)G1J:V>:0KIZ$QVN#*R89K>X7P-FLS(J@YW--\*WP8?H1>M;<V]=+MMV
M%<;^*^5]_T.)7_&3?:V*L60EM\%,F$&K&O30K49%X%\K /N3H^ )DTNH,W%6
M37]AY\W_Y.ZTX9YBQL;WO8@S/?#2PQ C0*XU?H/98J#4]=U@5N"ZL<"YR"N^
M3Z_CF(^R KK_$^&B>A(AI^=X=/FI?UJ*WH'7$P#<TZ37[$9_B/7LM":U;LTC
M]-=^-?O(Y#@QHNON#Y=FRHS!L@AO7GZ^ZB9&2<(5(Y:6E\HM+\:3\$IXD98]
M$?T%+#A05H<L@(F-1*WC4!SO.,[\!&BRJ4+.GLF225 >29)S4/OVM7I/T*MF
MRN!]1-EG1?G>BG!&E0H05UQ0G%R*Q2@BER)Z1R'.)X\UVQS%'L/+<A!9F1M0
MW3/GC6:_A16S<?9UI\E7#IB%8J7:H<BLT JX2#B)T@&E*]^4Z9Z%2A][1?Q9
MN=2"7*J!;K%V_#!L,(N^:@S..<%')CFNRI0*DK%G1)'UD-@7AN9ZF)0D)I32
M;L&EB@_I="+(%,YI3'W$S6PFR]XS540UT2?^W]<5+3!R2?$E,P5F+!FTKB_K
M15B4K?&ORDJINBM\R-#$8T;QY(?UO];!!U@S#^;)8GWDD$8BFZK2E-*35J2G
M)'6&& 9<]2DC$Q-XO2Z9%'*A=/'DS^:X++*)+,6/Q,2/<#5C50W$%>!Y*9&+
M<<%<' &29RTX:D1)^6A3?YWB,,R< 8_+G;82.Z 1I99C74^V6(X::B?0JRLN
MS,A_9GJ8Z!'-V5-2]%WWLJB-FLHKW\DNC>I"OOV9DL:!(>[Y+&:J:&XTU\<H
M"?<19>W9BZ''G!K OG0\/3T.,7FUU$=1(_MU&&N>PA)ON=3ZOHUTAN2LN-D-
ME:R4CS+<2H&T?D.%>.:,0,Y\DFI#Q5V)[*WP+4N&8W'U26=WVIJ+R.,+E@2Z
M=&Y^M(R=B4H_8QE#APW&(65"<,!RH3I)J)&WN+0G\G(=L:_T60J%H4(M=]+$
M#B&U&Z*ROGDAT5TP-,C4(5[WB'>]_5V;]LR=&B?V">#$;=A2?4/I?3(SA')[
M2'Z>ZV&NGC?-:W;)?OQGDMI$2\B?:6Q4H8*Q:)SO)!BZG[GAYWLW">?^+#=E
MT);D 76M<R?/Z:JJ KA+9\#I:H<$D,$-S)E**S.K(HTY<:1*YO*BY&]1SW H
MT[\36L9M7-(V3W?GI!E4G77<]/Q<*GSH!K@97*8V;]<"UT/<U.</G@ _+,#?
M!0=F/_[ "RWUM++F5+8*9D&B[Q@OC>2=*EF 6:"Q7>L+'XUJ0FF\.-22PE\>
M4H'=X J2U^N/TO!_N)LDC1?/,2&-RG'DH.DE@3 _VTMZV^7!B8*RJWRMPL;J
MQ*DO0BIF09PP MA\<\#H7_7 EI\?<LC,HR!;,55AX$1,<N7WCDW^/B)Q]*B/
M1\9&BUJAV\W!"KT;:6B\YPG@@B8(X\&_ST]0;P1N1=EUK3YU:VPT05>*7\^I
M\B.YE[=<L^0N6U>-;V$[N5L5=F)H5*F9+J4#(V!_$-O2L/LI[.+OJ:'73 IC
ME*-ZD]\QBV;RKB9O(=0U/KH1;>4E+$='!843$$7+-.MF8D!3O3-ADJ;(W#!)
M/4ZN;66K17NDCHH"E>>@V 9HPVAD'ET9>H>>%(2K5ZS'SI$WSC]9V<!L6?V>
M&Y9$*N.RY.153B%W5K+J#5R*4T&HWDM]*^7JSY_J=T AZ.K,RD';@OWDLO-K
M($6B4'T",R62I/5/,74&,#H*NZK7<&@6RXU6,J9)MFY,[DK8)/D(BR.S#[#P
MFM^+"DD03\6KPC."J_'*O#I]EX)-$@9CV58XAE68&.T+Y[G"*N'I9/O8X=A+
M>ZZ_A.](?R1Q)M%Y!\;Z&H/S\15/X:'SSC=<85VU@.KHF)].:TR8WW+9Z:NO
M(\4:-7SWI?(KK78R(?8K?.]V1:.HM05% PNP=<1W,-I"Q0&V%'"T,5 D6&;*
M@KME>460^\GE*U096=LY,)F'2 $E;G:[LO)!2LSCYIC91N8Q0M&VR\W%/)XG
M=S,YT4+X%7-S,0M9Q:XD]FMZ" -V\\2\SEUVF'#L>0PO3CY2OJ(1YY$B-8[J
MI21;CO>M=6^TIEX&&G;D*\TRI%^B[D#N6-8QCUHK51[\JE?OU@DAWTSF5+B>
M !&$9Y*E3X#]WT6VI(@!1LT>!G]N&[-_1I0 @P?&4V 4'W')R8KSWUS9\C/.
M_++\RD2@_P)S_.>=N0HKK%GXIV\IKBJ,?EAO1]C28$V56^L^!F(I?PEX)E!"
MK1 [G77@.N_)Z/_.<Z+*):Y*LF4AI$#H9?-^-\RQ,(]IP2:8/2>K)OA')7=#
MI4)RK%+,[EP=C?XG54N9.)Q-H\*[UZ1I:%CL>G.)MY7#@C%K#.Z-X-?B(Y3)
M$7%5R$S1IB[JGJ>A&B538<-&:O<BR4:Z9DP(S@DT(6VTQU\Z]G0:W3O#5Z:1
M, HG_-C/,N4"?D302,^VWW4I%[N>:;0NI*$!="/-XINCE1.7EQKJN=0K,$QB
M0#69&*5S2MSWP8W%O1C6G9N<33@T#-/B!V9IS&#I1A-W[<QOQCUQTO8M?.-
M[: $/--3+JS;  $Y!5],\XMBY4AAGG;EV&P]RK,=\HF&Q:U&(WL5+CGU2+&*
M0##59@4A(_AH2O'6EZ:D[-J[/4]!'2=X2)K1+E@Q"LPA0N6JKV"<KWO.?.2G
M<(X"^OPSZ#UYU-SK;PX8^8O,25-U_:055.F<@CB!PV*&(0<@]/=+* / GN*N
M-/TB/Y]-,'FUZI3>HN, SA<*&-L+%N2E?ERAY/F&(!>/:Z+WW%ZBJZ-$DSG1
M9-5A6!]_T"M#+@7G1\G9\W\<!F+!D6<>!A=C,^>":H@ST#@5:M">7>9%^?HJ
M2B7!"-,Q>4>)4,#R#3U'H2%"2CD^OLB+2/6B#9]G]CAC=.&6[TM3C^TC<<*H
MHEPN;HZL0ZUYA8BBH53[Z>R33?V""S'>-+NOY1* ?7,[Q\W?W4*6X6Y*G'68
M:"+$7 @&;/TB0D.E C(BIM)]E[C'VSL+>4$] +I4/EN@M$;'QE:[+)M?JGT@
M78A<CKTGX+^X]4.-+3,,,Y//RLB75GDD7/$@%L90#L#^M_TT*DBG,I_*I[G)
M:4<R"[7FNHV%CFJ^.IWQRF<?HR^N-";MN-O:;YYXW.]E;<YG%7/4X$2)Z0AH
M6]OPXY%[E;IS.&S<.U42D"7="'SH)2O:&13&1O)R33D]U&K48LAWCNE4,PKA
MJ][V[=J#*$A$+JEM4 BM<6<XM+>-YKKA*8BR-,C@^J(7.%AVH::,O8B=A_F>
M(L)OBSPAPL]35*66E\[=@VT%RHFUJ2"57XTW70:XK 9 "/<:+%9R[N+SC3P;
M,FS<.+R_'93 OP:EO"3XGANQ'J*IJK&P=U>VH/@%B7<\*T0W^..B+Z%R'\&2
M2N8X/UZM_P,Y:X)3@?;>;-3JJC:)=9\R;53@F*[(BF=>.2^I23R6XPI^],S
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M60-%5J?E?3H"L(-^ ^7N&?1%T!59%WWX "&"3C=!+A1)1T PKZ4PX&_4(:C
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M5(_KEQDH;A.)Z>*51E^'= 7%.<B#:Q6K(FYA5(&S+R""I9,X9[5_U=/=EO?
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M2C!DZ3=HUH.=60UVYKL7"_A-9C^H;WV7EKE\Y]74J><B[[V9=/S.E?H/BVR
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MG^%@]_5R5^T[Z8+\A[4E])1F9.]32)9NY[K5/*&@N,E6>_L@J U&,7[\_R8
M4$L#!!0    ( /6!5EA$W85?NST  %Y%   3    :6UG,3 U,C8Y-S4Y7S$Q
M+FIP9\6[!51<7;8NNHO"-1#<"1HTN&N"A>"N(;@5[E9  L$U0'""N[L$@KN[
MNTMPA\O?I[M/_WW.>;?[CG??VS6^/?:HO5:M->=>\YNR5SW-/*T +]Y+2$L
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MSEH?3#1)4+X.:;:%+8H0F8$7S3*"@6<A 0:B]B< JOX$E(6F]5J:E#<)7UU
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MB<"XSB&1#P+Q6EP4B9&XHWY?.WGX%Z7_IB+C=JJ[6%,IE%1@6<NJ^5"SSLU
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M,AOPT/V#7'$DUK7&BK&KG]<G<A#JNUZ^$F+4V(T+<++2S]*<;NHJFSRMPD5
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M>V'!#$2'<P=-XIEO\9JN#&_H$P72,/NOCL[W[9Z #RMN&'OM-XJVE[IS=T]
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M9-4:WM0SHP%KK6(JZBVSM7ZYZ@,=!LC O4DM$W.).IL576UCB+&_T>L!XO!
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M!6;Z+4A,59CH)IN!U?!DT575ZH4L+2CQT)7U?1PHBE/*ED"$XGS:D.2C-_5
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M5IOQL/677)G VB:1'QJ<J<OP0A:[HP\5[7_<X-_%C[I]2U<K)+R-_.M7F_<
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MOQ0)H+Q+ A*&;>5+$YR[3KV&XCY(]W>E-<C*RC"PIS0-G7S[N(="*K+=N<)
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M)^1;U$8$B8K:U6J$<YRX *H5\-;3%=.3@BF+2\TUB#XPAD,7W-PB8H*4WG9
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M"M'.<  ?_],-Z/]9*$B3_P502P,$%     @ ]8%66"Z>-J=M+@$ 'UP! !,
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ME3CUBMTF]EG,%S$;J#+K>T;DA3?/'-?U9X\[0/!3,8/Q*0SKO&47%D":(OZ
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M;[(IY+3>??N(1W1=0_T$?F2&8+.PM&UXG-1%T!V@ IP.NIM^AQ\D"!47#6[
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M9BOT NY<RK2,WMS'^GV&HPF>%6(!7PI9ZB0QI:ZW.D;KJ[)_?(DPR0IKQ5]
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M'6DTC367_5,(_F(B[LT^$1J];GZ#W"\XJE0_(TN^_\PFY+X#PF]6I"_.)^X
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M7/!-22AVY%3M"=H>XL R$YL5MLPT>%]Z_[7[E&.][U;(9W55^4G=1.X'E#M
M?X.=::=7T/16"+GG/5#*+;T7"@YWS!C,Y?BS#_XY>NJ62L=)\2ER>!==)-0A
MF)4H@[YJLEJ_3:IL*?_#VYKL$:H]YVY?7D^G@'3U;'!1?:-#>O3I^RLT[G,
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M8;854CBS:&BB4J'B<;.I&CB/R7"JN9B76Y'3$(^/K)34$[%HL5MMK4_;L/B
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M^AP/WBCW2%-1N;BJ",_O76N4(4E4H@WA"P7I@86+,R2T+;\)4S)EVQ<E.8+
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MO,'H'3RYY*]OOJ+Y[ZBU.RZ/M&BW0+-8[8NLA@E)ILZI%D/<WA?0CV^J.O]
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MRL;0]2ND%8.)/EG_T;].Q6=42<&@07+O]"3K;X)TA2/6"3]OE)$2$/#/:1U
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M%FL,:*TVDM]S&08U:4L@&Z4U-:\3O,&SGQW8\T-\FD+NAFP.;6MMKA.:+![
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M.X=02EHU>]2,/:C39^"5J=JT=:V@F[]!<B'Q]C;!\P?U)S;_=6PLGLC5Y".
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MZ-7Q$OMD XT;P._Z.7!.F)1(D.[C3BKYP:@<HX(Y@B )>_0-K4C(L^ ]$48
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MV$(L,C#5QM19 ]NH?4-HPNVZ%SPN"?U01?^8FMU?M)P(AN^:IH44ZS%Y\;)
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MI9)2VJWL[?D$*_H'8>:RV<:+CE?0U_.N:QM2EC(G,Y%!P.PMTT8^,)<CH@6
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M0D9'L.1'Y?>U<0$W!&2WN$!*=XEZ6;I)+4?PLI\EUU995@H9 Z,N11*UVIE
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MXJYQ_U+4R@-JZ'N ]UR@"/ETP7B.Y%!<Q H#:HAA1KSAR#J*5?.9J?AKM_&
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MP]DGHSFEFZ&TR1;I?;)V;%S,M^JOM_SH/"QEK0.MJ]/0L/-+_?8*^%FX?)/
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M&=&7:IV^W6W[N*VOAIL^&KSXV"O\":"#3OB?I%UYS".]X=1@V4(8_9%'$Z/
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M)U PE!^7E'VPS&F@X4R2'CJXEG \\-6]V'Z/5U--057=:VQFGU[IU,222-Q
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M1QJ_BJ884.V.=]F)G>;[G<%AG"9O2$>5$ROMY9XU>PC=#FGPK^)BR&]JHV_
M/!"( X^?D &^2G6J69[E+S1&$$@N<&:LI,A\T6'[=8T;3*Q(9%8BY!*8I?'K
M_BVCT-C(^C-LBTQ="_3=AD5)YVI#U?;.WE9?SZ\"O:V%.5YV*!\-IWRIR0!N
M6PPUJ$,H@KWCX%B-^^9]4KA<T_PGK_Y7@$'I<Z76MH5*== "*K*">W&18F4(
M/[!TNOC4_J_SBL^ZQXK<P@FEM5M:\I')S53C05T&S4V.T>R;!!^:B+<.M-77
MB J,&2^4/-C(TLK ).;!!E#'04KX%/1^'*":H[-/10C7#OXQ2>IU5;K4R]CF
MT';Y.9=YNW%+8RDD7"A17_K']3L2E?OSN@0<$WBX %%,N9TQSE[KL*PBA.WR
MT7SZH:=4: 9TW79^&7?RQ"Y?<"<M1K01V;MD-])JQ.GX\O=@$BFX*]/>-]/#
M'?XVA]([^ @H0[Y^C;.%.-*EO"@W;L;?C3?,L[F\QY7YL=*S?S;.*!Z<5)E+
M7&S4#0.U2UZTZ/E*#[N92 O%VDQ!9RQK8:WWU,P?C<\/M'$%&7PT$H5*EE3Y
MI SQ5>74=K8=I.^O!%@DE'AG%9TL\*QJ&SFN26?"_-]E2ZY'<=8$M+<AVMQ]
MOO#QLZ'O9+$_?MSY@URA7'$(31&([GIGJS42HSLBTW_Z_HJ_DD\.(M ^:%L8
MAE:V24KQ&\+"YM=^F9TRWPD7MPZ.7)Z;R?EG^EE=?\;G=R47)V$:?UX!RA+'
MAFJ^R B^GQH0C"+#_;/=?T/;]_3Y>>J7KX8P)221<\NX1'#/Z>EZ!8J)<^K_
M^T\**F2D!B$))HG-4=4YHI#EQH%7@-6L.$U:(NQ27C>YB"TM2562XW,$2*T(
M#47D*@FQG" OPIGVZ0*)'JY.+3XX0@[P[\18JNJ?L);.V9F5ETG850*TUMT*
M"F:&E%;>_,5B,JIR2RX7"=)M- "<GW'.#/0_,77NQ"O%"P\UIPZQCV.T9HQ7
M5PR%D6S&>_E^SN2FW,#*H[]V#M?>?3R3OJ@2GMR6837R8E7!/@3+HT5YSU5H
M63%Q)R7J]KU5>0]N0BZYK4KJFP[%)ZSVF%F:K@[Y2DHU+U>@8?=.V<^N%#HV
M?B8$FI9N:FTT RZ@HD\I/#&RE7#3W$!0Q;YRP2Z.PS#ISD?\9*]N*G.TIJH<
M:@MUI>S6@R3JLK[G/.?Y^97]:/R^-';.CI!+/M?V.:_RON#FX*'CZ+/U9V!>
MF:*.,/[AXXL\+(K=(.F:7GDT/D<N)N)/]<2D\]:PKAO1Q6/[ 0ERA7K)B?].
M_(DI+B(]"YQ@ 2#.&0-=L5'I4\];9"GAEWITG,5&;J>1"B*C()3<E0*3L9[$
MY>D44ZCIT_!#A.U/]=]#X-!8%34?]GK8$]_?2!WYTW]N4Y-%7[D[/O;'(G+1
MT@></K^*?]67G]6D.^=]D2WZ(7HTV0$!^.I\#! 3(JU+RB<@.%!*'5[U;3V^
M+1"T=G3,U+3F[^<OS#*"FVL3H%XC1R[RAW#_TMJ"D'ZV_X-SS-\IJB/G35E3
M;=$GX#-=J)6<.N3<&945$QIY9')OR#)0^AR]'C2[2RFSV@H0R/'.58YJ.,-9
M!W/*.:F!+-0T)60'1W4;4UT=Y3BS,PWI^'O5A8@U)D: A'A?)6EYG0ZFPEGS
M,MK2%"E%)HKQX8M/5:97.<#?2:,$IQG*=#_?-]6S_O8CE]F*8^K&IY IG1H@
ME6+,U<A:5^?L8V"@ISZ)I@&Y1$1E3^$[41'P7151*]-N1F;G.]W@#'%(:N9F
M-JK*B9.(D^DDK"(U)E'&"<L*J=G1N./M\QLCD3\V715C(E7(?_U5EB,L2Y+:
M!A+*FHIL+TPFWYRR&9%3@2-7TXCOJZR4#R$W@U_-=*=D/.DR^G0OS34D.!EA
M8K^A)HF0*#( 2^ES9 C\@8!QA63.CR9^C938(=XW-V=\"*"#9Q:VKOS(.PJ[
M5,9HEU4,]N)?6_91,1$'^'/AT9W$P*I*Y-Z6Y3'2 \#!7,#WN!9D5Q;:!7K@
MXJ*.IILB'=U@HA4%42?\%Z&5$&EBES7]<B>I*7F*KKRHO<7<NI-F-\ZDQ.9]
M*)YNNCT-VIX/6.149R$\1XS4;%+ZYD8OI)\=_NC$7RZ!B7N2E>"6&EI=>$-N
M_M<U\%Z @=P]J9RM->P67Q-DM^<$ZNWPN^]? 9U/8]\,OR:G-OW;]3/O[/16
MK&H3N]?7VF6DWRP7,9MM$C?NW_NWT&520*,YIA,GN-ONJ93SG'Q?C>!B.K*]
M]_Y<0U\^9.O][,I4"%#R7&:2H2U\)/J,P='L+7KT%%NPGQ>Q//\_*/3^R1@K
MBXIT;1[L^G(\0XXKWQ=$?"PA?XR1U,D+$*K:<,^VR_=<ZFLVCW.M:V@,IY1R
M7I):4S<H,;!=9[MG^";RU]<;.ZX(KTK_PVO_7]E=Q[]D:ZA'_R*)'/=O:G 8
M_\ED%(#I=X>UX=W%A/]10<> 9NO<]Y<I=EEN<!"5E#-U4G8^W[K*RO<5J(@G
M:'Z]2E5M*',/$=\J,4X0.,PB+ 2SK<&C=!0SCM=A*Q(KNRF&H"/691IF19$&
MD.GL97OV@6CMV0M++UF.;8]NL90W%KB6V*#C7/;Y1#BNSCZ@+WLC(AYT0N^5
M)5YPRRIL*TIQ?\0R(@ HB[>6,X9BF'G>CMC]-EY:32:S'A[5=#X2,)@92K[W
M-O2K?Y+9DLX QK"GN 0@NKU0VI8)<W1WS?Z,1_6Z1<WII;A^0#5$L,):MFVH
MU1_ X[;K=.<[S:C>%,;;%?YV^"&EZ5)6'N*05/3U!;=?]X.25K+2*P"U8]RA
M<RC!I:=+S;TP\<C>LCXUNZJI3[R! %Z!@[-^.O<!IOYE8DCE!1FF*<-E*,*=
MH$V)S81KF=Q5*%HAM&1U!!=Q>$T'?&&R&C1[(-UL_E9/M&*[;ZQ.(*OX*%B_
M[QR4M84>*[>BSR9AW4G8$]^GC$[3M'=1PMK*.H4IJ- 6=$V47>S8?<;MKU/D
M(RRL+O&P0SV5/%=J>VZU)PA*CDFD&2U(+=^/Z_%:=E2>RL=C0_R-?S[XAFX5
MT;%_WB+;I730R2:E78>:WOE-C,QM61:$B='?:]^X2+SAT*:BJ$K1_WUKNW86
MSG"64:H*\CICI,Q):7E/R/[; Z7$KS6)..;B+Z2-!2C(JT(/J(V]DEIC_GB5
MFY2IXPB!L!C8P2?#$%3DC[CV3/S9^6I1U3R\[]F?CJ3L2+L6$:TK(["=5SAC
MQ81M^4%1^FE2Q+ =T.'DY=QV<_JDM<>'):(?>>X__,G$A%U4@C^ZHO13I; <
M'>A0:=3)6S/GAIH%QD@0\-/!8I)3AE&2W?D9E?E)Z(,S'=)UJY,L1VU[J^9.
M2)P8,"8+ON<^6T>@]IA="SH=*>4,:VNA50\.CN,4H5:'(@/LN?,6WBQHV?+,
M*!CA'L1TZ,22EZQDK\164)&,*)(3\)7*U)7S84'79BOW[QYM.5VULEZ2OSP
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MG?W$M)^G,IL+:'01/"1DV%YB0:E/DN%Y408[5 P6R[C"-;,Y3*]]II.2'1A
ML@H()4J3FIRS<?\2QW=X2;6:G^ACU63"2:EGW5;<Z']81OG?G<Z+7YG#7/Q@
M+RK6P 7>BM2WAPM^_?:!*#3R))[2+R1FU&CG_$>QD_=S0G2V^G7\/!/W$%W4
M;32O\X)YJ>@;U=7CH>:\JR.>#(77N/@'%6^3ASUOSA-[+/(8'\3E+NW0@L/T
MAQ?J!YTBGLTR\N^IUJ:AAFB5@J$2(+%.1@#A!S#Y'F^SKR$5LX);."3=";D
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M[))*=U9ND1K8XH1N6L^'+AN.N96%QP2[YREH(*#M'$;=PEV7/[LZO0'O=^A
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MQ/ZEC44.X@5?0)G5K0P!*P^7&S4YV:,KZG<\NA::H)5- O.O=?RN=(8%&V,
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M;Y9 #'"Q.<M^$DC,7/F6;#/JA#&W*UOVS&0DF_$SMX:UPK>*;Q:&N?=4E=B
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M%LN/J>^%T1$TS.A:ZOT1J7@*HB<6A\Y:J1AMEX.]Y0E2V\2E7J:4]I]I4X3
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M#XPIBGR4W]>4ENHH-FG9NSED,]T3_&(P6@PXX:4&D#K:J _EQ7P2+AS-='$
M0#MF##5?#,1#;*8[J4U-QD_%==:;J-JZ>,CV2A=0?SS!E=5#\<9'&\P:<<!4
MW_O68#!9DD,;[>ABR74,/..R>R3A5*L@^OU!ZJ-[-Z^^5U[-PP[%%]S!Q4TV
MFYJ38IHIPZ<HWGE%3"G)9JT2^&N1'WP5M,TT2Z*;XMHD)R^EV?921D=6Y%S*
M-=!W/X]((TU6"7RO9#)3*$%E+V5IGKQYXNN3V-J%BE6*IA'^D'0;V?F!4Z+E
M&$AB3=I4#QF8"BN-0URU4%MO.A%#"DI:%NFN/_T.)L/5J$YPRX4T)9-.S-SA
MDW\[>[\X\B'O>7^1GU#!$IH-"VQM@C"FI: ZOW%&BGB^> 4I]C($&/2O7&*5
M(>' 9#?1G5JTCN+@<#;W;4 ITTY:O#2X[?/AG@'$]6"A>J/<#-[=9+4WG+F>
M,+F%93[:%03%U>#L,RR@3QQ$$8?(<R\OC_FZ&.'5IBPDFHQ()WQ7VM+UMY+3
MC&(^%G;:W'W8GQ:S^P3V[#HS[ZIY0BJ6PFS@:ZHMIN.^D$_^J2YR.A^O'O*F
M5#I7$QFKM4FQ)F^YH,HI#K=F"TSW,]=CX-1(EM&]BN"1-=V)O6:HFC?H6M36
MM2(5?H\8&LCOST/J(/2BDZ%J<\ZXU2)7Y@ 0^D4T)?]:&R#94O\I36:8_ <>
ME1BL6V/2,B*$J'\0B*7:WX''N)OP1_K,RXQ;F;B&6+V(R\Z42W^K.ZQA[N$
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M.*^Z5S+R5_]E)N\[9';$:D]W,U]8,1:WFWC4C\\#-1'7O97$X>)^OWW?;["
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MP\<AH"2CIJ(DHZ"@H>=DHJ%CAU!0,+]A87_-S<?'1\TD)";((\K)R\?SGT%
M:&AHF!B8)%A8)#RT%+0\_]OVMQO 145  7."070  BX(C OZVP]0_YLG$NB_
M#/B_#(0 1D1"1D%%0\?XUZ'Q%8   H,1$,%(2(B(_UH#_[4#B+A(>+3<DLCX
MZF8H=*X$/"%)7U$A;VM["#6F+^AYS=U"T=")B$E(R1@8F9A96/GX!=X("@E+
M2<O(RLDKO-/4TM;1U=,W@%E86EG;V-JY>WAZ>?OX^H5]#(^(C(J.24Y)34O/
MR/R<E5]06%1<4EI67E??T-C4W-+:UMO7/S X-#PR.C,[-[^P^'-I>6M[9W=O
M_^#7X='EU?7-[=W][X<__^$% L"@_VG_+2_<?[P0$!'!B"C_X05"\/Y/!UQ$
M)%IN9#Q)=10S5WPZGA!4@K=)7VM[T""\&A>$YF[3Z$3T?%L,E_^A]E_,_M>(
MA?X?,?N_B?T_O)8!3##HW^*!<0$)X/X/<WXP^O\?V&)_9Y0="1.%PRI_&BM@
M>OE]Q/(J!^%!QQM3+\_8$ALO)VK_ AA6V[[G>K^UJXMG88GQL>PND1RS.9_\
M[^$X%OD=!=(-EZHQ 2#[;V]BN6Z6]MZ\,:2+)N&S_.[5<0-P49_K1/;J-:[)
M]2V80.8[%'U+.4XPQ8?8[? $L&4WY>BW@@R &S^VB6\?7O]VFASD/L0J70[\
M*$7;TLZ^T?;9D,J$^_9@N2V1\/<G'UA?\G$0+/D*]1VICD"/W@CP7<4U9SOX
MC4WUV\=MHB^PRB.O>,1$ZZ+#'X'>/G'HQ>>M)"8G?4GZ$A>U]',-G3K3-P\-
M7^0/\8X$I"<IVG?079:,3M^[O,L";@S8?CRQ7:+?[2A.>9R:JG;$[&C.FA@Z
MRNS%/7_=46I=%C\OG301+/'QWR;LN=B(/&4_<6X\M7M9,,Q/_D&A0J=KN7IZ
M[Q<'H/"!#N=T,U=]SFR>+(O75[./L2A^\:ZOZ:W*U$Y/7[B5Y"2$U6XW/?'O
MW"QZVGBLC+,:"VR?+9ZFFQTH2$^[+MH^D%A0%@>+"/\O+=QH%Z>]-Y9OB8]7
MGS$9WRGBXM7J,USJ4XRTZP'D7,+9+E;OTG*B<6LCTJ_QR^H4^;/!&J<.*7J$
M(.UT[9P32AB4JE'&75S<V/.)TB^7(GMT;L4F+@+]A.<-(E-POS5AWV^$R\H.
M&%'.GXUH,]Z5KF>V_J3T9#F3;YB=K\5$XEX JDX9MQ>ARR]Y87P*G"4;=Y]A
MGPQ",.2+98R"5_PP=UI*G\ []J9DOUQ7Y3I,I A,[4T9"F22,NAIG0IH;AB#
MA4?9)CA?&(WU#_URW&Q=*;U6=(TY,6A95GB%D*@%AY'<_+S*E^\'YJ<;O[Q;
M<FRX;YHQ$3SK;^X5B?Y<VSX<EYC#Z3M""L=1R^^(.!_(.LO>^4YB8ONIN@!F
M6V*P[JM+[$CA6I+1<F)$_3E2K,U=\WL_N;T$[L;Q5=%AG2F69"G']V4%I8Y@
MUH^#8(N0=HEPP*^3<.\#^R53S%]@"UC,5I\)JMLE0G-W](=Y&6MEJ,&8T$=W
MQ%J.Q^5*GPQ?!K/LM2(&;1HJ_-U]G+[UZ^+7P^FA'P/V)$=&"$#'!%HZS=PF
M!E*>&$XQ-@O2XN6R<M=E-D!^#/-_@ZT/+,>.)39$?A;"4;/5_/[#IS);&3\>
M17W'DIV&!PE@EW#LHYA+\D3"];4 \ (9AX[<W,WGE_[[&A7%D29M]*V>D=5"
M]US?;_H=_CM;"EF]-C-/2RF(*=2I"O5[''D!:LA5A%OB9.US#4&O?FVL"!_$
M>*RIV"Z(#-^&7U<Z_?"4-_Z@Q53[1[?V^,]S8D1#QEPC49IC4II"#&-2G0H*
M. N8S>]XW!KJ;P\BD[VK#VW+XJO6$?'6>RH*8%EUXPWEX3W6^PL0\Z^DSSDT
M8$F8D(E>&HR7*4@L2XN,(M#%"I&N+NTL!XM9Q6S#&B.WK</XC.7MEJNS]V49
M8<7&ONQ&<3RU/<.(9)L!U"6FU!%MYS$,EXR=8B<ZBU/T[J:\TNU22.]Q:"-X
M<V[A.![Y'6#-W_&!WA?7DC61JI?\7PX^6]79N;^='N!$77M<6WJ_4>4O=M<.
M#JQ7G>'R./[BQOQSR))A-&(5A;Q;)'C7.@;XF=_1MW5['YVK2CX4Z).5_LW>
MOX[0VS)8?()0\K$L1T<E?IL:SY;,N;^B4U/-L%-5^>?TR60*?N8(B.!&S?5V
MB ]TTJ";9-.<U16R+<8SBO7V+Z IW!R9^[#5EC.J/!._]';#@V('G) :(.*_
M1FXTZS%)*%755[V^/,*NL6;G*,J[N1>93O+1DN042M4NX[8N4-^</,CVK-I/
MG*639-EF6-B8VF^]LX<T%T$B%FFTW;$CN]"X9J]XX93H7VKW>MF>^-Z!Z5K)
MF\= NKU QW52Z$B(!ML&O,I<#=F*J/ MM?'[4G0[UJQAZU<T$*K*LGI.AMM0
M>^;BFF?734W8^-4J*_$)DCYI[NDU([O22Y^L]*E(T@@T),0'.IK3S5:X%#]6
MG16%\HO1<9T:,YZ1RX0NNTU/7..L;<6$HACM>E7@_K[7:9R_K>(RFJERV)OE
M"RMMJ#$B)7Q&V).C;#UC!D_9?,/X"WP<?.P19ZR-5&MK[VK/ZULXQLIIQFJR
M'V&@3];;<DU)%XM@Z^B\3&@E^HX<8EFP;&SGJH?Q#"5/3AIL'1R>F-&//OR$
M!'@3Z(ILFN+]V#Y'U;=W-RAJR$"ZQN-^WV[T30.ER$,+4)<A^/^&^JHJ955'
MRJA\//(^C77,Y+\Y12I?]>?Z+@<M\8'*9"P2\6SC/NA_;IE$M3'%/4PHK!QS
M?>F!8]FQT4G@'28GX^D*'@74ATA><F:64HQMR4]XD0&+^;61,1[)_6@;"=_;
M^>E\8I63%-DKH;M/$<'X_7]8?1+[R-(33O!/O4Y?N?$01CVH;KK83YZ)OQIG
MZFUWQI KDVY+?2-[?MINB#0B=/]80AWN1V'PDLW':-G2BWV"6IHR0*85G/9Y
M0N+P,QS-H<&CYJ*?C+]56]X1J8["M==Q7.-"(K+XHB3,XQ1OV^<@?5K?0+X'
M?<G+B?>V@OHBU=;T>NW[>=B[+H:9)3#:!-HR<E_.%)+"$W&AD4_YAJD/_D3$
MVN950.'5AKL3NRR/X09_;>GAW9_B#,^25;B]?V86*?&\WON_@#!\G65&0Y/<
MB-!LCH O[R+MD%J $PV=1UX*2I$7V47$F;<9:"\YST_4UC:?L/0-UQ>]G(@[
M['E*PB!,YK>9IQERP5TTGUYQME*@^,:CA.JK4'UYGN'56M@@E$;7[M_01+2T
M;4BJ2BQ,5\5!O?J%1,M,;GZ7Y*Y0BOX@'"[U#K(/&\[QR*/VMA^D'F<N'9 "
M =%K;;[O$7\F(T_YR*L@6K5D@]F6#!^+]XEM&*-76S9?22*^\"_);:]1Z2XW
M<^1YT*4]Z19"3M[0-\/?VH!3.GX[!E6L2W+65Y.O'N(?WO-FALJ?0YPPX0%P
M+@#'+J,G"'O_8O\;Y?/6=$]STR,?1'5V@2CU/EU62&1X!PA9:$N[E$T>0M@-
M._NH.1G5T+T2<*7"VYL")6O0X3-AGK&B9^BA]QS%E5YGG:%AI=K=:P,^3B&/
M$\9SQ7B4"F1\[G:2O!J7^PN@1<3X&0G]D=W8@I(WZ/#^+E%(X/?^T@T+>:S7
M^!;E<4"J;THRN?J?C0E+Q#]T. OU6@VC=^"G?F)8?O/TU/S\R =JE9'#''%%
M4"8=%8[0/,)2@"(1:),V^@LRV5A\BC0IL(5CS.FX+K*C/#5*W(\4OJS/_@4.
M_JFV+F7 5EW_^\IRT-/=OX:"1Z^^%[^\Q]TIY#3"+\_-9G\!,=7G*UN)9H^_
MP,-)T'D*E$3UXEIA3E2S[#AK5^=/O7&E:P_2>%W=<CZX]T!H1(@IIC=OB]28
MQ>/Y33^>WI!S15.9A<Z\X4E_*.)[HA[@2B+-^_N* 'U0U3]O)5@&8W'1.,]7
M-N!/09%M"17YIK8?&"Z-%ZHH]M\T)SDFHS0FH='.5;OY>9;\^H[SC:-#QKKJ
M^(6I8Y'3 7=FW#+<7,\;D]?,O64G;M&(7T1S1G4F:[DJ/R[#N4<94"C5ZRL[
M;-8A!L41O^[@01(4T7OEXN]BVV;RQ;G05B?+L=3,V1Z][Y77JE=I]\AY=[GR
M=CR+7MGG*Q%?J\J!2OUQJINDIL<R M#$>H!83<?O6/OMNQ:7"]DW!@X/]*D(
M%;1"1Z AE=ZRHR#,F6OCKJ[Z!?JZYKDB!>?WAA;>5B;%0JK<!Q0[_'/?HQJ&
MK[.3AE" &9EM94Y=YF:*D%RM&*"_]8+ FRPQ^BP"/LR_0G)RAUJ_B_0V.V1R
M?+&$,)NZ-Y8H1IZ+'XV38W=J>WH)41+G[.?K5(H<BF#7Q(FVL@#UPMZ?]GDC
M"B4X>(?2(7=Q^).L,H#;O00.OYBJ]/?91F=BX[786/[ZCQBN%.K,[[TS^\QV
M=\CKA&>Y/A"S+\</#*0W,N3H5J!VRC3*>7.7&D^W[M-!#TBKRYX4B_+_55/\
MN(^,44_*1:,N*;7'3\C!_+!X\VB(9+@,.DI-B8[>)7:F.4]@ ;I(&EUF%^/,
MSTT5]\.:*>1.PE11N>)F!=.7WWR[BS<'@OK1$F?_$0AU>?U^YGB8!V%A'QFS
M_VUXSG05Q).@S7_C_JHLOJ3*+$%V_PL$9,E>,J;'MI;04.71[@?SEU8^<M@-
MJ7_YVI3:7GX&L:70"0<(U+7/G=_/GL8/]!'&O4(#B]D@#+@M+X:<=,AM5X@9
MZMJ<LU=QY#(W',*QJ.X@/'BJ3  FK-$V$?<P_,W#&/'<5X+$;4=6?G8G-Y3\
M%"A%Q->+Y$$;41G;XO7J[))C];=5ME@U+!B#W>?J+9X]PSM5QK-/&%6^[DO'
M+Z];%CS*3G/7%=_4)=!(88);5=S8"L099GK4[T(5,>-8^%)\,A2;_P*&O%Q=
M?5 *SY+>BB3.+X[E/LWJ<PV. EKI*ZK)#$H$CR$Y;MU!.;J%.M(?&&?VS"M$
M+  7M9BXW_5R&F"CUS\<1^)V^$ PR2GV@#?%V5AB%J]\OW'2!PZYU\(FYQ:(
MG]@ZZ>[[EZN;JZ6<*W[XP?1@;4TZAGI3N(WN.0?_HF\Y".^0N\RJ#<"!J7^+
MN?%2V["EH3ZG)0 9]G3AFZ+8WOL%$$?X"W'NMC1'#36?'!V(Z^WN@C<2&A45
M+LAL/R#,!7#R$R4Y(W6_0:9!]VU]H;B.^W-M*-7?IF_<Z]Z,>& V1#!PJ9,\
M'8W4YRAV1P8,SXLB9V6$-'S'_")38 AVDAE*10MBH^[+Y4TT8?M C?/K[D]'
M5H.P<:%?'#R:,YT03\!OKS9E2AM_AX. KK7%I6KJP5%#9GN<SBRU!?87<!@'
M9+;.,:I#*NP7?WA9"S=N+,>0W#T8P9S<W&^WRPU]B*8Y [06=3E<G;<9D6V\
M'*\B>@O!*;FMDX2% =J%2*M.\J1#JWP%_7_4'^OK U]-H4@4!(CZ8Q2X!WTS
M-IG$SGO.MF25K>&O%(>'NCV+.SNEB<=O^E<H^TWJ+C0^W,;&HI*M_Q@+@5W-
M=UUS(V:X >0M?W3Z<UEF8([%7DPMJ"HLWR_2;;8PR),!P1ZI+&#X<B/D3-1F
MV:ZZAOVTLN@Z:^E4^G+BR9$3 S-DDNK&Y#>7^IR#QV+;XIR]L'%/UL0?<D*9
M^'>GS.:KDHC^"?,MN?0S:]X<$[JD$[-J?X%>XX*#%W%JJBY#V(,:PF_=/K7?
MAG("W*L*[GSU8@,#_<'(6;I"5MV;@6(5.:81ZM61SL5!]N*TBQ)-HI,T;MY$
M5Y?M&]\.C:6[Z&>V]49RDFA[3S7<I;L@LS2) 2FO33[_M ''7LH%0VLNC6_,
MK]7R='+7]T7\U:+9<8C11_6V:A=12"ET!.*W*+T'A,^:@RH52I=[?,V0LE7]
M[3Z-,"Z!6_32HK1[=X1$D^UGR ?\WJ8\WM-XTO'(O/OG@LJ4@]'*P:E;:B;X
M-?]&Q!_OJ #)H+*-=Z2<#9,GMY$CB+U23GALUA$47M7V_<)4C?GVPIY[\(5S
M+HEZ\1[?4CU#&:YE+2HP1!SVX?&!:OY7[+8R=Y%/_WBK^,5/FY3^+ >Y_:27
M?%XHJ006']L&=H#$S,VX#**W:P5?4BAV[X0A8D(AV-C2\EL4WWZB3UI3[K\,
M O\GZ^KEKP/J12(G7L/X0,TRL/'M>$:LKV?8JN\_)AELAH(HL0 . O5_Q?+_
M#8)&UW;Y-JK:K,T/7JF%BOL4[DEQZ.>-(>UR[:1#9^,N&GQ](^]_$,GR=+Y]
MG$)\JU.7K+Q"LHLSM%QXG7)B!J$6^?(UY)=J%=&,E+/;N M&^)9 7*C$8+G2
MH&*Q2S;$;#H"#8Y%VG!I;S$CQ2+93&\=4Q'IKY>OH%6!.RA,[1<.2_;@C#'6
MPK].5AC@RF&(HS%R!"Q]>N[OX1B+7LF&0^1B@_MNR&->8G;\R>?#R8INH0(B
M;COGVNX0I8U#71*+!P*8J-]L^%B%]5U@U+"PH%->.*#=1.VX002DXJF*!B+I
MVY0T6[SMEA^%_O0%_&:D*%YU_Z#KT'\(LT[G^^50;84LG]E?^-[Z'!=*")=)
M7_0?E>*"8@O,TB3E(GX"WP^S"V\7M#3[6+(([T5-[+W0*N[Z<M-B8ON*& K"
M,2PQ%]'#]ME=JG=(;LMPJ=9]\UVJ#7CC< [5Q@^,2.!OT=23^S4&QYTIIANL
M)]B2'R8)0!K(+*3HG]>>R(4_\ <Z.)FMT'.B9(I;0@3+SY+2-%$V5/2O!Y2R
MPE=CFU#OD8Z&.@&.@?C"5US9$%+W!!R_JEU687IV[^\BV8WT=2,''QY(Z26\
MG=_:6J;U0<JT?2*(P4 ,4+.LY8.L0#XFIF)7/G0G4A77/]B7ZZ]U9<I7BAK^
MXT.:AEN/U/#1Q-!^SR$43>AM#UP?>EM8STT^L$Z2^UAA]:;91@LB^Y.23< =
ML[[T8\"1BYX''.,-\3>^=>EW. Y)RH[B1^SR"6^H"@BQ4B]7UN29R-U\Q-.J
MG3;5],9:AF!04@T%UP -(B5%8LBJUOX?>UB=GEN@',%\^]5>^DDQ&CF,H'9I
M3;5Q-SOE'(I;.2O+F.VT\ &%T/[$&V'%+]5<CC8"6FH5:E,L;Z+1_=0G%E4R
M[NC-T?7 R4O$PSMH Y[VZ);-L,/FW>-2^<*ZIC4SR)<M>8CW%V!MAB*Y+M?]
M!?IGW!.W7])^+C*5X_S.G A:?DD%0<NHW]B]!7_[L9 [.J#,35"M( A']G5
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MX.1D^N,J3EP-ECYTJ?V;ZWW"Z](C./9MGMADG@=%_##YKOKJGQG^M+Z6I/?
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M&=I2<$D:>/WJLP+&8V\D]1?CT!&+3R<9'N_<]Q[G?:R2)R=DFZ]Y%"9DQ1L
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M@]?)1VO#DRA"""7^;SX&EJ];RF?>3KX#ZOV+!I!JV^16Z-RXM?;2W\+:.3(
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M1_QY,>\S>0;8>8PREH^GH^Q3K-$S5Z"8J\RG6:]WVK+)M>:S?3%I2)1]VX/
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ME9; U4\*+>GH?5QK)ZO% H=HN,J+D;SCUDM$AVQINO68I?IFYXE\C5KTTLF
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MYI]:'(4"17BI#DCE:U?^C]H&D/F_8X'^'R,L>!L_>_94"N:@*'QJK=/^^N8
M2TD8NZ0HE"GD5#S.>58@6PV.0O*BA-8.=;!'?>&^((8J,'6\O (B0Z.#Z?TK
M.6.#V.8N"\W@$31YX[X'G!)1=53OLONDW967(:6\B8-Q?17[/Z\!0<?V]]D%
M&VH<2CFIGCC4%!/MJJSM(AZ;'Z\I'Q8(@B$&9-'.J]TSIK_)*K([$PE/(3-X
M\GX1F8@Y6/6NUF\5U.-34X'2M(/%K65OV$9-L+B90:RU.YS2$3P>8S#N46WY
M=[=B)4DV1!\GF:J(T]V0$I!4[%4-<<CYL\@LT4!;Y9#X%E7'9_Z1;Z.-3@>;
ME\\Q>AB5X@J:4?)C1GB8 9#SYX5_<*1TES2J1C]L9TO)A__-:GRVQIX0CW__
MN_NJ9/8-@JAI@D)T=V0\6ETNY(\K6*685_N5MD8E@F!*KPU\(TG$80I<T^M1
M 4*?J^*RIP;NFD.+?P;^O6>"XDOD^D6=R+N"R^$,DY?5;.,&Q7J6'3565NQH
M)X,>[\[M@BD'VB1QC?6>#\W\%FVQWP2@G5X<HC,_T;AW4<_-?^SFA?6K^24Y
M8MUF$)_2,5K(4/"X[B4M&62H#7U.+D]I'7^3<,ZAEAA(%NPP0QH":)SH?[J2
M6(CKXBWV^5DAT;XX>Z<Z4!/:J"BX#><B5U.VKD4JK>#18F1EN8K7]O>"(&V
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M6S^*Y(*#H'&FD )TM6]3G8@HOBA2&%7013FY&^M9,H9DRQ&.2Y]Y@87%0)?
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M@0NE;/T@DNY0?2R7GAPI;5 '.+@<B??B?;R^[+Q;<81$S+2?94[[MBL*"#\
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M5M4?]\!&.?MSIE=.PH42U\!?,=!0G?=G\&"?H?1TR%0@H:5P3Q\)P?_'WGL
M1?%]ZZ)-$B4J I(1 4&R2$Z#($E$<I"HH!)&0')F$ 1T2"(""A(D9T1R5K*(
M9!@DYS0,,.0PX;:_?U+/_YU[[GFWZE6]>ZG:5;U[IG?OV6NM;WW?VCT#G4#"
M5Q;NS6RAJ9ALP?<Z*./WS_H(8G05:28G;X#L\,%+UE.R#,X7&E7N'C:3J4TC
M][D2#FG4;42=3J-2@:RV:CW5=J4"-I]>.T+FB'A95@Y>XZ ?A0EKW)-^EA8%
MO@7[XG=WQJXQ/Q0@?WCU^G<MXCA3S-8%SMJ?A<>8\E9:'<*7:6^?:56F2GV)
M.O]L7<4\V*3$9O+,S?V\5&*X:*EH!EN#&QP(Z]4%_,*Z])[FR:8Y5(DK;A;\
MB$S;,I2.?#IU:V"VK8%@3<]2V^D U9V BC$%IHR[@_EECE&8I7L<NV0[;=3U
M^C]6NB)O+!T$JZCYV/5V*(WI'P:MMP3QTD>53.6H/F2Y3-[!-YIRYO0=SUF;
MN]^P#E5<-;'QC\8N95#?KJ9M?FS7+^V(?;FE2-LQ_'KV^H\$'IY&45&G4KJ/
MGNE?'<;=P_2R6UY3J?#?*F(D##K;24L0Y>+!\>:%M:C(;/4#W:(=U6XVT><[
M5 XJMA_C!]5_9/8J$^C*Q;C/WR--I AL[@WB:O1Q,I6OY57LZF2/4NI.4Q@T
M# 'RXXZ'!RS4<[%LA%\GJWV3[T(=E4V"9JX4%SX4L7GV2C8)R+[,U^SA)9F^
M(B;FJG:IKUJJBPOA+C9#@7X&19UNX1KEU@)9K6^:66OK+N.!_56BOC&E[?V>
MYYBV]SK*5VW,$G[TW_? 0/N9-;>716PJ/N,!9SQ0>M?Q1FLG\^N)B<,TK"^P
M.W ABE$GZOG]-%/KC^,WV85<TDSW;N0</8V,K_P,V1T"+S L<2^ER"ZJIQE6
MZ. C;EAAK4VG(F>[QTQ%I:;0<%#Z(.:O+\E@7,]O^SP7Y2R9A/$=T/[G_UZI
MX-Q@B2)S3(+W?LF%^X[?3_-W8S9?45?ZRM,2K&C1)I(+-!F\L-&M(!&_%,MQ
M;$HJ^]%;WS)>!? 9(BRD<"8N/"\->_-^)+]4U\#LA\IEGL*WO9=&Z^MXB7I2
M):.T-W/XS-*5$Q0JT%3J[L&&?89C;DE[!;Q$W[<XZOS.MMZ:([>QTS\9J2]D
M"&RY[M2ZU$?F]M[8#QP\OK&Q1V)^R3KV&P4=GVM@ZK[J02_RPF1Q5L;E3C*#
MU_RCJ^G4;.5E[WI>OWUT$\.G,W*4-&=-9?WF/*P&.IR73LT7+5GS+O56O'<+
MM<"*F'IB(H5AYJNW?23]T0&%(W;IU(*Q3MDBUZ*-7:6XJ2Z.YB3>J85/3A)=
M\T!5(')T%=DLK\1_V$V5-JRC+'"USV/X;$._$WWJR8+]:VSAZD_W3(Z7'UF/
M<61"!DO"ZB+EC)1,YF*XWW(L(CX,*+(]@C(K?'CGN/B-]\N8BP7%@<M7ARXT
M/=?3I]XEG^# +K.VQ* -YT17-]7D<SF;1K/F5&A9+<>K6\^?,%,+(BW#58"G
MU^W)!#0EWW(CZ^USU@X%G9Y7"#;+!6XL$#82P@'XJ+)@D1[=^#V"SEPZ05H=
M O.2?(HTIY1N>J4IH*0 #LRQW^'6O.SDYRA.G&0^>+Z=F7- RY<.-*=S;@_\
MG%%GNGZ2PUJBM"#+$U5IBLK581W2A,DUR4<AV)2@/3*'J90L),'N%5=YLJ0]
M7UZB9Z<\FQU7GOK-:1DG?"Z,%$B3/"6%[SF +Q N?=B)956*V4PJ=724FWZH
M1,_<M/LIE7\@+YV*T5HD7>5EER["?CEYN8_!5MV*3^I8R\M=AS3M7,Z[+ZDC
M,V6.SPT+W[)ZME,\28^,JT X@Q_[!M>RG)R3I\0Y,A_:3^<8RCMIX4$D'4,6
M*'#N7YQL4IBX7%)=*M"F=M,^;0D]S,-$%AZT!&%5:U3WKAQW?7GB=CQZ)B\:
MP1S+LK>:"]\$740./JW!NFB7HJ8CD:IUTUE^D%&Q.LX-G1(._^F%?:B%U#';
MA\\:WXS4'$Y6_;CL&N 9:U%,2] 9X:&DG;# 8D.:I-3;("!D/&1?T@$'O@P\
M.[5A+2*XNS!=G9<11-:&-K?T#.7RN_<)V1*96ED-^NWUH8E>]5S[MYZZC#E]
M1.0'-!/?/@I_.RV/-"X&'4/AE85\(6[9A@%69[ (M]-HC:.XF/>$#[>!N]H(
MAP/H8T<GN?X/CP0:@G5PAC+M 4_EFKE'M$FJF/:3>(EZ!5%LXPB'=@Y.;)P!
M-_2Y*QZPC7^_QTSI6TE+L(AN=9VM;SEF]_%D*G=S>/DDC%^-YCKRXWOC7/"^
MQE4G4X-:K^M*"UA&6U\Z%9D\>44CQ:WE]4:'-+&CFOYSP;BZ14V7_G>!V*DV
M7>*[0U*G$]1=\H5#X J*U'Y,&B<0"W1YP^9]M0*5_69<((8B:$$NOV0'=.56
M;TSYO3LV/. 4A04I1A]RW:U=V4S:D^$EZA[TB_#N<1V_H[ZJQ)0P+FU=;0LU
M=A;_F/\1Y[&VIT/ZIM-6;(CE\[K+KG\X89$ 3>+#"0[ISU=O=)7>S0B2:X$R
MOA:YIQ$C36:P[4!;52,DT3%G%4G"P]8(_1F]0A*[Q,D7NHP9N%0#'<(TS=)B
M_<.MD8AO<M0.^Z#+?FWJ=.52U92^&(MA[!1?7SN\M';W[\_"_Q_4&/EI0\<\
MR-1++PTI\"-%CSA-4_' UW#C,$8AL>/(^VHR_"@IUJY2^UBOCJ_OG8@?-TPC
MY[@;5UI7Y23%<4[%2Z_5G6^9\#=&7(C<6Z$E*+\4G?$RM[*F,D$S0HM17"/K
M#LE3-3Y2FZ2>Y/GO1;I?^>R\=MHIWTB6R]"UN73=Z),O<-2?6UJ:FJLI0U!^
M2-:T$%WT(3A,9U63,[B.$7$?\H!JHZR.\,!@^E"K#\3M&\,,XOV)#O$.YM:I
M14XE27'H]WA4R=OQT/K)//XK-DM/ OR8(I2/$AG+AQ!M],82E&ZV*]F+!?37
MNDO,[%CE0\W3/@N*+TWB@7&I2TR7!SV/K=QC%I GAF>;&#2]*.-SZHOEL:&A
M9<&C),_5*N(G&M[ON P&"8]C-#Z]>WC#Q-QLL_+UYK!LON39$!X&R+5.&S,%
M1C3?49RRA=G&)7J)S0]#*(9O0C=J;"K=9*Q:Z89FZT,W40]G[+F+:(K3[UU\
MVG$@O;BP9A$8GBD4-Q<AR'3/?[^ZRLS3W\:;B'BA$G"K8J=Y4EJ*TEFK_KAV
M&)<,M5!2E,O/8@4V;T13WOB,XQGUURB%MIQ,%3L*E% VZ,1;O8E._[A8O?9=
M.1<CF32XHEV=9OHZX))6[:EA=NP+PIC7!I<V":[645,>N520%SL\KMO% Q6E
M21N4R?X-01*G>TA%6EOTL$0J5[AFPY!0\6PJK%S%>\E3[FT7LUMLFBD<\L)H
M$!I^2\9QT.%Z[U<QK4@5FLCCMKT?\.ZX.?>84I4\&'1+??]"H%Q7M?K,!GV?
M]EVIPL+M$Y?Y,X@T(]OAG'?MK0PX#<&W]Y6KY0#9DW[B.EA;!/_IJ?J$5F-U
M65-LQJ?F-]1\GHRS7HR=C 4G5NWD%K=7M-4&MHJ+MY9?GW7B&C>HL^6,]F/2
MDIUK&TV4<;\D,YS(I)!X+:F[JXU =<5I&2?P<#ZA<ZXGP<B2O1HW/#FNA:E.
MQA3Y)!^Z("*=TBDA%-[3U'06Z@D)%[,_;4X\[<UB8;F?)ZV_7U)04\S\V<T>
MQV?AB=35X+[E3N[LQ+'KY17'<IUNO)_@'[^D\I\T4CHT49MI4T)2X+NY/E[D
MI=YVXI<-9P<TKW/NY7Q!TX^RDZV>+&$K@D>W#KWT.[LGU*4XPBTS:9,.6YN/
MU!N,/)(;'7:F.(.4'5F3?1S9#Z,WCXN0SJ%:]&E7PR7*N:;9_<I=1[.O<[H<
M:J[D;/KJG,E*.]]ONM;!2H/S0]VT-!&(<WZW)(RI</K,-L*.$9BX=O=-@JD%
M:G+\Q1L!W6=UDC%AJJ1-#I C10\IFR$A1W]%ZQ'WU>EQV:H@D=>3J1>&4]7W
M\RMBPE]FKM=Q;YB&2 ^UMVK52J=J-.W:5LOG$9HYLQ=O!H^'YD3X"?9X:=F+
M)QA:7B/5Z;G+%Y46PSWJKSWWMF*><VC_[&;@$.T+\JQ8/$#E=W_(]LA>X*7"
ME-ERG&&<[EGT8U$6&QLAGTX;[>W#5MO^2DJVU?5@YXV5.M>FNY+',S$,Z93.
M=-Z?[8S)<\=-)BW7:2:^2JDK8@=Y3U&I/U#FA^$8,X]\S=GCTDVG\4U<R_R\
M>G'L+=%XW,Y^7PZ_7]LT=<VHN+>'A:R!Q*6()P>OK[]09[NZ&,D6+H\4'9HK
M-VO]H((MOLSTZ/F!RH)6"<X6'9+V!E2'&.WJ*DT\4&V'2/@T82J^Z%+/<4,U
MEY28C5J>\A8>H./4KN#W=C.XJ.Q0G2,G=(?TZ&2;Q):GY5IHPX!$*<T[L6.!
MFYK^MBZD?F[?7/J*G;5F)1-.#A9.U=CM!RYI3"QA!R$QI6N*%V<PBF65E4/9
MU95)ZV9(JRJNV]W9#SHT:3K90Q^;>Y]LPAB.G!":Y= H3H-J^\@&PM9AWR>;
MO,.!C&H^CS*>-T2@DAQ??=J]&B2C'N0QD4KE4\S<3"QY$!->ZHX<KG#D8.)D
M>$X;SP(LL);'C 8Q0M'L6O7-YP4KOA%W&%;6"-3;VGT1 'K5E"/W"\K\=<N=
M*91+-+,M;U*V?2/Y=-O I\BM?P^PR<]98Z=PK(A2O<>12EK5ED,"??HHZCV;
MU\K[A_,E[;/)R<Z$:].LX;JAJ3T/LI*&U5]'Q@7GYEIV!,FP7C1PM+D3C49Q
M50JI[RS>[XR>C3Y;S+32P#KG,J?%L=$TC#BC86JTX, !:8D8\S-6_K?_UOT_
M-!^O#MOA;F\G2KYE.Z='38Y-!J%><Y+W%_+F&U7+/>1)M4>%Q9"%7>^6AI9W
M45W6A$W7N[;: >]TM&=9"49IH'*"0':<(3N,_P:'2I+Z_.0QNW[G8+UTH) I
MN7%C6-LW6Y+WKI,U_@RYK^:L3U;R41;7MN_&.1]([QT12WJ>\1&8+.-[?9MJ
MOK7F:T$@ZU' @^PCU\,[PPG,:^*,27X=%U!&;D-VJ.AA@BZH@F1<FZ_A&Q<\
MD&%I"O6,[17,G8R,=A5I923]0&>CBA[!?II8.WD<*[AW&#<C=>G2._XE!9G8
MH8E*3YTC<L60N_!VQT61=O=$:)V>68]5G<:F?/Z! FE_!?*;7SW4]EXQ!@\(
MO#-9Z)6.V\7R$E:F13O:'OG@@7/N!X,J9"V#<I<7@XN, :S*(U/_6\WA)F45
MB#V[O2ZA8J[Z75P_UWA$L!31=)U)@^"#1W/2_O(/F#KM;-Q5$@^#G+AV4QN2
MEAHXM[_NL7K*WSTY%KISOD*D#=[^=,JM)NVS#M&^]LM4HUQ:4_GGOJ$1)LS+
M=3>.'^A<U_]"EX ':,4%U101HT.:IT+9-@^%YA^[57?S,->RJIE[E:P?ML@(
M?<C3]'-[7,I5%?85(:5_09K3^6[C>G%BD#OYI7KWZ@1E+P>!Y=T<VZGSJPW]
MI&3^ 6Y9ZZ8JFZ6VLC-3=JM?:24A=;$_MFO-[U]$R-<9.\XUTTTY^(XLAQ>N
M96J/"&;<Z['GC6>2D"(6V4H='L,Q'SV6LGE9E&H 'QZ_G&#D6)8P]2P.(4_M
M,-@O=RW+V^Z.^RKCPV2VAY^Z'GH2I4_Z=%8"CKHJM,#_<U.3;Y/X6(&@R=+E
M_28724N=+T; 36>%.H!9G]J.SYX*W5CQ"7DL[^6>_R")_X61R4,-3I=X]R?!
M\B_220?^TX'_"\UP'/==F'Z@)/V2@"B'*.5B@,S(/_X%X7^G)6V69<I^--1]
MK:W(2S!L1!6_0,EOTDSON>SA961G:0+G6I=Y^_6TY5V!=]_M0>>EBK?F7=N\
MT/!@PC4G:J5%]X4D8-4N1T7 K27NUMQ"K#(_U7.VF[G_I<SX[]N#HQBK1&5-
M\>JA[*::NN1OZIGW&PFX%D^IY!VT*9#?YK5HY+4<'U7>8QU6$9YF-BGEK+X-
MC)5<FB<R5\B=0WIHVE:^GE>^,E5F0AYZ++F0U^N]93%BW%A6,>R8-'XPS?_"
MK,@U[SZ,2)'-+C&A>F#UH\4]T_&UI^OERMX?)1RSW@CI!'N/F2$B1P^?1W6/
M>X>Z/R,RXSZ-(."XPG+?"8B9FTJ-'T[AN2OC?.#RJ5K"9&+1Q^:Q0KQ\906]
MYYJS(YDR&07?E5F"#5ZBMX[:;55U!['0/+4<[N+)DI@#3T^;YP(*VPPLQO?,
M5UY %A]N]V$#P 23D50G QKB0UVTO>/5Z&DKOL=*-'=LH38A<" )OIM,3>&]
MR5 A7H/F*S<S[S[TM_5E0;&C JCOG.I5A\FY^W/#'LJI-X_K33,^2&;W%/PQ
MD3JCW1(D3P\/&Y3.* ^3?7=KJ(" *\C&S28.GO2_1OQE=54 ;URB_Y/-"=WA
MBBF%];G],+BJO?;$A0B47B&V_WIGKO@:4\11E//9H0=#;!-V7VIB6U>: 1LZ
MN]7Q!\,@C8P*K6TD8K?;Z< #O:4Z9WA"Q?FGC)4OR<2\%GJ^TS%_WI.RQ,!&
MH:4*^7Y;&Q/$A0=*)]*P3",#H /1]9A[CXY.=,"VHRKC)[0.;%Q6^!Y)H?
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M!YJ:O[E4H;2C-\__)W+UI/_Z?57I#L<EEIWP]#Z'[3YB,5\8O*+P@I=;96Y
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MA^@K@QP%S/<39.X\VAA+7FWU<_XE1P;!<&-I[G-6-E?@(- ]5VZWVA.:@LV
MPW3$'-V2,P35%@J!Q<9@'!J+9"->6\0H_5Z*:$!\$2[VAMZIJ:K?[LW8XIJ^
M?[WBH0T \ZV#'6E44I_053IC0!W3CJ!3?9^LNFWT<F# Q,@7B_J^J*,Q-W5[
MBO7CH[AOXZDKE$E3>;S_[LLH[>@S+X4*JA+IO:Y,Z'Q*_%X=G^@:K'KVP>1Y
M>W=*\M.KHRLH?<&1I<4.OWS/N7LQ]V4!@+#*+OULTW=2S'8,[H@V(&$&YPTZ
MG3]9 AR(V #!?[=%^'16#YM*?;S CMWAN\U+""G_@@?D0(,TJ;#;AN"\05KG
M#W\-!V(VMF%]#&!*CM4X,(,=SUW";O.9\A(*?YH (_QL\]:SVX)SK!PQN&,Z
M;EH"]EAJS YX3.MS'GR5]^=5>KJ*%X[_V5-W3)=_$(D'/JMHJ@ J_QB0E[Z?
MZE4'9/9*=D80YZD<9+<#<KJH>^ -6XF$'7;E\Z:?Q?518] _!V;VIC;Y:Y(:
MOUY_*MB,V8[ '=$)T@+@'P7!^)_<,)D+*J#-'%D8G.7'Y$%+T/9EMOBF3<5@
MB;A45G_1RD65LQ$T54/QJD[)-_=6X!M<E=7QAU^=+U;?^43HX,!+V#SVI ]3
M!RY08#O[?3#'IJE#ML8*:76("3OZW2M#<%BX0CL4#RB +&2F3'] \7P '($+
M^  F8^N8LI]06 $YW##8TR$^T]&__]?[M3_> T]GL1]N&(*Z@L#&3L;T,P3U
M-ON4M11SJOS35$EP('S#LWD71?WS _YZ.NB':6K57[?2.""''._]'*],!3 ^
M)4G#G-S\.4GA,11L99S]](#/EY>0NFS\;S/XG/F/\7X_G24A\7!Q_*]/9Y(1
MQ(\-[L,%7/XY]RSXV?M]\31JJ?6T%,-O?G_D7M=\0MG'4;"R35- -%]-E9&"
MV@%TKA4!#%W6V'''#<_>[;<T&D*,20Q]VQW:('WS6 D1BSA]D9MB*_"BK(NX
M[=Q(X.HK&+T\\D-&T'F@@$X1H !D]0;^U[Y:\]]MUM-'A>H?&UZ/SL\EV*%K
MB'GHH'='G^S;<2>TC^M>:*7,8EF06FY MDL@J.>AHYH^[S3,Z2)?>=,-8A3@
M)D7"M\KD'O:(L*KWL>U]CO</R D(5Z]-N):!&ZJ7>,E,4"=)'%*/9B]6R_?>
M-LG)%Y,11(V4O+L&G_?^ 1!3/3WWM0.:G/QEO!"I<,6J_.(CPLK>-]['N?[2
M1$,4S<7VK1\<0N:XE]Z/]HY_WQ 6VPZ69'R_"%?T.!'*5BB\7ZV_MFN2 !%P
M$WUMS$BZ=+5X8NJ+)[>(.GMW;(8_C)PJXP-\J&=@ON)MW47"S WK(BE@-CH^
M8LZ*3#A\J>E-GQNGEAMGNE^8QY@V<0C&,B=(1FLM<M/<EK'/-VQ^AT&PA&>2
M13%RL^"F' 4>N+U[.D..O @U-A4XBUX-G=$-6X&17V>XX#LKV6<H)SD7<6H<
MGQUCI-E6GB3=D\_4ZL*A)Q-ME7I3C&!&N?3'MP_*A:Q(BMBL9&!RG9F!F+K8
M,FF=]XK78T8#X7+(=< VV\=]FJJI?*BB+'?M=59I;H8E2>"=8/6NJ3[=L&*K
MC8@7^Z>[L ^3,U9:<C&.^9R8V#;C)<MF(1D;EGY2^^SUT9.<.-N\J];1ZR*K
MK\\SI\Z8-EMJN,UI69J(A3;$Z.U<NAM-$OU=-VGZO@^/UQ1JE_KV/M2NQ^AC
M1T]/US--Z:]2K-J-@";HR6<"RXO'5NFO[.J\:2=XFAR<L+BW9G( .^\O'>!'
MDMVX4#%4<\OJ6I@&AB^F7>I16LOM5^U<Q0=YO6/#95MCQF^]'W?LRQEGE?\P
M+XC(XDZB!R@.Y\O?)'G*WY&@BC>ERDJM2]TO<!!9D['H_>"2QC<MND&J']TZ
MN5<DJ\UB8G'DISDR>*[%X=*Y)V7G)=LV7,+V.GW#.R5DFLK.I&2ON0A]+3'2
M?)?-&'5!X7X1*0\/JSQ_7-V OV:NA;F*T%OAR[BA$'WE^S4W0UY>,(QVZQ\-
M3_ :GWFQ,"A4_"2C//7D9/6&BO,9 KYFGT_J+$8I48B)H@>U.X_">\R/W800
M5M;\46B0F#F/36BYS5G<>^XJ8ORRS5A$0NK1E]7 RMKT,0?1(]7I;^9)^IX#
M\;&#2EQ$<H_"T3:,5X(D!$MF&Z*RJE^I%Z 8.<NO?6%_1G=U[S+KM^"G5+X(
MZ3EA<FJJ5K<ZG\77]Q;OL\VE>"9R>\NCAQ'700LY!:CNW@J2D]&J3O:S<6L.
MN1&3 +%Z\QK&!&Q6!CA,J \ZB9/V#$R@ILO.:PN0[N=O5O)#9:TJNI8RI_-/
MRVH6WU.EF>[DR7'G283G*274?:SU,PRSRU$?E)[Q70QN*&/@<2FN[Z.PN#>U
M_M3>DYKU?=R8)E.F?W;\+B>5'\7C(-EB9=V0NY]J:U]M[ERQ-Q7G= %LGVG:
MPBB74HH_WT^S?_GHEBO1@S!H'T__9M- H8I7^I2E0[D8BBJG1,+G"54[LN/,
MF4G#<PW<!0H9E.OK[5EP BAWAJI*C2&0_WCI[.4]I");K8J$^#6F?*Y7 ->^
MV#K _[X9W?LLQ^K[(P_/KW(\5!D24E)]YL9JEHP+LK*U<C;Y#9Z)5&$WPTS>
MANQ$'Q7;W]3X$2LM54S]8* 2!;$*UMA;BRSK.&6(YP^)/"P@7R _@\[TOL_5
M;&_B/R-+]$T0"PH3/Y91TM:S*Y7]'E<3QA^Y2#]25<INTAT2CV(/E[-,T(4^
MGAY"A>CA!J#WPU%2//8QGI[8[I?9C&+PB+IZ>6HM!,J#/T#)0^VE@.WK<YK1
M:\.1G@6F//#>2A?Z[U=.F&5#A9T]URE<"?:DS0^^VQRY!BC?:1K9$!(C/S#[
MKF2?^;;@F-ODH9/TK.>:H9Q\CM6$=\:HEJ3ZL)@?Y/WZ>6T1J&?70C>CW$I-
M)QVG/*%F#4=M\+@&X7>%+4%MHW%1AZ:R@IL9:Y=,XWOO&*$3^1K-6(%#>7YJ
MDVUWW[271>*0BJD"E65&)0N9!3Y"%( &-51$QWA@:6$4_^TA#GUR\W,E/.\?
M<YL<DWUF>?\^T(#@&KI <TX6=OZ'O;&7T0Z'3X9>P38@/7GN?^R5[<I;]3W[
MKOV*NI,I7C;_5GYWLK+FG=WF[RQL>,)4V_H?<5O+B[X,#[OH,7WBWJ.K;_-N
MS"]57!S@YWC>OM=[147>]\#-'U*W3(PY-JV!>UF;;S^?XO' \W$6"_@VV:9)
MVKB;=2E//M]U,\][_JZ0;7=J*]:L=3Y>Y39W;5SFY,JC;][ZGKFDE>K&(<V^
M6J:/->5617+H)9OX%3&91B=.FO9DRIY;K.RSNWG.^I@OJZ??\EMLWIVPN[IT
MHOTFM3;/9 E_DXF-S>=-&)Y\_")NMFW2C<SPZY-\L_2>M!GL7M#S17=RS\<+
MQ5[WK**[;ZS=TBOW.?BS;MCK&I\NT8@)C'?<+=F[#GSX.FW[PXCD';EBS][<
MR_SH<O&0VXM4GQXS_[L*7U<=/W3=RG?IIM/+LC[?W[K0W]YGYZT53V\V;3CQ
M(GJ]4H.MW/N@:EOUM^M3"S[ELK^YJ/?\3GU[G[W4B>9CT^8G7TF]HJN7HV?R
M8:WIG@5BA_^>26Z>?-1+[^M:^8,!9VWGS%JV681+2L*#S=-N_YGKFKF+LZJ.
MMY=JKM/15[J>.D]ZI>\E%D\OLZ>=!OZG&(Y?>=9@K<M_Q'.-O^V::^%BYAM8
MR[?M./:V]V*CC."?U3%GA38&*S%9-1W:F<O&_=;YJ/D\A=T;9OOWK@VZ9J%^
M[-O!.V<<7A@?^+K&>CW'V<I'G.O5+R^I-X_F^93_^]J^,/[ZW;M[ M@7S5S$
M(7.JD=]-QR!;^XB=TK8/WR9=_W3L.[.%Q\*#Z18JC3^8X\J+EZEU%N?-VC?G
M\XN/=^YRZ-1<,'O:Z,XP<>HQA^==LQTNZY?:<Q[8&'E&=\'F/16"Y\I/*QLX
M<+YCKZ]B^/+:^\2Z-P]V.F]-ZTSE.CYA2?JLJ:I]CC.>A/]G*'FV9^X7VWS_
M#V\?975<CI58>_?=X3?AVX/,H_GJG*RJK^UOB#N6+YH=]+*J9)I9?%JCBTN3
M><W-8YS,GQ?PN^ XSG(H82;NU=K>5[G+LWE>+5?PEDBPMYHJJNS0L3#4C6G%
M 6 CG5&USW)QQE/7B1()JWN:?P3KKM5=L_C3V]Q'C<9S-RH$SE^P"'3:!/9S
MNW%A_O\W 5!+ P04    " #U@5983<<1 [EW  !NC0  $P   &EM9S$P-3(V
M.3<U.5\Q-BYJ<&?LO&547%VV-KIQ".X."1[<"0Y)L! TN"= H"! \ I62'"'
M (%@P:UPU^#N4$!AP5V#Z\?;]]SOO._;W=_I/MWCW'O'N+O&_+%'[5JUGKW6
M?.8SYUI[WT_?_P3P7LDJR ((B " \/ ![F>!%P Z*BH:*@HZ&AH:!@;Z(RPB
M;"Q,3"QR D)<(FH*6AIJ"BJJQPR<S(_IV.FIJ%B$GK)S\_#S\],R"XL_XQ7C
MY./G_:T1! P,#"Q,+#)L;#+>)U1/>/_IX_X'@(^.Z(7H@81 !R#B(R#A(]QW
M +0/_41!^,L!_,>!@(B$C(**AH[Q"//A@BH\ !$!"0D1&0D%!1GYX5O/A^\!
M9'P4@B<\TJB$:F_1Z.R)>'VBOZ/3/R]K)58?/63@>^?@B_&(A)2,G(*1B9GE
M*2N_@*#0,V&1%R]E9.7D%5Z]T=#4TM;1U3,U,W]O80FR<G1R=G$%?W+S^^P?
M$!@4'!(3^R4N/N%K8E)&9E9V3FY>?D%Y1655=4UM77U;>T=G5W=/;]_8^,0D
M;&IZ!KZTO+*ZMKZQN;5]=/SKY/3L_.+RZC=<"  2PO]]_$U<^ ^X$)&1D9#1
M?L.%@.CZVP7XR"A/>% )I-70WMH3TO'ZH!,]C_Y>UHI!SZ=^2/S.8?01"0/_
M$N/1;]#^@NP? ^;[WT+VOX'])RXX@(6$\#!X2/B )'!^Q9+A_>B_;24"%Q5'
M:&\.B9*(JO%:^87>R'.JOV1,)'W;%B6+@[&1!)P4L T?-+J+I?(?FL=_.3O>
M$MGE[=OO45QZ0X\FY@@K7O30./3Z5MP<Z5A@4QNAPJJ+_/I=^#U0/X2*<*>!
M,#-JD!#DQ7!AT7:5>^:2Z\IJ2$;B)+]DL9#UT^;'ZJ&R.(KQJ,?;+.LIU[/X
MF+X$DD>1]E1'9'V%X7T?W=]Y"^45O_:0/^R^H=M;%FH"GPP+IT?(!?O$=9L9
MF#><G$C$N;?3\(R*&=OQP\5GOOR8-0\>R8J.'6?]M %[^&T)UQ%MR(W1(D'.
M87?@/K\^.+-,L81/36Z#&=E<I79/?P0<?]Y.@:SM)=A4&F\=VFJ'E61@.WK3
MOH8FMO&D;FO,6Y25C4:%<"L:7"")71D# 2E\L(T3JZCI1P[;WTH5T>8A[8I$
MZF>LQU:6^976WS];BY^\LO&L;>-2%0TBXTC#?.&W-(P^B$4!W<$,UG9KQ[*A
MW[L[PARQGY@26EX,H] *S[9,@*OI7S@+MUU^UPE:44<.1$I9$>,B0MARTGZ2
M<]&\J'[D.]V>GSNS.DYPR4'3.SI)B2SZ2A_)[]QEU6U"T)A$C!("94I +< J
M5UB38WO93Q2Y215&*$4-)>[>621LY%IJTMIX/7' &'$\CP]G]$DN?1M=@Y0J
M+!$W8IFTD+(L3H?]1K%6/U2AE>4G_LA/7]S'?ETL2,]#6-(1_Y^RQN%EP^\-
M1\/>:E"X)?9)/\NTKDN4]_Y9R>L,;XE/XQY"!6#CE0"?#)%!SE!K@8XK)W\%
M#*J\CGR[]V2W[C G%_4MK:NISZ>7C0J4AMLX2L5I.9V\AH7<;'0]_0UB%B6V
MHE-C)ZIH,3I;3+,K.>'D$9_H*@Z796-?)^^3&Y1M4B)O[&AX<<*WKTA:;DO2
M6QE*2J:KHQWP:.."*8U]IFSEEHS&90!P=V0CLW,Z6+O55$4QIW+$XHT+[&-1
M.9/4P'<RO&D3%?HFJQO>@&'U(XFR91;.TYW\G&";M32U\H@%X3+?1[M(#*;4
MHE/Y:E(THD5@E=='*MW?"CWME*T+B<?PIQA'70-H.[(<?<&#>A<I2V!^R4 2
MDF::L=5KDI1\&9>SP_UH7_-0&@7FV*NIHH<F!+*L(8=?/!PJ)_><=J[=D3+%
MU!2=;4U_H;]3(-^+C6RK$QA?HZT(/\9\BM)N-=MW*??I=CELA7S+6'Y4BD;8
M$W(/H*MTLJ7A65.8[W4EY&U];$7I;$0U?CK!N4I?_5%EY;1 @J?.>ACI0ENO
MZK *%FUN >VV9TR2$F(WE6R$IYM*_-2N?6B)XQ-*=[ 7DW4,:'08;^*&10NN
M0/\TX*.@7VI@:MS0H+U@W>&*W(6[Q=*\+"[>[)QL^65\I_I<(<'8P3G:J<3,
M%6<(<#PHT=NRY';AJY#.RS+Z3B8NLX<9'0>WR>""&BO*0\!7^!WXJZ'*<7W<
ML_E-Z]'-_\%IV7X44>B< 1;5FMB-]1RLJE @HW^,)[(R"W58H#FL9XR/++D'
MVK3SJD[;BBH:$YYDUK'7\7P6PVU/94$:M2Q)]1!?#C>6&3_]YI*Z[ I;3Z+F
MKHA_*M);ZJVB3$F_]09TU0%+PX8Z8<Z#?B;= _KQ8_HSN8^['^$9[#/3YZ#!
MO"6\,QK9U(ZH$A91]>8%,"S2E"?IRV/<0<J7F00>6=S"H@FT!MI*AV=3:J&=
M0C&Z>M8N7C2"!5AZ[?$N:>)O[)G)TG%5,D)8@'_-2O((ZFU&U:7QZI!=?HZ@
MA+"M]S0J%8'2,(O9G2D+8W'RH(*)8 :;GGXF&KIYQRX9UWK#+\TB4U6U589Z
M5S .KCY?. S^L[-F%6WH@\.,1*,J6J&:T5M']F;<(TC@J?!I?LE)_ZQ%65U=
MO)1&3Z:#<'=_;)@%O*J9++1AC^ZZ0ZB\[]CJW$Y,?E=>WJ<-!2T7B1]A;E2&
M"%#[-]@,O4*&Y:H,>([8_&V4]*YU7.F%W5**J'K$&:8P'V;B8__U]R$DIR^9
M@2E=&<#110)EI(A@\%VURS7U7$)4(E69KK%HY'AJG%'W4DM D3-*(TFX:'Y<
MO&C"+SQR')T],0NZ^CX6I"]U%\Y+_?%-DN9@]6.=]_$LQN_L@M;DU7Z<GQ;G
M80%H5GK_ZA"Q #F*%(.8'?> \T3^%84G$4*_RN%Y^Y0$06@[G[[\E1-7,[>9
MZ&0-28]MDT*N-0TP(M#PI:[.UW*?A(=0T4[TY=ACLD=K*@,25>.C4E1GN3_#
MT30/.[RHDX;[Q]^QFD:0L*A&?!6W?M\UA"W2A<FF,8.,3A_N"9 1OPL!6#+^
M<>N;$)/)V4JJ3LN>>^TUXW7]))R4.??-YK,=C96CG&BF/';-7/@XI7,]#^V3
M;-H?M#GN&C1LE;S;7C3Q; YCV#(O>H)C"LLNF4M[BS7IZF/;!5.Q2$@5"UZX
M-:SQT+++EA_\JCE9]1+F1]C6T'+)S%'Q9+ C*?STGOBCUEP.Y=S^&UT1YZ;)
MR+ DN*'Z\3'3^,V/&JQ:K5\\442/@*W-?P+&W[/,HNU2RWJ-\W.$Q'=&^,(@
MRO*\?87ETO&N?(GHK#DXJ(9P83O(")/1&0OQ=GD #&@L,(U4*6F=M:VWW:%K
M#;L'6?@-:$6%H6X+(SV[FN+*L+S:]W^[-*^UWJ?8N_LS">XN3\0>%"&MCO",
M 7]8'!MP=6,J0ZW+O2T@ B<:9B21HU(\)5KZ<ATR6NS85F^X5OPM3\4M![ZA
MWA"_V9%%B/X!A7PK"I#4"]08.8">N,\D=-17;^[-^\R3K3Z5G$O'R0G)S1)5
MS)B6W]6%+_ .*"LPR@DX_ L"\W?&EC0EYIQQ8:<3JC*Y8*W&_G9L+8.))LND
M]">-*&PMXKMY_BRT,WQ"B+NT!YS,?<N".$BD)H7REO:2-O#6=_@NG+A!1^Y.
M;ND>,*FX!S)E -M_%P%H8CO>25$DW+KUWP/I%"T: L.7@)7QZ0[7G;<E@I/Q
M);"U>+I#>^?+>JHV"EE%RH5,%4&NT LG_AU_CM )GM68,HF"3V\EZ8Q_-C+O
MRB[H0\9WD!4\9;ZQQER*"/VN:UTS!3-B*INHH@R">%KG[LG3&_[81Q>_&+2]
MT0*;'F+/OHXJ)6C3&+A6TP>WVJF*1IS*_=#+7-PA13\&2Y_-;MPQ%+UNDEM8
MV;\']( 3D= ]P>65W3L/(Q>^M0/*%LXJ#G!1%.*X\2?5ZE2!IESM.2]X[D#7
M2/.W9N-S=U6T*BW\>R#Z C+-?@]LCFH+4(;KD=-3./LW]1%?PO7]R-&F;82+
M;$1L9.VHRB9LGE3;Y]SX/FT<B!1J02)"F%3335JH3*(N,%"P<'4(NU:9R5S0
M'DD%4Q<,I;@Y8Y+M*T$[\SWNMI<$ZW^N1,OTK<9$"CV?)%*3?B)#I(KP.T/!
M$("*T#]SST+%/?4;2ZV'A@X]T?_"RVL'N!KKE3AG@:R)YW[-AI<7;P7U,CPJ
MS&[VSUO@C^>)Y5?[P)#)272V[BT Y8*69((XLG6)=?+9IB=#H.9O;7([1N$=
M]++O.G#?:%G^-:E6/*!59NO7**_1?6)Z#9-LUQA<;SK#[+ZF^+3%],3 <^UT
M1XKR1$NF:JCX*D-.O( Q/Y1]I<+-&>KV1U[(4>179;HTDY_*V3!!P>57ZUQO
M#"H[G=-!N!Q!V@ZHNP<>8RO>-9G? R/81LC<R'C2J_@:SO_0+"SRY%)N-,8W
M:JR?OQF9[>%!]G?!VTFF$;6(S.8O9AI*"F')XOX3+"0AK=+ZYFO)F6+X8G\4
MGZDD=T'%YM7G&NV8G*R>6%D2@8U5@3H=O;,XE+GJ7[V,;0VOHM(XWZM5/HS:
M)@*D[!0+= \<\=J=0$Z;()_NW+36!(CH6+&6I)"8^;?_B@X_A*DSF1MV($J=
M%GLZW\I EZ*VE,G7>>(V?&('G3115@PXLJ"6]'P^QQ@*F&D>JJCRL)*;;^=W
M@QZS:?,17EYL6EV?.#]D).F$J8NL?K^C*,PTV"9U:?8\UG_\D>()!G.D!RP.
M(%*3^8-).UO8>"+X[B\\76(@I,HC5Z!^)N!#O."7>9'-7ZA$-CO?CV=J;V>&
M_%;A)Y_/-JLQI5)>ZY)U(G\[[P"Y6)>/JWRT+64?SB[ILV+%):_\/&-#163'
MQ3F0UI%\CG[GAT2LK!Q,!^6AYB\(6Y-1'AS?4[2O7V_%WP,?YEL&9F^,%[I?
M7Z\(E,@ Q)\AJUZT9YB25_Q:>_])8T0(:2N7G_7X63"#S1+0-7N0D,0B3@:1
M.K4@;ZLJ=+AHUKY$91UP^?5J,4>G]<4N4V<:@N*]# A?;TD\[\24=\-SC$C6
MY&!KO0?L#N>+3%4;JS79>RG;2[MF(UEQ!W*/<OOV'":^5]RU$.;?32??#M)=
MW&K*G69>JY\<UW/TTNS[74V).T.6([&"8%M[59CXQ[=EHW&Q=_4V#Y.O4(_#
M3NLX1FY48I00*_C#OI8,_80%$:.],@[%R;[^W>A$I!*%2I=SYAZ\["?H$6ZA
M01B$U1M<T/NLH::ILON-0(/I+W)BJ\4."AF86(KL3/"N&7 GF\:V*S/2[@A-
M:\B=Y;J>HOWY5&S/Z1[HA\;<FIO>LJD9&IB3<9^B\6]')^I7K0PGY$:^&[*<
M*8Z^J_\!^4&V<@K58T%BWKU:^KFHAVN/< ]02/1":>J3V4YJ:%?T)E11Q6#P
M+ZH*_/"A21GV5[-<@+;XDEE#JOZ:G_Z[Z_-?&":+>QX+S7%S8P":% I@[AFK
M1RT@KP*;@X2S!!H:7[J50TP)<7?T*E51M9S7[JC%C_97^%-=ZD5F9H3&WM..
M5>6E8Y546V.>5^;-WLY&W\K0PO6BKN'L+8?D(S H$4+<+=2I!2+72-/PJN;A
M+MO1NK^>0+LM&_Y+M]FNO>8\KZTG[@&W^;Q[X'.H,NVG=6/#D=KN+;W*=]Z\
MW4&5Q>=O(0M:M&.EI[0$KYPO.-B=Y5_RV= >';18NUF(WP.O=OJ>;F<>%W&\
MD&FJG5QNJHKO$PAZBQQ__=4M>>/X)!U[^T]AEEM,,6=F,<N.*1$U_Q-!&M,8
MJ(T-:>+GT<5RK1(J617F/*[,Q)3S%W6CRW@'P<TQY[?5[!OKCZ"=;K*%Z2"W
MZ<AKV4%FG@U3 LT$\8_2J!D);5<,< TWTZW2VPBFN6AO6=@ILF.:QPBJML\:
M^ 2JA5[3;P'*4R'^BB8<;N^O[N;M@#:6H#-50ONBY<W2H!J2OCR&A#;MTWO
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M-0-$SG)C6>$!69AM&4-89^"E_Z(87FII<2A9A; ;G\N7J"X)$4-:1-/_Z"6
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M]?VF5ACG]O9#]G8LDV!5A(VUUQL1LAB'?*E?.P^$W;=_J2C1.RGR8PR<IW1
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MLY_B?4M;]R?[.Z)2T:A=W)_I87FF]DDK/THJ4DAYX'6 ;R78LL@&9E=3EF<
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M6)E8&X?!_ .4O/R/GK)(LIZ>H5?P&Z96()7X5)R8.[)*,(&F0O]A#O[G6(S
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MKQ688BNPZ;\_%)*\G?D?4$L#!!0    ( /6!5EBZDSVH24,  .A0   3
M:6UG,3 U,C8Y-S4Y7S$W+FIP9^R\95A<W98NNG 2G #!20(!@@8-+B%XL 3W
MX%"X%EI(< L0(#A!@EMP=PCN5'#W %4$*;0.7]_;N[^]N_?MO?OTZ?/GKGK>
MYZE:-L98<\PQQSOF7(7\B5P%"!5DY&4 %%0 0+G_ ,@%0 K QL3$PL3 QL+"
M>O  ^R$N"1XN#@XN!?$C A(:2CI:&DIJZB<,'$Q/GK'14U,SOWK!]I*+EY>7
MCDE05(!;A(.'E_N/FZ \>/  %P>7' ^/G/LI]5/N?WI#=@!$V"BAJ.)H*,\
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MSY05I N67U,)2?4(/C,MKLLMW/=8IZONYCM=&.:"N(%JLPF8@]8=(A_U.B)
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M[Y:S_C>!13AL(VE>>_O)FUV-$Z=.ZNE$C$T']N@>IYSF%MOBLO%X(3H; &Z
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MN/1KE@%]S_$7 "TL^:UHS)2ZIC53@=CI5 +-Y.TN*,A#+^5_S#<HY\:IE]]
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MLB"@Y5#:C_GPP=83Q3P>%%"VO]*H'T1\]/WBI3LHOC=\:3 )-YRO7MW:GE7
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MWSN*/.610I'R\CXB*@F,K.9#ANCL%OQ]%]A;G/8?L:[3C_^L$PQ8:L8BWJ$
MW71PG3T**"\8+^C[R ^&C$C/5:, F+H 7!N*3EVNG]8I=AD)I%=5XY!-K$A%
M SZ#D8,,I"PU>.=(>;4BAF?(4 1)<'I-O3'/65/KWR%6V\+6A^'<S#Q;ZGV?
MI$A\$DN$\L#"EK;'Z98L1AO/#&D$R0L&+G ["C@2WI$^/5OHL2+;1TH42>]$
MHUG8W9+$% 'YEHD\-M6"4ZF(2E98JT(/1SV2(J4(!13\RJ*;X!/.X3\TL8?^
ML__KG#Q2\"_]H IC36>A;>&FY4>F<5L(K.5-\F+].T5_C4Y@%8O)\33C"=RC
M>"N9><RVB*8EM2K%\S.7OVGGZ$-L0-++JK;V\*./B1,/I#,U3U"I MKG4'YI
M3,#C:9@Z/]=A99O+-<!E+3NU8M]IWWT&D<R\L!XV&(($5NP^\#*8)'RX<;_9
M3#[IZU(O7S_F@9PB]LZ,4&#.)DUG<$'Y&0HP:ZQ0C[ESO'?C W;DI$SB'3KA
MO:2 HO3+(WJI3JN^ST]5TIR;>U9^T ^HET&YBU?+GU'WZ<]4M+OI>:9Z/SYA
M^D%U.6GTP+I>THDR0%/UV>[/F4$+]JA),T+'3-**96G>O=>Q/:*&[B-2C/Y(
MLK>0Z^R-_IM4GL6B9Q\>#PJ$V(]1[;_2M8J%NGQ\P3\KYC:$F\S2[S$F'B=9
M2QK=8>Y6<C&O<7HLO#>=;#_V\"256!_!_Q&6<E;=R PWQ&_710%.:QAEMG.#
MGO57IBD.2X$VR['4\91!2EH&I7MOOS73V2\$01-TROQUPA7>K>\]"\G'//PT
M(Y6#"YJ:>'TH6:#(K&#E0A)C%SLXRM0<>;9H!X;1#6.Y:_IGCIX20JNJ;TX/
MV;'=WA2Q8="Y-ZME_"'SP)+R8+?/W#TFPE5B)@%:'5C3FA<A3$)OQZ]K9WE3
M;UX?UJG\W?*U8F17?YT?R6B9<G"YR2COJ8S=@G%E$F0.419K'T;N).D^C&,]
MY+O/7AU#_=ZD7'NC)M24V[/SJU>7GET&3S=[%45)ZE:91>4YIGH0GY@#YTQS
M>Q<>$U'^,X;OFS@*Z6!2+5W]'JQL%18V _T4)J^$,[.K&;<"=^?4^*3TV2[R
MR$Y$\?>0R)"-S^:8<Q0ZR\CYA9?)UYDDMEBV+.5@$0)B^_V6?%)XV' O<SSU
M[JKYE^XR#MKA1&,'GQXZIU45G X*N1G-DMH2OT->(]+G:7$>@)RF,]Y/.X>@
M#Y:7CD&%<9,=VF?WR,)TQW:Z4PF_JA,J6;:><1B(?U$3>- 9=;.P0RNO^=)'
M<_.W'X^U"2E3[DC1'IHV$<6F=XY4$ U&;0F\9#8EP/3'I3O\M.VZ8]"1MJ-A
MP#3Z=OP]J]GG)YH;3T(*,_TTU+J9/N,5:;Z&>X'!7F!R*;;JJA$AVD\.+N^8
M--[-VN"SJ^.:7VI4Q)2ZTK9"R13/YEXJ2RE^;QS V3)V,^9V_E_,O7547,V6
M-MZ$$!R"NP0)2; @C7N"!PD$UR#!TKA;$Q+< @1(< CN[N[N--!XXTZC'?37
MN3-SYWWOW#O?.[.^M7[?'[5Z=9_J.J?J5#W[V;5W[9V^S^\KY2<R*E7V^8[T
M3:SN;J+Y9UF?C5$;)_'Y[.A^$Q*#!()RZ (KH9 K4K-,<]ZIFO5VR9E5<2C5
MF],W9((TN(Q$,D9_5YC@,%N,^;00XY#L CPC 9 H:DSP'CAV%[DH/K,]T/8W
M^>&&$QFTIV69CG7!1YIH_DU3DP^N-R_5:!K*#"T0#7!(11+1F/:5Y:OSEGO
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M]L@=*7@B,6FK^[T):A65&+OBX0G/2:M?Y+NRS6+2J7G.Y$'PG=ZY+X?<$,%
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M<N@N+A%:HP=J25_'/0"C5W^F9$J+E0<Z$'_"YL1-0%5QB#6[$KV,7DT5ASF
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M<A7@82JY;G=FR]C%M@=BK(O,A^F7$S2/HQE?YTF<)H3CGPY[Q;F/^HFOERZ
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MTO1D@^M)6>/I5-SJ)P%R>GCH=N&W8\V@/*LT*#0PU\[&PJ5@$3NPL@HTWO8
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M'LKXQ<KSLTXA1Q+%*4 #U)N*/WRE]1/BFY2IO<-/=CK7I:9X_=G)7I&H00K
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M^($W_[U5W2K51UHWC$+HMX!_:^,Y^$_5?R<@1%ZG_'U]]%]?%T(^^W?:I'N
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M/$RH6YZUUQ_G5[."'=7?:?-I^[SU/M(ZK\((2[X[F;U#6,+9)\M*1Q/N['
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MZYC_E/%?VQ/^A__P#R+U:^:_ %!+ P04    " #U@598;D0;++YF  !+>0
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M6W-S4*%R2<**/JO9ZPU+:[$X/>#$52*T@QAR,3-F7EPKS\N(:KWG%>#NR2Q
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M6QM$</.S((-,@-FN\K6V6%P[(/Y?#\Q/1[C9]88JZF%&L^RG'***< "#H4]
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M^[J-[457?8,_!6^B/ENGJ3,^Z#OE?P. ZHL3@=(?#V=KJ"7NT9K3SL <EXD
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M<U?-*%[9&DBCOY344+(JA<J V,D1YO:Y$),^,?.B...3LG)4R*>RI#,MTD1
M<E&*3<PF'-KH;LP24\\:;J?8BRFGMOWN$_#-%A/X_ O[4O>CWB>V$S&43Y#3
M(6IHEEMO#1:!V:P0_HF7CYY?C1!CTI+SI_C(0#(]QAG9F#/5"0)_K9I,,&_I
M;KFG_#UE^>!AK[5IIO9_<NN([.R_*FKQWCG:!X(/GB?<KCQ>1Y ;0.\T0+?I
M5$D>A?!G<?YR$\A)^]>:[(R:':JY2D\B<.Y4!1@:CG;)SI>S_/I+[,4;Z7/.
M?=URBY:HRP=',9QN!4*!QJB!9 BU#X\93!M$^'" '<O,$= S!!7C0.,P&0:?
M>#YL[\Y_%<^=_^_#\Z,/IS:U'C]Y>91D3_=?/_Z<4:\M_7] ^Q\ -#./4*7R
M@:+^XJ(!N^U$LH#VAOS1>L#/V-L9IU/ES"$=6-N+?0*N4-BYILR,#_M61E<F
MV$@^/E4S)@<<_2YTNQ(!,@^OK7JW,<GJSZF]-OMGHQM-$;.D#VLZ5+V0&>W.
MYF3+R2Q*_:VXTZ(A^Q@#[&-;;[7"=7?_\_&K*Z^'QFR<O\8OJ]L)<C^^43.-
MFH'=,GBI4'33*<LDT/->4$&'=*'LZ?_ZI7T2\G^* L;X?Y&.:\KJ@>GT"X%?
M6:%AG"N:!HTQ[X,NM4+Q-#F7I6^6K7' FP/S0;=YA<:=R'_^\_>,UHCY_>\[
M5]6]D@2^RG2!%)W,6_'+VC[]*GR) ,,4SXO-C?\,%.FT01#>EX2K>-BLY]K/
M&?<N+ RZ*: '_R8'W3:,F]92VC<<QR[U[CQ48-!*53_U,P),F"*]Y^I@^WSE
M:@>11^"FI69Q'CLW'Y'_$P*@'J(XL&#BS6T>B?= X)ELK*$LTBV'?+0*#+J>
M'8Q_X("VF#PXH1RQ\,_P.+Z/G=F_)]U)B,7!^0O]LRER_QW_4LM8,=VC"9:Z
M)C=H)\:.\RO.4\V&6S"I\_"??#&D1S,2<,])Z3K*,)_['M;1/GMQMS#\WI3J
ME=95@Q%IJ<:WCY+N8M866Z^QG1I:M#RF:C!5&E@DK3.MVB>F&+(Z6G+G:8_.
MET:O(,Z=?/I)1#T1..'A_N4,SBXG1YE\6.W&)]]XG1HKYF NI7D%;[M^Z>"9
MV_V$^</WI/Y@1CXX(8RC;B$"_II'9<*U'FU3UX)VPKUNY++?5'YHH!U6.F0.
M>WV#S2F]@''-0/<@?3/=F@BX^&F1; D?GM<_>X@_:KL)#X*L)UK"MO;X"*0M
M!,;M@1\"AM&CD+@; ;\\J> ZA3^M<KW[4H9@]Z< #)0G,M,76@POAUX41^TI
MSBC43$ G7;$G"8%7X!-@U#M4@*R7'U7<R"5"UZG@A',5^%Q\][[&CQ:R/L53
MD6<LAQ-"BE665!)Y2E-]-]!1T]S6$<\LWHO%X='9\$XKZ!J(#T&^KG_)T"NG
MLYM+5Q/-O4=U0@B:/]>,'L&Y'^[&$@[16(U_U4AE<4/X0+_4'$L$$C?G@GP,
MWBVD"O:LY:^:10R?"%4BR+^A%6J2%>T+V57#&OD= _.VKP@L.90(T!D1_AH.
M&TI^ >Y0NA=QGEO-OQKJ833^8KO,?C53&7.!9[,<P;M/WL)>1>-K\9<2JKFI
M?GPGJ6]I/=Y=]@D'9_IX,A&0!B,G6IC  *^5 ]/]/W5W_MN@1D"70]C')PF*
MS>/K45;HK6&U@TTB,&D47(> >#C7X49'.[*]>424GW#K'%P-C_]^2D)SN/KE
M#XU9CV;]76/1E44MZXO1=DNX98=?9J102GD#_H4E^+F8@8"MON+GSX7Q_(/+
MSC1?FV69+T1D5:G\[C*VL-7(UL1Y"#^"WNHZ=.$T?#R!"%!!)\_WP.>F?M<'
MIOOCH?"C&=8A GK1B$^*K=#U6"OHU@8??A^^GDXX;<M'\./Y83#CCMM? PO1
MB_+F\<BN6WM)H.MR,:BP5;P?PVQ6<>4#/EZG==]2M#9UT2;O/SG\^,I?\H1&
MOQ?EY3FQ\#704F*#=0-5>L6N)6WZ[#LF/]"4((\43#M%DE\;Q<\.9&9<_NMU
MO7E5\+IRW9?;C;W%H0KEQ8*L-J>I/L[+L06V(._PD[:BJEFPP8K]17A8G3&G
M]VRO5&>AGHV@F?:IRZV?3MU6O+N]@]+P;QW82.S7N9]6GM-,$R&;\_NUPE/N
M#6,\R76[.!\=MQSG]]:Z+RV>Q(AH40_QOO:_UT4B=1^K5H]"?1O#?QH5LB\Z
M:!',3U?\GMS+E@.ME2-[G+:1'PC/4\@8LWK,[9L)R\0X?!VY;T)"'?31#4,?
M&*CM(S8QFG2IX.Q+(=M+O /VF.JR8MC8K41N:[. "E9%";:NX_!Z95,9KG61
M4]DL/7.(71:0($H*[R\B]KKR+0B,*)#>Z?80@75V*^BD/I:/$.0+1F62!L#E
M;*'"+FOD&!\NB\"U8$SQJ V?8K,EC'NU1FA&&8(38#.!P#%NHP\I&-#K2!]&
M(G"S&O0#_R59#NTR>#7Z=;H3$?"%BQCG@LXQ^ 6V+;  QYXJ@M<6K^OBJ7 P
M BGR1L",0<+!TG[(D@QK<^B4D6R"!B$(LD&[5NP*_:E+Q4,!&#F\"Y5)!"8D
MNQTD[?\PP+O)J=&'/#_@'/WN!?@+N$O?43OZ/]I-16)UJD^ 80:F0@1J')6L
MAKZO'VN+W:+MB 5U\_!SW:8]%+#_JV-0T9$_%"UNWX&+#A&^$>:FB0"P?_"C
M@8L=;(VVHSH M-YV O6[]?K020,/@7\,VT!D[G[P;M,>%((]+OQEWQ1&:?AT
MD79D9M$WOHJT(Y3@E8W?%DC\^^#IJ_VDHQ&=CHY42.Q<,L+MD8])C/AZ502[
MVN%=>C#89SGI1MA!QB I(#T QP,DX?],[R(QY[:&&2+P( DA5K0"TIUUFKJ#
MNJUT!\+ZX=(XN#3_KBQ69XSJ#]&NF:U.<%,X?)T(//6@?(BHA$KN(9[W-,I
MK#B;_9?A4Y!QZP0"8^E3]#_\Q?(G'^@I& FLP3\H;??>9[^6<O9P1^U@7C?R
M4,?%GO%;U"*\2TV>"*C2N/\\/PE'_O='?]:3EQX8KL:4%TR.)!RT[7>7P2O1
M*=Z1/TW]WUVI&#T@%89/2/S]\3[=NVBSY%F(P]XNRNV'9G_-CS[V3Y.#7VS2
MFL^ZO+QJK$_8D:2=8EC[PY5,_[86V#1^"(+^+DC@==^B=ERC=@!'8WQAD2_%
MG2ZAU!&EWI7EM^Y;S)RR:25 YR"@$_X__MK$?_GQTE#,_)_7XO]Y:^'$H?\
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M,V045+3GL _JL %X. 0$>$0$)"1$1-A;7]A[ !$'"9?FC=@S/&5C9%I'?(Z
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M,ER^]Z-.%DQXZ[:H!AG.TJF.OG%;?5&@U'%/]?98ML-F0B_G]D;.GJ+AT^/
M[+L(!K-8XP)Z.-R8$Q/ZF1C,VQ"Y9;1#E9G?7(U)S\/H+&WM>-\5Y9DX4T8=
MO/P5,#&AW6SXV<77[N6+*6Y!W=J()^,0T46_'XG:/L;K#?$+W'.LSY?!18;"
M3H^;T;X>^48\>SGA --_)Y6"MXD;3^82C=^GA'BKZXC"=9NZJ7VK)%&%J S
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M_D?GK%UIKD/N/K9QF*(\4.",Y4Z]A F^\MHV<\DWXPUL0>CN\&1='L1E7M/
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M_@$3GL R*0M-8:^K,7(<QB1KUYNNR,C3-F2#&;/[:PJ!(=WB&YM(<S2.86]
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MSR4)#+OH@'#5\X23 )U4V\0M37>BY'/1J:$P8BVXA9*FJUWZZB<FDD*M!/#
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M7%>&&9XSP<Q%/^%^+GS.CFJ-_^!13%;D]'Y2):95I*XIY5(A# I08PA"VC[
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M(,4\D>E.S\>A-[P6=QMTQ+>1%'4'9MTS&)^0V< G"U#@3+W?XS&NHC=0ZEX
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MA+Y'Y>7*VK7P^M8144QWNQ30E,Y:.K=OB>I5=L7&C863)RP=;WEMGC^FR-C
MW"=3GN-['B_R/!RNJDQCO$I'*GW1 >".WKAN/E_9WCOGL O\XL<8]_+DLJ?,
M;:[70:44R,5EF-$><%%6M"UEK$GAZF*8:,H#ZTU PAYK.*GAVHTR]35$X2L
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M'MSX!%#6"]'S/D4&BZJU7_;?I<2EV6(IOA.O"&W?-H(XTO*2AZ/YHP%^CB<
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MQH]N\(VRSN:EJ-=9&+-))1DWP#!XWZ< YE;R7C0:N/(<*.A\TUZBM*<_I8S
M!.$/LW1@=UEYH2SI1N?2A-+8:/&1G_[H&E%L]RB+W** H0Y>RSO9B6R8TAFV
MMB92(UUZ(1>H@34>_QSZBH)AE1M6 9?O&XM06ROP;M:# ]D[]1Y(LY(,XO3,
M*@;8X>MYG^I@"<(WR<!%U=[PCW\W?_\P/#KWO?@N,(W+:JXNN(= O,[3$2V:
MV1@8OH++98FO)GG5 ,^SG3D4P$= DQ,8HC+#06_+BA6_WOZ#2() /&1UX3Q$
M<9 ;%HQM5^5Z3]ATS#Y\Q/W^3&,%'X6OZ[-29"'L:5S:N3"!FWK274B:NELU
M(EFB.P7:9F%I)LI!C:4@:7U-(YV9[MB&G#!#[T?X9>XR*P M?E"Q&1F 50HD
MHZ G<E5"&.&[[+.PR.5E8LP.I?QNWH;#DIB1TFDH1YB$4W; ^8-.M,KZ&9UB
MB49]I4M^NM;)6U.+^?226!Z!&(KP/79;-HWI79E!&XQAR\(WA?U(8^UM=(OF
M\)7]PIY'6L82KV_Z!,37UKA!2W.JB?. VLA#)PGECB/AGZFP@2%FJ]9+OAE9
M]<K274H*+,^K5)@< K^@,&URCUJJ$Y=Z^"L"9SE@@RBM;<5EU"T?.E $E:$[
MH@O)4(SG_NBO *30X^.UKMECNWR-;)%S-C>0LAISV/=R>Y?&MF'\)$FF[,:S
M0$"C!(KP.'Y'%BH]_9&M^*(=(Q5FCQ3A!SRR]2!TLN"%*:UO2_K\![:\TK;;
M9_G+#XR16Y>ELDAKQXM,2KM=IK)R5YX#*^V-HL]@UB^Y06DOE#S,I7C?WK5(
M63&",KYS-)>_5AY6C+L)%B;^9Q5@-?2/_&(D@?[Y9</]Q.G# S72Z_% =?I(
MKPQ>A6>7V+U+-T"%6;)0 5X^"OX?#D?LO>^E8&4#>EPIM[U4U-=86^NG; IQ
M";CCM3\':8>X)\$M 0-O_0SDB9QG%.C31[$3"JVBUP@)\K]7OL.A3LZ8U*"@
M&;Q]XSSA_D/U11^OM;8\?]RJ*'D07T"U6&@<T89T@)R3Q]T$6W9.T]4IZU@,
M=EE+U6K9#.<H]I"QI<^+B2N=S*XL>:*#*='J_(RLH5/^P8_P8Q\=MITAA&@V
M!7"P7ZK+I6TKH=U<%_FR5D:#Z:4#@AFF'3]8M+[HS^!4M>NJG"\O'S=(B<W1
MTR5I,EF$+ADVB<P@#8[?1/D"54Y66P;WA7@QJPPE*YWOZD"O%/YWQ\R^ /8_
M-TRJI)HO-SY5\3+69'<+Q3<YWSYZ*9P' EP0-F>TAP#L)W7Z C=E1J7OEN@;
M#21_V**NMB>FY83"6)L7=\)3$!_]5>@P?*=N_(6N94-#A#T*JGUA+\J\H)D[
M=]Q U_JZ <IYVD5Y8=%?#4VJ$0P]-5@0\C\JQCON\\VSX$84I,HU9=[S]W+/
MX/0AF-E@CC; W=SZ74GB'P@3JV(GYUA%?=5Z-]53)6_O2%4[%-7DGMU)=D>"
MOJ7E\I=*=-9C.26T4$,D;D/=Z7MK<H:!5A:S\P28*TBP&^AK]5 H.)0WL;;2
MFDO/([->+MJDCDT>)LTBFN=P/*5^%_4Q:&I7WPDZ^&ZW,4I(NFE^Z>Q8>]_X
M3+1V6I=G3_#A3F7"P[3<?K2LK=B01H/ /9'HDP(: C6QYZA=<:>=SX[./*':
M5"Y6PK+9$X#TC+?$_^.=BTGQU&X8?@0I0_$@->56M%39(U?O$F?1,)&Z*$]J
MGC/J^T<^TH[Y5*D-Z]BK4&2@S!<F,PR&DR93=8$8;#U9Z$U"F>7BG7 :V_S7
MH3;@V\Y.!)91+CET(]I=SQ"N^X%5?WD7;UOL/1*$4Y4C=Y($7]IX6D$-2N/X
M#_=YU_!U7JBK,VYJ\2M#?I+SU-^6*M-T=),ON/E-^769+=%3O@M:YC1$#K)'
M$*"5]D-7V?%K%G3U&I^;78MU/#KJA.86ZQPZ)]OAK9/&LTQ*--S,I(3&.1=T
MHDQCT3.;'A;B=Q;SCNZ>NN8.1=]YUXA+B5-)Z402>3FJ@Q[4"\:6=?,"G@#3
M8EOG^.6J+C))C=&,IP$384NBDBK*1W)UD[(KC SN5P%T208C(JJ7_([O)++R
MPNC@HV8GSO#E1 K5,S2MV/;=>XV2J0-(TQ5VB+QBO"X03*4VI')Y)!2&?$7R
M6"X4]>3O1:4H]=$9EWB(">]%61*-A +W8>80 9AR@!\Z..VGL"+TRY9T$- <
M>XBY00#76?<VER:1/*\->D4N4S2+.,XG"I%;(C?S:0N6UUKYAUI+$KOO'K:X
M >Z45]C3XO'6*1)47M7R\:]2/?KUW!A<\9]Y ^ O"B":6+_"?T)<?RK5=P,8
MP<?#E-M:!8PFA\U9LAUYGX824Y$OY;@A ]3V)+$>AFL,%^*44>;&_+HE0)][
M[2?!]8._[Y]7B+F1N?QQAS!\ITQVL@H:MAQ&C&I;Q4^4DWR>=:@]E33=/>J^
MVWSHY:.05T"5I.D6AN?O8LQ]S>[W7<AS-:%S2]<+$>:Q=H"OI(@,G+CJ8=WG
M=C<=H?T)0^]Y!_R.?V'V505/@FAC77-+Z)T&2&F$-DD4.2;U& 23D%+F#+LD
ME[L3)A(O4$T9EX% QEKY@%"<R"VKB4U01W8\[I%3<R'PYEY9K*Z%^QNYSPWX
M9!V<4TL?4L)'$NZN+B*&I?1G:I7.$R#,YPU3F,![%JH"N\CD^&-_VA<6\.7H
M.M/]8=]!MHS+"DD<&1HM5SC @K<QW&@::+@K$\] V%^:P6EWGQ>,$[<_82L-
MOF"E-8Q%A@J0W"L30P]G3XVHJX_>:.")I:A]][REZCRVQR PNBD+-9R>36[^
M J2D%KYDMH8A"1M7;2_J0.P.U>2\HDILW/,$6/0:+4M9]JQ\K=:<QH5!W]9#
M?;CX4 0#@5N^"ORZ@IK2A4$SSH7.W;<;$,XE./N2)1I]A-Z\>ZGDR N[/.?D
MHY9!3Q^:V\;'HQN%9^E_;/\W>N!'X_THOD1=)PFR;WD"5$L2)0DJ&S:@.&;D
MPLY+_>5EU+D*/;)_U/%9:,UB3IWNR6C"OF]B(>+<B&8+$D>$(!?5']=*K=!;
ML[Q[>XV#T^4Y*P7UA2X+$-\_@^)";%4U+Y;YGFRN?,M2JB%<"H>,5<9V'_&2
M':I!S%'K"1#);%O&N:#UA7FS1=(L:/T9GR9^)YP44>##X5C8IG64?N^\VT=C
M7H.&<\8%].2/='E[TU1%R.FF6.H<@F5?139/K5G?)CV;LC06X\L03?4S<NS7
M 0@1  XLRB6ZM>9RW8N6Q+RYTYEK-WP@=XI?[EABF3&(;N)W+9[NK: :C*J]
M#E^MH*J2B6'G^J&"*:CCPLT_@<OK13^4T-=\Y.$W09@(GCA7L\P<TK-=MB R
M)JK9.JE0S6+"4I,(<T6.XI-"M^I\E>21I4Z?GKI":^/>P8'[X1(96.(K39AT
M_W9.W4F[-%447Q@0N17@9^-X($SX25UHHTQ"N;5Q=FOF(3]I;9N\'Y<>CZ:L
M@1OV\DA3Z69N<TLBR>.[UN1N56-CW:>!:F=<>/IH/@+H/6LQS]&&"->PXUIZ
M9=[;(-<(Q1[K<US[6)<M.L0M8NO)(L!OJU=*9L7:MP5('[VYP.]K)W"+<L*%
ML51M1<'?9"J3KD!#(AAP"[3<>\3P<UG3'"4"NJ;6^MP(5<#1D*VCC-2 <6G
M1$Z" X HD@ 1IA@Z "?\7>06_YVJK+)*[>1WRM:VST.!"'"5\I3K#H*U4$[A
M(XWS%\N:+C<[C9TS"#@]M"_/(YV7?Z#54876&1>OKFDMO3-)&GUHZIOB;*#
M%_ B^03E]X>+I$LJ_"J2W_M".GZ0<@IA,QQ[Y8P3L8-46'Y#&-?BZY+O8UNA
M(2JH)"E4=24ODM1!P@@=V^Q/G4'/IC9OR^[/:"Z5%S>;)H%D9Q#..B*1-5!R
M(DL\\GP<^4.X&%HD+X:X2!8B34YT\"O(/_C>S7WG""O?JDH=PRFG\,1-I(P\
M\9XM;&F0'$Z.#6PT>$T9-X/NAXX%)8 ]BDZT/YJ_9 48,VK._+X/?+:^MB7
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M*%(.8*->?)ZEK*MUUW$182OCF^"^5UUWT]\QEV4MJI!3"QG0]B-""-$\A3S
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M?Q\B2Q;^9S -3X! _WWQ_,^M8MD06T;[!H:# "M!DM[EE8;^^IM)/XG>S2=
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MX$J]2I&=R"[3QKW=USO;=3JGO)V)B(.]F>=?'^^"OZ&[(B,D$A4W!D,5A?-
M@D'A]<Q;O1P05N=G!8H_$2%K4H-W/3Q/-8!U#K'&P!V]@2'*N596Q&.3)V$\
M&Z^MX\'2U9Z)/V>#Y!.19#L8V &Y4:%)'O,?WUL8D57;3$"K5?:0]XWSC&K/
M%CP<DYL6UE8V<9\#"0R-<;2.V &MXBG)S9]+W[CI:3*IO!/S/MXT^E/!4K'H
MI9F%RW%&EV5V'QHVHP7:?W$O+*8Q5'[15.,-#G1SW@)M)I)\.P38 W<"N*/%
M)KFK7$%H#7VYI)OK#<'J[=(Y#CPIO$U&R9@U<3M@(@7'TNTQRU-5O7N<4X^
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M-3E?,C N:G!GQ+MW6%/?UBZZZ"!->N\(*+WW)E(C H*$C@@H$*KT&D#I34!
MD2:]([TWZ2*]!.F$#@()74IR^.V[[_W*W><Y>W_?N>?./.\?R9I9F6.N.=\Q
MWC%FT'/H5>"^EIJF&H"!"0 8=R\ O0"H /BXN'BX./AX>'@$!/CWB"B)B0@)
MB>C(*4@IF>A9F)GH&1E9.06X6=GY.!@9>20?\@D)BXF)L7!+RTN)R F(BHG\
M=1,, @("(D(B6F)B6A$V1C:1?[FANP R? QAK'PL#'8 DPP#BPP#W0NPW(T3
M!^-O#?A[P\#$PL;!Q<,GN$=XUZ'^/H")@86%B8V%@X.-?7<U\.XZ@$V&0\XF
MK(Q+H6>%Q^Y&*1*2^!6?XW%U-]7S"02GZ*NWH03WJ&EHZ>@?<''S/'PD)BXA
M*24MH_)$54U=0U-+W^"%(=C(V,3:QO;U&SM[!W</3R]O'U^_=^_#PB,BHZ*3
MDC^FI*9]^IR>FY=?4%A47%):4UM7W]#8U-SRO:>WKW]@<.C'Y-3TS"QL[M?\
M&GQ]8W-K>V=W#WE\<GIV?G'YY^HONS  +(S_N_U#N\CN[,+$QL;"QOO++@Q,
M[[\ZD&'CL GCDBOKX5FY4;"+A.!3/D[\6MU-P"'Z'$'UZNW$/6I.L;4'R+],
M^YME_YQAH?\ER_X?P_[-KGF " OC[N%AD0&*P,453V[PO?^,1X)UW=M_F#V"
MO$0W#QDZ!>H""TD5!T_R3EK^^(<?#5< (%5*70Q5(1!=2B[YPT0U+:Q!%JU
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M76>Y3#*0H[!'(7+X\,5%XH=X[8O^>@8>2CO: ^]=_1+UQ-+HO$"VLUGTY!L
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MD6+?V;A)E$6CGV =X<N7"7(\$<(65SFNIY.;?1DR,+4.,:V>FN79]BL0<E5
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M,(LUDAIJ*CP/H^3Y!";N+R=3&JU%.EOZY]>]HM<,>OW;2U6JCTY1<X-:\K[
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M8YG!CG+F3]87I#SZ!=P391(X3T^VKXV9R[>%=P[4)=.C>P(%*M4_Y38U-1,
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M&"+E@*7W]_&X;*2+;*F34ZNAP(]7?JACN*9W# 4201\4^$E]R<.WR#^MT1>
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MH$CHBWM JQV27[-#5<:BF%UEEEU!E.E+#Q?9A6&YF"OF0H55!M<WS;)$B-C
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MC#<4;*L/:86PYQ7$YU\Z'PX64B.&.X\%:"[ZC]UK1'%AE)4WZ&N@OS3_AWM
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MQ5G]3@N7V!P)'A8$&C?@V_HODZ6UJ*2S[6 4<(2Y\+OG65S;DR,=X6+E!5T
M/&[TV"UYM.MA3*('8G%4V+F,;,,L/EOK*VAOA*S#B2?))%%M-SGD2$DWR7:Q
M+E<-?+J((]DL]OFQK"B"#&U0Q.7@6#Y9O&%<(4E?ZIB)%N32M^V$7/9H-0!?
M7SOTO:2Y=?S@"<CI7490@S]51RE6N^C, ]_R?0QCQ5$5_YH4]A:PE'TD^,.X
MMFJ<\\GW/6+XMP%SHZ?6O@H4K!_+!6.\/G)'!1,LE.A=1G4XD7!;P)QS=.?G
M[B+E]XUK#"FM^)K!K'J;0CNY]$+\DYW+3<2/871!H*HWE9]<'G5A_&K'EAMW
M/,N9N326'EOAUK'0"$^/-_LEBSF8^Q**L_ 3A<3OC&U 3KF.!$$P!]=7-#_N
M\"-6#/DZJR#4TTTF.CDO#;&P^<1(?)CU6IM<$\Y=-[U6=L'/_Q^?SAZT/+<O
M"8"4& >DD$'TGVCAUJI_8_(,U?*TV]6CDG;\'!L3!98?S'])"*0@,HP8QQN^
M&5/Z3?9-1F"E[Q[P=FSEBH-?4TU]@?%-E(W1A_ G6SC"9YT\Z_M 7\P; :0!
MO[,1RT2UN^! &XSC1QF0<&:@@V0$?@\P6U!HH6D.Y><N]E3:YY:\D1IO[KQ+
M=;T'Z-U6'=>;'5C?"K^OQ\+)2+2VYN!DK$$.-07U#QV8AKP6P!$2J1O@@8."
MXC:A>[.7'M'SU5H3H!O.@=Z5H+0R(!&AFB[(&#AU;GKM:D8-ZLB0O0<X6&_"
M,$#>N;#%<].K?LCQ&] &[A=!AUOS>BS\$55EQ@[B4N6[>"AS@L1$-WZL\H7_
M/JMURLK,LL'>[';C,(Y1B!9SA<<<.8=/1W1BX?2<'H5(HD 0PNF]:UE1AV\X
MT<L^^343@F_3D[XMYD$J(.6]F^[YL$4&2V.R,Y&6["?GW\=UAF[$C^Q2%RLM
MZ40?=$/^U$,/]3I1FCB3$-AQJ*E)H+ P+J]6 'FS%8_1-V-: U"#$U)FW[B4
MK++/ C^.X?<14$3;VL?2AB:]7)KLK-#5G5/$/7?<T]=B]B@K*%Q:71>I>UC:
MV=G9B+;,Q!ZYTHLP!DA+E(?,C3B0QVF2ZZ=;%&GI3O^:&@9+\ZSL7W['67?M
M1PU_M'J4=Z8GH3/^2=MKB+BKF@4X<),A): \^!9EXQ'W=K#FZTA=\53&!Y-=
M[T&:06\R9+=[*.KM=Z5[;6/PYN\!GPRJSV?7BMZ:Z#=&-.125^IAY'*;9EKI
M:,:>RW].*DY\%LD7A;?.U>N\Y-%NM]TF1*372 %L+)>V(13D!J%Q!044FP9W
MECDE93RGI)8GHXP4UC2P9^QL:L3_0W3_)O9>("-[RF]!.Z4ZJR"K'X;(P:;8
MWX"#0'[3=TD>W<Z$NOR\E2' RIODU[(?/B2\T2+"<>JDM P4JZ<6VU5+N >8
M*\I\O@=4'% (W5UWY;SH\CH_V'YC8!ZKXO[@GX[9U,5&2WJATP?_D$A]$@X,
MG2CF,(F7J"A)/_9^%<.O@NP_^6)!&[GBKKV)_-T2UD=VO!8@W7*3Z<RGAQY@
MGN<;BZELU;+7?^0_NQ87^UM\R7K[<H0]%D^KT_$NW@MIV!T9P1H!7:"HW989
MUHH)#-P !9DO/;#UJG%]OIIE(O"/>-A(M;4&'M#]0>W8W]T'1B%O.91>B=1F
M;+$+!UK<2([[Q9Y[+M\#<E;X_T<\J&+"F9LCIV[$C\7B[TXC\D+*MISM$SA\
MVO/R$/HK6TK0"IOTXU@GIA!-:/GM7,+@0TGS]3]0CG! D._ S98_)<A_R:S#
M:BG),1]F-[R,.79UC+*H@%0UOI7&ZQ<Q26T%2!!H$Q4T$Q\]5J%XE_(: ZO7
MGH#7/=(@ZJ$U>USS0V*+@/GN'A!T#P@LCNMCU=E0%#CG,8?97,HT2CW4P'B)
M@UN#6W6:PR"7;TAO'NCB9<ME@<?1/F5)692,%?07< 7W&JWW'@!=N0>L_+$!
M#>Z@.7T2A;P'=#[\J0Y1+_?=D/%IU-S2+?SQ3:-WJ1=(3N3+L#]+I_P_(@]8
M7,U>Y+#FRQVS8$&N3K_N8+T8;9#:$6-@U9PP8ZKZ4K+4)ZZKJW=(U$X;^B?U
M)):)CS#O'IG< UJ.H$?JN#/-F1<A(BUX,T-\#<3J00@N!7+$5L#4T>Z[6(T1
M1'&)S5[S%!#18YNA_C2@(?^LZ&&5\!?&DW">$]OOO+P%H?^$>VC$C(A5%5GZ
MK8==)-W=Y8I^JB@Z +(WRL=&'-S0O=.378QC'2*]M5C\"WP?#G"6#YS8+=P&
MJBH%JT_V/Z1 7S$\+ZI]M:7>U# >926@$ZPI,'6L^V-AV2S4Y*'4<\P]%Z+$
MR<B_!_PS:]\T+#R(YIRVBB&>S!EW/>RF:HLA,5?[1'O^:LNS4P)!K*GS2#D/
M)(2;UYB>H<ZNQ-N#2+4<^-_$_'N>9>\[X[J764.<X/MBDCWE<@PUK/:/GY+B
M9P($<Z5D!DMR]\>+$7Z]]2T_ND9Z,'I.QC=;E%[F_J7':1KVJ2^,@);75*_/
M7Z7-5WV41QI^"W\% XN9*5253T<,4):8#\NC2:[WW,Q6)+D[_!,?0=H*=<40
M>^":201=\QB3(=.L%;T-$TER!W7*W!C$48P=;F'A3CDXZ3Z1J7ZEQ3UHGS)G
MMU#X3]G[-[W+; KANGK;D^?]##Y"&WYM;WY$VTW(VN)6"5ND'\ZG_ PL%Y'Y
M<LSWA0CG0_&35F8JER*#_P$UX$]0\?\[U$3IVKO]3M_QTUD6M87?<SUA3K'X
MC04H*KE" &KE)AY/';B6HZD!KZ"S!9^KP?*S%,]G,O_>'YE(/)OGT&$FY9M[
M ,D]@$C=Q9FD:7H,N5@!4;N&5NHR$/04T0GLT@D!4,.5,4.K9/5 2BG=[ZNU
MLFH4<K73WDA*MG;ABD+/=CC_RJ:@",<'[?DKCVJ^0WHE^*./>W:$]ZSO 7&=
M)#I5E2-6!<V?;+)D@]BF*9.N/TC\2<?_G? 63GRQ'1I0BR0B.^S)LC>ZOXK5
MHR1^N= GP)QA;7:0@C?ZVL\Z5.6P^-XVLO;V4**HM_Q9Q+]S5;[70:U[9QL,
M#C4/"EO8(W>>\3H0.0KK2V8JR>:(=H1\CNP:FWU\?@5JQ]48!$MDJ_Y3CF?.
M_4'(U5VGD#P])='YR.T_RE]L\B7J<2YX5^.)>*+MAB%C5298WAN%ZC$:Y75"
MYC_SBMS^S?>FZ1H;&%S&,^?=PJ=^*WJT.'WGYV[N]FJSEX&/3V=-.1D$!0Y)
M_?L=/!>^VZWAJFK? _XJ<4A\NO[>R)&Q2^R7-1-U,TSM1':3'M8G\2*AYZ_3
M?S9+<8;%_R5%(DK3P4JV9:H(&$YPLQY_#YAY\R) X@?J4>&PB[1!BB3,E*IV
M_^1=%FZ; E,#%/?RRZ*4=X^]V%SMB9FACR> ZJ>;AN/+3B FJ<@.1%6&J,OZ
M?_7@ZE6/-!7K31GPL,+EK)\Q[14+%380FQ?S?_R1$9D4+O'C'A#".;."W$2*
M0KMJD56<Z[?0):K4#V$G7C2'2EV![<,8,P=X7P@?]Y QDV$D%UXFS,J/ORBU
M$KEIR#>R\'5RVE![_OR)T'8OT=A;CZ.-5P7M,_T_X1D%LY;/YW08$/78!15R
M$CU'FVF&T^,Z3E6YEM7^.X/[K"_0VR"MQL9$QJ<]NSIDL5MYXC.65%$(K@-U
MCOX-;#\JA?,U^[<<1N[2]EBN1PCV'((&%^JX74D"5=TL+_&QZ077!.NR1S.L
M5K$)O=%&OVS:Q+/EZ7?8,L&[LM56$?:XX?'/F(ZJY'>>("2)6?)TCF<\8%//
MPP2I]74]KK;#=$<9$5DIG_KSP'V0<D@X5<@8YO PVJFZ:8OW>HU\XH!V.V$D
M#YFX?N-HT WOYPNZ?=1'E'P94E7*=5LLCSH)QQTCB$:^T6/[OP^7$?X/;OHL
MF)HR&ES\#=>7?4$O-3%]2K-9F@4/;* T6ML+F)_D9]\CDE-3 A2$%&X7V$Z=
MI]T#IM3O >2# @OV 3;RM;'%I!X!R)WSZ[/\5L!' &9ID5A12E^W7+G/_%S%
M747V/6#X]10267(Y\O</$S9]87VQE:FQ9R<T%;F;=QY!$K/"!G=H0.C!SH.'
M:?[^0>,V[S;O/.H8V6RXMWUU#S"@&SH?C+T'2&$9W%RWK,K]_8-ZRTN)EV)9
MMRTE<>["7M"IGG\"(<Q"@G-W@WHP-?7LF/T>\'D;>OJ\ZB'."Y%\T+][X <?
M9QYGPI7[KZ^^_PONO^#^"^Z_X/X+[K_@_C^&:_8GN)CK<G\K@;AFRD/75^0J
M<VVV3WS,UU&+NS"O/E3Y,6;AE]J3:F,J$*P;GM(GU.0NO&42<%9L5FS(B"4]
M(70<NI%N*=&IG7"NC,#/@+E4O UD@07_VUTKA98&QU@-]X!BSC\^5U^A.O>:
M YCM&XGV0R5BEIZ(1S-(1@:N4!&M?&:!W$)^J,K@H_@*(-G^RGT/H+X'W$73
M3 O2G"!3+W$?FCO-E+SQFO8K:/RV\'C)D1=TC>/;/8!&LV6_^S8ASQ))Z6G0
M%5/SGJ*G:&4L*VRPJL$%-\[D->'/C_*MS&.!LV.5&V46R9OXE0WVOG ,WGU/
MRSNGX:!@_-C4#=NIR&C9U>K4B$WX0D!!"%BUIFITO:&Z.4HYPMIC[1<[/L?A
M3>C*-!DEY68)T8/['N^7&9NY$I5\3PX^U_'SGTYAH,CZV?B%)L[#3XEWG*B+
M;<(<]DZ9O_$0<EHO4'0X[=>4< V7?4G/HVQ#:>LO"6:;H%BW^1DQI#NEL!3"
M!&$#U6L;UG]5_C+&H"DN;XK^P<R$EL[$QRGX;-"U."$0L,H/(5&I&[NU(73J
M3%25!$I^%%T\=5#6%_\H)U0$-&ZKZ75TX$.\RAC3V)BTAUB&;WPLK7_U(8I%
MBUO:GQ*Q&\XVSI*&*S)RR^B(=FX/RCD0.">!?B+I8CHVC30U(0T&)#WRDCH.
M_FH5G=KN%IJ:HSODF/DNYG@&# 81YBPP1AHZXDT7DAR&RV-W1,U=WSCRR&?&
M"X#(ZTVHBGAX<.1V6%!_%WNP%B[(N<&]$N^BJ487/%/FZCEG+MKQL?T86)UD
MA72]DU+.]$1?.,'59^\!)CL%Y%9.SPE,@LFYKAS]2/IL!5&^2W"=PMDF6=*P
ME9^ %W5<K.'/7L.Q+(9K\=K)NQY9BRBH,ZK_:'NA (@*G/T/;@=AH[N]2FB4
M=Y-Y8BLVO2H1+I%L-:F1UZRXWC1R#]!H;7]QVHNN<"LK0=Y7\PLBO7K3-2)#
M%%#ZGSFB]<=[>""M!) G^;YY4E8 V<OV//XPZA)'1EBP,KV<4ZQJIQ!-5Y8)
M33I179Y.(D)X95Q(^B71G*S=A^)*OMJ&LGKMUR!(Y:M99"GGVPT8>:BF/]S+
M3)UL5+7RHN'61\\V%\X8VJ?P&3&75?$=%<WQU\6C5*8J0@G("<&C!?[HQS9G
M!>T^8J]6,J+>_(1U-@HVZT7WQT9R<K+SCK,Y862UC- UU5:$2\2$&VISIW*C
MH'%NL-S=);<H[\R*K]X#S.I;=M<O]QOPYJU^S<3P6F-GX+'GC;W\C%DZM" ^
MOFMU7C]%C_>V:Q+T@B=].W+>JW)WGC&WQ:J'T8_!X?&*.=JW4%^S]/R,L6"=
MA 77(+^:YWL?9@?M4X1HW@*U^_6*V494QMQ=[P'ZOIK"E:6+ Q;H44I';Q@9
MY F-C[+(A^.!Z-D50_R_/ZD'EZH4"$=Z-7Y8G-F\4=HY&2!-0<&9<^CVF-!R
M4( 85EA958$*S8/!O]VCQY.6@H?OJFZ;]:X]&GS.B347-V=+ADI+2EA\2,#:
MY)JU-R+MM1AR2-G<R@EBFTK8N-$DR.P)K2N*OBLI_Z,M=XVYN[3*?,?S>+W8
M.V/C-*H"A]$,0<W1.;0$D1S9XQD7O4R:$+SSJ:E3!-*0TQ BH7\/6.-YX(C5
MFQ/#:H)6 M>?[PJRW#CS\]8F9P>U8$4I1I._UJB6;9NO<N;-'VG/PS9"'Z?0
M,'2O8TQ+3"/W[0= -EE\O$_('3]K!^FB=RNO_/'M7Z_Y_O(KJ('+5*EJ\\'F
MG6<[\*S=#EA*K$:G1\^'/2ANA"%/7S.953.IL>QP#^# -VE@?VK] (+DP&R*
M<)K/OX9<^Z3=TT^+DG.Q![&M?@J6= 3/'E'FHQB5LA=\..E_CBN50%"4H%R2
M:[*XX]T5I-@)V9W/OI9H5)30C+.87)[8/V!.D EQ1OF5DG4.>+]?Y3,9\C-A
M884M;B6&WRXB:M?G,=]6);//PIR, _'&@IQ#U*</_J+Y9-L@)O_1V=X-/>NZ
MF&7F&+4X3!L9U-+\MRW QL8&SXN6GIPM^\6AH99Y*X]]F0(K@KM8U1NJ1F]@
MN?^:$(7!M/.C:LAT4Q%[-_M(/O/X2GEQI4(V>#JM"0^L5^8<W%WK+V9K/SPQ
MZU ?>MHUD/C!F\A+UV/UV[?Q(QUI.&L-Y]COP=P*V[?$MQXMQ9W@9",MZWW$
M<IE%2/D3*E]OV5'>Q2;176HK<+>IY12!XN-$"UMODKF4TY.<*.<\Y8VPTUK?
MCY";6C2S19@4=1A_:57D),*XUA\%E5>NSD05D<(J 8%RQGJE<JSJ_UJ BL][
M>7I7K7/#*P7*%1B.*YGH6GF$=G M4X;40UTV!5]6EZ U?PAB^ 8X6[K(,QI!
M YKTO_KDXY0B:[HA:S@TFA.DX MRL]9XM5H7]Q9OS*^U\P].78_=_M+_-6DP
MV;*FJ2>[?2M][C)B4GDLVE;6UC.T<'':*;ZH;<$I4W3N3^("?T-M6?;K_*/X
M=BXHBZ;F"2Q'BTY@8S[SPU;+7DI76OEP5E5==?1^IJ./0)"E=,67B."H%.4F
MSD7FD^-9Y;A[@.WJ\<FB002?VW#DD%+M\>.;SQE<#<V;^F[VH]E-=>&6&L2J
MKZ398L/#]EFV+Q-R<;Z)OAYD:M;P&;7AX3LNE3]E%K,<.%5*J$YV*_B=-T 8
M1]9JV':[G?L^=N'XCK,T(7MHWQ59/==?-<D1N8.DB"?M&G@Y*V]W7'X/P%T/
M5H]R=1;XEM.-O<=9\B@OMG:5?3'V)-] 2L'AID&;$3TG.5<."UF4\E,N3;9K
MPGK>S!^.RTK?9I H6J,S\+I\[.R$WS[MS"#6]$Z/B.-,I-=#Q$RLTH\#;NIW
M-.\OA;DCHXB1SXC,-BJ3'V$H!6UT2?A+=8NO)(E*5#C8#N;;G&?5RI]'55#)
MVB\4<01'[&Z^#Y5,__D]B$KK B/!SRKGMN1XAUF8V,)U5NE.HKCS,>*, "86
M,%G\-HN- Q$4%16L$9-JSZ:_./-['?X$E9ZZ@=0$MSW[;36C8P!G8]MW7YD*
M*B[[I'%R!R6X?Z9+WP<0;0@*:5]>%U1TXA<.OGY)B2)TB6S0TL[]<SU83V(I
M=+R*]3-/O[EIB$J#O.D'&JF47'@&Q'1AXS&0/<4I94ZI14@75SH!=$<.ZI]A
M!D5+,8B#V#HH\\[>3T_(E#9^UZH,78"$/ L=$NJL(_TV'#8%8^TKB(WMO[[I
M\S6O/6UJO >4U%;<-5.+2#]+BE2PH^]<WP=DEJA NR(5H7W53NZ")'A*I0HX
M1VW6OM0KA<K9_5;B4<\:BTT(%.B'*FBYR7JIDPMZA^=7C8'#[@$<:BL* A^I
MF@BQC]2R]>8=KYP,2GIR*84KMD_V[P%8'KVI[VL)@K3VL&.-)'BT.M(>=[E0
M-$1)36)7J\S!X97I%QB+=%WT]'E&[F/[#E?PNY+/Q;X$PH_7<*G//@K3Y!7D
M2AYWYL[L2W)ASF]T4;ZR!AFG6=8@HISN)& U+3T#[AC1#RWQKKO.(L^;*>(5
M+&DKR^.A+Z1%,K\06.-1VZIZ.X)!]MD_:Q*8XN?UITO[/]H-Y7J,MJ>#(.BY
M$4Z%]I]UV4.HU:-#Y>GYC6\$G%.Z+ Y$9X#),P'OK.>XO4/CLBU'-6*NG8Y;
M=M?4MV061*P6!Q=SXY],K8)>,<;,96U+S/QF[!*\!S2-49^.K0AIC"J\DQX(
M5<6BC7[KXXH)?><^ECW\)M\^OM65HWF,C#4\E[0-,R\?6L'Q+*KS/,@Q.HF;
MU3+],7);?R5L\2%A(ULD'ZHLLN3.*SL1JZ;Q:\^AZQN!!4KAFEKZO$+UU&R+
M;XH*2 >S^(O2$ &ZHV 4>"6;F\=<8:)]0BZGR-KT0^M2_L\N*OS;2*NWX=P[
MP6TBW)(Z9[:X(QT_PRJ!<P)AFJE)BLPW+W/I3S[C#OZL+E-=V$ 0JNI]?_P_
MVY?WC!&&?NL>"!EVNRW6,P.5>T X9.K.#KIF 6OM%.<?E:*_N(662W1%(0D@
MS,C$>\ BZJW5P.)!S61D@Y@OMEBFF#-H$NCHLN8.N7R-,L<]63+U8HGF\OBA
MH?>$P@PF^*F4/-W$".3=K5QE:N"Y=;4_^O! 1.H?L.L8_'N9OXILU%G*R"K2
M:S44)J,3#4F7Z&F1%E4U.-S8^:QXGN=R-]H177UE?JG%=>7:+3I!?/G-'%AL
M'04:-ZFN]G]B&JTNQ/N2AY:B'+Q))43=]/*I\#5;1.WEMUQM2U9C=PA_8X$Q
M./E$&AD\:FP9T0*<4& A!<@JZQ1"C[#E<@P4+3(7 HQ]MA'ZMCZO%C!F:4D]
MEAPWR0"K"8!]EB)/63T-"(KUWJ? 7ULRF\)S;9O&Z[WOV+R3+M"F^&U6/+T&
MI]HKYKNI\ZX;@8(S>[#&7*FU[T^Q>D-S\^FW):D01%USMZ!A!'+P@4OF##YL
M 2:<Y*Y/F.?[*C",Y_R>>6MD'Q5Q=^:]XRO<\!E<@[MV= 4PI"TM57PMD&B<
MIJH_DJ22(>J6.\+OVAA=<!?C56W@:>?['<[^V5A+ER%>Y-!6F4)A?I9O^];=
MT+Q<0&>MWWX=GA&WO-#\5E[IBI*#:S52JA>5$&5J1#>Y)>QT=G>6 B(.W]B;
M?QT5&4(>-Q$?NU_ALT8$F44U)II409$A_/-X%\.R&; 2C=JUBIV;3GC-,D=0
M%CRI&9/*+HVPQ:W'0J$+>Y="<2JA8Y8HZ(Y5"ITS.(+UL>%^K.=UU#O3Y+J=
M:=GL.D!>TJS*)0K>7L[_=])\"10+0AK>.-[FT/RO7\U//MT#4BE:;I:@(=:J
M<F70W]3S4-;O&P/W '%!Z$7K/8!<]-^D@7^J[AF<8-88]!E>54"'0A;O#B6Z
MP@1LKHX>V-:,>3FY3NA.<MN&F#J.\_J\>++J? _PP#W*'$A$>CPT3P?>2/XZ
M&>K.>P"7^[] _'\'8O"_ HC_$I;X/P=B[+\"B/\2EOC_"8@?^9X2>#JD<K>G
MM8;>]P 4M*AKC9#H2.U,CRX%DU>1LCO=U[A2&GF%(8PDGC,$!6M%E5(RA!K^
M4O\SX:N?X5YAS$.G2)"R16H\_FI%*&I<4@>O43N3J!#=;N]HWIX=[$%XD=[G
M+1?KT%]1-Q3O[@%ICB5W5P:'Q2U%'%WB TD77UM6!P_NSI!5L,(M'@,#Z;SI
M'5X+N*]JG,?6B*ZHR;>J:']<>MI#.?&<2@0""".$->*]IHBD5ZF[+;#<2*K+
MMM<J9*-,[O81G?[(;:4YLH KJJOW//2D:/H$X_&ONXG9RF>U^72'ZI7"BI,I
MG$RL=N>Z9:K1Q\3\-*DQO&?\XZIJO'&-AR:"XB^BU //E@@:O^AVT(8$!W\%
MJ,^ F%Y_M75%+=O(3&V=K-@^G*G:6Z8//1-$UXWXHF!SL^E, W-T4$%_4QF^
M33>XLM3_XGN?:S4ZNYW/-"5NMEG;<MY'9%OG[^\WU*AHKJ@77[L(@)?81V '
M%4PBDO9"*WNK<XBL5H>M#-K:; >"*\SO1;R";%L;VRQ5ER7BXMN+AE)S_+/5
M<$O.O&[Z-Y$O&_;[?AKZDQH'7[0A]&0(45K#'BU*Y7<_RREQ)2H$SS\I_M6E
M%SR:66Y,2M,AC=*]K;G?3#/34S!9HVC#]]XUG/=U9)&ED7P@D:TTMFRNV!?A
M*0,9@-UUV%>C\8R*FL0/M5;F>.H12P%QY=6(K5E[ LKC]Y0HP48-3_\3;>2_
MQO^5X^E WG3V4H55OV.]&"U/GOU#@ABT5-B'(%3U5UR6-3X&FMBFE6UAN$]Y
M[VCT#159LIEM; <58T*?&U\</FM_69@4CDMVL;T]=?MN--<=QJ85^SX!;)\/
MEH.8ISW$",]O:&-':)-WIR8+=91=GK:.,C8)2<SA '>':B^MACVRASDA?*Z5
M(V9\@+36A(-N3I ($VVUF,=M"GT5BKE#WEQHYXHZ$P0.TDJ/65GN:XH+->"J
MM[6/Z%95L1!G&T4X6L&@&KQ%\(3\F@[V7Y,=XCWQ0X??C<!'A%JX"AGY._!@
M-Z4PU[R>[-%)S+B"LX]I25[1FZ"5 Z+M:]G8E9"WBN)Z+Y$F<N6!/"5/Q9W"
M9]:6'"206=&MI\[C1<;-()*F&G -F3RY.D[[C'V41F'?+6/.HN*138>S8,7,
MG%AF]X8(^-FF@YE-C/)<:ZO0KIY<2%7A/".[<<7$9X<#L6G1J%\G?9*4CU=4
MG-VO[:1UIG$25G861HCVK>G\R'S\(W[Y=*=M-N'-SRJ*ELK8$0S@B$Y/M)D,
MO0O-/"HAGQ!5\%Q1?B1[_4.VMN((VVG!J,/X!(#FHW(W-O1VY_;%/8!1NIOF
M  S=PDAEH?:6L=/GG*IJH"':(A<(8RPR4R/ M/IQ@?X2Y5D;HK?;;:CZR*G.
M"K*B)ZA2/T:B-HIMRIF+(41FLJ6%G;SPU9'AJ0;JB.43&^#'X\;=..,3 Q/W
M-51W-^PS\8EU 21PZHP&@2"UM)U#C*;L8RV6-M61TG(]M96GIQ4LX3=0JFLJ
M/_SN[3==WD@BG 5"B<2.,V8N&UH<5-KQ2','$JTY+^+S!W">B00]@4VR4538
M$"=\7HO8CY;'[I(A?3_NC53ZO?#B2 "VLGO'+%M;65D3^HNMTCT.B\=:Q6E5
M3$'LVBA4 S.=^"E/!\I8@LZ1GK+>E(=JYB6;"CC1W2)GW",C@T=S4/.%;O Q
ME[#;9$N A]G*,_H.WIFY1:EL<$=9D$5NJ:MA@Y&XT6 N"^_6,\HTMV0>;6,?
MYA@+8J%A8C/[KVG.#*=Y11PR&\F0+PS^R@*,GH?5JN6\T6+=V:Y>%<6701UN
MS$'[0*;R[_)CMS>\$(8WO2SJ5[-.+D*O:&*;&(HQ<W/23=G#NZG6&QI[-]X4
MTC+)((^#C\4ZM4M>'LX?1,-<7L[NG>=Z^;4,1F#&U6HL21@BF>(M5IL@'C)9
M7=?%J7G@1?T@[8S*RG#IY\RH)K\Q3A:IQZ\DSP+9^O=%P2N%\[P=PLA$,5]A
MKT2^ZB-X_Q,SS[C^F*$_KK$_O2BD.8QR252=/*7B5*ZK\*MZ1L;)%&,NB&8?
MJ05PW?XJ;"_'0ATAX^H@\;PJZS#]A*XJ5@?R<1M/H?)'D-U)Q.4J43;NCT;%
M3*LI<IP\H".HCN^*DSVK)KA+;YQFOO2"ON3R\$NIR#5;?R/]:LA[E2D(@E],
M?QA$QUT[ML^NOZ 5A^U-MB:Q^@WQ 2C.M'.A)E,@Q\ #[W5<3WXI\@H[",>N
M90"5HF$UF[((5]]9?M6"P?2-"HB7$H#YQ:)TZ-EO5C[\K#*AOL;/9%KN>/HV
M!58I]%.)G4&Y(%.,^&R&ZB&T$6)W'[R:Y)DK]]7# 8=4G):UE*V6LX,[1::B
MKSLL&8&2?WOG :R2C/ALFB!JK6LL)AQ8\<$Q[ I=^93F]WNPMUL@2Q;*A^*J
M9(XN&Z8#M8J:6+(9]IV0L'1^IT;WCF$%NR.O;?K#.>$CY(#TN87I!ZR>J^,Y
M=R^^T5KJ*BMW*T_<9#/[9QW:L\UDJ,6>/"_=3A0U.PA<0%(C1465B7J/#C[4
M0GG$4MS Z*U 7QI>O.I"7&JKLBW-6-/,>(?":=&;=/,1V$1AY!-U:W7OW4"/
M-+=LHG42&D).VG$/>>7H<U+#J)N7KY,4Z'C2-R^;/PT-:V99<+K??;=@RNBQ
M>?=T+%P@S\,D[.,SIB+T:[9>PZ/]*MP??%6>FLKCP -.OZ)2N(X\W0_N5C81
M .5%)[C^:*,L=[M^,/Z5OS(>>(?5[-.CCV_+*3,A]P 'P6WE:._M,^Q8IQ%=
M&1O&#@71NN-5,Y14*EOA)$W4E0.\71T9N(Y4L<4AB"@N.B-T9)\Y1?)5'TN'
MN:=E=FQ [J3C(HK>G/;,U=3A7#Q-7_\+=?HUYOU-PB_>VP(7&A=V\<#<0!/L
M#Y76I(^$@T-/:P0USFWY+MYWHK&%C+Y=_N#%U)C8KE,U&':(7 $KOO[5MC;)
M&#S@5'3Y/GA/!JW!7<.I;@4BIW_IN=(/E%5/KKQ"^#H_FDFS(,K"_"D:F@JC
M3'.W??&3B]:'YW$>HAAV0'<",0MT.9:]3.+JV>%A^U8^)2J7Z1(E->884%0,
MX?^A)5M]1"BP5X##HS#WBC)UM$X1LU-3G/*0*=KBTY&4>&;>'#/<-"!+2U7+
M&A+43RV+_C"!*5&/"T5'3?W,.(2S)WYOWJ.AH\9%;9F4D@HV[/.8SZ50?R+C
M""=Z>0![MMW5JX1M;HYC/8#027]MZ1X0]:NZ&K4DH[%&Y6BP)7M+G*FJ3@!6
M9!XIB?[;#KG_(<+_R?OA)63SA(=5,]M8U1U'NUK=V)JB]1/Q04/?L/*W!/2B
MM[L]US?OUU&;:ANKJOQR:NO\27\BS")^Y8G[)B0T,G7MJI9?*A;HSU<EGP+S
MOD;H2K5LGG#MS8ANTE/'%6_LZAXQ5:T,@-X<WIYKJ&ZK=GV*6:';T+0+3W/2
M;[Q16<%TEW%UOF5_9J,Z)BK(E$I41%)S4:ZMRU"@([;K';%(N7E:R.52V"F0
MOS(@( \[$WLO+Y\RO^1;$D<3]1,S"<=6>)7P2ZD87>#)$*I+_8GV)$-YP^3>
M_CW OK'U/ 1B1Q&:QOFR3\P^X5184>NAL\A"-V=VM2Y>^0P)&.<0&Z?9U;",
MSKWU_=L[=->/)N"?'V6FK%!HD5L%&/LSD)E%^!3<*>2S15W&WP,8=K7O <6@
M>T Z#$L#8]SKQ8AIA'&8UMC\G)\Z^"=#U#!*PF@)ZV%UQ)=N^4B#[\(.*HB
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M;OU11S96F\]G%!:P])[(#^&0=U^^N+]G;U3(V-&H(1'0R2XZG'TT)OKE$3W
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M*6N\@A!2.R+3+Y#=T<Y51.IF:S@9(9>JA[M94TU'CB4'WROMO76EDW=$%7X
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M#]T YUUH-!CK:&(R:FE-;*62&WW1M"5]ZZJCOBH5NRA[C[XU@ADTA^WM@$)
M*KUN0(N=/CK5&RS]=,-CW@1X:9!]:0[C)((:I_:C8!86,D/T;K6=X-0%,"QO
MC7%T4IHX]QD?O'VN_>U66*NP,9>TCCQ^T!:/A3#.]1LZ[S-DYYZ2.J_&L4+9
MJT:=4%:5%%@\V.CE5M"V>WMZ5IF6]RAF9%Z]$7@)DU*Q;4A2I93U?]FPJ3N*
M%])_B2ET-.]NH"[-N4GQA2(G^>Z'&@1QA=X0JP1<=UD0-E("IGXA%Q7,J1&P
M"P;;&M'Q?EB_O$\F%:X<7OCUMY. ;UG!X/=4^1IYD[+5PM-ID(9';[@^QCG2
M@Q+,L<LT?"1$>//#A7]9M69=$/C=QGY+S]W(PV'!#GYB*XT#T%]\>[F7;N(0
M9*?2-N&^X6@7FRFK)"6/MR%MRYX@N%1A=-6E-.G$BVG,<CY+LXI0;O2,7W1/
M(582<X&.VIN$Y..%%M?7Q"S-&Z-B5'BL:R*">"A4EN2ZONOKHTG6-&,[#5^_
M-J-W-&"V9DC=8!']\#*;Q7 7M27E<[-9O2MY/8Z,I^\V&>3XGEEDJS+7 "B^
MH$?=$.9-O>Y:$FR<Y-W_T.:E-E"6!MC%_L(Z-?N06&EQ7H_6)N\S<$J:V[GJ
M_?L%=7<NF@R+>"^LC#QV6\.'YQ).'T&)OM5B'[=:)P[AAT@?5K_R:<9_2'M2
M=.\CG=$ER[V^[RLRL,X2O%:-CU[W@8:E*T$_/LW##+2&/)UOG,Y5I"YJ@GG"
M9-G&2>01;SYTM'\_+-'7),3DMK-F:0XRW;O_T_Z +H-1UN"I8:+YM_S>W"JH
MP;QQ"RIOTT??I@YH5@[@,M 4-&70FETK(Q<MJS0U@2:^J8EZ$7$TNKGNO\SD
M1"G3A'!6.1;]7CE -R1&S?-QL,&,EC1=H'2/MDYL&1OV.-BGS]XW!"[V\8"?
MAW^_&AG-"JER=RH5IQ".>P:;QS-8JW@EQ^U[,;0$/D'#AZ;W=NO5L1T]9*)$
M;&(,L;&5CD8OG."NE:9FO#WK8X_4%)V^<FJYPZHNLV5&5V.6_Q&E^$^)O(4Q
MJ](ZE]-M+R0#6BX?YS'&2$'G3.\WQOX H(._EQ<%I;U-P*;$!S$GL?/#<LOV
MU6P%CN#R^65A@T+@0'=Y2' <:W,%*3>?C#MJ_88]VK,PG;IDX?G+/A^P;W+1
M</E+::@5CLZB$J&5[6;@YT_;FG]OL85-YB1H^&BTY^U<*0JFYG?(12;4T#_9
M^3$XLX\U>MM,_Y\<NO\*_G.>'9FVRD, X0I6GEW[PQS"O+-ZK0<6[NU;\(?8
MZ+080-_1<J1CBU Q(A?"4]M;*QVRT>%0,_ +!Y)$HD7$2P;X^$! 2;F5DK(7
M5X;3[O/#=A9:PH2(.,)/(9^6_G[-*8#%CLT._SLNX^\(3A=B\6U%,JQ$^)7;
MO&G3^%:>,<A1<MNIZ.D*KN7LNL>-03O @[(P!B '8 E^Z3M6[_O8A /0/N(Z
MS#9%M>(^DU#_]]\ @'8 B;S:_UN1QC]SA%M>!M2E2!!B6U#>ON$Y=?>]]5A*
MI")I:)>-A).XQ.&^YM2=((9722W%K8ZD =ZM,?,EV0?":!'Z!$44$JKAYN8[
M$U@>G1M3!5-M[]6$2^:VKQ4?W9<[(8J>MELX.A&]E?!?>OL@.P4ASNQ<+;%O
M? 3E.L"[Q3:1EVE$#W4> +<;KFW4KP0>D*%^$;LFD2!]B<A,B>7O) +1=#V?
MGUS70LR=&%[1FZ/?Y+K.V&WO:IE"W76@GC3>7VN_A9^+MD6I2C%+?EWGYA=L
MSK$X(6&.FW%4?(Y-TGD36%9F-$I?)(7R:90G_)2)?G2$._$"T,B8[["6U6E.
MO)MD#+X1=C%NC4\KH?O9#$ZXC%+[3B-ZM":=L[*VG+ 9PX?W5"SR?!;T!Z!D
M\<%1:0=C9-DL(!W-;/THB9.9;A(DL=MCW6/IN2JQQX=8KP/F-[X7UE9SZ90
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M&J(,L-2 %?-[41J-5T**6.$N[V=!9<]5>:*"%TFF#F+[>]0B2HWX7]@;_?!
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M%0-&5V2[XB;D(:$T\:6O? 9$;90J)?TRR3BOP\-JJ=63Z4HFTM))@^TGLVW
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M^>^!0?:XC\JC#7?[A>4QX_Z[GG<_)K3DR<8X*/H>^7?6N;PQK*&5.Q.=?(V
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MXNCJ<>AMPE9"//03>B:P_-TJMGOLR;TC'*?+2=:Z]X%Q;G0ADC9>A[7N]$@
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M@7*)5ESK1YD!?#:HP58-:1\W'6JAMEA8O8*$%H*3="_(F)EVRSF9[%!#%RF
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M(8>;]:]D<N*B:SX[]\5>"+:YHL6FSG9=&4!@P3AE;E[TU5?X2R^I&<2:7G-
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M<F_6U7[?376<;" !"%X?/0\<SVO1T<B+L;_<3O[^+2Y>P-AR-A(00(T$1!3
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MS5Q6/[,RN-QM:VU(L&\XLOZ8GF]I(@?WJJ ^C=@UF:.>"Y@?1P(L \:HO)$
M'S&7$UB@4!NP*^=ES0R_+ '1==V<4H4EGO^Q*XJ0.0J%4Q!H#+6%^L4-6>\D
M;.)[>_KRMA!P*-:+^#B"Q.T$UA8F=ZH3EJ="=Y5:-=6? U06!;/8/NZRJJ)*
M$7>M8,L4+5I7?%0IG'SQWHZ%,EJ80&CPD>#)K[Y/%5;+[(G;Y'[4RBD7>ZU#
M+*0#/)\4=>;KL8+0^51WNAXIDU:]9@R8</+'?X^X.VW7]S1]\+[[W";Q[M0]
M:NUW8<[@TDAW5$UQCES"X*UYW-.Z*G%2SP_;7H5):G:)B2,8H^MB?16HZ(!Q
MM*O@/^GZ<2828%R#!.S2-()-]9H1/9=C8;RD1-C,_&>7V I9* <4_B7+;4]%
M%#[7 GD__*CTUP-DA?0*7^X9!ODRG7[]&'[Q.QD_BVVQ  FP^&Z!UO&=+D?B
MM"&NQ,30&B%3HI0P8OM3N#PV_;K\D>UT9CO.:VW@6%2FS(89WHI!T^RH1;GD
M#]E-;2>>M#VN9/\$_<3WE0VUA3>Z1Z,Y5DTB1G_Z D1I>MAA'S9\QWK@1/PG
M53 .BZU_,GR3VY,F <\]C?%T(C+ZK#T\!7T%?_/((-X>U/3@(3\MRK?&PH&[
MVY#6G*R;Q+/OH?.3-QH'TS0'T_565\/G=/;7;6B!4X"3Z=NF1KO)YL7^EKC5
M&4B^%5E F"U\5B5B(R37"Y=%:&PF@O?)=CL.C-*?T;B3.,SA<"UU\KEHB2RU
MI;8QZ:DWA6[5#(FK#PE?9K:!H)./<Q1%K;T$=[54;(KWO\B=]R_SZNV)-E:.
MY=18['.EA@TOC:DY5-O *I?,YVD@<]>*F5_1#_M)$G)B<J+V04J!@B=XGI_/
MN_W9)\R:]#+?_5CB3:@92'SOR'_K6H0(^.+Z .H2</=VBRF"7*$L#"9\?=/9
MOXD35N1.H(Z>+;6V0B"_3G+9"S1I*(ZZ4LMX'RPHBG^T7.KI((N8#5.91@+F
MR8RV'A;2&EMR#D\"I'ZNXBI=*C&A)$Q=J&C=''H&70G2*O)V0Q-H?8_2W!6H
MEB^SO5:!V;J&"-!2L[QEQ4(/!4X):V5!&;6&T0/!DZT)*V-!.QILS$-OV8ZT
M!OX9]:!MKD5V\2L6BY-?WE]S&-O;HWMA9[O%/:296&;]^V(LC?F!@IA( /I^
M&O7S[Z?3GSF.GD7R"@6D,:_F^*>4K'/@FMB8=IE8OD("NIO/A$H6YWYK.SH=
M&)D3/-G1%2>?O># W_>.C?A4LN]ND/2[&G7*UJKP6*I/1MWXAJ/;.RS(_O"$
MG:UH^KC:M/&LX)<L!@M*/85+C[<Y : _N5"AI%0=VQ$.2U\OO<S<#AU2FW5M
M^8ZE<UU%L)#EC$X1><+T'4?S3^(8RN[+MG8-:4VD%9UJ/:(0FB<Z63.\(LQ>
M!^-W@S?L)$S&V0YW^*_B4-B&0^3T[G2]9 %>/6.AK2;K=RUZOAH,N=:%G4PI
M1Y5#/._E)16/#'27B6;819U\*@P6V2JY]^0F29/O!QA6I?I*".$3DE3*99[R
M/3DTM9 I/C$.A5B]0AF&'W'I^EJ7**0#/3;+-YH&$Z*Z;F KG52#E+8+*W8V
M^P402VGOEBT59+=>'3UCR?./ZQU?W<(YCH_R.]I3Z"+AK\+SM87F$P;&O/,J
M;M1ZO(^3K"VIX@KV..'*%& */+/103^GL]B2K-G*"4D*HNJBFW(VXWT%VTJ^
M-O8]8G/P1@C_,-KS/X@,1*WE%%$'TT(5C_)GUJ9Q"K ^6I#,;5P'O,>X%&9"
M&3N\J":VR8#ELN=9%N\1Z8#;/]G(M'5>[/VLVC]^XF;)U^*:0HJ[SJ6I(4FE
M4FBP#T_KPI;Y9>#?/7U81=4;P-5P%%YC^\CL9+04%EPO(L:\/%#?HBA:^M4<
M3DC_@U-1$$Q2G\G$9WTIF/?"0YC5N3G+ :58_OW=#!QP9NW[9)W$E[#,TWGE
M\.Q=1N2B'G$:=3-VED"1S6(70N!#'3^:&+%:K.S9\KJ I9OAQU7OV7P-28I2
M:-V-W^F5WL2UO+E]G],!75C'>F_:VG(2?\RJGS!\36ETUR)!35UOAQILOV^@
MG0/&<ER19H@4(E+_>JKO14JYO_7_;.+6U)Z)%_[![+,3^2Y#B.2K8[=;9^%F
M4MTG^X+=_,B/?T=F*>X_QBY@^>DNUZ?$P;MWTB/ ''@B0-]P9B^)%_"S9KG!
M_@G_9. +$5S :HZ8CVX0;@RQMZ*=F.L[FJ4,T2'7X44*9Z>!BJ_T8J'YRWW0
M"6-:) !S_?HQT#%@Y?QOO;TW;4C =PKJZWLD(,3D1]E<M27M0FGUG^<G!.&#
M!$@*2IS\_J=.9E]C)& <!_?N,>!7W"?-'SY"5$NRGG'W'%$KMT\ZD8" L7_J
MC/YOFGTPLH/G^Z_V6;H#_D[VQH2XXP(E^!$)R#TMF-,ZI!J5AVK\BU91_2KY
M>.4LUAR)H/X[X4?BGI,'P"H2T+%SSW1%*()>EW TK1N.!/R=-/5I.T? +CKZ
M Q(@L2;_QT&QK#C[_%;YOY/^B[=B(:J=AYL^;H3K$G\G_7?>'C*[X_['8U6[
MCPU5;;);XR*G[/%XTF?H<:OE+>(P<;@PK,^#EWU ]7/1;6%ASYA/H$]Y[V,B
MWT1>3+H"3EU6=>-Z)@@Q^+@,8S)1B+20Q3#S&M6[S?EGV(Z3_V^'[?_D)0:#
M1/"KE> *F2XYHY%1WMV(HMQ+&$Q7/V^^62DU%,7*,)"FB1=YEG6_<5<2FV+Y
MOX7)_YC>__.Q.H_#\55/,OCA$U$/B4F5_J;H+(RRZ .;0Y1*G*T'G.P@ 085
M^Y",MK##DKD#IBI#SY_4OYTEKL^1 + :%2OZHY$$ @EXA'!4:!]2#?K%ID;N
MA$7\,3W-Y#[@ST\^X+[ZDVFPK]P@ 7\4I<WLNQ/7I9FZ1_8:^4B<G2 !<0&7
MY;(P%R2 50*QGVLJ_FLSH4+6$EM7XFP(": J(U8?NZ][L/81>KUE#F?^T3)V
MZ@^A&<E=*]OZ7,-&$+CY8?+E_TSM/+N:F(QR/N98X[Z=;$9 26*)<L0.;GGH
M:-8D;K#9V$4E$F?0-3NS(-6JM]&8,.Q+WYIC&/8 .P0YC[\R![R9_@V*WV$5
M//;) &3\1U'C@IT%$EDD$PP5HTH'7BK1OK8LNZ0J:+.!Z32&(PP<0DFYW$BI
M;)?UT,7DRZ[^[MS2?]5XMFHV_D2;3Z3[QY0]N^$J#9[8F$WR,O"I5&/XJ]D=
MPD[/3/TDXQ8CCO=H"LGWPVTD2$ @N'32);6%;;A":S,N<TX%7:MYNE*V>+O;
MF9#D) ?45@=15G:+\;X6+VYR>+X'LI)VXXH9]M.;-3RNZ1W=P?B>Z(?J^>U9
M#:&-*37<?EGAL#1;V"G_ELU/[O=I1&LNG^BBI<5:[F!A-0:";3DOW_/@/4*T
M:MEHX86V#ZM7[\K=#CJBVBG4+.=9.@F!&Q9N3;5-D?B[7)>W<MW).GB>+>\;
MFU/A?6/MGJIT_#6DA&I-%)I\ 81 ZV6*UIGO,<7\C;B80=&%\9Q2FVZEFRE'
MG_2S46F%\X_=,<04>SY[JG73=M]B>7^#G@FTL(_,]^(PET1PL+)SY$\ZL&\$
M<;".O+5<."PXWSDM2#G7C]AU352A8&G6)R0NUEL/WX[\]*U0GJI\ODK1P13&
M6B_!5Y!5M!=IZ%PY&,US<PFFE(-A<]^I-=7$?$I5#@F9Y/I"D[5#NU#E5[JU
MRY*I^YI<_PN&U#_O[HN&O";6:E$O_?Y^]9G=H+CI^#7AE=W 4]AGI<!7M89F
MKB=')J0V[_C+W ?5@WGB34DTSZF")YLY6^IL@+5@ @VCT+7_\ H@(1VGL@MW
MUS,UUBK'TDC]B*NG@;3YX+&B?:*Z/NR1E&X\!4G95)J0N 8;D2&1&/$SH')I
M!DNX7F'XDM:MAM/?GF4LIOQ< NXQYAXL![KH/SH4&><P .:$G\]^G:LFR_I8
MB]5_-:.;2*;SPZ8'9\]<K),K6U?1B^'1L:[$YZ^_SJ^NBBBK,ZJ>L]2MCQO)
M-L+X-C4=?%D^R^_!;QOE\NQ'?3B=%$W*8DD>Z9'L^,N)#U+/9C4+B1"B=0KN
M^31;WVZ?J"0*1,K%OC-SI=?7^Q@D'"R)G1\)><CV>$A_*-H4F+M?81PYZB#M
MVY(DM*J P=DK?)YGS+YOS:']Z?G=0O/FB[K1O-&<$DTK)&-9FAO/:A!/S-&J
M^2D&LV5=4^PD"Q2:8K=%;YI<AK'I!KCNX5]>!E9\ Z]*GPUVOI+_H 90?^:J
M!>6?TE]2MG,BC;4R+ SWKD )8F8&7*@]00+ZB1QNCP/BJ]J$==^L2OQ&44$"
MC,;."/=_Z.D?9#"FFV/(E +CEN4ZSL:]UYLIIE]GSLUF#!C^5#*_RL-)MYK%
M1WO]LKR<6S].DEGV&<6K(!:>;J4#$,BUIC["SC&QOYS;/7A$16<:*)U4RRI3
M-4(YTZI[Z]I0YKA@&M_XJ>6'X"[(X2AUHE&^,0(HXFB(DJNT!<%6G07ZD(L)
MW?_&VF-)T0R?45443Y%>-Z*W0#SSL )[G[_"T4IE1"'W.S>L+;.'<CG7['*X
MH+:O"%MM+$WY/,GX80]>4Y\<(WO*C<E)2K@#5:8S*,=6]='3KC35\NF/JG(Z
M?]+?.6(-M(:=F]PX+UL"YW26/U,F!RYQ=3Y",C/-FB@7\?IX072J56$%;_OY
M" SR&UKANJD>;(VY_IZ]3I';%R0<'\8TH%/TH2N#TW08]-&U(1> 5\NATZL3
MK1:U!\1.<B,EY>E/XRL7[G! 0@JIHS#E!:"E5LXV27HSNN.+^_W"VUL#SU1*
M?E,"1[&\1AZ1C6?\7(;RD6X@D:&*N5065&PS,&'W:=V (PG%<\04]6B<A'(<
M\/3P=K\"B 28X>9HL^;5]9X\MIDRR%B61;680^X4&\.EHG^']"[Z@3B,$4^M
MO6GV^7.T!],+PC^=B5M@>%$;G'OAN4ZXWH4C<,(>*GBJ<_%%K4F1 !U].9S%
MG8N*-)VK@[5L.9"*'.Q8"$*N\];ZE4*!W4'V]Z39:L)TQDJ<9'5AC/\)LM-N
M)]9'JK:(/UGHQ&H?:_L'J-C"WS:GS-K%-(=H/^4CT5E$IXP+ '_R3"A0PUGA
M+1Y_'9?D_B*J&O$$#K4-Y^??<O_8W7CV>**Z//U$C)#BG+X53X4656&Z#G_N
M2<99',9-G!X52_WTI4@9N1("*TG>&C\W%0]\9CKE2/#DP%47<WU$37.Z5?O3
M&B4-HM+ 2F5D"8[5+(<#,)'VL^%9DWCIZ:-1VSH.:3F2QF<"#JE(?QSL]Z[-
MPGHE27E)N.DO,>YP+U'24PKW+ !RN/A1,/!GV6D[NT3C+%6TGIZ$FD@E6E,#
MIR^I^207O)@^?COF1 6X$NC(1UPFCXOR!935D ;1J'O7K,GO1&ZT4]H(M\56
M.'WW##I6/-YNB'U$2]X\^BCP^I8,<!'),A2:Z;?N$$%%5QOPTJ:!_^HS/H%[
M$BHU-]:I5$6S46_=&@<YW#- 8X9AAG=)B0&D7P4XIW7;+XPM>*:.GJ]A&-8=
MXW_=M8R?NM_)>"?3_#J5=Y$6-53QHG_5)\.M+_:(U8YW,[%+/>U#:YRO^ZNN
M]!^"K/*?>@!N];JO<U_5N^3;D$4G+$G?NJ VUZ>*U?8J_NSG3:5^Q;LP="!(
M7SO-]J;=KB%-X.51K.D<RHDD90CAUMD!'K@DANQ.LRT(TTY5<#T1)2U"T9A8
M+.+1;<*&2JQFBL^T0-ZTU,2D\"U3+)QR*SEZ.U!XGR4=@MB.<EK+C'%7I(-"
M&UP()@:_)=!1_]*=35#?RQ&K:9]AJ[^KP)91R3C$MW%X,U?G@W)P)$EI_N]!
MKDKV6PH[YZJ>>L]IXXA9830@C+IGS^ R#=Q/&SF>?I^UV,NSZ=72M'>4:SQ3
M]F^[FV;+-$T#JF\30\#O'3(\%</\#,@E?H?,U^E[+I?UB# X[QV(W'9'1/Y;
M '.>SVFSBCB^TUJVSCKL2#<YX:SZD7!/2^<$7T3?J@7CU:;O;(NHY:^ EQR\
ME#I&+#TO"3YW^H^C8=SE:IP8)ZVK*#V_\!Q_G^=@]%F7(J8DT1,)L.0+63]!
ME5T7\?E6\ XX3:- )^KH72:> BW:4['S<\!_>\9[(!M$1!OZ&6V;.A %P3<4
MXKI$TMB74GR<"A?/*5$!&E\W]?NJD!G7K+VY4IRI8OTF:D-PUO9\;^^^0GBA
M1U/MU& M/SFJPM:@"3W^Q>JC]H'N2WD7.U8\IK<T!!]]@KB,.;Y["NB$J<,N
M,#.%-J9."%-%@CI>FPO)5<$_1(7DRCM_GC*X$*'^ZECH_SQ65IU,/ZOF<H?0
M85VE57'5S]A-DMY5<E@XGN1S7>L+^I40WB97(XO!;89(':OB6%H:A9+Q*I"E
M27TK0C?435GPNQ6>WD_H>2C,'5V(]L<&(=YDM8!RQ+TNYR.1WI! T)&%D?0V
M/;[$<9+]5.@U:=4QYO/7&>L?!09$3MS]?3X^.3+DZ+H;BL.]L=H3#LWT3OLQ
MN*7QB4XQ*2%(L.IQOMC'"KY&R,",69X5Z,<,,LFNM6S*=EN[ T4%"ZOPXGE%
M,7&]Y.Q4VDG8M0':43&QIV[K[S1E2SV?XG>W',=!M9K0=^%FE7=TLGL[8!)_
MAN;45^)]TZ<I-%.-LSZ?_?BY1?%WG.#1175=%3=;4>_]H>#\]3^UO$.D5<&>
MP.&EG7;?E;;K.!/OO5_'(V7V@\D:LN[D(?_1O,1N)M@=FWE6]QO7?4B %-_@
MS .Q3JXTC W"HBV7@;:8URO__D-BLY6:Z;B#F]7W";D$/[!\I<E(N2PK.6D6
M\+6]O^G!U--B!%_H%_"!.'L0^8NU:59:GPY(_?PYJ<)B"U>@T'IKNTA)[*5]
M(-7G?CJ4!I>,.23@:RT2<*>LUSY/G%G>C5#E^HD]2YUB>0B?R]$$3]TSEBSO
MNO0YY3]$FD_E[+.$M:-9FAO-GW4T.^E/6GF;WC"(C/"H*O^6;;]K"6FF 5KS
M+$L<;[1I4;]TN$\="?G2["-C23\?_CN&:JEQU'N]3'9]'ER?;GOD>H#I91%\
M>+8D3T7G>HPK.-!GJ%[ 62>B?T^X=B2D^;Z-:'=[6.GZQ)](-KEX]9G)TA@5
M9+O9;NDJM[0PPW92WM6%C-?$<R=6O F<WFHIMI2EL6+M[;8UK!Z.MV\5$<]$
M0KKS[,LBS"$,,G\O5-E3#I1Y5O<.IY/[6%VAU[]^O3"I<=)/M:)/=[)GK0U3
M>MJ>[$ /<L[0E+#@\HZ:W)1QVJ.POJ5IO)V [3CU"'7D^/NGIL:X,"WMP2H?
M%%C3D4LW")RW5+AW5<>;8SKR].6QSV:B-9PX\H171"0*EP9^]FLU-!&V+[:K
MYTH[/C'XVY;%RN$&I-,Q<S%&H%AJI.A"9\ C5_UF8*'5*>>R$$Z4Q%\.+F>;
MZ8%TA"6>EGX[7D1S?+$K5I&4UJL;=]43.CH()Z^0L?H<Q!89KNK9YWO-.R]J
M6JIPQA5+T9[%NW&6>^G?86!8=8N:/BE5N$?LL?QJQG5(OY*VH]63(<225:N
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M7[WY:BQR=K%W $'<"8PQ&S]QJ /*ZAB&OW?;U^TC*/BY+E\;,S7C</JTZ Z
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MLW[O,RBW;NGK#]9@.54_<')AQ!_G]/EL9+&WO8^D:&O%.TC++I*(&!12[-T
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M9)06*N5(;C>B_;(4.(%7\7 3X;F^&;A.X;^P,Q6MD_U[5KQI)+IMR+P#C,@
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M%\.8:M(&I0+%NJ,5<]K\_>U=JA?J%HG!"-7:Y?.**$/EBCJ^3Q\37]\!@$N
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MNY,+2W1"C-?*W.KC[6LYASS$N8$U)6EC=C)V '3E#+8QWX?E5$U.$PI./Q"
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MDVQ$S&@L)8B1>C?2SU+L;/-^?'3]R!U'$85Q+'N??B(N'Z9C?@<P)HLF%G2
M-= _9TH^I?L.PVA)QWLJ@;8X;;#8G^,2[B[$CWW"::1-\JWIQ9NRZ]I,9:2=
M;<[LMNJS3-[N7 .Q-?=($SA^G<I9<9K<>+QV9?0R1S%'VUL$.$6@;,8N:L]R
MK_S^=U>JR&#MU9E?SNCF,+-:J:?Z85-RZNYCTYN8W>!E;,W[TZ;F1L88*=(V
MA Q6(1';7=#=KO.3C9J?*_[!9$+!B6U-&[N%HIO8%U7YWEH >KU[K[.Z*-WX
M0]0MJZ(84"3%\/HM"/2E_YN4B7&';8W9NAA"DGJ]V:=DK::,$A[$6;*WIZN
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MW5>1T'!E*\X^[;K2D#Z_WGN$&C\_E,=L60PXCH-.X29W !Q6QYTZ@8F+@SO
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MAAJ*VS.6GPX?F=J1@W:5BA-[BZ*9 EH(%2.N]R;-V^VC=KAU:,F'B-J%B8%
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MG6V7(;1]CG.+W%UV6ZS(EX"K23J$P/%&=]M3*X4U7X-JR?I5PUS,+ED9ASO
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M(5>@]TQ:3PD]X&-RN(AF%3':H(MSF],"[1B_5<T\H]5UC! Z?9,J ]6KT^*
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MO]XP3D:A,732+TV1[T8,Q!9A;*  QP2PL"2K)!W='MW>*?DO#KL)D,^@]A'
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ME7OM-DB<U+_76@3_\#=VIR>$(&$5ZA:K&7XV5%^TRA#*Z,J9C)7)U<[)<PC
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MVRB>KN/"?!"K86%VFW/3#]>4I8W^@Q>$FY.6G'LK>*<!]>.P@\MB5O# 'BE
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M[GS*U@OK2>X:#C1AK4P=UZ[$&=C0?*A90]*$3!79UK8"-GL_S%_P+ZT-VD8
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M$]HRMX?63$@[LP*9:92I1()QC&]QS4*W4^J+<%/];71.]8IW4ZD:#=Z>*K:
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M]:V))87ARC>KN(^,*;8CPS]84@++5.T6QHCOHJ?]BJV\K*P<6)1H"F864:&
M8,%KV$/\U,=\C/9"@L\TG](#D)[RL?V[F807 ?^*I?3$8< ?5RBB5>#?L_W_
ME@"#G86W"H>2@1M,&?E%O06ZMV>E/(K3&D=6^[DE:0!%OC&YP4E-R);@YTMM
M$P8CU#S7)TF\-.BFP]L[N6[8CP\O35.4>0)Q"WQ%,N6F<[,Z<^+=2311&7)B
M_JQ#U0#M$P88QJ'\9M18$[BGU3K-$+?)80)7R77'4%+%^]0YX']+R/!O(\<E
M :)7)8N50_YR9:="_AZ.>\SBT;5'B&;X3O)F=FI!N_,EKUZ1ONPJ=$21Q%/[
M/:N&*0M(WRO=0J#2CLY\M!J=G+^:0=F<-H]D\$\(WP%V?]=,5Y_BNG%EMG_Q
MKA.N\=4E8@KL#\K(H!B+LIZ.P%F54-EH8CY1_"]*D_N7Y0GU,=$.(K49 1*2
M<C-G#*,PY-/XE*A_92S_##TQJHPP^RLO*P3^>IEO1Y1_+>3N1>N['!^3VN^)
M.U$\\KC,8E6>MF7.:>9?CC5?W&2N,;LDY$WI<ZD1Z0+I(H[(%#DFEZOL.C97
M#X ')/X7A&4=H8F)9Y89 NEKTC'#+&;)8K<.VQ3IED/E;@IS<_H/;TZB*N>N
M]W;67=$+:,V1L:Z_B!AE;]76@0DLYM%Y.*T(O:G:;+_(E.CH!3C)[+R4YO[I
M)5D&=^4U]?-9_Y90V;=[*5G,+-)[5/O(%(03PNZKYN?E?9,,PI-HF1.9U(T&
M&0EY#Z(GHPTE_N;:>U05LE3X&Z8X_LTR6\G%#Z]/9L!%3R"Q/$@V7:Q"^X[@
MG2P@JI'TQ#KF)M:QP,C(0X&+WS:_@]?J+4\>3I4CN.6[.46YSG?;C:2-CK"?
M+IH6Y5WB4@XRD:9^Q/E#Y0XM H\F?<V(00BMS5'7GV:1:4%4S[F"E21JG8 D
M24JG;N$E.]<"^<';\ZR'RJU#83X] /-/^Q.-OFS6\L"H^0UK>SSG5N8KI$9*
MMD6L9B7 !K!<4(*G(?,YMZ5+0)QEA\F<Q[A_B3DEYB*Y?SEI$=OHV62/E\%Q
MJ&(;PJC+VG,9,R8Q&.<,@>WH!-B;[M=/+MK61XQN+E3!25R6Q4P^;0/&*R.D
MU5DM$0J0!&O<N-I1N&[EA<RU(!NE^>\ RUV,<%VV)]2ZZMTF)6V-K>D3MKZE
MYD@_=QAMN\\<C99T:!%\<A$WP^*G0G&2^<NW\5*\7*I4TOT56"KJ['XO/.2Z
ME;T9ZUZ91M4+2N,*,.X&=KYK6N(5GV(3\C0N-;IID&IMJ8\,#9G&)Y<)$_)I
M\YKEO=)+IWDSO=)M2#=^R8KUS;VQNDT998/6.'1D-T;*42F.%ZUFH;SB;5L]
M:&O&- 5%G<N):NB+,#+W9@;]380[>Y1_M<N(S:[F,SC2^,>(D?>?<)#GI1S3
MT$$76/!6$64W@HKM\@QE"=\_P$L@-]+ZY'[?X![Z0G'RG;$3"HBQAPQ9O8NS
MVS W*[@)5>J8/KK0KB W$.\B/.0/*QJ#H[S8\U9W6V8;/_HYO1'BB68)2.U\
M9UQ#/ ILNU:26V_E]K0M?# [?;<\AM^1\B%F:$T"H'Y]55:)NB3AR]O34NJ.
M(\&B*L"WTWG[F>OV685;U*E:URX>#IE"6&K6,W[&41$[$=T=>]=#9J7Q6<WF
M]A!!1.5!'B=2\L^7(Y[@T(/RT(/[(MG-/D/MPMA4BT$S'[A,&]2!*3W[H'8R
M?<.H>77GS-JCGTAC??ZK5$6;6M_9QE3&'_S7RMW< _L>DL?1;E6E!KYEF2;
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M9$XX_;%6B^?X.C?6">N&PJM&DO#MNQT(]@GD W^F_(3MX18-^5N$SUBBVG%
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M@5D<!#@OIW\]4W<<%K'N:R]MP(;&Y]-(:0G7TD')05.I9A@AB<?S+ZX!XT?
M7QE2>=*DC)_;S6G:OX$"]%U*!7J7#M.PV]([TN0?'LSA=K5R]!E,2/(B81S:
M.PPOY24=[0Z$ (B SAP0D]1_#H:IR%"<^P8]HY;.P>YKCBWYQ1Y#.?KO-7KT
M)6\U$L58[H'^Y*BJH"6PW)FT6Z)4[(^:JF'<J93#=LI%B@OFMQZ">< !?]VU
M_6U.@0K7)@&:W>H2)CS^NP&&\GU;@0DEA*4]+ *[W%2K=B6XGX<W*4*<A;I6
M*,7//S=\?KM"0?OV'((_].7,*=(_V>CN/KHA'!29_U"QDG3[F4MS*SAG86E.
MJ7A/M5;SF8/;I?.N4JKRR60WK>/..8TM%>VYYYC-N7C6K7K>1/LL4IC^*$>$
MVW(? OZ$!8&N]8Y 2':1;O)(#3J@5_$E7]F2XK%L$XA[LHQ\KMLL.6\I=E=.
MW?-MP6;=[I1CY8A*E^3NK+R?&;->LLU1;F-P_>!S1#7#[L+E%]F%76Z9;NH8
M8(E%K<C9W!L<YQ<AI[B0$E6D[^<&<QJ:)0*^Q-M;%Y^*F=)5IE0D\2^01H/_
M@;HBMA)RK)/(20GMV]7+<H%*1\RU-FGAW0($.8:<W\ .1H.;6<>>Q9#H/0?_
M3N>&2/]\^;@H?ME5-XXN]]"(D RO\ZA(POMJ\X8O$W;YTW3F6C&K#+OQLW#+
MM>NQ+\+I(G^2(B+-IQ[![>2 1/\G-D;WQ".AT7%F^:\,W>?1LBZ(6^R?WO7
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M"B-1ZY)S7FMBT[@S%0IT5NU2PM0KN0'\V;+Z?].L@HS52.ZOB"LA+RU0LH$
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M/?QAW58VO+2=!S4O3K<33 7COT+WC&#1=H,;Z_VHH7WH7^ V(P8^Q/,@4
MT/S+E4"VGXDUV>MI?8TU]NG1>E]Z$U[$B\ 'LM;>K@+IHWF!?O2T*V4LZYW;
MV@E:RR^"C)WKI",%3N9KO+YJ=#@EFD?/.C\M&!!_>R/ZO0(F12X_/GGZ<+AK
MZHK2PRM/!42;D3&3^8D<HBI9LXOW'^]:N@JH. 0?UOL\>2UN/WOW/<9"?(.O
M;Y/D115^^P[&"YV"2A8AX.)'+TIL].OII^&[6QRJ.&?4M5_8T1V[,.8WY/DJ
MX05)VK[1O X*MOG#A"^?65X!BVQ/_9HE_AJ[<^JCSM[5:2<\@QPVC28B8MA*
M@/\*Q/^=8$;;M&FC!L8^GX[0+$_RZ%N4H@2_8$8PL@)U8_U5"5T0!= [<9@B
MC"%>AA 8,KH01_Q>IV.+R&0M^?<'RH:ZE<S@[P92W?M9V%!_6B9_EM7_.FL@
M;'WD"PH7H_^M@]<VA]_3B, ]O%\I8*DW,+(N6^T_,L-"W/8.DYW8KQ1; 9XK
MQ#FLG."WS<<ZJ1P%K<^0$^H"# 17JW.!$@&]T]5Z!KKE<?DZ[WR-_LQDU,)Z
M^5(WGW6-EOKFU#T(/H,K7ELH"""O).'8SZ81@7OYU:ZT\^0KEU%FB^<4_/A?
M[BRJV_1%.T[U+)#]D";KW5X@([G9#K[R?92]@K;,P<?Z)IX$<=57P'[.P[.W
MQ:JHHTTCQH_8BD('[L/"A1Q%USWM)-SRD1NJDAO]BS^949?L6BOXKF(TR/R^
MWM[>@]4YHR\"6!<O)K$62K+N+P'F175/G4K]V(I:^/%YKX#H^<YGS^%70#:E
MD-+;M^^3SXZVNPHC,Z@6T SY9GUR0<+P4U)*?/O5Q?5L$8Q_,ORI7E1U?\JC
M/R2_ E9)1S)59[;8JZ6&J03\=E7BPCW0+/P/:\+NI]N:R=[CY]"\HR96N5P\
MQR[[P/&G3)(C=&'$W2225I>$4A$#C)[2"(C+^%4">\%W/SA>A_PA%;A&,;'6
MEX:NEQY5+JCV@9=NLGGJJK1'=B#3:N?:" _A$D=:]0*CJB5Q@?X;!2@8Y4TF
MEIM@!K.NG^B\)11;ZA*QW@=VRYY]H!PB==NO(BU'9/_PQ7*3&$H;*!T@)/K"
MD6M=^/LWBA:X%_W949B>?+D/,X+EM")[M)1147P%7G=T99\??2"57Q?*_B6,
M*ZG1W@"Q:QBF0>CG[=-!A\D'"3$QQZJ[W/'T]V#>X(ADVJ$=SVC>R#3G<FLV
M!8*$Y#3JQ-]TP[%?,_O0=Y6VIG2:WV09[Q]5@G\GJ+&[VQ>Q-]M]E/.FF#WI
MZ:7#G-UM@!$05WK)#TV#!ZE7422O@'\I:N^\K]'+DGULPZU(0>MC(J?R5UEH
MP9M38@L<&/@CL%#R1:MZ$7KVY]OI6D\9'1HG45M7E1)9*"?NUNN]8-#JT,7R
M+W/8BK"FDA,>,E>.(3=@[T78="F_4C>_/@V"#*[%'V48&(I,Y3/0L7.=Z53E
M-(/8+$?K#RCN2[19R,713#-3D/V*J&6QA&!:@_9W86B*$G2$%P],>9LT1V'B
MOE-@8\SH,=+/TP&7BT7B(__:Q3-3SG+X4GMV>18(S&>N,8< XV0][D^K52R3
M.'_8%1#8' 6>,AAG8K?&R7_(O.CD*/2_*"[7.\U'O#D60X/_1.=64W_-4\*Y
MO0*V'[:?YU[J#9.K!FK805E\SH)U#\D%B?E2JV_NB8JD"G//]"A]$@H%S\"*
M84%.G-0A.WB*)@=DB.%G;"!,%O[>HB&=0*RPISI+=3D-"E3C01 T^L*?_0IP
M4N$XJY2', C95QX5,ROP @3CZQ35A/]R5O\^L]T,)I8H0JZ4CQ&<5#J<+)"'
MF[)GG@"W8*GQ[E1%\ON?4FTP&0-U;=J9=[)+[]I6!G)MA%](E57*B;A"KM*C
MR^SOLTKIX5'C#@7CH8[F%,4 .'%EKX#!A817@+[1/4&K9Y&6>=6GQ;@\EKHP
M@L33,3O +56QY;^QGA]'T7_(!N07HS.NK Z4F?CAZN92!MMYER0%USO/67]E
M-Z%]GX$NCG^BK2J^MH!8IJC'T441CO+>P4.=/UO((O_#K,W^%U-TXVW*19_^
M0[J,Y5;]%MDQO7"[[8LS91%GG(&WHQ.$,/>B%Y6KS+IXL%'#)RP41?2F?V:F
MM O$!T$S2P*?S.8Z=_ =W]#"\KWRKY?/&+Z+U"^6LG_Y,>AL3ODW5N]+@="M
M!*0 F>\;VPC#%B8/7!K9*,8L5>:_]8:*E)(LZX2T6OTCOR4,M\L7!9CW(CO>
M8MP'"U^*.>TPF\ R1N%.3R7CV*=P[I^LJ>)'&<J8/A)*LQO$LH2;'H@N:0ZS
MRMQ4U57[88P9U$0)>ZJ":'7>84XL<,O06F/V:=L+^T$[IFTOLGN#YGBY&X(=
M:%7XX%5(>L&%.6$_=#]]V@X73ZRB0]_$"%>)[D:M,^0FEXQVK,>&>E")_]]S
MYFS;Z_<XIO_(?(Z5J4HIW79\M26,1J"(?$;(]["-\MU1_6=%>%62U?O3(,?=
M\3V@6%3:.;/CO0\[U*P7+XUSQ)?!]%_P*P\VE>*5/'<N4@O.F*-U\</Z\K_R
M/3@ W]P:MB#$B%O5&0O(806XPY1]Y7AP$/B9K/3? W11_M;&U9$O,[XU82'&
M7Q(,VA(="&U\;-EB%OG5*D/831:L-C1L9,OGZX[L;3F[-G4=X%6N\2A\.$A^
MY*R8Q^KIZ:^%C7^^CA\G'P *8W]355_.G/#CU/2G-9I"2>T+ZT\U'F#.V?D0
M/="=_6TW6GCT[8)\#Z9>:%AUS67\NF,$+*IP8'HW$!NJK9"^XXZ\0EP"VTMG
M)TSDD!LSO+_@1SU'!9+',AN*S65-@63_ .X2E[HTCX[SCBSWI\KVX58-LA<X
M0,@!XY#(@A;>_TV6_TJ6-7E68W99QJD!\LZQ ^2%9(SH"V73RK8>N_JK56^N
MVI? _U .1**X[9Z!_F&4PA0%*$-D6F_RIQ%3?HN865(=D1D)Y_./N#]T;]Z2
MT([%KY?F0DA9)_J;QNDM? ,@SEGH-G]#%[\NY /W+J :8XGE/#7)OM.4E"@\
M;<3Y%^YU=0D]>R2IUZK.UY56<CJ\ LQ5P<9\@@?[MC(+SW]QR/[S):5K3WKR
MH-Y^&M?XEU7F8-K27S1,ZGD3HUU0D*=&!;.NC_VMKAR>-ZJL&&><FJ%LH9-C
MC529Z!:]FZJ:MG<> A!?CU7JFDBM(RL)2YN?63QBCU9)LQKDZ3OTF>EAYQ4P
M;M'_79PH4FM=KZ"^<"(WO^X/QP<KB\(B@')13@,+F_.'^2_*R-S90DQ#_9%G
MH]CC M=1M5V,V0'<A$O-J%$%O O%W/CLT.^&=M0$AR\O'=EL+9IYW!4'W#+E
MYYR%W@_"I<EL:'[769."[ML=0H5X;Q][TY/H8UJ"Q4NMOV%R#%DF8;I75;/Z
M[WB59[!$R3C03U74$Q)"YT!NUE8Z5[&^%K<>Q*F)P$*CB92'RW-W7OBT6^=H
MK8"33_-C733S<*W"D.%@OXAR4?,0_CB92<L@7[2VN<8)E)ELT40M76[%@^\2
M/9T<:]XVJQ1[@_?\3$6K%AY6-2LC<3]38NGC?_91B40ETU(3#VYJ.\W%4*Q6
MSS>DEP>DD8K*94&#H&"-'6BR_A6M_GO$VG2P$T(W^0K0Q;I?S#1W&"4N@9ZB
M:PLDOWQ?31&3D0YOKQ?PEUL^^K&]N5$X1F8HZQ1@%' D3%S8._X*6-9*2HEX
M%+3R.*T4J^2ZLY&V2!H;I.A#I.[D./BGS9!)2/_F$L$UA)V@LVU_S*9#A'D7
MNN^W+E8D)@36&  :#&G$/RZ]H+;ZC0.<P)E/X1[4"[[/L&KC#@1M6O<7G$F[
MJTMTB9G#J%B8\-.+&?6Y.VZ%+[Y.DX_G;^90F'!.#3UF*_/^>5;HK/<5$$$B
M ?+=OY5Y!72BO[!#M8L9W)/0O@(R5]E>GH3NIO_'4'6F8NFM"#[9IC8N#Z,0
MA8YUR@'[N[GS0A!E$ _<:3)7D94[TXJW&4QV3I57%/:;8W":\@KP(7TR@_ K
MOP*$6DR?[WPOLE /Z1&&+N2?7@XR;S=? 0-1P'ZAR\<"W_7@5P !8.U_C+7(
MR+3?\KQX0] L7F'! <_2:2># MY_8$K^/YS#_,%ZK:1EKH$@/K'F%9 ;&I/U
MN>F^.B 5L/P_' E @4P$!6,H4'R,F5B84KZ2_8$&9J!-V;Q$VY+16>+2^!M$
MY@/4G-.!BE.8YW*Z$NQL_*^L[NCMP$''$[WAT@/.EO$P\"J5R*Z&L^@A76/P
M$Y]EEA9VV&U<Y\-PR&Y[>R! ORIH:VV"O;69"VN;B6HJ*]. 3S7U3?S^4A2E
M\PJ(M&':;*N%Z'UIT*",^<Q6'&N@;N$?<&;$/4EL*:V;J?BAQ<"_FR)<AQ9E
M%HX'[ ;$AII1U!2R6G@%_,%!?X&-.L\]25U_AG[#,5TQ+]A0Y6+&S[7:KX L
M%:$[3*&>J 9+WRNDMXV"EKA3@*_'B;L9MWWYH? *V)!\!2#]<+;^=K9;1_#%
M<SN"@OH$",MB@"!_(PNPF?Z_G:$8'];C0?GC#X998X/ (W^ILO6_=*MZ$NNK
M=]9&[@F0<TA,P.B$AV,*"!1KZFVWUD<<TE/_=1;OO\R0'.8@2W!H_]$9=;=J
MP/OK?,O0HTGC*T XV?><PC>0:9FC\P%.]!7P _A$IU0_8G/#453&EZZM5M/H
M&7J5_)37;9T$2#.MZK=1Q71\6 LHLG!9M.\NU_E,I83+4%KG:8RR%?=EB@.5
M=6&&I[XU] N939A%@N!O('=%$*C"U!)IY):G7?]STSR_M*5#34CY5B/=V+=(
MX4$7E\T?@\3]AGI@M^)U10U"I8BA.,::[(@DU],^^B8</@\(WV6:NJ^8Y"2#
MM[1>@.),F:T-$_E<YC!&+_%(PH#<)=T^0P:O*4RGUG3CK)>B RSK9,FR6-K8
MF4,@6#@J-E >(_'WX!_Z3IK\W@3"8,!VC%P6&I33)(X,<<8>! %*PUV)!FTW
MFE/"-\E;C#-SFV.!X1MHZZ ,(Y7Y>#-4GJ4Y^A2?DG-C(W.@'1,$N*2IF\35
MUM0&@U&5>("!2ER6\2PE?J*GL#O5W&27RX4<X#N/A8<1L*?G[\+D3X7#L:YK
MNY((<=?C5O_C[V[!D<[(/%X"]E9)"G5;8F,BW=\")G%VYP\[&,]3+2X(1SF0
MO0)BP(I_O(]&B0FXC)WI#NU&Q-^Q0RUZ";;5U\PQ$1QNT:CF /")&-UO*^4D
MI(S4Q5'"6?&(_.G'VX@WL3R&BRTPME:(^K'0KX/G'M7S_0  %"CP?]7(KCJJ
M9PRJUP4QU0;V5&-6:.E.O"\A.A?F.=/%$3\7HQ^ ?(F\2,ME]5=YB/H:^^]A
MK/6EH[^$:MP5Q2@P1W='*F,ER3:@[E1(".89.6AL!*<I,/%^N]0A^\'06!?&
M#4W06R=H$\83$85'!J5@OU\NUC"4G(OM(_=#%)#'AJ+\YU;@<$AG5A\D?2 U
M ZV/?EZSZDJ0=T#0SW?DU0_A0.2@UZ!Z),-,0"<R#XZS,]I#<^M2C)G4.BH(
MH@])I<V5 GX+DE 0>0A0[#<RAQ)%+<-(GBO!#D?-NH8AA@/(_PMJZHB=A=IF
MS3.>S'CS ]9;FFFC03"8$9?.(S\F>*A!)X?PU77V9)8:[V("!(U(68@1K]D!
M#8X<X_%8-2?F0'7Z/Y(3=!;_W>K]E6#P*Z3[>=NO([,PP2<&D@P^,^]S&M/6
M#"MF8](,;KIWU+45Y$TM'2F4=+1%Z7N6<\W?LX@>(OXQ@[8?(C+\YSO@I??<
MY7<2,*WYD,/#;R;XU*&H0SB<9[+3SV;X0JPI_]=V)&W4$/?;E,O9?"%YP_.)
M<:VA2RZ_6?IISVGO\D_1-=&+V9.KULO(+V6(7+0Y_^M?=1]SIM\!3???7%RS
MN;*WM^-X1O(;?]&T6_\N?8I\O'V'9QP;IT;PW)85"?P/'/]D,)T5C?OTZ]HA
MT6GO2MK,2GN,YS"=*6"_,FNC@\Q_AF[]IQLWM=Q^Y7:I4F:-Q\35-N_[1/(>
M\'SR7_ V<I;?QI6GUSK*GKV3NZ\R=\F67O&L%H>: X6[)_^H.;1K]5Z[TP&A
MT;>MJZ<&3Q5V6<=^66F:-;=%'N^1L DJ3YDJNR5XMY1(ON[/8M@(ZPUH/O(-
M^^QW9>V3;7O#.FP*SV:(\C%/8C:K2Y[<8'B9959]RU?OVR]5O%?OW\JVM>EY
MV=%XS24L4WZZ._89GRTQBHPZ72I[9=J%O4>2.;7=N!=\LW45NU:V+?'HVBT&
M[$GOE!QVS_AN\2J#J8K YDRN@U=J5)>]JMIB_EF19[F1TI?IETWWNC(HK0CE
M6L#*S,!W90ON)?1RF8]SRV,OV_B4_+5ZY1*YP/L)8Q%+P31C_3\<N2NVU'=L
M/_E-9<?F:2_BU&]]%V[_]$0O,*#\EDA*]?5E-@(G%<J[S J6.ALU%53U+S6(
MO-7>>72+XB/IY(1F#5OVI0R5N?>/G'7SSK7[I\T>&CUIDZMP7J3@PC3IW0W+
M6?YJK[RX)U-O\:.76SQS%X6$)(M\W/=0[<*2B3T]LG?Y.+ZO6ZB3JQR[,INI
M9]J!'CY_EG\F&R-O'=2<IIV1/&%%T*D&(7;'^5X,\W"D;V(PG_(Q._;I1_XI
M7-:S.7'=_],]63>SWY>.GW2PZRF..5+/N\=GVJ_*2?_4=WQ.J9[6%[0O6CQV
MDO[IDQP+"X]?VUO5Q?#)LT[Z1]_SWT'F5Z:9[9@;FQ>6,UVN[._OL@^G]O#Y
M^WOM37XP7R#JQW37_6<W>+MX/"\N.",97J"B*<ESD[VYY^O9JER,(8:AB!G_
MWP0 4$L#!!0    ( /6!5EBB[KC*)E(  +MI   2    :6UG,3 U,C8Y-S4Y
M7S4N:G!GW+QU7%3=VC>^:9#N!B4$I:2E001$!*13$%")$1!I!AP$Z08!Z>Z2
M;I 6D.[NEJX!AIG?>)_2^YSG.>>YSW/>W^=]A\_Z8\WLM?:Z]KKB^[VNM4%,
M(A8!HL?RBO( "BH H"#_ ,0,( M@8V)B86)@8V%AX>!@W\ CP\?#Q<6C)B$E
M)*.G862@IZ&CN\G"S7:3B9.9CHY=^ [G/5X! 0%&-A&)^WSBW/P"?#\F0<'!
MP<'#Q:/"QZ?BNT5WB^]__$%\ 8BQ43Z@?41#80)0B5'0B%$0[0 C<IT8*+]]
M@#]_4%#1T#$PL;!Q;N B+Z@D E!1T-!0T=$P,-#1D;]Z('\'T(DQ2&[QRF"2
MJIE@,=F1\;V/2,-F?E#:0JX^=,#";_K6"^<&!245-0WK;3;V.W<%!(6$[XN(
MRCZ4DU=XI/A80U-+6T=73]_LQ<M7YA:65O8.CD[.+JYNWA]\?/W\ P(CHSY&
MQ\1^BHM/S\C,RL[)S<LO*Z^HK*JNJ:UK;6OOZ.SZVMTS/#(Z-CXQ.36]M+RR
MNK:^L;FU?7AT?')Z=@Z]N/PA%PJ AO*7SS^4BQ@I%RHZ.AHZU@^Y4%"=?UQ
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MY/WGI?P8IGM7J#',:!-9@).FSDUQX[Q)%V>-\<I=0'=FJI.!%^/(D+JV$Q/
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MT")A0K6+<5OD%TAMX@A*HC'P*^(R[Y TQ#MEOACWX8NJ05HVWL_ZR!$##4
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MPFR16GAN+NSRE522P*EPF\JINEA="<1.,#O)WL[6ZEQ#CE3<:5/:4A?/!_T
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MWTY*M=PQRYK.:JPQG=&,U O39CE2/!4,.B2%/RPHN=RW1@ 9*\79M;8_.R7
M4>+_)]]BWIYR0743 92\1&I)?*-*0_FR*BR8"#)1A@ VE34D0CG;H&RW;$HE
MVBW%L]GU/%U1]^Z*)3H79X.2&&@U+#.WE_NQ#)78IA+[A*_Z)L%XVI@AUN1[
MU6:@>[?OY&B^(>##R6G\B";7W(#Q(?Q9(3M_YS#5\?Z7PJ%5#1M>:Q:-VE J
M&VJN#=)VT4=$Q1"T9\T_>9"=Z(FB6Z5C\;B.'%2!MX'$HZ>DE_';350(H.OZ
M_/JM\8:*6/Q2=.D=U^1H.3+MG*8?P422A]PEY>IV5\MGD$X5$4LLI?V\8&Z
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MG,PA>L2TE]1XD&\@I+B]7W44;]SB*'>^[_;$ZMOII(ZY.5B4\1T#+^"YQBL
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M2&BBX>&M&'L/N[5.N$$S%?X O42(^I"-:?D$IXVY=:F<:'VB.<  ,LD85HD
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MHXA_4C4L=FYG8!.E'WUZ_4FI47CCG5C$UJX>XP$RU&Q]@2P,P"L!9P$=? 2
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M^?KDPPIP:1^)P14:EM?U.DIO&P?CVT%<1F7H*[T7,K,H76;O$\<D-)236\S
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MEQBN*V?)ZIW=&= ]GU6U5.8J<:R7T9T]':;2> 6"4E7?07?&JQH1& RK^YZ
M ^.H_@D\O/$ -?S4)9YM8#M<=M/2:2X/4QLI?IWE2B+F'W_;(@'DV8;N/7D\
M7JAM[E^)(Y""MQT??+>(JRBS_*:-3[0B-:S ;), ]!1JD&FE:C.\';_Z"M=E
M=Z*G^65/ZA>V4(/1\V+OMG=TE0=-G\8I8BFC.H?CE.:^O70/Q^0#VPTWN W
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M[DC,CSM=-$/CSWO8:QBPSA8NWXXB48NQ, (@5?AY-O :$C.B7=E>BR 7SY.
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MU@<#/'PWG[Z/4X(08M'IY$,-6NN<O4_R!';O]9M$ODH*/K(U_0ZP27F6\(W
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ML2Q;MZGWV2E\S*L@X/M.]1H ?Y= Z.V97\@K-TW#_N;K:QNH7:%3:#C7-I\
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M2PE] K3M@)"XR_=::-WP;:5_E4Y7\D%6[3#6>>0=65<S]>A0K;/)Z5ZX3\F
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MF81+3!=!^]AE\ (=M_@"S^Z/I?UI9?_>PH+^T,K^NK"_K6L2(,/#P0H/CPH
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M]M*,N=^Z^I46Z'[\##@L 9$A.U5V?<P5HUV&<W.:[D=9"HC!T[)G Z4*LB(
M_NS&_Y4=QEE.9SU,Q@#EXG,7C*B=W(L3;F3LKX2P! @9[DGT(>\-^ DA1S$
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M.)^QTK_8X#]?'RVZ939R(#=2]TKHU+UI3A)GFL6%$L:E6/EM2U%J]#M:U":
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M<> Y7VGAZ'"9G7XX'J958F('HCB()4^G;'Y,AQ $[ZG>TNSNGJE6.%G+V-B
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M-I>?P]S9O+B:=DR'7,K[+2Y=D%R=/MP49&YMXJS:)4A*9J->(-IYW"_@KU8
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M5S:.O]Q^4C7DA#);]&X0>"W0R7)4[_"6\.1^]WLX"B0 '(G@>$7JC;S3&92
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MC"@HJXQD7GXM^Y">3/%!"GQ9(.#%R-S-U'L"J>]AH(UDB7]9VN_=^QM W,<
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M)'N2ZL#W[]9SGT"U+!(#QM0@G3%'%O,]:Q<X35%>GH6-Q%XA.8J>:1210XP
M)/EA -_DPB^MY(UK%!>\@[A 21HV%>A,Y:M0VRGZR4ZN!L)W<YJ.9(\:P:MD
M+5QL6,5BXY2,IVJ/S"5<XH9F^"+?^)A<\'P*+Q/#PQ>4"(WM.*0[J1-H]%?
M/VOAGRF= $*_MHS)UK(+8Y:0[Z0>J["38*YSH$"G*]0FV]PPVKRSGC9&?:*M
M]G=^K;,X']1IM4DOYR)B;@]1I 9>1>=\2;%:<9D)'DNA*);#0GH%QIV"";(L
MIDBK?HNR?=PUI^S9B^C:F CNQ[='B$A>Q_%I0Y^+KS\1_I#< 8U-DBWB!/I@
MFXMNV%E'J==RYXI2"78VJZ=7G"-B*")X:--E0@.Y>H+SCBGI50DK6Z#.[N1C
MO2KR<-,%6&:@I=:^,J3*\*R';.<@.RH=28]6@%MH#2XP0TN=5MZ3$E'JPPA^
M545YG)I9$6>BUV@#W*-3R0&F] US)2H,[PH!XP(D409/^#[(SC@D^SE!N#/@
MR )H@ERTXK0AG/=A6T'&T\2]-<SBS&X*&[/'K3&A=>RP(Z^"@N;KOB>(O2:H
MENYYR6]:M*L:[!9']@\*Z;&L>D\A4RADV-6:=;8,+^=,PTOS?LG-)@2/Q?'F
M:E4G'-JX<<B3NLCO;.!;T&(S6%C)@\U!XY60G#Y1'\?L0P9BP,4H<U=SO>]W
M8I&?)PLYI9X_U?&+Q(:.F%IPPNRQH@QM3 04BA'+9/R,Y0J?$W(<:17(.2KU
M!8(: :C:8X" ES#FH496]*Z+AK;UO%0UQCK&#1W8<L!]LZ6,R/.<>J4P#%D8
M!+,>A=<L*\ZZ.)V]:RA6E0^2-_25P8Q1S'%KPN$"-4V;C:.9<3@GD>*Z5'9*
MU V']X]:RP;>NE#I%-VY:ZC<:UIR$>6=_F&J7S-&L-2D);&---!7R5V==!92
MZ6-S&GPCX.;.#XX9,YC1TI!<.D*V[L (%(7E*>:R3>OT]0F78,@U$0I7(2Y+
MK[T]R37\D5))Z2^&NDK$YK8G"3L*IV&B5TKFKBX3H5P%39@]HR;ON6#P7/U.
M=^>\W9'-&Y^LD,KD/TGOL7<I@V^>3F0\NOP"^:FR[$MX $LY>G%\IR?I%IA6
MXZ)OTU1'*VP@Q:H[5TGHH#TZ%+MUB-APN0/,GV.CLX(CQ?'MKU$6Y&:/Z^'N
MW0==:YT^>6"JZKGPBU#UJ@FSS*$@'TVOUUE?'?6?6N9!</ WJPES%A*3JM$+
M2WM;!QMO9+;-\'763?4;M\]CFE.DB9D=- ,JGHC3VQMWZ40B;$]\#-&L]LW?
MPX>VY_'BBYE^%;-0._M1C<:<<CB*8X/?45&2KAV?.I@":1NF2&D3E^+*?71$
MFD9EI\"D:NPDU<YXPU-WS-O]A7_4-Q]:D/72\GQS?);99@[&;'_A5O5DCR_5
M^4ZI;L^7%R7X4]ZLI76,H[WWT%JU7^+#"JBU<F2-3DY%9,%M/[(AR+M[Q?08
MP*%^)Z55%%N)<@^&ZV1<UP]SOQXI*]O&LJX+E$PF)I,@LUD+FA%"^O-))JO4
M8\"=Y/ZE/DN.<D=ICZ=W<P1OKL- #H-:^CBF?X?H-%EV;Q_26PN#E_C23A>@
M#G*XE8)OK)\$!(IZM8'(C).9665!:"MJFA7G0WEYDU2UH08VUO0;RZ<:?!8H
M5L5N+LS*%F&AO:INKMSA2M_5^K^U4B"5:-G#_J%')S%DG)9M6)%/'PSQXM5'
MF<>KQLN,8B:Z'7V(KQ2O6#N=%"5 --+B/!S6N;ZY][8,9NX'.\7\=!7H*PZL
M+V9ZM&*PN;AV/W]DE>0Y@3J)_!\TEO#K7?;ZU/OJ:1!]'1SR[%:KXO/GW9I-
M[H/VH 7O@$H.N9CEF,>V87X5Q"^*[?=1R@$D]E[6:WH6Y[H'B(%Y?#O!Q$9E
M0V)R>^5]46+#]!_"OEN1F@D\9B@<3OVCJ_@0/9Q6XITI5+W#;W"BG*>@7?(F
M7+WMUOAD5G+E=PQ]8;;_4$I,,4K:G]_=*JR['(-,H;\=6Z_!P5I%8Q,G(]V]
M9*F7$J2L7I8@9VYL.&@49R^4>VLAU1*0_H+MHX6<J5I!CI>CP06]?S :GIYT
MAV*XMIF+K2%O*Y\]-N8B-M(XRG&N7WI O=&<5^Z, ,M#!X%>P0R5MWV+*TVB
MP[O:US_:Q7^W)$T1',/WVD$*R<SRD*PV+M**^_Q/_GV7!M[+O3VLLC!.A%+#
MZV/ \^3 L9N%,\R\#X?A!?-3$>RS/LK9947O&Z,K)Z:-VM.[_#-:M'[*J#MN
MXOKR$N1W74(_[H<<0=)YZ]-,,M);E*Z,61?$WL7JYG.YG6..RNFWD,'5)3_)
MTZUX7:Z1=T^KRZ_!&8+ -%KRL_AO-4B)A$:7'1S,@#)([Y7S!Y ]/3&7?[0I
M;9X62YVL^Y'"O9J)Y: M4;4N[VDV;WQ#QN94OW:['[5MTGOGW!/E<3^(/P0F
MH<-0?3O3\2SXS?C*:);BL\8/P9ZOU>Y=!7UES=G/Y]!?J#J0OJLC.F(8V[,A
M6L]!$NDX!BA\?S@0LG/UB_$;8^E[77-*[[_I?H-UN48(=L\I,'4CYGD;1)]-
M=&"1<6Y5#W\T(=:/ >@<#UQ(;3;T9]Y;B"/]\UZ0M=QLPUW.7^DL/G\W96X=
MOZ0HF_1<I-\#@G*W?,?VV=1$@569N&<+@:1+7;$R6LJ B, (YKMU'<G?SGPV
M"\85K0,KFGJ%8&5E0^-/\ "82:"DI!26R%L4-P8>8R+6Q$B<KBS8".X-_AZ_
MR7/&A:FVK2O S.X036HJ]7IE>F&OJ+L&*!4$9$VT;W[RF()N]VWF.-(9E3C]
M]+,=-?,\P4]3R5E/?:ZK38#)Y]S1GO"9WS$(W&H\M)-M^A.QMWIQ+W!%_D!"
ML1N=>JB@;:[V><$V?D6T<;2LQ'6%1#8I=W$P835^=D.OR+<E[H,J,!ZN:GZ^
MX] K?F?C"MQZ4A/TOIY([,P6S>3$Y^\N/Y41J>D+=6M@@.**-S^5UA.2.\:,
MA\5DG"_6+BNDD.^$N_XFM,$C&+K4)\Z]/ AF.33IC?&^\CK3J,CVR]>LF-],
M0D TR54(J6M07,^->&T>.66@5*9J];B5>',V0$DC4?-PH*4%_P>R6L8"%X>!
M]V47,)=UV."++KWGZ2\?\=S<$=2W&=G=D)X7W(_-:ZTR%R=FZ__$G>V"2X@M
MAM0^<DB9W\WGT1^A/(8C\VD!8=S;CL.S$X@B4F0&&Q])CSY](I2]4KU=7.GS
MQZJU1^.NY5.S<ADC"9("NM=NM(@? [B):?PP"7Z&&69'5'"ILF25'%;S4/8)
M]-Y+E0[VETI%Z(KL8P!74)3ED*HX).R* U(5'DA==RB;W6P5 0AWBGSHSN>F
M@1G38[\N)AC\=G:EWMLSX*T)8HN=P/7=?MK6>_&D!P[,;;,ABD+A +QDE62U
MJF[C--7FUO^J2Z3N$O81&)B/RT5\W(IXKB-,B9\TK*U-7C>_GI*IU'5B>166
M.'2D7=%:S!2\3).WJB#"XO"V::]>9+6JY]\\RU(OW#;575Q/LVF9+(>-,J$J
MFRN1?"(\2V'3$J_6,(V_=43&/*U5%(&#>0;[^Y>9##I!ATJW,;:7E+"^:G-?
MA@\?Y 4+MW.%_S*%"O7#9/Z,OZ]C[SGS@J?6(+AKT_7=+.\@'K%S/OOS^@R8
M00\8DHIWO)C1+W):.K6E(SB?FWY+8GK:T:<V2_3D7BY^$J+:&ZBD=#-#XY0A
M$'9OMR*"\[%!'9$97.BR2@XO1)>[DE)A[!M0A6P1><J<@K:%F8V6S/SX@^'O
M]'4M$?\W;;)%3V62P/.]6YH\9%X"2]B:,IC $,J;/P:PK_(Q'^WBC]2H4RX.
M72<H#/(<!73CH240]C;H)Z*HN7HD -8'LJTFPJJ]-&6""2S[J9U< Q(C64B&
MY^785JNL5DB1J.!BD6F9,<D[\,:%*_XD+<2[ETZP<#G&27JS? RZ&#+IO2\4
M.#@# -6]U,TC\[ F\H2D6 ZBH#IGOD&LH?M<$1R.!YGSX:C)52?I<7; +N0:
M4-?T'Y+ _Q1LAP/6S)WNU-&^YSMN('B+""3P*=QO^4Q.V?Q\>XBH&:;+M3L\
MFI_@'AJX+2NR^,7N!E#,WN5_*<<3?8J-][06+RS.+49"V.G%@@S-^_)V+!;Q
M>;V@.F\WN-/5[V])Q[\UE3H%^'92[G_^Y\;_ZP >3_P54$L#!!0    ( /6!
M5EBWA^"R63$  #]$   2    :6UG,3 U,C8Y-S4Y7S<N:G!G[7L'5%/=MNZF
M5XETI 4%!$7DI]<0% $1D:*"=!40$ &1W@R"%.F@H(+T7D+O5:DBO6/H!.DE
MH08(R8O_/>=>]9Q[SW_*>V>\\5Y@,D:R]UQ9<ZXYO_G-M1?X<?PL</J&JKHJ
M0$0, $2$'P _ 2@#E.3D%.1DE!04%%14E-2T3*=H:6AHSS P@IBXV,'<7.R<
MG#Q\EP5XSEWBY>04E+YPZ3=1"0D)L( L1$9,X;*XA-CW08BHJ*AH:6C93IUB
M$SO+>5;L[W[A/P+TE$0CQ*(D1.< 8GHB$GHB?"L )LR3C.CW%_"G%Q$Q"2D9
M.04E%34-X8:*TP Q$0D),2D)&1DI*>&J#^$Z0$I/QG!6] HYH\X#BG..3&(O
MHE,I>:^6?&+6'4#QB3]\YD=%S<+*=H:=_[R X(6+$I)2TC*R<LK75%35KJO?
MN'WGKI[^/0-#<PO+1U;6-H^=G%U<W=P]//U?!@0&!;\*B7G])C;N[;OW\6GI
M&9E9V3FY>:5EY1655=4UM<TMK6WM'9\[OPP.#8^,CHU_1<S-(Q>^+2XMKZRB
MMW=V]_8/,(='W^TB DB(_OSZJW;1$^PB)B4E(:7X;A<1L=OW&^A)R<Z*DC-<
MT:%XX,AX3NP%)=/5Z-223U2\XKHHYH?/!JA9^"3F^-'?3?O=LC]FF-\_9-E_
M&O9?=B$ 6A(BPN*1T -0X.!(,,V7^E\J>6\1A8E9'C"'IHJ*'2JJI>[<.B['
MUWV&0)6*9"*#.*]8'E%UB0S@N9A2.ORD@NWFJ'3<@0Y)>3T#A;:/V"G (*V,
M!\T=Y.+$7]%8EMVE</]M^&6=]XYC/-RB^G9%PD4/Q1#&R@KW-T08 \_L?DZA
MRDD+ 03_S2+TJ<E&)LD%U:U3N,*M/J*6JV@J-&W;@@>L10XI,?*XQ@R<8S_9
M3*"IY&L3%'E1RN.PK@(;J9C6+H%I=[\HJ@.S6AC(<%Z!=_Y"/00%NB>U_U:\
MT\<'4O2> EO<+;13LB[DA"1_X36+!QA4D U4KFW.< <8&_CRHDE&]'++'G"0
MUP2"+4S5F^"P>.!(6)!$:,Y;[MHT_1@'COXX=N3LX!8?;N29=Q;9C76=(1EH
M;P/%O@L>B'$A_'EP ;IK[&(V-X9-2#PX\3+% ^M[RK-:(?70-'>ZQ8D[HP67
MLNVNJM$;&U\4U0TF^@21@<8"7HG,;S/=7U\;,[TVZ&(KM!1,<F[B5BDS1=93
M=_B-?_]JT+2:TO77Z_._B>]Y7VTK($+$4&LG<.8XPVHSHJ).!;@](E$G;*M1
M/>1"R>*E\?(KGUV2VO SQ8K(;'=02[Q^X)8"U.J^^9 (S9FYG<0J>P#\[D,$
ML&R;D>8KZCQ#M5RK%IB!VHM-C;P9;:$:U/WHL_?FX:L^6<C:6SP0<!9UC/,-
MQP,OG&!HE^4[VA32<Y%$[DZ?AHPU4\<YK*JU2U^+-\[*@MT_N!3&A @":?]?
M_D\*<5+!6&CZ=&52:M$UNOL4J:]M)H[FZQE&\< M=JE8MW1W_]O)'=N3[:^-
MU)^M6[QUV]+IQZ8"4X?4^\GLB,?2..I18>>89IR1_CW7#PR._6!=,2C[=L-M
M0U1$)FH:3&>-\,(#S2K?U)@KPES#WIXVIO5N*VFGY*NT)OGJ E&7"!?36 NV
MY[_W49BK7%5?%AG &;\DC.-=85QE<=4R+S#J]/C-3Z"FV#VJ9EE:FBL_IU@=
M.01/K_4YH&&@,CKN!3JQ.\95D3#D4G/R/I<_'KCB":Q;_[>94.)0;S;7(X5>
MWZJ8DD,L*CB$& 7HF8I_/N\KE9/';EJ5:>NH?CDV!S'=P6'G6O5&YO:RH_[R
M'_-DJ601PXHG**ZJ2I _>H"%_T$3W82R7:_K4NZ&H525WD'EBJ.-PNV/>,#U
M^@>Q*GO*V7[281T5@$E'V]34:&7?R=2D.VJB.6 ANI<X9U43T%)Q1*BU-H'6
MY!(KPAX>36WN[*O;;W +;L+6$KA/N4H .L8F>*!-Y-3*44!;?L5ZB6'G-^/I
M*X^W'$B.)'SO/ZRHV&);GN8JK:BI2_QV_(!XE,.ZNU2K_;D*9Y(@B6?(4KT\
M4I.W=7!R I$0ZM5UGW;_;=0[2R5/!OC$=,DW3-E<</9SA^DOL@K9P[H]B!$C
MF<6;YD6>P*9UP2E8NZ%TD+#=^;IX]234_"C-O=_'O6N:SK6B((T4%F@#.9)%
M5P=N3W#[9$Z>OY!.D7K1RZN?XHH*DS;1'Y&;]*I\8J3:"_<K9:'AB@3LBD!O
M8;TQ6KB68MBRB$FXXS0$#T0F4^&!<5?0"=DR2<E_MR:%C/.!"?>GF6.^%=C%
MSQ4)7WG3G!F\$^72[NEH,N4XP]BT<-/A"%N!!P8ZE;CNPL,S0TH1AI_L"YXU
M"S83^Z!O#WQ?GK\MSY+$4-R)2+,RFD-:6^ 9K6/A?.N#6YO5MWNG@QJ<W%@0
M#0>1=EB!3%N&%81I0D:^&23MDN74!(DU"74K[8)S9Y%6T=G^6;14)A+,C$EN
MJ9*Z9(A9:9\^-#+/N %86BZ<5D<V ,Z*Y-7#3Q1NSXO0FJPZK;HB8*^%*]H^
M35U\Q103-H4.T7HEEV;3D[V%+D]BGVEZ6<YX.-[Q+7+-2!&$JD_B]MM?/%HW
M73UZ,V/=4$-385#BFR=_,8+,F=%P8A+9YW?!=7?Z1<EA/T4,!FH:LM4FI2W2
M=J'"KZVIW^@6_2MW!?N-B*8 9QB;A0O&PY&-CV],"JV^&7[13Z@\HKGW#&FT
MH5*$G%@[$3A<&ZWZ O0**^V5WG,VV/@\R]TSHL6R>N"K1"ET^O.M-@ZSH;)S
M2J5?5UDB[96.,ZY3@%^<J\OOY(8H>ISV7F,4BWPJ] (/O-1O9]\],DD.$=EM
MR;09RFPY"3?KKG<^3BAK#MM6*NPY.X('YGC>?ZNNL#L#;^Z@5%Y\Y=0I/&0O
MW@8XPNC@/ FS\-HO>6LNMD]W-L],=O?5*9;W <H9 BU]IS#I!M;(Y%O%[H.;
M5A\C(*U@>U^08;@"!Q("UFQ +0;DKKQ*G:Q/NKF3_G[#_)G&Q1<M+C+GW\]K
M!;%/32J"AW8U-F2=P[F9:6QA''(]@DBOG-FC%X1D-4!]*VB40 <LA2Z6>9EP
MK=,E6L00QYBH&@D+T:5PA\XP-0K6E0Z5BZ(.FD<=)U>EI1:GA-\N:EQ/\.?+
M+EZ(3E*'"U]LF:=5_>8",5*.$7^R E16N5RXK'C5"<M;76C5@J/ !,WEG-<X
M9=X"EVP-- I]#\_PR'KH%&>/&R8:;TE=-F49*I^Z?3M.\JUJ,4O:OA7/Q?M6
M$1^0:X@2+.^IL5?>-AY(#V'N+\T:5RP?<(96JB-/57]I*19(V<UKO(0R"_-6
M=TF[Y0(Y,]K,LSTQ>76#MHKSVQ>Z%$=?3R<34. ZUL$A1Q3-DID^:>!A<<GU
MJ9R,=QAGDFA8/\7=/YK4W\78[7><AOT)I]=M?TIL):YP)ATELK\F/Z<J 0%^
M2=W_5O%7T2LM+A]*M7X"3_>3<HV.D_QXJ8/O1#U?XF_/_?IU+IO''&^_<ELS
MNO)--Y8[F!GV[IPL[YRL,/9:;YD92A?!K3QPNX1?"MDL.NL<^(RW!QZ D&G<
MS-@D8 3)C_T ;Y([/"7&(]$\1/+R9@>1TAF^,6)%H8F+*CD]*8^+,9X&I#;Y
MM8*1KWV_.56?A:S=G@_M!+> 3Y=?"SSFI8V\J@3-LHVLTV)=;B2J0C,A$@/:
MPBLR=#52.21_8P/,WL@>AA+U>EI5 )ZKQ9:T&:=5KW"M1?[H:*.AR1D3]^?R
M< 9YA_(>!G5B$Q9Z7R6%C:740II6K?G1D?J+DN/E%A4X1!!YYX)(G2URB]8<
M#G@&_&]?GC\BVB-@"VH?3;."R-.*7??Z\G4M[KB&6H*@TY'0Z5+<P)8: K)J
M[[@3GP1KX(8U6)ZD3T>6>PT\79+;D#R88-PZ(3,N:* Z&"_! PY'U,/Y:I;2
M[BF$6G%),*UZ S8?]!(KFM^9N5KKW^+&GB]&:5),^7D!= -8V>.Z.J8^5"A)
M\_6:7N6R1=Q5*D1Z[GRXM$[YR.Z$S]5V'6%X,]6Y*&+I"UL]'FIA.!%W$7V4
M:4FVP:K]@;14$><-NTG+X%F+D(W&,[!.,=36B7L'-H<D_SO_:C@);\S.GKPW
MU<Y751V>%@URX26O!F'T$*VC]-:L29?B8;2J=WQ>KW\Y[S[LQVOC] 4=\;[-
M$\($C".OI]\;N)KFFY>>0EP#XL8#'7TO"<V*/ 7.;V]\C LY@SE$)9\$W<<#
M_::^\NP_M:0%4,8U)^NX* U:ZT6UBVY+$>)*'&_T$PE<[6,3'DBVA7W& ^%@
M5+$('EA"S&Q#D;<^>O(S+\%^^$0->XD&#QSN5V$C,0/W(0S56Z]FML]+GSPW
MQ /+"P5]F'NL>&!GP^$0C"[H@;668?PUI%CIU3@?W?LVZ;LD.!=T>U6PF+M(
MQ6.&,-#6G\;! S3$> #G \<#O#B)>Z!K:?5;.!8R/( ]-L*I8:T)#<4+&!Y0
M)/#3:#S ?HDB3<?4[6>E]'FR0QZ?^.]35/'=E;O(87!S/ZK[([FS'H]72'S4
M/Q5^3C@AGSCMY/VUE$*S]JTRK2K%4O W]77S8->LK]V'WP%@[_W2P-*HFT*1
MM<U_O1]XNA^4[FYRL!(!6\G>9:XRWO('/P];PL4G+PBEP5DZX%>FXPGK\CY'
M7PC) :->\;R[%5PQ=:YWZ7,8JUN5?O3Q13\8D<E=QR;F1^55&"MXPT:ZB?+"
MQO8P<O$2<:77_5D<$]%B)S*<W'KT>B-HJI.#-A\>=3:HB,JT9R[_W9:"9+:Q
M<K94 F>4D'#"Y2%*W H;6YN'WNM<[\>1U\NO#4K4:%]-Y=;3_N;8_G3*T;0B
M53VW*]5 L8S)\;'F:>D+](=WCU\HL?^9[S!WN!_@%+T%")WR.'27M;"]>NNG
MV-LE&A]080)T_B3Z8#0%[DIE\MXX(2S.UU$C<3QXX+/4$*X.?$+:3Y&DH\)\
M]2^V3.X>MZRIWVAR][$F03AO'9(30FJ,&7>U8,1.'G<EKFFO#1:5+\G[3^W*
M$.91.24VAJM-_F82X&C&P&'_U@H/F$1N9PI'>)NA+)Z:VFGP.:DXT&X&/$Q0
M-()Y49"7>2-6$#NW_%O8H1,%2<O)\O:=E7:'QZ/7T6=M3#<)(2G.VI/>DR^^
M:LCQZ5Q+AA9GYG4U:;X Q>H.R=>+Q_T7)"K=(&8?[>JN1N&!(7-L@ MSI[>"
MW33X^ULG/) "=ZDH<(5,2J/,EPF.%G]:)(ON",-*>]@4N%]%FD2J#UN$7;.L
M>U%?S\GH'T8?(3>6K@]!7I#(!YTR>^R9%,F=?:K<"P'F-WEG02>^UP-X)(7/
M.K!I/J UA+;=B4=(T+#Y;A%Y@>IMQYSEY7N@RF7EPPZ:&PNB9/$+86>,ZO1[
M#J;Y,$[/TO9G/B'VW]<%U PM;@?ZU$R8EJ'&.HY4"Z,P-K"*A\/"J9--"%^/
M,D&(&UW&(U\(=XA@"G&(T)<]*,=J_-O64\2GSFD)M61KV\I:L>&!F[%WXFAP
MS;M]3LDW@+T;R'I"/PA69,0#Q>O@(YHQ\S^Q@K_>O0E%8@B?\DQH':W#=AD)
MRX0'3L,6.&R^KQ/.SYJDCW!3ZE\DZ<63N;V,3+-ZQ7*B#3DWK+\P;"T$#YS5
M>UQ)P#>>+K.C^:;/=^.C_]N"]D?D*1Y@A"XP_T?$%,Y7PUXE;U.7X8'"CL,[
M7>8)9[!4W.:&E:[L=FUIZB[PS/(/B^=?3#C,RQ3DK3BS.0L^P8UY>9&8+1P^
M->9E&TJ"O]CQ$9)P=T[O$9+W;DUNWB^QWLHM+..X2K1]\+%S,5FESW!Q+64D
M/033Z>8XKV'[/O;6YU$!L(I.&/72\H.[*E 7HR4\0)8$1R%Q*E]A:[.$5!/Z
MW5UTT 63M[A&$,ZO8ERO9/S@:=.GR!1"6O;Z%IK/<T?GK#62C)1/7?@RK4EW
MFB0<PQ/;5TWZ7')H3!)Y8G_<TD@^XF(B)2*V25D&[JJ^P'>JU:W=":--$?O8
M5&9,,I)<VG\>XY7#CXV;'SI%?[I=J7VN@VU5%CE:Y7R*IE776QV%!_;#\P_9
MR:-XDK!+C%]6OO@]WQ<_8N])^)0D58;JPJ3C6"2'3/FK$-U/.C[SVF_4](I.
M9 D-8[GR3=8:08,N&LO>"?D)+C'7VF7W2(HA,'9@DE S22C:/>V+"MQU#VX-
MB/"6-59KAXHOD.D^MU?CB8Z.WX8X74?W1N:ZB]RRJ8>POG8U'XJ9%J ,.WV"
MW6/;W3+=T^ET(.WCZ**U1W,-E GR@W)V4ZCU*UD-(T+WU9KB>U<&E"<-H@H*
M1!-K*,+&B.9%3DVNL%<%V)]'L\!S<D=3S<YOJUB0YN\T1\#:&Z[^WPE^<[CS
ML,\7^PC3^&;2]E,LY\9U2(EC&!3:R[.'&(2E;]08L#6LR=Q7HZGP"].S<S!:
M1=Q><66IVG=SX$^050W43MFTF_03XG._,VPRW 17S0I@7SV"A[T6/:9E^%R8
MSA&"/+._6+R6D]PJIV&\*AUU;UIX:EU7M6U1-[2N473#N$%*+H]F;@=B-->!
M#2TE&/J)P%;TOCN*$_:Y3N3$&WQ"9EL,-R_9G(/Y@Y720BXD$AF8\@]H!7O+
M>V70U-@ICH#CK((MWUA8[:Q@1N%,1,A3* #B6^)PYG%6_U,>H6T0AFY=7W,.
M'.BFR#)V;MBLS3,KE<FQ_"%B%OLAC&XIT^4(5UA+Y^^15U$^)F3'O4/+>QG7
M7%I_ 2F#U7KC(Z ]9+6M-\=;%TE\_=VL6#&RR-Q?B0ORG]SWY\V(M9)"^8XF
M],X<])B.8$A* ^ J\<-. 7,']@H>B+++/G&%'E$5-E?C@6#H]JGR[[!! #\)
MHJ4W.BK:?K_CZ0\2^QQU-*A;- TV!/83?P@!HUN$P2R+3AS-%B[V7&_^5>WO
MD1_Q2]_1&-K:=TAF0%@-<VR>94E/&(XT4A1^<DX+U! 5@B.N\DV>OM[-^V""
MWP,<>U]?)5UMKJV$854\KF$2YG*N)ESMR<8"SB5>00[*JO5>>"^,_JN&9&,
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MF&[+$5?WL6"U46/^DH+.)[HVB%45NH&)MOKV[+IGHMBULB)0[9BW?"K6$:V
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M-4%4=I!^5D 6*#,-%@"X]^TG)>,!Z'[3P2&L/7(# L7!-F!;A!0)]X)BS^'
M!%7N!()J[O>IB\SA@2.BE28,=?+<K5GWCG]45^4C^J?;P0A/&!8/(/# S#<\
MP+X/PZA@H7A "2*-!XAN8P7QP$NS%CRP2S($0S%#FT-?('_1@);OXH%#/$#
MP:8NG.0Z'D"%8F X7T\'''$V1H?@R:8@0FVGR,(#LQ=A :PD[3]K2,!L5O#
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MKV(,$1Y;4]WK/<2PU3=V)I>_HBJQ2H-45VKPO3/I!D1MT%<A!#<OPHV9N=.
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MU8S38;XO(CYX:9.F9_Z[:=W_A0+&?_U?4$L#!!0    ( /6!5EA84<N\(]T
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M<OS^YNT]H ,2)6[\8[&M$.T/M;A_> _D+WHB[FOG$04S+ID=2WQCEL];^ W
M=;ZOHO'D5UR0?<1L0%8L3U9O4ZK66X++X?> \GA.V7A::))A)'Z1DZ6*DNT/
M[%]2E%Y5.RWX=T_GX4B2 5TM<U7D[7T6"+U*$AR_/%$E*>6]\49,^6,G[X$
M5D?R <G 8UF5: O])T_5>6[Z">LH-K!&T,+@.A?*\'18^'B7='953EB6Q"A+
M+^B7*#B3K\VCEA['Q\OK0D<=>K%6/-14VK>:BF=&/:O1G^\R04?;%^X$L?H
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MQJ*@DS1LM_];U5=2*KKRQ(OWH*?OH\4$[;\$W51BS+)<>J6IL6!/9F\'ECC
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MM6L'7H[*!FJX!@.=DP"AB 9P9/K?V;7!Y8:"[Q)6K:GA S(3I;3E<5L0*TC
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M9C?G'@C4B1%QS=F=N()Z#RC[2?UV6ZR^Z0:3B+86C(.U8#ZZCVMA!N(D&)D
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M=;-$H*JR1.'QO/G1GX507(G< 4O<.";>GTOZAE$WGH17&5N/*S5V:2G\W"M
M, O=SULU_ '^M(Z,<?:B?_9A^$4CZ$O,I4?0!NUG"Z]?V^3IWL?!]W(=+"?M
M274-([97(33?1UJMD0A&GWMY:4<W1OEQ>#"*U[6IYI=?)3>]D-3ID%S:9F^]
M-)'U=@LLT05YX6:4%@:P5FQ@%:'$M#L?IP F_TR@B3Q0$4(JS4CPN_=5;WY1
M5W9+;[$7T7-T(([A/D19%F#J$8NM5/!SF%D6Y.I8\RXO>HV1DDO(_%23UYM8
M&4L)980-L;&%_P5&,A[.ZRB'(7D_P3'UR%WV#^67*%H-+>% ;%>DF^"?=S/Z
MRNA#D[N&<#RU191DGBE2 9<H36F:Q;I8$_FR.!HX3\A5 8%F30U^0D<H-NI>
MO "K=E]=)%B\->PZ.GYQ:U2<J%^,<[9>32YPO35,3DT+<G(#NG$1#WZS+7?:
MK0EN+VMM%^=N*"$*K2^P!K;<WB(+#&@[$,2:3L_Q^(A"VG5K2ST^ZLFVBLEE
MM'I<+'?=GVN[' ,\O%5-J?6(FT.=::?L1WWEEW\Q&EXPST_$]C/?^C_%'$$:
MJ1#<^NXZ/;*OOB6*><XD%F\SW\C);[V>WV@W[7"OG; =QI0*I&GU5_-7/,R)
M%##3@42KXY@P10$8+W0O3:'9Y.M=/I>/@$ 8R0=R]$-:UU3=CO89.I2@]Y]#
M[@&"Y.DNLT):F05TP\0,K%T <E8 /5EANT%."I!PM%TQ!?B?Z1?&&ONSS.&[
M.Y75<N:6''RWER5<0 & IKZAMFI'7+^UM[UP(+AZ@"#PH%<8+F(]HFS]Y+Q\
M0YKTQ^MMF%* --@=[TI\J P&-'1QOU%<)(X@FGX5NXPW=+HW1_:SG#B:7J4M
M=;2YJB'%P,PGGIG$5Z$D);30I;&T8,_M=,1]ZR9FLEH'8M2S9@[V@M/T/E0N
M TWH\A$EKBX^ FKK!2@C=WNW<[]O@270T;G@$,T=C_5F6'5*GWZ[ GPD4_E_
MC+U).N%&+4J2R'MP@;.)_.!$,U$6W]+",523%B0J*_3GZRR^W9#]U9"Z<0QO
M9*RT-;]H4#?9\&(A>X-FS<E+6_L1@%*[?OT+Z=N9EOT#54N[6;<>?3@1W<Q%
MJ_X4,A6WB&G#3H4XTY8K%&G=/]2V[9?EZPE6G"!-(]H56)];T59+3%" @"DD
MFK@WLTX[U/Y"J=K9+NF-S/%6C<\ZG4 WP.N5T:D1_3H[(0Q;#19=:)V!=_*9
M4_BK_%5\N,Q;Y'ZF+"Q)!)+XN7QOB[_$NB0)W2_46:JSS0*; P8+$T+H)]M
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M(^;M0'R30-=0,>ZQDUR"S*E"=OQT*>.NY#YS<L+Z3M"[Z Q5=&NK2"[=;#5
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M. JV(0S2#3-< @:9DBG2=#D!DH2D?\R18CO0CT39,'M6W[LU5+&']8R\%:D
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MI[V%Y'\7[.$\02S]$,N K+?Q9_<WM)ES##WO1C+XL2W/L5PGI+[6[>\!]Y.
M.SC5>Y>659K1AD4)MG>^XR4KB_CN?%:B"3^ORYR#%'3P"^=#"Y@T=NV^*8,C
MB\[=RWU%C?GV=OD_V!C 'D:$WSO^CP:@C,A>'D@I?$0*@0/HR"D*VM>!-=F
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MW_9Q#(T0:P84?2+A6GRD/G<I>,0U#;]Q55CR5%-UT0^1&##7P,/@I]T[.A$
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M1)G\H+YT0UHL2GNHI*T)EZ@R_$A]QI%">*RC*U=7UZ8&Q=1L%O\3Q\2E>B8
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M06A<Q*V (P://;M+*J+9DCN$A!A-?T_HV#5'95TIPC9]?ADT8&-+T4S)H%C
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M0W#?7$NA3.R\)S -)S 8ZNU9:B/W&99PB%57FBCBLN)WP[ARJ*U*1I?%"PW
M1^I!Y(K!$A!ZD$"%TI#W 7V;U;]4WUJKO^KOR,0+MQ]I,G?GB]OU"M3"K D_
M$M!,-[&3I>2E34%TZ8.NB6&+')WE2Q8S_):X+J4[SD3&19E\(QBAMZ8I9]M!
M(:2OGONK$@.8 #V2V=]P.TYN<&YE;8+O@'TJ\^LP,6,[SJ,(_J*F?GS2E 0,
M$-_VK1ZFB-YX X8>]MP\).4.T O+YG$>[<'\H6&)GM"-RG^RI^*NN6I%ULU@
M/>\[1+!4-M2T49BB/4:^%7 'D(^BL:W-D2DC^E8/N&=IFJ*'W/@PV4/"&B/Z
MF]CKO- 1&-*PY*ZAC8JEI5T>O;VC$A/V(>J1-Q"JR.*_(=8G)7XBQZ\L1,X)
MZ^Z T8(Q,%F')VDYK.KSM!,.AQ139SRF\4?Y+3XA8,V;U5W 9G7A#B!!!'@(
MR(L5+8QL+,OQ#K#11/M\:3_G1>8:0:C-8W&L1P19.O 6K8T/?;73D<!PSV<[
M56H5LF/,@N-T"!'I3J.6472G9UM\MHH^DJME;0P)U:^E.1T"0T#M_ I^I]/E
MX^GZF]R_<F)K9#B\7)+JTK#F_P'5Y!,ANA88$[2R!PO_F-$_B(H2_%*-B1>3
MVE^'$'X(D5Q>8Q@[8X+7.@Z-T5#_="IY_QOE=\!GO6.FW99SDH9[TO=&&6DZ
MEBDJ8%-?SZOE&*6$!N-?_X%TWE9R130J6.)6+R7M&)TXQ49<$6=XH13CL\4L
M=1XO<Y%@=TWXLWU53)GL(M^^6BMS8"EB=,9FC26 GR6(RZ\@>S@]>U>^X47=
MA+5@3JQM* \*):--AS#AN/N+K# !Z1HV\0;[.(,A&N?7"A]$B5.QN$#FS80[
M1"8JQP<'3H/BIOKO?U)YOHIO.QA'O#F$T13R)"8/=3X,X.D>:LM9<2>#+6W<
M#(XM[E;'Q=L]9K9D*@X&#<X-:]JF]MXPUD^<7LDQ*OBV=Z/X3J,\)C=CQ4<'
M*O[>9. D!'Z7*9REQXGYRC1NC2QH+ #CF;R&:^AW%:=\BHL#-#=.]H(0(0I<
MG5P![98EX4 TWN+ +BJ<TPC\%= N^Y";?OY"6+Y'[M"&;,U5UNI/>W5!AM4;
MNK9Y^WGSJ%XM]16ASJ%FS:2II"; YJ\[DO\?*%,&Q-UK5(2?US'RS+U&\=G?
M >7C[BQU5]Q%ZUC84,&&6JXOUL'1PD;QL=0>:+N,);"5 $MW%K"SS<<)=AT=
MH<D4\ /G9HY0I!Z"B#6%@'F>H"K'J:ZNVX0?#V=G$AU[8FF*V?S:T,(10X!M
M_'0,(G>-)7R\]9FT \O^$<>G>6/;6IS16]6I:[K)HD-APAWV7_DA$"V^3ZW[
MKSK)+VU'UD'-1+"4J-4;UEES5G::ZE]&42&"1:'6!EXWJD,6>FB- GD6/.IL
M2Q9QBLO"5PT"LAF1VMSV<=I4H\& 33O:E9I?D05].%/)64%2DI-^&#R:U8O5
MZ]4I?WZ.>9RK<))-KOGYCHVYM0]-&#_]'2"TN_0?-CK;WG+":\Y1(LU)5?,G
MW:7<V<Q-<OVI3L;%YZ1$M)UVR59;[B,M?:[I@A]+8>*=KMY#2]#MS%N7W QL
MX5K*5F4X43L5#B*^DX=T:6DYEV 1*NZ"YZ_XP,>GITJ@H^5QI0@6..ZR*ON\
MX#7,>CYF\5 \EB8JPA481K#G&QNOZ3!LB-N:%PZ3"EZW09""3GEYA:>24&R*
M]E()R12DDDVK9#42I/J/"S$+TRZHUT^**SJ],"MMGNP>%& 42;UOB1*LVYHH
M%LSD7\440:%\:(VPZ>#7\^=T&#]-LB6HCQZ4&9#N*6 [E ,,W'FFF9AOB<TN
M#-Y*'Q1.,\BR(F$:@DTG#J=%VE2B;= M^#-S>L^$E-WR>JYH_6\M+-Q6_'1)
MZYMJXTC.!!AE\U'B^3V*QF1=ANU/F/G='K M$"R97WH4Q^:VZ1NB=X"M?7G7
M=8,S_E:0\\^ K>YS1,GJ'8"Y+&/L]N,Q\SHOQ&J=G4#X<S@29<(0X%2IAA8@
M: Z] XC%7M>_3(M_^=HE*I9^)U65FMSMM'#)<"W5SP%+S8-#>>HZI/<1KM2Y
M"\B<1NA-U+*W "EC^%@S X*GD[2J.3['XM9CH^TY[^W(JT-J7)=7:*(63%)K
M6[Z<1>^V%)JF&PL*S$D9/NR/)Q?FHA@QXW B+2AI6\? 06W\RYD$_N$->-K]
MMJ1]>-W$YT"Y3ZK%?AZ047K&0K2M)17TNI)Q[XA1N0FI"'J\>(02R8>,'.F:
MN/@_O>;-@T8W:%(+W@"TUO$M?Z5U[_0!6<E@DZ@!J\+H5"HNI.8M+*R0AW_C
M:$X_H5]R&20LSQ'QE118R"AS%U\;(FJ??V.1V#3K.]>KT?MF\&>H-T!2>&\Y
M;Y_4PM;!0WDR6,&+&&KF3"O/WS1XMZ+5\.V(4A01D./UV-N0PZJWLQ2W9[O%
M2 A>_ U]4%K4%C>W/EF4(V?MQA",9E55VI79$<554JV\NM)1;L?88_@\/9$&
MR=(-S4TG,+DW(CE]SR7(9&A^/ ^M8&M%GDP$' F2K$IVU.O?7A85[=O/BFT2
MI8@D?$I8%*.P]1N/$8.C)JQ9,7 )/=\Z(+0>+'C9K1WY"?(1"S#_2\DQ!2<>
M)D";7LDIJ-6#P-*]6#0/7.@ @%WF4A$U#+_71#:()N7E$GDPA3Q;I*2$\#TR
MA1@*I C/JRX\A/7R'>!9A'K$CL/0O50[,B@I$'Z*U/+O'\(9OD?*T?!0E>2U
M/$!9"52J)R^[6\->)%_,R>?3SAH4O685>!YI.T,>89NX7^GA)3MSFCUYVC![
M6#A+M4QGZ8CBB#9[(DJJHHY,UQT!2-!(7AZ2R*!XQ%FW7'2!S:B>"C*M?2E^
M-G8F4MEG]311Z6=ODJ+SKZ\FWOS!C-YW@/\,[ ZX]5OYQ<AS!SP%-9/!9P*N
MM4^D,BRBEF0>/5R?[6UUA7K3N@7_-BFCC,D=E*&+B-OKF+YH. .I+G%2@K R
M(]9HT/*VS9"M_QC/1<-Y.DO0(>_LK7Y8!#&WCLQ!/]!$Y%$YE[@KHH$D["B)
M$<E0!<*E$"$.Y3O@_2L-T&  -[6KJ=\IRM0*'F2KHQDG>EG(6?&*41N5#8=A
MY1/QR!(:A03@H**>>@>T[R,\[@"QH^O8I#L@J+C;"JQ0,YJD%;?*G%+JD394
M>0<4=-N'FN96 7H9I>Y<ZT+(W4\7A?T]F>,6\^(OY)-DAH5AE %9<+K@4[U'
M<Q+.1<L><8^-CL<:J]VK'W?C4[:.HDX1M.*$>>',>=\ND\.'"CON */BS?'C
M^=MQQ@:9]91EU27RLE)C_5VLOV@;_)_PV1\E&J"027N8D6]>WYQ:*,69Z+BH
MKM3!X+_\<C&]%27T5$CJ7<,?0VZ"=Q/J$T<EQ?M%S&LI:Q,V\[C<(W$@7K05
MOR[EL6O-C+W+\'3]'%V7"W[W%)U^%\MFD%&HD3<.]>E?.4=*GR/'Z01KG.#/
MLLTW->%%1U,V0SI5<PHLWEFF&5^?/,T?/+<C?/RR6VZ65Y 5+8\K\[<59]A%
MZTQHXM/W@B5YU=?2_(II[3BY)LXJ,_(1^64BL/QO:JM%3H8O5R^3P[C+?G1K
M&OLN!B6X%M3TY\),4!NW5@-]'61_LX\V%D[<\_X'U\>X%VQHQU,:Q:CVD[XR
M%^<EJG#*,*(@=[Z\'3RKQ\[(;TD"WI11,1K.KMX20#T?(?QYVI/(4M$A#3*3
MXJ#!$0N89!:^@7UH5-3WR-:4V@-1RH3L:\:Q2CV*EF#.OL/7(9@> 2N/'_=#
M?8BWY;%1@>>-(;K3IUC(Z\,-+FM"KW?57@KY(CV0#7S&NJ#A,TKIL5<%4P]U
M!ZVO!%58<#]P8WDDREWYH;.EL3T2L/18DU_W_83Z>">QF5S[=B+Q=J/WBNR,
M<FP4M<?;77T5!P_R36N;$A^$@7AF/@W=?Q9A1OPA0%E:A.>DA(%TTR?-W1(N
ML15TFIFOD13R;?KI_5/9'Y"!(_F11YH\5)ZJ_*1'FU4?)/4**13$@T]TD1;G
M6MES-0PY/@(Y8"Z$IOGU(5,QI#T2E"N @'H\G\/.4U=O7G"21=E^L:8-9M3O
MT\FRLI9NHVF&$)R]ME#F4NX* @B%]C9%O@ASCS;32N@;0E>P=2G,#P$B7-&0
M9]I4D5:TWV-27 V:(\:8B@M/&3' .XU[>45C+V.N!O$?>/$#)RVDB/@KGK6C
M (?4?:N76P=*Z5<Z0\V_U@9JVX4]=1.NY53A>IUW .X.%=Y"NZMPC*G'YMN4
M-]P;=OM)Y2 G[O#<<#]XX5%0:VI$,P8O[_&'.T!21N7LHQ>T@'/=+^S+R$U#
M%0#>21&$%_O F4<Z*%E#%.(H9#<#0**B[[?(%)39'U&'7EU>44 ".R,5>EH>
M?B=W4;H#MGM*;-)P(J\5#']H7VO!Y0[#%ZQ/&[[8=+.#GM9O(9-'?5\]1ZV_
M T(H7U?#4]M;L'=A^D;@.-D@/Z,>>KT$A1/*3K5 GTR<*VE$M@Y[:+RH+R^-
MJ_I#.*@]OAECYI!SSY#NG."T!5PE^EA""/TD]9O#&0T^TJ2[1ZJ.\?BS^IIJ
M.0)1;KMT8<.6N(8.S%.TW >5MZ\HC)NQS,-*-#7G]9).407$CBT?M2E\&&93
M]AQ=3<6"@(#4A$N<<]RJ9N$'GB3FW@^\QC/N@#$K4<J"=*_>EEROF4JORT=%
MZ/ PGG,?6%5*O+G5R^3"^ #\L. .2G: W/ULYY883I$;?(KA8=+-L%Z3ZC25
M+&KK*T6-*^ ZBD:P?A14GY.P!J9Z!%$;QRARVG\PQ/?K.0HN*CM?Z]((\;Z]
M5("@S/J00!<<X=PUKZS3P6\=^*$TZ)>%BPC?*E(;!=(P_V8=%54F0F ])W:=
MX@T?2.H;O8M!:$W<6Q-VG!;)2W7];'=U/3S$^8H$;,AGDK.%T7'JA%'RN6"T
M*$W4J!T:7QIFD^P:3HB[PCKHWA%#$$X/\Q;*R(:]V=M4I5Z-"O5F?T2.ZPI7
M;WP*I]*HA7OT^+D;&MN8%TKRB+]&>TR/S-M&%RW\44HI!94Q&):2"X:%K"D$
M%;J_JWFBN1)Y/A/PO+^?)(A7.\79:5N*R[1#>N6)I^# VL$KAGB)4F0>W!X?
MFD?G#ZFTMV8=]T1)=^",W?4CX6<MC[>U=.-.M(9W"":OIIZ%:?B.]"TJ#(1Z
M2A9?<R.^K&&I=Y/&?W97L@$F7T\%)3[L?E=-S,,K)/F((!76I7#-'$$9+;)1
M\7']-I$T&PI('7"LT?A%O+2V/?R*Y-%,C1CIH:2;=%A!ZM+'"OCNZ=90:D^G
MR'^Z*-;:,QF\(_AB_4#+!F>/2)=US&3\D#-RY+7O2^D<I=2ZVN-%0Y(>FNG&
M+>C%%RMA0D1-IRM=",9<X?BO*/G2!L8G"N\Q(\50R%UG0)0M/]RU8#S!!TR5
M<55EKSXHU!D.M:DM$MF4]*.*=<L!QB#(U9IN4^82HD:R=-QPC/I$L$$F?(=6
M@HYI$E>=LB"E=7JS FZPXXFKA>B1J?"Q-J[5H/7]2:AJ&3G;AG+,6T(^JH]P
M-H6"?-8@CDIKC*:.W&:#OH:I7Y%]B4:W*'"T]AH_9(OEWHY$R5AE+>Z G?.D
M>*M2O/B^DGO;^X1Z8[,M>W-S*5"YO_=Z++;.*"<@6SFVKF+B7W[\+A=YD$;P
MF1# M]6B%;'6$W2&@WM-,G;F!M8PK&AR=&O5B/MR!WQF>1]Z>+"C=?E-!#:P
MS6I_$WL?_M,6VVM4)WK-.2L<9YK\C];.*Q[NY^OC7UFQ2%C=ZF()T3;1^R*Q
M6M0@6H0?B;)(E""BA2A9K/8+(5$2B5ZB]\X2G56B6U;/)A:1C?K(__7</!?/
MW?]R7C,79\Y\WN<U\YJ9<_8RY(,@C1_Z1K9%0/Y=6<(D^:C6RSS_K ^W<RE<
MXWRZ]BHQ,X>=HG$O^,8B#6FZ&\[NUNB7-RM1K<;MY%L?T"XTHS$@:>/G?Y4"
MMS-5^>/9@K+E:49>S9?Z_3P<D3]\38[!9*_96_$((]:VJYN%6QY.%WKE3-3]
M]">QJ$PWQ0&&(60 !'B0 >GQX9S)E$?U D(;]_U*XZQ=(=-@[->=:<PY(/G"
M',) WK DU;47M^C-]D]R(Y(*X]X+A-\<VY\G+F^T/#]+\\?_9' -C-R(DS7P
M-R$I[ M4?Z'X=@NVA@4_%DQZP^TKBPN0$JX_S6RV0E%*J7;J^6.+])\:'QR"
M$)& +P+\Y-E :&3&NP4K*[7X)RB5U$=1Z^G8O1W^D841'C!K'=XH1B[0N6.$
MK ?WG1,3U'6Z4X7[N)?K/Z].*_74R#0DKT*-9:<Q>+HC\[Y65/!L9&;F1$I7
M1=2DQ[&A5T2V6\_XB7+H"F(F3_F!$DQHD+W2ECIL0(=UCA]BRWW&0E'9*D6N
M\L)WK$)EB&+'(L)OQ<VOZ(P]VU?: %Y$++&.N?&QK*7A^4ZN*VE5"Q"4L(?[
M:V_X_*!/-=0F^^>"''9/RSN?C3]P]O!PCT^JW+,*\6CR]\3*_?YU6)*N(OL<
MOS33N4\<': ;(O;;0FV]T3I7>CVIO-2YY+,9U(1MR5)PZ)SKK'G6&]IB7>9+
M(PJ;3ATJUP,!GU\[=L7+V<R]JQ :RQU=]G]QA4Q(>LUZ!7O52K&P5O 9QTLD
M?6CEQ]4SRIJ'^.E8]R#F7:4NBXF<AE1(S5>V.=_+E0\J.F 8$=#,SJ#:C1/D
ME JDV&5J]D%\Z>QB2JNB>6S%/&#.'\><??O!662)#3E"LW*2R'2GKBE&G[,?
ML(>4T;"NM/%Y\N)Z[)@;,&SI*RF#EFG%B=N:"3[C89([#QG4!,C7#WO-27+I
M^:VQ@>TJ;.VIM1=;R[K?I!%%,$]Q#CF>!#,9_3PNDT#G>@ZX3?[R95)WLBTJ
M7'X*D<BVHQ)[3?Y NF)(.GR9'^#<E?I;WOK-0K]*XMMT:S8.+GIM84$"ADIT
MNON%S0@5N;@C2U1.VO;;UA1I;MY=<;:=,>ZP3YCWDS'EH@ Y@<35WC9SJ/3C
MW:<1B8'XNC[N7(S46TJ'#I7#PY\V;6SY*587'!IUW2IA4BL.2A[BXO6[3M-;
M)_'G?M:)#>DP>]5B%*=3TXCB0KVO(53\BTP*7[\)>:IT#J38O?3@0IT#/#D2
M5TUM7)2L@>,&*VZG$)4D=09R]D7PKG[X&M31R/8F?_Y/(C(UW+3??,8G5;'#
MF&(5.)Y2(*>1($B2[R)DPG=!\ARPJK>7$$3>X$PE,&_7CW!S5ODUG!9>$_*^
MG+&\>I:.@^/\B;KN>H0K9OQ)HW]\+P[)<!YRV=+*G<6KI" _N/*'9 ZB!BAO
M&5P F[BD/*V(1_Q1)+XXG3D'DB<7U/G(;OKW(A*JA!7.@;QG_6WH[\WLQ^JH
M(VSNY<%:_%JL1R.5^Q?;9_R."=; D1MZ7Q6T&AVMHE5NM<66REGBL_!U+5>?
MZ3)X/EKXH/SN?S>_:?.[PY=39=4C%%VN[FML9X3;8F(,?H E1IG;QZ[*+I04
MT5%G)[7K$&WTX/=A<O!'Z&_'P>7P-EM>U4V*,SKR"[Q-*.76E]989^]IMD+!
MRGG-<EB5B+ X\@5IRS1 'K^0'T9\]K!B:?YNVKO,#_:4KG'$WGN)]%)&LAV;
M"%[Q:B-ZC<\[@==S>4L?L2<ZHF\RO(':_K W(_5UE,7B#7[&R0;SF4T&::D,
M.*BM.GK(V-\$BUO>XD+O 2-NP!X?14!Q)R]WMK41\R;8+!D59N_@RCT'+"3M
M)\41?,M==PV;\!#&+<[)C:@@M4:;#AJTA5Q2YS!M,I7Q>XS8V].L1,:5S*_G
M -QK%79Z=&B@I;EU_YTZ7WU(Q&F*.M^-(!G2PX@39=<"[9502*:IU2>+R,A/
M/NX =\+[N!#6;R>(%!V2/+:-V$8WTY&[5;O+X/%@3/ -.E$/"]G 4*D:^)P#
M-&JPS3-0Y23_9$EY/JK09'2NNP0 (C('55%Z(Z:UI(U>.BZ+W;)X+]03D& =
M9JS$*<QPW>,3YA5]@PS%0>GSJ)<KB)H@C^GJA]^#1>%5/4W$"AMB0\HK_)(*
M)EB9]N"(]/ *Z!R@$UJ)B$B E9]<%J&0&7D=HD@RBJG)IM^T]DN6+!5.E)CH
M>2/PVK+,TBFYFXA5."P-C<QFJ/G)B,HHCP[2]J!=VNK7316::Z*KCN+H-;V)
M%+NRW)A$8L9VAR/&^=Z'XBP*6WEO\/$V.W> ^CV7B)^!P-Z8&O/1$\6";0P-
M6^U/.$CX90:I+=R.!1=T.]\M1'QZ.<*TN;[1B6K])OY6U...5<&DN;C[=6YR
M)F[6'D-QVYQB,1ERE$[V<??# L1ZI(/X)FKXK@34#I-\_S@O>?AP/[_K*_'C
MD_VN+A0K GIH5T$V*21G#)C6D+@Y92??X=,,'XHT170<UU-R[X%ETXZU#!@G
M521NG1*4!7VP_I($1'\# CH?8-1]]#DK>YF/;J$&WP"7[<SEDWDAJ=NK*+@*
M+:M:[3;5+@R0DM?D@#URF*:4\:7(S0M2)]\OW+:H92!SB]<QB>N-?)XC4K[W
MV?<M-<+,?L6=2.0'.!H:I[@EEV@J3,3=J5]VS%=&JDK;-5;D&/O!C?3^X.[A
M:B#H<X!3EOK@U*!Z4^;5#.MXKJ=!-(=)TCZ[\'O,9< ('ZNHQAKTJ'J, #M&
M6-1@)+J\N/I B@H;@^!IBN(/I[D5YP"UWYNL[-F+A55W(YS!3B1)])$YY3&>
MS3;^I2UQL:_JM1>@@MZ?FORQ@>8_T4='Y.+E<R#RESU-,NHSLZ22 I*N?:L/
M\9*%@CWF1'_WXRI^?BK5S\^HA$M+9ZCE)49##JQ\B*$@[(^T^)\#EXBR7$91
MJ5W&5BRZRE_=RYXS<CMBNI035FT:^<*;Q8^N9TH'/-&5>A?PK:$J09 (5NRU
MWE'_6S846 D1(O\)HOG0(\X@-/S9[\R\1/(;QX]!Z>1<3&;?EFW&10S.CW[B
M#I<E<LZ9X,K?TT@<D&/U/;+F7P02O";,$-7@Z'*XN$Q\R*Q\!H\<DIWQ(Z'H
M%CATE+5WU>(7'&,=W.5JT<I<E6(Q(3DO7CO"=2V.$:=P/'/0UZXR2I60<";@
M=G0_QO<<N!)PWQ"S;]VL<4WZDH608B\'[ZMD0X U!=*-8",+=Q]R(A*6*U+[
MCV/*OY,[^@@8!<JP /#[?2LU^=104-#C\1/78$>5C$?= HJ?8GXP-FB64/3:
M:P"K*I-PWAV_);;F^SDNK4Q+?JG#C^H;7=*9;NH0"* PL(H_= AXMJA(3B\G
M^ZSP9$<=9$J-']C9?'CM)&3;O_8FQ'W54YVX,^1L':1):HMN%;(,>-*3>A0T
MNFT8+E=E>@F\["%< "[@SRA?J4;LCH=PK?);]PZK$@K5A&]<K"9NV93B''C
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MX:%A%A01X )^XN;A^L]'$-#1T;$PL4BQL4FYZ"CIN/Z'[;4'@(^&<(]TCHA
M#WB#CX"(C_ Z *#YER<RPG\9X+\9PAM$)&045#1T#,Q_ 8UX@#<(B(AOD!"1
MD9&0_JWZ_UL'(.$C$]!Q2J"\535%I7<FY I.S$-C^%S;2Z0V V?D_NH2@HY!
M3$)*1OZ.B?G]!Q8>7CY^ 4$AR2]2TC*R<O+J&II:VCJZ>F;F%I96UC:VKF[N
M'IY>WCZAW\+"(R*CHI.2?Z2DIOU,S\@O*"PJ+BDM*Z^K;VAL:FYI;>OK'Q@<
M&AX9'9N=FU]87/JS#-V";>_L[NW_/3@\O[B\NKZYO;M_^ \N!  BPO]J_Y>X
M\/_A>H.$A(B$^A]<"&\\_Q. CX1,QXE"(*&*:NK\EIXK&(WP<V)>;2\Z [<:
MG.BKRPP&,2//UKOS_T#[+V3_]X"%_#]"]K\!^]]Q00%8B C_#@\1'R &N'UX
MGQ^$\?_[_^><VZ'QA&ML]^3TDX?\S]4N?4ISJYI;",ME/.$K8&38\_4?JP!^
M$W=25ZG*,3&>$JI*B?=%O__UYG\V[ZB 57_WD_IEEV&8$^&_@_DS3GTLMIGO
M&,> 4KM\*>()?-F]Q?*[:_*E>^QY ]39'=?A#BEEW+>T43+2BYWGC8\A)RHX
M)(\4LXAT2+C7F@)<"Z.(WU9+PSUCP1T2F[N+U^ALQQUI'&O<(P2\SG$NPT&>
M[,8&KD:N@05^)DL0&M!\)G%=C"Q6TPC:E:@QH]92)) %2 /G5Y]3K. Y/E<"
M1G,43<R$QIL :,)LWA$G>70^D#!FIZ9=B)!Z17RQH8VQ(_=.VD3$^/YC(NB*
MA7MZ2\W83D\KG7XXL&Q93_AYH27;C/D@V<@8OM$G).3%MS&8YC%TI!ZC &1G
MC(U\JAO[]5[@!>LRXW+MK1Z\<V$]+W!;'PQ2ZVSURPL.TJ3N]E?V1?B-H%9:
MO-9&4/;O1:,\R*.-_[%F)$FZG^5O3XA(9,E2A!_C.:,'>5KD1U/?,AXOMIWN
M$$'G3B)2Q"'GEG"R?3*BI0,QT@Z12MO%#'!G3FF]H7PM@QRAJ00SHH"+\YV&
M?$RR#<%!PY4PZXFGS-P[?./#)KXD_(3D54:K"Z9*Z+K>ACAS?6LXC,"),:R_
M[$G*;]<9C!KQI%#6'><G[%OJGZ\VZL3L-:Q^^8$4-T?X/"[EH!O3'.Y,\GVK
M["QUJ\?[I&KU5',:">$B@3LF)M>H4;VP@")OC%A;^,LY<<2[CB7TRH,3+,:/
M=9B%K&2"/699B+U'!UJ5C9AL\KBB0Z?KAY3;$R'B1[FEO)NY6!T,)7?5>@M#
M%7L*-M:]86UC*L*U)NB]TP@@D-[BC/UTB"A?\??B<;JY:A(4IJ\!:F'A_O(U
MFP_^-F,QZC8B*FN\Y8HW%,]FBK--KP#K0[Y4WY<S*+/.Y=6JE&X(#+-4R\Z[
M((/IL9H"1?V*OLMBSD]RZT3=<-[=D4+_4.A;<@W'L$,/"XX7LT\60A!@&^+6
MC0640<F&37Z=5GQ4MYY=&7=&(D%R^!SJ-(5.-B1#Y755\E%8EHJ5 7K6"&%5
ML#"45*]KL'S,A[G'Y!;+EDFM\GO@.ENX(T6J-BG&D2$,&\3$L0Z\4-Q9@<ZO
MA^HK[Q(4O,4RRDDFS0$)<D#*\QY$ =*JQ_Z -]][4Q_:5VP]N7M=*6!K/6C9
M3OY_<+B'_(6^,J,-*QQ^D&)C+T,-NSYZQ*;1Z#IGC[Y2TJ2#?O45CKS)ZZ<J
M#%--[1DV2AGU$AX*X#BW[*;(Q;/12NW;1?PCRZ#+^-FECU:CWE3B3+<;RRV3
MRJHWYT-S=^A4%+!5T[-N:X&1%BYE?,?PRR9MW+/"8,6QJRY;JJ/+##M=/0>A
M]TD"4D0Z*%<'E=]WW?3M=(&] E0-]0<>1&O)PRX*:E+(\G:>3TI;C@6GY0^J
M>2<9E+--NA;LP98.B=-.D<-PI@[U+?>K#/, WNY(Q'>03,6@J['[;X$L>PU4
MVKT7DK[.L$=#?=7Y4\:/[\+""?$$IZ[?U>?\BDOY%+OS"I 0\K1_<&>4,]-E
M<'<S3;$01/*W3;;+D#?^CK+P,16>Y9^U2ILL=KK/N]6%=@[>2]OL)M:#*G%&
M+^*S)8\$6#<W]5\!RWJV:1\6N_NK(X1HHH"TT.)BYM2;/;DW\G5U/VN<$T-'
M1YBSYH58^%V^NLUV3G:'=[$M\;X""(\\?+)O<QWM<9-RU#YM9,65(P!]E@K7
MVJ4L@)%.XQ0<HM\PSAU#G'FH69?R/#\=$"^Z/GT1Y3::#GP%T!Y5/_Q+?F2V
M,BD[H9RQ*&_S 36ZB\4KC]F?^O:$%>&-Y*Y>\:QK? >*#_G"7 #C77V_*&VH
M\GEC\RD3+0^$H("6F:(7E/+#LT(,06Q[W. 54)7P"F N\?/!#[2R+CRY[%CV
M>#CIV[\>M+\W!%F-55H?[X^;+>ZW-3<V\Y.\'23$X#)/["NE41^4,*TXR/AE
M5G+(EV8:<+N\K\MYW<N[N2Z\^ 6Z$=$P"3[MKH/8@W=:PC<HUM*YAI&"<]97
M%Y5N(SL$B[PB%!<ZR,!E.CS8+XE$_6^J6BD1.^,9G&C/9_-,3Z,TJN*+/IV!
M[6FYUPWZ'=$V1WF""0.8H\/[M>=XE3:6'V*+UC<Z;[P7%?V=E+Q>NDG/FX<:
M?O.2O7N9:$#6(K2WPC\3^PPB.PIBK6ZX4R\Z,/K0N.CFNP(1%>!0:@"W<$[3
MUA-X)/;20"2_?6WT28 E+:0Z5%WWGE.S>CV!"H:+DMH;2E)$9S>8!0PS6X'/
MIRGSQD="1JD:MN0IV>FF*21O*[T?S*,OV$ ORGQS1S0O497L;Z&!9D\2"]5/
M^K_6#GW\!RK!:Y9>O^G$F,A\MISX=C0?W['ZD(SZ^E _6Y0NVZJ2V3NRG190
M&:%K#N]AN^10M2WNGC=!L,^B&KX_BP#/&$!-B5CPK^(D7FAH4*X2Q@L9O?TN
M4J5-SX4JFOZ34GWC<;(U&T^ZH?42!QP*ZIV,(3AO3\-=[[9P4M$WS@U9#<_!
MOBR-1V%7.A?H?JWQX8-E*N$A>6S1+\?VFZA%X#.7E)*=)]@?D#,+HX@$R=$[
M'0;B&]'!S_H]<O&NJ8P-S[D5O& J^>R<B2X].>42/9L M#>5-JG3FS0Q"=9M
MYA=\F:7(:XA-3J24 ;1QN"6$0@HZ)>5O0Z /.5V\D ]5)8WDV8DMS6J77Y@-
MS]\/*6#MX,@8Z^E3F2DND"V!YBM/Q_S/'85&FX]"G(UHJ,/ ,+$X\JI,GXOO
M,JG2*0PN728J:&HR]D&!&!E@^KG>#4J>3"6&B9!%R_A;WW$348TJN5&J^Y)C
ML\;KQN'C)=>UHX$.2=@&U>0YA0K\%1#A6%_["G!%34$%T)I="CW[9-Q [[<-
M7C9> 6$+98%]W*\ .L/]L5> ]MP81=<K8'Q.Q$9%KCE@34K.L+ZHX5_4],T?
MT;F7@@EC[A?@RZGWP;3\M>YU["?HO7W)?"6LW6*U1DZH\IN+:T/6=NB]=K:7
MU0MQ]Q.CA_'*Q@7F>L#,*X"ZVQ.5QG7O*"YE\DFFQE![FSJ]I".>TE.U%[..
MDJIR@H(FF%>9Q:6^>:2$V@HL*M, M2,W?%(;MRK371W&?5@*=W?*5<.EB95T
MA"EAG.[HZ]OIN<TE!Q-ZRDZ BA$FG:G9X25A0+'-LDJIJ[9W69<5K9$-$*=-
MR@](2?U="  SWCW13W,-^N W0V=?X"_5YB%2L8T4$_FK!(5/Y7)',3LF3C:?
M?UC4$YH4^I,%5ARTJ0U!X_)L+!D9Z5K2S=;B6E:E?>9H#&;-NHC9RW79M@2(
M3YQ"/OOS[?-NYY*\2PI$O1.U,>A($M?]<\TX3,94X2<)%TW>ZD8Z$,K.'W\N
M8/R;]K:A<DAMIOYMB).@$6=<Y]]8TH:J6V2D$\_6DS2A]60KCZ8TO:(?)&RQ
M->-.T?LB'(5[U=PL'RQIWY,QY@"J4<[Y0ZY6',.TNMXEEF3JMN@X,+4F:7U]
M<4!'>AO'[WXT*/.O2. ;YX:)$M0_?LD7_KM#@IV;ODA/B'@H.+WY7D.]F?4"
MU\H__60QXR8^T E\?&U'$36LL]4J8WJ'F.&7T95.G)_AEA&;;RRVUF0S+[LA
M-:7DMU)E2XU&KMD*7\BIM:H0/^S;LR3U<V?&<?*-_:6MOJTP'EX+UX[7Q(6^
MD4Y#PB&;/Z7)87SZT$9>S?G( &5WSV97SA%@;V05UBWZ=[,H+\NY+^,0@)>@
M[@6W$Q:>9-7NQGH98<TJ)IU^&G&=F*7I7 *'XG.Q&%Z%%10NW0.M6K_-*[4Q
M=.K'PJ=@2"Z^K0P,-^J)K.C#!L7*L,AOJO36A ",B,NB8QZE;E5?D?033[V4
ML-BZU;7U%?V>U2B+%%403/E][?PQKP!42?0!>LHKP.;(,H(*0Z\FFK.GOTL\
MU]:,UTG2FKLZIPU?UK?^4X7'3H5PZ+R>//@ %,-ZLLJW#:#RI@T_^"E2+ZN#
M5]G^(WE4C=2=.3'#:- X]2&B7M]8'?INT:V%O:N?K\B*:GWV17(J7^D7@?*L
M:\P;U[^LW^^BMOEKX%[S?MR5>AWC'HG IA/*S3>DF_NT;E7,PWKV/L-#*R)"
MVF[1.Y*483@X?3B;N"TC3W:.L(@(GERL)W[B-JF?35'7:&M#-U\G&\/EOH)L
MG4L(MP-^Y2<;6;EO/0=P;V8S:RU>8WH9P9!LF+-GWUDQP,ENB%K_PV/V:7QI
M^ ;BKP 7'0.A9H'-.%S>2X=@GQS.<Y((-Q&/K<U9\+8.;9@  0?IT>$$9V[_
M>E=*."ED4]8TUBR:%R,R%$'\+Z"L AGEP_ /?T)5G?0P0E5QY/_FU,ZPW'O2
MTU? )LW#FZ6"I2RODA=IX>X[U)>@QK_7E2^$BIZF4H1:4O^)I3R+NU:8I.@5
MRLDKF=Q9^QQMEFP-+FR+^X;_.Z-H,Y= 9+]_34QOZ9J40 XK1#]][$LK05UU
M?AR L/OM*V GRT[L>E+LZNM2SNHK8+1)+W!)_150Q*;?QZ)B5)P8[7R?T\D?
MV:#@M97D;P:*8E:9X5ZCCT+XJY$\\J 5(B1'/DK!6@#0_+&#YQMJ1%-TARC3
M?2<CVNVZ+U?V'*?_[>?(GQB9=EOD*<XPQ-R^7S-/DKYF<.*G7N!WE@T*'K_-
MH1BBN(W'@VXA*L(7DL7^&[L"D21PH(*9LQVX?%GD0GK@<W*!+!K-VE2@/.P%
MWZM"[URJJOQA\ RJAQHC[5>H]"M\>@U1!-GTSG@K-:K43_B[1MHT>2&<YWRU
ML+)+'>L$@!CCQ)T3D!(/GU//E8&3Q+AC?D6"#Y/%Y&Y])46\L^(UF@+6*?BC
MCE7.BC0=&<T<5X4UKD/,')U\I-CZ&%Z^[$$FW1T=;9?4080>?]NAVDZE)//)
M0ZQ[2K@J<)D;S>$GQB:?P76(<#W%3QU3[M\Q+:.GGHB&,B'7F=\WPJ@_S3&E
M[$0/;7"DO1"Y._[PM4!_LD[!1)^M/8Z%*:&SF;7YVRGK>Z.C?V@3CY%!117@
MS<,Z-^A+EF!1>!M3,=2;$E%+93<H2N8G.M.AM.7MCFUAV>*1\BM8RU(5(\Z%
MPV<G>4JF414>5U]ZITQ#88-G0/96.5HKJ':+41?8V>.[0].CYJ95SJZ!D['
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M%_O>(>::5]E4?DSU0U8G7(8R9"!'XF V3_5[71>$H*P$#/+LZ&J8V^1>7Y,
MHQTQSB(93\SSD4^EE1.3!Q19>6A8A'4<,:%VH5<+WJ7;;;57$]A$Z"VP[Z7R
M4KA]E^WHIV6\ZJ50<)MR<1YTUOHM4>2G_SNPGN?[,P%Z822D<X6&HX)3S4F.
M%@^MESFOB%Q>M7/@5X8PQ.X?>98,L6*C8)YDF!>SP;UE71/D[B/7'I;R=&T?
M+(L8:__8\J6!2!X&0]Q=<E5PJ;"]22*[=S:OJBO%'M K\-B?Z *I]&CY=([,
M=K=C1ES$+NBW_]H6*?% .L-A&481Y:NV#Q9%QWS:0K&%_*YF8R&Z"^9^6=CE
MRLH@RO\:'J>.M8676%A/CI"\K31_,==.\0(';G'>+90=,>_7S5[44@_$)XH!
MN;79JO2J(K:S]2Z'C&C:YT\<F"S#-=.WE8KB9DG-@"9F#*2%I1709P1U[=JK
M=]G/.06XV6:>R!/&&R'B1_>A!FEAGZY'.T!EPZ5WN3+S$$*Q9!LK%IX:OR='
MC* 8'!RYO5I1$H7-U.XV4:JD%\P#=2Z]M1$OQ?@VU+$_USLO[M-//+JY,)KO
M:FLA4S,&:']N''E,7MPZLUL37*#[U89WW[_,[7,8'9'[-_17NAK2<SRA3QK]
MGT>L5G7?%>#7DPO5L4^<I0:&<G3TF\KGB;D2"11963M+M7Z<@9C8U#!VK-6U
MD;Q^$-%*]M]A >& O]/EU\.-1!_>5^3)$VL+>Q?'0=&9T_NDR-,\1(C$1WEA
M2\;X3V:P24M?$+(N85/D4YVW_)3,;7;NKL$-S50GP_"+XQ,M^7YR]H:YW_9C
M]^"#92LH.'SE!>]HFMT1*@I==ZSBJUI]='^V+DX*S=1&6Y8:Z?T.8XY]HBGK
MQ8VQ!Q[9@-8Y\YN$4\SOE47$4GQVVEX2'4W!_JYE4/T5P_=>YCD6,0(,#!21
MTR@MN;$Y,D^T97O'EP%+-"DYK?U6-.%VTT_&>X%]>7#'].R5PB%_P>&#Z"[9
M>3GHH$M9X8W(P[YJ;7T]29IV*EPOBT945U,])Y=38*_5D<+K=*6_B]100:FU
MMJ,E*]B^R\MD6^ C0(P#M8J5!B;SE#CR"CC*KK[4VVY<^S3E&.Q#7,(HV-',
M)%"X&J!I0^$TY.0:/*^A7D)B^?A'-62F:[_"BV8@\>Y[OX?K>*"=<^G/T-7A
MMU5_1YG)5&\#R6<S!WRH.F<:<W7G\EM049C;I/R>T2>]A23LMD A&RMZBFR.
M98=.PUA+F P$+L.,;YQPN.>H;)?"1(G^DI\%L3F<(O6K=42.?&JNO1AE)E4,
MDE'<3YZFSRKKU^4OZAT2JO^#@(6 A.>-I&7W3]/&G1U75QZ,NV9Y,QT@[L^1
M37IWQQ&?;;T"^BG\R<?5V[*K/@$3A1/(&&B3*N)"8_S1]XL4"I_HX-?[(> <
M"?:;[,GRB4\3E6^$/VWR74&Y#W)]4I3YVGTP4_1.<O(\O>U,;6^UTSA6](OY
MQ[F_28WVC )Q9&EBU9('?"@Y^GDRIK(2E;G?-LXB)V?YE0 O<.7A)^SZ'?-=
M:'=)?8>2+#JC]G26@G3D&O<!H8XT>K6%=Q1R[7<B[C#6AE1#F=%46?-+';00
M3I4\'SR/G-8C:,6?HG/1)IIZ!0]?__7:H@/X,.]ID168L("S8ZZ<-?XKB->6
M++\ES#+D2RHSF;8T5J5(9#4Z7":4YXS@#E%U@=>JI:6E6=>T86("N:W\E)1L
M>-VL%Y;<&T#;-1N ZY5J9Y-MT9B.A)U['6"C^<Z?,RF@08C5_%J12G2X8;+Z
M[^)2KEFN=DWTD<"%T2[1Y<N!( 1/@HPR^MY7L0/^'KY::WNCUP%=S1MMBZP:
M^*J\^F:;H=A%Q&[A!>.(7RCM6TE]JT?"G^G=H6/7"_R$[N#IK7AYS?<7%;]2
MA%ES4O[UQR@24H0J"/\]-S(]9^W3V^N&91-<*M9>GIP$7>9.2JU<ALY$,L?+
M7SVPY/&CN@F,IZPAN]+@766>N/:TI686]^ZO3>YZ.Y]I3KV3!M8B_A(Y*LG_
M89C=*RR<51WDIM#)W$-,+@VQ9VB12K'\5E?3+[M/IB8QPM#MLW4,9-\^0S V
MZMWR8N-EX]NZ+9\XQ'@@P&2?C!-@I-2N5=4JYUDY5<M<FM@%OG.$C=I7R<0P
MUJ584*BM,:@Y^9PR[#)0FN5";"6W''&A$\DKUGH&W$.>,O2Z0V2D;K3!B7I7
M&JU\IPI6Z<9RYT93+[OT=;/NOC("XKWX@.M>=_M' IL-G [T<NN'Z]M(]\;F
MD--=7;7%#0IU5Y2O'G A$X2,JS:6;&T[1FWAQOBL+FKFJ#G=178@^XV- UU/
MZN+^Z411O%\,GDSIT6+[-.H=\\#;NREC$J_F,84>W!2'& KL9FMFI* W5V3,
MP)M]UYY7P+^JOH7=/>_0W?"R?--3X+C\U/F3\7K5=0G:KC=;9-<\IG%H>^R-
M)4IP7AWL?G3P1(=<])+MM=(1E:UM,MI#6W?!)2VQW^G^@O=]*.FYZ$G_74*(
M%!U;@=0G=)&Q?TK<+,G?W^>!55##12_?8&7U?$4,W6N_1Z_Q %[(EQ&7[;:,
M/W7(%YQESLW.(# "? 5\2NL38H_95E(^&VC+E%UZ#V-%=CJ,6=T7(<0)0HRS
MZ\S/+(<N(&9:I3SQP0/:?WD%#O"U9<<G\JZ:FA@+4GC_V2ZO14P26G@%?,LA
M701R%MNJ'!$'6B;9I!10VXJ*&]"T*?FP$19ICMT>XH W)BYR(ZA1%QK:X_&E
MJG6\^3*^&:D\7XA>OPO%_9'EY+L@PMZ_@?^$X7!U\F9]7'VN**'#D;7TCRRB
M!^8'5(#S"*PS.CI@N6E%/Z+!4V"-6>J<J79+_YE_2)MOZM;YWIKM-TJ,607^
M17(6)<)*->_0WPS4@0T,_55K'PTM@C_"M7&G,@8RN3#5=J?K7G6C4:EWFA5_
M,>PONL.ZL);\V*L/9P^;5NA211*5]@J\"_E<@P9BXKRKE=NE4\>\?EMD\*F(
MR!'Q$I;P?W#EE%=6/KY_!8C#JP=!F(4'!<O^Z5:T(\ 5[55IY]NH876]!\_^
M7.*[ N/F>3]'UY=X=*2!65;NF'UK](M2D2.H-83*6\2^2KU\6O!\(X37;BV@
M?V"=+(EQ_H20]<O.>R?N$.[ASQ*HC4S)[(,*SU]1YDWF>%;>]:0XU3E0C6!,
MN-X%&\5+R31XU'_>]ZC=,^*&2[>^ M#=J#_!"P;<D0$*2#$DSIC-M#EHK+U(
M\7 EKGZ843W,SN[DZQX;^1"E=X*^;&7=>T':3_M(.>G,\;.=0M$B%8V5E*>+
MP+['/KV=#7+(DP15G%O#A[9 7H$!?=!XNZ>Q;6-E]R"FB.W6U1^>3I"R7^26
MA08"Z#:4*^OF<4 [?T:FT<<057 W !/^J2V'+WDP@#9\=LB>/\W&+L:!M5Y
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M8Y5'+IZYU*#-)V$'FQ-G>P#\RIEY #S]\  (5]>K$]7* FOWB\I"F-)<GM8
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M.. 12G/\;FH)^A9+'C^ \M[;.W1[@UKV6#51PN JHGW4N7M$8=)!O=Z'TLV
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M^DDM<Z)S38(_&;K8L]1M=[S4B/G3\DV)57?:*>X$\(#+Z &0.=[P:>O.[ %
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M&!;;VD0>0#][BR2+$R>9M+R JBB[D?%RVWVYC +_IONF&W#3S=:SN0/$Q]3
M@3RM"BMROESE,ZB++6\05X7&>)=+>6;\! 96@T?\;CPSXI4Y?UU6!66KS[?B
M2@P+^W"G:==FFKDB?V;UY("O#$ ^AT2YETDZ+]$> #" %=/=K2H_DF3:X H&
MR4H"GO<ZH+ Q)28P4XIX#PL[[G_&$)4U*[SZ1BV,'.D4]NM:[(+/?ZKEI"'4
M!4>F/'N^JV+N^ =)-GU.OC9]0=G5W"0'"2S)7@AK#"U8Q[IR4^\)XRU<U!Z1
M"^^FY4N?_);ZKEG#G-DB5>:"RB&S*U'M*-<E7=8$+Z$F,=1NT"D/[G7J(GJ/
MSHL2P]&27>3^;NK\8IH+RGOUU6^.8Y-UCO7-X_S"M96E+WDJ/KYV*XG ^1-@
M>;S=4IW:50(UJH..<[[%C#L>1;XO_'D!T0]R7;C1379*?P=(7,PFJ'R2^503
M$2D-TQZ;.(=JWVJUS%PXT]?6N:E S$RCT4]'-^X&!9F8+GA1AN8@9SM C"JK
MBOZR$0?>2/:#>@)4MNC92V+B/X$6O"&J+6--!C"8VPL6-TB-2;A-6@)  VNI
MIKCI9;[<R:U<.;0FL3M%1*>=W!>P)O4% RW\'6VVJ;S+.O0]<_'7\>+S>BP\
M_HL20B/4ELF-L^-'SS4=MP#NT%#EO_H.BY7-R^T)CYY#P5[? P##\I?9&@Y$
M;?R+E)(A!WEF6#Q5^1=<T$QX]2XS9H;_MTYL$K'[_1\MXHR^BDW!NJ^6=2>,
MH"<LT8*A'VZSWG1XF*$R@QSRYMT%IXR1\^'7F0O0TN)LD4M# QMJRIG4BT*[
M["Y8EM8>:>)TOF&4]LNHXF/L3\Y]QA>B%T4BL.=[ULYRG=Q8FM\:)^?=U=\(
MSCU']\)H&]EMRT:\3EH3N3IO?LO!<L2;\#*L)%HD;]TL&:].5@P%M188^X9R
M5; TNZD1@6HN7&D:27\?1]F8$Y4+H*I'#W5HZ]'/-IR]"N[1\I&[AW3]@7LL
M%'6S@07L94@% 5Y9W.MBD.K*YFE.]V;Q[?9BDV^[F[P^EZ\)<KC;2\47U(UC
MT(-%.0SADC4Q)(5F+P3F+)_V?U239<*E+&6J!NB>T#2+UV<.<QJ3OM!6&/7X
MI?'$B*K08$'54PR!!N?+#JMN[JUTVVVJ;6!K[ LUL$/9[RU.>4+]C4-$>'/0
M3D]FL[\[G?V3*W/;-DU.OG/EA\:I;Q5-$X8?)^VOFW;0TASN56],GD3:"R;]
MCY79=&E0M3Y]U[%9T5YBZL]L%V9H5@4C6KCGY18@34^L5<RD 1&7RUC=Y&HA
M_!;]V=IN;KBMJL/SIHL_]ZQ0Q:OP>?7DCMS?1;L\KPX?H?7:+T!/\ZOWGP?
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MEM67K$><ZZ6\J2=GI1WZ,,AY2UCEH,/!DNZ,.VJK?['%EO)Z/D3LBC9W#0A
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M+[A1YCWU6@DF="-GWDJ->Y'L_9IB$0Y&=X5]?%K!RUI'H?US%Y^KRLA_1>!
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M @<:3?O/X$B\0.V'GX';J8\>&$95EP,/FN(>D/K[E'[R_1?@ARS3N1HU[7?
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M^E2*3NJT)+?D6:472O+T^M6J65]67BX$'[[U'9_<K^]8XB8RF*Y4-,UYPOR
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M)H1R@R^8LYT)C[KH$1ON=@:0+PHZ>OZ^E<2*GJ3AZSYY_+#!YEVVEYI;V*:
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MH,62J0U_&>.[VBF:[VKUCB^N)G7TU2^:]ZL<&U+3'$^%>IK%/+W#(Y:AUE/
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M-OBLR4J110SGUP5[G@&_D3C+OU!0563$Z'E887I 'LTY5*7\E/QS:CKF-\G
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M,"Y;UW5B"4UGJ'W!>FOD\_AJUH16;Y4?:KB/$#_5IVSBDQ?0,/K9FTDBP;;
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MX"9_$&@4\N6KZ,@_G>7/\+K/WKV Z\[AIE/I6CVT!P^,CD;184UQ*>=T#*C
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M4$L! A0#%     @ ]8%66!NZZX5[^P, G>(H !$              ( !
M &%T:&$M,C R,S$R,S$N:'1M4$L! A0#%     @ ]8%66(<$*=#G&0$ +'T0
M !$              ( !JOL# &%T:&$M,C R,S$R,S$N>'-D4$L! A0#%
M  @ ]8%66*:\'PN3 P  [A0   \              ( !P!4% &%T:&$M97@R
M,U\Q+FAT;5!+ 0(4 Q0    ( /6!5EA3X.R>H0@   <Z   /
M  "  8 9!0!A=&AA+65X,S%?,2YH=&U02P$"% ,4    " #U@598SC'5^:,(
M  "M.0  #P              @ %.(@4 871H82UE>#,Q7S(N:'1M4$L! A0#
M%     @ ]8%66*$,4=4C!@  :2,   \              ( !'BL% &%T:&$M
M97@S,E\Q+FAT;5!+ 0(4 Q0    ( /6!5E@A <@.+@8  $LC   /
M      "  6XQ!0!A=&AA+65X,S)?,BYH=&U02P$"% ,4    " #U@598E20Y
M0VX8  #I P$ #@              @ ')-P4 871H82UE>#1?,RYH=&U02P$"
M% ,4    " #U@598,=O!#14;  !\U0  #0              @ %C4 4 871H
M82UE>#DW+FAT;5!+ 0(4 Q0    ( /6!5EB!4<4V^$L! $?< 0 2
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M,C8Y-S4Y7S$T+FIP9U!+ 0(4 Q0    ( /6!5E@R_]T#IL<  /O8   3
M          "  6:J"P!I;6<Q,#4R-CDW-3E?,34N:G!G4$L! A0#%     @
M]8%66$W'$0.Y=P  ;HT  !,              ( !/7(, &EM9S$P-3(V.3<U
M.5\Q-BYJ<&=02P$"% ,4    " #U@598NI,]J$E#  #H4   $P
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M9S$P-3(V.3<U.5\R,"YJ<&=02P$"% ,4    " #U@598FY2R;@NY  "][@
M$P              @ %Q%P\ :6UG,3 U,C8Y-S4Y7S(Q+FIP9U!+ 0(4 Q0
M   ( /6!5EB!4<4V^$L! $?< 0 3              "  :W0#P!I;6<Q,#4R
M-CDW-3E?,C(N:G!G4$L! A0#%     @ ]8%66"RR3,QR>@  BIH  !(
M         ( !UAP1 &EM9S$P-3(V.3<U.5\S+FIP9U!+ 0(4 Q0    ( /6!
M5ECYWG*Z0$0  #-)   2              "  7B7$0!I;6<Q,#4R-CDW-3E?
M-"YJ<&=02P$"% ,4    " #U@598HNZXRB92  "[:0  $@
M@ 'HVQ$ :6UG,3 U,C8Y-S4Y7S4N:G!G4$L! A0#%     @ ]8%66(>:AH^(
M4P  "VT  !(              ( !/BX2 &EM9S$P-3(V.3<U.5\V+FIP9U!+
M 0(4 Q0    ( /6!5EBWA^"R63$  #]$   2              "  ?:!$@!I
M;6<Q,#4R-CDW-3E?-RYJ<&=02P$"% ,4    " #U@5986%'+O"/=  "B$@$
M$@              @ %_LQ( :6UG,3 U,C8Y-S4Y7S@N:G!G4$L! A0#%
M  @ ]8%66+-)W9N#( $ ^E0! !(              ( !TI 3 &EM9S$P-3(V
@.3<U.5\Y+FIP9U!+!08     (  @ /,'  "%L10    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>atha-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atha="http://athira.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atha-20231231.xsd" xlink:type="simple"/>
    <context id="C_8d0e6b76-9bb3-4df6-8c45-7670935b83c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_bf2c465b-8587-438c-a9ea-4095cfc62594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1a260444-47e3-4eab-963c-2dcc49dd3cc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa6a601d-80ed-42d8-a96f-8238a263db27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_922fddad-facf-4336-aa77-97c53317edac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_82ce7c28-19ff-4ba2-94b4-dcbd68834f11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91a3cdff-44c7-4be8-8690-9251ebfd8a0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bfc5356d-4026-41a2-a82b-2bbf62ac66e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d98123fe-9e7e-4c2e-8b91-5f07a93c8aaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_70e3a64b-76f2-4b45-b67d-b2027a3e900e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_224dd772-6aaa-446a-ae9e-b8d743a062d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1ab0bd04-d950-4018-bfb6-93d46d159ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_16f4eb07-f770-4874-8b9e-47c09374ee0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">atha:PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_226d7a94-53b9-413a-83c4-4c853fb51f40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ffcc58d-1976-40bc-bf55-155e02e95431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_3b2efe00-aef3-4b37-ae0e-6491160765f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e33a3149-ce72-41bd-94ff-d0cab93ff8db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:JawandhaVAthiraPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7714a687-7731-4c13-9881-449c6a18a2ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e32575d-a6b9-41a8-91fa-2a9ebdb1b43a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c4d91a5-91db-41e6-9a2a-b4d994e6373c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cfa9f2b7-2752-4887-a960-266fea4dee22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e72d8ea-ec67-44e7-a900-766be31764bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_426e1064-11b7-4ec3-aed5-1a083b3b037d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f8d204cf-7cc0-42a8-aeea-d8322af589cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a7402318-2099-403e-80e2-e4d9762b5a2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_151605f2-8e8c-4ccb-9f19-d395e2a884b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_df96098e-d6ae-4e99-9e22-f4b1da15f310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6694722e-57a7-407b-9dfb-5cabe2faff30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f87c6bfa-07b2-48b3-b0a9-3098dcc3e0c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_008d8a94-a39b-433f-b0b0-77ae3c042f6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eaee46db-7780-4ebe-846f-913aa5aea294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1ff49d7f-fac0-41a7-929e-e4558c77c522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a4594933-cd27-4b2d-b47f-3c26d3044474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:FurnitureFixturesAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a58c8276-7213-4745-af91-33501a2c6737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a65c107a-c260-47d4-aa36-25401168c1ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3f1121d9-b05d-4e5f-9477-a1f96b0362c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a0eab557-b7e2-4d8e-b61f-6fd05508c61b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_2bceb79c-22f4-4e48-96e9-071508ac7697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7faad1c-e70a-40a8-bf1f-ea0da7846fb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d1e4e5a0-6260-4827-a357-156d12d260b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_187e872f-6f06-4138-a5a3-73aa8c516e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6b0b8ce-ab31-4162-be7e-4e0e4f188f69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d6a26653-10d9-4f44-88dc-82ea78ded141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7c67d33-aae0-4112-9efb-f133ec67b36b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_69c9026a-c50a-44e3-a00c-4b6fe771b199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_fd062a54-8e0f-43d9-b4fd-677356eb4cb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:LicensedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e4222da-d4ac-4e84-9095-1eaa081f11b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_94d38940-3716-4ae8-8dcc-05162812b209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:AthiraPharmaIncVDrKawasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f18bc7ab-5af1-44c8-924a-3f2688d049f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atha:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_3c6c7189-5e14-4367-b988-8d2df4618d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d40879de-c9cf-4ff8-8428-c0e65b0b4d5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c75da740-1967-4b45-a209-94145e24aaeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0bbc5dbc-159a-4e8b-8825-ecd0d466bf04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <instant>2024-02-19</instant>
        </period>
    </context>
    <context id="C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_42990ac9-086f-46cd-8523-da23f22d1e85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e5ff6d80-d652-482d-85d9-7a260cc2826b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:NonVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_53baa5a0-6766-48f8-b2f6-ddb46f1ed143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9ed353a2-ea15-493f-8aa1-8373fc805f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_690c503b-308d-4f02-ae74-3a40f7694b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">atha:PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atha:WashingtonStateUniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e1e4cdcc-57d2-49b5-a143-ac39a470f80c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a516322c-a580-416f-a571-a5d4cce10d51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f3b7167-3bdb-4617-add9-35c0246bd8d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:SlyneVAthiraPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1a2f43c4-1117-4672-90c6-75792b11123e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d4a3946d-c3f8-41ed-a196-a68791521aff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_a9177032-05f2-4b4d-b7e2-81d23fa814d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_c68e4dfb-d60e-49f2-96b2-46587068c474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2df3ffa4-7e0f-4475-8dc6-103f27566e6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1bdc52f-55b0-42e4-9b73-d791b4867499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_056747a7-1c94-4990-92ab-823ab0bc1868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12a10015-c94d-4aee-aab4-44e3ae370c9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d250931b-a0c2-4920-858c-160fb803eaac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6e73c2da-bf36-4271-ae86-4b1f0e2f86d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0aeb7363-11f2-4452-9d7a-75e6115d7d8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49dc3275-db5d-457d-9e82-3b59ada8e823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dea600eb-6bff-47e0-a4fc-ba972dd836c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1316502c-52a2-42d4-b1b3-95c55a6319ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8ac800dc-b01c-45e8-b2ee-046ba0e16083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">atha:WangVAthiraPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3680b5de-5819-4049-8d87-083dce72c5cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_897ba1ad-56e2-437d-9cf7-9403bc286825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_710fe844-0726-4f65-be5c-3fa87ea575cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9095dfc0-3298-479d-99a1-25f51998f25b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_053a40d1-bb28-4f1e-bcd3-ded475336474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_28696d50-3838-41f2-a0ee-404e5265a50e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f1c93451-1f41-49f8-b231-c5cf477afc39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3ab74e21-5321-4b29-9cf8-94356358cf01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:NonVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_39cb2c60-d4de-4766-bbf7-e3322d14b6f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_719ee044-1cd6-4354-9d45-5838c649c6cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5545a951-56b7-41cd-9b84-87819c3182e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atha:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_580e918a-d59f-4636-90ec-2ca1df182f19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1a2a914d-8abd-447a-9b84-978f4cf3df2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f7cba87e-57f4-4dd8-a43e-4d3b53a7003d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_656fadf4-0d29-4caa-a75d-c735f8deb466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4d6df006-0245-4a7f-aaeb-b183142fe722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:FurnitureFixturesAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_efe731a6-8644-49ad-81df-a7f77a40963f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe8e26c7-136f-405d-890c-308874394d43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a5908b88-dd8b-4d05-a20d-6351018e760a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a3cbf114-5760-4876-a9ac-f26ffd0959d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atha:ShortTermInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a5c26a41-a1f5-40f5-9d35-4bb1846d30b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atha:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_df1e6e77-ce5e-4ac7-b222-0ce56ac33d5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4726f01b-7636-4549-a578-0b2798df0841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_41b276ca-ace1-420e-a094-64afac7af863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_10175cd6-83a3-4603-bad5-7b3b43f819ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3e32a1c8-6ec3-4e35-b166-fee2b12394c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_303a3846-845e-456f-8c82-d8f63126fa9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cf9a9c4d-ab5c-403b-b958-e051da05ad42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atha:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab70a86c-b366-4a92-835f-b2e57888bb70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">atha:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e223ef3-d9c1-4fbc-a123-56fabdfa0705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atha:BothellWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atha:LaboratoryAndOfficeFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aef30744-a5ec-4f04-bf7c-7c0d2dcb4975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_89aa2ae1-d511-40d1-b6b5-55800463bae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1961c4e3-fcb5-421a-969d-a6cea22d51f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>atha:Segment</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_56099921-7fc5-49df-ae85-a3e4a88a58dd">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_09e53c69-5e8c-48df-b3c1-14bbd57a338d">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_c89404e0-2311-4662-97b2-93f429554497">0001620463</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_008d8a94-a39b-433f-b0b0-77ae3c042f6f"
      id="F_b400847d-1662-41db-b50c-4bdbe2ef14f7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_4a281260-fb9a-463b-8549-038a2ea1ba92">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:DocumentType
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_7b26413e-2717-4bd5-8554-bf9c963d0a64">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_5f3bc295-d377-41c0-940d-687ac488a9e7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_924aeb93-d06a-4996-b345-d15edc195f54">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_35007346-0aac-4942-9670-3f5941cadb5a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_0bc91f8e-cce8-49a2-881e-90a73ead47dd">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_e35e32d6-d878-421f-b969-fc56b59b2ac7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_5cca3d8a-4a2f-420c-b708-19d5daad653e">001-39503</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_47adc4cd-e08a-4145-b0bb-6bbb66a6b413">Athira Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_cb99d7f0-2774-4182-a49c-f1a757c1ad9d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_68c23bed-257e-4b0f-bcbb-334a6a4232dd">45-3368487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_e5bc9124-ddd4-4bf6-825e-dec0f1239ec3">18706 North Creek Parkway,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_805ce964-73b9-4e5c-82be-6d14c6237504">Suite 104</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_3c7c2163-7af8-4eb7-a9f7-5409deb447a5">Bothell,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_7a499113-b0fd-4153-9bf9-c917535ec736">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_24d59df7-af68-4b52-afb3-ea823058a155">98011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1e39efea-38c1-498f-be22-d7775106cae4">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_23a4b2c1-a267-497f-8074-25c08e8c538a">620-8501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_799010fb-8e6c-4fbc-87a5-90598d1b88fd">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_68fc2e2e-c1e9-45fd-90e4-9ce5f21fe090">ATHA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1f466f58-8c94-40b0-8e78-a35eccd321b7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_e828e187-7d46-4b31-9d88-9a88c6fefdf8">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_0df31b0d-19cd-41a4-9a98-b24e772dd253">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_f0e46f8d-8180-421f-af64-8e87aad6041c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_386643e5-a11d-47a4-94cd-75f03fbeff77">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_226f6418-b14d-40ce-a62e-8bf2c9bb2bdc">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_d31edab6-62ea-4587-b70e-8b9a929b1029">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_87844833-162c-4513-8e91-9c5a79c104ef">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_7385b879-2f87-4792-8c6f-c768968fbe18">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_8404fdb3-91bb-4923-82ec-b6a3a024d5ec">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_22890cea-8b59-4b80-bb9d-3bda884aca8c">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_f18e5629-9c4e-4111-9df1-2a340b1e244c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_d4a3946d-c3f8-41ed-a196-a68791521aff"
      decimals="-5"
      id="F_57d7fc42-dcbb-4878-977d-8dd9bff8a77f"
      unitRef="U_USD">96300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0bbc5dbc-159a-4e8b-8825-ecd0d466bf04"
      decimals="INF"
      id="F_e9fe8a11-bedd-4e3c-8899-d4546b2fc2a3"
      unitRef="U_shares">38326652</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_b451bc93-f562-4f77-8ec4-a5888bdb06d7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;"&gt;Portions of the definitive proxy statement to be delivered to stockholders in connection with the 2024 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#x2019;s fiscal year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_aa1eace3-1e30-43da-b214-52f0a8add3a6">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_f4c159d8-8ecc-4383-a6f5-3403b9623165">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_261056d5-ea41-4e39-8f1c-24c42ad5d6c4">Seattle, Washington</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_6454332f-8b73-4198-8283-8af0605f63c2"
      unitRef="U_USD">90584000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_d2d8cdd0-f472-440f-9c0a-9d0754cb4ae9"
      unitRef="U_USD">95966000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_ca82a795-7f51-4752-8686-b26f07bf1973"
      unitRef="U_USD">56835000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_c2fb53b4-ffdd-4309-a231-55def65dcbed"
      unitRef="U_USD">104378000</us-gaap:ShortTermInvestments>
    <atha:UnbilledGrantReceivableCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_8d894d79-448b-4892-9262-b2ae67ce3ecc"
      unitRef="U_USD">1227000</atha:UnbilledGrantReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_fb91448e-5a2e-4ee5-a001-972e5ef4fa92"
      unitRef="U_USD">5682000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_e8041bc6-cf1b-4641-829f-c9e00cc0eb39"
      unitRef="U_USD">5962000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_cc24044d-9651-49cf-a3f9-99780736da87"
      unitRef="U_USD">1628000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_0859c435-8536-493c-9559-3d884d46e142"
      unitRef="U_USD">154729000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_c4498946-9e3c-4874-8c38-4e2f4af2a7c5"
      unitRef="U_USD">207533000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_72c9b6d9-31f4-4e93-a7c5-6ed2563ef6fb"
      unitRef="U_USD">631000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_03c16c83-069c-499d-ac70-690860b82af5"
      unitRef="U_USD">420000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_b598461d-0d7e-426f-9dee-231ab4277bfb"
      unitRef="U_USD">3388000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_88ad8841-200b-47c3-9949-a9f4e89c2b19"
      unitRef="U_USD">4053000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_2a09e98a-5a77-428a-9d6d-7812fa226b85"
      unitRef="U_USD">1049000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_0577975a-9084-4a17-a457-c3d9abdad433"
      unitRef="U_USD">1263000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_459b6c8d-f7d4-48e4-a2a6-2bb74dc18ceb"
      unitRef="U_USD">44829000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_837e2882-8c4e-4dd8-a930-577613cfc3ca"
      unitRef="U_USD">448000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_cf3969d8-c6db-445e-a61b-86b09986b44a"
      unitRef="U_USD">55000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_a1acf749-050f-4d0c-88d1-dda553776d7e"
      unitRef="U_USD">160245000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_be21ea31-835b-4cee-9c3e-7151cf3cd8c1"
      unitRef="U_USD">258153000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_3bd0abd7-9c8e-4478-91e5-2da8fd42abcd"
      unitRef="U_USD">129000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_1803487c-7f54-477f-a298-5b7dc4dee33f"
      unitRef="U_USD">2501000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_40b277d6-0260-422f-a822-5324e45009f9"
      unitRef="U_USD">18343000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_62544e47-2610-4601-b826-6ce7349a365d"
      unitRef="U_USD">8604000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_4869d438-6230-4c7f-9564-5393e9e86158"
      unitRef="U_USD">10000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_e068bd2a-2068-47f1-be1b-a6c46da0e7ef"
      unitRef="U_USD">10000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_3c97614d-b99c-4142-a626-59e4f0432bf8"
      unitRef="U_USD">368000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_0a1eba38-dc1d-4776-981e-f665df2ddce6"
      unitRef="U_USD">326000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_0e0209a8-80f4-4846-97e6-fda6df6dab05"
      unitRef="U_USD">28840000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_c0a90e98-e25f-4f29-8fd7-f76760066224"
      unitRef="U_USD">21431000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_5fb99bcb-09fd-49f1-9b37-b8e46beab7b1"
      unitRef="U_USD">1217000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_9110324d-fe2b-42f0-9b68-423ee0ac4365"
      unitRef="U_USD">1585000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_12b92181-d40e-4365-83d6-f3b58f6183cc"
      unitRef="U_USD">30057000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_999e639a-e373-48ff-81ac-b38326c93af5"
      unitRef="U_USD">23016000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_0e712a6a-2dc7-4ff8-86c5-93513e85e542"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_3a4d8585-b645-4a20-a0a0-0375dcdacc81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_f11bf4df-dc18-43eb-9c82-0f78196e2679"
      unitRef="U_shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_b363f0a4-a2ff-4a0b-9e53-29097dc41aa8"
      unitRef="U_shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_4dda03be-689f-44e1-b5dc-760b97ffabdb"
      unitRef="U_shares">38172603</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_b5704737-e656-44ea-9de7-da8b2c57fd95"
      unitRef="U_shares">38172603</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_674222cd-5151-4c29-9ca6-74e55ebf6aa6"
      unitRef="U_shares">37877387</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_099c998e-4532-4806-87a9-1909dfba147b"
      unitRef="U_shares">37877387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_911f69c3-23cf-4583-82dc-ffc1363d6bf4"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_55c03263-0344-4bb7-8eae-cc8fdfcdb9db"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_0dda5c6f-adcd-4266-b763-a6e7235f610d"
      unitRef="U_USD">439739000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_8425b109-86e1-46a7-a21e-12207ea898b4"
      unitRef="U_USD">428623000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_df3ab6ff-1cc1-4a8b-8736-1d2b9fc4f58a"
      unitRef="U_USD">-349000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_6082c9e7-1a01-4618-a5bb-7793a8034dc6"
      unitRef="U_USD">-1956000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_97a1f562-7e2f-4cb6-9b28-b236ff6697d4"
      unitRef="U_USD">-309206000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_b86999bc-fd33-4f20-b875-3aee5b982acc"
      unitRef="U_USD">-191534000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_867d036f-f25e-4acb-b421-4b383829f1b1"
      unitRef="U_USD">130188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_6e831535-6dc3-4b65-a310-17acdc6a3e2d"
      unitRef="U_USD">235137000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_1191983e-b5c5-4eb3-baf5-ebf8b5747d37"
      unitRef="U_USD">160245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_f2d88191-2a5d-4e6b-b870-0b8682d9ea49"
      unitRef="U_USD">258153000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_d724a475-3fb5-41ad-a95c-baee1c1b454b"
      unitRef="U_USD">93790000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_0e3be7ff-126c-4e7f-8495-8c2ab6c50038"
      unitRef="U_USD">61464000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_41cd6e85-a86f-4661-80a2-29348e821368"
      unitRef="U_USD">33304000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_b8427f55-a10a-49a3-9bc7-4d3dc07a243b"
      unitRef="U_USD">32552000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_fbbf3436-fae3-45a5-aa11-36870976e586"
      unitRef="U_USD">10000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:InsuranceRecoveries
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_7eb9fd5a-d15d-4334-a0f6-8a341d4a5bfb"
      unitRef="U_USD">1628000</us-gaap:InsuranceRecoveries>
    <us-gaap:CostsAndExpenses
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_41950d62-3ed8-4ad7-9294-44a1ca1b57cc"
      unitRef="U_USD">125466000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_1292b5ff-010c-4963-82c7-ba65e06492c6"
      unitRef="U_USD">104016000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_4e569aa7-2b65-4a26-a728-51eee26d3b3c"
      unitRef="U_USD">-125466000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_8986ccfd-224a-44fd-b4e4-d287ba21b586"
      unitRef="U_USD">-104016000</us-gaap:OperatingIncomeLoss>
    <atha:GrantIncome
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_b6426937-75e9-49cb-89db-57a0ed85baee"
      unitRef="U_USD">157000</atha:GrantIncome>
    <atha:GrantIncome
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_3ca33427-b378-42e2-9f39-8cf9754de354"
      unitRef="U_USD">5161000</atha:GrantIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_f8cfa22f-7a6c-4f95-b4b6-543137275fd1"
      unitRef="U_USD">7637000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_d24a8cff-014b-4741-b665-30ee0e5cc517"
      unitRef="U_USD">3216000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_4b2f073b-ef9a-459e-a3da-acb294b0e20b"
      unitRef="U_USD">-117672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_6df01ed5-1879-47f0-8a15-e345cc5065f2"
      unitRef="U_USD">-95639000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_a130db3e-7392-4b71-a625-f7bf4a731c83"
      unitRef="U_USD">1607000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_a5f0518b-caa1-44ee-b120-1863cf3e7353"
      unitRef="U_USD">-1568000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_4d1bfd8a-9805-442c-8497-76cc9bd214b0"
      unitRef="U_USD">-116065000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_e6b20283-e92b-4f3c-aa73-305fa8f62cc5"
      unitRef="U_USD">-97207000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_c240b0ea-8342-4415-b7a9-ee741d63774c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_9d59cbef-694c-4c2f-9515-7edb87e11eb6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="2"
      id="F_dfec29e8-59a4-412c-a681-9fe67c2170c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="2"
      id="F_ac4cfb7e-f2e7-4741-b5ba-6e5f1236d0d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="0"
      id="F_7ddcae88-8a1d-4c0b-8564-c2481e361527"
      unitRef="U_shares">38020182</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="0"
      id="F_fb1fabc8-a142-40ea-b97f-d8973e853052"
      unitRef="U_shares">38020182</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="0"
      id="F_764f51a8-cf71-44c4-9d4e-55459e22ba5d"
      unitRef="U_shares">37733240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="0"
      id="F_65707767-b59d-41f7-acae-b3d2e010d1f4"
      unitRef="U_shares">37733240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_49dc3275-db5d-457d-9e82-3b59ada8e823"
      decimals="INF"
      id="F_75da91fd-923e-4848-9245-97029cf6a1a1"
      unitRef="U_shares">37379077</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_49dc3275-db5d-457d-9e82-3b59ada8e823"
      decimals="-3"
      id="F_78a1ba22-dc1d-453d-adb0-76a769341ccd"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f87c6bfa-07b2-48b3-b0a9-3098dcc3e0c5"
      decimals="-3"
      id="F_f4cdae48-49da-46a4-a999-ca1dbb298695"
      unitRef="U_USD">417363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_efe731a6-8644-49ad-81df-a7f77a40963f"
      decimals="-3"
      id="F_d494ac8d-d651-44f8-970d-0abf34a32f18"
      unitRef="U_USD">-388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4e32575d-a6b9-41a8-91fa-2a9ebdb1b43a"
      decimals="-3"
      id="F_e5967c3b-299a-4497-8c74-8ef92538ed71"
      unitRef="U_USD">-95895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09"
      decimals="-3"
      id="F_82c2306c-b4b8-4e7d-bb4a-84ec84df58bd"
      unitRef="U_USD">321084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_91a3cdff-44c7-4be8-8690-9251ebfd8a0b"
      decimals="INF"
      id="F_02645baf-683e-4727-ac19-a07dae97a2f3"
      unitRef="U_shares">419949</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8"
      decimals="-3"
      id="F_430a577c-963a-4fa4-8214-92306ec915bc"
      unitRef="U_USD">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_69f6357a-7b99-42ab-9857-094f5aabcb00"
      unitRef="U_USD">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="C_91a3cdff-44c7-4be8-8690-9251ebfd8a0b"
      decimals="INF"
      id="F_17a12739-ffae-4e8f-930a-ec932e634a57"
      unitRef="U_shares">78361</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8"
      decimals="-3"
      id="F_166cdbc0-714c-4e3b-918d-8a2a9be7970d"
      unitRef="U_USD">345000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_c75f0144-f0e4-432b-b67f-f4ab1c4a807b"
      unitRef="U_USD">345000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9806ea9f-78ce-4a6b-aa04-863760a03bc8"
      decimals="-3"
      id="F_c27bedc7-0220-431f-9b96-c5abe0a690cb"
      unitRef="U_USD">10606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_7926d48b-0add-413c-a9a9-3fb24a61d9c2"
      unitRef="U_USD">10606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_28696d50-3838-41f2-a0ee-404e5265a50e"
      decimals="-3"
      id="F_fc9820e1-ef99-4fa8-8989-c9b092d045ee"
      unitRef="U_USD">-1568000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_13071ec6-f027-4712-ba1e-fdf4b4df3b63"
      unitRef="U_USD">-1568000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_1a260444-47e3-4eab-963c-2dcc49dd3cc1"
      decimals="-3"
      id="F_00aa9105-210c-4dda-8f51-472e8feb4886"
      unitRef="U_USD">-95639000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_cbb0e9a9-5dc1-4763-a04a-0a808a6040b0"
      unitRef="U_USD">-95639000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_42990ac9-086f-46cd-8523-da23f22d1e85"
      decimals="INF"
      id="F_cd0a0cd6-88ff-45ff-81cf-b3693337ef92"
      unitRef="U_shares">37877387</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_42990ac9-086f-46cd-8523-da23f22d1e85"
      decimals="-3"
      id="F_887df976-a164-42eb-975e-9290598b0d59"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1a2f43c4-1117-4672-90c6-75792b11123e"
      decimals="-3"
      id="F_4c9761b9-2ca4-46e0-93d2-a7bc98711aea"
      unitRef="U_USD">428623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_39cb2c60-d4de-4766-bbf7-e3322d14b6f4"
      decimals="-3"
      id="F_10f15bdf-b3cc-45ff-841f-b7638ef5910b"
      unitRef="U_USD">-1956000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a516322c-a580-416f-a571-a5d4cce10d51"
      decimals="-3"
      id="F_8c70654c-8fb8-4942-95e9-afe5e721d3f1"
      unitRef="U_USD">-191534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_05a57b58-4f41-48fb-a7d1-e7a400f8a1ed"
      unitRef="U_USD">235137000</us-gaap:StockholdersEquity>
    <atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares
      contextRef="C_bf2c465b-8587-438c-a9ea-4095cfc62594"
      decimals="INF"
      id="F_34b66f75-7b2e-4332-8b6e-25087105957d"
      unitRef="U_shares">128534</atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares>
    <atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits
      contextRef="C_a58c8276-7213-4745-af91-33501a2c6737"
      decimals="-3"
      id="F_ac87c4ee-56e0-4205-bbc4-7d728e43f6b6"
      unitRef="U_USD">167000</atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits>
    <atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_4e8ec307-f9f1-4363-a829-6f412aba3e4d"
      unitRef="U_USD">167000</atha:IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="C_bf2c465b-8587-438c-a9ea-4095cfc62594"
      decimals="INF"
      id="F_fd51b2bc-1215-48f4-90b3-b2635e213334"
      unitRef="U_shares">166682</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_a58c8276-7213-4745-af91-33501a2c6737"
      decimals="-3"
      id="F_9561c21d-f292-43fc-a947-ff079a84212b"
      unitRef="U_USD">326000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_1cdfd5c4-9b68-4420-8583-fb266c16353b"
      unitRef="U_USD">326000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a58c8276-7213-4745-af91-33501a2c6737"
      decimals="-3"
      id="F_0c805998-ff5b-40f1-bd9d-46a6e7c12005"
      unitRef="U_USD">10623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_4fdfc992-5ea9-4718-acd0-3b8742f081fe"
      unitRef="U_USD">10623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_3b2efe00-aef3-4b37-ae0e-6491160765f3"
      decimals="-3"
      id="F_68b2b96c-92f0-4e1d-a305-2179e302e5b1"
      unitRef="U_USD">1607000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_194e302e-f54b-46a1-8e34-f11f9623cb25"
      unitRef="U_USD">1607000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_4726f01b-7636-4549-a578-0b2798df0841"
      decimals="-3"
      id="F_300d9a3b-9bdd-4b43-aced-dfbd5dd3a5b0"
      unitRef="U_USD">-117672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_8f4c7d06-e47a-42a7-999f-3e978ad75194"
      unitRef="U_USD">-117672000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_eaee46db-7780-4ebe-846f-913aa5aea294"
      decimals="INF"
      id="F_2c3652b4-c5b9-49ed-9aa5-b674da80dbf1"
      unitRef="U_shares">38172603</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eaee46db-7780-4ebe-846f-913aa5aea294"
      decimals="-3"
      id="F_a00aa878-e52b-4d1f-9ebb-4a19311f018e"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_89aa2ae1-d511-40d1-b6b5-55800463bae5"
      decimals="-3"
      id="F_82e7dfbc-9870-4c4f-be1b-97efed43d6cf"
      unitRef="U_USD">439739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f8d204cf-7cc0-42a8-aeea-d8322af589cd"
      decimals="-3"
      id="F_2c915fad-c57e-4955-b61b-d828979b60a3"
      unitRef="U_USD">-349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_897ba1ad-56e2-437d-9cf7-9403bc286825"
      decimals="-3"
      id="F_e4d5c7a8-ad03-4de2-9b9b-50f7b937dbc1"
      unitRef="U_USD">-309206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_c60d8076-6d87-4010-9daf-01d6c47ac2d8"
      unitRef="U_USD">130188000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_214017f5-9abd-4b28-aded-73b67f686e75"
      unitRef="U_USD">-117672000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_d1aa3060-b2c1-4523-8591-d4be2f26f7e1"
      unitRef="U_USD">-95639000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_668ef31e-b44d-4977-882c-3d4867a009de"
      unitRef="U_USD">10623000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_93566066-85fc-4e50-adab-4b06ddfa577c"
      unitRef="U_USD">10606000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_67d0493c-2b1b-4c23-a0d7-3e9a2fc5811e"
      unitRef="U_USD">969000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_56291506-2645-4586-a903-1bb40e12b5c0"
      unitRef="U_USD">845000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_27b660f4-f302-4c8f-b2ca-aa7438fec6a7"
      unitRef="U_USD">214000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_0ed66582-07d6-4315-a4d9-e857293ab208"
      unitRef="U_USD">203000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_c90cf984-8495-44b3-be31-d58d1e2b3065"
      unitRef="U_USD">1414000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_b6a0fa98-2c6c-4a47-a97a-fd0289e7755b"
      unitRef="U_USD">422000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <atha:IncreaseDecreaseInUnbilledGrantReceivables
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_e15c3ed4-a4e2-47ac-b58c-be41fc373cf8"
      unitRef="U_USD">-1227000</atha:IncreaseDecreaseInUnbilledGrantReceivables>
    <atha:IncreaseDecreaseInUnbilledGrantReceivables
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_11c24dd4-2df1-407e-a1aa-3fe6a928c1ba"
      unitRef="U_USD">-1109000</atha:IncreaseDecreaseInUnbilledGrantReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_c80c2a7f-bfae-4004-8484-9cbd253427d7"
      unitRef="U_USD">113000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_7834f8d9-e807-42f5-a0e1-7a347647a710"
      unitRef="U_USD">1257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_22963cb4-bef7-49d6-8e67-632f5cd1f94d"
      unitRef="U_USD">1628000</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_df89004a-3138-44a8-8f8d-64c5dd2060e9"
      unitRef="U_USD">7367000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_a9f957e4-0b1c-45b6-a943-39a4a4341a2e"
      unitRef="U_USD">2101000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <atha:IncreaseDecreaseInAccruedLegalSettlement
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_e8f98531-5fba-49b8-823a-bb05be3aed3a"
      unitRef="U_USD">10000000</atha:IncreaseDecreaseInAccruedLegalSettlement>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_a328dd13-76e0-45e1-81c0-5bfc81238434"
      unitRef="U_USD">-326000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_0afdc923-3d92-4892-bd5a-0fe686463d6a"
      unitRef="U_USD">-15000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_c6c28f0f-6069-4edb-8e28-8648040e68cc"
      unitRef="U_USD">-100753000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_a22b751c-7075-4165-a074-cca88832abf6"
      unitRef="U_USD">-72469000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_34c78476-9e91-468f-a9d6-1a2cf19cf0c8"
      unitRef="U_USD">27671000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_332a4730-6a67-43cb-89a9-c13de20a0141"
      unitRef="U_USD">95288000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_ff180d9c-a7c1-4253-bea6-d97dac12e8b7"
      unitRef="U_USD">123064000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_57264dbe-70bd-4079-bcb4-4698f6bd76a4"
      unitRef="U_USD">154093000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_6f250ff2-ab43-44a3-8659-3429afaa0610"
      unitRef="U_USD">304000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_9a844069-ffa8-41c3-945c-24060cd89786"
      unitRef="U_USD">1141000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_75efb0f6-3c8d-4cdc-8ec1-54fd7b73d6fd"
      unitRef="U_USD">95089000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_990c27de-ce5c-4948-9901-cc97bfb6091a"
      unitRef="U_USD">57664000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <atha:ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_26de9625-e22d-4beb-9d42-2d515d250309"
      unitRef="U_USD">493000</atha:ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <atha:ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_9f1a1258-a01c-436f-99ea-5e4a190bd583"
      unitRef="U_USD">654000</atha:ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_442f17b4-17d0-4de8-8528-e40a518744fd"
      unitRef="U_USD">493000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_f26389c6-6d00-4a76-a29b-f236532e3324"
      unitRef="U_USD">654000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_3fb620d5-3943-4ed3-8ddf-641024c5815b"
      unitRef="U_USD">-5171000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_cd55be34-096d-4ce8-a4ff-3a395f0476c1"
      unitRef="U_USD">-14151000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_b5afb549-f3d3-4462-91ef-9251613a04bb"
      unitRef="U_USD">96386000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09"
      decimals="-3"
      id="F_62f2856b-df36-4289-9799-8431c6749486"
      unitRef="U_USD">110537000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_4eb02045-3ca8-41d2-8ebf-94da39562145"
      unitRef="U_USD">91215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_4fc00c4e-56a4-4be7-bb61-3053984b7fe0"
      unitRef="U_USD">96386000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_7bc632c3-5703-4236-b537-dde1a071cc93">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;1. Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Athira Pharma, Inc. (the &#x201c;Company&#x201d;) was incorporated as M3 Biotechnology, Inc. in the state of Washington on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;March 31, 2011&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and reincorporated in the state of Delaware on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;October 27, 2015&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Since the Company&#x2019;s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company&#x2019;s inception through December 31, 2023, it has raised aggregate net cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million primarily from the issuance of its common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. As of December 31, 2023, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;147.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million in cash, cash equivalents, and investments and had not generated positive cash flows from operations. Since the Company&#x2019;s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company&#x2019;s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Based upon the Company&#x2019;s current operating plan, it estimates that its $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;147.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million of cash, cash equivalents, and investments at December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months following the date of the Company&#x2019;s Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;At The Market Common Stock Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In January 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;the Company entered into a sales agreement with Cantor Fitzgerald and BTIG to sell shares of our common stock having aggregate sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, from time to time, through an &#x201c;at the market&#x201d; (&#x201c;ATM&#x201d;) equity offering program under which Cantor and BTIG are acting as sales agents. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;not&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; sold any securities pursuant to this ATM offering.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_cf9893d6-18de-45f3-826b-0f4334608a5a">2011-03-31</dei:EntityIncorporationDateOfIncorporation>
    <atha:EntityReincorporationDateOfReincorporation
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_28edcb9c-3a0b-4c17-ae20-ac1b78a4da25">2015-10-27</atha:EntityReincorporationDateOfReincorporation>
    <atha:ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_68540617-0aae-47fd-9c52-968adbe784f8"
      unitRef="U_USD">407400000</atha:ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants>
    <us-gaap:InvestmentsAndCash
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-5"
      id="F_abe2f733-4205-4ba4-82b0-3d2c88ce0425"
      unitRef="U_USD">147400000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsAndCash
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-5"
      id="F_58f3a63a-56b7-4aab-bc97-a1c719c0ff73"
      unitRef="U_USD">147400000</us-gaap:InvestmentsAndCash>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5545a951-56b7-41cd-9b84-87819c3182e2"
      decimals="-5"
      id="F_d2637dfe-9144-4e0e-a34d-d230eb1090fd"
      unitRef="U_USD">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f18bc7ab-5af1-44c8-924a-3f2688d049f8"
      decimals="INF"
      id="F_911c1b1a-d39a-400f-8e06-4566dfde2f50"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_644ebdfe-7ae7-4551-a349-17880239931f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). The consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;factors &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Restricted cash consists primarily of collateral pledged in connection with the Company's corporate credit cards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Short-term and Long-term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment consist of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment, excluding leasehold improvements, are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_b400847d-1662-41db-b50c-4bdbe2ef14f7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of their useful life or the remaining lease term. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess of the asset's carrying amount over its fair value. Gains and losses from asset disposals and impairment losses are classified within the consolidated statements of operations and comprehensive loss in accordance with the use of the asset. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; impairment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;losses &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;in the years ended December 31, 2023 and 2022 as there have been no events warranting an impairment analysis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In December 2020, the Company accepted a grant from the National Institute on Aging (&#x201c;NIA&#x201d;) of the National Institutes of Health (&#x201c;NIH&#x201d;) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company&#x2019;s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer&#x2019;s disease. The Company recognizes income related to the NIH grant in the accompanying consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred. As of December 31, 2023, the Company has recognized aggregate grant income of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million in connection with the NIH grant, equal to the total grant amount approved. The Company will &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t recognize any additional grant income in connection with the NIH grant in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the years ended December 31, 2023 and 2022, the Company recognized grant income of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, which is included in unbilled grant receivable on the consolidated balance sheets. The Company received cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million related to the NIH grant during the year ended December 31, 2023, compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company&#x2019;s proprietary drug discovery platform (&#x201c;ATH platform&#x201d;), the Company&#x2019;s drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company&#x2019;s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;General &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Topic 842 - Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company&#x2019;s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company&#x2019;s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company&#x2019;s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company&#x2019;s lease agreements do not contain residual value guarantees or covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company&#x2019;s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company&#x2019;s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company&#x2019;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In assessing the Company&#x2019;s ability to realize deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future income, tax planning strategies in making this assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company accrues interest and penalties related to unrecognized tax benefits in its provision for incomes taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Comprehensive loss attributable to common stockholders consists of net loss and other gains and losses affecting stockholders&#x2019; equity that, under U.S. GAAP, are excluded from net loss. The Company&#x2019;s comprehensive loss attributable to common stockholders is comprised of net loss and unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transaction Remeasurement Adjustments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at the balance sheet date. Income and expenses denominated in foreign currencies were translated into U.S. dollars at the average exchange rate for the period and the transaction remeasurement adjustments are reported within other income, net in the consolidated statement of operations and comprehensive loss. The functional currency of the Company&#x2019;s Australian subsidiary is the U.S. dollar.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has determined that it operates and manages &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; operating segment, which is the business of developing and commercializing therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_4a281260-fb9a-463b-8549-038a2ea1ba92;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;ASU 2016-13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and it did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t have a material impact on its financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_8a820bdd-9880-4ece-bcee-fe2f95b7d5f4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). The consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_33fbb955-7b0a-4975-9a55-85b4ab4f8aab">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;factors &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_d0e761dc-fc5c-44d8-9f43-b3af560d874a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1ea70a7b-748a-497a-a4c0-104faf053ad2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Restricted cash consists primarily of collateral pledged in connection with the Company's corporate credit cards. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_838acaab-6291-4d1e-90f8-36a81f2d70b2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the consolidated statements of cash flows.&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_bce973df-ff0b-4771-9d15-ca4f99bf98e5"
      unitRef="U_USD">90584000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_3511c026-74a4-417d-bae0-9c5b5d15abf7"
      unitRef="U_USD">95966000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_13fa9c1f-bca7-4c20-86d7-842ea1d03e9f"
      unitRef="U_USD">631000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_48a8831d-212f-4517-9a7e-155908a33549"
      unitRef="U_USD">420000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_77e8dbf9-32ab-4f2c-9eb2-e61f38ee8bd0"
      unitRef="U_USD">91215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_09d50a39-dc19-44a3-b83e-b7c0c6a1f5e7"
      unitRef="U_USD">96386000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_d1e6f610-88d0-4264-ac1b-349421c25d5e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Short-term and Long-term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_15f86720-951a-49b7-b0aa-c0d9ba4152cc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_184fb083-e0fc-4e20-851c-0bb95b5e4b10">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment consist of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment, excluding leasehold improvements, are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_b400847d-1662-41db-b50c-4bdbe2ef14f7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of their useful life or the remaining lease term. Maintenance and repairs are charged to expense as incurred, and costs of improvements are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess of the asset's carrying amount over its fair value. Gains and losses from asset disposals and impairment losses are classified within the consolidated statements of operations and comprehensive loss in accordance with the use of the asset. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; impairment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;losses &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;in the years ended December 31, 2023 and 2022 as there have been no events warranting an impairment analysis.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a7402318-2099-403e-80e2-e4d9762b5a2a"
      id="F_47de4f7c-6401-480e-9111-649bd46ad8df">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_480556c8-f90f-446a-b9fb-671222232384"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="INF"
      id="F_c0b87bb9-3e38-4b84-a137-d5e9ade2c23c"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_90319e19-23fa-41cc-8e75-f671d03fec0e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <atha:GrantIncomePolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_8f6df98b-36a7-4fb3-8598-aec6f9a6d8be">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In December 2020, the Company accepted a grant from the National Institute on Aging (&#x201c;NIA&#x201d;) of the National Institutes of Health (&#x201c;NIH&#x201d;) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company&#x2019;s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer&#x2019;s disease. The Company recognizes income related to the NIH grant in the accompanying consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred. As of December 31, 2023, the Company has recognized aggregate grant income of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million in connection with the NIH grant, equal to the total grant amount approved. The Company will &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t recognize any additional grant income in connection with the NIH grant in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the years ended December 31, 2023 and 2022, the Company recognized grant income of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, which is included in unbilled grant receivable on the consolidated balance sheets. The Company received cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million related to the NIH grant during the year ended December 31, 2023, compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</atha:GrantIncomePolicyTextBlock>
    <atha:AggregateGrantIncome
      contextRef="C_056747a7-1c94-4990-92ab-823ab0bc1868"
      decimals="-5"
      id="F_c20d2e19-a705-4ed8-8f1f-cf7ca483a509"
      unitRef="U_USD">15200000</atha:AggregateGrantIncome>
    <atha:AdditionalGrantIncome
      contextRef="C_303a3846-845e-456f-8c82-d8f63126fa9f"
      decimals="INF"
      id="F_69d24b4d-6422-48dc-a106-02f7efa45147"
      unitRef="U_USD">0</atha:AdditionalGrantIncome>
    <atha:GrantIncome
      contextRef="C_303a3846-845e-456f-8c82-d8f63126fa9f"
      decimals="-5"
      id="F_bbb00dd1-3c9e-41e2-a96d-be53eadc7ee7"
      unitRef="U_USD">200000</atha:GrantIncome>
    <atha:GrantIncome
      contextRef="C_cf9a9c4d-ab5c-403b-b958-e051da05ad42"
      decimals="-5"
      id="F_85953d2b-79b1-42ee-8b7c-4f676ea6b4e0"
      unitRef="U_USD">5200000</atha:GrantIncome>
    <atha:UnbilledGrantReceivableCurrent
      contextRef="C_12a10015-c94d-4aee-aab4-44e3ae370c9d"
      decimals="-5"
      id="F_483a48ee-64b4-4a2d-9464-c19c846ed0ca"
      unitRef="U_USD">1200000</atha:UnbilledGrantReceivableCurrent>
    <atha:GrantsReceived
      contextRef="C_303a3846-845e-456f-8c82-d8f63126fa9f"
      decimals="-5"
      id="F_5d538caa-0c8a-466e-b205-16a4c9c542df"
      unitRef="U_USD">1400000</atha:GrantsReceived>
    <atha:GrantsReceived
      contextRef="C_cf9a9c4d-ab5c-403b-b958-e051da05ad42"
      decimals="-5"
      id="F_72a4c9cb-6180-4db1-98c5-627a8dea1fe9"
      unitRef="U_USD">6300000</atha:GrantsReceived>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_0337defd-09c7-4cad-82b2-69ae76b6e274">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company&#x2019;s proprietary drug discovery platform (&#x201c;ATH platform&#x201d;), the Company&#x2019;s drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company&#x2019;s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_f98ebe84-9751-4fac-9078-8c168ca5a453">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;General &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. &lt;/span&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_2b018278-ad8a-4902-a61f-cad1e981c391">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Topic 842 - Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company&#x2019;s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company&#x2019;s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company&#x2019;s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company&#x2019;s lease agreements do not contain residual value guarantees or covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company&#x2019;s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company&#x2019;s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0aeb7363-11f2-4452-9d7a-75e6115d7d8c"
      id="F_e15293fa-0f1c-4e5c-a40e-1c41375e50ae">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0aeb7363-11f2-4452-9d7a-75e6115d7d8c"
      id="F_090322bd-7e5d-4407-a1bd-bbe9c771e3b8">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1a9b0fb4-6637-4d92-9324-c10a1d3645f5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company&#x2019;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_d6a9c295-e107-4d3e-bba3-bbdc3fa04232">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In assessing the Company&#x2019;s ability to realize deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future income, tax planning strategies in making this assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company accrues interest and penalties related to unrecognized tax benefits in its provision for incomes taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_80293b74-4ba1-425c-b757-d8094979b6b9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Comprehensive loss attributable to common stockholders consists of net loss and other gains and losses affecting stockholders&#x2019; equity that, under U.S. GAAP, are excluded from net loss. The Company&#x2019;s comprehensive loss attributable to common stockholders is comprised of net loss and unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_854713c6-db5d-4d05-baeb-bac2fd01f6e6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_54d54d6b-39fb-4599-8059-e30ae9932be6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transaction Remeasurement Adjustments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at the balance sheet date. Income and expenses denominated in foreign currencies were translated into U.S. dollars at the average exchange rate for the period and the transaction remeasurement adjustments are reported within other income, net in the consolidated statement of operations and comprehensive loss. The functional currency of the Company&#x2019;s Australian subsidiary is the U.S. dollar.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_0051fb47-9689-4403-b379-6908e920f7b7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has determined that it operates and manages &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; operating segment, which is the business of developing and commercializing therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_f7764a9d-3b91-44ae-b8e7-37ee337cdd12"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <atha:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_e61cdcb3-d40d-469f-a58c-4e822c08086b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;</atha:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_73afb95b-6efe-4e93-9b67-1aa1f4fab10b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_4a281260-fb9a-463b-8549-038a2ea1ba92;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;ASU 2016-13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and it did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t have a material impact on its financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      id="F_bed5ec41-d1b4-43f2-8c93-b528205d314b">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      id="F_bb4ed510-ce86-441d-ad95-45d4d249ece7">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      id="F_b1ec0d48-8db1-4a50-9c3a-cd6c580609bc">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_9533eb05-f11a-4912-b141-03b4348ac22d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;Inputs are generally unobservable and reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The determination of a financial instrument&#x2019;s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following tables reflect the Company&#x2019;s financial asset balances measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;U.S. government debt and agency&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;U.S. government debt and agency&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Long-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;U.S. government debt and agency&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;All the commercial paper, U.S. government debt, and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; from the respective balance sheet date. Those that are designated as long-term investments have an effective maturity date that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, but less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, from the respective balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of December 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized gains (losses) for available-for-sale securities were recorded in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_d8e7d0a4-c433-4507-873f-fa0140b4fa66">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following tables reflect the Company&#x2019;s financial asset balances measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;U.S. government debt and agency&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;U.S. government debt and agency&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Long-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;U.S. government debt and agency&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a7c67d33-aae0-4112-9efb-f133ec67b36b"
      decimals="-3"
      id="F_f348bf76-450a-400d-8639-9dff7afca7b4"
      unitRef="U_USD">63000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a7c67d33-aae0-4112-9efb-f133ec67b36b"
      decimals="-3"
      id="F_b2972dea-4ede-4858-add9-841e612de624"
      unitRef="U_USD">63000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4"
      decimals="-3"
      id="F_8dc0bbd6-dbbc-49ac-809c-35088c1e6c94"
      unitRef="U_USD">59227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4"
      decimals="-3"
      id="F_628bcf1a-eb10-44de-b75c-fee92c74bf22"
      unitRef="U_USD">30000</atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e70c532f-f0e6-4c3b-9d08-9e9fee29e3b4"
      decimals="-3"
      id="F_79c46fb8-05b3-47fe-a072-5be525308bbf"
      unitRef="U_USD">59197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b"
      decimals="-3"
      id="F_7e618c96-f6b4-4983-b381-33f48d0be890"
      unitRef="U_USD">59290000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b"
      decimals="-3"
      id="F_434b3e52-0123-4cc6-aafe-03bfedee552c"
      unitRef="U_USD">30000</atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cd28a3d7-4467-4019-aee4-0b3c67a7f18b"
      decimals="-3"
      id="F_02c6af9d-548d-4f0e-82da-c242784902d1"
      unitRef="U_USD">59260000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9095dfc0-3298-479d-99a1-25f51998f25b"
      decimals="-3"
      id="F_874cedda-c70f-41eb-898d-389b586e2845"
      unitRef="U_USD">6431000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9095dfc0-3298-479d-99a1-25f51998f25b"
      decimals="-3"
      id="F_c7297e05-3851-4694-b4a7-6961e169c2cf"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9095dfc0-3298-479d-99a1-25f51998f25b"
      decimals="-3"
      id="F_e1c078e4-4664-419d-84a0-d0b6dc432c0f"
      unitRef="U_USD">6427000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1ff49d7f-fac0-41a7-929e-e4558c77c522"
      decimals="-3"
      id="F_670cb96e-7cd3-4e67-8390-f8035f7ea2f6"
      unitRef="U_USD">50723000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1ff49d7f-fac0-41a7-929e-e4558c77c522"
      decimals="-3"
      id="F_e32350a1-de93-4141-b9ef-548321373846"
      unitRef="U_USD">315000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_1ff49d7f-fac0-41a7-929e-e4558c77c522"
      decimals="-3"
      id="F_28d4a7b2-f050-42c7-b7f3-e158b89d416e"
      unitRef="U_USD">50408000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d"
      decimals="-3"
      id="F_4febaccc-6828-46ad-9a93-9f78080934a3"
      unitRef="U_USD">57154000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d"
      decimals="-3"
      id="F_f01a3ac8-44c0-40ff-987c-c50df0c5ff3a"
      unitRef="U_USD">319000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_017439f9-30d8-41f1-9a7e-19ec7fa68e5d"
      decimals="-3"
      id="F_d5b419ea-7fb0-4467-98a3-3122bf10aa39"
      unitRef="U_USD">56835000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_187e872f-6f06-4138-a5a3-73aa8c516e11"
      decimals="-3"
      id="F_95882b82-5a89-4bea-9089-a30fdaa470da"
      unitRef="U_USD">7000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_187e872f-6f06-4138-a5a3-73aa8c516e11"
      decimals="-3"
      id="F_191f84bb-e913-4a61-8930-01d05ee0b9e9"
      unitRef="U_USD">7000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f"
      decimals="-3"
      id="F_cf490e48-9e2a-4fef-8a8a-6c6c039ca72f"
      unitRef="U_USD">78028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f"
      decimals="-3"
      id="F_a9878412-95aa-461e-ae64-9a6b4a18cae7"
      unitRef="U_USD">26000</atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6dd3fcc3-1158-44bc-bf06-c4af592fbf8f"
      decimals="-3"
      id="F_a3dd8876-7538-4d46-aaad-5ae29c9d6402"
      unitRef="U_USD">78002000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d1e4e5a0-6260-4827-a357-156d12d260b6"
      decimals="-3"
      id="F_53d68293-b40d-42a9-a0fd-179272675e21"
      unitRef="U_USD">78035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d1e4e5a0-6260-4827-a357-156d12d260b6"
      decimals="-3"
      id="F_52695db6-b752-43a5-90ea-39743025181a"
      unitRef="U_USD">26000</atha:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d1e4e5a0-6260-4827-a357-156d12d260b6"
      decimals="-3"
      id="F_1282f798-b46b-4993-a14b-26e2540ac869"
      unitRef="U_USD">78009000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1"
      decimals="-3"
      id="F_3b3c6d71-5d4e-4401-b2c5-02afd7e65cf0"
      unitRef="U_USD">36933000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1"
      decimals="-3"
      id="F_262b0948-17bf-41f0-8506-740c79c32dd3"
      unitRef="U_USD">168000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a55a5de6-07ce-43e6-981d-e6fa7b2187b1"
      decimals="-3"
      id="F_1adc2fde-0c70-4921-9603-a77d96771d30"
      unitRef="U_USD">36765000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7714a687-7731-4c13-9881-449c6a18a2ae"
      decimals="-3"
      id="F_ce484033-5162-4e9a-aec7-2cd8d2796336"
      unitRef="U_USD">65157000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7714a687-7731-4c13-9881-449c6a18a2ae"
      decimals="-3"
      id="F_75998d4c-4039-48be-b746-6bb80baaa652"
      unitRef="U_USD">784000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7714a687-7731-4c13-9881-449c6a18a2ae"
      decimals="-3"
      id="F_0618e9b3-c312-4b7c-b21a-bef54c6f82a9"
      unitRef="U_USD">64373000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e1bdc52f-55b0-42e4-9b73-d791b4867499"
      decimals="-3"
      id="F_2837f0f8-826d-4672-86f9-6c8a52765a56"
      unitRef="U_USD">3302000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e1bdc52f-55b0-42e4-9b73-d791b4867499"
      decimals="-3"
      id="F_f52e96f3-5a54-4c9f-9f3f-f2c026bbdee7"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e1bdc52f-55b0-42e4-9b73-d791b4867499"
      decimals="-3"
      id="F_f991b8ab-5174-4059-890b-d2e43c26a6c0"
      unitRef="U_USD">3240000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc"
      decimals="-3"
      id="F_00ce9e0a-aa50-410d-8ca2-3122aaccec49"
      unitRef="U_USD">105392000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc"
      decimals="-3"
      id="F_64154ab8-07c0-4255-84f8-449e3d854b6e"
      unitRef="U_USD">1014000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a19b2676-9211-45ae-b28c-50e65aaa2bcc"
      decimals="-3"
      id="F_384d7425-2055-4570-9ffe-b162fdb0dd14"
      unitRef="U_USD">104378000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_719ee044-1cd6-4354-9d45-5838c649c6cb"
      decimals="-3"
      id="F_a6d4e249-cd34-4cc9-b09b-bfa75165de53"
      unitRef="U_USD">45745000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_719ee044-1cd6-4354-9d45-5838c649c6cb"
      decimals="-3"
      id="F_4b685e3f-0c39-4481-87b9-f52d6aadc5ed"
      unitRef="U_USD">916000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_719ee044-1cd6-4354-9d45-5838c649c6cb"
      decimals="-3"
      id="F_fab2c16f-f96c-4d2b-8fa2-796a01258197"
      unitRef="U_USD">44829000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_922fddad-facf-4336-aa77-97c53317edac"
      decimals="-3"
      id="F_586987aa-9a3b-4d3a-b483-7f57d0b5a5ed"
      unitRef="U_USD">45745000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_922fddad-facf-4336-aa77-97c53317edac"
      decimals="-3"
      id="F_1770eead-527f-4dff-8f1a-8c5df120019e"
      unitRef="U_USD">916000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_922fddad-facf-4336-aa77-97c53317edac"
      decimals="-3"
      id="F_66d4d7d7-a8ae-462c-8e6a-a05f9a372795"
      unitRef="U_USD">44829000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <atha:ShortTermInvestmentsMaturityTerm
      contextRef="C_3f1121d9-b05d-4e5f-9477-a1f96b0362c3"
      id="F_a8c0e22b-c455-478a-be17-16a951cd6819">P1Y</atha:ShortTermInvestmentsMaturityTerm>
    <atha:LongTermInvestmentsMaturityTerm
      contextRef="C_d98123fe-9e7e-4c2e-8b91-5f07a93c8aaa"
      id="F_2abc4b27-dd8b-4e56-bd68-11012479af7e">P1Y</atha:LongTermInvestmentsMaturityTerm>
    <atha:LongTermInvestmentsMaturityTerm
      contextRef="C_3f1121d9-b05d-4e5f-9477-a1f96b0362c3"
      id="F_bb9b4e5e-aec8-40ab-bbc3-95e302fcfdf6">P2Y</atha:LongTermInvestmentsMaturityTerm>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_dfa91633-4c1d-49a0-9fff-942c3dad4b45">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;4. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture, fixtures, and&lt;br/&gt;&#160;&#160;&#160;computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;969,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;845,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_de1e251d-632a-4f19-8070-3bbc03665a45">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture, fixtures, and&lt;br/&gt;&#160;&#160;&#160;computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d6a26653-10d9-4f44-88dc-82ea78ded141"
      decimals="-3"
      id="F_712f1947-1d97-4ee3-8b78-995f48eefcf1"
      unitRef="U_USD">688000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_41b276ca-ace1-420e-a094-64afac7af863"
      decimals="-3"
      id="F_9ded9df3-9486-4053-ae2f-0b2edb0b1c50"
      unitRef="U_USD">433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a4594933-cd27-4b2d-b47f-3c26d3044474"
      decimals="-3"
      id="F_461bf61a-28d8-40bd-a6ea-1982e60a451e"
      unitRef="U_USD">712000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d6df006-0245-4a7f-aaeb-b183142fe722"
      decimals="-3"
      id="F_f1647742-6836-47a9-b474-e4c771048824"
      unitRef="U_USD">692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0e4222da-d4ac-4e84-9095-1eaa081f11b0"
      decimals="-3"
      id="F_286adaf3-4b50-4ada-bf29-d0c686e14a0f"
      unitRef="U_USD">4322000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e6b0b8ce-ab31-4162-be7e-4e0e4f188f69"
      decimals="-3"
      id="F_f5a92b62-c3bc-4a32-9093-5286c7aa9fdc"
      unitRef="U_USD">4296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_cddacca8-be7b-4e54-ad76-057b1de89199"
      unitRef="U_USD">5722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_eaa0873f-6377-4db4-971a-1bafe1c0f9b5"
      unitRef="U_USD">5421000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_b42e2dd5-892d-4bd0-8bf9-4e33da03fe63"
      unitRef="U_USD">2334000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_641394b2-16aa-4fac-b5f3-f39331984278"
      unitRef="U_USD">1368000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_d59d7d52-2e9b-47bf-993e-1fa1c62687da"
      unitRef="U_USD">3388000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_f3f7241c-028c-46c1-8207-e93d8b87ba71"
      unitRef="U_USD">4053000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="0"
      id="F_1a21f7b4-0473-471d-96f3-5c00685df613"
      unitRef="U_USD">969000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="0"
      id="F_8580eb02-d429-4299-8a5d-604611cbb2a2"
      unitRef="U_USD">845000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1ce90d43-d7eb-4fb1-9a84-15110ab09e12">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Professional services and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_ce75641b-cd55-490d-b4db-e6bf20a86f9c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Professional services and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <atha:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_77bde78e-44b0-429f-a51d-c479a100fd38"
      unitRef="U_USD">11916000</atha:AccruedResearchAndDevelopmentExpensesCurrent>
    <atha:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_9002f3fc-d7a5-4dcc-8710-70336e5b6ce8"
      unitRef="U_USD">3843000</atha:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_82a6bc45-71f4-468e-bab6-129a3c92c1e6"
      unitRef="U_USD">4545000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_f80a4a79-db29-4133-b38f-5193502db8e0"
      unitRef="U_USD">3415000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <atha:AccruedProfessionalServicesAndOtherCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_63f88142-9d94-46f0-a150-c94a4e02a14c"
      unitRef="U_USD">1882000</atha:AccruedProfessionalServicesAndOtherCurrent>
    <atha:AccruedProfessionalServicesAndOtherCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_f29822dc-6256-4c12-b047-08ea0ebcda3f"
      unitRef="U_USD">1346000</atha:AccruedProfessionalServicesAndOtherCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_fcf3f0bd-0539-43fd-bb78-d12579d0dfc4"
      unitRef="U_USD">18343000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_a2dbd334-2134-487b-909b-77dbaff1e833"
      unitRef="U_USD">8604000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_22f1c9a4-53e0-4648-bbb3-2317681e3e0c">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Significant Agreements&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;WSU License Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is party to an amended and restated exclusive license agreement with sublicensing terms with WSU that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2020, the Phase 2 clinical trial milestone had been reached and a payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; to WSU was recorded.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company may also be obligated to pay the following if the related milestones are reached:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &#x2013; At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &#x2013; Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; of net sales being exempt from royalty payment, and annual minimum royalty payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; beginning after the first commercial sale of a licensed product. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; sales of any licensed products had occurred and the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t incurred a royalty obligation under this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based payments received, and low twenties of net sales based sublicense royalties. As of December 31, 2023, the Company has not entered into or incurred any liability from a sublicense agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <atha:PaymentOnAchievementOfDevelopmentMilestone
      contextRef="C_690c503b-308d-4f02-ae74-3a40f7694b5a"
      decimals="0"
      id="F_22792b92-078c-48f9-a857-5b8fda37053c"
      unitRef="U_USD">50000</atha:PaymentOnAchievementOfDevelopmentMilestone>
    <atha:MilestonePaymentsAmountPayableUponTrialInitiation
      contextRef="C_16f4eb07-f770-4874-8b9e-47c09374ee0c"
      decimals="0"
      id="F_1ddd3461-eb4f-40ac-949c-4129e3eb0196"
      unitRef="U_USD">300000</atha:MilestonePaymentsAmountPayableUponTrialInitiation>
    <atha:MilestonePaymentsAmountPayableUponMarketingApproval
      contextRef="C_69c9026a-c50a-44e3-a00c-4b6fe771b199"
      decimals="0"
      id="F_bc7e5e9c-4987-450e-a42a-2d92a79e0479"
      unitRef="U_USD">600000</atha:MilestonePaymentsAmountPayableUponMarketingApproval>
    <atha:NetSalesExemptFromRoyaltyPayment
      contextRef="C_a0eab557-b7e2-4d8e-b61f-6fd05508c61b"
      decimals="0"
      id="F_3d99806f-24eb-40a3-baeb-b53623286c06"
      unitRef="U_USD">100000</atha:NetSalesExemptFromRoyaltyPayment>
    <atha:AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale
      contextRef="C_a0eab557-b7e2-4d8e-b61f-6fd05508c61b"
      decimals="INF"
      id="F_2706a031-216b-4d4f-998b-329413854826"
      unitRef="U_USD">25000</atha:AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale>
    <us-gaap:Revenues
      contextRef="C_fd062a54-8e0f-43d9-b4fd-677356eb4cb7"
      decimals="INF"
      id="F_21873b4e-b86f-4a61-8aab-47d1e784040d"
      unitRef="U_USD">0</us-gaap:Revenues>
    <atha:RoyaltyObligation
      contextRef="C_aa6a601d-80ed-42d8-a96f-8238a263db27"
      decimals="INF"
      id="F_1e2f0729-73a5-4a03-9c77-2609f7051ff1"
      unitRef="U_USD">0</atha:RoyaltyObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_93e96cd0-2e12-475e-817f-f575e117725f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;7. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.44%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;From time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Securities Class Actions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;June 25, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, plaintiffs &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Fan Wang and Hang Gao&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Company&#x2019;s former chief executive officer Dr. Leen Kawas, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Wang v. Athira Pharma, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Company&#x2019;s business. Specifically, the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Wang &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendants&#x2019; positive statements about the Company&#x2019;s business, operations, and prospects were materially misleading. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Wang &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys&#x2019; fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;That same day, on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;June 25, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, plaintiff &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Harshdeep Jawandha&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company&#x2019;s then chief financial officer, certain members of the Company&#x2019;s board of directors at the time of the Company&#x2019;s initial public offering ("IPO"), as well as the IPO underwriters, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Jawandha v. Athira Pharma, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, No. 2:21-cv-00862. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Jawandha &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933 ("Securities Act"), alleging that that the Company&#x2019;s IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas&#x2019;s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Company&#x2019;s efforts to develop treatments for Alzheimer&#x2019;s disease, and that the defendants&#x2019; positive statements about the Company&#x2019;s business, operations, and prospects were materially misleading. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Jawandha &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys&#x2019; fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Also on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;June 25, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, plaintiffs &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Timothy Slyne and Tai Slyne&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company&#x2019;s then chief financial officer, and the same members of the Company&#x2019;s board of directors and underwriters as in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Jawandha &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;complaint, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Slyne v. Athira Pharma, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, No. 2:21-cv-00864. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Slyne &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas&#x2019;s doctoral research at WSU should have been disclosed in the Company&#x2019;s IPO registration statement. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Slyne&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; plaintiffs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;seek unspecified compensatory damages, reasonable costs and expenses, including attorneys&#x2019; fees, and injunctive and other equitable relief.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Company&#x2019;s then chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering ("SPO"), and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas&#x2019;s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs&#x2019; consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;August 12, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, defendant &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Dr. Kawas&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; filed a motion for partial reconsideration of the court&#x2019;s July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On March 10, 2023, following a mediation and the parties&#x2019; agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffs&#x2019; motion for preliminary approval without prejudice, citing the motion&#x2019;s failure to satisfy the court&#x2019;s questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffs&#x2019; renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024 proposing a date on which the court may schedule the final approval hearing, among other things. In its order, the court preliminarily approved the proposed settlement and certified a class and two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As a result of the foregoing, the Company recorded a legal settlement expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million in operating expenses in the fourth quarter of 2022 and an accrued liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million on the accompanying consolidated balance sheets. Additionally, the Company recorded an insurance recovery of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million on the accompanying consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by the Company's insurers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Shareholder Derivative Actions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Company&#x2019;s board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Bushansky v. Kawas et al.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, No. 2:22-cv-497. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that the Company&#x2019;s board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Company&#x2019;s public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint seeks unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys&#x2019; fees.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Houlihan v. Kawas et al&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;., No. 2:22-cv-620. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that certain of the Company&#x2019;s current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Company&#x2019;s public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint seeks unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys&#x2019; fees.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. The Company believes it has adequate reserves related to this matter as of the latest balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Government Investigations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice (the "Demand"). The Demand seeks documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH, and our receipt of a NIH grant in 2020. The Company is cooperating with the Department of Justice with respect to the Demand.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In February 2023, the Securities and Exchange Commission ("SEC"), sent the Company a subpoena seeking documents and information relating to, among other things, the Company's former chief executive officer's alterations of images in certain research papers. The Company is cooperating with the SEC with respect to the subpoena.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company cannot predict the outcome of these lawsuits or government investigations. Failure by the Company to obtain a favorable resolution of these actions could have a material adverse effect on our business, results of operations and financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date the Company has not&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company enters into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;August 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. The initial terms of the leases range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;options to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; the leases for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; that it is not reasonably certain to exercise. As of December 31, 2023, the Company was not party to any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following table reconciles the Company&#x2019;s undiscounted operating lease cash flows to its operating lease liability (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Present value adjustment for minimum lease&lt;br/&gt;&#160;&#160;&#160;commitments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.143%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Operating lease expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;368,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022, respectively. Separately, variable lease expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;186,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for operating leases during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyLawsuitFilingDate
      contextRef="C_8ac800dc-b01c-45e8-b2ee-046ba0e16083"
      id="F_0f7b6a10-5ef5-41d4-97a9-b035e99f19a0">June 25, 2021</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff
      contextRef="C_8ac800dc-b01c-45e8-b2ee-046ba0e16083"
      id="F_474fac8f-d9da-4573-95b4-7b80cc5b00fd">Fan Wang and Hang Gao</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyLawsuitFilingDate
      contextRef="C_e33a3149-ce72-41bd-94ff-d0cab93ff8db"
      id="F_0d4baf36-3694-4cd5-8ab5-8f0e5f3ead8e">June 25, 2021</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff
      contextRef="C_e33a3149-ce72-41bd-94ff-d0cab93ff8db"
      id="F_08ef418d-139b-45f5-8692-55e9e0c5a2cf">Harshdeep Jawandha</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyLawsuitFilingDate
      contextRef="C_9f3b7167-3bdb-4617-add9-35c0246bd8d1"
      id="F_82e7fdf1-fdc2-464b-9334-335575bd04e2">June 25, 2021</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff
      contextRef="C_9f3b7167-3bdb-4617-add9-35c0246bd8d1"
      id="F_a8b5c89c-b25c-4bf0-9f2d-774b23821d80">Timothy Slyne and Tai Slyne</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyLawsuitFilingDate
      contextRef="C_94d38940-3716-4ae8-8dcc-05162812b209"
      id="F_864d3854-c45b-4e7f-a7c2-905494eb695d">August 12, 2022</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfDefendant
      contextRef="C_94d38940-3716-4ae8-8dcc-05162812b209"
      id="F_c531fb02-0df3-4da3-b4ca-1e4e873d0f1e">Dr. Kawas</us-gaap:LossContingencyNameOfDefendant>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_1316502c-52a2-42d4-b1b3-95c55a6319ad"
      decimals="-5"
      id="F_a8c5ec86-eaed-4182-a78b-7a8a7fae821f"
      unitRef="U_USD">10000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-5"
      id="F_6b30699b-8573-401c-b395-7dfa6ac6ed35"
      unitRef="U_USD">10000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:InsuranceRecoveries
      contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc"
      decimals="-5"
      id="F_75649e64-c0ab-4f87-9e9b-cd0a127a2c58"
      unitRef="U_USD">1600000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-5"
      id="F_605b4895-f6b2-45ee-a716-6912341d3091"
      unitRef="U_USD">1600000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <atha:OperatingLeaseExpirationMonthAndYear
      contextRef="C_e1e4cdcc-57d2-49b5-a143-ac39a470f80c"
      id="F_326b2794-05ae-4125-ba58-45e1f7c34a79">2027-08</atha:OperatingLeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_151605f2-8e8c-4ccb-9f19-d395e2a884b6"
      id="F_5496fc95-8093-45b6-9d04-ce4183a87a12">P6Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_8e223ef3-d9c1-4fbc-a123-56fabdfa0705"
      id="F_7f961bde-50fd-4d7c-9cee-710ba57dd301">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_e1e4cdcc-57d2-49b5-a143-ac39a470f80c"
      id="F_129fc8a9-29a9-492b-a83e-32dbc387e254">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_2df3ffa4-7e0f-4475-8dc6-103f27566e6e"
      id="F_425179f8-0154-41e6-b81d-c17cb686a7f2">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_ac30f4e4-a423-48aa-8c39-b89f313e83c7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following table reconciles the Company&#x2019;s undiscounted operating lease cash flows to its operating lease liability (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Present value adjustment for minimum lease&lt;br/&gt;&#160;&#160;&#160;commitments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_e5c2d454-1201-4a46-a541-13ad0537ad2b"
      unitRef="U_USD">480000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_84dc826a-5ff9-4d47-a30c-292c4b97bf2c"
      unitRef="U_USD">494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_fb889257-c8da-4042-a492-1b13a0e45134"
      unitRef="U_USD">509000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <atha:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_bd25c41d-c22a-41c1-8864-e786bd88103a"
      unitRef="U_USD">346000</atha:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_1206a565-a9f0-4319-9eee-764254b90e55"
      unitRef="U_USD">1829000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_2e54d12f-1720-43e2-b579-0e2aee775e6c"
      unitRef="U_USD">244000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_3feb3f8d-0f64-4c35-8cb6-1a04a75f585e"
      unitRef="U_USD">1585000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_4763e717-e80e-4e46-a73c-892a6118f2b3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.143%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      id="F_f87fb9ad-e3b8-4b7b-af70-e4b55658f398">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="3"
      id="F_d6d19827-e52b-42be-9c06-54a57ada51a7"
      unitRef="U_pure">0.081</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="0"
      id="F_93f5e399-bf15-4b44-ae18-a9395ba98161"
      unitRef="U_USD">353000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="0"
      id="F_746fd1ac-53e2-4668-afab-2ffa31bb7e7d"
      unitRef="U_USD">368000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="0"
      id="F_e3345171-4ecc-4f25-8808-6c172a7a9b28"
      unitRef="U_USD">186000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="0"
      id="F_3e715733-4824-491f-9f7c-803f514fbc00"
      unitRef="U_USD">167000</us-gaap:VariableLeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_474f19bc-131b-40f9-8923-1afcc6789f66">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Common Stock&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Company&#x2019;s board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.568%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.557%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.716%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares issuable upon the exercise of outstanding&lt;br/&gt;&#160;&#160;&#160;common stock options and the vesting of&lt;br/&gt;&#160;&#160;&#160;outstanding common restricted stock&lt;br/&gt;&#160;&#160;&#160;units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,130,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,269,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for future grant under the 2020&lt;br/&gt;&#160;&#160;&#160;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,158,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,253,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for future grant under the&lt;br/&gt;&#160;&#160;&#160;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,128,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,417,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,440,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s 2020 Equity Incentive Plan (&#x201c;2020 Plan&#x201d;) provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,230,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Effective January 1, 2023, the Company&#x2019;s 2020 Plan and ESPP reserves increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,893,869&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;378,774&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Effective January 1, 2024, the Company&#x2019;s 2020 Plan and ESPP reserves increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,908,630&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;381,726&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_7abd9397-eb48-4be6-bca5-1421ed342702">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.568%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.557%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.716%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares issuable upon the exercise of outstanding&lt;br/&gt;&#160;&#160;&#160;common stock options and the vesting of&lt;br/&gt;&#160;&#160;&#160;outstanding common restricted stock&lt;br/&gt;&#160;&#160;&#160;units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,130,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,269,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for future grant under the 2020&lt;br/&gt;&#160;&#160;&#160;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,158,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,253,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for future grant under the&lt;br/&gt;&#160;&#160;&#160;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,128,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,417,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,440,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1961c4e3-fcb5-421a-969d-a6cea22d51f1"
      decimals="INF"
      id="F_e1678767-17b5-4ad9-99ab-a586b696627c"
      unitRef="U_shares">7130956</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_aef30744-a5ec-4f04-bf7c-7c0d2dcb4975"
      decimals="INF"
      id="F_1ceef88b-da00-4df7-a0bd-f62401964a5a"
      unitRef="U_shares">4269861</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1a2a914d-8abd-447a-9b84-978f4cf3df2c"
      decimals="INF"
      id="F_8eaba3cc-56e8-473d-b57f-ef11e8660671"
      unitRef="U_shares">3158094</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3680b5de-5819-4049-8d87-083dce72c5cb"
      decimals="INF"
      id="F_0ba378fc-f105-428c-bb2b-e40ab5398921"
      unitRef="U_shares">4253854</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2bceb79c-22f4-4e48-96e9-071508ac7697"
      decimals="INF"
      id="F_10fda105-aa3e-4c7a-bca8-da4289b40b5e"
      unitRef="U_shares">1128732</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cfa9f2b7-2752-4887-a960-266fea4dee22"
      decimals="INF"
      id="F_6b4ab7a4-545d-4860-aee7-2095017d9b2d"
      unitRef="U_shares">916640</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_d9449ea3-8765-4b79-9640-3cdbefc3db62"
      unitRef="U_shares">11417782</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_89cccbf8-391f-472a-a6ec-14fb5d06117f"
      unitRef="U_shares">9440355</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan
      contextRef="C_a3cbf114-5760-4876-a9ac-f26ffd0959d6"
      decimals="INF"
      id="F_c578381a-39fc-44a9-83ee-f6eb35b983cd"
      unitRef="U_shares">3230000</atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan>
    <atha:ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding
      contextRef="C_a3cbf114-5760-4876-a9ac-f26ffd0959d6"
      decimals="INF"
      id="F_efc82eb1-e0e3-4713-9bcc-4a6f776a295b"
      unitRef="U_pure">0.05</atha:ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding>
    <atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan
      contextRef="C_226d7a94-53b9-413a-83c4-4c853fb51f40"
      decimals="INF"
      id="F_7db238ae-4a61-4873-9595-55053ba6daa0"
      unitRef="U_shares">646000</atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan>
    <atha:ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding
      contextRef="C_226d7a94-53b9-413a-83c4-4c853fb51f40"
      decimals="INF"
      id="F_38b69fa3-9be7-414e-9267-a9b2bd94c84a"
      unitRef="U_pure">0.01</atha:ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f7cba87e-57f4-4dd8-a43e-4d3b53a7003d"
      decimals="INF"
      id="F_567bd508-ce68-406a-8c53-cb7e44bc6e1b"
      unitRef="U_shares">1893869</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8d0e6b76-9bb3-4df6-8c45-7670935b83c7"
      decimals="INF"
      id="F_a16a9dd0-442f-4a4a-978e-78c911ec78b1"
      unitRef="U_shares">378774</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a5c26a41-a1f5-40f5-9d35-4bb1846d30b8"
      decimals="INF"
      id="F_48d9948e-9e59-4de9-9fbe-dbfa186d59cd"
      unitRef="U_shares">1908630</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a9177032-05f2-4b4d-b7e2-81d23fa814d3"
      decimals="INF"
      id="F_71c35157-430b-4992-baf9-dc29d4864347"
      unitRef="U_shares">381726</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_bd9f7262-8a7a-4187-b7c4-9d55f84e75fb">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Stock-based Compensation&lt;/span&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The fair value of each share of common stock is based on the closing price of the Company&#x2019;s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The fair value of each stock option was estimated using the Black&#x2011;Scholes option&#x2011;pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The grant date fair value of restricted stock units is based upon the fair market value of the Company&#x2019;s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The fair value of options granted during the years ended December 31, 2023 and 2022 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively. The fair value of restricted stock units granted during the year ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Changes in shares available for grant under the 2020 Plan during the year ended December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;br/&gt;Available &lt;br/&gt;for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for grant at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,253,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2020 Plan reserve increase on January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,893,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Options and restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,834,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Options and restricted stock units forfeited, &lt;br/&gt;&#160;&#160;&#160;cancelled, or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;845,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for grant at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,158,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;A summary of option activity for the year ended December 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;br/&gt;per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,033,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,696,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Forfeited/expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;780,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,820,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.24&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,000,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Options exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,820,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.56&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The total fair value of options granted that vested during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#x2019;s common stock underlying all options that were in-the-money at December 31, 2023. The aggregate intrinsic value of options exercised was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million during the year ended December 31, 2023 and 2022, respectively, determined as of the date of option exercise. As of December 31, 2023, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;1.99&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; years. The Company utilizes newly issued shares to satisfy option exercises.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock options outstanding and exercisable consisted of the following at December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-family:Arial;min-width:fit-content;"&gt;Exercise Price ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,709,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,005,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,759,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,615,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;352,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,820,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,820,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;A summary of RSU activity for the year ended December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.879999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Share&lt;br/&gt;Equivalent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-vested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Under the ESPP, eligible employees can authorize payroll deductions for amounts up to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of their qualifying wages or the statutory limit under the U.S. Internal Revenue Code. The ESPP provides for offering periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; in duration with one purchase period per offering period beginning May 18 and November 18 of each year. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Participants in an offering period will be granted the right to purchase shares of our common stock at a price per share that is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the lesser of the fair market value of the shares at (1) the first day of the offering period or (2) the end of each purchase period within the offering period. A maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock may be purchased by each participant at the purchase date during the offering period. The fair market value of the ESPP options granted is determined using the Black-Scholes model and is amortized on a straight-line basis. Stock-based compensation expense recognized during the years ended December 31, 2023 and 2022 associated with the ESPP was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,682&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock to employees under the ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_f0a5a3c3-bbd0-4a08-9a4a-a6b983f4ac3f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4e72d8ea-ec67-44e7-a900-766be31764bf"
      decimals="-3"
      id="F_6174ec34-5e37-4f5d-a030-f8f698b42082"
      unitRef="U_USD">4003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a5908b88-dd8b-4d05-a20d-6351018e760a"
      decimals="-3"
      id="F_e5f01457-6a7b-4220-97af-329c265b84e5"
      unitRef="U_USD">3217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_df1e6e77-ce5e-4ac7-b222-0ce56ac33d5b"
      decimals="-3"
      id="F_bff9b6dc-21e8-4f10-bb62-dba1a7b4f1d0"
      unitRef="U_USD">6620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c68e4dfb-d60e-49f2-96b2-46587068c474"
      decimals="-3"
      id="F_0c211590-1e13-49bb-82fc-a19b3fd85dbb"
      unitRef="U_USD">7389000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_f44b21a1-b538-4041-91a4-d0a1acaa323b"
      unitRef="U_USD">10623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_f10f8e00-0c0c-4e9b-9432-d8a8195db73e"
      unitRef="U_USD">10606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_048724a3-205f-4cf2-937b-240616258909"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_0f396b60-dcd4-4375-80c0-7272013d66b7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The fair value of each stock option was estimated using the Black&#x2011;Scholes option&#x2011;pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="4"
      id="F_b37d6bb0-a594-4259-b564-63d3de8f49b5"
      unitRef="U_pure">0.0354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="4"
      id="F_27cbb03d-ea8c-44a0-9cfc-11b5befefbf1"
      unitRef="U_pure">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="4"
      id="F_48a45637-748c-444b-b881-0e82629c7e41"
      unitRef="U_pure">0.9918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="4"
      id="F_dc03cba1-0616-4387-bc8e-80ce9f965a79"
      unitRef="U_pure">0.9295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_9dd67770-0ceb-4ade-af4d-4695500661bd">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      id="F_b5ebf1eb-6a87-4546-b362-c9b3d80889df">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_ed89fdbd-6d8c-4dff-99f0-091c090bbf42"
      unitRef="U_USD">9800000</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-5"
      id="F_c2a2b36a-2c2c-477c-98ff-21b8856d29f8"
      unitRef="U_USD">16300000</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_447f49fc-0331-4364-8e22-2f9d2c38140a"
      unitRef="U_USD">500000</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-5"
      id="F_65181d41-2698-4890-ad38-677143da1455"
      unitRef="U_USD">100000</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue>
    <atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_6b2b64d5-9f95-486c-8740-092402307558">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Changes in shares available for grant under the 2020 Plan during the year ended December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;br/&gt;Available &lt;br/&gt;for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for grant at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,253,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2020 Plan reserve increase on January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,893,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Options and restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,834,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Options and restricted stock units forfeited, &lt;br/&gt;&#160;&#160;&#160;cancelled, or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;845,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares available for grant at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,158,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_7aabbc2b-078d-4373-890f-b3d1939df00d"
      unitRef="U_shares">4253854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_6e824ff4-9d57-405d-9a7e-f85c8ce95e70"
      unitRef="U_shares">1893869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_7513aed9-ad3f-4687-830d-109bcec31df0"
      unitRef="U_shares">3834783</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_1891b4e4-1590-4135-9f0c-e9b545da9124"
      unitRef="U_shares">845154</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_310fdd69-9c72-407c-b31f-e7163f626079"
      unitRef="U_shares">3158094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_b23b4dc8-ef11-4335-852a-01b4baef312d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;A summary of option activity for the year ended December 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;br/&gt;per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,033,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,696,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Forfeited/expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;780,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,820,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.24&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,000,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Options exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,820,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.56&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="INF"
      id="F_527f0bc2-4605-4a6c-b00e-7b6b0bcb60a3"
      unitRef="U_shares">4033522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="2"
      id="F_868f4213-7800-4b36-bc80-a03d03c6006d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      id="F_7ac321ef-ec51-4bea-8673-63095a2f0373">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_052e1cd5-2cf7-488e-afef-8e271d40c151"
      unitRef="U_USD">827000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_8d712fbf-e625-424d-bef8-487a0ed55c04"
      unitRef="U_shares">3696783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_8c9367c8-161e-436b-b841-3743288a779d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_aaacf40f-3b36-40d2-8cc8-43eb6573207b"
      unitRef="U_shares">128534</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_042f6b89-a606-463b-8b30-c461a5d9234c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_a489df0f-ee96-482a-8058-0de7fa81b4d6"
      unitRef="U_shares">780902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_171e363f-e6a5-4956-bb80-f451b37ef80c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_a9c94b84-cc37-42bc-bbe6-c332627c3a31"
      unitRef="U_shares">6820869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="2"
      id="F_38232f17-d05a-410d-9929-e899860a7c61"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_e19eb2a3-7d9f-4fad-a17b-224d6726ec42">P8Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_ade322fe-deb1-4457-bb55-f16024c258a7"
      unitRef="U_USD">387000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_7e56ecfc-0174-4302-aa63-716d1187dbf9"
      unitRef="U_shares">4000554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="2"
      id="F_c72e63e8-28fd-46e8-a68f-c01e4bfb0cb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_08f6a16b-c871-4ccf-af03-526596c4b61a">P8Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_32bada16-cf03-485b-9ff9-3e954c554b61"
      unitRef="U_shares">2820315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="2"
      id="F_5eeb1cfd-8058-40ab-94c5-2b30f32d0066"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_d179af65-79bd-41ad-884a-7addccb09ec5">P7Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_8283ef4c-ed61-4bd5-ac6d-2966fd97ee6e"
      unitRef="U_USD">387000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_d60529c4-e17a-42c1-a30f-0fceefd72551"
      unitRef="U_USD">9800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-5"
      id="F_aa32e554-dcb5-4da2-a7f4-c41ead5518ad"
      unitRef="U_USD">6800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_f72cb4d6-60e5-4442-91b5-f53fdd21bb24"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-5"
      id="F_87782b0b-85da-475d-bf2d-e0f4c56884a7"
      unitRef="U_USD">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-5"
      id="F_b03dac58-bb31-404c-925c-1e7d5aba05ea"
      unitRef="U_USD">16000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1b4681b0-d2bc-4b40-ab78-1ac9e7f47d6d">P1Y11M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_3db57156-58d9-446d-afce-bd4897bb4bcd">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock options outstanding and exercisable consisted of the following at December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-family:Arial;min-width:fit-content;"&gt;Exercise Price ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Shares&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,709,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,005,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,759,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,615,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;352,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,820,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,820,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="C_d40879de-c9cf-4ff8-8428-c0e65b0b4d5a"
      decimals="INF"
      id="F_5403aa37-8fff-48b4-aed4-0afee8b9c162"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.16</atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="C_580e918a-d59f-4636-90ec-2ca1df182f19"
      decimals="INF"
      id="F_d035eb2a-9abc-4d7c-a581-380100193e46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.22</atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077"
      decimals="INF"
      id="F_ed1833db-95c9-43a5-8ee5-70589a724daa"
      unitRef="U_shares">3709593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_44cc996e-953e-4a9f-8ffc-0fdc1c17a077"
      decimals="INF"
      id="F_920fbf5b-42b6-4d32-868f-9d78a7929049"
      unitRef="U_shares">1005785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="C_1ab0bd04-d950-4018-bfb6-93d46d159ba7"
      decimals="INF"
      id="F_88650d0c-ebac-4462-bc71-ec3e7a4e743d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.93</atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="C_82ce7c28-19ff-4ba2-94b4-dcbd68834f11"
      decimals="INF"
      id="F_1e9c806c-eaf1-4498-a831-8e953c61bbdc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.94</atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_dea600eb-6bff-47e0-a4fc-ba972dd836c1"
      decimals="INF"
      id="F_98260cb2-1097-4324-9582-e95f7ae42d12"
      unitRef="U_shares">2759028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_dea600eb-6bff-47e0-a4fc-ba972dd836c1"
      decimals="INF"
      id="F_5d455443-069f-4066-b16a-60b4e669c535"
      unitRef="U_shares">1615758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="C_ab70a86c-b366-4a92-835f-b2e57888bb70"
      decimals="INF"
      id="F_7e617fdb-8b35-4f3e-92f8-bef89d8c539c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.55</atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="C_426e1064-11b7-4ec3-aed5-1a083b3b037d"
      decimals="INF"
      id="F_ba3e0f11-c2d1-4f2f-917c-898790273705"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.41</atha:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c75da740-1967-4b45-a209-94145e24aaeb"
      decimals="INF"
      id="F_1f3cac46-077b-4a56-8663-c23833d1bd08"
      unitRef="U_shares">352248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_c75da740-1967-4b45-a209-94145e24aaeb"
      decimals="INF"
      id="F_a4ac6004-d4e8-48af-af9d-82e6a024ef78"
      unitRef="U_shares">198772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_b0c9960d-0577-4440-bc34-9f60a3b651e6"
      unitRef="U_shares">6820869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_c4eb2d3c-b53e-4896-96f0-ca432a049fff"
      unitRef="U_shares">2820315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac"
      id="F_4007b0cf-a5bd-4330-93ab-0ecd186708d5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;A summary of RSU activity for the year ended December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.879999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Share&lt;br/&gt;Equivalent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-vested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a65c107a-c260-47d4-aa36-25401168c1ef"
      decimals="INF"
      id="F_96d7255a-a2f4-43e6-a2ba-1e57e28c8441"
      unitRef="U_shares">236339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_a65c107a-c260-47d4-aa36-25401168c1ef"
      decimals="2"
      id="F_1f4f277f-6757-49d7-96cc-8d86217e5f58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac"
      decimals="INF"
      id="F_3eaf2946-2468-421b-8dcf-7042b355bc44"
      unitRef="U_shares">138000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac"
      decimals="2"
      id="F_c8c3a13c-e4f0-492f-ad64-2abb8b775abf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac"
      decimals="INF"
      id="F_d9ce3c9a-c83e-4fc9-90b3-db18123139ee"
      unitRef="U_shares">64252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_d250931b-a0c2-4920-858c-160fb803eaac"
      decimals="2"
      id="F_4d547eb2-6c66-4d72-abc5-49c700260a36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_70e3a64b-76f2-4b45-b67d-b2027a3e900e"
      decimals="INF"
      id="F_6dddb10c-3af8-445b-9ab8-61d159b62e14"
      unitRef="U_shares">310087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_70e3a64b-76f2-4b45-b67d-b2027a3e900e"
      decimals="2"
      id="F_0d2503cc-30e6-451c-9cf7-c3a31e8d7cf1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_9ed353a2-ea15-493f-8aa1-8373fc805f50"
      id="F_bdc52a36-9091-456b-b87c-fc498134ce55">Under the ESPP, eligible employees can authorize payroll deductions for amounts up to the lesser of 15% of their qualifying wages or the statutory limit under the U.S. Internal Revenue Code. The ESPP provides for offering periods of six months in duration with one purchase period per offering period beginning May 18 and November 18 of each year. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit
      contextRef="C_4ffcc58d-1976-40bc-bf55-155e02e95431"
      decimals="2"
      id="F_7c26f5fc-413f-42ce-a1ce-0ab8fe0cc87d"
      unitRef="U_pure">0.15</atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfPayrollDeductionsForQualifyingWagesOrStatutoryLimit>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_6e73c2da-bf36-4271-ae86-4b1f0e2f86d6"
      id="F_1b1f51fb-e3ec-4bf5-b1bd-5c86628f1f51">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_6e73c2da-bf36-4271-ae86-4b1f0e2f86d6"
      decimals="2"
      id="F_0f9ed5e6-d7e5-401d-a7b0-f5ccbc09d0ad"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_a7faad1c-e70a-40a8-bf1f-ea0da7846fb1"
      decimals="INF"
      id="F_e23ad1c8-7947-4758-aaf7-d3cc24b72f07"
      unitRef="U_shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9ed353a2-ea15-493f-8aa1-8373fc805f50"
      decimals="-5"
      id="F_0d18b55c-71c5-4c6f-867d-c978baa4fb81"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6694722e-57a7-407b-9dfb-5cabe2faff30"
      decimals="-5"
      id="F_cd0bed4e-79b5-4c93-9a83-e5e6e37848fb"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_bf2c465b-8587-438c-a9ea-4095cfc62594"
      decimals="0"
      id="F_2f3d47a2-6c8e-48c1-828d-091acab61b64"
      unitRef="U_shares">166682</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_650a74f4-9c1c-45d8-830c-f3f4077dc2c2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Components of Income and Income Tax&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company did not record a provision (benefit) for income taxes for the years ended December 31, 2023 and 2022. Net loss is attributable to the following tax jurisdictions (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;Net Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The provision for income taxes differs from the amount expected by applying the federal statutory rates to the net loss before taxes as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-deductible expenses and others&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development tax credit&lt;br/&gt;&#160;&#160;&#160;carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Deferred income taxes reflect temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes, and operating losses and tax credit carryforwards. The Company considers a number of factors concerning the realizability of its net deferred tax assets, including its history of operating losses, the nature of the deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible, all of which require significant judgment. As of December 31, 2023, the Company has recorded a full valuation allowance on its net deferred tax assets as the Company has concluded that it is not more likely than not that such losses or credits will be utilized. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;28.3&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million during 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;At December 31, 2023, the Company has federal net operating loss and tax credit carryforwards of  $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, respectively, which expire over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; years. Net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;138.7&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million were generated after 2017, and therefore do not expire. As of December 31, 2023, the Company also had state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, which expire over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 costs incurred in years beginning on or after January 1, 2022.  Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software, or technique. This provision changes the treatment of Section 174 costs such that the expenditures are no longer allowed as an immediate deduction but rather must be capitalized and amortized. We have included the impact of this provision, which results in a deferred tax asset of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million as of December 31, 2023.&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company files federal income tax returns. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years prior to 2016. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;were generated and carried forward and may make adjustments to the amount of the net operating loss or credit carryforward amount. The Company is not currently under examination in any jurisdiction.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits for uncertain tax positions were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Additions for tax positions taken in prior&lt;br/&gt;&#160;&#160;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Additions for tax positions taken in the current&lt;br/&gt;&#160;&#160;&#160;year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023 are recognized, there will be no impact to the effective tax rate due to the valuation allowance. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated financial statements. At December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; material interest and penalties on uncertain tax benefits. The Company does not anticipate any significant changes to its unrecognized tax benefits in the next 12 months.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_6530ab1d-d078-4730-aa54-f81736ed5ff2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company did not record a provision (benefit) for income taxes for the years ended December 31, 2023 and 2022. Net loss is attributable to the following tax jurisdictions (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;Net Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_3f09adfc-9c9a-45da-80ea-08c98eb5bf04"
      unitRef="U_USD">-117440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_7e549e31-e396-4a57-8f99-6e5eb5738245"
      unitRef="U_USD">-95778000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_ff4ace4d-47e0-46fd-ae1f-6d07374b20f3"
      unitRef="U_USD">-232000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_915dfe8e-1d0f-4233-9158-0d5694df0b01"
      unitRef="U_USD">139000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:NetIncomeLoss
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_a2ad8133-dd1a-4b7d-91f6-c80b5cbbf0a2"
      unitRef="U_USD">-117672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_3adab774-e542-42f7-be1c-ea09162e3e2c"
      unitRef="U_USD">-95639000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_1efe2ee9-cd35-4bbd-9179-eb297a8346aa">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The provision for income taxes differs from the amount expected by applying the federal statutory rates to the net loss before taxes as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-deductible expenses and others&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="3"
      id="F_473e4ace-8c52-42ae-9cec-47419010ffc3"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="3"
      id="F_cebc939f-19b3-462c-aed5-bd04306ffaeb"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="3"
      id="F_908202a8-9001-4db4-a4e3-4813ef0a1d24"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="3"
      id="F_b88022e0-80a4-44ed-845f-7abb83b653fe"
      unitRef="U_pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="3"
      id="F_1fb371ab-8aaf-42bb-af43-b13d1cb0dd5a"
      unitRef="U_pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="3"
      id="F_6d391b5a-79e6-4277-9705-90063ce40935"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="3"
      id="F_db5e486d-1380-4855-8c36-b6baedaa5e4e"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="3"
      id="F_4819e022-6ca0-423d-82b8-69fad88a6441"
      unitRef="U_pure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="3"
      id="F_49ff5c53-4a8f-4713-a9f9-37ed0c1ea656"
      unitRef="U_pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="3"
      id="F_20eb00ce-eca9-4633-b8c9-0bd1d4b167a2"
      unitRef="U_pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="3"
      id="F_f8dac838-7228-44a7-b072-c209cea561cd"
      unitRef="U_pure">-0.214</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="2"
      id="F_3e732ae4-7af7-46dd-9afa-cde2fa825899"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="2"
      id="F_01c108c5-d588-4c6d-8c8e-7705bb712022"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_c4ce0495-1edd-4749-bd0f-b89f22974c35">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development tax credit&lt;br/&gt;&#160;&#160;&#160;carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_c0cded50-84cb-4a22-8807-01e3bd34ecc3"
      unitRef="U_USD">31342000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_5156a88d-74d3-452e-a6e9-920fdef4d0e3"
      unitRef="U_USD">24092000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_97a150f9-24f9-4899-8351-770f45dff448"
      unitRef="U_USD">9327000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_97711b1d-d72e-4aad-b78f-9eda73f0d2fb"
      unitRef="U_USD">4218000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_ec580dbb-78e2-4def-b8c6-dd8ba1623718"
      unitRef="U_USD">2828000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_9a436a76-42e4-44ad-805d-aa0fcd4a99e6"
      unitRef="U_USD">2781000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_67ec60de-5268-4939-ac94-1b99cbe0717c"
      unitRef="U_USD">2564000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_3e094bfa-9100-46de-ae7c-5ea6e4e4f19b"
      unitRef="U_USD">1676000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <atha:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_34fb36b1-8ad2-4b4d-9745-1ab88be16aff"
      unitRef="U_USD">333000</atha:DeferredTaxAssetsOperatingLeaseLiability>
    <atha:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_f80c1e11-c251-40e9-8799-d47885099bb9"
      unitRef="U_USD">404000</atha:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_83b64d2e-30fb-4444-b0df-7f653b1e0db8"
      unitRef="U_USD">180000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_f468e2e3-0357-44c0-adfb-6f582a638147"
      unitRef="U_USD">121000</us-gaap:DeferredTaxAssetsOther>
    <atha:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_619d19fa-a45b-4e01-ba1e-3863c1e59aab"
      unitRef="U_USD">25182000</atha:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <atha:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_d2a911ea-6eb9-45e2-90f3-862cc59e5b4a"
      unitRef="U_USD">10729000</atha:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_0a3dadef-80fe-4a08-842d-172a7c98df0e"
      unitRef="U_USD">71756000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_abb45758-0862-4863-80e1-d42079c11f6c"
      unitRef="U_USD">44021000</us-gaap:DeferredTaxAssetsGross>
    <atha:DeferredTaxAssetsRightOfUseAsset
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_1eb5669d-aaea-4c0a-8079-63fa0fab9f77"
      unitRef="U_USD">221000</atha:DeferredTaxAssetsRightOfUseAsset>
    <atha:DeferredTaxAssetsRightOfUseAsset
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_c510799c-e80c-4e8d-8e60-899fa743ebda"
      unitRef="U_USD">267000</atha:DeferredTaxAssetsRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_9664d4f6-041c-4c9a-8578-3824b9ff6053"
      unitRef="U_USD">75000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_ed85c4d2-b7ff-436b-b77e-67fc4d093cac"
      unitRef="U_USD">475000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_1289c964-81d2-4834-9ca8-3d98b773eeab"
      unitRef="U_USD">214000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_acba3768-5967-4f6b-817c-de49791eb7e4"
      unitRef="U_USD">294000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_0d7e1d0f-31a5-4f95-bfa7-a39eaf6547f1"
      unitRef="U_USD">510000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_b1f4a75f-2df4-407e-affa-b440673e772b"
      unitRef="U_USD">1036000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_a6b80fbe-cbfc-4e27-8615-3ee420f6841d"
      unitRef="U_USD">71246000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_349ca7f2-a925-4815-b2ea-1a5857a4d50a"
      unitRef="U_USD">42985000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_f790d076-35da-4ee5-a74c-6097d35b5988"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_9eaac286-cc59-4720-ba1e-6105723e3a93"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_ad59a4e9-dd5c-4662-b366-64db9728a089"
      unitRef="U_USD">28300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-5"
      id="F_862d122a-12d5-4516-a470-f9535068500c"
      unitRef="U_USD">20400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_053a40d1-bb28-4f1e-bcd3-ded475336474"
      decimals="-5"
      id="F_34b0bce5-2048-4655-a40b-b5e822baa773"
      unitRef="U_USD">9500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_053a40d1-bb28-4f1e-bcd3-ded475336474"
      decimals="-5"
      id="F_331f0ef0-091e-4c17-a895-51f4e40c092d"
      unitRef="U_USD">12400000</us-gaap:TaxCreditCarryforwardAmount>
    <atha:NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod
      contextRef="C_df96098e-d6ae-4e99-9e22-f4b1da15f310"
      id="F_6e7d97c8-29cb-444c-865d-2006d0ca03ff">P8Y</atha:NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod>
    <atha:NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod
      contextRef="C_710fe844-0726-4f65-be5c-3fa87ea575cb"
      id="F_d8343e6c-73d0-40ea-a886-181377ea8425">P14Y</atha:NetOperatingLossAndTaxCreditCarryForwardsExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-5"
      id="F_e479ef6b-d0c1-4c33-ada6-9679f218bb04"
      unitRef="U_USD">138700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7c4d91a5-91db-41e6-9a2a-b4d994e6373c"
      decimals="-5"
      id="F_eab4833f-0c76-4546-bba0-a4ad88edac25"
      unitRef="U_USD">3300000</us-gaap:OperatingLossCarryforwards>
    <atha:OperatingLossCarryForwardsExpirationPeriod
      contextRef="C_3e32a1c8-6ec3-4e35-b166-fee2b12394c3"
      id="F_a48361b6-f8c0-431f-955c-8a50be22a06e">P18Y</atha:OperatingLossCarryForwardsExpirationPeriod>
    <atha:OperatingLossCarryForwardsExpirationPeriod
      contextRef="C_656fadf4-0d29-4caa-a75d-c735f8deb466"
      id="F_11545012-286a-4005-b99f-17f9650bc31e">P20Y</atha:OperatingLossCarryForwardsExpirationPeriod>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-5"
      id="F_3820a36d-7ce6-43c0-86fe-ff26e348d3d0"
      unitRef="U_USD">25200000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_30a1345c-64e0-4d05-ad5d-131820aa85eb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits for uncertain tax positions were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Additions for tax positions taken in prior&lt;br/&gt;&#160;&#160;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Additions for tax positions taken in the current&lt;br/&gt;&#160;&#160;&#160;year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_03135702-241a-4f7f-a6da-338f995000d9"
      unitRef="U_USD">1406000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b55a09af-5dc9-4df7-b9a8-4abd66541c09"
      decimals="-3"
      id="F_f21e340a-976e-41ba-8f98-3e2d7b84bbe1"
      unitRef="U_USD">722000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_bf769b81-c14e-4054-9b4e-ca2f4e5b5b47"
      unitRef="U_USD">182000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-3"
      id="F_a7e8091d-d82e-4db5-bc6b-eeec878a7c40"
      unitRef="U_USD">1521000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-3"
      id="F_c06ea06c-a8d9-4252-82e0-fb341493d318"
      unitRef="U_USD">684000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="-3"
      id="F_2d12a8ee-8202-488c-849d-9afb153abe76"
      unitRef="U_USD">3109000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_224dd772-6aaa-446a-ae9e-b8d743a062d3"
      decimals="-3"
      id="F_783ee32c-c2b4-4e78-b589-07f2a0322d66"
      unitRef="U_USD">1406000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_fcc5fd18-8424-4126-b998-8a3ad1ffc264"
      decimals="INF"
      id="F_a93adc54-4f58-4e89-b7d7-52a8ee86c768"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_c17aa8b9-7bca-4de3-9b44-4e9a60135e8b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;11. Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has a 401(k) Plan for all of its employees. The 401(k) Plan allows eligible employees to defer, at the employee&#x2019;s discretion, up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of their pretax compensation up to the Internal Revenue Service annual limit. The Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#212121;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="INF"
      id="F_8bc96673-f717-4b3a-90af-33feafc7cdcc"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="-5"
      id="F_d49661d3-5b51-4bc9-a825-ea4879140b81"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="-5"
      id="F_2a4896a5-4710-44e5-9f9e-ea6440c64637"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_0baff936-12f7-4af2-95fa-08865646102e">&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;12. &lt;/span&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.248%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.777%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.777%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,820,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,033,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-vested Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,134,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,275,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      id="F_20172ed7-d8bc-47d0-a04d-5c576bfad06d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.248%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.777%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.777%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,820,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,033,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-vested Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,134,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,275,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fe8e26c7-136f-405d-890c-308874394d43"
      decimals="0"
      id="F_32c05fcb-0816-43a8-9e1a-762cd5a5540c"
      unitRef="U_shares">6820869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bfc5356d-4026-41a2-a82b-2bbf62ac66e0"
      decimals="0"
      id="F_db286fa8-650b-41c7-bbac-2f0fe433fde6"
      unitRef="U_shares">4033522</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e5ff6d80-d652-482d-85d9-7a260cc2826b"
      decimals="0"
      id="F_61de9796-0eb4-4c56-9b21-df78b805ba96"
      unitRef="U_shares">310087</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3ab74e21-5321-4b29-9cf8-94356358cf01"
      decimals="0"
      id="F_e3a8300a-87e4-4f5d-a052-f8aa8c190012"
      unitRef="U_shares">236339</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_10175cd6-83a3-4603-bad5-7b3b43f819ec"
      decimals="0"
      id="F_129dcca4-b406-464d-85ea-fed5d29367b7"
      unitRef="U_shares">3495</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53baa5a0-6766-48f8-b2f6-ddb46f1ed143"
      decimals="0"
      id="F_7ddbe2b3-5b09-438b-8274-5b83c202ccf7"
      unitRef="U_shares">5148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f1c93451-1f41-49f8-b231-c5cf477afc39"
      decimals="0"
      id="F_095211c3-678e-4ee4-94d4-95271bee4dfd"
      unitRef="U_shares">7134451</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3c6c7189-5e14-4367-b988-8d2df4618d96"
      decimals="0"
      id="F_b493cddd-28c1-46ca-9aca-ecfdef65d7e3"
      unitRef="U_shares">4275009</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc"
      id="F_91dfc117-c56b-414b-a2c5-e5b3fcf0f7c6">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc"
      id="F_36caf105-b7ac-45c8-a0be-85f981943da2">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc"
      id="F_730fff7c-9d23-4688-80cb-5b9ee683ffc9">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_f0336f14-ecce-4690-83b6-8b9ffc9ea3dc"
      id="F_321c7619-6a5b-4b94-9e9a-f71ef53ca790">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
